PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chang, BY; Harte, RA; Cartwright, CA				Chang, BY; Harte, RA; Cartwright, CA			RACK1: a novel substrate for the Src protein-tyrosine kinase	ONCOGENE			English	Article						Src; RACK1; PKC; signal transduction	MIDDLE TUMOR-ANTIGEN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; SH2 DOMAIN; C-SRC; PHOSPHORYLATION; PP60C-SRC; ACTIVATION; FAMILY; CELLS	RACK1 is one of a group of PKC-interacting proteins collectively called RACKs (Receptors for Activated C-Kinases). Previously, we showed that RACK1 also interacts with the Src tyrosine kinase, and is an inhibitor of Src activity and cell growth. PKC activation induces the intracellular movement and co-localization of RACK1 and Src, and the tyrosine phosphorylation of RACK1. To determine whether RACK1 is a Src substrate, we assessed phosphorylation of RACK1 by various tyrosine kinases in vitro, and by kinase-active and inactive mutants of Src in vivo. We found that RACK1 is a Src substrate. Moreover, Src activity is necessary for both the tyrosine phosphorylation of RACK1 and the binding of RACK1 to Src's SH2 domain that occur following PKC activation. To identify the tyrosine(s) on RACK1 that is phosphorylated by Src, we generated and tested a series of RACK1 mutants. We found that Src phosphorylates RACK1 on Tyr 228 and/or Tyr 246, highly-conserved tyrosines located in the sixth WD repeat that interact with Src's SH2 domain. We think that RACK1 is an important Src substrate that signals downstream of growth factor receptor tyrosine kinases and is involved in the regulation of Src function and cell growth.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Room 3115-C,269 Campus Dr, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [F32CA069810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER; NCI NIH HHS [CA69810] Funding Source: Medline; NIDDK NIH HHS [R01 DK43743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lou Q, 1996, BIOORGAN MED CHEM, V4, P677, DOI 10.1016/0968-0896(96)00063-6; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PARK J, 1995, MOL CELL BIOL, V15, P2374; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zhou Songyang, 1995, Nature (London), V373, P536	30	95	105	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7619	7629		10.1038/sj.onc.1206002	http://dx.doi.org/10.1038/sj.onc.1206002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400005				2022-12-28	WOS:000178756200002
J	De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A				De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A			Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines	ONCOGENE			English	Article						signal transduction; cytokine receptors; kinases; phosphatases growth factors; AIDS; HIV	PERIPHERAL-BLOOD LYMPHOCYTES; PROMONOCYTIC CELL-LINES; TAT-ASSOCIATED KINASE; FACTOR P-TEFB; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; HIV-1 TAT; IN-VITRO; INTERLEUKIN-6; TRANSCRIPTION	Cdk9 is a member of the Cdc2-like family of kinases. It binds to members of the family of cyclin T (T1, T2a and T2b) and to cyclin K. The Cdk9/cyclin T complex appears to be involved in regulating several physiological processes. In fact Cdk9 is the kinase of the P-TEFb complex, involved in basal transcription. Cdk9 has also been described as the kinase of the TAK complex, homologous to P-TEFb and involved in HIV replication. Here we show that Cdk9 interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines,,which includes Leukemia Inhibitory Factor (LIF), Oncostatin NI (OSM), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1). IL-6 is a key regulator of hematopoiesis, immunological responses and inflammation. In addition, IL-6 plays a major role in the endocrine and nervous systems. Signal transduction by gp130 is mediated by physical interaction of the cytoplasmic region of gp130 with cellular kinases and results in the transcriptional activation of cellular and viral genes. We found that Cdk9 interacts in vitro with the cytoplasmic region of gp130 and we succeded in reproducing this interaction in vivo. Cdk9 expression was found both in the nucleus and in the cytoplasm. The binding occurring between Cdk9 and gp130 increased upon IL-6 stimulation. We also observed that Cdk9 synergized with IL-6 in inducing the activation of an IL-6-responsive reporter plasmid. In summary, these results point to a previously undisclosed role for Cdk9 in signal transduction.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Ist Anat & Istol Patol, I-53100 Siena, Italy; Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, I-44100 Ferrara, Italy; CNR, Ist Citomorfol Normale & Patol, IOR, I-40137 Bologna, Italy; Univ Naples Federico II, Dipartimento Biol Evolut & Comparata, Naples, Italy; Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples 2, Ist Anat Topog, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Neri, Luca Maria/J-2462-2017; BELLAN, CRISTIANA/L-3903-2013; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; De Luca, Antonio/AAD-9562-2020; leoncini, lorenzo/P-8361-2018; Neri, Luca Maria/AAU-1772-2021	BELLAN, CRISTIANA/0000-0001-6119-9007; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; De Luca, Antonio/0000-0002-3905-6154; leoncini, lorenzo/0000-0002-7457-300X; Neri, Luca Maria/0000-0002-7924-1477				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BELLAN C, 2002, J CLIN PATHOL S1, V55, pA29; BOULTON TG, 1994, J BIOL CHEM, V269, P648; BULLRICH F, 1995, CANCER RES, V55, P1199; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DEFALCO G, 2002, CANC BIOL THER, V1, P66; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001; Giordano V, 1997, J IMMUNOL, V158, P4097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; OFFIT K, 1993, GENE CHROMOSOME CANC, V7, P1, DOI 10.1002/gcc.2870070102; ORLOW I, 1994, CANCER RES, V54, P2848; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; ULRICH A, 1990, CELL, V61, P203; von Laue S, 2000, J ENDOCRINOL, V165, P301, DOI 10.1677/joe.0.1650301; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	38	25	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7464	7470		10.1038/sj.onc.1205967	http://dx.doi.org/10.1038/sj.onc.1205967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386808				2022-12-28	WOS:000178618200001
J	Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS				Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS			Novel candidate tumor marker genes for lung adenocarcinoma	ONCOGENE			English	Article						lung cancer; biomarker; subtractive hybridization; microarray; differential expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; MESSENGER-RNA EXPRESSION; BINDING PROTEIN PHBP; CHROMOSOMAL LOCALIZATION; CANCER; IDENTIFICATION; COLLAGEN; INTEGRIN; CLONING; DIAGNOSIS	Using the representational difference analysis (RDA) technique on pooled mRNA of five primary lung adenocarcinomas and their corresponding non-neoplastic lung tissues, we identified six genes that were putatively overexpressed in this type of lung cancer. Five corresponded to previously isolated genes, while one (Lc19) matched with the sequence of an unannotated EST. Real-time RT-PCR analyses of expression levels in a panel of 34 paired primary non-small cell lung cancer (NSCLC) and corresponding grossly normal appearing lung tissues confirmed the common overexpression of these genes in non-small cell lung cancer. Among these genes, overexpression of Lc19, hyaluronan binding protein 2 (HABP2) and crystalline-mu appeared more specific to adenocarcinoma, whereas ceruloplasmin, integrin alpha-11 and collagen type XI alpha 1 were overexpressed at high frequency among both adenocarcinoma and squamous cell carcinoma. These genes represent novel candidate tumor biomarker genes for NSCLC and its histological subtypes.	Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Ming.Tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHEN HM, 1992, GENOMICS, V14, P1115, DOI 10.1016/S0888-7543(05)80143-0; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith AJ, 1998, AM J HUM GENET, V62, P816, DOI 10.1086/301789; Hibi K, 1998, CANCER RES, V58, P5690; HIROTA M, 1985, CANCER RES, V45, P6453; Hsu NY, 2001, CANCER RES, V61, P2727; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Lehnert K, 1999, GENOMICS, V60, P179, DOI 10.1006/geno.1999.5909; Liloglou T, 2001, CANCER RES, V61, P1624; LINDER MC, 1981, JNCI-J NATL CANCER I, V67, P263; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; Manda R, 1999, GENOMICS, V61, P5, DOI 10.1006/geno.1999.5939; MAO L, 1994, CANCER RES, V54, P1634; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAH HD, 1992, J BIOL CHEM, V267, P22581; Palmisano WA, 2000, CANCER RES, V60, P5954; Pastorian K, 2000, ANAL BIOCHEM, V283, P89, DOI 10.1006/abio.2000.4622; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SCHRAML P, 1994, CANCER RES, V54, P5236; Sozzi G, 1999, CLIN CANCER RES, V5, P2689; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Wigle DA, 2002, CANCER RES, V62, P3005; WYNDER EL, 1994, CANCER RES, V54, P5284	38	75	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7598	7604		10.1038/sj.onc.1205953	http://dx.doi.org/10.1038/sj.onc.1205953			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386823				2022-12-28	WOS:000178618200016
J	Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE				Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE			gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth	ONCOGENE			English	Article						lung cancer; NSCLC; gamma-catenin; tumor suppressor; cell transformation	BETA-CATENIN; MALIGNANT-MELANOMA; COLORECTAL-CANCER; CARCINOMA-CELLS; FACTOR RECEPTOR; ALPHA-CATENIN; N-CADHERIN; CYCLIN D1; PLAKOGLOBIN; MUTATIONS	Lung cancer is a heterogeneous disease categorized into multiple subtypes of cancers which likely arise from distinct patterns of genetic alterations and disruptions. Precedent exists for a role of beta-catenin, a downstream component of the Writ signaling pathway that serves as a transcriptional co-activator with TCF/LEF, in several human cancers including colon carcinomas. In this study, we observed that beta-catenin was highly and uniformly expressed in a panel of NSCLC cell lines and primary lung tumors. By contrast gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in similar to30% of the specimens. Treatment of NSCLC cells expressing reduced gamma-catenin protein with 5-aza-2'-deoxycytidine (5aza2dc), a DNA methylation inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, increased gamma-catenin protein content in NSCLC cells with low gamma-catenin expression. Significantly, the activity of a beta-catenin/TCF-dependent luciferase reporter was markedly elevated in the NSCLC cell lines that underexpressed gamma-catenin relative to those lines that highly expressed gamma-catenin. Moreover, transfection of these cells with gamma-catenin expression plasmid reduced the elevated TCF activity by 85% and strongly inhibited cell growth on tissue culture plastic as well as anchorage-independent growth in soft agar. This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCFdependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, C272,4200 E 9th Ave, Denver, CO 80262 USA.			Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58187] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Beekman A, 1998, CANCER RES, V58, P910; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fukuchi T, 1998, CANCER RES, V58, P3526; Graziano SL, 1999, J CLIN ONCOL, V17, P668, DOI 10.1200/JCO.1999.17.2.668; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; IMRAVET S, 2002, J BIOL CHEM, V277, P1884; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 2000, GENE DEV, V14, P1319; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NICHOLSON RI, 2001, EUR J CANC S4, V3, P9; Ohsaki Y, 2000, ONCOL REP, V7, P603; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391; Polakis P, 2000, GENE DEV, V14, P1837; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyoyama H, 1999, ONCOL REP, V6, P81; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Westra WH, 1996, CANCER RES, V56, P2224; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	41	95	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7497	7506		10.1038/sj.onc.1205963	http://dx.doi.org/10.1038/sj.onc.1205963			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386812				2022-12-28	WOS:000178618200005
J	Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA				Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA			Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells	ONCOGENE			English	Article						adenomatous polyps; colorectal cancer; cyclooxygenase; macrophage	FAMILIAL ADENOMATOUS POLYPOSIS; NITRIC-OXIDE SYNTHASE; CELLULAR-LOCALIZATION; INCREASED EXPRESSION; TGF-BETA; IN-VITRO; CANCER; GROWTH; RECEPTOR; INHIBITOR	In human colorectal adenomas or polyps, cyclooxygenase-2 is expressed predominantly by stromal (or interstitial) macrophages. Therefore, we tested the hypothesis that macrophage cyclooxygenase-2 has paracrine pro-tumorigenic activity using in vitro models of macrophage-epithelial cell interactions. We report that macrophages can promote tumorigenic progression of intestinal epithelial cells (evidenced by decreased cell-cell contact inhibition, increased proliferation and apoptosis, gain of anchorage-independent growth capability, decreased membranous E-cadherin expression, up-regulation of cyclooxygenase-2 expression, down-regulation of transforming growth factor-beta type 11 receptor expression and resistance to the antiproliferative activity of transforming growth factor-beta(1)) in a paracrine, cyclooxygenase-2-dependent manner. Pharmacologically relevant concentrations (1-2 muM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct effect on intestinal epithelial cells but inhibited the macrophage-epithelial cell signal mediating tumorigenic progression. Cyclooxygenase-2-mediated stromal-epithelial cell signalling during the early stages of intestinal tumorigenesis provides a novel target for chemoprevention of colorectal cancer (and other gastro-intestinal epithelial malignancies, which arise on a background of chronic inflammation, such as gastric cancer) and may explain the discrepancy between the concentrations of cyclooxygenase inhibitors required to produce antineoplastic effects in vitro and in vivo.	Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hull, MA (corresponding author), Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	M.A.Hull@leeds.ac.uk	Chapple, Keith/AAL-6484-2020	Chapple, Keith/0000-0001-6523-2230				Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Chulada PC, 2000, CANCER RES, V60, P4705; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; GAGLIARDI G, 1995, VIRCHOWS ARCH, V426, P149; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162; HAUPTMANN S, 1993, AM J PATHOL, V143, P1406; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Hull M, 2000, GASTROENTEROLOGY, V119, P600, DOI 10.1053/gast.2000.16156; Hull MA, 2000, CLIN EXP METASTAS, V18, P21, DOI 10.1023/A:1026553605636; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jacoby RF, 2000, CANCER RES, V60, P5040; Khan KNM, 2001, SCAND J GASTROENTERO, V36, P865, DOI 10.1080/003655201750313405; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; MANNING AM, 1991, ONCOGENE, V6, P1471; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Morris CD, 2001, AM J GASTROENTEROL, V96, P990; Muller-Decker K, 1999, INT J COLORECTAL DIS, V14, P212, DOI 10.1007/s003840050213; Mutoh M, 2002, CANCER RES, V62, P28; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; Pitot HC, 2000, ALIMENT PHARM THERAP, V14, P153, DOI 10.1046/j.1365-2036.2000.014s1153.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rosenberger CM, 2000, J IMMUNOL, V164, P5894, DOI 10.4049/jimmunol.164.11.5894; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sharma RA, 2001, CARCINOGENESIS, V22, P1557, DOI 10.1093/carcin/22.9.1557; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Taketo MM, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P129; Takeuchi M, 2002, INT J COLORECTAL DIS, V17, P144, DOI 10.1007/s00384-001-0372-5; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; WILLSON JKV, 1987, CANCER RES, V47, P2704; Wilson KT, 1998, CANCER RES, V58, P2929; Yang VW, 1998, CANCER RES, V58, P1750; Zhang T, 1997, CANCER RES, V57, P1638	64	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7175	7186		10.1038/sj.onc.1205869	http://dx.doi.org/10.1038/sj.onc.1205869			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370807				2022-12-28	WOS:000178504600005
J	Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G				Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G			RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death	ONCOGENE			English	Article						radioresistance; farnesylation; Ras; RhoB	FIBROBLAST GROWTH-FACTOR; FARNESYLTRANSFERASE INHIBITORS; IN-VIVO; GERANYLGERANYLATED RHOB; ENDOTHELIAL-CELLS; RAS ONCOGENES; PROTEIN; RADIATION; PRENYLATION; FORMS	Farnesylated Ras oncoprotein induces a cellular resistance to ionizing radiation that can be reversed by farnesyltransferase inhibitors (FTI). We previously demonstrated that, expression of the 24 kDa FGF2 isoform in wild type ras bearing HeLa cells, induced radioresistance which was also reversed by FTI. We tested the hypothesis that wild type Ras or RhoB, which has been proposed as a potential FTI target, could control the FGF-2-induced radioresistance mechanisms. For this, we expressed inducible dominant negative forms of Ras (RasN17) and Rho (RhoBN19) in 24 kDa FGF2 transfected HeLa cells and analysed their survival after irradiation. While no cell survival modification was observed after RasN17 induction, the expression of RhoBN19 induced a radiosensitization of FGF2 radioresistant HeLa cells in the same range as the one observed after a 48 h treatment with the specific FTI, R115777. Moreover, we showed that activated RhoB but not RhoA induced radioresistance in NIH3T3 cells. The radiosensitizer effect of RhoBN19 expression was due to the induction of the radiation induced post-mitotic cell death. Taken together, these data demonstrate that 24 kDa FGF-2-induced radioresistance is controlled by Rho pathways and suggest that RhoB should be a major determinant in cellular resistance to ionizing radiation.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Favre, G (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		delmas, caroline/O-9241-2014; FAVRE, Gilles/K-9189-2014; Toulas, Christine/P-3838-2014; Moyal, Elizabeth/A-9802-2015; Ader-Perarnau, Isabelle/F-7160-2017	FAVRE, Gilles/0000-0002-2344-1883; Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BRUYNEEL EA, 1993, EUR J CANCER, V29A, P1958, DOI 10.1016/0959-8049(93)90452-L; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; CohenJonathan E, 1997, CANCER RES, V57, P1364; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; Du W, 1999, MOL CELL BIOL, V19, P1831; End DW, 2001, CANCER RES, V61, P131; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FUKS Z, 1994, CANCER RES, V54, P2582; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Miquel K, 1997, CANCER RES, V57, P1846; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VAN AL, 1997, GENE DEV, V11, P2295; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5998	6006		10.1038/sj.onc.1205746	http://dx.doi.org/10.1038/sj.onc.1205746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203112				2022-12-28	WOS:000177671300003
J	Schimmel, M; Bauer, G				Schimmel, M; Bauer, G			Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts	ONCOGENE			English	Article						transformed; reactive oxygen species; apoptosis; catalase	INTERCELLULAR INDUCTION; HYDROGEN-PEROXIDE; APOPTOSIS-INDUCTION; RADICAL GENERATION; HYDROXYL RADICALS; SUPEROXIDE ANION; OXIDATIVE STRESS; NADH OXIDASE; NITRIC-OXIDE; CELLS	Oncogenic transformed fibroblasts are characterized by extracellular superoxide anion generation through a membrane-associated NADPH oxidase. After cellular glutathione depletion, extracellular reactive oxygen species (ROS) generated by transformed fibroblasts exhibit a strong apoptosis-inducing potential. As apoptosis induction under glutathione depletion is inhibited by catalase, the NADPH oxidase inhibitor apocynin, superoxide dismutase, the hydroxyl radical scavenger terephthalate and the iron chelator deferoxamine, the metal-catalysed Haber-Weiss reaction seems to be the responsible signaling mechanism. In contrast to extracellular ROS, intracellular ROS play no role for apoptosis induction in glutathione-depleted transformed fibroblasts initially, since a high level of intracellular catalase scavenges intracellular hydrogen peroxide. Intracellular catalase seems to be induced by extracellular hydrogen peroxide, as pretreatment of transformed fibroblasts with exogenous catalase downmodulates endogenous catalase and renders glutathione-depleted transformed cells susceptible for the effect of endogenous hydrogen peroxide. In contrast to transformed fibroblasts, nontransformed glutathione-depleted fibroblasts do not generate substantial extracellular ROS, but apoptosis is efficiently induced in these cells by intracellular ROS. Our data show that extracellular ROS of transformed fibroblasts exhibit redox-related signaling and at the same time represent a potential apoptosis-inducing hazard through the metal-catalysed Haber-Weiss reaction.	Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, D-79104 Freiburg, Germany	University of Freiburg	Bauer, G (corresponding author), Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	tgfb@ukl.uni-freiburg.de						Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; ARUOMA OI, 1988, BIOCHEM J, V256, P251, DOI 10.1042/bj2560251; Barnes AC, 1999, MICROB PATHOGENESIS, V26, P149, DOI 10.1006/mpat.1998.0260; Bauer G, 2000, HANDB EXP PHARM, V142, P275; Bauer G, 2000, ANTICANCER RES, V20, P4115; Beck E, 1997, EXP CELL RES, V234, P47, DOI 10.1006/excr.1997.3587; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Bittinger F, 1998, MELANOMA RES, V8, P381, DOI 10.1097/00008390-199810000-00001; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.3.CO;2-H; Engelmann I, 2000, REDOX REP, V5, P207, DOI 10.1179/135100000101535762; Enoiu M, 2000, FREE RADICAL BIO MED, V29, P825, DOI 10.1016/S0891-5849(00)00370-1; Faure H, 1996, FREE RADICAL BIO MED, V20, P979, DOI 10.1016/0891-5849(95)02187-6; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Girotti AW, 1998, J LIPID RES, V39, P1529; GORCZYCA W, 1993, CANCER RES, V53, P1945; Haufel T, 2001, ANTICANCER RES, V21, P2617; HEIGOLD S, 2002, J LEUKOCYTE BIOL, V23, P939; HEIGOLD S, 2002, IN PRESS CARCINOGENE; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; Herdener M, 2000, FREE RADICAL BIO MED, V29, P1260, DOI 10.1016/S0891-5849(00)00422-6; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lai CC, 1996, J MOL CELL CARDIOL, V28, P1157, DOI 10.1006/jmcc.1996.0106; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li PF, 1997, CIRCULATION, V96, P3602; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Morre DJ, 1997, J BIOENERG BIOMEMBR, V29, P281, DOI 10.1023/A:1022466212083; Mylonas C, 1999, IN VIVO, V13, P295; Nappi AJ, 1998, BBA-GEN SUBJECTS, V1380, P55, DOI 10.1016/S0304-4165(97)00125-6; Oettl K, 1999, BIOCHEM BIOPH RES CO, V264, P262, DOI 10.1006/bbrc.1999.1520; Oyama Y, 1999, EUR J PHARMACOL, V384, P47, DOI 10.1016/S0014-2999(99)00649-4; Paul K, 2001, ANTICANCER RES, V21, P3237; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rohrdanz E, 1998, FREE RADICAL BIO MED, V24, P27, DOI 10.1016/S0891-5849(97)00159-7; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROSEN H, 1979, J CLIN INVEST, V64, P1725, DOI 10.1172/JCI109637; SARAN M, 1994, CHEM-BIOL INTERACT, V90, P35, DOI 10.1016/0009-2797(94)90109-0; Saran M, 1999, FREE RADICAL RES, V31, P429, DOI 10.1080/10715769900300991; Schimmel M, 2001, INT J ONCOL, V19, P299; Schwieger A, 2001, CARCINOGENESIS, V22, P1385, DOI 10.1093/carcin/22.9.1385; SHI XL, 1992, ARCH BIOCHEM BIOPHYS, V292, P323, DOI 10.1016/0003-9861(92)90085-B; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THART BA, 1990, FREE RADICAL BIO MED, V9, P127, DOI 10.1016/0891-5849(90)90115-Y; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; Zucker B, 1997, CELL DEATH DIFFER, V4, P388, DOI 10.1038/sj.cdd.4400258	61	66	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5886	5896		10.1038/sj.onc.1205740	http://dx.doi.org/10.1038/sj.onc.1205740			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185588				2022-12-28	WOS:000177520900008
J	Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S				Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S			Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype	ONCOGENE			English	Article						colorectal carcinoma; beta-catenin; mutation; gene targeting; TCF/LEF-dependent transcription	COLORECTAL-CANCER; METALLOPROTEINASE MATRILYSIN; INTESTINAL POLYPOSIS; GROWTH; TRANSACTIVATION; SUPPRESSION; PATHWAY; TUMORIGENESIS; EXPRESSION; MUTATIONS	Most colorectal carcinomas harbor genetic alterations that result in stabilization of beta-catenin. A colorectal carcinoma cell line, HCT116, which has both mutated and wild-type beta-catenin genes, was engineered by homologous recombination to investigate the significance of beta-catenin gene mutation. As expected, the mutant allele-targeted clones showed decreased beta-catenin expression and down-regulation of T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription. Morphologically, targeted clones were only minimally altered under usual culture conditions, but under low serum conditions, mutant allele-targeted clones still grew in plane, in contrast to parental cell line and wild allele-targeted clones, which formed spheroids. The mutant allele-targeted clones showed no significant changes in growth rate and anchorage-independent growth in vitro, and displayed rather increased growth in vivo. Although beta-catenin stabilization affects some biological characteristics including adhesive properties, it may not have growth-promoting effects at least in some colorectal carcinomas.	Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo, Japan	National Cancer Center - Japan	Hirohashi, S (corresponding author), Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan.		Sakamoto, Michiie/N-2917-2015					Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mariadason JM, 2001, CANCER RES, V61, P3465; Nagasawa Y, 1999, CANCER RES, V59, P3539; Naishiro Y, 2001, CANCER RES, V61, P2751; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 2000, GENE DEV, V14, P1837; Roh H, 2001, CANCER RES, V61, P6563; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sparks AB, 1998, CANCER RES, V58, P1130; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wagenaar RA, 2001, CANCER RES, V61, P2097; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yamada T, 2000, CANCER RES, V60, P4761	22	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5906	5911		10.1038/sj.onc.1205756	http://dx.doi.org/10.1038/sj.onc.1205756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185590	Green Submitted			2022-12-28	WOS:000177520900010
J	Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL				Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL			The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer	ONCOGENE			English	Article						tyrosine kinase; growth factors; steroid hormones; signal transduction; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; CYCLIN E-CDK2 ACTIVATION; GROWTH-FACTOR; PHOSPHATASE CORKSCREW; SIGNALING PATHWAY; TYROSINE KINASE; MCF-7 CELLS; EXPRESSION; PROGRESSION; ALPHA	Grb2-associated binder 2 (Gab2) is a recently identified member of the Gab/Daughter of sevenless family of docking proteins, which localize, amplify and integrate signaling pathways activated by various receptors including receptor tyrosine kinases (RTKs). To date, Gab2 signaling has been primarily investigated in hematopoietic cells. Here we report marked overexpression of Gab2 in a subset of breast cancer cell lines relative to normal breast epithelial strains and a trend for increased Gab2 expression in estrogen receptor (ER)positive lines. Overexpression relative to normal ductal epithelium was also observed in some primary breast cancers. In MCF-7 breast cancer cells Gab2 was markedly tyrosine phosphorylated in response to heregulin and also following EGF, insulin or bFGF administration, indicating that a variety of RTKs implicated in breast cancer development or progression couple to this docking protein. In hormone-responsive breast cancer cells, GAB2 mRNA and protein expression were induced by estradiol in a manner sensitive to the pure anti-estrogen ICI 182780, indicating that this regulation is mediated via the ER. Gab2 therefore represents a novel link between steroid and growth factor signaling in breast cancer, and when overexpressed, may modulate the sensitivity of breast cancer cells to these important growth regulators.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol & Oncol, Boston, MA 02215 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152, R01CA066600] Funding Source: NIH RePORTER; NCI NIH HHS [CA66600, CA49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Allard JD, 1996, DEVELOPMENT, V122, P1137; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke R, 2000, J MAMMARY GLAND BIOL, V5, P245, DOI 10.1023/A:1009527609611; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; JANES PW, 1994, ONCOGENE, V9, P3601; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa H, 2000, CANCER RES, V60, P5887; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Rocha RL, 1997, CLIN CANCER RES, V3, P103; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	38	76	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5175	5181		10.1038/sj.onc.1205522	http://dx.doi.org/10.1038/sj.onc.1205522			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140767				2022-12-28	WOS:000176975900015
J	Dubina, MV; Iatckii, NA; Popov, DE; Vasil'ev, SV; Krutovskikh, VA				Dubina, MV; Iatckii, NA; Popov, DE; Vasil'ev, SV; Krutovskikh, VA			Connexin 43, but not connexin 32, is mutated at advanced stages of human sporadic colon cancer	ONCOGENE			English	Article						gap junctions; connexin 43; connexin 32; colon cancer; mutations	GAP JUNCTION PROTEINS; CARDIAC MYOCYTES; GROWTH-CONTROL; MUTATIONS; GENE; EXPRESSION; TUMORS; COMMUNICATION; LOCALIZATION; DOMAIN	The membrane-spanning connexin proteins form microscopic intercellular channels that directly connect the cytoplasms of adjacent cells and as such have been implicated in maintenance of tissue homeostasis. They are considered to act as tumor suppressors since their function or expression is frequently aberrant in tumor cells. Several mechanisms appear to be involved in this, but irreversible mutational alterations have not yet been proved to be among them. In this study we have demonstrated for the first time that connexin 43 but not connexin 32 is specifically and quite frequently mutated in human colon sporadic adenocarcinomas. All tumor-associated mutations led to a shift of reading frame and were located in the multifunctional carboxyl-terminal domain of the protein. Expression of mutated connexin 43 protein was restricted to invasive structures of tumors. These findings suggest that mutational alterations of connexin 43 are involved in advanced stages of progression of human colon cancer towards malignancy.	St Petersburg State Pavlov Med Univ, Dept Pathophysiol, St Petersburg, Russia; St Petersburg State Pavlov Med Univ, Dept Surg Dis, St Petersburg, Russia; Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Krutovskikh, VA (corresponding author), St Petersburg State Pavlov Med Univ, Dept Pathophysiol, St Petersburg, Russia.		Dubina, Michael/E-1888-2014	Dubina, Michael/0000-0002-6606-3309; Popov, Dmitry/0000-0001-9112-0232				Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Jin CS, 2000, METHODS, V20, P219, DOI 10.1006/meth.1999.0939; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Lamartine J, 2000, NAT GENET, V26, P142, DOI 10.1038/79851; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; MESNIL M, 1995, CANCER RES, V55, P629; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; NEVEU MJ, 1994, J CELL SCI, V107, P83; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Saito T, 1997, CANCER RES, V57, P375; Saito T, 2000, INT J CANCER, V86, P67, DOI 10.1002/(SICI)1097-0215(20000401)86:1<67::AID-IJC10>3.0.CO;2-1; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199	25	49	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4992	4996		10.1038/sj.onc.1205630	http://dx.doi.org/10.1038/sj.onc.1205630			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118378				2022-12-28	WOS:000176874800014
J	van Hogerlinden, M; Auer, G; Toftgard, R				van Hogerlinden, M; Auer, G; Toftgard, R			Inhibition of Rel/Nuclear Factor-kappa B signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development	ONCOGENE			English	Article						NF-kappa B; skin cancer; gamma-radiation; G1 arrest; I kappa B-alpha transgene	X-LINKED DISORDER; INCONTINENTIA PIGMENTI; MOUSE SKIN; P53 MUTATIONS; ECTODERMAL DYSPLASIA; ABERRANT EXPRESSION; METHYLENE-CHLORIDE; GROWTH ARREST; LUNG-TUMORS; B6C3F1 MICE	In recent years a growth inhibitory role in skin for the Rel/NF-kappaB transcription factors has been established, and the block of Rel/NF-kappaB signaling results in rapid development of spontaneous skin cancer. The molecular mechanism underlying tumor development is however unknown. In the present study, we show that inhibition of NF-kappaB signaling in mouse skin by targeted expression of degradation resistant IkappaB-alpha generates transgenic keratinocytes unable to arrest the cell cycle in response to DNA damage induced by gamma-radiation. The results indicate that transgenic keratinocytes have a defect at the G1-S checkpoint whereas the G2-M checkpoint response was found to be intact. However, transgenic keratinocytes still respond by induction of the cyclin dependent kinase inhibitor P21(Cip1/Waf) after exposure to T-radiation. In the spontaneous skin tumors that develop in transgenic mice no mutations were found in the Ha-ras or p53 gene, suggesting that inhibition of NF-kappaB signaling in skin can induce cancer development independently of initiating mutations in the Ha-ras gene or additional mutations in the p53 gene. These findings demonstrate an involvement of NF-kappaB signaling in the DNA damage response and cell cycle checkpoint control in the skin.	Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Canc Ctr Karolinska, Dept Oncol Pathol, Div Cellular & Mol Tumor Pathol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.	rune.toftgard@cnt.ki.se		Auer, Gert/0000-0003-3911-0285				Ahmed NU, 1997, J CUTAN PATHOL, V24, P223, DOI 10.1111/j.1600-0560.1997.tb01585.x; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; AUER GU, 1994, VIRCHOWS ARCH, V424, P343; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; COLEMAN WB, 1995, CLIN CHEM, V41, P644; DEVEREUX TR, 1993, CARCINOGENESIS, V14, P795, DOI 10.1093/carcin/14.5.795; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEGI ME, 1993, CARCINOGENESIS, V14, P803, DOI 10.1093/carcin/14.5.803; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inohara S, 1996, DERMATOLOGY, V192, P94, DOI 10.1159/000246329; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KORSTANJE MJ, 1991, DERMATOLOGICA, V183, P234, DOI 10.1159/000247678; LANDY SJ, 1993, J MED GENET, V30, P53, DOI 10.1136/jmg.30.1.53; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Matsuta M, 1997, J DERMATOL SCI, V14, P233, DOI 10.1016/S0923-1811(96)00579-8; MCGREGOR JM, 1992, BRIT J DERMATOL, V127, P463, DOI 10.1111/j.1365-2133.1992.tb14841.x; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1996, INT J CANCER, V69, P174, DOI 10.1002/(SICI)1097-0215(19960621)69:3<174::AID-IJC4>3.0.CO;2-X; RO YS, 1993, BRIT J DERMATOL, V128, P237, DOI 10.1111/j.1365-2133.1993.tb00164.x; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; Sakai H, 2000, DERMATOLOGY, V200, P258, DOI 10.1159/000018371; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smahi A, 2000, NATURE, V405, P466; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; SUTTER C, 1993, MOL CARCINOGEN, V8, P13, DOI 10.1002/mc.2940080106; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tong Y, 1997, J TOXICOL ENV HEALTH, V51, P219, DOI 10.1080/00984109708984023; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tron VA, 1996, AM J PATHOL, V149, P1139; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weinberg WC, 1999, CANCER RES, V59, P2050; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	59	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					4969	4977		10.1038/sj.onc.1205620	http://dx.doi.org/10.1038/sj.onc.1205620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118375				2022-12-28	WOS:000176874800011
J	Emerling, BM; Bonifas, J; Kratz, CP; Donovan, S; Taylor, BR; Green, ED; Le Beau, MM; Shannon, KM				Emerling, BM; Bonifas, J; Kratz, CP; Donovan, S; Taylor, BR; Green, ED; Le Beau, MM; Shannon, KM			MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia	ONCOGENE			English	Article						monosomy 7; deletion 7q; myeloid leukemia; trithorax genes	BONE-MARROW CELLS; MYELOGENOUS LEUKEMIA; MUTANT MICE; GENE; FUSION; REGION; NEUROFIBROMATOSIS; T(7-11)(P15-P15); TRANSLOCATIONS; LEUKEMOGENESIS	Proteins encoded by Polycomb and Trithorax-group (Pc-G and Trx-G) genes regulate developmental fates by maintaining or repressing HOX gene expression, respectively. In a search for candidate myeloid leukemia tumor suppressor genes from a similar to2.5 Mb commonly-deleted segment within chromosome band 7q22, we identified a novel human Trithorax (Trx) family member named MLL5. Trx-G genes encode proteins that modulate transcriptional programs through protein-protein interactions that are mediated by PHD and SET domains, and by binding to DNA via A-T hooks and methyltransferase homology motifs. MLL5 is a homolog of the Drosophila gene CG9007; it encodes a 6.5 kb mRNA that is expressed widely. MLL5 includes a SET domain and a single PHD finger, but lacks A-T hooks and methyltransferase homology domains that are found in MLL. The leukemia cell line RCV-ACV-A carries a heterozygous missense mutation within the PHD domain; however, no mutations within the MLL5 coding region were detected in primary leukemias. MLL5 is a novel mammalian Trx-G gene that might modulate transcription by protein association.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA; Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Chicago; University of Chicago	Shannon, KM (corresponding author), Univ Calif San Francisco, Dept Pediat, 513 Parnassus Ave,HSE 302, San Francisco, CA 94143 USA.		Kratz, Christian/AAC-9726-2021		NCI NIH HHS [CA 40046] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen RJ, 1998, LEUKEMIA, V12, P1119, DOI 10.1038/sj.leu.2401002; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; KALRA R, 1994, BLOOD, V84, P3435; KANEKO Y, 1989, LEUKEMIA, V3, P36; Kratz CP, 2001, GENOMICS, V77, P171, DOI 10.1006/geno.2001.6636; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LeBeau MM, 1996, BLOOD, V88, P1930; LEBEAU MM, 1986, J CLIN ONCOL, V3, P325; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Thirman MJ, 1996, HEMATOL ONCOL CLIN N, V10, P293, DOI 10.1016/S0889-8588(05)70340-3; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	35	81	85	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4849	4854		10.1038/sj.onc.1205615	http://dx.doi.org/10.1038/sj.onc.1205615			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101424				2022-12-28	WOS:000176716300015
J	Neve, RM; Holbro, T; Hynes, NE				Neve, RM; Holbro, T; Hynes, NE			Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells	ONCOGENE			English	Article						ErbB2; p27(kip1); p38MAPK; PI3K; MAPK; heregulin	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; DOWN-REGULATION; CDK INHIBITORS; ERBB RECEPTORS; MYC; PROLIFERATION; NEUREGULIN	Addition of the ErbB-ligand, Heregulinbeta1 (HRG), to breast tumour-derived T47D cells promotes D-cyclin expression, p21(cip1) synthesis, cyclin-dependent kinase (CDK) activation through re-disiribution of p27(kip1) and DNA synthesis. In contrast EGF has no effect on T47D cell cycle progression. By comparing these two ligands and the use of specific inhibitors for phosphatidylinositol-3 kinase (PI3K), mitogen-activated protein kinase (MAPK) and p38MAPK, we have identified several molecular mechanisms required for ErbB receptor-mediated proliferation. The PI3K, MAPK and p38MAPK pathways each displayed distinct activation profiles in response to either HRG or EGF, with obvious differences in both the intensity and duration of signal output. Through inhibition of each of these pathways it is apparent that each pathway is necessary, yet insufficient alone, to stimulate proliferation. Each pathway regulates distinct subsets of essential cell cycle regulators and integration of these signal networks is required for the timely expression of these components, which culminates in cell cycle progression. Significantly, the mechanisms controlling ligand-stimulated proliferation through ErbB2 are strikingly similar to the mechanisms through which overexpressed, constitutively activated, ErbB2 orchestrates uncontrolled proliferation in cancer cells. This suggests that downstream effectors of ErbB receptors represent good therapeutic targets for breast cancer.	Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Buck Inst, Novato, CA 94945 USA; UCSF, Dept Hematol Oncol, San Francisco, CA USA	Friedrich Miescher Institute for Biomedical Research; Novartis; Buck Institute for Research on Aging; University of California System; University of California San Francisco	Neve, RM (corresponding author), Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	rneve@buckinstitute.org						Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; JONGEWARD GD, 1995, GENETICS, V139, P1553; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORKIN A, 1993, ONCOGENE, V8, P3021; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woldeyesus MT, 1999, GENE DEV, V13, P2538, DOI 10.1101/gad.13.19.2538; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3	62	92	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4567	4576		10.1038/sj.onc.1205555	http://dx.doi.org/10.1038/sj.onc.1205555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085235				2022-12-28	WOS:000176476700011
J	MacKenzie, KL; Franco, S; Naiyer, AJ; May, C; Sadelain, M; Rafii, S; Moore, MAS				MacKenzie, KL; Franco, S; Naiyer, AJ; May, C; Sadelain, M; Rafii, S; Moore, MAS			Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras	ONCOGENE			English	Article						telomerase; oncogenes; transformation; immortalization; endothelial cells	MAMMARY EPITHELIAL-CELLS; LIFE-SPAN; HUMAN FIBROBLASTS; IMMORTAL CELLS; EARLY REGION; H-RAS; GROWTH; ANGIOGENESIS; CANCER; HTERT	We have modelled multiple stages of malignant transformation of human endothelial cells (ECs) by overexpressing the catalytic subunit of human telomerase (hTERT), together with SV40 T antigen (SV40T) and oncogenic N-ras. Transfection with hTERT alone, led to the immortalization of two out of three cultures of bone marrow-derived ECs (BMECs). One hTERT transduced BMEC culture underwent a long proliferative lag before resuming proliferation. BMECs transfected with hTERT alone were functionally and phenotypically normal. BMECs transfected with SV40T (BMSVTs) had an extended lifespan, but eventually succumbed to crisis. BMSVTs exhibited a partially transformed phenotype, demonstrating growth factor independence, altered antigen expression and forming tiny, infrequent colonies in vitro. Transduction of BMSVTs with hTERT resulted in immortalization of 4 out of 4 cultures. BMSVTs immortalized with hTERT formed large colonies in vitro and small transient tumours in viro. BMECs coexpressing SV40T, hTERT and N-ras exhibited an overtly transformed phenotype; forming very large colonies with an altered morphology and generating rapidly growing tumours in vivo. These investigations demonstrate transformation of human ECs to an overtly malignant phenotype. This model will be useful for understanding mechanisms underlying vascular and angiogenic neoplasias, as well as for testing drugs designed to curtail aberrant EC growth.	Sloan Kettering Canc Inst, James Ewing Lab Dev Haematopoiesis, New York, NY USA; Sloan Kettering Canc Inst, Dept Human Genet, New York, NY USA; Cornell Univ, Med Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	MacKenzie, KL (corresponding author), Childrens Canc Inst Australia Med Res, High St,POB 81, Randwick, NSW 2031, Australia.		Mackenzie, Karen/F-1310-2011; MacKenzie, Karen/N-5849-2019	MacKenzie, Karen/0000-0003-2996-1617	NCI NIH HHS [CA59350] Funding Source: Medline; NHLBI NIH HHS [HL 61401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA059350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1989, CANCER RES, V49, P4682; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; Couch V, 2000, MAYO CLIN PROC, V75, P265; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelhardt M, 1997, BLOOD, V90, P182; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FICKLING SA, 1992, EXP CELL RES, V201, P517, DOI 10.1016/0014-4827(92)90303-P; FOX PL, 1994, ONCOGENE, V9, P3519; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; FROMENT O, 1994, CANCER RES, V54, P5340; GIMBRONE MA, 1976, CELL, V9, P685, DOI 10.1016/0092-8674(76)90132-X; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOHENWARTER O, 1992, J BIOTECHNOL, V25, P349, DOI 10.1016/0168-1656(92)90167-8; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LAND H, 1983, SCIENCE, V222, P769; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; MAHER J, 1995, ONCOGENE, V11, P1639; Mark RJ, 1996, CANCER, V77, P2400, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.3.CO;2-K; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RAFII S, 1994, BLOOD, V84, P10; RAK J, 1995, CANCER RES, V55, P4575; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Scott-Taylor TH, 1998, GENE THER, V5, P621, DOI 10.1038/sj.gt.3300633; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	55	62	65	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4200	4211		10.1038/sj.onc.1205425	http://dx.doi.org/10.1038/sj.onc.1205425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082607				2022-12-28	WOS:000176174200002
J	Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF				Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF			Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells	ONCOGENE			English	Article						SV40; methylation; RASSF1A; mesothelial cell; mesothelioma	HUMAN PLEURAL MESOTHELIOMA; LARGE-T-ANTIGEN; EPIGENETIC INACTIVATION; PROMOTER HYPERMETHYLATION; MALIGNANT MESOTHELIOMA; DNA METHYLATION; LUNG CARCINOMAS; CPG ISLANDS; SIMIAN-VIRUS-40; 3P21.3	Mesotheliomas are tumors arising from mesothelial cells and are associated with asbestos exposure and approximately 50% contain simian virus 40 (SV40) DNA sequences. SV40 infection of human mesothelial cells (HM) causes early cellular immortalization and late transformation. Aberrant methylation is a major mechanism for loss of function of tumor suppressor genes (TSGs). We recently reported that of seven genes frequently methylated in epithelial tumors, only RASSF1A gene was frequently methylated in mesotheliomas, and its methylation was correlated with loss of RASSF1A expression and the presence of SV40. We studied whether SV40 infection of normal HM induces aberrant methylation of the genes previously studied in mesotheliomas. Of six infected foci examined at early passages (passages 8-30) there was no methylation of the seven genes examined. Of two foci examined at late passages (passages 51-86) after the appearance of morphological changes suggestive of transformation, methylation and loss of expression of RASSF1A was detected. Sequencing of the CpG dense region around the transcription start site and semi-quantitative real-time methylation specific PCR (MSP) assay for RASSF1A methylation demonstrated progressive methylation during late passages. Exposure to the demethylating agent 5-aza-2'-deoxycytidine restored RASSF1A expression, while exposure to the histone deacetylation inhibitor trichostatin A had no effect. These data, together with our previous findings, support a causal relationship between SV40 infection, progressive RASSF1A methylation and its silencing, and the pathogenesis of mesothelioma.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Loyola University Chicago	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Adi.GAZDAR@UTSouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618, U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [5U01CA8497102, R01 CA2657, R01 CA 71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Antman K, 2001, CANC PRINCIPLES PRAC, P1943; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, CANCER RES, V60, P2368; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morrissey C, 2001, CANCER RES, V61, P7277; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waheed I, 1999, CANCER RES, V59, P6068	28	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4340	4344		10.1038/sj.onc.1205381	http://dx.doi.org/10.1038/sj.onc.1205381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082623				2022-12-28	WOS:000176174200018
J	Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH				Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH			Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2 +/- cells	ONCOGENE			English	Article						tuberin; hamartin; glia; astrocytoma; tumor suppressor gene	NF1 TUMOR-SUPPRESSOR; MISSENSE MUTATIONS; ALLELIC LOSS; HAMARTIN; MICE; PROLIFERATION; PROTEIN; GROWTH; LESIONS; IDENTIFICATION	Tuberous sclerosis complex (TSC) is an autosomal dominant tumor predisposition syndrome characterized by benign proliferations (hamartomas). In the brain, individuals with TSC develop autism, mental retardation and seizures associated with focal cortical dysplasias, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs). We hypothesize that dysregulated astrocyte function due to mutations in they tumor suppressor genes, TSC1 and TSC2, may contribute to the pathogenesis of these brain abnormalities. In this report, we demonstrate that mice heterozygous for a targeted defect in either the Tsc1 or Tsc2 genes (Tsc1+/- and Tsc2+/- mice) exhibit a 1.5-fold increase in the number of astrocytes in vivo. Whereas increased astrocyte numbers in vivo were suggestive of a proliferative advantage, Tsc2+/- primary astrocyte cultures did not show a cell-autonomous growth advantage, anchorage-independent growth, increased saturation density, or increased fluid-phase endocytosis compared to wild type astrocytes. Tsc2 null mouse embryonic fibroblasts (MEFs) however, did exhibit increased saturation density compared to Tsc2 wild type controls. In both Tsc2+/- astrocytes and Tsc2 null mouse embryonic fibroblasts, p27-Kip1 expression was decreased compared to wild type cells, and was reversed by tuberin re-expression in Tsc2-/- MEFs. In contrast, no change in endocytosis was observed upon tuberin re-expression in Tsc2-/- MEFs. Collectively, these results suggest Tsc heterozygosity may provide a non-cell-autonomous growth advantage for astrocytes that may involve p27-Kip1 expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Apicelli, Anthony/AAB-8879-2021; Haenen, Alexandra/HIR-5839-2022	Apicelli, Anthony/0000-0001-6791-8113; Gutmann, David/0000-0002-3127-5045; Burke, Stephen/0000-0002-8489-6953	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031535, R37NS031535] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31535] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Gutmann DH, 1997, ONCOGENE, V15, P1611, DOI 10.1038/sj.onc.1201314; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Henske EP, 1996, AM J HUM GENET, V59, P400; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lantuejoul S, 1997, HISTOPATHOLOGY, V30, P570, DOI 10.1046/j.1365-2559.1997.4600811.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Parry L, 2000, HUM GENET, V107, P350, DOI 10.1007/s004390000390; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1999, J MED GENET, V36, P285; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wolf HK, 1997, ACTA NEUROPATHOL, V93, P93, DOI 10.1007/s004010050587; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	46	58	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4050	4059		10.1038/sj.onc.1205435	http://dx.doi.org/10.1038/sj.onc.1205435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037687				2022-12-28	WOS:000175869900011
J	Williamson, EA; Dadmanesh, F; Koeffler, HP				Williamson, EA; Dadmanesh, F; Koeffler, HP			BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						BRCA1; p27(Kip1); transcriptional regulation	TUMOR-SUPPRESSOR BRCA1; BREAST-CANCER; CELL-CYCLE; DNA-REPAIR; GENE-EXPRESSION; CDK-INHIBITOR; PROTEIN; ACTIVATION; PROMOTER; ARREST	The p27(Kip1) is a member of the universal cyclin-dependent kinase inhibitor family. Previously, immunochemical analysis of a series of breast cancer cell lines demonstrated a correlation between the expression of P27(Kip1) and the breast cancer susceptibility gene BRCA1. BRCA1 has a number of activities including DNA repair, growth inhibition and as a transcription factor. Here we demonstrate that BRCA1 transactivates expression of p27(Kip1). This transactivation is dependent on the presence of a functional C-terminal transactivation domain. Promoter-deletion analysis identified the presence of a putative BRCA1-responsive element located at position -615 to -511 of the p27(Kip1) promoter. These results suggest that the transcriptional regulation of p27(Kip1) by BRCA1 may be a mechanism for BRCA1- induced growth inhibition.	Univ Calif Los Angeles, Sch Med, Dept Med, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Anat Pathol, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Williamson, EA (corresponding author), Cedars Sinai Med Ctr, Dept Med Hematol Oncol, Davis Res Bldg,Room 5016,8700 Beverly Blvd, Los Angeles, CA 90048 USA.							Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Ciaparrone M, 1998, CANCER RES, V58, P114; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELSTNER E, 2002, IN PRESS BREAST CANC; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; HALLIGAN BD, 1995, GENE, V161, P217, DOI 10.1016/0378-1119(95)00299-L; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Katayose Y, 1997, CANCER RES, V57, P5441; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Masciullo V, 1999, CANCER RES, V59, P3790; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spirin KS, 1996, CANCER RES, V56, P2400; StCroix B, 1996, NAT MED, V2, P1204; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3199	3206		10.1038/sj.onc.1205461	http://dx.doi.org/10.1038/sj.onc.1205461			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082635				2022-12-28	WOS:000175373600011
J	Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD				Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD			BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor	ONCOGENE			English	Article						BCR-ABL; c-kit; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; TRANSGENIC MICE; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CD34(+) CELLS; KIT-LIGAND; LINE	Chronic myeloid leukaemia (CML), a hematopoietic stem cell disorder is characterized by the expression of BCR-ABL. To investigate the effects of BCR-ABL on multipotent hematopoietic cells, a temperature sensitive BCR-ABL tyrosine kinase was expressed in the cell line, FDCP-Mix. BCR-ABL mediated an increase in c-kit expression that correlated with an enhanced mitogenic response to SCF. This was not observed in the absence of Ber-Abl kinase activity or presence of the BCR-ABL inhibitor STI571, which also inhibits c-kit. When cultured in a combination of SCF plus G-CSF the FDCP-Mix cells undergo neutrophilic differentiation over a 7-10 day period. When BCR-ABL was active there was a marked inhibition of cell maturation compared to control cells in which BCR-ABL was either inactive or not present. However, BCR-ABL did not block differentiation as the cells eventually undergo terminal maturation. These data argue that BCR-ABL is directly responsible for the enhanced response to SCF reported in CML progenitor cells. Furthermore, although the primary effect of STI571 is via direct inhibition of BCR-ABL, STI571 additionally reduces the enhanced response to SCF. Thus there are two sites of STI571 action of potential importance in Bcr-Abl expressing cells.	Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England	University of Manchester	Whetton, AD (corresponding author), Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.	Tony.Whetton@Umist.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878; Pierce, Andrew/0000-0001-5995-2469				AGARWAL R, 1995, BLOOD, V85, P1306, DOI 10.1182/blood.V85.5.1306.bloodjournal8551306; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Eaves A C, 1998, Stem Cells, V16 Suppl 1, P77; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Moore S, 1998, BLOOD, V92, P2461, DOI 10.1182/blood.V92.7.2461.2461_2461_2470; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 2000, ONCOGENE, V19, P5487, DOI 10.1038/sj.onc.1203940; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; Wisniewski D, 1996, LEUKEMIA, V10, P229	32	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3068	3075		10.1038/sj.onc.1205424	http://dx.doi.org/10.1038/sj.onc.1205424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082538				2022-12-28	WOS:000175262700015
J	Hamad, NM; Banik, SSR; Counter, CM				Hamad, NM; Banik, SSR; Counter, CM			Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells	ONCOGENE			English	Article						telomerase; hTERT; immortalization; transformation; tumourigenesis	HUMAN EPITHELIAL-CELLS; MALIGNANT HEMATOPOIETIC-CELLS; CATALYTIC SUBUNIT GENE; LIFE-SPAN; IMMORTAL CELLS; TUMOR-CELLS; CARCINOMA; CANCER; MAINTENANCE; PATTERNS	A hallmark of cancer cells is the ability to proliferate indefinitely. This acquisition of an immortal lifespan usually requires the activation of telomerase, the enzyme that elongates telomeres. Human telomerase is minimally composed of the reverse transcriptase subunit hTERT, and the RNA subunit hTR. While hTR is ubiquitously expressed in human cells, the hTERT subunit is generally transcriptionally repressed in most normal somatic cells, but is illegitimately activated to restore telomerase activity in cancer cells. Indeed, in the thousands of different human tumours assayed, 85% were scored positive for telomerase activity. However, the levels of telomerase activity detected in tumour samples can vary substantially and even some normal somatic cells have been found to have low levels of enzyme activity. As the functional significance of low levels of telomerase activity is unclear, we investigated whether there is a minimum level of telomerase activity required for tumourigenesis. Using mutants of hTERT that induce varying levels of telomerase activity, we show that there does indeed exist a threshold of activity required for the processes of immortalization, transformation and tumourigenesis. Thus, low levels of activity detected in certain somatic cells would not be expected to contribute to tumourigenesis, nor does the mere detection of telomerase in cancer cells necessarily signify an immortal lifespan.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481, R01CA094184] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481, CA94184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BANIK SSR, 2002, IN PRESS MOL CELL BI; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Norrback KF, 1996, BLOOD, V88, P222; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Rich JN, 2001, CANCER RES, V61, P3556; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stewart GS, 2001, J MEMBRANE BIOL, V180, P49, DOI 10.1007/s002320010058; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Yasumoto S, 1996, ONCOGENE, V13, P433; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	36	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7121	7125		10.1038/sj.onc.1205860	http://dx.doi.org/10.1038/sj.onc.1205860			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370834				2022-12-28	WOS:000178424900015
J	Chen, C; Bhalala, HV; Qiao, H; Dong, JT				Chen, C; Bhalala, HV; Qiao, H; Dong, JT			A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer	ONCOGENE			English	Article						chromosome 13; 13q21; KLF5; hemizygous deletion; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN NEOPLASMS; FACTOR FAMILY; GENE; 13Q21; PROGRESSION; DELETION	The 13q21 tumor suppressor locus, as defined by chromosomal deletion, harbors the KLF5 transcription factor which may have tumor suppressor function. To investigate whether KLF5 plays a role in breast cancer, we evaluated all genes and/or expressed sequence tags (ESTs) within a 3.3 Mb common region of deletion at 13q21. Of these, only KLF5 mRNA was expressed at high levels in non-neoplastic breast epithelial cells and in normal human mammary tissue, but at lower levels in various breast cancer cell tines. Using the real time TaqMan PCR assay, hemizygous deletion at KLF5 was detected in 13 out of 30, or 43% of breast cancer cell lines tested, and various degrees of loss of expression were detected in 21 out of 30, or 70% of these cell lines. Each of the cases with hemizygous deletion also exhibited loss of KLF5 expression, suggesting that loss of expression can result from chromosomal deletion, and that KLF5 may undergo haploinsufficiency during carcinogenesis. Only one of the 30 breast cancer cell lines tested exhibited a mutation in KLF5, and neither promoter methylation nor homozygous deletion was detected in any of the cell lines. In contrast, loss of heterozygosity (LOH) was frequently detected at KLF5. Re-expression of wild-type KLF5 in T-47D breast cancer cells significantly inhibited colony formation in these cells. Of the KLF5-transfected clones that did form colonies, none were found to express KLF5 mRNA. These findings suggest that loss of function by deletion and/or loss of expression frequently occurs at KLF5, and KLF5 suppresses tumor cell growth in breast cancer.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365-B Clifton Rd,Suite B4100, Atlanta, GA 30322 USA.			Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA87921, CA85560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085560, R01CA087921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong JT, 2000, CANCER RES, V60, P3880; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Roylance R, 1999, CANCER RES, V59, P1433; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Tirkkonen M, 1997, CANCER RES, V57, P1222; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8	18	124	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6567	6572		10.1038/sj.onc.1205817	http://dx.doi.org/10.1038/sj.onc.1205817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242654				2022-12-28	WOS:000178202300002
J	Okuda, M				Okuda, M			The role of nucleophosmin in centrosome duplication	ONCOGENE			English	Review						nucleophosmin; B23; centrosome; CDK2; cyclin E; duplication	NUCLEOLAR PROTEIN B23; TRANSCRIPTION FACTOR IRF-1; LEUKEMIA HL-60 CELLS; CYCLIN-A; LOCALIZATION SIGNALS; DOWN-REGULATION; KINASE; IDENTIFICATION; NUCLEAR; FUSION	In higher animal cells, duplication of centrosomes is triggered by CDK2/cyclin E-mediated phosphorylation. Nucleophosmin (NPM)/B23, a multifunctional protein, has recently been identified as one of the substrates of CDK2/cyclin E in centrosome duplication. Centrosome-bound NPM/B23 dissociates from centrosome upon phosphorylation by CDK2/cyclin E, which in turn triggers initiation of centriole duplication. Duplicated centrosomes remain free of NPM/B23 till mitosis. When the nuclear membrane breaks down during mitosis, NPM/B23 relocalizes to centrosomes. Upon cytokinesis, each daughter cell receives one centrosome bound by NPM/B23, which again dissociates from the centrosome upon exposure to CDK2/cyclin E at mid-late G1 phase of the next cell cycle. Thus, NPM/B23 would constitute one of the licensing systems for centrosome duplication, ensuring the coordination of centrosome and DNA duplication, which limiting duplication once per cell cycle.	Yamaguchi Univ, Fac Agr, Lab Vet Internal Med, Yamaguchi 7538515, Japan	Yamaguchi University	Okuda, M (corresponding author), Yamaguchi Univ, Fac Agr, Lab Vet Internal Med, Yoshida 1677-1, Yamaguchi 7538515, Japan.			Okuda, Masaru/0000-0003-4690-8244				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; KOFF A, 1992, ONCOGENE, V15, P1275; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nigg E A, 1988, Int Rev Cytol, V110, P27; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDRE DD, 1989, CENTROSOME CYCLE ANI, P39; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	55	143	157	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6170	6174		10.1038/sj.onc.1205708	http://dx.doi.org/10.1038/sj.onc.1205708			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214246				2022-12-28	WOS:000177840500005
J	Janz, C; Wiesmuller, L				Janz, C; Wiesmuller, L			Wild-type p53 inhibits replication-associated homologous recombination	ONCOGENE			English	Article						aphidicolin; DNA synthesis; gene conversion; SV40 chromosomes; tumor suppressor	SIMIAN-VIRUS 40; DNA-REPLICATION; MAMMALIAN-CELLS; IN-VITRO; MIMOSINE; PROTEIN; REPAIR; PHOSPHORYLATION; DISSOCIATION; CHECKPOINT	In mammalian cells homologous recombination is stimulated, when the replication fork stalls at DNA breaks or unrepaired lesions. The tumor suppressor p53 downregulates homologous recombination independently of its transcriptional transactivation function and has been linked to enzymes of DNA recombination and replication. To study recombination with respect to replication, we utilized a SV40 virus based assay, to follow the synchronous events after primate cell infection. gamma-ray treatment at different times after viral entry unveiled an increase of interchromosomal exchange frequencies, when the damage was introduced during DNA synthesis. Elevated recombination frequencies were fully suppressed by p53. With respect to the downregulation of spontaneous recombination, we noticed a requirement for active p53 molecules, when replication started. After a transient treatment with replication inhibitors, we observed inhibition of the drug induced recombination by p53, particularly for the elongation inhibitor aphidicolin. Consequently, we propose that p53 is a surveillance factor of homologous recombination at replication forks, when they stall as a consequence of endogenous or of exogenously introduced damage.	Univ Frauenklin & Poliklin, D-89075 Ulm, Germany; Heinrich Pette Inst, Hamburg, Germany	Ulm University; Heinrich Pette Institute	Wiesmuller, L (corresponding author), Univ Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							AKYUZ N, 2002, IN PRESS MOL CELL BI; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fernandez JL, 2001, EXP CELL RES, V270, P102, DOI 10.1006/excr.2001.5328; Gersten KM, 1997, NAT GENET, V17, P378, DOI 10.1038/ng1297-378; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SARASIN AR, 1978, P NATL ACAD SCI USA, V75, P346, DOI 10.1073/pnas.75.1.346; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tooze J, 1980, DNA TUMOR VIRUSES; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	43	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5929	5933		10.1038/sj.onc.1205757	http://dx.doi.org/10.1038/sj.onc.1205757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185593				2022-12-28	WOS:000177520900013
J	Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW				Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW			Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1	ONCOGENE			English	Article						prostate cancer; androgen receptor; ErbB receptors; Ebp1	DIFFERENTIATION FACTOR HEREGULIN; LIGAND-INDEPENDENT ACTIVATION; PROSTATE-CANCER CELLS; GROWTH-FACTORS; CYCLIN D1; EXPRESSION; MECHANISM; C-ERBB-2; COMPLEX; BENIGN	Members of the ErbB family of receptors have been implicated in regulation of androgen receptor (AR) activity. Ebp1, an ErbB-3 binding protein recently cloned in our laboratory, possesses an LXXLL motif important in mediating interactions with nuclear hormone receptors. Therefore, we sought to determine if Ebp1 could bind AR and influence AR transcriptional activation potential. We demonstrate in this study that Ebp1 bound to AR in vitro and in vivo, and that this binding was increased by androgen treatment. The C terminal 79 amino acids of Ebp1 were sufficient to bind AR. The N terminal domain of AR was responsible for binding Ebp1. Ligand-mediated transcriptional activation of both artificial and natural AR regulated promoters was inhibited by ectopic expression of ebp1 in transient transfection systems. Ebp1 deletion mutants that either lacked the C terminal AR binding region or had a mutated LXXLL motif failed to inhibit AR activated transcription. PSA expression from its endogenous promoter was also decreased in LNCaP prostate cancer cells overexpressing Ebp1. The growth of AR positive LNCaP cells was inhibited by ectopic expression of ebp1, but mutants that failed to repress transcription did not inhibit cell growth. These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School	Hamburger, AW (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	ahamburg@umaryland.edu	Wang, Qianben/E-4267-2011		NATIONAL CANCER INSTITUTE [R01CA076047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76047] Funding Source: Medline; PHS HHS [R21 088882-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; Barton J, 2001, UROLOGY, V58, P114, DOI 10.1016/S0090-4295(01)01253-5; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jenster G, 2000, J PATHOL, V191, P227; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Knudsen KE, 1999, CANCER RES, V59, P2297; Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Morote J, 1999, INT J CANCER, V84, P421, DOI 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Slagsvold T, 2001, J BIOL CHEM, V276, P31030, DOI 10.1074/jbc.M104310200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; Wen Y, 2000, CANCER RES, V60, P6841; Whitfield GK, 1999, J CELL BIOCHEM, P110; WILSON EM, 1991, ANN NY ACAD SCI, V637, P56, DOI 10.1111/j.1749-6632.1991.tb27300.x; XIA X, 2001, J CELL PHYSL, V187, P809; Xia XM, 1999, BIOCHEM J, V341, P831, DOI 10.1042/0264-6021:3410831; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; YEH S, 1999, NAT MED, V5, P280; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874	46	63	74	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5609	5618		10.1038/sj.onc.1205638	http://dx.doi.org/10.1038/sj.onc.1205638			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165860				2022-12-28	WOS:000177442000011
J	Takakuwa, T; Dong, ZM; Nakatsuka, S; Kojka, S; Harabuchi, Y; Yang, WI; Nagata, S; Aozasa, K				Takakuwa, T; Dong, ZM; Nakatsuka, S; Kojka, S; Harabuchi, Y; Yang, WI; Nagata, S; Aozasa, K			Frequent mutations of Fas gene in nasal NK/T cell lymphoma	ONCOGENE			English	Article						nasal NK/T cell lymphoma.; Fas; apoptosis; mutation	LETHAL MIDLINE GRANULOMA; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; HELICOBACTER-PYLORI; GASTRIC LYMPHOMA; APO-1/CD95 GENE; LUNG-CANCER; KILLER-CELL; ANTIGEN	Fas (Apo-1/CD95) is a cell-surface, receptor involved in cell death signaling through binding of Fas ligand. Mutation of Fas gene in lymphoid cells results in accumulation of these cells, which might thus contribute to lymphomagenesis. We examined the open reading frame of Fas cDNA in 14 cases of nasal NK/T-cell lymphoma. Mutations of Fas gene were detected in seven (50%) of 14 cases which comprised four frameshift, two missense, and one silent mutations. Frameshift mutations were caused by insertion of 1 bp () at nucleotide 1095 in two cases and by deletion of 1 bp at nucleotide 597 and at 704, respectively, in one each. Mouse T-cell lymphoma cells transfected with two missense mutated genes and frameshift mutations caused by insertion of I bp (A) at nucleotide 1095 were resistant to apoptosis induced by the anti-Fas antibody. These findings suggested that accumulation of lymphoid cells with Fas mutations provides a basis for the development of nasal NK/T-cell lymphoma.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Univ Ryukyus, Dept Otorhinolaryngol, Fac Med, Okinawa 9030215, Japan; Asahikawa Med Coll, Dept Otorhinolaryngol, Asahikawa, Hokkaido 0788510, Japan; Osaka Univ, Dept Genet, Grad Sch Med, Osaka 5650871, Japan; Yonsei Univ, Dept Pathol, Coll Med, Seoul 120749, South Korea	Osaka University; University of the Ryukyus; Asahikawa Medical College; Osaka University; Yonsei University; Yonsei University Health System	Aozasa, K (corresponding author), Osaka Univ, Sch Med, Dept Pathol C3, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.		Nakatsuka, Shin-ichi/AAW-5968-2020; Nagata, Shigekazu/AAG-3203-2019	Nakatsuka, Shin-ichi/0000-0002-0055-8149; Nagata, Shigekazu/0000-0001-9758-8426				AOZASA K, 1992, INT J CANCER, V52, P673, DOI 10.1002/ijc.2910520429; Bertoni F, 2000, LEUKEMIA, V14, P446, DOI 10.1038/sj.leu.2401708; Boldrini L, 2001, ONCOGENE, V20, P6632, DOI 10.1038/sj.onc.1204727; ENNO A, 1995, AM J PATHOL, V147, P217; Gronbaek K, 1998, BLOOD, V92, P3018; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HOLM LE, 1985, NEW ENGL J MED, V312, P601, DOI 10.1056/NEJM198503073121001; Hongyo T, 2000, CANCER RES, V60, P2345; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jaffe ES, 1996, AM J SURG PATHOL, V20, P103, DOI 10.1097/00000478-199601000-00012; KATO I, 1985, JPN J CANCER RES, V76, P1085; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; Li T, 2000, LAB INVEST, V80, P493, DOI 10.1038/labinvest.3780055; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muschen M, 2000, CANCER RES, V60, P5640; Ng CS, 1999, HUM PATHOL, V30, P48, DOI 10.1016/S0046-8177(99)90299-X; Ohsawa M, 1999, INT J CANCER, V81, P865, DOI 10.1002/(SICI)1097-0215(19990611)81:6<865::AID-IJC5>3.0.CO;2-S; Park WS, 2001, J PATHOL, V193, P162; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Seeberger H, 2001, LAB INVEST, V81, P977, DOI 10.1038/labinvest.3780310; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takakuwa T, 2001, CANCER RES, V61, P1382; WEISS LM, 1992, BLOOD, V79, P1789; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	31	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4702	4705		10.1038/sj.onc.1205571	http://dx.doi.org/10.1038/sj.onc.1205571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096347				2022-12-28	WOS:000176625100012
J	Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS				Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS			Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines	ONCOGENE			English	Article						XK469; apoptosis; caspases; DN-caspase 9; Bcl2; Bax	CYTOCHROME-C RELEASE; P53-DEPENDENT APOPTOSIS; BCL-2 PROTEIN; MITOCHONDRIA; BAX; CLEAVAGE; DEATH; CASPASE; FAMILY; CHEMOSENSITIVITY	XK469, a synthetic quinoxaline phenoxypropionic acid derivative, has been found to have selective activity against a broad panel of solid tumors including several drug-resistant cell lines and has been approved for phase I clinical evaluation. Recent studies suggested that XK469 is a selective topoisomerase IIbeta inhibitor, but the mechanism of XK469-induced cell death remains unknown. Here we investigate the ability of XK469 to induce apoptosis of human cancer cells. In the human ovarian cancer cell line PA1, XK469 caused the release of cytochrome e, activation of caspases including caspases 9, 7 and 3, cleavage of PARP, and subsequently cell death. Moreover, 1362 and Bax were cleaved in XK469 treated cells. PA1 cells expressing the dominant negative-caspase 9 were less sensitive to XK469. Importantly, in these PA1 cells expressing DN-casp 9, the activation of caspases including caspases 3, 7 and 9, and cleavage of Bax and Bcl2 were inhibited, suggesting that the activation of the mitochondrial pathway is required for XK469-induced anticancer activity. These results indicate that the induction of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for the activation of the mitochondrial pathway. Thus, our study defines a possible mechanism, at least in part, underlying XK469-induced anti-cancer activity.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Immunol Microbiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Obstet & Gynecol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.	wug@karmanos.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Blagosklonny MV, 1999, LEUKEMIA, V13, P1028, DOI 10.1038/sj.leu.2401449; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Corbett TH, 1998, INVEST NEW DRUG, V16, P129, DOI 10.1023/A:1006174622061; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding ZH, 2001, CLIN CANCER RES, V7, P3336; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao HL, 1999, P NATL ACAD SCI USA, V96, P12168, DOI 10.1073/pnas.96.21.12168; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LoRusso PM, 1999, INVEST NEW DRUG, V16, P287; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Snapka RM, 2001, BIOCHEM BIOPH RES CO, V280, P1155, DOI 10.1006/bbrc.2001.4249; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	35	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4530	4538		10.1038/sj.onc.1205545	http://dx.doi.org/10.1038/sj.onc.1205545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085231				2022-12-28	WOS:000176476700007
J	Fagard, R; Mouas, H; Dusanter-Fourt, I; Devillers, C; Bissieres, P; Martin, A; Lenoir, G; Van Tan, H; Feuillard, J; Raphael, M				Fagard, R; Mouas, H; Dusanter-Fourt, I; Devillers, C; Bissieres, P; Martin, A; Lenoir, G; Van Tan, H; Feuillard, J; Raphael, M			Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells	ONCOGENE			English	Article						EBV; apoptosis; Burkitt cell line; fludarabine; STAT-1	CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR SUPPRESSION; CANCER-THERAPY; STAT PROTEINS; P53; INDUCTION; BCL-2; DEATH; LYMPHOMA; MDM2	The Epstein-Barr virus (EBV) transforms B cells in part by inhibiting the cellular apoptotic programme. This is also observed when Burkitt lymphoma cell lines are infected with EBV. Induction of apoptosis is one of the mechanisms by which fludarabine inhibits the growth of cells with low proliferative capacity. This compound can also inhibit several other mechanisms in the cell, including inhibition of the synthesis of factors such as STAT1. To analyse the relationship between EBV status, fludarabine-induced apoptosis, and transcription factors we studied the EBV-negative Burkitt lymphoma cell line BL2, its EBV-infected counterpart BL2.B95.8 and the EBV-transformed cell line PRI. The BL2 cell line was found to be very sensitive to fludarabine. The BL2.B95.8 and PRI cells were both resistant but the latter to a lesser extent. In the PRI cells fludarabine activated p53, but not in the BL2.B95.8 cells in which the p53 pathway is inactivated. We observed that this inactivation results in part from the lack of expression of the MDM2 inhibitor p14ARF. Conversely, there was a substantial constitutive activation of STAT1, and not of the other STATs, in the BL2.B95.8 cells and a modest one in the PRI cells. Furthermore, expression of STAT1 was significantly reduced by fludarabine treatment in the PRI cells, but not in the BL2.BL95.8 cells. Finally, the expression of p21WAFI/CIP1 was detected only in the BL2.B95.8 and PRI cells. This protein, known to play a role in cell survival, may therefore be involved in the resistance of the BL2.B95.8 cells to fludarabine.	Univ Paris 13, EA 3406, ATHSCO, UFR SMBH, Bobigny, France; Hop Avicenne, APHP, Serv Biochem, F-93009 Bobigny, France; Hop Avicenne, APHP, Serv Hematol Biol, F-93009 Bobigny, France; Hop Avicenne, APHP, Serv Anat Pathol, F-93009 Bobigny, France; INSERM, ICGM, U363, F-75014 Paris, France; Inst Gustave Roussy, Villejuif, France	Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Gustave Roussy	Fagard, R (corresponding author), Univ Paris 13, EA 3406, ATHSCO, UFR SMBH, Bobigny, France.		Dusanter-Fourt, Isabelle/P-4558-2017; Feuillard, Jean/O-8587-2016	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Feuillard, Jean/0000-0001-6223-2454				Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Petersen AJ, 1996, EUR J HAEMATOL, V56, P213; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; ROSS SR, 1993, DRUGS, V45, P737, DOI 10.2165/00003495-199345050-00009; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thomas A, 1996, ONCOGENE, V12, P1055; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; WeberNordt RM, 1996, BLOOD, V88, P809; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0	34	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4473	4480		10.1038/sj.onc.1205554	http://dx.doi.org/10.1038/sj.onc.1205554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085225				2022-12-28	WOS:000176476700001
J	Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH				Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH			STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells	ONCOGENE			English	Article						transcription factor; STAT3; transformation response; matrix metalloproteinase; mouse skin cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; TRANSCRIPTION FACTORS; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; TRANSGENIC MICE; PROTEIN-KINASE; AP-1	STAT3, a member of signal transducers and activators of transcription (STATs) originally discovered as mediators in cytokine signaling pathways, plays an active role in oncogenesis. However, the function of STAT3 in signaling multistage carcinogenesis, especially in transformation of tumor-promotion sensitive epithelial cells has not been elucidated. The present study demonstrates that STAT3 is activated in interleukin-6 induced transformation in mouse skin epithelial cells. DNA binding and transcriptional activities of STAT3 were significantly increased by interleukin-6. This induced anchorage-independent transformation in tumor-promotion sensitive JB6 mouse skin P+ cells but not in the resistant variant P- cells. Two forms of dominant negative STAT3 (mutant of transcriptional domain, mF, or DNA-binding domain, mD) were stably transfected into P+ cells. Activation of STAT3 was abolished and importantly, interleukin-6 induced anchorage-independent growth was absent in both mutant STAT3 transfectants. To determine the genes targeted by STAT3, three matrix metalloproteinase proteins linked with carcinogenesis of epithelial cells were analysed. Both basal and interleukin-6 induced expression of collagenase I and stromelysin I, but not gelatinase A, were inhibited in the mutant STAT3 transfectants. Furthermore, transfection of a wild type STAT3 restored STAT3 transactivation and response to interleukin-6 induced transformation in mutant STAT3 transfectants, which up-regulated collagenase I and stromelysin I as well. Together, these results provide the first evidence that STAT3 activation is required in the progression of multistage carcinogenesis of mouse skin epithelial cells, and matrix metalloproteinases are actively involved in STAT3-mediated cell transformation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; NCI, Cytokine Mol Mech Sect, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; NCI, Lab Basic Res, NIH, Frederick, MD 21702 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44106 USA	City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cleveland Clinic Foundation	Li, JH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Halper S Bldg,H115,1500 Duarte Rd, Duarte, CA 91010 USA.			Li, Jian Jian/0000-0003-3694-9675; Yu, Cheng-Rong/0000-0001-7246-0362				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; BENEDETTI FD, 1990, MOL CELL BIOL CYTOKI, V1, P275; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin JB, 2000, CANCER RES, V60, P3971; Dokter WHA, 1996, LEUKEMIA, V10, P1308; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang CS, 1996, MOL CELL BIOL, V16, P6427; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAWANO M, 1989, CANCER SURV, V8, P905; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SIU X, 1999, BLOOD, V93, P2525; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Takeda K, 1998, J IMMUNOL, V161, P4652; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu CR, 1998, J LEUKOCYTE BIOL, V64, P245, DOI 10.1002/jlb.64.2.245; Yu CR, 1996, J IMMUNOL, V157, P126; Yu CR, 1999, J IMMUNOL, V162, P2785; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3949	3960		10.1038/sj.onc.1205499	http://dx.doi.org/10.1038/sj.onc.1205499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037677				2022-12-28	WOS:000175869900001
J	Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y				Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y			Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells	ONCOGENE			English	Article						INI1/SNF5; SWI/SNF complex; tumor suppressor; G1 arrest; apoptosis	SWI-SNF COMPLEX; MALIGNANT RHABDOID TUMOR; SINGLE-CHAIN ANTIBODY; SWI/SNF COMPLEX; VIRAL INTEGRASE; TRANSCRIPTION; MUTATIONS; PROTEINS; LINES; GENE	Ini1/hsnf5 gene encodes INI1 protein, a chromatin remodeling factor associated with the SWI/SNF complex. In yeast, this complex modifies chromatin condensation to coactivate various transcriptional factors. However, in human, little is known about the SWI/SNF complex and INI1. To elucidate cellular functions of ini1, we constructed a recombinant adenovirus (AdexHA-INI1) capable of overexpressing INI1 in ini1-deficient cells. AdexHA-INI1 produced intranuclear INI1 in three ini1-deficient cell lines, changed their morphology, and decreased the proportion of viable cells. Flow cytometry and a BrdU incorporation assay showed that after the infection, growth of these cells was partially arrested at G1. In two of the three ini1-deficient cell lines, apoptosis was found to occur after the infection, as detected by the presence of cleaved poly (ADP-ribose) polymerase. To determine functional domains of INI1, we constructed plasmids expressing INI1 and its deletion mutants, which were used for a colony formation assay. Repeats I and 2 of INI1 were found to be required to suppress the growth of the three ini1-deficient cell lines. The results support the hypothesis that ini1 is a tumor suppressor gene and suggest a novel link between human SWI/SNF chromatin remodeling complex and apoptosis.	Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, Tokyo 1038639, Japan; Natl Inst Infect Dis, Div Mol Genet, Tokyo 2080011, Japan; Tokyo Med & Dent Univ, Sect Orthoped Spinal Surg, Dept Frontier Surg Therapeut, Div Adv Therapeut Sci,Grad Sch, Tokyo 1138519, Japan; Japanese Fdn Canc Res, Dept Orthoped Oncol, Canc Inst Hosp, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Kitamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, 4-6-1 Shirokanedai, Tokyo 1038639, Japan.							Biegel JA, 1999, CANCER RES, V59, P74; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brand A, 2001, GYNECOL ONCOL, V80, P99, DOI 10.1006/gyno.2000.6032; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GRAHAM FL, 1977, J GEN VIROL, V36, P9; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kitamura Y, 1999, J ACQ IMMUN DEF SYND, V20, P105, DOI 10.1097/00042560-199902010-00001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Okui N, 1998, J VIROL, V72, P6960, DOI 10.1128/JVI.72.8.6960-6964.1998; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SEKIGUCHI M, 1985, BIOMED PHARMACOTHER, V39, P372; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; Wong AKC, 2000, CANCER RES, V60, P6171; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000	32	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3112	3120		10.1038/sj.onc.1205414	http://dx.doi.org/10.1038/sj.onc.1205414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082626				2022-12-28	WOS:000175373600002
J	Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT				Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT			Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis	ONCOGENE			English	Article						p14(ARF); p53; Bax; mitochondria; apoptosis	DRUG-INDUCED APOPTOSIS; P19(ARF) TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; HUMAN ARF PROTEIN; BREAST-CANCER; CYTOCHROME-C; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; METASTATIC MELANOMA; BCL-2 PROTEIN	The human INK4a gene locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF), which are frequently inactivated in human cancer. Whereas p16(INK4a) acts through engagement of the Rb-cdk4/6-cyclin D pathway, both the pro-apoptotic and cell cycle-regulatory functions of p14(ARF) were shown to be primarily dependent on the presence of functional p53. Recent reports have also implicated p14(ARF) in p53-independent mechanisms of cell cycle regulation and apoptosis induction, respectively. To further explore the pro-apoptotic function of p14(ARF) in relation to functional cellular p53, we constructed a replication-deficient adenoviral vector for overexpression of p14(ARF) (Ad-p14(ARF)). As expected, Ad-p14(ARF) efficiently induced apoptosis in p53/Rb wild-type U-2OS osteosarcoma cells at low multiplicities of infection. Interestingly, Ad-p14(ARF) also induced apoptosis in both p53-deleted SAOS-2 osteosarcoma cells and HCT116 colon cancer cells with a bi-allelic knock-out of p53 (HCT116-p53(-/-)). Similarly, adenovirus-mediated overexpression of p14(ARF) induced apoptosis in p53/Bax-mutated DU145 prostate cancer cells as well as in HCT116 cells devoid of functional Bax (HCT116-Bax(-/-)). Restoration of Bax expression by retroviral gene transfer in DU145 cells did not further enhance p14(ARF)-triggered cell death. Infection with Ad-p14(ARF) induced activation of mitochondrial permeability shift transition, caspase activation and apoptotic DNA fragmentation irrespective of the presence or absence of either Bax or functional cellular p53. Nevertheless, overexpression of the anti-apoptotic Bcl-2 homolog Bcl-x(L) markedly inhibited p14(ARF)-induced apoptosis. This may indicate that p14(ARF) triggers a so far unknown activator of mitochondrial apoptosis which can be inhibited by Bcl-2 but which acts either independently or downstream of Bax. Taken together, this report demonstrates the participation of signaling pathways apart from the p53/Mdm-2 rheostat and Bax in p14(ARF)-mediated apoptosis.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, D-13125 Berlin, Germany; Charite, Dept Radiat Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BOSANQUET, 2002, IN PRESS LEUKEMIA, V16; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Groth A, 2000, J BIOL CHEM, V275, P27473; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Inoue R, 1999, ANTICANCER RES, V19, P2939; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Krajewska M, 1996, CANCER RES, V56, P2422; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2000, CANCER RES, V60, P3689; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	64	95	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3149	3161		10.1038/sj.onc.1205458	http://dx.doi.org/10.1038/sj.onc.1205458			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082630				2022-12-28	WOS:000175373600006
J	Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N				Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N			BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl	ONCOGENE			English	Article						Bcr/Abl P190; Crkl; Ph-positive; acute lymphoblastic leukemia; null mutant	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL TRANSFORMATION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; LEUKEMOGENESIS; CELLS; GENE; PROLIFERATION; PEPTIDES	The Bcr/Abl fusion protein directly causes chronic myelogenous leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Multiple independent studies have implicated Crkl, a small adapter protein, in transduction of oncogenic signals of Bcr/Abl and CrkI tyro sine-phosphorylation is used as a diagnostic tool for Philadelphia-positive leukemia. To evaluate the contribution of CrkI to this type of leukemia, we generated mutant mice that lack CrkI expression. We found that the overall survival of P190 BCR/ABL crkl-/- mice was comparable to that of genetically matched P190 BCR/ABL crkl +/+ mice. Both genotypes developed lymphoid lineage leukemia/lymphoma. Western blot analysis of -/- and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr-Abl P190. These data indicate that possible therapeutic approaches that target CrkI may be complicated by the presence of pathways that compensate for lack of CrkI function.	Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Dept Pathol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Heisterkamp, N (corresponding author), Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, MS 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Hemmeryckx, Bianca/AAR-2360-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NCI NIH HHS [CA 90321, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050248, R01CA090321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hemmeryckx B, 2001, CANCER RES, V61, P1398; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1992, CANCER RES, V52, P4534; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; VOSS J, 2001, SIGNAL TRANSDUCTION, V1, P1	36	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3225	3231		10.1038/sj.onc.1205452	http://dx.doi.org/10.1038/sj.onc.1205452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082638				2022-12-28	WOS:000175373600014
J	Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH				Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH			Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth	ONCOGENE			English	Article						AP-1; breast cancer; estrogen; peptide growth factor	DOMINANT-NEGATIVE MUTANT; C-JUN; ESTROGEN-RECEPTOR; RESISTANT PHENOTYPE; RETINOIC ACID; DNA-BINDING; CELL-GROWTH; FOS; ACTIVATION; TRANSFORMATION	AP-1 transcription factors play a critical role in signal transduction pathways in many cells. We have investigated the role of AP-1 in controlling proliferative signals in breast cells, and have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells. In this study, we investigated the role of AP-1 in transducing proliferative signals induced by peptide and steroid growth factors. We used MCF-7 clones that express a specific inhibitor of AP-1, a dominant-negative cJun mutant (TAM67), under the control of an inducible promoter to investigate the role of AP-1 in regulating breast cancer growth. In the presence of doxycycline (Dox), the AP-1 inhibitor was not expressed, and the MCF-7 clones proliferated normally in response to serum stimulation. However, when Dox was withdrawn, TAM67 was expressed, AP-1 activity was inhibited, and serum-induced proliferation was blocked. We next investigated whether the mitogenic response to specific growth factors also requires AP-1. MCF-7 Tet-Off-TAM67 cells were grown in the presence of increasing concentrations of IGF-1, EGF, heregulin-beta, bFGF, or estrogen under un-induced and induced conditions. These studies showed that the AP-1 inhibitor completely blocked proliferation in response to the peptide growth factors (IGF-1, EGF, heregulin-beta, and bFGF), and partially blocked the response to estrogen. To investigate the effect of AP-1 blockade on in vivo tumor growth, we injected the MCF-7 Tet-Off TAM67 cells into nude mice receiving doxycycline to suppress the expression of the AP-1 inhibitor. After the mice developed tumors, they were randomized to either continue to receive Dox or not. In mice not receiving Dox, the expression of TAM67 was induced, and tumor growth was inhibited, while the tumors in mice receiving Dox continued to grow. Analysis of the tumors from these mice showed that the expression of TAM67 caused reduced proliferation of the breast cancer cells without inducing apoptosis. These results demonstrate that AP-1 blockade supresses mitogenic signals from multiple different peptide growth factors as well as estrogen, and inhibits the growth of MCF-7 breast cancer cells both in vitro and in vivo. These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer.	Baylor Coll Med, Dept Med, Breast Ctr, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Dept Med, Breast Ctr, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NATIONAL CANCER INSTITUTE [P50CA058183] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DREBIN JA, 1988, ONCOGENE, V2, P387; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Liebermann DA, 1998, INT J ONCOL, V12, P685; Lin F, 2000, CANCER RES, V60, P3271; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; RAPP UR, 1994, ONCOGENE, V9, P3493; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yang LM, 1997, CANCER RES, V57, P4652	34	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7680	7689		10.1038/sj.onc.1205883	http://dx.doi.org/10.1038/sj.onc.1205883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400010				2022-12-28	WOS:000178756200007
J	Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM				Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM			ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth	ONCOGENE			English	Article						ATF3; p53; DNA damage; gene regulation	TRANSCRIPTION FACTOR; MOLECULAR-BIOLOGY; C-FOS; P53; GADD45; GENE; CYCLE; ACTIVATION; INHIBITOR; STRESS	Mammalian cells have a remarkable diverse repertoire of response to genotoxic stress that damage DNA. Cellular responses to DNA damaging agents will initially exhibit gene induction, which is regulated by complex mechanism(s) and probably involves multiple signaling pathways. In this paper, we demonstrate that induction of ATF3 protein, a member of the ATF/CREB family of transcription factors, by ionizing radiation (IR) requires normal cellular p53 function. In contrast, induction of ATF3 after UV radiation (UV) or Methyl methanesulphonate (MMS) is independent of p53 status. Induction of ATF3 by DNA damage is rapid, transient, and through a transcriptional mechanism. The ATF3 promoter is induced by UV and MMS, but not by IR. In addition, ATF3 promoter can be activated by MEKK1, an upstream activator of the ERK and JNK kinase pathway, but not induced following p53 expression. Those results indicate that regulation of ATF3 induction after DNA damage utilizes both the p53-dependent and independent pathways, and may also involve MAP kinase signaling pathways. Using the tetracycline-inducible system (tet-off), we have found that overexpression of ATF3 protein moderately suppresses cell growth. Interestingly, over-expression of ATF3 protein is able to slow down progression of cells from G1 to S phase, indicating that ATF3 protein might play a negative role in the control of cell cycle progression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; NCI, Lab Basic Sci, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.	qzhan+@pitt.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; mazzacurati, lucia/0000-0002-8336-8032				Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Holbrook N J, 1996, EXS, V77, P273; HOLLANDER MC, 1989, CANCER RES, V49, P1687; Ishiguro T, 2000, ONCOL RES, V12, P343, DOI 10.3727/096504001108747792; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kumari SR, 2000, CANCER INVEST, V18, P715, DOI 10.3109/07357900009012203; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; MIYASHITA T, 1995, CELL, V80, P293; Rajanbabu R, 1999, CRIT REV ONCOGENESIS, V10, P275; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Schmutte C, 1999, ANTICANCER RES, V19, P4665; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	50	151	159	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7488	7496		10.1038/sj.onc.1205896	http://dx.doi.org/10.1038/sj.onc.1205896			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386811				2022-12-28	WOS:000178618200004
J	Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N				Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N			P130 and its truncated form mediate p53-induced cell cycle arrest in Rb-/- Saos2 cells	ONCOGENE			English	Article						p53; cell cycle arrest; p130; p53 binding sequence; E2F	RETINOBLASTOMA GENE-PRODUCT; GROWTH SUPPRESSION; KINASE INHIBITOR; CARCINOMA CELLS; E2F PROTEINS; TUMOR-CELLS; G(1) ARREST; DNA-DAMAGE; P53 GENES; IN-VIVO	In the present study, we investigate the mechanism of how p53 induces growth arrest in Rb-defective Saos2 cells that express temperature-sensitive mutant p53 (ts p53). The activation of p53 at a permissive temperature (32.5degreesC) induces the cell cycle arrest at both the G1 and G2 stages. The induction of several p53-responsive genes as well as a small form of p130 (S-p130) was detected upon p53 activation. S-p130 retained the functions as a pocket protein and was dominant over p130 at the protein level after 36 h at 32.5degreesC. A canonical p53 binding site was identified in intron 4 of p130. Furthermore, a novel p53-inducible transcript containing a partial intron 4 sequence downstream of the p53 binding site and exon 5 of p 130 was detected by RT - PCR, suggesting S-p 130 is induced by p53 at transcriptional level. The results from gel shift assay and immunoprecipitation showed that S-p130 as well as p130 formed complexes with both E2F1 and E2F4 at a permissive temperature. Moreover, the transient expression of E1A (12S) and E2F1 effectively abrogated p53-induced cell cycle arrest. These results strongly suggested that p130 and its truncated form might substitute Rb in mediating p53-induced cell cycle arrest in Rb-/- Saos2 cells.	Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Craniofacial Embryol, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Tsuchida, N (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chan TA, 2000, GENE DEV, V14, P1584; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 1996, CANCER RES, V56, P2003; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1997, MOL CELL BIOL, V17, P38677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HERMEKING H, 1909, MOL CELL, V1, P3; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KATO J, 1993, GENE DEV, V7, P333; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Robles SJ, 1998, DNA CELL BIOL, V17, P9, DOI 10.1089/dna.1998.17.9; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stiegler P, 1998, CANCER RES, V58, P5049; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG NP, 1993, ONCOGENE, V8, P279; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yageta M, 1999, ONCOGENE, V18, P4767, DOI 10.1038/sj.onc.1203063; YAMATO K, 1995, ONCOGENE, V11, P1; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z	70	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7569	7579		10.1038/sj.onc.1205933	http://dx.doi.org/10.1038/sj.onc.1205933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386819				2022-12-28	WOS:000178618200012
J	Guo, Y; Stacey, DW; Hitomi, M				Guo, Y; Stacey, DW; Hitomi, M			Post-transcriptional regulation of cyclin D1 expression during G2 phase	ONCOGENE			English	Article						cell cycle; Ras; cyclin D1; in situ hybridization; single cell-based analysis; post-transcriptional regulation	INITIATION-FACTOR 4E; HISTONE MESSENGER-RNA; IN-SITU HYBRIDIZATION; CELL-CYCLE; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; NIH3T3 CELLS; RAS; PROGRESSION	During continuous proliferation, cyclin D1 protein is induced to high levels in a Ras-dependent manner as cells progress from S phase to G2 phase. To understand the mechanism of the Ras-dependent cyclin D1 induction, cyclin D1 mRNA levels were determined by quantitative image analysis following fluorescent in situ hybridization. Although a slight increase in mRNA expression levels was detected during the S/G2 transition, this increase could not explain the more robust induction of cyclin D1 protein levels. This suggested the involvement of post-transcriptional regulation as a mechanism of cyclin D1 protein induction. To directly test this hypothesis, the cyclin D1 transcription rate was determined by run-on assays. The transcription rate of cyclin D1 stayed steady during the synchronous transition from S the G2 phase. We further demonstrated that cyclin D1 protein levels could increase during G2 phase in the absence of new mRNA synthesis. alpha-Amanitin, a transcription inhibitor, did not suppress cyclin D1 protein elevation as the cells progressed from S to G2 phase, even though the inhibitor was able to completely block cyclin D1 protein induction during reentry into the cell cycle from quiescence. The half life of cyclin D1 protein was shortest during S phase indicating that a change in protein stability might play a role in post-translational induction of cyclin D1 in G2 phase. These data indicate a fundamental difference in the regulation of cyclin D1 production during continuous cell cycle progression and re-initiation of the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM 52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH S, 1993, J CELL SCI, V105, P113; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dirks RW, 1996, HISTOCHEM CELL BIOL, V106, P151; DIRKS RW, 1995, HISTOCHEM CELL BIOL, V104, P391, DOI 10.1007/BF01458133; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kotelnikov V, 1997, CLIN CANCER RES, V3, P669; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palakurthi SS, 2000, CANCER RES, V60, P2919; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Raap A K, 1997, Methods Mol Biol, V75, P367; Ramljak D, 2000, CARCINOGENESIS, V21, P1537, DOI 10.1093/carcin/21.8.1537; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shu JY, 1996, ONCOGENE, V13, P2421; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Srivastava R A, 1994, Methods Mol Biol, V31, P281; Stacey DW, 2000, MOL CELL BIOL, V20, P9127, DOI 10.1128/MCB.20.24.9127-9137.2000; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	57	51	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7545	7556		10.1038/sj.onc.1205907	http://dx.doi.org/10.1038/sj.onc.1205907			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386817				2022-12-28	WOS:000178618200010
J	Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ				Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ			Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells	ONCOGENE			English	Article						autocrine TGF beta; carcinoma cell; growth; apoptosis	RECEPTOR SUPPRESSES TUMORIGENICITY; COLON-CARCINOMA-CELLS; II GENE MUTATION; TUMOR-SUPPRESSOR; MICROSATELLITE INSTABILITY; C-MYC; EXPRESSION CLONING; EPITHELIAL-CELLS; MCF-7 CELLS; APOPTOSIS	Using a cell model system established by ectopic expression of a soluble TGFbeta type III receptor (sRIII) containing the whole extracellular domain of the type III receptor in human breast cancer MDA-MB-231 cells, we observed that the expression of sRIII antagonized TGFbeta activity and inhibited both anchorage-dependent and anchorage-independent cell growth. Further studies revealed that sRIII expression induced apoptosis both in vitro and in vivo. Treatment with TGFbeta neutralizing antibodies or a recombinant human sRIII also induced apoptosis in the MDA-MB-231 parental cells, suggesting that the increased apoptosis after sRIII expression was specifically due to antagonization of autocrine TGFbeta signaling. Western blotting showed that sRIII clones had a higher PTEN expression level than the control cells did. Treatment with TGFbeta(1) decreased PTEN and inhibited apoptosis in sRIII cells to a level similar to that in the control cells. sRIII clones also showed a lower level of phosphorylated-Akt than the control cells, consistent with the inhibitory activity of PTEN on Akt activation. Treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, also induced apoptosis in a dose dependent manner in the control cells. Our results suggest that autocrine TGFbeta signaling is necessary for the growth and survival of MDA-MB-231 cells.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.		, LuZhe/AAW-4095-2021		NCI NIH HHS [CA75253, CA79683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075253, R01CA079683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GORSCH SM, 1992, CANCER RES, V52, P6949; Grady WM, 1998, CANCER RES, V58, P3101; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1998, CANCER RES, V58, P5667; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki K, 2000, CANCER RES, V60, P1394; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1991, TRANSFORMING GROWTH, P419; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schutte M, 1996, CANCER RES, V56, P2527; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tomita S, 1999, BREAST CANCER RES TR, V53, P33, DOI 10.1023/A:1006167210269; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WALKER RA, 1995, J PATHOL, V177, P123, DOI 10.1002/path.1711770204; Wang D, 2000, CANCER RES, V60, P4507; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wilentz RE, 2000, CANCER RES, V60, P2002; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; ZAR JH, 1984, BIOSTAT ANAL, P122; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	66	63	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7514	7523		10.1038/sj.onc.1205966	http://dx.doi.org/10.1038/sj.onc.1205966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386814				2022-12-28	WOS:000178618200007
J	Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK				Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK			Functional analysis of cyclin D2 and p27(kip1) in cyclin D2 transgenic mouse mammary gland during development	ONCOGENE			English	Article						cyclin D2; transgenic mice; mammary gland development; cyclin D1 phosphorylation; p27(kip1)	G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; INCREASED EXPRESSION; BREAST CANCERS; CELL; D1; OVEREXPRESSION; ONCOGENE; GROWTH; MYC	Two mammary gland phenotypes were detected in pregnant MMTV-cyclin D2 transgenic mice; line D2-53 exhibited a lack of alveologenesis and failure to nurse, whereas line D2-58 featured a reduction in alveologenesis, but retained normal nursing behavior. In pregnant mammary glands, cyclin D2 protein levels were twofold (P<0.107) and 3.8-fold (P<0.0076) higher in line D258 and D2-53, respectively, compared to wild type. Concomitantly with the increase in cyclin D2 was a fivefold decrease in cyclin D1 hyper-phosphorylated isoform in mammary glands of pregnant cyclin D2-58 mice. Because cyclin D1 is a critical molecule in normal mammary lobuloalveolar development, these data suggest that overexpression of cyclin D2 may block mammary lobuloalveolar development through inhibition of cyclin D1 phosphorylation. During mammary gland development, p27(kip1) protein level oscillated in a similar profile in wild type and cyclin D2 transgenic mice, but was consistently higher in the cyclin D2 mice suggesting that P27(kip1) functions downstream of cyclin D2. The ratio of p27(kip1)-cdk4/p27(kip1)-cdk2 was 6.5-fold (P<0.0003) higher in cyclin D2 mammary glands compared to wild type in pregnant animals. This ratio reversed to 2.2-fold (P<0.005) higher in wild type compared to cyclin D2 mammary glands in involution suggesting that overexpression of cyclin D2 moderately induced apoptosis during pregnancy but accelerated involution. Collectively, the effects of cyclin D2 overexpression on mammary gland development during pregnancy and involution are attributed to two major factors, altered p27(kip1) protein level and inhibition of cyclin D1 phosphorylation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Said, TK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	tsaid@bcm.tmc.edu		Moraes, Ricardo/0000-0001-5455-092X	NATIONAL CANCER INSTITUTE [R01CA011944] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; JIANG W, 1993, ONCOGENE, V8, P3447; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUKAS J, 1995, ONCOGENE, V10, P2125; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOTPOKURA T, 1991, NATURE, V350, P512; MURRAY AW, 1992, NATURE, V349, P603; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; Oyama T, 1998, CANCER RES, V58, P2876; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ravanko K, 2000, CANCER RES, V60, P5244; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; Said TK, 1998, MOL CARCINOGEN, V22, P128; SAID TK, 1995, CARCINOGENESIS, V16, P2507, DOI 10.1093/carcin/16.10.2507; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Yasogawa Y, 1998, PATHOL INT, V48, P717, DOI 10.1111/j.1440-1827.1998.tb03972.x; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	44	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7214	7225		10.1038/sj.onc.1205895	http://dx.doi.org/10.1038/sj.onc.1205895			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370811				2022-12-28	WOS:000178504600009
J	Lee, KS; Hong, SH; Bae, SC				Lee, KS; Hong, SH; Bae, SC			Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein	ONCOGENE			English	Article						Runx2; junB; p38; TGF-beta 1; BMP-2; osteoblast	OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; C2C12 MYOBLASTS; DNA-BINDING; CBFA1; CELLS; OSF2/CBFA1; ACTIVATION	The Runx family of transcription factors plays pivotal roles during normal development and in neoptasias. In mammals, Runx family genes are composed of Runx1 (Pehp2alphaB/Chfa2/Aml1), Runx2 (Pebp2alphaA/Cbfa1/Aml3) and Runx3 (Pehp2alphaC/Cbfa3/Aml2). Runx1 and Runx3 are known to be involved in leukemogenesis and gastric carcinogenesis, respectively. Runx2, on the other hand, is a common target of transforming growth factor-beta1 (TGF-beta1) and bone morphogenetic protein-2 (BMP-2) and plays an essential role in osteoblast differentiation. Runx2 is induced by the receptor-activated Smad; Runx2 mediates the blockage of myogenic differentiation and induces osteoblast differentiation in C2C12 pluripotent mesenchymal precursor cells. However, Smad does not directly induce Runx2 expression; an additional step of de novo protein synthesis is required. Here we report that Smad-induced junB functions as an upstream activator of Runx2 expression. Furthermore, not only the Smad pathway but also the mitogen-activated protein kinase (MAPK) cascades are involved in the induction of Runx2 by TGF-beta1 and BMP-2. Our results demonstrate that following TGF-beta and RMP induction, both the Smad and p38 MAPK pathways converge at the Runx2 gene to control mesenchymal precursor cell differentiation.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Engn, Cheongju 361763, South Korea	Chungbuk National University; Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@med.chungbuk.ac.kr						Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian J B, 1995, Iowa Orthop J, V15, P118; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; North T, 1999, DEVELOPMENT, V126, P2563; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; Sambrook J, 1988, MOL CLONING LAB MANU; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	36	263	293	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7156	7163		10.1038/sj.onc.1205937	http://dx.doi.org/10.1038/sj.onc.1205937			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370805				2022-12-28	WOS:000178504600003
J	Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S				Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S			Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations	ONCOGENE			English	Article						in vivo mutant rates; MYC; mutator phenotype; B-cell neoplasia; genomic instability	DOUBLE TRANSGENIC MICE; IN-VIVO MUTATIONS; DNA; SELECTION; TARGET; MODEL	lambda-MYC-induced mouse Burkitt lymphoma (BL) harboring the shuttle vector pUR288, which includes a lacZ reporter gene to study mutagenesis, was employed to assess genomic instability associated with MYC deregulation. The frequency of lacZ mutations in lymphomas was elevated only 1.75-fold above that in normal tissue, indicating that mouse BL does not exhibit a phenotype of hypermutability. However, the nature of lacZ mutations was strikingly different in normal tissues and lymphomas. While point mutations comprised approximately 75% of the mutations found in normal tissues, apparent translocations, deletions and inversions constituted the majority of mutations (similar to65%) in lymphomas. Genomic instability in mouse BL thus seems characterized by a preponderance of illegitimate genetic rearrangements in the context of near-background mutant frequencies. SKY analyses of cell lines from primary BL tumors revealed substantial changes in chromosomal structure, confirming the lacZ studies. Bi-allelic deletions of the tumor suppressor p16(Ink4a) were detected in six out of 16 cell lines, illustrating cellular selection of advantageous mutations. Together, these approaches indicate that MYC may contribute to lymphomagenesis through the dominant mutator effect of inducing chromosomal instability. The results further suggest that a phenotype of hypermutability (elevated mutant frequency) may not always be required for oncogenesis to occur.	NCI, Genet Lab, CCR, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, Bethesda, MD 20892 USA; NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, CCR, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Morse, Herbert/0000-0002-9331-3705; Kovalchuk, Alexander/0000-0003-2761-0442	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000858, Z01AI000858] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; Buettner VL, 1996, ONCOGENE, V13, P2407; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOEB LA, 1991, CANCER RES, V51, P3075; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MUSHINSKI JF, 2002, IN PRESS CRIT REV ON; Roth D., 1988, GENETIC RECOMBINATIO, P621; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	19	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7235	7240		10.1038/sj.onc.1205697	http://dx.doi.org/10.1038/sj.onc.1205697			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370814				2022-12-28	WOS:000178504600012
J	MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM				MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM			Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia	ONCOGENE			English	Article						caspases; CD95; c-FLIP; IAPs; DISC	FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; SIGNALING COMPLEX; CANCER-CELLS; CD95-MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; LEUKEMIA CELLS; DEATH DOMAIN; APO-2 LIGAND; RECEPTOR	Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative 'decoy' receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIPL but not c-FLIPS. Both caspase-8 and c-FLIPL were cleaved to form two stable intermediates of similar to43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIPL to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Pathol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Hematol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				Ahmad M, 2000, ONCOGENE, V19, P3363, DOI 10.1038/sj.onc.1203679; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fulda S, 2000, CANCER RES, V60, P3947; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; King D, 1998, LEUKEMIA, V12, P1553, DOI 10.1038/sj.leu.2401153; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Leverkus M, 2000, CANCER RES, V60, P553; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Mori S, 1999, J IMMUNOL, V162, P5616; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; OBRIEN KAF, 1987, TOXICOL IN VITRO, V1, P85, DOI 10.1016/0887-2333(87)90005-1; Pai SI, 1998, CANCER RES, V58, P3513; Plumas J, 1998, BLOOD, V91, P2875, DOI 10.1182/blood.V91.8.2875.2875_2875_2885; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang DK, 1997, BRIT J HAEMATOL, V97, P409, DOI 10.1046/j.1365-2141.1997.422688.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Xerri L, 1998, BRIT J CANCER, V78, P225, DOI 10.1038/bjc.1998.469; Xerri L, 1997, LEUKEMIA, V11, P1868, DOI 10.1038/sj.leu.2400815; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	56	166	170	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6809	6818		10.1038/sj.onc.1205853	http://dx.doi.org/10.1038/sj.onc.1205853			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360407				2022-12-28	WOS:000178315800011
J	Fang, WZ; Mori, T; Cobrinik, D				Fang, WZ; Mori, T; Cobrinik, D			Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants	ONCOGENE			English	Article						pRB; PML; Mad; transcriptional repression; senescence	ACUTE PROMYELOCYTIC LEUKEMIA; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; RAR-ALPHA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GROWTH-SUPPRESSOR; TUMOR-CELLS; PREMATURE SENESCENCE; ONCOGENIC RAS	The retinoblastoma protein (pRB) is thought to suppress tumorigenesis, in part, through interactions with E2F transcription factors. However, certain low penetrance pRB mutants substantially reduce tumor incidence despite having a minimal ability to bind E2F. These low penetrance mutants retain the ability to induce a senescence-like state, suggesting that they may suppress tumorigenesis through a senescence-associated process. Here, we identify a novel pRB function that is associated with senescence and which is retained by non-EN binding low penetrance pRB mutants. It was found that pRB and these mutants substantially increased the production of PML nuclear bodies (NBs). In keeping with the role of PML in transcriptional repression, pRB also promoted PML-dependent transcriptional repression by the c-Myc antagonist Mad1. In a series of pRB-p130 chimeric proteins, the ability to increase NB production correlated with the ability to induce a senescence-like phenotype. However, neither NB formation nor PML function were required for pRB to induce the senescence-like response. Together, these observations indicate that a pRB-induced increase in PML NB formation is coordinated with, but separable from, the pRB-induced senescence program. The data further suggest that PML may contribute to an E2F-independent tumor suppressor function of pRB.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	dc197@columbia.edu			NCI NIH HHS [P30CA 13696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	55	13	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5557	5565		10.1038/sj.onc.1205666	http://dx.doi.org/10.1038/sj.onc.1205666			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165854				2022-12-28	WOS:000177442000005
J	Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H				Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H			Identification of MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal carcinomas with microsatellite instability	ONCOGENE			English	Article						DNA mismatch repair; microsatellite instability; coding mononucleotide repeats; frameshift mutation; colorectal carcinoma	SOMATIC FRAMESHIFT MUTATIONS; DNA MISMATCH REPAIR; C-KINASE SUBSTRATE; II RECEPTOR GENE; MUTATOR PHENOTYPE; GROWTH-FACTOR; CANCER-CELLS; GASTROINTESTINAL CANCER; MONONUCLEOTIDE REPEATS; COLON CANCERS	Somatic frameshift mutations in some genes containing coding mononucleotide repeats (cMNRs) are well known characteristics of tumors with high microsatellite instability (MSI-H). We identified 22 novel and 11 known target genes containing cMNRs with a length of 10 or more nucleotides by using a systematic database search. Frameshift mutation analysis was performed with these 33 genes in 39 MSI-H and 24 microsatellite stable (MSS) colorectal carcinomas by assessing the mobility shifts of PCR products in gel electrophoresis and by sequencing. All the 39 MSI-H colorectal carcinomas, except one, showed mutations in more than one gene, while no mutations were found in 24 MSS colorectal carcinomas. Of these MSI-H tumors, 11 genes were mutated in more than 40%. The most frequently mutated novel genes were MARCKS (72%), FLJ11383 (74%) and TAF1B (82%). Bialletic inactivation in MARCKS and FLJ11383 was also frequent in MSI-H tumors. The observed mutation frequency of the 11 known target genes was compatible with that found by previous studies. The very high frequency of mutations, biallelic mutations and the predicted truncation of protein products suggests that mutations of MARCKS, FLJ11383 and TAF1B are selected, and play a role in the tumorigenesis of MSI-H colorectal carcinomas.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea; Yonsei Univ, Dept Canc Metastasis Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Brain Korea 21 Projects Med Sci, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120749, South Korea.	hkyonsei@yumc.yonsei.ac.kr		LEE, JIN-SUNG/0000-0002-1262-8597; Kim, Nam-Kyu/0000-0003-0639-5632				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CHEN JS, 1995, CANCER RES, V55, P174; CHOI SJ, 1998, J KOREAN CANC ASS, V30, P527; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 1999, ONCOGENE, V18, P6806, DOI 10.1038/sj.onc.1203287; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; Kim JJ, 1999, LAB INVEST, V79, P1113; Kim NG, 2001, CANCER RES, V61, P36; Ku JL, 1999, EUR J CANCER, V35, P1724, DOI 10.1016/S0959-8049(99)00206-3; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Manenti S, 1998, CANCER RES, V58, P1429; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori Y, 2001, CANCER RES, V61, P6046; Ohmiya N, 2001, GENE, V272, P301, DOI 10.1016/S0378-1119(01)00517-0; Park J, 2002, CANCER RES, V62, P1284; PARK JG, 1987, CANCER RES, V47, P6710; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, BIOL CHEM, V377, P675; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhang L, 2001, CANCER RES, V61, P3801	33	46	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5081	5087		10.1038/sj.onc.1205703	http://dx.doi.org/10.1038/sj.onc.1205703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140758				2022-12-28	WOS:000176975900006
J	Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE				Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE			DNA binding and 3 '-5 ' exonuclease activity in the murine alternatively-spliced p53 protein	ONCOGENE			English	Article						alternatively-spliced p53; DNA binding; exonuclease activity; phosphorothioate-modified DNA-binding sites	SUBSTRATE-SPECIFICITY; TERMINAL DOMAIN; IN-VITRO; EXONUCLEASE; INVOLVEMENT; EXCISION; SITE; INHIBITION; TARGET; LATENT	In this study we show that the naturally occurring C-terminally alternative spliced p53 (referred to as AS-p53) is active as a sequence-specific DNA binding protein as well as a 3'-5'-exonuclease in the presence of Mg2+ ions. The two activities are positively correlated as the sequence-specific DNA target is more efficiently degraded than a non-specific target. In contrast, a mutated AS-p53 protein that is deficient in DNA binding lacks exonuclease activity. The use of modified p53 binding sites, where the 3'-phosphate is replaced by a phosphorothioate group, enabled the inhibition of DNA degradation under the binding conditions. We demonstrate that AS-p53 interacts with its specific DNA target by two distinct binding modes: a high-affinity mode characterized by a low-mobility protein-DNA complex at the nanomolar range, and a low-affinity mode shown by a high-mobility complex at the micromolar range. Comparison of the data on the natural and the modified p53 binding sites suggests that the high-affinity mode is related to AS-p53 function as a transcription factor and that the low-affinity mode is associated with its exonuclease activity. The implications of these findings to a specific cellular role of AS-p53 are discussed.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Technion Israel Institute of Technology	Shakked, Z (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	zippi.shakked@weizmann.ac.il; bitali@techunix.technion.ac.il	Haran, Tali E./AAF-7816-2021	Haran, Tali E./0000-0002-9700-3392				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Molinari M, 1996, ONCOGENE, V13, P2077; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nichols NM, 2001, BIOCHEMISTRY-US, V40, P3847, DOI 10.1021/bi002088z; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OKOROKOV AL, 1999, ONC RES, V9, P267; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	51	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5117	5126		10.1038/sj.onc.1205667	http://dx.doi.org/10.1038/sj.onc.1205667			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140762				2022-12-28	WOS:000176975900010
J	Lan, KH; Sheu, ML; Hwang, SJ; Yen, SH; Chen, SY; Wu, JC; Wang, YJ; Kato, N; Omata, M; Chang, FY; Lee, SD				Lan, KH; Sheu, ML; Hwang, SJ; Yen, SH; Chen, SY; Wu, JC; Wang, YJ; Kato, N; Omata, M; Chang, FY; Lee, SD			HCVNS5A interacts with p53 and inhibits p53-mediated apoptosis	ONCOGENE			English	Article						HCVNS5A; p53; apoptosis	HEPATITIS-C VIRUS; NONSTRUCTURAL PROTEIN 5A; HUMAN CELL-LINES; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; X PROTEIN; NUCLEAR-LOCALIZATION; DNA-BINDING; WILD-TYPE; IN-VITRO	Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis and hepatocellular carcinoma. HCV NS5A, one of non-structural proteins of HCV, was suggested to play a role in oncogenic transformation. Since the tumor suppressor p53 is important for preventing neoplastic transformation, we investigated the functional effects of HCV NS5A on p53. In vitro and in vivo coimmunoprecipitation and confocal microscopy were used to determine the interaction of NS5A and p53. HCV NS5A binds directly to p53 and colocalizes p53 in the perinuclear region. NS5A inhibits transcriptional transactivation by p53 in a dose-dependent manner by use of a reporter assay. Down regulation of endogenous p21/waf1 expression, which is activated by p53 in Hep3B cells, by NS5A was demonstrated by using FLAG- and FLAG-NS5A Hep3B stable cell lines. The effect of NS5A on p53-mediated apoptosis was determined by flow cytometry in both NS5A permanently and transiently transfected Hep3B cells with exogenous p53. The p53-induced apoptosis was abrogated by NS5A and the inhibition effect correlates well with the binding ability of NS5A to p53. In addition, HCV NS5A protein interacts with and colocalizes hTAF(II)32, a component of TFIID and an essential coactivator of p53, in vivo. These results suggest that HCV NS5A interacts with and partially sequestrates p53 and hTAF(II)32 in the cytoplasm and suppresses p53-mediated transcriptional transactivation and apoptosis during HCV infection, which may contribute to the hepatocarcinogenesis of HCV infection.	Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Dept Family Med, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Ctr Canc, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Dept & Inst Pharmacol, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Inst Biochem, Taipei 11217, Taiwan; Univ Tokyo, Dept Gastroenterol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; University of Tokyo	Lee, SD (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, 201 Shih Pai Rd,Sec 2, Taipei 112, Taiwan.	sdlee@vghtpe.gov.tw	Sheu, Meei-Ling/AAT-3401-2020	Sheu, Meei-Ling/0000-0002-0431-1282				Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chung KM, 1997, MOL CELLS, V7, P661; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fukuma T, 1998, HEPATOLOGY, V28, P1147, DOI 10.1002/hep.510280433; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Muralidhar S, 1996, J VIROL, V70, P8691, DOI 10.1128/JVI.70.12.8691-8700.1996; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohashi M, 1999, GUT, V44, P366, DOI 10.1136/gut.44.3.366; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ray RB, 1997, J BIOL CHEM, V272, P10983; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHAULSKY G, 1991, ONCOGENE, V6, P2055; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHIEH YSC, 1993, INT J CANCER, V54, P558; SHIRATORI Y, 1995, HEPATOLOGY, V22, P1027, DOI 10.1002/hep.1840220403; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Uchida T, 1996, INT J CANCER, V67, P892; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	66	171	181	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4801	4811		10.1038/sj.onc.1205589	http://dx.doi.org/10.1038/sj.onc.1205589			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101418				2022-12-28	WOS:000176716300009
J	Dhillon, NK; Mudryj, M				Dhillon, NK; Mudryj, M			Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest	ONCOGENE			English	Article						cyclin E; MCF7; tamoxifen; breast cancer; cell cycle	BREAST-CANCER CELLS; LASER-SCANNING CYTOMETRY; DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; FUNCTIONAL INACTIVATION; CDK INHIBITORS; P27(KIP1); E2F; PHOSPHORYLATION; PROGRESSION	Estrogens stimulate proliferation of estrogen receptor positive MCF7 breast cancer cells; while antiestrogens signal a G0/G1 growth arrest. In MCF7 cells, arrest is mediated through the CDK inhibitors p21 and p27 and through a decrease in cyclin E/CDK2 kinase activity. We found that in MCF7 cells, overexpression of cyclin E partially abrogates a tamoxifen mediated growth arrest. Overexpression of cyclin E is accompanied by a decrease in the levels of RB and CDK inhibitor p21 but an increase in CDK inhibitor p27. Cyclin E overexpression also alters the composition of E2F transcription factor complexes. The E2F4/p107/cyclin E/CDK2 complex, a minor component in proliferating control cells that is absent in growth-arrested cells, is more abundant in both proliferating and tamoxifen treated cyclin E overexpressing cells. Conversely, levels of the quiescence associated E2F/p130 complex is not detected in these cells. Expression from the E2F dependant promoter is elevated in proliferating and tamoxifen treated cyclin E overexpressing cells. This study suggests that a modest overexpression of cyclin E abrogates the tamoxifen mediated growth arrest through modification of the RB/E2F pathway. Moreover, these, results provide one explanation of why some cells that express the estrogen receptor may be unresponsive to antiestrogens.	Univ Calif Davis, Dept Med Microbiol & Immunol, Sch Med, Davis, CA 95616 USA; Martinez VA, Martinez, CA 94553 USA	University of California System; University of California Davis	Mudryj, M (corresponding author), Univ Calif Davis, Dept Microbiol & Immunol, 3149 Tupper Hall, Davis, CA 95616 USA.							Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chiarle R, 2001, BREAST CANCER RES, V3, P91; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kamentsky LA, 2001, METHOD CELL BIOL, V63, P51; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; SAMBROOK J, 1989, MOL CLONING LAB MANU, P737; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1996, CANCER RES, V56, P1389; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Su TT, 1997, J CELL BIOL, V139, P13, DOI 10.1083/jcb.139.1.13; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; TAYLOR IW, 1983, CANCER RES, V43, P4007; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	51	43	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4626	4634		10.1038/sj.onc.1205576	http://dx.doi.org/10.1038/sj.onc.1205576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096339				2022-12-28	WOS:000176625100004
J	Ru, HY; Chen, RL; Lu, WC; Chen, JHS				Ru, HY; Chen, RL; Lu, WC; Chen, JHS			hBUB1 defects in leukemia and lymphoma cells	ONCOGENE			English	Article						mitosis checkpoint; hBUB1; chromosome instability; lymphoma; leukemia	SACCHAROMYCES-CEREVISIAE; CHECKPOINT; INSTABILITY; CANCER; GENES	Tumorigenesis is a multi-step process involving a series of changes of cellular genes. Most solid tumors and hematopoietic malignancies often show abnormal chromosome numbers, the aneuploidy. The chromosomal aneuploidy keeps cells in the state of chromosomal instability (CIN) that will increase the mutation rate of cells affected and thus push them deeper into the process of tumorigenesis. The yeast genetic studies showed that normal distribution of chromosome during mitosis is under the surveillance of a set of genes, the spindle assembly checkpoint genes, that include the BUB and MAD gene groups and MPS. In some colorectal cancers with CIN it was found to have hBUB1 gene mutated and the mutated gene functions dominantly. We have examined a series of breast cancer cell lines with or without CIN for the hBUB1 gene mutation and found none. However, we detected various degrees of deletion in the coding sequences of the hBUB1 gene in cells from T lymphoblastic leukemia cell lines, Molt3 and Molt4, and cells from some acute lymphoblastic leukemia and Hodgkin's lymphoma patients. So far the lesions of deletion are in the kinetochore localization domain of the hBUB1 gene that may explain why the deletion lesions in the BUB1 gene cause aneuploidy in lymphoma and lymphoma cells. The deletions are heterozygous in nature. Like the mutated hBUB1 gene in colorectal cancer, the mutant hBUB1 cDNA from lymphoblastic leukemia cells behaves dominantly.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; Tzu Chi Univ, Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Dept Pediat, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JHS (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd,Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw	LU, Wei-Cheng/O-5577-2017	Chen, Rong-Long/0000-0003-0290-9886				Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOEB LA, 1991, CANCER RES, V51, P3075; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057	16	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4673	4679		10.1038/sj.onc.1205585	http://dx.doi.org/10.1038/sj.onc.1205585			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096343				2022-12-28	WOS:000176625100008
J	Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P				Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P			Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis	ONCOGENE			English	Article						AP-1; epidermis; inflammation; papilloma; tumor promoter	CALCIUM-BINDING PROTEINS; MALIGNANT PROGRESSION; MOUSE KERATINOCYTES; EXPRESSION; RECEPTOR; GENE; TRANSCRIPTION; DIFFERENTIATION; MRP14; AP-1	The two calgranulins S100A8 and S100A9 were found to be differentially expressed at sites of acute and chronic inflammation. Here we have employed the phorbol ester-induced multistage skin carcinogenesis protocol in mice to determine the expression of both genes in inflamed skin and in skin tumors. We show that expression is coordinately induced by the phorbol ester TPA in epithelial cells as well as infiltrating leukocytes. By comparing S100A8 and S100A9 mRNA levels in wild type and c-Fos deficient mice (c-fos(-/-)) we found that expression is negatively regulated by c-Fos/AP-1. Glucocorticoids, which exhibit potent anti-inflammatory and anti-tumor promoting activities repressed TPA-mediated S100A8 and S100A9 induction in wild type, cfos(-/-) mice, thus identifying both genes as but not in the first examples of AP-1 target genes whose repression of TPA-induced transcription by glucocorticoids depends on c-Fos. Finally, we show that enhanced expression is not restricted to the initial TPA-induced inflammatory response but is observed at all stages of skin carcinogenesis. These data identify S100A8 and S100A9 as novel, tumor-associated genes and may point to an as yet unrecognized function of both genes in the development of epithelial skin tumors.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz-heidelberg.de	Gebhardt, Christoffer/F-8170-2015; Gebhardt, Christoffer/B-5713-2009	Gebhardt, Christoffer/0000-0001-7090-9584; 				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BELMAN S, 1972, CANCER RES, V32, P450; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER C, 1991, DEVELOPMENT, V111, P253; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Klempt M, 1999, J CELL BIOCHEM, V73, P49, DOI 10.1002/(SICI)1097-4644(19990401)73:1<49::AID-JCB6>3.0.CO;2-2; LAGASSE E, 1992, BLOOD, V79, P1907; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nacken W, 1996, BBA-MOL BASIS DIS, V1315, P1, DOI 10.1016/0925-4439(95)00108-5; Nacken W, 2001, J CELL BIOCHEM, V80, P606, DOI 10.1002/1097-4644(20010315)80:4<606::AID-JCB1015>3.3.CO;2-B; Newton RA, 1998, J IMMUNOL, V160, P1427; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Passey RJ, 1999, J IMMUNOL, V163, P2209; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rammes A, 1997, J BIOL CHEM, V272, P9496; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rennecke J, 2000, BBA-MOL CELL RES, V1497, P289, DOI 10.1016/S0167-4889(00)00067-7; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHNARR B, 2000, INT J CANCER, V88, P345; SCHONTHAL A, 1989, ONCOGENE, V4, P629; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Wang HQ, 1999, J CELL SCI, V112, P3497; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON MM, 1988, J CELL SCI, V91, P221; WINTER H, 1983, ARCH DERMATOL RES, V275, P27, DOI 10.1007/BF00516551; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	57	104	114	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4266	4276		10.1038/sj.onc.1205521	http://dx.doi.org/10.1038/sj.onc.1205521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082614	Bronze			2022-12-28	WOS:000176174200009
J	Johnson, BA; Blackwell, TK				Johnson, BA; Blackwell, TK			Multiple tristetraprolin sequence domains required to induce apoptosis and modulate responses to TNF alpha through distinct pathways	ONCOGENE			English	Article						tristetraprolin; TNF alpha; immediate-early; apoptosis; zinc finger	NECROSIS-FACTOR-ALPHA; AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE; ZINC-FINGER PROTEINS; MESSENGER-RNA DEGRADATION; NF-KAPPA-B; C-ELEGANS; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; CELL-DEATH	Expression of the immediate early protein tristetraprolin (TTP) is induced by numerous stimuli, including tumor necrosis factor-alpha (TNFalpha). Evidence indicates that TTP limits production of TNFalpha and other cytokines by directly binding and destabilizing their mRNAs. This effect seems to require only the conserved TTP zinc finger region, and is characteristic of the related proteins TIS11b and TIS11d. TTP, TIS11b, and TIS11d each also induce apoptosis through the mitochondrial pathway analogously to certain oncogenes, suggesting that they influence growth or survival signals. Among TTP/TIS11 proteins, TTP alone also promotes apoptosis synergistically with TNFalpha. Here we show that other regions of TTP along with the zinc fingers are required for TTP to induce apoptosis. We also demonstrate that TTP acts through an additional pathway to sensitize cells to the pro-apoptotic stimulus of TNFalpha. This modulation of TNFalpha responses specifically requires the TTP N-terminal region, which is not conserved in TIS11b or TIS11d. We conclude that the physiological functions of TTP depend upon multiple regions of the TTP protein, that TTP has diverged functionally from TIS11b and TIS11d, and that modulation of TNFa responses may be a unique and important aspect of TTP function.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA084418] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA84418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai CY, 1996, MOL CELL BIOL, V16, P6661; Baker SJ, 1996, ONCOGENE, V12, P1; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; EHRENFRIED JA, 1995, ANN SURG, V222, P51, DOI 10.1097/00000658-199507000-00009; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guedes S, 1997, DEVELOPMENT, V124, P731; HAAS CA, 1993, NEUROSCIENCE, V53, P91, DOI 10.1016/0306-4522(93)90287-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; JOHNSON BA, 2002, J BIOL CHEM; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lai WS, 2002, J BIOL CHEM, V277, P9606, DOI 10.1074/jbc.M110395200; Landesberg LJ, 2001, AM J PHYSIOL-LUNG C, V281, pL1138, DOI 10.1152/ajplung.2001.281.5.L1138; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MESNER PW, 1995, J NEUROSCI, V15, P7357; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tenenhaus C, 2001, GENE DEV, V15, P1031, DOI 10.1101/gad.876201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	58	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4237	4246		10.1038/sj.onc.1205526	http://dx.doi.org/10.1038/sj.onc.1205526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082611				2022-12-28	WOS:000176174200006
J	Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK				Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK			Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells	ONCOGENE			English	Article						radiation; Erb-B; EGFR; Akt; p70 S6 kinase	GROWTH-FACTOR RECEPTOR; MESSENGER-RNA TRANSLATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MALIGNANT GLIOMA; IN-VIVO; INHIBITION; GENE; PROLIFERATION; TRANSDUCTION	In this study we have investigated the effects of low dose ionizing radiation (2 Gy) on p70 S6 kinase and Akt signaling with respect to Erb-B receptors in both the A431 squamous and the MDA-MB-231 mammary carcinoma cell lines. Ionizing radiation caused a 2-3-fold increase in p70 S6 kinase activity that was blocked pharmacologically using an EGFR inhibitor (AG1478) alone, or in combination with an Erb-B2 inhibitor (AG825). These results suggested that both EGFR and Erb-B2 receptors could initiate radiation-induced activation of p70 S6K. EGFR dependent Erb-B3 signaling also contributed to p70 S6 kinase activity through recruitment and activation of PI3K, which has been shown to regulate p70 S6 kinase activity. Furthermore, inhibition of the EGFR blocked IR stimulated increases in protein translation, a biologic consequence of p70 S6 kinase activation. We also report that ionizing radiation stimulated Akt activity that was partially independent of PI3K activity, but dependent on Erb-B2 function. Erb-B2 inhibition also correlated with enhanced apoptosis following IR exposure, suggesting an important role for Erb-B2 in cell survival. Together this work demonstrates that the Erb-B receptor tyrosine kinase network stimulates cytoprotective p70 S6 kinase and Akt activity in response to clinically relevant doses of ionizing radiation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA72955, R01 CA65896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto Tetsuo, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P714; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Huang SM, 1999, CANCER RES, V59, P1935; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KIM HH, 1994, J BIOL CHEM, V269, P24747; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu AX, 1998, CANCER RES, V58, P2973; Milas L, 2000, CLIN CANCER RES, V6, P701; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	44	136	142	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4032	4041		10.1038/sj.onc.1205500	http://dx.doi.org/10.1038/sj.onc.1205500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037685				2022-12-28	WOS:000175869900009
J	Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P				Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P			Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients	ONCOGENE			English	Article						SDHD; endocrine tumors; mutation; allelic loss	COMPARATIVE GENOMIC HYBRIDIZATION; PANCREATIC ENDOCRINE TUMORS; COMPLEX-II GENE; SUPPRESSOR GENE; HEREDITARY PARAGANGLIOMA; CARCINOID-TUMORS; HETEROZYGOSITY; CHROMOSOME-11; PHEOCHROMOCYTOMA; OXIDOREDUCTASE	Allelic loss of the long arm of chromosome 11 is frequent in neuroendocrine tumors (NET) of different organs. However, the MEN1 gene on 11q13 is mutated only in a subset of NET and allelic losses on 11q frequently extend to the telomere. In this genetic region lies the tumor suppressor gene SDHD which is associated with hereditary paragangliomas (PGL1). We sought to determine whether SDHD plays a role in the development of sporadic NET. By mutation and deletion analysis of SDHD we were unable to detect any SDHD mutation in 45 NET of the lung, gastrointestinal tract, pancreas or parathyroid. However, we found allelic deletions in 20 to 50% of all tumors but parathyroid adenomas. Furthermore, we found heterozygous germline variants in 2/8 paragangliomas. A first case of variant c.149 A > G (H50R) was found in a patient with an extra-adrenal pheochromocytoma, the other variant c.34 G > A (G12S) in a patient with a paratracheal paraganglioma, C-cell hyperplasia of the thyroid and hyperplasia of ACTH-producing cells of the pituitary gland. Both variants were absent in 93 controls. Our results demonstrate that somatic SDHD mutations are rare in sporadic NET. However, LOH alone could lead to a complete loss of function since SDHD is an imprinted gene. Furthermore, we describe two germline variants possibly causing hereditary paragangliomas.	Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Inst Pathol, CH-5404 Baden, Switzerland	University of Zurich; University Zurich Hospital	Perren, A (corresponding author), Univ Zurich Hosp, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Perren, Aurel/A-9383-2018; Perren, Aurel/N-5979-2019	Perren, Aurel/0000-0002-6819-6092; Perren, Aurel/0000-0002-6819-6092				Badenhop RF, 2001, GENE CHROMOSOME CANC, V31, P255, DOI 10.1002/gcc.1142; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; D'Adda T, 1999, LAB INVEST, V79, P671; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; EUBANKS PJ, 1994, AM J SURG, V167, P180, DOI 10.1016/0002-9610(94)90071-X; Farnebo F, 1997, HUM GENET, V99, P342, DOI 10.1007/s004390050369; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FRIEDMAN E, 1992, CANCER RES, V52, P6804; Gimm O, 2000, CANCER RES, V60, P6822; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hirawake H, 1999, BBA-BIOENERGETICS, V1412, P295, DOI 10.1016/S0005-2728(99)00071-7; Iwasaki H, 1996, INT SURG, V81, P71; Jakobovitz G, 1996, J CLIN ENDOCR METAB, V81, P3164; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; KOMMINOTH P, 1994, AM J PATHOL, V145, P922; Malik K, 2000, CANCER RES, V60, P2356; Perren A, 1998, J PATHOL, V186, P363; Petzmann S, 2001, HUM PATHOL, V32, P333, DOI 10.1053/hupa.2001.22762; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Rigaud G, 2001, CANCER RES, V61, P285; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Speel EJM, 1999, AM J PATHOL, V155, P1787, DOI 10.1016/S0002-9440(10)65495-8; VANDERMEY AGL, 1989, LANCET, V2, P1291; Walch AK, 1998, AM J PATHOL, V153, P1089, DOI 10.1016/S0002-9440(10)65653-2; Zhao JM, 2000, AM J PATHOL, V157, P1431, DOI 10.1016/S0002-9440(10)64780-3	28	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7605	7608		10.1038/sj.onc.1205812	http://dx.doi.org/10.1038/sj.onc.1205812			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386824				2022-12-28	WOS:000178618200017
J	Alavanja, MCR				Alavanja, MCR			Biologic damage resulting from exposure to tobacco smoke and from radon: implication for preventive interventions	ONCOGENE			English	Review						lung cancer; radon; smoking; pathologic mechanism	OXIDATIVE DNA-DAMAGE; LUNG-CANCER RISK; S-TRANSFERASE M1; SISTER-CHROMATID EXCHANGES; P53 MUTATION HOTSPOT; ALPHA-PARTICLES; MAMMALIAN-CELLS; CIGARETTE-SMOKE; FREE-RADICALS; UNITED-STATES	Cigarette smoking and residential radon are, respectively, the first and second leading cause of lung cancer in the United States today. Of the approximately 157000 lung deaths occurring in 2000, approximately 90% can be attributed to cigarette smoking and 30% 4 the lung cancer deaths among non-smokers can be attributed to residential radon exposure. Although dwarfed by cigarette related lung cancer, lung cancer among lifetime non-smokers is a leading cause of death in the United States, and many other countries, accounting for approximately 16000 deaths per year in the US. Laboratory studies and epidemiological investigations, particularly those conducted in the past decade, are yielding evidence that tobacco smoke and radon may share important elements of lung cancer's pathologic mechanism(s). Lung cancer prevention among smokers, ex-smokers and lifetime nonsmokers can be enhanced as we learn more about the etiologic mechanism(s) of lung cancer resulting from these and other exposures including diet, non-malignant respiratory diseases, occupational exposures, and susceptibility-gene. In this article we review both laboratory and epidemiologic data that gives insight into the biologic damage done to the lung from these exposures.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Alavanja, MCR (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Room 8000, Rockville, MD 20892 USA.	alavanjm@mail.nih.gov			NATIONAL CANCER INSTITUTE [Z01CP010123] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GED, 1986, INTRO CELLULAR MOL B, P154; ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1995, CANCER CAUSE CONTROL, V6, P209, DOI 10.1007/BF00051792; Albanes D, 1999, AM J CLIN NUTR, V69, p1345S; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; Asami S, 1996, CANCER RES, V56, P2546; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2000, CANCER RES, V60, P2623; Bartsch H, 1996, MUTAT RES-REV GENET, V340, P67, DOI 10.1016/S0165-1110(96)90040-8; BARTSCH H, 1995, PHARMACOGENETICS, V5, pS84, DOI 10.1097/00008571-199512001-00007; BARTSCH H, 1995, LANCET, V346, P121, DOI 10.1016/S0140-6736(95)92144-3; Bartsch H, 1997, EUR J CANCER PREV, V6, P529, DOI 10.1097/00008469-199712000-00007; Bartsch H, 1996, ENVIRON HEALTH PERSP, V104, P569, DOI 10.2307/3432825; BARTSCH H, 1991, MUTAT RES, V250, P103, DOI 10.1016/0027-5107(91)90167-M; BENDICH A, 1994, PURE APPL CHEM, V66, P1017, DOI 10.1351/pac199466051017; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P637; BREIMER LH, 1991, FREE RADICAL RES COM, V14, P159, DOI 10.3109/10715769109088945; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; BROOKS AL, 1990, INT J RADIAT BIOL, V58, P799, DOI 10.1080/09553009014552181; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CANDELORA EC, 1992, NUTR CANCER, V17, P263, DOI 10.1080/01635589209514195; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHAMULITRAT W, 1991, ARCH BIOCHEM BIOPHYS, V290, P153, DOI 10.1016/0003-9861(91)90601-E; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG FL, 1992, CANC CHEMOPREVENTION; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; CUETO R, 1994, VIB SPECTROSC, V7, P97, DOI 10.1016/0924-2031(94)85045-3; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EMERIT I, 1995, FREE RADICAL BIO MED, V18, P985, DOI 10.1016/0891-5849(94)00220-E; EVANS MD, 1991, CHEM-BIOL INTERACT, V79, P151, DOI 10.1016/0009-2797(91)90079-M; EVANS MD, 1994, AM J PHYSIOL, V266, pL593, DOI 10.1152/ajplung.1994.266.6.L593; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Feskanich D, 2000, JNCI-J NATL CANCER I, V92, P1812, DOI 10.1093/jnci/92.22.1812; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; Garcia-Closas R, 1998, NUTR CANCER, V32, P154, DOI 10.1080/01635589809514734; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hecht SS, 1999, J NUTR, V129, p768S, DOI 10.1093/jn/129.3.768S; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; HICKMAN AW, 1994, CANCER RES, V54, P5797; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4727; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1997, CARCINOGENESIS, V18, P511, DOI 10.1093/carcin/18.3.511; Houlston RS, 1999, CANCER EPIDEM BIOMAR, V8, P675; Hussain SP, 1998, CANCER RES, V58, P4023; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; *IARC, 1986, IARC MON EV CARC RIS, V38, P389; Jansen MCJF, 2001, INT J CANCER, V92, P913, DOI 10.1002/ijc.1278; JEFFREY AM, 1976, J AM CHEM SOC, V98, P5714, DOI 10.1021/ja00434a060; JONAS SK, 1992, FREE RADICAL RES COM, V17, P407, DOI 10.3109/10715769209083145; KALRA J, 1991, INT J EXP PATHOL, V72, P1; KENNEDY A, 1997, CARCINOGENESIS, V8, P683; Kennedy CH, 1996, CARCINOGENESIS, V17, P1671, DOI 10.1093/carcin/17.8.1671; Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820; Knekt P, 1999, J NATL CANCER I, V91, P182, DOI 10.1093/jnci/91.2.182; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7; KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI 10.1146/annurev.nutr.13.1.561; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEANDERSON P, 1992, CHEM-BIOL INTERACT, V81, P197, DOI 10.1016/0009-2797(92)90034-I; Lehnert BE, 1997, CANCER RES, V57, P2164; LEMARCHAND L, 1993, CANCER EPIDEM BIOMAR, V2, P183; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Little MP, 2001, RADIAT RES, V156, P695, DOI 10.1667/0033-7587(2001)156[0695:TBEICC]2.0.CO;2; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; LOFT S, 1995, TRANSPLANTATION, V59, P16, DOI 10.1097/00007890-199501150-00004; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; Lubin JH, 1994, RADON LUNG CANC RISK; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MCDONALD JW, 1995, CANCER EPIDEM BIOMAR, V4, P791; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; MOONEY LA, 1995, CANCER EPIDEM BIOMAR, V4, P627; Mortensen A, 1997, FREE RADICAL RES, V27, P229, DOI 10.3109/10715769709097855; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; National Research Council, 1999, REP COMM BIOL EFF IO; Nyberg F, 1998, INT J CANCER, V78, P430, DOI 10.1002/(SICI)1097-0215(19981109)78:4&lt;430::AID-IJC7&gt;3.0.CO;2-V; OSBORNE MR, 1976, INT J CANCER, V18, P362, DOI 10.1002/ijc.2910180315; Prieme H, 1998, CARCINOGENESIS, V19, P347, DOI 10.1093/carcin/19.2.347; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345; Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; ROOTS R, 1972, INT J RADIAT BIOL RE, V21, P329, DOI 10.1080/09553007214550401; Rossman TG, 1998, MUTAT RES-FUND MOL M, V402, P103, DOI 10.1016/S0027-5107(97)00287-X; SAMET JM, 1989, J NATL CANCER I, V81, P745, DOI 10.1007/s00484-020-01860-w; Slater T. F., 1972, FREE RADICAL MECH TI; Speizer FE, 1999, CANCER CAUSE CONTROL, V10, P475, DOI 10.1023/A:1008931526525; Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STONE KK, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3432235; Surgeon General, 1988, HLTH CONS SMOK NIC A; TAYLOR JA, 1994, LANCET, V343, P86, DOI 10.1016/S0140-6736(94)90818-4; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TINKLER JH, 1995, NAT MED, V1, P98; U.S. Department of Health and Human Services, 2001, WOM SMOK REP SURG GE; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R; VAHAKANGAS K, 1985, CARCINOGENESIS, V6, P1109, DOI 10.1093/carcin/6.8.1109; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; van Poppel G, 1999, ADV EXP MED BIOL, V472, P159; Verhagen H, 1997, CANCER LETT, V114, P127, DOI 10.1016/S0304-3835(97)04641-7; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; VONSONNTAG C, 1994, INT J RADIAT BIOL, V65, P19, DOI 10.1080/09553009414550031; Voorrips LE, 2000, CANCER CAUSE CONTROL, V11, P101, DOI 10.1023/A:1008906706084; Wei YH, 1998, P SOC EXP BIOL MED, V217, P53; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Williams JA, 2001, CARCINOGENESIS, V22, P209, DOI 10.1093/carcin/22.2.209; WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Yarborough A, 1996, CANCER RES, V56, P683; Yngveson A, 1999, CANCER EPIDEM BIOMAR, V8, P433; Yu R, 1998, CANCER RES, V58, P402; ZHANG LX, 1992, CANCER RES, V52, P5702; Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Ziegler RG, 1996, J NATL CANCER I, V88, P612, DOI 10.1093/jnci/88.9.612; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	134	38	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7365	7375		10.1038/sj.onc.1205798	http://dx.doi.org/10.1038/sj.onc.1205798			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379879				2022-12-28	WOS:000178618000009
J	Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX				Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX			Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappa B/rel complexes	ONCOGENE			English	Article						NF-kappa B; p53; c-Myc; IEX-1 and transcription	IMMEDIATE-EARLY GENE; INDUCED CELL-DEATH; MICE LACKING; TARGET GENE; B RELA; APOPTOSIS; EXPRESSION; PROTEIN; BINDING; GROWTH	NF-kappaB/rel proteins, tumor suppressor p53, and oncogene c-Myc are critical transcription factors involved in coordinating cellular decision-making events in response to external stimuli. Consensus sequences for binding these three transcription factors are found in the promoter region of IEX-1 (Immediate Early response gene X-1) gene that can either suppress or induce apoptosis in a cell- and stimulus-dependent manner. Utilizing an electrophoretic mobility shift assay (EMSA) and a promoter/reporter assay, we show that the NF-kappaB/rel consensus sequence in the IEX-1 promoter is specifically bound and activated by multiple NF-kappaB/rel complexes in descending order p65-c-rel-->p65-50-->p50-50. Interestingly, NF-kappaB/rel-mediated activation of IEX-1 expression was synergized by p53, but strongly inhibited by c-Myc in a dose-dependent fashion. Moreover, the ability of c-Myc to inhibit IEX-1 expression requires the presence of functional p53, which may partially contribute to the varying effects of p53 on IEX-1 expression in different cells. In support of coordinated regulation of IEX-1 expression by these three transcription factors in vivo, binding of endogenous p53, c-Myc and NF-kappaB/rel proteins, including p50, p65 and c-rel, to the IEX-1 promoter was demonstrated in living cells by chromatin immunoprecipitation using specific antibodies. The study reveals a novel integrative regulation of specific gene expression by NF-kappaB/rel, p53 and c-Myc transcription factors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Shionogi BioRes, Lexington, MA 02420 USA	Baylor College of Medicine; Shionogi & Company Limited	Wu, MX (corresponding author), Boston Med Ctr, Dept Mol & Cell Biol, 715 Albany St Evans 4, Boston, MA 02118 USA.				NIAID NIH HHS [AI45003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHARLES CH, 1993, ONCOGENE, V8, P797; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kawai H, 1999, CANCER RES, V59, P6038; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ravi R, 1998, CANCER RES, V58, P4531; Sala A, 1996, CANCER RES, V56, P1991; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	50	41	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6819	6828		10.1038/sj.onc.1205854	http://dx.doi.org/10.1038/sj.onc.1205854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360408				2022-12-28	WOS:000178315800012
J	Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM				Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM			Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation	ONCOGENE			English	Article						AP-1; menin; Elk-1; MAPK; JunD	MULTIPLE ENDOCRINE NEOPLASIA; SIGNAL-REGULATED KINASE; CELL-PROLIFERATION; SOMATIC MUTATION; GROWTH-FACTORS; FOS PROMOTER; HA-RAS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	Menin, a nuclear protein encoded by the tumor suppressor gene MEN1, interacts with the AP-1 transcription factor JunD and inhibits its transcriptional activity. In addition, overexpression of Menin counteracts Ras-induced tumorigenesis. We show that Menin inhibits ERK-dependent phosphorylation and activation of both JunD and the Ets-domain transcription factor Elk-1. We also show that Menin represses the inducible activity of the c-fos promoter. Furthermore, Menin expression inhibits Jun N-terminal kinase (JNK)mediated phosphorylation of both JunD and c-Jun. Kinase assays show that Menin overexpression does not interfere with activation of either ERK2 or JNK1, suggesting that Menin acts at a level downstream of MAPK activation. An N-terminal deletion mutant of Menin that cannot inhibit JunD phosphorylation by JNK, can still repress JunD phosphorylation by ERK2, suggesting that Menin interferes with ERK and JNK pathways through two distinct inhibitory mechanisms. Taken together, our data suggest that Menin uncouples ERK and JNK activation from phosphorylation of their nuclear targets Elk-1, JunD and c-Jun, hence inhibiting accumulation of active Fos/Jun heterodimers. This study provides new molecular insights into the tumor suppressor function of Menin and suggests a mechanism by which Menin may interfere with Ras-dependent cell transformation and oncogenesis.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87036 Arcavacata Di Rende, CS, Italy; Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Calabria; University of Rochester	Musti, AM (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.		vivacqua, adele/I-2771-2015; Musti, Anna Maria/M-2520-2019; Maggiolini, Marcello/Z-4729-2019; Bonofiglio, Daniela/AAV-8371-2020; Weiss, Carsten/I-1811-2013	vivacqua, adele/0000-0001-5333-8396; Weiss, Carsten/0000-0002-5380-3208; BONOFIGLIO, Daniela/0000-0002-4142-0496; MUSTI, Anna Maria/0000-0003-1443-2739; Maggiolini, Marcello/0000-0002-7485-854X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Marx SJ, 1998, J INTERN MED, V243, P447; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wang HL, 1996, ONCOGENE, V13, P2639; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	52	70	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6434	6445		10.1038/sj.onc.1205822	http://dx.doi.org/10.1038/sj.onc.1205822			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226747				2022-12-28	WOS:000177925300004
J	Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD				Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD			Gene expression in epithelial ovarian carcinoma	ONCOGENE			English	Article						ovarian epithelial cells; oligonucleotide arrays; RT-PCR; periostin	CELL ADHESION MOLECULE; TISSUE TRANSGLUTAMINASE; GROWTH-FACTOR; SERUM LEVEL; CANCER; PROTEIN; CLONING; PERIOSTIN; ONCOGENE; HOMOLOG	We analysed the mRNA levels corresponding to 12 600 transcripts in primary cultures of ovarian epithelial cells derived from nine normal ovaries and 21 epithelial ovarian carcinoma. The class distinction and hierarchical clustering of expression data revealed a clear distinction in gene expression between normal and carcinoma-derived ovarian epithelial cells. Comparison of expression levels revealed 111 genes with mean expression values of >2.5-fold higher in carcinoma cells. Similarly, 62 genes were expressed at >2.5-fold higher levels in normal ovarian epithelial cells. For a few selected genes, we demonstrate that the pattern of differential expression observed in cultured epithelial cells is present in the normal ovaries and epithelial ovarian carcinoma. Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Factor 11-934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ddchang@mednet.ucla.edu		Graeber, Thomas/0000-0001-8574-9181; Matei, Daniela/0000-0003-2169-5035	NCI NIH HHS [T32CA09297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; AUERSPERG N, 1994, LAB INVEST, V71, P510; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Foster KA, 1996, CANCER RES, V56, P3622; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greenwood M, 2000, HIST TODAY, V50, P3; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hough CD, 2000, CANCER RES, V60, P6281; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Ismail RS, 2000, CANCER RES, V60, P6744; JACOBS I, 1989, HUM REPROD, V4, P1; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MARKS JR, 1991, CANCER RES, V51, P2979; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Ono K, 2000, CANCER RES, V60, P5007; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; PRESS WH, 1992, NUMERICAL RECIPES C, P226; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; YOUNY RC, 2001, CANC PRINCIPLES PRAC, P1226	43	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6289	6298		10.1038/sj.onc.1205785	http://dx.doi.org/10.1038/sj.onc.1205785			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214269				2022-12-28	WOS:000177829000005
J	Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC				Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC			TGF beta inducible early gene enhances TGF beta/Smad-dependent transcriptional responses	ONCOGENE			English	Article						Smad; TGF beta; TIEG; transcription; zinc-finger	GROWTH-FACTOR-BETA; N-TERMINAL KINASE; TUMOR-SUPPRESSOR GENE; PANCREATIC-CANCER; EPITHELIAL-CELLS; FAMILY MEMBERS; DPC4 GENE; SMAD7; PROTEIN; TIEG	TGFbeta inducible early gene (TIEG) encodes a three zinc-finger Kruppel-like transcription factor whose overexpression has been shown to mimic the effects of TGFbeta in human osteosarcoma and pancreatic carcinoma cells. In order to investigate a potential role of TIEG in the TGFbeta signal transduction pathway, we studied its impact on a Smad binding element (SBE) reporter which is known to be regulated by TGFbeta through the R-Smad proteins. We demonstrate that TIEG overexpression enhances TGFbeta induction of SBE reporter activity. TIEG overexpression also enhances induction of the endogenous TGFbeta regulated genes p21 and PAI-1. The ability of TIEG to enhance TGFbeta actions is Smad dependent since TIEG has no effect on SBE transcription in the absence of Smad4 expression or when an inhibitory Smad protein, Smad7, is overexpressed. Furthermore, TIEG overexpression enhances TGFbeta induced Smad2 phosphorylation. Lastly, TIEG appears to function by binding to and thereby repressing a specific element in the proximal promoter of the inhibitory Smad7 gene. In conclusion, these results describe a novel mechanism for the potentiation of TGFbeta/Smad signaling via repression of the inhibitory Smad7 gene by TIEG.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Spelsberg, TC (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Janknecht, Ralf/0000-0003-1741-1562	NIDCR NIH HHS [1R01 DE14036-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOYER PL, 1993, ONCOGENE, V8, P457; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Fautsch MP, 1998, MAMM GENOME, V9, P838, DOI 10.1007/s003359900878; Frey RS, 1997, CANCER RES, V57, P628; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Imai K, 1999, FEBS LETT, V456, P375, DOI 10.1016/S0014-5793(99)00988-6; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SK, 1996, CANCER RES, V56, P2519; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schutte M, 1996, CANCER RES, V56, P2527; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yajima S, 1997, J NEUROSCI, V17, P8657; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	46	115	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5783	5790		10.1038/sj.onc.1205681	http://dx.doi.org/10.1038/sj.onc.1205681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173049				2022-12-28	WOS:000177463400014
J	Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH				Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH			ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation	ONCOGENE			English	Article						ETV6-NTRK3; IGF1 receptor; IRS-1	FACTOR-I RECEPTOR; CONGENITAL MESOBLASTIC NEPHROMA; DOMINANT-NEGATIVE MUTANT; MOUSE EMBRYO FIBROBLASTS; TYPE-1 IGF RECEPTOR; GENE FUSION; PLECKSTRIN HOMOLOGY; TUMOR PROGRESSION; BREAST-CANCER; INHIBITION	Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation. The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6.-NTRK3 (EN). EN transforms N1H3T3 fibroblasts through constitutive activation of both the Ras-mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'kinase (PI3K)-Akt pathway. However, the role of trisomy 11 in CFS and CMN remains unknown. In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors. Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation. EN only very weakly transformed so-called R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFR1), but transformation activity was fully restored in R cells engineered to re-express IGFRI (R + cells). We also observed that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunoprecipitated with EN in either R- or R+ cells expressing the EN oncoprotein. IRS-1 association with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, respectively, was enhanced in both cell types in the presence of EN. However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R- cells compared to EN-transformed R + cells. This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI. Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.	BC Res Inst Childrens & Womens Hlth, Dept Pathol, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; BC Res Inst Childrens & Womens Hlth, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Hop St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada	University of British Columbia; Universite de Montreal	Sorensen, PH (corresponding author), BC Res Inst Childrens & Womens Hlth, Dept Pathol, Room 3082-950,W 28Th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca						BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERNSTEIN R, 1994, CANCER GENET CYTOGEN, V78, P82, DOI 10.1016/0165-4608(94)90051-5; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Dal Cin P, 1998, CANCER GENET CYTOGEN, V103, P68, DOI 10.1016/S0165-4608(97)00350-6; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Downward J, 1996, CANCER SURV, V27, P87; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Fisher C, 1996, EUR J CANCER, V32A, P2094, DOI 10.1016/S0959-8049(96)00287-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; Hongo A, 1996, ONCOGENE, V12, P1231; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KANEKO Y, 1991, CANCER RES, V51, P5937; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Kriauciunas KM, 2000, MOL CELL BIOL, V20, P6849, DOI 10.1128/MCB.20.18.6849-6859.2000; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MASCARELLO JT, 1994, CANCER GENET CYTOGEN, V77, P50, DOI 10.1016/0165-4608(94)90148-1; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2001, J CELL PHYSIOL, V186, P35; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OMalley DP, 1996, ULTRASTRUCT PATHOL, V20, P417, DOI 10.3109/01913129609016344; Pahlman S, 1996, MOL MED TODAY, V2, P432, DOI 10.1016/1357-4310(96)84847-7; Pass HI, 1996, CANCER RES, V56, P4044; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLYCHRONAKOS C, 1995, DEV GENET, V17, P253, DOI 10.1002/dvg.1020170310; Ponten J, 1971, Virol Monogr, V8, P1; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOFIELD DE, 1994, AM J SURG PATHOL, V18, P14, DOI 10.1097/00000478-199401000-00002; SCHOFIELD DE, 1993, AM J PATHOL, V143, P714; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHARIFAH NA, 1995, DIAGN MOL PATHOL, V4, P279, DOI 10.1097/00019606-199512000-00009; Steller MA, 1996, CANCER RES, V56, P5087; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tognon C, 2001, CANCER RES, V61, P8909; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang W, 1998, CANCER RES, V58, P4426; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Werner H, 1998, MOL CELL ENDOCRINOL, V141, P1, DOI 10.1016/S0303-7207(98)00099-9; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	70	61	63	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5684	5695		10.1038/sj.onc.1205669	http://dx.doi.org/10.1038/sj.onc.1205669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173038				2022-12-28	WOS:000177463400003
J	Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE				Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE			Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G(1) arrest associated with induction of p16ink4a and activation of RB	ONCOGENE			English	Article						rhabdoid; SWI/SNF; hSNF5/INI1/BAF47; RB; p16ink4a	SENESCENT HUMAN FIBROBLASTS; SWI-SNF COMPLEX; CHROMATIN-REMODELING COMPLEXES; HUMAN-DIPLOID FIBROBLASTS; MALIGNANT RHABDOID TUMOR; RETINOBLASTOMA-PROTEIN; CELLULAR SENESCENCE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; REPLICATIVE SENESCENCE	Truncating mutations and homozygous deletions in the hSNF5/INI1/BAF47 subunit of human SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies. How loss of hSNF5 contributes to tumorigenesis remains unknown. Because the SWI/ SNF subunit BRG1 is required for RB-mediated cell cycle arrest, we hypothesized that hSNF5 deficiency disrupts RB signaling. Here we demonstrate that unlike BRG1, hSNF5 deficient cells retain functional RB since ectopic expression of either p16ink4a or a constitutively active form of RB (PSM - RB) led to cell cycle arrest. To determine how hSNF5 loss might contribute to tumorigenesis, we used a retrovirus to introduce hSNF5 into multiple deficient cell lines. In all cases, re-expression inhibited colony formation and induced cell cycle arrest characterized by a flattened morphology. Flow cytometry revealed that these cells accumulated in G(0)/G(1). Importantly, arrested cells exhibited strong induction of p16ink4a, hypophosphorylated RB, and down-regulation of cyclin A, suggesting that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t abolished hSNF5-induced G(1) arrest and activation of RB. Likewise, HPV-16 E7 was sufficient to partially overcome cell cycle arrest. These results suggest that hSNF5 loss is not equivalent to BRG1/BRM loss in human tumor cell lines. Furthermore, hSNF5-induced cell cycle arrest of deficient cells is mediated in part through activation of p16ink4a expression. These findings provide insight into mechanisms of hSNF5-mediated tumor suppression.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati	Weissman, BE (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA091048, R01CA082525, T32CA071341] Funding Source: NIH RePORTER; NCI NIH HHS [CA82525, CA71341, CA91048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jiang H, 2000, ONCOGENE, V19, P3878, DOI 10.1038/sj.onc.1203722; KARNES PS, 1991, CANCER GENET CYTOGEN, V56, P31, DOI 10.1016/0165-4608(91)90359-3; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; ROBBINS E, 1970, J EXP MED, V131, P1211, DOI 10.1084/jem.131.6.1211; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Suzuki A, 1997, DIAGN MOL PATHOL, V6, P326, DOI 10.1097/00019606-199712000-00004; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	82	155	163	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5193	5203		10.1038/sj.onc.1205706	http://dx.doi.org/10.1038/sj.onc.1205706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149641				2022-12-28	WOS:000177193900001
J	Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G				Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G			Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells	ONCOGENE			English	Article						HER2/neu; ATRA; Grb2; Akt	GROWTH-FACTOR RECEPTOR; TUMOR NECROSIS FACTOR; GRB2 DOWN-REGULATION; PROTEIN-KINASE-B; MCF-7 CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ALPHA GENE; RAR-ALPHA; INHIBITION	We observed that all-trans retinoic acid (ATRA) inhibited the growth of MCF-7 breast cancer cells, but not those transfected with HER2/NEU or its transactivating ligand HEREGULIN. This suggests that Her2/neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. To confirm this observation, MDA-MB-453 and BT-474 cells, which have high levels of Her2/neu and are resistant to ATRA, were incubated with the trastuzumab (Herceptin(TM)) antibody so that we could determine whether inhibition of the expression and function of Her2/neu would resensitize these cells to ATRA. Indeed, we found that MDA-MB-453 and BT-474 cells treated with trastuzumab were growth inhibitory by ATRA. We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Liposome-incorporated Grb2 antisense oligonucleotides (L-Grb2) and a dominant negative (DN) AKT mutant were used to down-regulate Grb2 expression and inhibit Akt activity, respectively. When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. ATRA sensitivity was also correlated with RARalpha protein levels since higher RARalpha protein levels were observed in cells in which the Her2/neu pathway was inhibited.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, 1515 Holcombe Blvd,Box 422, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Esteva, Francisco J./0000-0003-2437-3920	NATIONAL CANCER INSTITUTE [K23CA082119] Funding Source: NIH RePORTER; NCI NIH HHS [K23-CA82119] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baselga J, 1998, CANCER RES, V58, P2825; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carter CA, 2000, EXP MOL PATHOL, V68, P170, DOI 10.1006/exmp.2000.2301; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; De Luca LM, 1997, J CELL PHYSIOL, V173, P297, DOI 10.1002/(SICI)1097-4652(199711)173:2<297::AID-JCP39>3.0.CO;2-A; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FRAKER LD, 1984, CANCER RES, V44, P5757; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; Lenferink AEG, 2001, CANCER RES, V61, P6583; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; LOTAN R, 1979, CANCER RES, V39, P1014; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Mangelsdorf David J., 1994, P319; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; Muller A, 1997, CANCER LETT, V113, P95, DOI 10.1016/S0304-3835(97)04601-6; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rishi AK, 1996, CANCER RES, V56, P5246; ROULIER S, 1994, MOL CELL ENDOCRINOL, V105, P165, DOI 10.1016/0303-7207(94)90166-X; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; SANG H, 1995, J NEUROSURG, V82, P841; Schneider SM, 2000, CANCER RES, V60, P5479; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tang CK, 1996, CANCER RES, V56, P3350; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang LM, 1997, CANCER RES, V57, P4652; YU DH, 1992, ONCOGENE, V7, P2263; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LF, 2002, LAB INVEST, V82, P71, DOI 10.1038/labinvest.3780396; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	59	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5224	5232		10.1038/sj.onc.1205660	http://dx.doi.org/10.1038/sj.onc.1205660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149644				2022-12-28	WOS:000177193900004
J	Blons, H; Laccourreye, O; Houllier, AM; Carnot, F; Brasnu, D; Beaune, P; Zucman-Rossi, J; Laurent-Puig, P				Blons, H; Laccourreye, O; Houllier, AM; Carnot, F; Brasnu, D; Beaune, P; Zucman-Rossi, J; Laurent-Puig, P			Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck neoplasm; chromosome 18; tumor suppressor gene; allelic losses; mutations; dHPLC	TUMOR-SUPPRESSOR GENE; HOMOZYGOUS DELETIONS; CHROMOSOME 18Q; ALLELIC LOSS; TUMORIGENICITY; IDENTIFICATION; HETEROZYGOSITY; CHEMOTHERAPY; METHYLATION; PROGRESSION	The 18q chromosome arm is frequently lost in advanced head and neck squamous cell carcinoma. Twenty-four microsatellite markers located on chromosome 18q were genotyped in 145 primary tumors and 10 cell lines in order. to identify putative tumor suppressor genes implicated in tumor progression. Two different minimal common regions of loss (MCRL) were identified at 18q22 and l8q23 respectively. To refine and delineate boundaries of an homozygous deletion found in one cell line, 44 extra markers located at 18q22 were analysed and the homozygous deletion was precisely defined within a critical region of 4.9 Mb. Four known genes (CDH7, CDH19, DNAM-1, FLJ23594) located in this critical region and two EST clusters (Hs.96900, Hs.98628) were selected for further investigations. For these six genes, genomic structures were established, somatic mutations were screened in 20 HNSCC and 10 cell lines and transcription levels were determined in eight cell lines. No somatic mutations were found in any of the candidate genes analysed (57 coding exons). However, differential transcription levels were observed for CDH19 and Hs.96900 in head and neck cancer cell lines supporting their putative involvement through down regulation mechanisms in head and neck cancer progression.	INSERM, U490, Unite Toxicol Mol, Mol Toxicol Lab, F-75006 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Serv Otorhinolaryngol & Chirurg Cervicofaciale, F-75015 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Lab Anatomopathol, F-75015 Paris, France; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Laurent-Puig, P (corresponding author), INSERM, U490, Unite Toxicol Mol, Mol Toxicol Lab, 45 Rue Sts Peres, F-75006 Paris, France.	Pierre.Laurent-Puig@biomedicale.univ-paris5.fr	j, zucman-rossi/AAV-3594-2021; Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; laurent-puig, pierre/B-2226-2013	j, zucman-rossi/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; laurent-puig, pierre/0000-0001-8475-5459; Beaune, Philippe/0000-0002-6569-9014; Blons, Helene/0000-0002-0572-8426				Adeyinka A, 1999, INT J CANCER, V84, P370, DOI 10.1002/(SICI)1097-0215(19990820)84:4<370::AID-IJC7>3.0.CO;2-7; Blons H, 1999, MOL CARCINOGEN, V26, P254; Blons H, 1999, INT J CANCER, V84, P410; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; Califano J, 1996, CANCER RES, V56, P2488; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hidaka E, 1999, J CANCER RES CLIN, V125, P439, DOI 10.1007/s004320050300; Hilgers W, 1999, GENE CHROMOSOME CANC, V25, P370, DOI 10.1002/(SICI)1098-2264(199908)25:4<370::AID-GCC9>3.0.CO;2-S; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kim SK, 1996, CANCER RES, V56, P2519; Kisielewski AE, 1998, ONCOGENE, V17, P83, DOI 10.1038/sj.onc.1201910; KOMURO H, 1999, NEOPLASIA, V3, P253; Kools P, 2000, GENOMICS, V68, P283, DOI 10.1006/geno.2000.6305; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7; Mao L, 1996, CANCER RES, V56, P5128; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NAWROZ H, 1994, CANCER RES, V54, P1152; Padalecki SS, 2000, INT J CANCER, V85, P654, DOI 10.1002/(SICI)1097-0215(20000301)85:5<654::AID-IJC10>3.0.CO;2-D; Padalecki SS, 2001, GENE CHROMOSOME CANC, V30, P221, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1093>3.0.CO;2-L; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Riggins GJ, 1997, CANCER RES, V57, P2578; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; Takebayashi S, 2000, CANCER RES, V60, P3397; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Worm J, 2000, ONCOGENE, V19, P5111, DOI 10.1038/sj.onc.1203891; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; YAMADA H, 1995, GENE CHROMOSOME CANC, V13, P18, DOI 10.1002/gcc.2870130104	32	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5016	5023		10.1038/sj.onc.1205626	http://dx.doi.org/10.1038/sj.onc.1205626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118382				2022-12-28	WOS:000176874800018
J	King, D; Yang, GY; Thompson, MA; Hiebert, SW				King, D; Yang, GY; Thompson, MA; Hiebert, SW			Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype	ONCOGENE			English	Article						NF1; p19(ARF); cell cycle; oncogenesis; sarcoma; lymphoma	NF1 GENE; IN-VIVO; TYPE-1; SUPPRESSOR; MICE; PATHWAY; RAS; HAPLOINSUFFICIENCY; INACTIVATION; DISRUPTION	Inactivation of the neurofibromatosis-1 (NF1) gene deregulates RAS and cooperates with mutation or loss of the p(53) tumor suppressor to induce tumorigenesis. p19(ARF) acts upstream of p53 in an oncogene checkpoint to induce apoptosis in response to activated RAS and other factors that stimulate proliferation. Therefore, we bred p19(ARF-/-) to NF1(+/-) -mice to determine if loss of these genes collaborates in tumorigenesis. As expected from the embryonic lethality of NF1 null mice, no mice lacking both p19(ARF) and NF1 were born. Unexpectedly, the loss of one allele of NF1 did not greatly shorten the time to tumor formation in a p19(ARF) null background. The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. However, seven out of 12 animals developed multiple tumors, some With metastases. This multiple tumor phenotype was not previously observed with p19(ARF)-null mice and suggests a distinct form of cooperation between the loss of these tumor suppressors.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, PRB 512,23rd & Pierce, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA087549, P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01-CA87549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Zhang YY, 2001, J CLIN INVEST, V108, P709, DOI 10.1172/JCI12758; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	22	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4978	4982		10.1038/sj.onc.1205632	http://dx.doi.org/10.1038/sj.onc.1205632			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118376				2022-12-28	WOS:000176874800012
J	Cullingworth, J; Hooper, ML; Harrison, DJ; Mason, J; Sirard, C; Patek, CE; Clarke, AR				Cullingworth, J; Hooper, ML; Harrison, DJ; Mason, J; Sirard, C; Patek, CE; Clarke, AR			Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes	ONCOGENE			English	Article						pancreas; SMAD4; APC; mouse	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; TGF-BETA; DIFFERENTIAL EXPRESSION; EXOCRINE PANCREAS; THYMIC LYMPHOMAS; MUTANT MICE; DPC4; CANCER; MUTATIONS	Mutations in the tumour suppressor genes SMAD4 (DPC4, deleted in pancreatic cancer locus 4) and adenomatous polyposis coli (APC) have been implicated in the development of pancreatic cancer in humans. Treatment of wild-type, Smad4(+/-), Apc(Min/+) or Apc(Min/+) Smad4(+/-) mice with N-Nitroso-N-Methyl Urea (NMU) results in abnormal foci in pancreatic acinar cells characterized by increased levels of beta-catenin. Previously such foci have been shown to be the precursors of pancreatic neoplasia. Interestingly, only NMU-treated Apc(Min/+) Smad4(+/-) mice exhibit a significant increase in abnormal pancreas, which was found to be due to increased number of abnormal foci rather than increased focus size. A, range of foci sizes were analysed, but only smaller abnormal foci were characterized by morphological nuclear atypia. These studies suggest functional co-operation between TGF-beta and Wnt signalling pathways in the suppression of pancreatic tumorigenesis in the mouse.	Western Gen Hosp, Sir Alastain Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh Sch Med, Sect Biomed Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Cardiff, Dept Biomed Sci, Cardiff CF10 3US, S Glam, Wales; McGill Univ, Brain Tumor Res Ctr, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Edinburgh; University of Edinburgh; Cardiff University; McGill University	Hooper, ML (corresponding author), Western Gen Hosp, Sir Alastain Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.		Clarke, Alan R/A-6256-2008; Mason, John O/A-1926-2010; clarke, alan r/P-2820-2014	Mason, John O/0000-0002-0489-2400; harrison, david/0000-0001-9041-9988; Clarke, Alan/0000-0002-4281-426X				Abraham SC, 2002, AM J PATHOL, V160, P953, DOI 10.1016/S0002-9440(10)64917-6; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ASAMURA H, 1989, CANCER, V64, P1657, DOI 10.1002/1097-0142(19891015)64:8<1657::AID-CNCR2820640817>3.0.CO;2-4; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BARKA T, 1982, J NATL CANCER I, V69, P1115; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CLARKE AR, 1995, ONCOGENE, V11, P1913; COROMINAS M, 1991, CANCER RES, V51, P5129; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; DIAMOND LE, 1987, CELL IMMUNOL, V107, P115, DOI 10.1016/0008-8749(87)90271-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grau AM, 1997, CANCER RES, V57, P3929; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, DIGESTION, V59, P493, DOI 10.1159/000007526; Hahn SA, 1996, CANCER RES, V56, P490; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1997, SURG ONCOL, V6, P1, DOI 10.1016/S0960-7404(97)00001-7; KEIGHREN M, 1993, HISTOCHEM J, V25, P30, DOI 10.1007/BF00161042; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; MONIS B, 1991, INT J PANCREATOL, V8, P119; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rozenblum E, 1997, CANCER RES, V57, P1731; SCARPA A, 1993, AM J PATHOL, V142, P1534; Schutte M, 1996, CANCER RES, V56, P2527; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOKAL RR, 1995, BIOMETRY PRINCIPLES, P151; Suzuki K, 2000, ANTICANCER RES, V20, P1257; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667	44	21	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4696	4701		10.1038/sj.onc.1205673	http://dx.doi.org/10.1038/sj.onc.1205673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096346				2022-12-28	WOS:000176625100011
J	Manzano, RG; Montuenga, LM; Dayton, M; Dent, P; Kinoshita, I; Vicent, S; Gardner, GJ; Nguyen, PM; Choi, YH; Trepel, J; Auersperg, N; Birrer, MJ				Manzano, RG; Montuenga, LM; Dayton, M; Dent, P; Kinoshita, I; Vicent, S; Gardner, GJ; Nguyen, PM; Choi, YH; Trepel, J; Auersperg, N; Birrer, MJ			CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential	ONCOGENE			English	Article						MKP-1; ovarian; cancer; phosphatases; growth; motility	PROTEIN-TYROSINE PHOSPHATASES; IMMEDIATE-EARLY GENE; MAP KINASE; IN-VIVO; CONSTITUTIVE ACTIVATION; EXTRACELLULAR-MATRIX; DNA-SYNTHESIS; CELL-LINES; GROWTH; MKP-1	Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and nonadherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer.	NCI, Cell & Canc Biol Dept, Rockville, MD 20850 USA; Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V6H 3V5, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Virginia Commonwealth University; University of British Columbia	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, 9610 Med Ctr Dr, Rockville, MD 20850 USA.		Vicent, Silvestre/K-4261-2017; Montuenga, Luis M/AAF-7783-2020	Vicent, Silvestre/0000-0002-9457-6881; Montuenga, Luis M/0000-0002-8739-1387; Gonzalez Manzano, Ramon/0000-0003-2266-6965	NATIONAL CANCER INSTITUTE [R01CA088906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Birrer MJ, 1999, CANCER RES, V59, P5270; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLIBY W, 1993, CANCER RES, V53, P2393; Dayton MA, 1997, RECEPT SIGNAL TRANS, V7, P241; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; DODSON MK, 1993, CANCER RES, V53, P4456; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hendricks DT, 1997, CANCER RES, V57, P2112; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Ozols Robert F., 1997, P919; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wiener JR, 1996, GYNECOL ONCOL, V61, P233, DOI 10.1006/gyno.1996.0131; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5	37	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4435	4447		10.1038/sj.onc.1205542	http://dx.doi.org/10.1038/sj.onc.1205542			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080474	Green Published			2022-12-28	WOS:000176317100009
J	Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A				Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A			Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression	ONCOGENE			English	Article						cell cycle; clusterin; ODC; PNT2; prostate cancer; SV40	HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; VENTRAL PROSTATE; SULFATED GLYCOPROTEIN-2; POLYAMINE METABOLISM; GENE-EXPRESSION; ANDROGEN RECEPTOR; HUMAN HOMOLOG; CANCER	Clusterin is a highly conserved, widely distributed glycoprotein whose biological significance is still debated. Involved in many biological processes and disease states, clusterin is induced by cell injury and tissue regression, but is repressed during cell proliferation. We have previously reported that clusterin mRNA induction is associated with epithelial cell atrophy in the rat prostate and both clusterin transcript and protein accumulated in quiescent normal human skin fibroblasts. Here we show that transient clusterin overexpression, in SV40-immortalized human prostate epithelial cells (PNT2), resulted in increased accumulation of cells in the G(0)/G(1) phases of the cell cycle, accompanied by slowdown of cell cycle progression and decrease of DNA synthesis. The activities of ornithine decarboxylase (ODC) and S-andenosylmethionine decarboxylase (AdoMetDC), and the level of histone H3 mRNA (markers of cell proliferation) concomitantly decreased, while Gas1 mRNA (a marker of cell quiescence) accumulated. Thus it appears that clusterin, by opposing the effect of SV40 on the proliferation rate of PNT2 cells, acts as an antioncogene in the prostate, suggesting a role for this gene in controlling proliferation of normal and transformed prostate epithelial cells.	Univ Parma, Dipartimento Med Sperimentale, I-43100 Parma, Italy; Univ Modena, Dipartimento Sci Biomed, I-41100 Modena, Italy	University of Parma; Universita di Modena e Reggio Emilia	Bettuzzi, S (corresponding author), Univ Parma, Dipartimento Med Sperimentale, Via Volturno 39, I-43100 Parma, Italy.	saverio.bettuzzi@unipr.it	Bettuzzi, Saverio/B-2609-2009	Bettuzzi, Saverio/0000-0003-2080-6979				Astancolle S, 2000, J ENDOCRINOL, V167, P197, DOI 10.1677/joe.0.1670197; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bettuzzi S, 2000, CANCER RES, V60, P1472; Bettuzzi S, 1995, FEBS LETT, V377, P321, DOI 10.1016/0014-5793(95)01359-8; BETTUZZI S, 1992, J ENDOCRINOL, V132, P361, DOI 10.1677/joe.0.1320361; Bettuzzi S, 1999, FEBS LETT, V448, P297, DOI 10.1016/S0014-5793(99)00375-0; Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; BETTUZZI S, 1994, FEBS LETT, V348, P255, DOI 10.1016/0014-5793(94)00609-1; BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; Blanchere M, 1998, J STEROID BIOCHEM, V66, P319, DOI 10.1016/S0960-0760(98)00056-9; BUCK MRE, 1995, CANCER RES, V55, P2959; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CANELLAKIS ZN, 1989, YALE J BIOL MED, V62, P481; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FINK TM, 1993, GENOMICS, V16, P526, DOI 10.1006/geno.1993.1222; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRASSILLI E, 1991, BIOCHEM BIOPH RES CO, V180, P59, DOI 10.1016/S0006-291X(05)81254-9; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; Huang HFS, 1997, J ANDROL, V18, P250; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; Konishi H, 1996, CANCER RES, V56, P434; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Latil A, 1996, J UROLOGY, V156, P2079, DOI 10.1016/S0022-5347(01)65439-9; LOWE NJ, 1980, ARCH DERMATOL, V116, P822, DOI 10.1001/archderm.116.7.822; LUK GD, 1987, ADV ENZYME REGUL, V26, P91, DOI 10.1016/0065-2571(87)90007-0; MARINELLI M, 1994, BIOCHEM CELL BIOL, V72, P515, DOI 10.1139/o94-069; Miyake H, 2000, CANCER RES, V60, P170; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PEARSE MJ, 1992, INT IMMUNOL, V4, P1225, DOI 10.1093/intimm/4.11.1225; PEGG AE, 1988, CANCER RES, V48, P759; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Scorcioni F, 2001, BIOCHEM J, V354, P217, DOI 10.1042/0264-6021:3540217; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x	45	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4328	4334		10.1038/sj.onc.1205594	http://dx.doi.org/10.1038/sj.onc.1205594			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082621				2022-12-28	WOS:000176174200016
J	de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC				de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC			Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy	ONCOGENE			English	Article						choline kinase; breast carcinomas; anticancer drugs; estrogen receptors	CANCER; INHIBITORS; TAMOXIFEN; PROGNOSIS; ANTIBODY; THERAPY; PROTEIN; MARKER	Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in viro. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.004). Here we provide evidence that ChoK may e related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Hosp Puerta Hierro, Med Oncol Serv, Madrid, Spain; Univ Autonoma Madrid, Dept Estadist, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Dominguez G, 2000, BREAST CANCER RES TR, V63, P17, DOI 10.1023/A:1006446709715; Fentiman IS, 2000, EUR J CANCER, V36, P1085, DOI 10.1016/S0959-8049(00)00088-5; Ferlay J, 2001, 5 IARC; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Lacal J C, 2001, IDrugs, V4, P419; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Powles T, 1998, LANCET, V352, P98; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; SALAZAR JM, 2001, REV ONCOLOGIA, V3, P171; Schneider J, 2000, ANTICANCER RES, V20, P4373; SLUYSER M, 1990, Anti-Cancer Drugs, V1, P127, DOI 10.1097/00001813-199012000-00003; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Tripathy D, 1992, Cancer Treat Res, V63, P15; VELASCO FB, 2001, REV ONCOLOGIA, V3, P130	20	203	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4317	4322		10.1038/sj.onc.1205556	http://dx.doi.org/10.1038/sj.onc.1205556			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082619				2022-12-28	WOS:000176174200014
J	Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ				Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ			Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer	ONCOGENE			English	Article						Fas; FADD; caspase 10; lung cancer; metastasis	APO-1/CD95 GENE; APOPTOSIS; DEATH; CARCINOMAS; RECEPTOR; RESISTANCE; MUTATIONS; MELANOMA	Many types of cancer cells are resistant to Fas-mediated apoptosis by several mechanisms, including the mutations of the genes involved in Fas-mediated apoptosis. In this study, to explore the possibility that the mutations of the genes involved in the proximal pathway of Fas-mediated apoptosis (Fas, FADD, caspase 8 and caspase 10) are involved in cancer metastasis, we have analysed somatic mutation and deletion of these genes in 80 non-small cell lung cancers (NSCLCs) with (n=43) and without (n=37) metastasis to the regional lymph nodes. We found 12 mutations (four Fas, four FADD, and four caspase 10 mutations) in 11 of 80 NSCLCs (13.8%). Interestingly, of these mutations, most mutations (10 out of 12) were detected in the NSCLCs with metastasis, and the frequency in the metastasis lesions (23%) was higher than that in the primary lesions of the NSCLCs without metastasis (5.4%). Furthermore, transfection study revealed that the tumor-derived mutants have decreased apoptosis inductions compared to the wild types. These data suggest that the inactivating mutations of the genes in the proximal pathway of Fas-mediated apoptosis may lead to a decreased cancer cell death and play a role in the metastasis of NSCLC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Thorac Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022	Park, Yong Gyu/0000-0002-8721-3230				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan ASK, 1996, LUNG CANCER-J IASLC, V15, P51, DOI 10.1016/0169-5002(96)00570-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOBZIK L, 1999, LUNG ROBBINS PATHOLO, P697; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATOLI G, 1995, ONCOGENE, V11, P1157; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Petersen S, 2000, BRIT J CANCER, V82, P65; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4	21	58	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4129	4136		10.1038/sj.onc.1205527	http://dx.doi.org/10.1038/sj.onc.1205527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037669				2022-12-28	WOS:000176186000007
J	Dunican, DS; McWilliam, P; Tighe, O; Pale-McDermott, A; Croke, DT				Dunican, DS; McWilliam, P; Tighe, O; Pale-McDermott, A; Croke, DT			Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; chromosomal instability; gene expression	NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; II RECEPTOR GENE; MUTATIONS; CELLS; PROTEIN; YEAST	Two distinct pathways of tumorigenesis exist in sporadic colorectal cancer. The microsatellite instability pathway (MIN), which is characterized by widespread microsatellite instability due to aberrant mismatch repair machinery, accounts for 15% of all sporadic colorectal cancers. The chromosomal instability (CIN) phenotype, which accounts for 85% of sporadic colorectal cancers, is characterized by gross chromosomal lesions but the underlying mechanism remains unclear. We have addressed differences in gene expression between the MIN and CIN colorectal cancer phenotypes in vitro by the use of high density cDNA filters to compare gene expression patterns between MIN and CIN colorectal cancer cell-tines yielding a panel of 73 consistently differentially expressed genes. Nine of these genes were subjected to confirmatory analysis by independent methods, of which six were confirmed as being differentially expressed; PLK, RanBP2 and CCNA2 were overexpressed in CIN tines while BTF3, H2AZ and PTPD1 were overexpressed in MIN lines. These six genes are involved in diverse processes, such as maintenance of chromatin architecture, DNA-damage checkpoint and cell cycle regulation, which may contribute to the CIN and MIN phenotypes.	Royal Coll Surgeons Ireland, Dept Biochem, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Croke, DT (corresponding author), Royal Coll Surgeons Ireland, Dept Biochem, 123 St Stephens Green, Dublin 2, Ireland.		Dunican, Donncha/A-8147-2011	Croke, David/0000-0003-2718-3583; Tighe, Orna/0000-0003-0931-1254				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; DRUCK T, 1995, CANCER RES, V55, P5348; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HEINEN CD, 1995, CANCER RES, V55, P4797; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lal A, 1999, CANCER RES, V59, P5403; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; PARSONS R, 1995, CANCER RES, V55, P5548; Partanen S, 1996, ANTICANCER RES, V16, P943; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sambrook J., 2002, MOL CLONING LAB MANU; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	20	110	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3253	3257		10.1038/sj.onc.1205431	http://dx.doi.org/10.1038/sj.onc.1205431			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082642				2022-12-28	WOS:000175373600018
J	Devilard, E; Bertucci, F; Trempat, P; Bouabdallah, R; Loriod, B; Giaconia, A; Brousset, P; Granjeaud, S; Nguyen, C; Birnbaum, D; Birg, F; Houlgatte, R; Xerri, L				Devilard, E; Bertucci, F; Trempat, P; Bouabdallah, R; Loriod, B; Giaconia, A; Brousset, P; Granjeaud, S; Nguyen, C; Birnbaum, D; Birg, F; Houlgatte, R; Xerri, L			Gene expression profiling defines molecular subtypes of classical Hodgkin's disease	ONCOGENE			English	Article						cDNA array; gene expression profiling; mRNA; Hodgkin's disease	REED-STERNBERG CELLS; NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CLASSIFICATION; LYMPHOMA; CANCER; PTEN; ACTIVATION; BREAST	Although the prognosis of Hodgkin's disease is relatively good, around 20% of patients do not benefit from current therapies and succumb to their disease. A large-scale molecular characterization of disease might help improve HD management. Using cDNA arrays, we studied the mRNA expression levels of similar to 1000 selected genes in 34 benign and malignant lymphoid samples including 21 classical Hodgkin's disease (HD) tissue samples. Hierarchical clustering identified three main molecular groups of HD tumours relevant with respect to histology and clinical outcome (response to therapy and survival). Samples from all bad outcome HD (BOHD) patients clustered in one group whereas the two other groups contained most good outcome HD (GOHD) cases. The nodular sclerosis GOHD samples overexpressed genes involved in apoptotic induction and cell signalling, including cytokines, while the BOHD samples were characterized by the upregulation of genes involved in fibroblast activation, angiogenesis, extracellular matrix remodelling, cell proliferation, and the downregulation of tumour suppressor genes. Our results establish a molecular taxonomy of HD correlating with response to therapy and clinical outcome, thereby suggesting the possibility of improving the current prognostic classification.	Inst Paoli Calmettes, Dept Pathol, Marseille, France; Inst Paoli Calmettes, TAGC, Marseille, France; Inst Paoli Calmettes, Dept Haematol, Marseille, France; Inst Paoli Calmettes, INSERM, U119, IFR 57, Marseille, France; Univ Mediterranee, Marseille, France; CHU Purpan, Toulouse, France	UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; CHU de Toulouse	Xerri, L (corresponding author), 232 Blvd St Marguerite,BP 156, F-13273 Marseille 9, France.	xerril@marseille.fnclcc.fr	Houlgatte, Remi/P-3020-2017; Granjeaud, Samuel/AAE-6488-2022; loriod, beatrice bl/L-2948-2016; Nguyen, Catherine/M-4119-2016	Granjeaud, Samuel/0000-0001-9245-1535; loriod, beatrice bl/0000-0001-5801-2264; Nguyen, Catherine/0000-0001-9376-6360; Bertucci, Francois/0000-0002-0157-0959				Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; [Anonymous], 1999, NAT GENET S, V21, P1; Bartlett N L, 2000, Curr Oncol Rep, V2, P163, DOI 10.1007/s11912-000-0089-6; Bertucci F, 1999, ONCOGENE, V18, P3905, DOI 10.1038/sj.onc.1202731; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brice P, 1996, CANCER-AM CANCER SOC, V78, P1293, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.3.CO;2-M; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Chan WC, 2001, HEMATOL ONCOL, V19, P1; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; Cossman J, 1998, LAB INVEST, V78, P229; Cossman J, 2001, J HISTOCHEM CYTOCHEM, V49, P799, DOI 10.1177/002215540104900617; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dales JP, 2001, J CLIN PATHOL-MOL PA, V54, P17; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; HARRIS NL, 1994, BLOOD, V84, P1361; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Izban KF, 2001, MODERN PATHOL, V14, P297, DOI 10.1038/modpathol.3880306; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kennedy BJ, 1998, CANCER-AM CANCER SOC, V83, P1041, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1041::AID-CNCR31>3.0.CO;2-5; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li SY, 2001, AM J PATHOL, V158, P1231, DOI 10.1016/S0002-9440(10)64073-4; LOHRI A, 1991, BLOOD, V77, P2292; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; Morente MM, 1997, BLOOD, V90, P2429; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; POPPEMA S, 2000, LAB INVEST, V78, P229; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Theil J, 2001, BLOOD, V97, P3191, DOI 10.1182/blood.V97.10.3191; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Wakkach A, 2000, EUR CYTOKINE NETW, V11, P153; Warzocha K, 1998, BRIT J CANCER, V77, P2357, DOI 10.1038/bjc.1998.391; Wellmann A, 2000, BLOOD, V96, P398; XERRI L, 1994, HUM PATHOL, V25, P449, DOI 10.1016/0046-8177(94)90116-3; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	54	77	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3095	3102		10.1038/sj.onc.1205418	http://dx.doi.org/10.1038/sj.onc.1205418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082542				2022-12-28	WOS:000175262700019
J	Lemoine, FJ; Marriott, SJ				Lemoine, FJ; Marriott, SJ			Genomic instability driven by the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax	ONCOGENE			English	Article						HTLV-1; tax gene amplification; genome stability; PALA; cell cycle	MAMMALIAN GENE AMPLIFICATION; 1ST 3 ENZYMES; WILD-TYPE P53; ASPARTATE-TRANSCARBAMYLASE; TRANSACTIVATION FUNCTION; CHROMOSOME BREAKAGE; CYCLE ARREST; DNA-DAMAGE; PROTEIN; LYMPHOCYTES	The importance of maintaining genomic stability is evidenced by the fact that transformed cells often contain a variety of chromosomal abnormalities such as euploidy, translocations, and inversions. Gene amplification is a well-characterized hallmark of genomic instability thought to result from recombination events following the formation of double-strand, chromosomal breaks. Therefore, gene amplification frequency serves as an indicator of genomic stability. The PALA assay is designed to measure directly the frequency with which a specific gene, CAD, is amplified within a cell's genome. We have used the PALA assay to analyse the effects of the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax, on genomic amplification. We demonstrate that Tax-expressing cells are five-times more likely to undergo gene amplification than control cells. Additionally, we show that Tax alters the ability of cells to undergo the typical PALA-mediated G, phase cell cycle arrest, thereby allowing cells to replicate DNA in the absence of appropriate nucleotide pools. This effect is likely the mechanism by which Tax induces gene amplification. These data suggest that HTLV-1 Tax alters the genomic stability of cells, an effect that may play an important role in Tax-mediated, HTLV-1 associated cellular transformation.	Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA-09197, CA-77371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAO SY, 2000, RES ADV VIROL, V1, P1; KEMPE TD, 1976, CELL, V9, P541, DOI 10.1016/0092-8674(76)90036-2; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MONDELLO C, 1995, MUTAT RES LETT, V346, P61, DOI 10.1016/0165-7992(95)90052-7; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OTTO E, 1989, J BIOL CHEM, V264, P3390; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REID RL, 1993, ONCOGENE, V8, P3029; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WETTERGREN Y, 1994, SOMAT CELL MOLEC GEN, V20, P267, DOI 10.1007/BF02254717; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAOKA S, 1992, ONCOGENE, V7, P433	39	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7230	7234		10.1038/sj.onc.1205898	http://dx.doi.org/10.1038/sj.onc.1205898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370813				2022-12-28	WOS:000178504600011
J	Bachelor, MA; Silvers, AL; Bowden, GT				Bachelor, MA; Silvers, AL; Bowden, GT			The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT	ONCOGENE			English	Article						UVA; COX-2; p38; HaCaT	MESSENGER-RNA STABILITY; COLON-CANCER CELLS; SINGLET OXYGEN; GENE-EXPRESSION; 3'-UNTRANSLATED REGION; MAP KINASE; HUMAN SKIN; POSTTRANSCRIPTIONAL CONTROL; ULTRAVIOLET-RADIATION; HEME OXYGENASE	We examined the expression of cycloxygenase-2, the rate-limiting enzyme in the production of prostaglandins, in the UVA-irradiated human keratinocyte cell line, HaCaT. UVA induced a dose-dependent increase in COX-2 at the protein level at 2 and 4 h post-irradiation and at the mRNA level at 1 and 2 h post-irradiation. Experiments using semi-quantitative RT-PCR demonstrate that UVA increased the half-life of the COX-2 message by more than fourfold in the presence of Actinomycin D (with a half life between 4 and 8 h post-irradiation), suggesting that UVA induction of COX-2 is post-transcriptionally regulated. Through the use of the specific p38 inhibitor, SB202190, increases in COX-2 message and protein levels were abrogated in UVA-irradiated cells. In UVA-irradiated cells treated with S13202190, the half-life of the COX-2 message was decreased to basal levels (between I and 2 h postirradiation), indicating that p38 was responsible for the stabilization of the message. Luciferase activity was increased in UVA-irradiated cells transfected with reporter constructs containing the 3' UTR of COX-2, a region containing AU-rich elements (AREs). These regulatory sequences of AUUUA have been proposed as one mechanism of post-transcriptional regulation. Increases observed in luciferase activity could be decreased using a p38 dominant-negative construct. We report for the first that UVA can induce COX-2 expression in the human keratinocyte cell line, HaCaT. Additionally, p38 appears to play a critical role in the UVA-induced expression of COX-2 in these keratinocytes and may serve as a potential drug target in the chemoprevention of skin cancer.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA23074, CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BASUMODAK S, 1993, CANCER RES, V53, P4505; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HANSON D, 1990, J INVEST DERMATOL, V95, P158, DOI 10.1111/1523-1747.ep12477928; HANSON DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P423, DOI 10.1111/j.1751-1097.1989.tb09190.x; HIAL V, 1976, EUR J PHARMACOL, V37, P367, DOI 10.1016/0014-2999(76)90044-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MATSUI MS, 1991, CANCER CELL-MON REV, V3, P8; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Nabors LB, 2001, CANCER RES, V61, P2154; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Silvers AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P302, DOI 10.1562/0031-8655(2002)075<0302:UIIAOA>2.0.CO;2; SNYDERMAN CH, 1995, ARCH OTOLARYNGOL, V121, P1017; Soriani M, 1998, FEBS LETT, V439, P253, DOI 10.1016/S0014-5793(98)01387-8; Subbarayan V, 2001, CANCER RES, V61, P2720; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Thompson EJ, 2001, NEOPLASIA, V3, P402, DOI 10.1038/sj.neo.7900182; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P407, DOI 10.1001/archderm.122.4.407; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	54	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7092	7099		10.1038/sj.onc.1205855	http://dx.doi.org/10.1038/sj.onc.1205855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370831				2022-12-28	WOS:000178424900012
J	Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B				Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B			The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)	ONCOGENE			English	Article						DEP1; adherens junction; p120(ctn); protein tyrosine phosphatase	CELL-CELL-ADHESION; E-CADHERIN; SIGNAL-TRANSDUCTION; BETA-CATENIN; ALPHA-CATENIN; PHOSPHORYLATION; SUBSTRATE; COMPLEX; ASSOCIATION; DIFFERENTIATION	The receptor-like protein tyrosine phosphatase DEPI, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes. Expression of DEP1 is enhanced at high cell density, and this observation suggests that DEP1 may function in the regulation of cell adhesion and possibly contact inhibition of cell growth. In order to investigate the function of DEPI, substrate-trapping mutants of the phosphatase were used to identify potential substrates. GST-fusion proteins containing the DEPI catalytic domain with a substrate-trapping D/A mutation were found to interact with p120(ctn), a component of adherens junctions. DEPI also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin. The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression. Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEN with these proteins is specific. DEN expression was concentrated at sites of cell-cell contact in A549 cells. p120(ctn) was found to colocalize with these structures. Together these data suggest an important rote for DEP-1 in the function of cell-cell contacts and adherens junctions.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Holsinger, LJ (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.	leslie-holsinger@sugen.com						AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Gaya A, 1999, LEUKEMIA LYMPHOMA, V35, P237, DOI 10.3109/10428199909145726; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	49	70	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7067	7076		10.1038/sj.onc.1205858	http://dx.doi.org/10.1038/sj.onc.1205858			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370829				2022-12-28	WOS:000178424900010
J	Niu, G; Bowman, T; Huang, M; Shivers, S; Reintgen, D; Daud, A; Chang, A; Kraker, A; Jove, R; Yu, H				Niu, G; Bowman, T; Huang, M; Shivers, S; Reintgen, D; Daud, A; Chang, A; Kraker, A; Jove, R; Yu, H			Roles of activated Src and Stat3 signaling in melanoma tumor cell growth	ONCOGENE			English	Article						melanoma; Stat3; Src; tumor cell survival	TYROSINE KINASE INHIBITORS; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; FACTOR RECEPTOR; SUPPRESSES GROWTH; GENE-REGULATION; IN-VIVO; C-SRC; APOPTOSIS	Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases. Moreover, a critical role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers. However, the oncogenic signaling pathways in melanoma cells remain to be fully defined. In this study, we demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examined. Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines. Consistent with a role of Src in the pathogenesis of melanoma, we show that c-Src tyrosine kinase is activated in melanoma cell lines. Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited. Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the antiapoptotic genes, BCI-X-L and Mcl-1. These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Immunol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Cutaneous Oncol Program, Tampa, FL 33612 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48105 USA; Pfizer Global Res, Dept Canc Res, Ann Arbor, MI 48106 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; Pfizer	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA.		Shivers, Steve/E-6438-2013; Daud, Adil/T-3079-2019; Shivers, Steven/AAE-9288-2022	Shivers, Steve/0000-0001-9538-4016; Daud, Adil/0000-0002-6617-8421; YU, Hua/0000-0003-0931-1000	NCI NIH HHS [CA75243, CA82533, CA55652, CA89693] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA082533, R01CA089693, R01CA055652, R29CA075243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Dorsey JF, 2000, CANCER RES, V60, P3127; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HUANG M, 2002, IN PRESS ONCOGENE; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moasser MM, 1999, CANCER RES, V59, P6145; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	41	359	381	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7001	7010		10.1038/sj.onc.1205859	http://dx.doi.org/10.1038/sj.onc.1205859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370822				2022-12-28	WOS:000178424900003
J	Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF				Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF			Cell transformation by v-Jun deactivates ERK MAP kinase signalling	ONCOGENE			English	Article						v-Jun; MAP kinase; autocrine; transformation	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; GROWTH-FACTOR; CYCLE ARREST; RAS; EXPRESSION; PROLIFERATION; FIBROBLASTS; ENTRY; GENE	Previous studies have shown that v-Jun accelerates G1 progression and enables cells to sustain S phase entry in the absence of serum growth factors. Since growth factor-dependent ERK MAP kinase signalling plays an important role in regulating the G1/S transition, we investigated whether aberrant ERK regulation might contribute to cell cycle deregulation by v-Jun. Contrary to expectation, we find that cells transformed by v-Jun exhibit a profound reduction in the basal level of active, dual-phosphorylated ERK. In addition, ERK becomes refractory to stimulation by a subset of agonists including serum, LPA, and EGF, but remains partially responsive to the phorbol ester, TPA. Biochemical analysis indicates that these defects are attributable to a combination of inefficient signal propagation between Ras and Raf within the ERK pathway and increased tonic deactivation by MAP kinase phosphatases. Taken together, these results demonstrate that cell transformation by v-Jun induces alterations in cell physiology which antagonize ERK signalling at multiple levels. The potential significance of this phenotype for oncogenesis by v-Jun is discussed.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Black EJ, 2000, CURR BIOL, V10, P1119, DOI 10.1016/S0960-9822(00)00699-0; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kilbey A, 1996, ONCOGENE, V12, P2409; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SU HY, 1991, ONCOGENE, V6, P1759; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Treinies I, 1999, MOL CELL BIOL, V19, P321; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	31	15	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6540	6548		10.1038/sj.onc.1205851	http://dx.doi.org/10.1038/sj.onc.1205851			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226757				2022-12-28	WOS:000177925300014
J	Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L				Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L			p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol	ONCOGENE			English	Article						kinases; inhibitors; CDKs; MAPK; erk; purvalanol	CYCLIN-DEPENDENT KINASE; ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; P70 S6 KINASE; CELL-CYCLE; NUCLEAR TRANSLOCATION; CHEMICAL INHIBITORS; SELECTIVE INHIBITOR; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE	Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. Intensive screening of a combinatorial chemistry library of 2,6,9-trisubstituted purines has led to the identification of purvalanol, one of the most potent and selective CDK inhibitors to date. In preliminary studies, this compound demonstrates definite anti-mitotic properties, consistent with its nanomolar range efficiency towards purified CDK1 and CDK2. However, the actual intracellular targets of purvalanol remain to be identified, and a method for the determination of its in vivo selectivity was developed. In this technique, cell extracts were screened for purvalanol-interacting proteins by affinity chromatography on immobilized inhibitor. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. The Chinese hamster lung fibroblast cell line CCL39 was used as a model to investigate the anti-proliferative properties of purvalanol. The compound inhibited cell growth with a GI(50) value of 2.5 muM and induced a G2/M block when added to exponentially growing cells. It did not appear to trigger massive activation of caspase. We next tested whether CDKs and p42/p44 MAPK were actually targeted by the compound in vivo. p42/p44 MAPK activity was visuatized using an Elk-Gal4 luciferase reporter system and CDK1 activity was detected by the phosphonucleolin level. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases. We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs. These observations highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation.	CNRS, Stn Biol Roscoff, F-29682 Roscoff, France; Ctr Antoine Lacassagne, UNSA, CNRS, UMR 6453, F-06189 Nice, France; Novartis Inst Funct Genom, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Novartis	Meijer, L (corresponding author), CNRS, Stn Biol Roscoff, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Lenormand, Philippe/N-5996-2018	, laurent/0000-0003-3511-4916				Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Barvian M, 2000, J MED CHEM, V43, P4606, DOI 10.1021/jm000271k; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carini DJ, 2001, BIOORG MED CHEM LETT, V11, P2209, DOI 10.1016/S0960-894X(01)00416-4; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Clare PM, 2001, J BIOL CHEM, V276, P48292, DOI 10.1074/jbc.M102034200; Damiens E, 2000, PATHOL BIOL, V48, P340; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Dreyer MK, 2001, J MED CHEM, V44, P524, DOI 10.1021/jm001043t; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P1; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fischer PM, 2000, CURR MED CHEM, V7, P1213, DOI 10.2174/0929867003374048; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Hardcastle IR, 2002, ANNU REV PHARMACOL, V42, P325, DOI 10.1146/annurev.pharmtox.42.090601.125940; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Kaubisch A, 2000, CANCER J, V6, P192; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; KNOCKAERT M, 2002, IN PRESS TRENDS PHAR; Lane ME, 2001, CANCER RES, V61, P6170; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Legraverend M, 2000, J MED CHEM, V43, P1282, DOI 10.1021/jm9911130; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Nugiel DA, 2001, J MED CHEM, V44, P1334, DOI 10.1021/jm0100032; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park SG, 1996, MOL CELLS, V6, P679; PARKER CW, 1986, PHYTOCHEMISTRY, V25, P303, DOI 10.1016/S0031-9422(00)85471-0; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; RIALET V, 1991, ANTICANCER RES, V11, P1581; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; ROSANIA GR, 2000, EXPERT OPIN THER PAT, V10, P1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Shum PW, 2001, NUCLEOS NUCLEOT NUCL, V20, P1067, DOI 10.1081/NCN-100002493; Sielecki TM, 2001, BIOORG MED CHEM LETT, V11, P1157, DOI 10.1016/S0960-894X(01)00185-8; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; Toogood PL, 2001, MED RES REV, V21, P487, DOI 10.1002/med.1021; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Zaharevitz DW, 1999, CANCER RES, V59, P2566; ZIMMERMANN J, 1995, Patent No. 9509853	89	55	60	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6413	6424		10.1038/sj.onc.1205908	http://dx.doi.org/10.1038/sj.onc.1205908			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226745	Bronze			2022-12-28	WOS:000177925300002
J	Reis, PP; Rogatto, SR; Kowalski, LP; Nishimoto, IN; Montovani, JC; Corpus, G; Squire, JA; Kamel-Reid, S				Reis, PP; Rogatto, SR; Kowalski, LP; Nishimoto, IN; Montovani, JC; Corpus, G; Squire, JA; Kamel-Reid, S			Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer	ONCOGENE			English	Article						oral cavity cancer; chromosome 22q; quantitative real time PCR	POLYMERASE-CHAIN-REACTION; COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CHROMOSOME 22Q; GROWTH-FACTOR; ALLELIC LOSS; NECK-CANCER; RT-PCR; HEAD	Quantitative real time PCR was performed on genomic DNA from 40 primary oral carcinomas and the normal adjacent tissues. The target genes ECGFB, DIA1, BIK, and PDGFB and the microsatellite markers D22S274 and D22S277, mapped on 22q13, were selected according to our previous loss of heterozygosity findings in head and neck tumors. Quantitative PCR relies on the comparison of the amount of product generated from a target gene and that generated from a disomic reference gene (GAPDH-housekeeping gene). Reactions have been performed with normal control in triplicates, using the 7700 Sequence Detection System (PE Applied Biosystems). Losses in the sequences D22S274 (22q13.31) and in the DIA1 (22q13.2-13.31) gene were detected in 10 out of 40 cases (25%) each. Statistically significant correlations were observed for patients with relative copy number loss of the marker D22S274 and stages T3-T4 of disease (P=0.025), family history of cancer (P = 0.001), and death (P = 0.021). Relative copy number loss involving the DIA1 gene was correlated to family history of cancer (P<0.001), death (P=0.002), and consumption of alcohol (P=0.026). Log-rank test revealed a significant decrease in survival (P=0.0018) for patients with DIA1 gene loss. Relative copy number losses detected in these sequences may be related to disease progression and a worse prognosis in patients with oral cancer.	Univ Estadual Paulista, Dept Genet, Sao Paulo, Brazil; Hosp AC Carmargo Fundacao Antonio Prudente, Sao Paulo, Brazil; Univ Estadual Paulista, Hosp Clin, Sao Paulo, Brazil; Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	Universidade Estadual Paulista; A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade Estadual Paulista; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Rogatto, SR (corresponding author), Univ Estadual Paulista, Dept Genet, Sao Paulo, Brazil.		Kowalski, Luiz P/D-1701-2012; Squire, Jeremy A/F-4437-2012; dos Reis, Patricia Pintor/F-4701-2012; Squire, Jeremy A/A-9352-2012; Rogatto, Silvia R/E-6535-2012	Kowalski, Luiz P/0000-0002-0481-156X; dos Reis, Patricia Pintor/0000-0003-3775-3797; Squire, Jeremy A/0000-0002-9863-468X; Kamel-Reid, Suzanne/0000-0002-4386-0292; Rogatto, Silvia/0000-0003-4637-5687				*AJCC, 1998, CANC STAG HDB AJCC C; Bergamo NA, 2000, CANCER GENET CYTOGEN, V119, P48, DOI 10.1016/S0165-4608(99)00213-7; Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Blancato JK, 1999, PRINCIPLES OF CLINICAL CYTOGENETICS, P443; Bockmuhl U, 1998, HEAD NECK-J SCI SPEC, V20, P145, DOI 10.1002/(SICI)1097-0347(199803)20:2<145::AID-HED8>3.0.CO;2-2; BOYD JM, 1995, ONCOGENE, V11, P1921; Bryan EJ, 2000, INT J CANCER, V87, P798, DOI 10.1002/1097-0215(20000915)87:6<798::AID-IJC6>3.0.CO;2-X; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Dracopoli N. C., 2000, CURRENT PROTOCOLS HU; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grati FR, 2000, CANCER GENET CYTOGEN, V118, P57, DOI 10.1016/S0165-4608(99)00199-5; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Helenius MA, 2001, CANCER RES, V61, P5340; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; Kim NG, 2000, INT J CANCER, V85, P633, DOI 10.1002/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.3.CO;2-X; Kitamura Y, 2000, GENE CHROMOSOME CANC, V27, P244; Lehmann U, 2000, AM J PATHOL, V156, P1855, DOI 10.1016/S0002-9440(10)65059-6; Lo YMD, 2000, CANCER RES, V60, P6878; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; Miyakawa A, 1998, INT J ONCOL, V13, P705; Nakanishi H, 2000, INT J CANCER, V89, P411, DOI 10.1002/1097-0215(20000920)89:5<411::AID-IJC3>3.0.CO;2-5; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Peter M, 2001, LAB INVEST, V81, P905, DOI 10.1038/labinvest.3780299; Poli-Frederico RC, 2000, HEAD NECK-J SCI SPEC, V22, P585, DOI 10.1002/1097-0347(200009)22:6<585::AID-HED7>3.0.CO;2-4; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; REIS PP, 2002, MED SCI MONIT, V8, pBR89; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Rogatto SR, 1999, CANCER GENET CYTOGEN, V110, P23, DOI 10.1016/S0165-4608(98)00192-7; Ruiz-Ponte C, 2000, CLIN CHEM, V46, P1574; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; Simpson D, 2000, MOL VIS, V6, P178; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Ueki K, 1999, CANCER RES, V59, P5995; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; *WHO, 1990, INT CLASS DIS ONC; Wight AJ, 1998, ORAL ONCOL, V34, P441, DOI 10.1016/S1368-8375(98)00022-0	42	37	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6480	6487		10.1038/sj.onc.1205864	http://dx.doi.org/10.1038/sj.onc.1205864			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226751				2022-12-28	WOS:000177925300008
J	Tarapore, P; Fukasawa, K				Tarapore, P; Fukasawa, K			Loss of p53 and centrosome hyperamplification	ONCOGENE			English	Review						centrosome hyperamplification; cancer; p53; p21	P53-DEFICIENT MICE; CELL-CYCLE; GENOMIC INSTABILITY; MAMMALIAN-CELLS; CDK INHIBITORS; HUMAN CANCER; DUPLICATION; MUTATIONS; PROMOTES; PROGRESSION	Loss or mutational inactivation of p53 has been shown to lead to abnormal amplification of centrosomes through deregulation of the centrosome duplication cycle and failure to undergo cytokinesis. In mouse cells, most cases of centrosome hyperamplification are attributed to deregulation of centrosome duplication. The presence of excess copies of centrosomes increases the frequency of mitotic defects, leading to unbalanced chromosome transmission to daughter cells. p53 controls centrosome duplication via transactivation-dependent and transactivation-independent mechanisms. In its transactivation-dependent control, p21(Waf1/Cip1) acts as a major effector, likely guarding against untimely activation of CDK2/cyclin E kinase, hence ensuring the coordinated initiation of centrosome and DNA duplication. p53 appears to exert its transactivation-independent control through direct physical binding to the centrosomes.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661	NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Bunz F, 2002, CANCER RES, V62, P1129; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Hainaut P, 2000, ADV CANCER RES, V77, P81; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MORO F, 1995, CARCINOGENESIS, V16, P2435, DOI 10.1093/carcin/16.10.2435; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PURDIE CA, 1994, ONCOGENE, V9, P603; Reed SI, 1997, CANCER SURV, V29, P7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang LHV, 1998, IEEE ENG MED BIOL, V17, P45, DOI 10.1109/51.664029; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	59	151	159	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6234	6240		10.1038/sj.onc.1205707	http://dx.doi.org/10.1038/sj.onc.1205707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214254				2022-12-28	WOS:000177840500013
J	Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A				Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A			Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)	ONCOGENE			English	Article						RNA interference; BCR/ABL rearrangement; apoptosis; STI 571; gene therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; POLYMERASE-CHAIN-REACTION; BCR-ABL; CLINICAL-SIGNIFICANCE; INHIBITOR; RESISTANCE; GROWTH	Short 21-mer double-stranded RNA (dsRNA) molecules have recently been employed for the sequence-specific silencing of endogenous human genes. This mechanism, called RNA interference (RNAi), is extremely potent and requires only a few dsRNA molecules per cell to silence homologous gene mRNA expression. We used dsRNA targeting the M-BCR/ABL fusion site to kill leukemic cells with such a rearrangement. Transfection of dsRNA specific for the M-BCR/ABL fusion mRNA into K562 cells depleted the corresponding mRNA and the M-BCR/ABL oncoprotein. This was demonstrated by real-time quantitative PCR and Western blots. The BCR/ABL knockdown was accompanied by strong induction of apoptotic cell death. Leukemic cells without BCR/ABL rearrangement were not killed by M-BCR/ABL-dsRNA. In addition, to corroborate the extraordinary sequence specificity of RNAi, we designed another RNA oligo matching the M-BCR/ABL fusion site but having two point mutations within its central region. We show that these two point mutations abolished both p210 reduction and induction of apoptosis in K562 cells. Finally, we compared leukemic cell killing by RNAi to that caused by the ABL kinase tyrosine inhibitor, STI 571, Imatinib. For full induction of apoptosis, dsRNA targeting M-BCR/ABL required 24 h more than Imatinib. This may be caused by the relatively long half-life of the BCR/ABL oncoprotein, which is not targeted by the RNAi mechanism, but is affected by STI 571. When we applied ds M-BCR/ABL RNA and STI 571 in combination, we did not observe a further increase in the induction of apoptosis. Nevertheless, these data may open a field for further studies towards gene-therapeutic approaches using RNA interference to kill tumor cells with specific genetic abnormalities.	Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Borkhardt, A (corresponding author), Pediat Hematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany.	Arndt.Borkhardt@paediat.med.uni-giessen.de						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DHUT S, 1990, LEUKEMIA, V4, P745; DOBROVIC A, 1991, LEUKEMIA, V5, P187; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Goldman JM, 2001, NEW ENGL J MED, V344, P1084, DOI 10.1056/NEJM200104053441409; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2001, SCIENCE, V293, P2163; HOOBERMAN AL, 1989, P NATL ACAD SCI USA, V86, P4259, DOI 10.1073/pnas.86.11.4259; LESTINGI TM, 1993, HEMATOL ONCOL CLIN N, V7, P161, DOI 10.1016/S0889-8588(18)30262-4; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; Spiller DG, 1998, BLOOD, V91, P4738, DOI 10.1182/blood.V91.12.4738.412k31_4738_4746; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; WESTBROOK CA, 1992, BLOOD, V80, P2983	36	239	365	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5716	5724		10.1038/sj.onc.1205653	http://dx.doi.org/10.1038/sj.onc.1205653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173041				2022-12-28	WOS:000177463400006
J	Sato, M; Horio, Y; Sekido, Y; Minna, JD; Shimokata, K; Hasegawa, Y				Sato, M; Horio, Y; Sekido, Y; Minna, JD; Shimokata, K; Hasegawa, Y			The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines	ONCOGENE			English	Article						epigenetic modification; DNA methylation; tumor suppressor gene; DNA methyltransferase; methyl-CpG-binding protein; lung cancer	TUMOR-SUPPRESSOR GENE; COLON-CANCER; EPIGENETIC INACTIVATION; SATELLITE REGIONS; RETINOBLASTOMA; LOCUS; ISLANDS; HYPERMETHYLATION; MUTATIONS; 3P21.3	Promoter hypermethylation is an important means for the transcriptional repression of a number of cancer-associated genes. However, the underlying mechanism of this aberration in cancer remains unclear. Here, we examined 5' CpG island methylation status and expression of the p14(ARF), p16(INK4a) and RASSF1A tumor suppressor genes, and investigated the relationship of these factors with the mRNA expression of DNA methyltransferases (DNMTs) and/or methyl-CpG-binding proteins (MBPs) in 30 lung cancer cell lines including 12 small cell lung cancers (SCLCs) and 18 non-small cell lung cancers (NSCLCs). When beta-actin was used as an internal control, the mRNA expression of three DNMTv (DNMT1, DNMT3A, and DNMT3B) and five MBPs (MBD1, MBD2, MBD3, MBD4, and MeCP2) was upregulated in SCLC, while only that of DNMT1, DNMT3B and MBD3 was upregulated in NSCLC, compared with normal lung tissues. However, when normalized using proliferating cell nuclear antigen (PCNA) as an internal control, these differences disappeared or diminished; there was even a significant reduction in the expression ratios of DNMT1, MBD2 and MeCP2 in SCLC and DNMT, MBD2 and MBD4 in NSCLC. Furthermore, although significant correlations between PCNA expression and mRNA expression levels of the three DNMTv and four of the MBPs (excluding MeCP2) were observed, there was no obvious correlation between promoter hypermethylation of these tumor suppressor genes and the expression level of any of the DNMTs or MBPs. Our results suggest that upregulation of DNMTs and MBPs probably reflects an increased cell proliferation in human lung cancers and that there are likely to exist gene-specific mechanisms for epigenetic gene silencing.	Grad Sch med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Grad Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horio, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Internal Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	yhorio@aichi-cc.jp	Sato, MITSUO/I-7280-2014; Sekido, Yoshitaka/P-9756-2015; Hasegawa, Yoshinori/I-1277-2012	Sato, MITSUO/0000-0001-5458-9576; Sekido, Yoshitaka/0000-0002-2428-3848; Horio, Yoshitsugu/0000-0003-4661-6399	NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Eads CA, 1999, CANCER RES, V59, P2302; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; FRANCOIS J, 1975, OPHTHALMOLOGICA, V170, P405, DOI 10.1159/000307248; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Gazzeri S, 1998, CANCER RES, V58, P3926; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kim DH, 2001, CANCER RES, V61, P3419; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MAO L, 1995, CANCER RES, V55, P2995; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Phelps RM, 1996, J CELL BIOCHEM, P32; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sambrook J, 1989, MOL CLONING; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1992, MOL CELL BIOL, V12, P1747, DOI 10.1128/MCB.12.4.1747; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SHAPIRO GI, 1995, CANCER RES, V55, P6200; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Wei MH, 1996, CANCER RES, V56, P1487; XU L, 1994, CANCER RES, V54, P5262; ZHOU XL, 1994, ONCOGENE, V9, P3737; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	47	68	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4822	4829		10.1038/sj.onc.1205581	http://dx.doi.org/10.1038/sj.onc.1205581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101420				2022-12-28	WOS:000176716300011
J	Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M				Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M			Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway	ONCOGENE			English	Article						telomerase; TERT; EGF; MAP kinase	CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; GENE-EXPRESSION; C-MYC; TERMINAL DOMAIN; PROTEIN-KINASE; CELLS; PHOSPHORYLATION; JUN; TRANSDUCTION	Telomerase is a regulated enzyme and its activity is tightly associated with cell proliferation. The mechanisms of this association are unclear, but specific growth factors may regulate telomerase activity. The present study examines the effect of epidermal growth factor (EGF) on telomerase activity and identifies the signal transduction pathway involved in this process. EGF upregulated telomerase activity in EGF receptor-positive cells after the activation of telomerase reverse transcriptase (TERT) mRNA expression. This activation was rapid, peaked after 6 or 12 h and was not blocked by the concurrent exposure to cycloheximide, suggesting a direct effect of EGF on TERT transcription. Transient expression assays revealed that EGF activates the hTERT promoter and that the proximal core promoter is responsible for this regulation. The activation of hTERT mRNA expression by EGF was specifically blocked by MEK inhibitor, and in vitro kinase assays demonstrated that ERK is activated in response to EGF. Transient expression assays using mutant reporter plasmids revealed that an ETS motif located in the core promoter of hTERT is required for the EGF-induced transactivation of hTERT. Overexpression of wild type Ets in cells enhanced the EGF effect on hTERT transcription, while that of dominant negative Ets significantly repressed EGF action. These findings suggest that EGF activates telomerase through the direct activation of TERT transcription, in which the Ras/MEK/ERK pathway and Ets factor play major roles. Our data support the notion that growth factors directly regulate telomerase via specific signal transduction pathways.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9208641, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Kanazawa University; University of Tokyo; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.			Gotoh, Noriko/0000-0003-3733-260X				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; BORNAR AG, 1998, SCIENCE, V279, P349; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, J BIOL CHEMN, V267, P24798; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; Tsumuki H, 2000, RHEUMATOL INT, V19, P123, DOI 10.1007/s002960050115; Tu WW, 1999, BRIT J HAEMATOL, V104, P785, DOI 10.1046/j.1365-2141.1999.01272.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Z, 2000, CANCER RES, V60, P5376; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Yang XY, 2000, LIFE SCI, V66, P1545, DOI 10.1016/S0024-3205(00)00472-0	38	116	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4071	4079		10.1038/sj.onc.1205509	http://dx.doi.org/10.1038/sj.onc.1205509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037663	Green Submitted			2022-12-28	WOS:000176186000001
J	Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH				Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH			Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma	ONCOGENE			English	Article						metastasis; lymphovascular invasion; tumor emboli; E-cadherin; sialyl-Lewis X/A; MUC1	POLYMERASE-CHAIN-REACTION; PERIPHERAL-BLOOD; RHOC GTPASE; CANCER; CELLS; EXPRESSION; MODEL; PROLIFERATION; METASTASIS; SELECTIN	Inflammatory breast carcinoma (IBC) is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a human-scid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2K(d)-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/alpha, beta-catenin axis which mediates tumor cell-tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the effects of palpation on MARY-X with the effects of palpation on a derived dominant-negative E-cadherin mutant (H-2K(d)-E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24(met)) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10-->30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10-100-fold (P<0.001) only in MARY-X. The mechanism of this effect was through an immediate post-palpation release of circulating tumor emboli detected 2-3 min after palpation (P<0.01) by human cytokeratin 19 RT-PCR of extracted RNA from 300 mul of murine blood. Although circulating human tumor cell-derived growth factors (IGF-I, IGF-II, TGF-alpha and TGF-beta) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P>0.1). Our findings support the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in IBC.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.	sbarsky@ucla.edu						Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 1999, CANCER RES, V59, P5079; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; Battaglia M, 1998, BONE MARROW TRANSPL, V22, P693, DOI 10.1038/sj.bmt.1701405; BISCHOFF J, 1995, BIOCHEM BIOPH RES CO, V210, P174, DOI 10.1006/bbrc.1995.1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; FUJIWARA T, 1993, CANCER RES, V53, P4129; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334; Kruger W, 1996, J CANCER RES CLIN, V122, P679, DOI 10.1007/BF01209032; LEVINE PH, 1985, JNCI-J NATL CANCER I, V74, P291; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1976, CANCER RES, V36, P889; MOORE DH, 1992, GYNECOL ONCOL, V47, P44, DOI 10.1016/0090-8258(92)90073-R; Mori M, 1996, INT J CANCER, V68, P739; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nguyen M, 1997, AM J PATHOL, V150, P1307; NISHIZAKI T, 1990, J SURG RES, V49, P92, DOI 10.1016/0022-4804(90)90116-J; Noun G, 1996, J IMMUNOL, V157, P2455; Rutz HP, 1999, MED HYPOTHESES, V53, P526, DOI 10.1054/mehy.1999.0805; Silverstein M. J., 1997, DUCTAL CARCINOMA SIT; Tomlinson JS, 2001, CANCER RES, V61, P5231; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wong IN, 1997, BRIT J CANCER, V76, P628, DOI 10.1038/bjc.1997.436; Wyld DK, 1998, INT J CANCER, V79, P288, DOI 10.1002/(SICI)1097-0215(19980619)79:3<288::AID-IJC14>3.0.CO;2-4; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhu AJ, 1996, J CELL SCI, V109, P3013	29	81	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3631	3643		10.1038/sj.onc.1205389	http://dx.doi.org/10.1038/sj.onc.1205389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032865				2022-12-28	WOS:000175793700014
J	Mao, L				Mao, L			Recent advances in the molecular diagnosis of lung cancer	ONCOGENE			English	Review						molecular marker; lung cancer; diagnosis; sputum; serum	NONSMALL CELL LUNG; GROWTH-FACTOR RECEPTOR; ABERRANT PROMOTER METHYLATION; BRONCHOALVEOLAR LAVAGE FLUID; GASTRIN-RELEASING-PEPTIDE; CIRCULATING TUMOR-CELLS; CODON 12 MUTATIONS; K-RAS MUTATION; STAGE-I; GENE-EXPRESSION	Despite extensive effort in improvement of diagnosis and treatment of patients with lung cancer in past three decades, the overall survival of patients with the disease remains dismal. Because the development of lung cancer takes a few decades, early diagnosis of the disease or identification of truly high-risk populations may provide us opportunity to successfully cure or prevent the disease. Recent advances in understanding biological basis of lung tumorigenesis provide new tools for detecting malignant cells or the process of malignant transformation and progression. Along with identification of molecular abnormalities in the early lung tumorigenesis, advanced molecular analytic technologies have been emerged, which may facilitate development of rapid and effective methods for early diagnosis and risk assessment. Here, I discuss recent progresses in understanding of early molecular abnormalities in lung cancer, efforts of translating laboratory findings to clinical tests, and prospective of biomarkers in lung cancer diagnosis and risk assessment.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	lmao@mdanderson.org	Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Allan JM, 2001, INT J CANCER, V91, P359, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1058>3.0.CO;2-E; Aoyagi Y, 2001, CANCER RES, V61, P7950; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bessho A, 2000, ANTICANCER RES, V20, P1149; Brichory F, 2001, CANCER RES, V61, P7908; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Caballero OL, 2001, GENE CHROMOSOME CANC, V32, P119, DOI 10.1002/gcc.1173; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; Chen JJW, 2001, CANCER RES, V61, P5223; Chen XQ, 1996, NAT MED, V2, P1033; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; De Luca A, 2000, CLIN CANCER RES, V6, P1439; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Eerola AK, 1997, J PATHOL, V181, P172; Esteller M, 1999, CANCER RES, V59, P67; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Feng G, 2001, CANCER RES, V61, P7999; Fernandez-Madrid F, 1999, CLIN CANCER RES, V5, P1393; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Fleischhacker M, 2001, ANN NY ACAD SCI, V945, P179; Foa P, 1999, ANTICANCER RES, V19, P3613; GORGOULIS V, 1992, ANTICANCER RES, V12, P1183; Graziano SL, 1999, J CLIN ONCOL, V17, P668, DOI 10.1200/JCO.1999.17.2.668; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gure AO, 1998, CANCER RES, V58, P1034; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hibi K, 1998, CANCER RES, V58, P5690; Hirao T, 2001, CANCER RES, V61, P612; Iizasa T, 1998, CANCER IMMUNOL IMMUN, V46, P345, DOI 10.1007/s002620050496; Jang SJ, 2001, CANCER RES, V61, P7959; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Karnak D, 2001, LUNG, V179, P57, DOI 10.1007/s004080000047; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kong LF, 1998, CANCER LETT, V130, P93, DOI 10.1016/S0304-3835(98)00115-3; Kurusu Y, 1999, SURGERY, V126, P820, DOI 10.1016/S0039-6060(99)70020-6; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; Lee JC, 1998, LUNG CANCER-J IASLC, V21, P99; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Liloglou T, 2001, CANCER RES, V61, P1624; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Miozzo M, 1996, CANCER RES, V56, P2285; Mishina T, 1999, BRIT J CANCER, V80, P1289, DOI 10.1038/sj.bjc.6690500; Mishina T, 2000, CLIN CANCER RES, V6, P11; Mitsudomi T, 1998, JNCI-J NATL CANCER I, V90, P1563, DOI 10.1093/jnci/90.20.1563; Mulshine JL, 2000, CANCER-AM CANCER SOC, V89, P2465; Nakajima E, 2001, INT J ONCOL, V18, P105; Niklinski J, 2001, LUNG CANCER, V34, pS53, DOI 10.1016/S0169-5002(01)00345-2; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; Noel-Georis I, 2001, DIS MARKERS, V17, P271, DOI 10.1155/2001/607263; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Oh JMC, 2001, PROTEOMICS, V1, P1303, DOI 10.1002/1615-9861(200110)1:10<1303::AID-PROT1303>3.0.CO;2-2; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; Palmisano WA, 2000, CANCER RES, V60, P5954; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Patz EF, 2000, NEW ENGL J MED, V343, P1627, DOI 10.1056/NEJM200011303432208; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ponticiello A, 2000, EUR RESPIR J, V15, P547, DOI 10.1034/j.1399-3003.2000.15.20.x; PUJOL JL, 1993, BRIT J CANCER, V67, P1423, DOI 10.1038/bjc.1993.264; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Rosell R, 1997, INT J CANCER, V74, P330, DOI 10.1002/(SICI)1097-0215(19970620)74:3<330::AID-IJC17>3.0.CO;2-F; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; RUSCH V, 1993, CANCER RES, V53, P2379; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Salgia R, 2001, ANTICANCER RES, V21, P1241; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Scott FM, 1997, CLIN CANCER RES, V3, P479; Sekine I, 1997, JPN J CANCER RES, V88, P559, DOI 10.1111/j.1349-7006.1997.tb00419.x; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; SIEGFRIED JM, 1993, ANAT RECORD, V236, P241, DOI 10.1002/ar.1092360129; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Somers VA, 1998, J CLIN ONCOL, V16, P3061, DOI 10.1200/JCO.1998.16.9.3061; Soria JC, 2002, CANCER RES, V62, P351; Soria JC, 2000, CANCER RES, V60, P4000; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; Sozzi G, 2001, CANCER RES, V61, P4675; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Sutedja TG, 2001, LUNG CANCER, V34, P157, DOI 10.1016/S0169-5002(01)00242-2; Takamochi K, 2001, AM J PATHOL, V159, P1941, DOI 10.1016/S0002-9440(10)63041-6; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tas F, 2000, J EXP CLIN CANC RES, V19, P477; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Tomizawa Y, 1999, ONCOGENE, V18, P1007, DOI 10.1038/sj.onc.1202384; Tseng JE, 1999, CANCER RES, V59, P4798; Tseng JE, 1999, CANCER RES, V59, P5666; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang L, 2000, CLIN CANCER RES, V6, P2988; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; WEBER S, 1985, J CLIN INVEST, V75, P306, DOI 10.1172/JCI111690; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Wu WG, 1998, CANCER RES, V58, P4082; Yamaguchi K, 2000, INT J CANCER, V89, P524, DOI 10.1002/1097-0215(20001120)89:6<524::AID-IJC10>3.0.CO;2-O; Yashima K, 1997, CANCER RES, V57, P2373; Zhou X, 2000, CLIN CANCER RES, V6, P559; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	116	22	25	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6960	6969		10.1038/sj.onc.1205564	http://dx.doi.org/10.1038/sj.onc.1205564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362277				2022-12-28	WOS:000178640200010
J	Murakami, Y				Murakami, Y			Functional cloning of a tumor suppressor gene,TSLC1, in human non-small cell lung cancer	ONCOGENE			English	Review						tumor suppressor gene; functional cloning; non-small cell lung cancer; TSLC1; TSLL1; TSLL2	YEAST ARTIFICIAL CHROMOSOME; MICROCELL-MEDIATED TRANSFER; PROSTATE-CANCER; BREAST-CANCER; HUMAN DNA; TUMORIGENIC EXPRESSION; MALIGNANT PHENOTYPE; COLORECTAL CANCERS; MULTIPLE PATHWAYS; CARCINOMA CELLS	The identification of a tumor suppressor gene in non-small cell lung cancer (NSCLC) is one of the most important issues to elucidate the molecular mechanisms of this type of refractory cancer and to establish a novel strategy against it. Since NSCLC, like most other human cancers, develops as a sporadic disease, linkage analysis is not available for gene cloning. This review describes the functional cloning approaches to a tumor suppressor gene in sporadic cancers. Suppression of the malignant phenotype of cancer cells by fusion with a normal fibroblast was the first demonstration of the recessive phenotype of cancer cells in 1969. Evidence of tumor suppressor genes on the specific chromosomes was later provided by functional complementation of the cancer phenotype through microcell-mediated chromosome transfer. Further introduction of more restricted DNA fragments by YAC transfer provides a potent tool to localize the gene to a small segment, appropriate for the subsequent gene cloning. TSLC1, a novel tumor suppressor gene in NSCLC, was identified on chromosome 11q23.2 through a series of functional complementation of A549 cells in tumorigenicity. Two-hit inactivation of the TSLC1 by promoter methylation and gene deletion was observed in 40% of primary NSCLC tumors. The strong tumor suppressor activity of TSLC1, and its possible involvement in cell adhesion, suggest that the functional cloning approach could cast a new light on a group of genes that have not yet been characterized, but are important for general human carcinogenesis as well as tumor suppression.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genomics Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genomics Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Aoe K, 1999, ANTICANCER RES, V19, P291; Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANERJEE A, 1992, CANCER RES, V52, P6297; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Cao Q, 2001, CANCER GENET CYTOGEN, V129, P131, DOI 10.1016/S0165-4608(01)00442-3; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CAVENEE WK, 1995, SCI AM, V272, P72, DOI 10.1038/scientificamerican0395-72; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ICHIKAWA T, 1992, CANCER RES, V52, P3486; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanamori M, 2000, ONCOGENE, V19, P1564, DOI 10.1038/sj.onc.1203454; Kawanishi M, 1997, CARCINOGENESIS, V18, P2057, DOI 10.1093/carcin/18.11.2057; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MINNA J, 2002, ONCOGENE; MISRA BC, 1989, AM J HUM GENET, V45, P565; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami Y, 1998, MUTAT RES-FUND MOL M, V400, P421, DOI 10.1016/S0027-5107(98)00031-1; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; MURAYAMA F, 1965, BIKEN J, V8, P103; Myohanen SK, 1998, CANCER RES, V58, P591; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1992, ONCOGENE, V7, P2013; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Nomoto S, 1998, CANCER RES, V58, P1380; OBriant K, 1997, ANTICANCER RES, V17, P3243; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Ohsaki Y, 1996, ONCOLOGY, V53, P327; Ordonez C, 2000, CANCER RES, V60, P3419; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Phillips KK, 1996, CANCER RES, V56, P1222; PONTECORVO G, 1976, CYTOGENET CELL GENET, V16, P399, DOI 10.1159/000130642; PRESCOTT DM, 1972, EXP CELL RES, V71, P480, DOI 10.1016/0014-4827(72)90322-9; RASIO D, 1995, CANCER RES, V55, P3988; REEVES RH, 1995, CURRENT PROTOCOLS HU; Robertson G, 1996, CANCER RES, V56, P4487; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SACHSE R, 1994, ONCOGENE, V9, P39; SANTON JB, 1986, CANCER RES, V46, P4701; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4783, DOI 10.1093/nar/21.20.4783; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SPENCER F, 1994, GENOMICS, V22, P118, DOI 10.1006/geno.1994.1352; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Todd MC, 1996, ONCOGENE, V13, P2387; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WELCH DR, 1994, ONCOGENE, V9, P255; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; White R, 1992, CURR OPIN GENET DEV, V2, P53, DOI 10.1016/S0959-437X(05)80321-1; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yamori T, 1997, JPN J CANCER RES, V88, P1205, DOI 10.1111/j.1349-7006.1997.tb00350.x; YOSHIDA A, 1994, J SURG ONCOL, V55, P170, DOI 10.1002/jso.2930550308; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	115	48	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6936	6948		10.1038/sj.onc.1205825	http://dx.doi.org/10.1038/sj.onc.1205825			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362275	Bronze			2022-12-28	WOS:000178640200008
J	Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG				Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG			The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells	ONCOGENE			English	Article						melanoma; tumor progression; PRSS11; HtrA1; serine protease	MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; GENE-PRODUCT; EXPRESSION; MAC25; SUPPRESSOR; ASSAY	Differential gene expression of cell lines derived from a malignant melanoma or its autologous lymph node metastasis using cDNA arrays indicated down-regulation of PRSS11, a gene encoding the serine protease HtrA1, a homolog of the Escherichia coli protease HtrA, in the metastatic line. Stable PRSS11 overexpression in the metastatic cell line strongly inhibited proliferation, chemoinvasion and Nm23-H1 protein expression in vitro, as well as cell growth in vivo in nu/nu mice. A polyclonal anti-HtrA1 serum demonstrated a significantly higher expression in primary melanomas when compared to unrelated metastatic lesions in a human melanoma tissue array, and down-modulation of HtrA1 expression in autologous lymph node melanoma metastases in seven out of 11 cases examined. These results suggest that down-regulation of PRSS11 and HtrA1 expression may represent an indicator of melanoma progression.	Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, I-00158 Rome, Italy; Natl Inst Canc Res, Genoa, Italy; CNR, Ist Neurobiol & Med Mol, Rome, Italy; Univ Naples 2, Sect Pathol, Dept Biochem & Biophys F Cedrangolo, Naples, Italy; San Gallicano Dermatol Inst, Rome, Italy; Regina Elena Inst Canc Res, CRS, Immunol Lab, Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ifo.it	Noonan, Douglas M/A-8620-2010; Paggi, Marco G./K-3494-2018; Felsani, Armando/D-1784-2010; Baldi, Alfonso/ABG-2397-2021; De Luca, Antonio/AAD-9562-2020	Noonan, Douglas M/0000-0001-8058-0719; Felsani, Armando/0000-0001-8851-6295; De Luca, Antonio/0000-0002-3905-6154; Albini, Adriana/0000-0002-9624-5103; Baldi, Alfonso/0000-0002-8693-3842				ALBINI A, 1987, CANCER RES, V47, P3239; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Berwick Marianne, 1997, Current Opinion in Oncology, V9, P178; Bishop JAN, 1997, CANCER METAST REV, V16, P141, DOI 10.1023/A:1005752510012; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guldberg P, 1997, CANCER RES, V57, P3660; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; Kato MV, 1996, ONCOGENE, V12, P1361; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Ponting CP, 1997, PROTEIN SCI, V6, P464; Robertson GP, 1999, CANCER RES, V59, P3596; Shridhar V, 2002, CANCER RES, V62, P262; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	30	152	167	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6684	6688		10.1038/sj.onc.1205911	http://dx.doi.org/10.1038/sj.onc.1205911			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242667				2022-12-28	WOS:000178202300015
J	Deng, CX				Deng, CX			Roles of BRCA1 in centrosome duplication	ONCOGENE			English	Review						BRCA1; GADD45; p53; centrosome amplification	GENETIC INSTABILITY; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; ESTROGEN-RECEPTOR; DNA-DAMAGE; P53; MICE; PHOSPHORYLATION; TUMORIGENESIS	Centrosome duplication is under precise control and occurs only once in a normal mammalian cell cycle. Disruption of this process causes centrosome amplification, unequal segregation of chromosomes and, ultimately, tumorigenesis. Recent studies indicate that breast cancer suppressor gene 1 (BRCA1) plays an important role in regulating centrosome duplication. BRCA1 is located in the centrosome and binds to gamma-tubulin. It interacts with a variety of proteins that regulate centrosome duplication, including BRCA2, CDK2 - Cyclin A, CDK2 - Cyclin E, Gadd45, p21, p53 and Rb. Furthermore, targeted disruption of murine BRCA1 results in centrosome amplification, suggesting that BRCA1 serves as a negative regulator for centrosome duplication. This review will examine these data and discuss possible relationships between BRCA1 and its interacting proteins in centrosome duplication.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Deng CX, 2000, BIOESSAYS, V22, P728; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 2001, CURR BIOL, V11, pR698, DOI 10.1016/S0960-9822(01)00412-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pihan GA, 1998, CANCER RES, V58, P3974; PRICE BD, 1995, ONCOGENE, V11, P73; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHANG W, 1994, CANCER RES, V54, P4448; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	62	94	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6222	6227		10.1038/sj.onc.1205713	http://dx.doi.org/10.1038/sj.onc.1205713			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214252	Bronze			2022-12-28	WOS:000177840500011
J	Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO				Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO			Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway	ONCOGENE			English	Article						EMMPRIN; MMP2; phospholipase A(2); 5-lipoxygenase; breast cancer cell; fibroblast	MATRIX-METALLOPROTEINASE INDUCER; PROGELATINASE-A; COLLAGENASE; EXPRESSION; CARCINOMAS; ACTIVATION; RECEPTOR	Metalloproteinases (NIMP) produced by both cancer and normal stromal fibroblast cells play a critical role in the metastatic spread of tumours, however little is known of the regulation of their release. In this report we demonstrate that breast cancer cells in culture release apparently full length soluble EMMPRIN that promotes the release of pro-MMP2 from fibroblasts. The generation of MMP2 is mediated by activation of phospholipase A(2) and 5-lipoxygenase. These results suggest that the production of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therapeutic intervention.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Wakelam, MJO (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	m.j.o.wakelam@bham.ac.uk		Wakelam, Michael/0000-0003-4059-9276				Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; DERRICO A, 1991, MODERN PATHOL, V4, P239; ELLIS SM, 1989, CANCER RES, V49, P3385; Ferry DR, 2000, ANN ONCOL, V11, P1165, DOI 10.1023/A:1008303715515; Guo HM, 1997, J BIOL CHEM, V272, P24; Huang MT, 1997, J CELL BIOCHEM, P26; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Light DB, 1997, J MEMBRANE BIOL, V158, P229, DOI 10.1007/s002329900260; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; NOMURA H, 1995, CANCER RES, V55, P3263; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sun JX, 2001, CANCER RES, V61, P2276; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	24	121	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5765	5772		10.1038/sj.onc.1205702	http://dx.doi.org/10.1038/sj.onc.1205702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173047				2022-12-28	WOS:000177463400012
J	Yao, RS; Wang, Y; Lubet, RA; You, M				Yao, RS; Wang, Y; Lubet, RA; You, M			Differentially expressed genes associated with mouse lung tumor progression	ONCOGENE			English	Article						mouse; lung; adenoma; adenocarcinoma; lung tumor progression gene; gene expression	CELL-CYCLE ARREST; CANCER-CELLS; RETINOBLASTOMA PROTEIN; PRENEOPLASTIC LESIONS; CDK INHIBITORS; BETA; ADENOCARCINOMA; ACTIVATION; NEOPLASIA; MUTATIONS	To detect altered gene expression associated with mouse lung tumor progression, we compared the gene expression profile of lung adenocarcinomas with that of lung adenomas and normal lungs. Autoradiographic analysis showed that among the 588 genes surveyed, 152 genes were detected and the remaining 436 genes did not give any signals. A gene-specific semiquantitative reverse transcription polymerase chain reaction method was used to confirm the expression profile. A total of 29 genes was found to be differentially expressed in mouse lung tumors when compared to normal lungs. The pattern of expression, either underexpression or overexpression, was the same for 10 genes between adenocarcinomas and adenomas. Among them, seven genes were over-expressed, two genes were underexpressed and one gene was lost. Interestingly, 19 genes showed differential expression or increased incidence or difference in level of change between lung adenomas and adenocarcinomas, including Stat1, ADAP, IGFBP-6, PDGF-A, TGF-beta2, Int-3, VEGFR2, BAX, BAG-1, c-Jun, FasL, TRAIL, YB-1, CD31, Cdc42, B-raf, Rab-2, Abi-1, and ACE. These,genes can be designated as candidate 'lung tumor progression' (LTP) genes because their expression changes may specifically affect lung tumor progression in mice. Further analyses of these candidate LTP genes may provide new leads for elucidation of lung tumor progression in mice.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005113] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA058554, R01CA078797, R29CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [CA58554, CA78797, CN05113] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1993, CANCER RES, V53, P4817; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIBA I, 1990, ONCOGENE, V5, P1603; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DeRisi J, 1996, NAT GENET, V14, P457; Frank DA, 1999, MOL MED, V5, P432; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Herzog CR, 1997, J CELL BIOCHEM, P49; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin L, 2001, EXP LUNG RES, V27, P217, DOI 10.1080/019021401300053966; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mielnicki LM, 1996, BIOCHEM BIOPH RES CO, V228, P586, DOI 10.1006/bbrc.1996.1702; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OITVAI ZN, 1993, CELL, V74, P609; Palmisano W. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P94; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rhee CH, 1999, ONCOGENE, V18, P2711, DOI 10.1038/sj.onc.1202623; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHISEKI M, 1994, CANCER RES, V54, P5643; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; SOZZI G, 1992, CANCER RES, V52, P6079; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Volm M, 2000, BRIT J CANCER, V82, P1747; XU HJ, 1991, CANCER RES, V51, P2735; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	38	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5814	5821		10.1038/sj.onc.1205422	http://dx.doi.org/10.1038/sj.onc.1205422			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173053				2022-12-28	WOS:000177463400018
J	Prokhortchouk, E; Hendrich, B				Prokhortchouk, E; Hendrich, B			Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs?	ONCOGENE			English	Article						epigenetics; cancer; DNA repair; transcriptional repression; methyl-CpG binding proteins	DNA METHYLATION; INTESTINAL NEOPLASIA; CHROMOSOMAL PROTEIN; TRANSCRIPTIONAL REPRESSOR; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; VERTEBRATE GENOMES; ISLAND METHYLATION; SOMATIC MUTATIONS; MESSENGER-RNA		Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Inst Gene Biol, Grp Transcript Control & Oncogenesis, Moscow 117334, Russia	University of Edinburgh; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Prokhortchouk, E (corresponding author), Univ Edinburgh, Ctr Genome Res, Roger Land Bldg,Kings Bldg, Edinburgh EH9 3JQ, Midlothian, Scotland.		Prokhortchouk, Egor/I-9108-2014; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BULMER M, 1986, MOL BIOL EVOL, V3, P322; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; Cormier RT, 2000, CANCER RES, V60, P3965; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS S, 1997, NAT GENET, V13, P256; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Esteller M, 2000, CANCER RES, V60, P129; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kerr AM, 2001, BRAIN DEV-JPN, V23, P208, DOI 10.1016/S0387-7604(01)00193-0; KERR AM, 1985, BRIT MED J, V291, P579, DOI 10.1136/bmj.291.6495.579; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Muller-Tidow C, 2001, BRIT J CANCER, V85, P1168, DOI 10.1054/bjoc.2001.2041; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	61	40	49	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5394	5399		10.1038/sj.onc.1205631	http://dx.doi.org/10.1038/sj.onc.1205631			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154402				2022-12-28	WOS:000177197700006
J	Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J				Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J			p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation	ONCOGENE			English	Article						growth inhibition; mTOR; p53; polypeptide chain initiation; protein synthesis	CAP-DEPENDENT INITIATION; MESSENGER-RNA; MAMMALIAN TARGET; FACTOR 4E; PHAS-I; DIFFERENTIAL REQUIREMENTS; SIGNALING PATHWAYS; BINDING PROTEIN; PHOSPHORYLATION; RAPAMYCIN	p53 is an important regulator of cell cycle progression and apoptosis, and inactivation of p53 is associated with tumorigenesis. Although p53 exerts many of its effects through regulation of transcription, this protein is also found in association with ribosomes and several mRNAs have been identified that are translationally controlled in a p53-dependent manner. We have utilized murine erythroleukemic cells that express a temperature-sensitive p53 protein to determine whether p53 also functions at the level of translation. The data presented here demonstrate that p53 causes a rapid decrease in translation initiation. Analysis of several potential mechanisms for regulating protein synthesis shows that p53 has selective effects on the phosphorylation of the eIF4E-binding protein, 4E-BP1, and the activity of the p70 ribosomal protein S6 kinase. These data provide evidence that modulation of translational activity constitutes a further mechanism by which the growth inhibitory effects of p53 may be mediated.	St George Hosp, Sch Med, Dept Biochem & Immunol, London SW17 0RE, England; Case Western Reserve Univ, Sch Med, Dept Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	St Georges University London; Case Western Reserve University	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Biochem & Immunol, Cranmer Terrace, London SW17 0RE, England.	M.Clemens@sghms.ac.uk			NIDDK NIH HHS [DK43414] Funding Source: Medline; PHITPO CDC HHS [HK07147-21A1] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHITPO CDC HHS		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hensold JO, 1996, J BIOL CHEM, V271, P23246, DOI 10.1074/jbc.271.38.23246; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MERRICK W, 2000, CURR PROTOCALS CELL, V11; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Morley SJ, 2000, FEBS LETT, V477, P229, DOI 10.1016/S0014-5793(00)01805-6; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SMITH M R, 1990, New Biologist, V2, P648; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1995, J IMMUNOL, V155, P3418; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WANG Y, 2000, P NATL ACAD SCI USA, V97, P5486; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	82	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5325	5334		10.1038/sj.onc.1205662	http://dx.doi.org/10.1038/sj.onc.1205662			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149653				2022-12-28	WOS:000177193900013
J	Crnogorac-Jurcevic, T; Efthimiou, E; Nielsen, T; Loader, J; Terris, B; Stamp, G; Baron, A; Scarpa, A; Lemoine, NR				Crnogorac-Jurcevic, T; Efthimiou, E; Nielsen, T; Loader, J; Terris, B; Stamp, G; Baron, A; Scarpa, A; Lemoine, NR			Expression profiling of microdissected pancreatic adenocarcinomas	ONCOGENE			English	Article						pancreatic adenocareinoma; laser capture microdissection; cDNA arrays; tissue arrays	SUPEROXIDE-DISMUTASE; CANCER; GENE; AMPULLARY; DUCTS; CD59; ARG	Pancreatic ductal adenocarcinoma is characterized by a paucity of neoplastic cells embedded in a densely desmoplastic stroma. Therefore, laser capture microdissection was performed to obtain homogeneous populations of normal and neoplastic ductal cells. These were subjected to a comparative study of gene expression utilizing human cDNA arrays. A variety of dysregulated genes were identified, comprising cell cycle and growth regulators, invasion regulators, signalling and developmental molecules. In addition to genes already found to be overexpressed in pancreatic cancer, such as TIMP1, MMP7, CD59, rhoC and NDKA, we present evidence to implicate genes which have not previously been reported in this tumour type. These include the overexpressed genes ABL2, Notch4 and SOD1, as well as XRCC1, a DNA repair gene whose transcript was found downregulated. Quantitative real-time RT-PCR (QRT-PCR) was employed to confirm differential expression of ABL2, Notch4 and SOD1 and immunohistochemical analysis was used to verify decreased protein expression of XRCC1 using a custom-built pancreatic tissue array. Combining microarray-derived gene expression profiles of pure pancreatic cell populations, QRT-PCR and pancreas-specific tissue arrays therefore proved to be highly informative in elucidating the molecular pathology of this highly malignant tumour type.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK,Dept Canc Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Histopathol, London W12 0NN, England; Oxford Glycosci Proteome Discovery, Abingdon, Oxon, England; Univ Verona, Dept Pathol, I-37100 Verona, Italy	Cancer Research UK; Imperial College London; Imperial College London; University of Verona	Lemoine, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK,Dept Canc Med, Hammersmith Campus, London W12 0NN, England.	nick.lemoine@cancer.org.uk	scarpa, aldo/K-6832-2016; Terris, Benoit/P-1497-2017	scarpa, aldo/0000-0003-1678-739X; 				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; BANKSON DD, 1993, CLIN LAB MED, V13, P463, DOI 10.1016/S0272-2712(18)30449-9; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; CRNOGORACJURCEV.T, 2002, METHODS MOL BIOL RT; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Furukawa T, 1996, AM J PATHOL, V148, P1763; GOLD EB, 1995, SURG CLIN N AM, V75, P819, DOI 10.1016/S0039-6109(16)46730-7; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Maio M, 1998, INT J ONCOL, V13, P305; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; OBERLEY LW, 1979, CANCER RES, V39, P1141; Rice PA, 1999, NAT STRUCT BIOL, V6, P805, DOI 10.1038/12257; Schmitt CA, 1999, EUR J CANCER, V35, P117, DOI 10.1016/S0959-8049(98)00290-1; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sirivatanauksorn Y, 1999, J PATHOL, V189, P150, DOI 10.1002/(SICI)1096-9896(199910)189:2<150::AID-PATH451>3.0.CO;2-G; WESTMAN NG, 1981, CANCER RES, V41, P2962; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Zhou W, 1998, CANCER EPIDEM BIOMAR, V7, P109	31	172	185	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4587	4594		10.1038/sj.onc.1205570	http://dx.doi.org/10.1038/sj.onc.1205570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085237				2022-12-28	WOS:000176476700013
J	Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL				Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL			N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-Myc; Bcl-2; MMP; invasion; tumorigenesis	MATRIX-METALLOPROTEINASE INHIBITORS; AMYOTROPHIC-LATERAL-SCLEROSIS; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; MATRIX-METALLOPROTEINASE-9 EXPRESSION; IV COLLAGENASE; TUMOR-CELLS; BREAST-CANCER; IGF-I; INVASION	Neuroblastoma is a peripheral nervous system tumor that accounts for 8-10% of all solid childhood tumors. N-Myc is the most reliable prognostic indicator for neuroblastoma. Bcl-2 is detected in 40-60% of primary neuroblastoma tumors and demonstrates anti-apoptotic action by conferring resistance to chemotherapy and radiation treatment. In neuroblastoma cell lines, the coexpression of N-Myc and Bcl-2 leads to increased tumorigenic properties. Matrix metalloproteinases (MMPs) are endopeptidases that degrade a wide range of basement membrane components, a process important for tumor invasion. This study investigates the effect of N-Myc and Bcl-2 on MMP expression and activation. MMP-2 expression and secretion are increased in SHEP neuroblastoma cells expressing Bcl-2 alone (SHEP/Bcl-2 cells) or both N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2 cells). MMP-2 activity is increased in the SHEP/N-Myc/Bcl-2 cells yet remains unchanged in SHEP/Bcl-2 cells. TIMP-2 expression is high in SHEP/Bcl-2 cells, which likely inhibits MMP-2 activity, and absent in SHEP/N-Myc/Bcl-2 cells, allowing MMP-2 activity. Invasion is increased in SHEP/N-Myc/Bcl-2 cells and prevented by the use of a pharmacologic MMP-2 inhibitor. These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge 3,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007222, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ara T, 1998, J PEDIATR SURG, V33, P1272, DOI 10.1016/S0022-3468(98)90167-1; Ara T, 2000, J PEDIATR SURG, V35, P432, DOI 10.1016/S0022-3468(00)90208-2; Barille S, 1999, J IMMUNOL, V163, P5723; Beuche W, 2000, NEUROREPORT, V11, P3419, DOI 10.1097/00001756-200011090-00003; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Butler AA, 1998, CANCER RES, V58, P3021; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Crowe DL, 2001, NEOPLASIA, V3, P27, DOI 10.1038/sj.neo.7900135; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; DEVEAS RG, 1995, J CANCER RES CLIN, V121, P275, DOI 10.1007/BF01209593; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; George SJ, 2000, EXPERT OPIN INV DRUG, V9, P993, DOI 10.1517/13543784.9.5.993; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kelly T, 2000, LEUKEMIA LYMPHOMA, V37, P273, DOI 10.3109/10428190009089428; Khasigov PZ, 2001, BIOCHEMISTRY-MOSCOW+, V66, P130, DOI 10.1023/A:1002879128392; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Lim GP, 1996, J NEUROCHEM, V67, P251; Long L, 1998, CANCER RES, V58, P3243; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McLennan SV, 2000, KIDNEY INT, V58, pS81, DOI 10.1046/j.1523-1755.2000.07713.x; Mitsiades N, 2001, CANCER RES, V61, P577; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1998, Cell Res, V8, P179; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Ravanti L, 2000, INT J MOL MED, V6, P391; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 2001, LIFE SCI, V68, P1161, DOI 10.1016/S0024-3205(00)01030-4; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Singleton JR, 1996, CANCER RES, V56, P4522; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Sugiura Y, 1998, CANCER RES, V58, P2209; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	62	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4549	4557		10.1038/sj.onc.1205552	http://dx.doi.org/10.1038/sj.onc.1205552			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085233				2022-12-28	WOS:000176476700009
J	Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH				Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH			Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines	ONCOGENE			English	Article						syntenin; migration; invasion; breast cancer; gastric cancer	SUBTRACTIVE HYBRIDIZATION; EPHRIN LIGANDS; PDZ DOMAINS; NUDE-MICE; EXPRESSION; PROTEIN; CARCINOMA; RECEPTOR; BINDING; ESTABLISHMENT	Two human breast cancer cell lines of differing invasive and metastatic potential, MDA-MB-435 and MCF7, were examined using subtractive suppression hybridization in a search for any genes associated with metastasis. Of the 17 cDNAs identified as being differentially expressed genes, it was determined that syntenin was overexpressed in metastatic MDA-MB-435 cells. Expression analysis showed that the expression level of syntenin was well correlated with invasive and metastatic potential in various human breast and gastric cancer cell lines. Moreover, gastric tumor tissues exhibited a much higher syntenin mRNA expression than their normal counterparts. Syntenin-transfected MCF7 cells migrated more actively, and showed an increased invasion rate relative to vector-transfectants or parental MCF7 in vitro, without evidencing any effect on the adhesion to fibronectin, type I collagen and laminin. Similarly, the forced expression of syntenin to human gastric cancer cell line Az521 increased its migratory and invasive potential in vitro. Syntenin-expressing MCF7 cells were associated with the appearance of numerous cell surface extensions and with pseudopodia formation on collagen 1, suggesting that syntenin may be involved in the signaling cascade to actin-reorganization. Mutation study suggested that PDZ2 domain of syntenin could be an essential role in its stimulatory effect on the cell migration. This is the first demonstration that syntenin, a PDZ motif-containing protein, can be overexpressed during the metastatic progression of human breast and gastric cancer cells and that it can function as a meta stasis-inducing gene.	Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, Taejon 305600, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Seoul National University (SNU); Pusan National University	Lee, JH (corresponding author), Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, POB 115,Yuseong, Taejon 305600, South Korea.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byers RJ, 2000, INT J EXP PATHOL, V81, P391, DOI 10.1046/j.1365-2613.2000.00174.x; Cos S, 1998, CANCER RES, V58, P4383; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Davies EL, 1999, EUR J CANCER, V35, P902, DOI 10.1016/S0959-8049(99)00031-3; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK JG, 1990, CANCER RES, V50, P2773; PRICE JE, 1990, CANCER RES, V50, P717; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SHEIKH MS, 1994, INVAS METAST, V14, P329; SIMU G, 1978, CELL MOL BIOL, V23, P145; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOVER DM, 1994, CANCER RES, V54, P3092; Takai N, 2001, ONCOL REP, V8, P567; Talts JF, 1999, J CELL SCI, V112, P1855; Tang XX, 1999, CLIN CANCER RES, V5, P455; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; WHELAN SL, 1990, PATTERNS CANC 5 CONT; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yasoshima T, 1996, JPN J CANCER RES, V87, P153, DOI 10.1111/j.1349-7006.1996.tb03153.x; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	38	102	107	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4080	4088		10.1038/sj.onc.1205514	http://dx.doi.org/10.1038/sj.onc.1205514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037664				2022-12-28	WOS:000176186000002
J	Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S				Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S			G-protein alpha olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells	ONCOGENE			English	Article						cAMP; PKA; rho GTPases; src; PI3 '-kinase; PTHrP; trefoil factors	HORMONE-RELATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER CELLS; SMALL GTPASE; TRANSFORMING ACTIVITY; KINASE ACTIVATION; COUPLED RECEPTORS; ADENYLYL CYCLASES; TREFOIL PEPTIDES; GENE-EXPRESSION	The heterotrimeric G-protein subunits Galpha and Gbetagamma are involved in cellular transformation and tumor development. Here, we report the expression of Galphaolf in human digestive and urogenital epithelial cells using RT-PCR and Western blot. When the constitutively activated form of GalphaolfQ214L (AGalphaolf) was stably transfected in canine kidney MDCKts.src and human colonic HCT-8/S11 epithelial cells, it induced cellular invasion in collagen gels. AGalphaolf-mediated invasion was abrogated by agonists of platelet activating factor receptors (PAF-R) and protease-activated receptors -1 (PAR-1), pharmacological inhibitors of P13'-Kinase (wortmannin), protein kinase C (Go6976 and GF109203X), Rho GTPase (C3T exoenzyme), but was independent of protein kinase A. Accordingly, the invasive phenotype induced by AGalphaolf in HCT-8/S11 cells was reversed by the RhoA antagonist RhoD (G26V). Although AGaolf protected MDCKts.src cells against serum starvation-mediated apoptosis via a Rho-independent pathway, both AGalphaolf and Rho inhibition by C3T induced neuroendocrine-like differentiation linked to extensive neurite outgrowth and parathyroid hormone-related protein expression in human prostatic LNCaP-AGalphaolf cells. Since prostate tumors with a larger neuroendocrine cell population display increased invasiveness, persistent activation of the G-protein alphaolf may exert convergent adverse effects on cellular invasion and survival in solid tumors during the neoplastic progression towards metastasis.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Hop Lariboisiere, CRC Bernard, F-75475 Paris 10, France; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Chiba University	Emami, S (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	emami@st-antoine.inserm.fr	Vakaet, Luc/A-6467-2010					Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Astesano A, 1999, J HISTOCHEM CYTOCHEM, V47, P289, DOI 10.1177/002215549904700303; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bolt MJG, 1998, GASTROENTEROLOGY, V115, P1494, DOI 10.1016/S0016-5085(98)70028-9; Bouvet M, 2001, J CLIN ENDOCR METAB, V86, P310, DOI 10.1210/jc.86.1.310; Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Cox ME, 1999, CANCER RES, V59, P3821; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Debruyne PR, 2001, MUTAT RES-FUND MOL M, V480, P359, DOI 10.1016/S0027-5107(01)00195-6; Deftos Leonard J., 2000, Cancer, V88, P3002; DEL PL, 1997, SCIENCE, V278, P687; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Escande B, 2001, SEMIN PERINATOL, V25, P76, DOI 10.1053/sper.2001.23194; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ferrand N, 1999, J MOL CELL CARDIOL, V31, P1137, DOI 10.1006/jmcc.1999.0945; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gujral A, 2001, CANCER RES, V61, P2282; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Jung YD, 1999, CANCER RES, V59, P4804; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Regnauld KL, 2002, AM J PHYSIOL-REG I, V282, pR870, DOI 10.1152/ajpregu.00374.2001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIUS RA, 1994, BRAIN RES, V643, P50, DOI 10.1016/0006-8993(94)90007-8; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shankar PP, 2000, BRAIN RES, V868, P230, DOI 10.1016/S0006-8993(00)02335-0; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Spada A, 1998, MOL CELL ENDOCRINOL, V142, P1, DOI 10.1016/S0303-7207(98)00116-6; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 2000, BIOCHEM BIOPH RES CO, V272, P513, DOI 10.1006/bbrc.2000.2804; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZIGMAN JM, 1993, ENDOCRINOLOGY, V133, P2508, DOI 10.1210/en.133.6.2508	85	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4020	4031		10.1038/sj.onc.1205498	http://dx.doi.org/10.1038/sj.onc.1205498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037684				2022-12-28	WOS:000175869900008
J	Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF				Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF			Blocking NF-kappa B activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector	ONCOGENE			English	Article						NF-kappa B; tumor promoter PMA; Jurkat; leukemic cells; survival; apoptosis	PROTEIN-KINASE-C; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; MEDIATED APOPTOSIS; INCONTINENTIA PIGMENTI; EMBRYONIC LETHALITY; ALPHA PROTEOLYSIS; PHORBOL ESTER; IKK; PHOSPHORYLATION	The transcription factor NF-kappaB promotes cell survival. Using a variant of Jurkat leukemic T cells expressing IkappaB-alphaDeltaN, a super-repressor of NF-kappaB activation we first show that the tumor promoter PMA could prevent Fas-induced apoptosis via activation of NF-kappaB. Moreover, we demonstrate that in the absence of NF-kappaB activation, PNIA became a strong inducer of apoptosis through stimulation of the upstream caspases 8 and 9 as well as of the effector caspase 3. A RNase-protection analysis showed that PNIA stimulated the expression of several known anti-apoptotic genes (TRAF1, TRAF4, c-IAP-1, c-IAP-2, Bfl-1, Bcl-xl). In the absence of NF-kappaB activation, these survival influences were strongly lowered revealing the apoptotic effect of PMA. These results suggest that NF-kappaB activation could be an important step in the tumor promoting effect of PMA.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Fac Med Pasteur, INSERM, U526, IFR 50 Genet & Signalisat Mol, F-06107 Nice 02, France	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Peyron, JF (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Peyron, Jean-Francois/M-5682-2016; AUBERGER, Patrick/G-1491-2013; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022	Peyron, Jean-Francois/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X				Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	49	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3213	3224		10.1038/sj.onc.1205433	http://dx.doi.org/10.1038/sj.onc.1205433			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082637				2022-12-28	WOS:000175373600013
J	Hsieh, SC; Lo, PK; Wang, FF				Hsieh, SC; Lo, PK; Wang, FF			Mouse DDA3 gene is a direct transcriptional target of p53 and p73	ONCOGENE			English	Article						DDA3; p53; p73; intronic response element	CELL-CYCLE ARREST; KINASE C-ABL; APOPTOTIC RESPONSE; CANDIDATE MEDIATOR; PROTEIN; DNA; INHIBITOR; FAMILY; IDENTIFICATION; ACCUMULATION	The p53 tumor suppressor is a transcription factor that activates the expression of many target genes. We hake previously reported the identification of a p53-regulated mouse gene DDA3. The 5' upstream genomic region of the mouse DDA3 was cloned, and sequence analysis revealed the presence of a potential p53 response element (RE2) residing at nucleotides +390similar to +409 relative to the first translation start site. When fused upstream to a luciferase reporter gene, 5' genomic regions of the DDA3 gene containing RE2 were shown to be responsive to the wild-type, but not mutant p53, in a transient transfection assay. RE2 was sufficient to confer the transactivation responsiveness to p53. Furthermore, gel mobility shift analysis showed that RE2 formed specific complexes with wild-type p53. Induction of DDA3 was found in adriamycin treated normal mouse embryonic fibroblast cells (MEF), but not in p53 knockout (p53(-/-)) MEF. Overexpression of p73 induced DDA3 mRNA expression, and luciferase reporter analysis indicated that RE2 was responsive to transactivation by members of the p73 family proteins. Consistent with these findings, elevated expression of p73 protein and DDA3 mRNA were observed concomitantly in the p53(-/-) MEF cells treated with cisplatin. These results together demonstrated that DDA3 is a transcriptional target gene of p53 and its related-protein p73.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435				Agami R, 1999, NATURE, V399, P809; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Gong JG, 1999, NATURE, V399, P806; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEWART N, 1995, ONCOGENE, V10, P109; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, CANCER RES, V58, P5061	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3050	3057		10.1038/sj.onc.1205417	http://dx.doi.org/10.1038/sj.onc.1205417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082536				2022-12-28	WOS:000175262700013
J	Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S				Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S			p53-dependent downregulation of metastasis-associated laminin receptor	ONCOGENE			English	Article						p53; laminin receptor; transcriptional regulation; AP-2; promoter	WILD-TYPE P53; GENE-EXPRESSION; OVARIAN-CARCINOMA; BREAST-CARCINOMA; CELL-GROWTH; PROTEIN; PRECURSOR; PROMOTER; ESTROGEN; CANCER	Based on observations suggesting a role for the tumor suppressor protein p53 in regulating expression of the 67-kDa laminin receptor precursor, 37LRP, we analysed the 37LRP promoter activity in a wild-type p53 (wt p53) ovarian carcinoma cell line and in a cisplatin-resistant subline with mutated p53. We observed an increased promoter activity in wt p53 cells as compared to the mutated-p53 line when the first intron of the 37LRP gene was present in the reporter construct. Cotransfection experiments showed that the promoter is downregulated by both wt and mutated p53. Deletion analysis of the first intron localized an enhancer activity in the first 5' 214 bp that upregulates both 37LRP and SV40 promoter activity and is repressed by both wt and mutant p53. Cotransfection, mutagenesis and gel-shift experiments identified a functional AP-2 cis-acting element in this intron region that is repressed by increased levels of both wt and mutated p53. Coimmunoprecipitation studies revealed AP-2 in physical association in vivo with both wt and mutated p53, indicating for the first time that interaction of p53 with AP-2 is involved in the repression mechanism and in the regulation of genes involved in cancer growth and progression.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Inst Canc Res & Treatment, Candiolo, Italy; Metastasis Res Lab, B-4000 Liege, Belgium	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione del Piemonte per l'Oncologia	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.		Berno, Valeria/AAN-3997-2020; De Bortoli, Michele/B-5418-2013; Tagliabue, Elda/B-9377-2017; menard, sylvie mm/C-7940-2011	Berno, Valeria/0000-0001-5848-494X; De Bortoli, Michele/0000-0002-6666-9052; Tagliabue, Elda/0000-0001-9877-2903; Galmozzi, Enrico/0000-0001-8831-2401				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; Buto S, 1997, INT J BIOL MARKER, V12, P1; CASTRONOVO V, 1990, BIOCHEM BIOPH RES CO, V68, P1110; Clausse N, 1998, BIOCHEM BIOPH RES CO, V251, P564, DOI 10.1006/bbrc.1998.9431; DiLeo A, 1995, EUR J CANCER, V31A, P2248, DOI 10.1016/0959-8049(95)00481-5; Foley J, 1996, CANCER RES, V56, P4056; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jackers P, 1996, ONCOGENE, V13, P495; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Nadji M, 1999, CANCER-AM CANCER SOC, V85, P432, DOI 10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J; Pal S, 2001, CANCER RES, V61, P6952; Perego P, 1996, CANCER RES, V56, P556; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; PERREM K, 1995, ONCOGENE, V11, P1299; RAGHUNATH PN, 1993, J BIOL REG HOMEOS AG, V7, P22; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; Righetti SC, 1996, CANCER RES, V56, P689; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAO KS, 1995, CANCER RES, V55, P4367; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	37	28	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7478	7487		10.1038/sj.onc.1205957	http://dx.doi.org/10.1038/sj.onc.1205957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386810				2022-12-28	WOS:000178618200003
J	Liu, G; Chen, XB				Liu, G; Chen, XB			The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis	ONCOGENE			English	Article						FDXR; ROS; p53; p63; p73; apoptosis	COLORECTAL-CANCER CELLS; ADRENODOXIN REDUCTASE; CYCLE ARREST; TARGET GENES; DNA-DAMAGE; P21; INHIBITOR; BINDING; P73; P63	The p53 tumor suppressor protein, a transcription factor, induces cell cycle arrest and apoptosis via the upregulation of downstream target genes. Ferredoxin Reductase (protein, FR; gene, FDXR) transfers electron from NADPH to cytochrome P450 via ferredoxin in mitochondria. Here, we identified FDXR as a target gene of the p53 family, that is, p53, p63, and p73. We found that FDXR can be induced by DNA damage in cells in a p53-dependent manner and by a mutated form of p53 that is competent in inducing apoptosis. In addition, we identified a p53 response element located within the FDXR promoter that is responsive to wild-type p53, p63alpha, p63gamma, p73alpha, and p73beta. Furthermore, we showed that p53, p63alpha and p73alpha directly bind to the p53 response element in vivo and promote the accessibility of the FDXR promoter by increasing the acetylation of histones H3 and H4. To determine the role of FR in p53 tumor suppression, we generated cell lines that express FR using a tetracycline-regulated promoter. We found that overexpression of FR in lung H1299, breast MCF7, and colorectal HCT116 carcinoma cells have no effect on cell proliferation. However, we showed that FR increases the sensibility of H1299 and HCT116 cells to 5-fluorouracil-, doxorubicin- and H2O2- mediated apoptosis. Our data support a model of feed-forward loop for p53 activity, that is, various cellular stresses, including reactive oxygen species (ROS), activate p53, which induces the expression of FDXR; and the FDXR gene product, FR, in turn sensitizes cells to ROS-mediated apoptosis.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660, 1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069, R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen J, 1996, ONCOGENE, V13, P1395; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chenery HJ, 1996, APHASIOLOGY, V10, P1, DOI 10.1080/02687039608248396; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMER RE, 1982, ARCH BIOCHEM BIOPHYS, V215, P478, DOI 10.1016/0003-9861(82)90106-0; MIYASHITA T, 1995, CELL, V80, P293; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; MUNGER K, 1989, J VIROL, V63, P4417; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	41	153	156	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7195	7204		10.1038/sj.onc.1205862	http://dx.doi.org/10.1038/sj.onc.1205862			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370809				2022-12-28	WOS:000178504600007
J	Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW				Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW			Hypomethylation and hypermethylation of DNA in Wilms tumors	ONCOGENE			English	Article						DNA hypomethylation; DNA hypermethylation; Wilms tumors	PROMOTER METHYLATION; PERICENTROMERIC DNA; COLORECTAL TUMORS; CARCINOMA-CELLS; CPG ISLANDS; GENE; EXPRESSION; CANCERS; BREAST; 5-METHYLCYTOSINE	We quantitatively analysed hypermethylation at CpG islands in the 5' ends of 12 genes and one non-CpG island 5' region (MTHFR) in 31 Wilms tumors. We also determined their global genomic 5-methylcytosine content. Compared with various normal postnatal tissues, similar to40-90% of these pediatric kidney cancers were hypermethylated in four of the genes, MCJ, RASSF1A, TNFRSF12 and CALCA as determined by a quantitative bisulfite-based assay (MethyLight). Interestingly, the non-CpG island 5' region of MTHFR was less methylated in most tumors relative to the normal tissues. By chromatographic analysis of DNA digested to deoxynucleosides, about 60% of the Wilms tumors were found to be deficient in their overall levels of DNA methylation. We also analysed expression of the three known functional DNA methyltransferase genes. No relationship was observed between global genomic 5-methylcytosine levels and relative amounts of RNA for DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. Importantly, no association was seen between CpG island hypermethylation and global DNA hypomethylation in these cancers. Therefore, the overall genomic hypomethylation frequently observed in cancers is probably not just a response or a prelude to hypermethylation elsewhere in the genome. This suggests that the DNA hypomethylation contributes independently to oncogenesis or tumor progression.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Human Genet Program, New Orleans, LA 70112 USA; Amer Hlth Fdn, Dept Biochem Pharmacol, Valhalla, NY 10595 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Hop St Justine, Serv Hematol Oncol, Montreal, PQ H3T 1C5, Canada; Arkansas Childrens Hosp, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Univ Bristol, Sch Med Sci, Dept Pathol, Canc & Leukaemia Childhood Unit, Bristol BS8 1TD, Avon, England	Tulane University; Tulane University; American Health Foundation; St Jude Children's Research Hospital; University of Southern California; University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; Texas Children's Cancer Center; Universite de Montreal; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of Bristol	Ehrlich, M (corresponding author), Tulane Univ, Sch Med, Human Genet Program SL31, 1430 Tulane Ave, New Orleans, LA 70112 USA.	ehrlich@tulane.edu	Dome, Jeffrey/AAH-7825-2019; Parham, David M./AAN-1059-2020; Laird, Peter W/G-8683-2012; Tomlinson, Gail/AAR-9776-2020	Parham, David M./0000-0002-6912-9748; Laird, Peter W/0000-0001-9117-3641; Widschwendter, Martin/0000-0002-7778-8380; Liang, Gangning/0000-0001-8664-922X	NATIONAL CANCER INSTITUTE [P01CA046589, P01CA070972, R01CA075090] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 46589, CA 75090, P01 CA 70972, CA1506, R01 CA075090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1992, INT J CANCER, V50, P863, DOI 10.1002/ijc.2910500605; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EHRLICH M, 2002, IN PRESS CANC GENET; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaughan DJ, 2000, GENE, V257, P279, DOI 10.1016/S0378-1119(00)00392-9; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Hollander M., 1973, NONPARAMETRIC STAT, P68; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Malik K, 2000, CANCER RES, V60, P2356; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Shridhar V, 2001, CANCER RES, V61, P4258; Strichman-Almashanu LZ, 2002, GENOME RES, V12, P543, DOI 10.1101/gr.224102; Toyota M, 2000, CANCER RES, V60, P4044; Tuckwell KD, 2000, AUSTRALAS I MIN MET, V2000, P121; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wang ECY, 2001, IMMUNOGENETICS, V53, P59, DOI 10.1007/s002510000290; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; YOUNG R, 2001, J GERONTOL A-BIOL, V56, pR268; ZHANG XY, 1987, NUCLEIC ACIDS RES, V15, P9429, DOI 10.1093/nar/15.22.9429	39	149	165	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6694	6702		10.1038/sj.onc.1205890	http://dx.doi.org/10.1038/sj.onc.1205890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242669				2022-12-28	WOS:000178202300017
J	Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR				Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR			Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas	ONCOGENE			English	Article						annexin 1; esophageal squamous cell carcinoma; down-regulated protein	LIPOCORTIN-I; PROTEIN; DIFFERENTIATION; INDUCTION; CANCER	The development and progression of human cancer are believed to be due to the alterations of multiple genes or/and their protein products. For identifying the proteins associated with esophageal cancer, we analysed the protein profiles of 24 pairs of esophageal squamous cell carcinomas/matched adjacent normal epithelia. Microdissection of routinely unstained frozen sections was performed to purify cancerous and epithelial cells. The protein expression profiles were obtained by two-dimensional electrophoresis. Selected proteins dysregulated in tumors were identified by MALDI-TOF-MS. Three isoforms of annexin I were detected in normal esophageal mucosa and down-regulated in esophageal squamous cell carcinomas. RT-PCR analysis showed annexin I mRNA levels were significantly reduced in 17 out of 24 carcinomas. Immunohistochemistry demonstrated that annexin I appeared strong positive in all normal epithelia layers except basal cells. In cancer tissues, decreased expression of annexin I was observed in 12 out of 16 well differentiated tumors, 16 out of 17 moderately differentiated tumors, and 3 out of 3 poorly differentiated tumors as compared with the corresponding normal esophageal epithelia. There was a significant correlation between annexin I expression and the status of tumor differentiation. Well differentiated tumors presented stronger immunohistochemical reaction than moderately and poorly differentiated tumors. These data suggested that there existed three different isoforms of annexin I in normal esophageal epithelia, which may be the results of post-translational modification. Down-expression of three annexin I isoforms was a frequent event in esophageal carcinogenesis.	Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Chinese Acad Med Sci, Inst Basic Med, Natl Lab Med Mol Biol, Beijing 100007, Peoples R China; Peking Union Med Coll, Beijing 100007, Peoples R China; Natl Ctr Biomed Assay, Beijing 100085, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wang, MR (corresponding author), Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	wangmr@pubem.cicams.ac.cn	Hu, Hai/G-3864-2012					Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Beranova-Giorgianni S, 2000, RAPID COMMUN MASS SP, V14, P161, DOI 10.1002/(SICI)1097-0231(20000215)14:3<161::AID-RCM859>3.0.CO;2-7; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2; Koseki H, 1997, SURG TODAY, V27, P30, DOI 10.1007/BF01366936; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.3.CO;2-1; Ou K, 2001, ELECTROPHORESIS, V22, P2804, DOI 10.1002/1522-2683(200108)22:13<2804::AID-ELPS2804>3.0.CO;2-G; Paweletz CP, 2000, CANCER RES, V60, P6293; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; Wu YL, 2000, BRIT J HAEMATOL, V111, P807, DOI 10.1046/j.1365-2141.2000.02397.x	21	83	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6641	6648		10.1038/sj.onc.1205818	http://dx.doi.org/10.1038/sj.onc.1205818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242662				2022-12-28	WOS:000178202300010
J	Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I				Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I			reaper and bax initiate two different apoptotic pathways affecting mitochondria and antagonized by bcl-2 in Drosophila	ONCOGENE			English	Article						apoptosis; Drosophila; bcl-2; reaper; bax; mitochondria	PROGRAMMED CELL-DEATH; NF-KAPPA-B; IMMUNE-DEFICIENCY IMD; CYTOCHROME-C; CASPASE; HOMOLOG; PROTEIN; FAMILY; GENES; HID	bcl-2 was the first regulator of apoptosis shown to be involved in oncogenesis. Subsequent studies in mammals, in the nematode and in Drosophila revealed wide evolutionary conservation of the regulation of apoptosis. Although dbok/debcl, a member of the bcl-2 gene family described in Drosophila, shows pro-apoptotic activities, no anti-apoptotic bcl-2 family gene has been studied in Drosophila. We have previously reported that the human anti-apoptotic gene bcl-2 is functional in Drosophila, suggesting that the fruit fly shares regulatory mechanisms with vertebrates and the nematode, involving antiapoptotic members of the bcl-2 family. We now report that bcl-2 suppresses rpr-induced apoptosis in Drosophila. Additionally, we have compared features of bax- and rpr-induced apoptosis. Flow cytometry analysis of wing disc cells demonstrate that both killers trigger mitochondrial defects. Interestingly, bcl-2 suppresses both bax- and rpr-induced mitochondrial defects while the caspase-inhibitor p35 is specific to the rpr pathway. Finally, we show that the inhibition of apoptosis by bcl-2 is associated with the down-regulation of rpr expression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, F-78035 Versailles, France; Univ Versailles, Lab Genet Mol & Physiol, EPHE, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Paris Saclay	Guenal, I (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, 45 Ave Etats Unis, F-78035 Versailles, France.	guenal@genetique.uvsq.fr	Mignotte, Bernard/A-3499-2009; Guenal, Isabelle/F-3415-2019	Mignotte, Bernard/0000-0002-8512-8518; Guenal, Isabelle/0000-0003-1186-1458; Brun, Sylvain/0000-0002-6714-4012				Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; CAMPOSORTEGA JA, 1995, EMBRYONIC DEV DROSOP; Chen P, 2000, J CELL BIOL, V148, P625, DOI 10.1083/jcb.148.4.625; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Cohen SM., 1993, DEV DROSOPHILA MELAN; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Gaumer S, 2000, CELL DEATH DIFFER, V7, P804, DOI 10.1038/sj.cdd.4400714; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	54	16	16	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6458	6470		10.1038/sj.onc.1205839	http://dx.doi.org/10.1038/sj.onc.1205839			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226749	Green Submitted			2022-12-28	WOS:000177925300006
J	Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D				Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D			Serial analysis of gene expression in normal p53 null mammary epithelium	ONCOGENE			English	Article						SAGE; p53; mammary gland; breast cancer; gene expression; preneoplasia	TUMOR-SUPPRESSOR GENE; BREAST-CANCER; C-MYC; CELLS; GELSOLIN; MODEL; ADRENOMEDULLIN; INSTABILITY; APOPTOSIS; MECHANISM	Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of 'normal' mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53(null) epithelium of <1% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, POB 389,PK Rd 1-C, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NCI NIH HHS [CA84243] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asch HL, 1996, CANCER RES, V56, P4841; Charpentier AH, 2000, CANCER RES, V60, P5977; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DEAR TN, 1988, CANCER RES, V48, P5203; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Griffioen M, 1998, MOL IMMUNOL, V35, P829, DOI 10.1016/S0161-5890(98)00074-1; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; KLEIN B, 1991, CANCER, V67, P2295, DOI 10.1002/1097-0142(19910501)67:9<2295::AID-CNCR2820670915>3.0.CO;2-T; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lal A, 1999, CANCER RES, V59, P5403; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MORRISON BW, 1994, ONCOGENE, V9, P3417; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Williams JA, 2000, CANCER RES, V60, P4667; Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhao RB, 2000, GENE DEV, V14, P981; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	28	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6366	6376		10.1038/sj.onc.1205816	http://dx.doi.org/10.1038/sj.onc.1205816			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214277				2022-12-28	WOS:000177829000013
J	Dugan, KA; Wood, MA; Cole, MD				Dugan, KA; Wood, MA; Cole, MD			TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis	ONCOGENE			English	Article						Myc; E2F; TIP49; TRRAP; apoptosis; proliferation	HISTONE ACETYLASE COMPLEX; CELL-CYCLE PROGRESSION; ESSENTIAL COFACTOR; S-PHASE; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; GROWTH CONTROL; DNA-BINDING; TRANSCRIPTION; PROTEIN	We previously described two nuclear cofactors, TRRAP and TIP49, that have functional roles in Myc-mediated oncogenesis. We have now expanded the analysis of these Myc-associated cofactors to investigate their roles in apoptosis and cell proliferation. Although TRRAP and TIP49 are both essential for transformation, TIP49 modulates c-Myc-mediated apoptosis whereas disruption of TRRAP activity has no apparent effect on apoptosis. We extended our analysis of TIP49 to show that it also binds to the E2F1 transactivation domain and modulates both transforming and apoptotic activities. These results indicate that individual cofactors differentially potentiate c-Myc and E2F1 functions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wood, Marcelo/G-9527-2012					Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V85, P549; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lim CR, 2000, J BIOL CHEM, V275, P22409, DOI 10.1074/jbc.M001031200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mehmet H, 1997, CELL GROWTH DIFFER, V8, P187; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sladek TL, 1997, CELL PROLIFERAT, V30, P97, DOI 10.1111/j.1365-2184.1997.tb00926.x; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANCHINA E, 1998, GENE DEV, V12, P2434; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5835	5843		10.1038/sj.onc.1205763	http://dx.doi.org/10.1038/sj.onc.1205763			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185582				2022-12-28	WOS:000177520900002
J	Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H				Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H			Dominant negative MEKK1 inhibits survival of pancreatic cancer cells	ONCOGENE			English	Article						MEKK1; ERK; JNK; AP-1; CRE; pancreatic cancer	ACTIVATED PROTEIN-KINASES; LUNG-CARCINOMA CELLS; C-JUN; CONSTITUTIVE ACTIVATION; AP-1 FUNCTION; RAS; TRANSFORMATION; GROWTH; PROLIFERATION; PATHWAY	Human pancreatic cancers harbor mutations in the K-ras gene, and these mutations convert the gene oncogenic and constitutively active forms. However, in pancreatic cancer cells little is known about the activation of the downstream pathways of Ras, MEK - ERK and MEKK1 - JNK, and their roles in cell survival and proliferation. An analysis of nine pancreatic cancer tissues revealed JNK activation in all tumor samples and ERK activation in three tumor samples. Colony formation assays by transfection of dominant negative mutants of Ras, ERK or MEKK1 into pancreatic cancer cell lines (BxPC-3, PANC-1, MIAPa-Ca-2 and AsPC-1) and an amnion-derived cell line (FL) revealed that DN - MEKK strongly inhibits the survival of colonies in pancreatic cancer cells, but not in FL cells. In vitro kinase assays and luciferase assays using the Gal4c-Jun system revealed that in pancreatic cancer cells DN-MEKK fails to inhibit JNK activation. In PANC-1 cells, c-Jun was found to be a major component of protein component binding to AP-1 site and CRE, but not in FL cells. The inhibitory effect of DN-MEKK in PANC-1 cells was thought to be the result of the inhibition of c-Jun DNA-binding. The difference of suppression in pancreatic cancer cells and non-pancreatic cancer cells suggested that the MEKK1 pathway mainly contributes to cell survival in pancreatic cancer cells and may provide an advantage for the gene therapy of pancreatic cancers using DN - MEKK expression vectors.	Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan; Chiba Univ, Dept Med & Clin Oncol K1, Grad Sch Med, Chiba 2608670, Japan	Chiba University; Chiba University	Shirasawa, H (corresponding author), Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BRUNET A, 1994, ONCOGENE, V9, P3379; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; SCHNEIDER MTY, 1999, INT J ONCOL, V15, P271; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tessari G, 1999, ANTICANCER RES, V19, P863; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Xiao L, 2000, CANCER RES, V60, P400; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	28	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5923	5928		10.1038/sj.onc.1205643	http://dx.doi.org/10.1038/sj.onc.1205643			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185592				2022-12-28	WOS:000177520900012
J	Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T				Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T			DNA damage, death receptor activation and reactive oxygen species contribute to ultraviolet radiation-induced apoptosis in an essential and independent way	ONCOGENE			English	Article						apoptosis; cytochrome c; DNA damage; reactive oxygen species; UV radiation	SUNBURN CELL-FORMATION; CYTOCHROME-C RELEASE; SKIN-CANCER; MITOCHONDRIAL CONTROL; RADICAL REACTIONS; OXIDATIVE STRESS; CD95 FAS/APO-1; REPAIR; LIGHT; CARCINOGENESIS	Nuclear DNA damage and death receptor (CD95) activation by ultraviolet-B radiation (UVB) play a major role in UVB-induced apoptosis. Removal of DNA damage combined with inhibition of death receptor activation resulted in pronounced but not complete suppression of apoptosis, indicating that a third independent pathway is involved. Since reactive oxygen species (ROS) cause apoptosis and are induced by UVB, the radical scavenger pyrrolidene-dithiocarbamate (PDTC) was used. PDTC prevented UVB-induced apoptosis partially, H2O2-induced cell death largely, but not CD95-mediated apoptosis. The same was observed for cytochrome c release from mitochondria, another important event during apoptosis. The proapoptotic protein Bid was cleaved upon exposure to UVB or to agonistic anti-CD95-antibodies, but not to H2O2, indicating that H2O2 uses a different pathway. The fact that PDTC neither inhibited CD95-mediated apoptosis nor affected UV-induced DNA damage indicated that ROS generated during UVB irradiation may directly trigger mitochondrial cytochrome c release, thereby contributing to apoptosis. Accordingly, complete inhibition of apoptosis was observed when in addition to DNA damage removal via photoreactivation and blockade of CD95 signaling by caspase-8 inhibitor zIETD, PDTC was added before UVB exposure. This indicates that DNA damage, death receptor activation and ROS formation contribute to UVB-induced apoptosis in an essential and independent way.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany	University of Munster	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, von Esmarchstr 58, D-48149 Munster, Germany.	schwtho@uni-muenster.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Black HS, 2001, CURR PROBL DERMATOL, V29, P140; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; EKER APM, 1990, J BIOL CHEM, V265, P8009; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Petit-Frere C, 2000, J INVEST DERMATOL, V115, P687, DOI 10.1046/j.1523-1747.2000.00093.x; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; TYRRELL RM, 1995, BIOCH SOC S, V61, P547; Wenk J, 2001, CURR PROBL DERMATOL, V29, P83; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WOODCOCK A, 1976, BRIT J DERMATOL, V95, P459, DOI 10.1111/j.1365-2133.1976.tb00854.x; YAROSH D, 1992, CANCER RES, V52, P4227; YAROSH D, 1994, TRENDS PHOTOCHEM PHO, V3, P175; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	45	197	202	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5844	5851		10.1038/sj.onc.1205743	http://dx.doi.org/10.1038/sj.onc.1205743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185583				2022-12-28	WOS:000177520900003
J	Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM				Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM			Mismatch repair deficiency in hematological malignancies with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hematological malignancy	NUCLEAR EXTRACTS; CELL-LINES; CANCER; GENE; LEUKEMIA; BETA; HETERODIMER; SUPPRESSION; MUTATIONS; EXPRESSION	Mutations in human mismatch repair (MMR) genes are the genetic basis for certain types of solid tumors displaying microsatellite instability (MSI). MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear. Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR. In vitro complementation experiments, using characterized MMR mutant extracts or purified proteins, showed that these hematological cancer cells were defective in either hMutSalpha (a heterodimer of hMSH2 and hMSH6) or hMutLalpha (a heterodimer of hMLH1 and hPMS2). Furthermore, cell lines deficient in hMutSalpha showed large deletions or point mutations in hMSH2, while those deficient in hMutLalpha. exhibited point mutations in hMLH1 or a lack of expression of hPMS2. From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutSalpha or MutLalpha. We also report here, for the first time, that an MSI-positive cell line derived from Burkitt's lymphoma is proficient in MMR.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Gu, LY (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, 800 Rose St, Lexington, KY 40536 USA.	lgu0@uky.edu	Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NCI NIH HHS [CA85377] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DeVita S, 1997, BRIT J HAEMATOL, V97, P463, DOI 10.1046/j.1365-2141.1997.252670.x; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Hayami Y, 1999, LEUKEMIA LYMPHOMA, V32, P345, DOI 10.3109/10428199909167395; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaneko H, 1996, INT J CANCER, V69, P480, DOI 10.1002/(SICI)1097-0215(19961220)69:6<480::AID-IJC11>3.0.CO;2-5; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kodera T, 1999, GENE CHROMOSOME CANC, V26, P267, DOI 10.1002/(SICI)1098-2264(199911)26:3<267::AID-GCC13>3.0.CO;2-V; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Larson RS, 1997, BLOOD, V89, P1114, DOI 10.1182/blood.V89.3.1114; Leung WK, 2000, J BIOL CHEM, V275, P15728, DOI 10.1074/jbc.M908768199; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1999, ONCOL RES, V11, P393; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Molenaar JJ, 1998, BLOOD, V92, P230, DOI 10.1182/blood.V92.1.230.413k17_230_233; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	41	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5758	5764		10.1038/sj.onc.1205695	http://dx.doi.org/10.1038/sj.onc.1205695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173046				2022-12-28	WOS:000177463400011
J	Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L				Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L			Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors	ONCOGENE			English	Article						Wnt signaling; beta-catenin activation; Int2/Fgf3; cytokeratin expression; pilar tumor; transdifferentiation	PROTEIN-KINASE CK2; BETA-CATENIN; TRANSGENIC MICE; CYCLIN D1; FUNCTIONAL INTERACTION; HAIR FOLLICLE; FEMALE MICE; GENE; GLAND; EXPRESSION	The Wnt/beta-catenin signaling pathway controls cell fate and neoplastic transformation. Expression of an endogenous stabilized beta-catenin (DeltaE3 beta-catenin) in mammary epithelium leads to the transdifferentiation into epidermis- and pilar-like structures. Signaling molecules in the canonical Wnt pathway upstream from P-catenin induce glandular tumors but it is not clear whether they also cause squamous transdifferentiation. To address this question we have now investigated mammary epithelium from transgenic mice that express activating molecules of the Wnt pathway: Wnt10b, Int2/Fgf3, CK2alpha, DeltaE3 beta-catenin, Cyclin D1, and dominant negative (dn) GSK3beta. Cytokeratin 5 (CK5), which is expressed in both mammary myoepithelium and epidermis, and the epidermis-specific CK1 and CK6 were used as differentiation markers. Extensive squamous metaplasias and widespread expression of CK1 and CK6 were observed in DeltaE3 beta-catenin transgenic mammary tissue. Wnt10b and Int2 transgenes also induced squamous metaplasias, but expression of CK1 and CK6 was sporadic. While CK5 expression in Wnt I Ob transgenic tissue was still confined to the lining cell layer, its expression in Int2 transgenic tissue was completely disorganized. In contrast, cytokeratin expression in CK2alpha dnGSK3beta and Cyclin D1 transgenic mammary tissues was similar to that in DeltaE3 beta-catenin tissue. In support of transdifferentiation, expression of hard keratins specific for hair and nails was observed in pilar tumors. These results demonstrate that the activation of Wnt signaling components in mammary epithelium induces not only glandular tumors but also squamous differentiation, possibly by activating LEF-1, which is expressed in normal mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Univ Tokushima, Sch Dent, Dept Biochem, Tokushima 7708504, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; McLaughlin Res Inst, Great Falls, MT USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Kyoto Univ, Grad Sch Med, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tokushima University; University of California System; University of California Davis; Boston University; McLaughlin Research Institute for Biomedical Sciences, Inc.; Harvard University; Massachusetts General Hospital; Kyoto University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101,8 Ctr Dr, Bethesda, MD 20892 USA.		Robinson, Gertraud/I-2136-2012	Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841; Seldin, David C/0000-0003-0168-2333	NCRR NIH HHS [U42 RR14905] Funding Source: Medline; NIEHS NIH HHS [P01 ES11624] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR014905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; KLINT P, 1999, FRONT BIOSCI, V4, P165; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Niemann C, 2002, DEVELOPMENT, V129, P95; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; ROSNER A, 2002, IN PRESS AM J PATHOL; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tekmal Rajeshwar Rao, 1997, Frontiers in Bioscience, V2, pD519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	46	93	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5548	5556		10.1038/sj.onc.1205686	http://dx.doi.org/10.1038/sj.onc.1205686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165853				2022-12-28	WOS:000177442000004
J	Channavajhala, P; Seldin, DC				Channavajhala, P; Seldin, DC			Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis	ONCOGENE			English	Article						casein kinase II; protein kinase CK2; c-myc; lymphoma; proteasome	II-ALPHA; COMPETITIVE INHIBITOR; PHOSPHORYLATION SITES; EPITHELIAL-CELLS; CASEIN KINASE-2; EXPRESSION; MICE; PROTEASOME; ACTIVATION; SUBUNIT	Protein kinase CK2 (formerly casein kinase II) is frequently upregulated in human cancers, and transgenic expression of CK2alpha in lymphocytes is oncogenic. Lymphomagenesis is dramatically acclerated by coexpression of a c-myc transgene, suggestive of a synergistic interaction between the kinase and the transcription factor. Since c-myc can be phosphorylated by CK2, we hypothesized that the synergy between CK2 and c-myc might be due to a functional interaction of the two molecules. Pharmacologic inhibition of CK2 activity in cell lines established from CK2alpha transgenic T cell lymphomas reduces their proliferation and concomitantly with this, the steady state levels of c-myc protein decline. This is caused by acclerated c-myc protein turnover, which occurs in a proteasome-dependent manner. Transfection of cells with sense or anti-sense CK2 constructs modulates c-myc protein levels in concert with the alteration in CK2 activity, validating the findings obtained using the kinase inhibitors. Thus, CK2 is a critical regulator of c-myc protein stability and of the proliferation of these T cell lymphomas.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Seldin, DC (corresponding author), 650 Albany St, Boston, MA 02118 USA.	dseldin@medicine.bu.edu		Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [R01 CA71796] Funding Source: Medline; NHLBI NIH HHS [T32 HL07501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Battistutta R, 2000, J BIOL CHEM, V275, P29618, DOI 10.1074/jbc.M004257200; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BOLDYREFF B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P32, DOI 10.1016/0167-4781(93)90239-A; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Critchfield JW, 1996, AIDS RES HUM RETROV, V12, P39, DOI 10.1089/aid.1996.12.39; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Dobrowolska G, 1999, MOL CELL BIOCHEM, V191, P3, DOI 10.1023/A:1006882910351; Dumont FJ, 1998, J IMMUNOL, V160, P2579; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Kamei H, 1998, CANCER BIOTHER RADIO, V13, P185, DOI 10.1089/cbr.1998.13.185; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lin JK, 1997, J CELL BIOCHEM, P39; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Penn L J, 1990, Semin Cancer Biol, V1, P69; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; Trochon V, 2000, INT J CANCER, V85, P691, DOI 10.1002/(SICI)1097-0215(20000301)85:5&lt;691::AID-IJC15&gt;3.0.CO;2-Q; VONDEIMLING A, 1990, VERH DEUT G, V74, P432; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; Yin F, 1999, ANTICANCER RES, V19, P4297	54	115	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5280	5288		10.1038/sj.onc.1205640	http://dx.doi.org/10.1038/sj.onc.1205640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149649	Bronze			2022-12-28	WOS:000177193900009
J	Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R				Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R			Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo	ONCOGENE			English	Article						MDA-7; TRAIL; CD31; apoptosis; gene therapy; antiangiogenesis	DIFFERENTIATION-ASSOCIATED GENE; MELANOMA DIFFERENTIATION; TUMOR-GROWTH; APOPTOSIS; CELLS; VEGF	Overexpression of the melanoma differentiation associated gene-7 (mda-7) in vitro results in suppression of lung cancer cell proliferation. However, the ability of MDA-7 to suppress lung cancer in vivo has not been previously demonstrated. In this study, we investigated the possibility of inducing overexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its effects on tumor growth. Adenovirus-mediated overexpression of MDA-7 in p53-wild-type A549 and p53-null H1299 subcutaneous tumors resulted in significant tumor growth inhibition through induction of apoptosis. In addition, decreased CD31/PECAM expression and upregulation of APO2/TRAIL were observed in tumors expressing MDA-7. In vivo studies correlated well with in vitro inhibition of lung tumor cell proliferation and endothelial cell differentiation mediated by Ad-mda7. These data demonstrate that Ad-mda7 functions as a multi-modality anti-cancer agent, possessing both, pro-apoptotic and anti-angiogenic properties. We demonstrate for the first time the potential therapeutic effects of Ad-mda7 in human lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ramesh, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 45, Houston, TX 77030 USA.	rramesh@mdanderson.org			NCI NIH HHS [R43 CA86587, P01CA78778-01A1, P50-CA70907, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672, P50CA070907, R43CA086587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; GEORGES RN, 1993, CANCER RES, V53, P1743; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kagawa S, 2001, CANCER RES, V61, P3330; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishizaki M, 1999, CLIN CANCER RES, V5, P1015; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80008-1; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	20	142	175	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4558	4566		10.1038/sj.onc.1205553	http://dx.doi.org/10.1038/sj.onc.1205553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085234				2022-12-28	WOS:000176476700010
J	Zhao, YL; Piao, CQ; Hei, TK				Zhao, YL; Piao, CQ; Hei, TK			Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells	ONCOGENE			English	Article						asbestos; Betaig-h3; tumor suppression; human bronchial epithelial cells	GROWTH-FACTOR-BETA; SMOOTH-MUSCLE; MALIGNANT MESOTHELIOMA; EXTRACELLULAR-MATRIX; MAMMALIAN-CELLS; IN-VITRO; BETA-IG-H3; LOCALIZATION; EXPRESSION; PROTEIN	Although Betaig-h3 gene has been suggested to modulate cell adhesion and tumor formation, its physiological functions are not well understood. Using human papillomavirus immortalized human bronchial epithelial (BEP2D) cells, we found that Betaig-h3 expression was markedly decreased in asbestos-induced tumorigenic cells. Fusion of tumorigenic and control BEP2D cells resulted in the recovery of Betaig-h3 gene expression to control level and the loss of tumorigenic phenotype. Furthermore, ectopic expression of Betaig-h3 gene in asbestos-induced tumorigenic cells inhibited cell growth in vitro, anchorage independent phenotype, as well as tumorigenicity in nude mice. Betaig-h3 gene is ubiquitously expressed in various normal human tissues, with the exception of the brain, where there is little or no expression. In contrast, there was a decrease or absence in expression of the Betaig-h3 gene in 14 human tumor cell lines of diverse histological types examined, when compared with normal human cells or tissues. The result strongly suggests that loss of Betaig-h3 expression is a frequent event in human cancer and causally related to acquisition of tumorigenic phenotype in asbestos-treated BEP2D cells.	Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Zhao, YL (corresponding author), Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, VC 11-128,630 W 168th St, New York, NY 10032 USA.	yz93@columbia.edu			NCI NIH HHS [CA49062] Funding Source: Medline; NIEHS NIH HHS [P30 ES 09089, ES07890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES007890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; Brezinova J, 2000, CANCER GENET CYTOGEN, V117, P45, DOI 10.1016/S0165-4608(99)00142-9; Brody AR, 1997, ENVIRON HEALTH PERSP, V105, P1165, DOI 10.2307/3433527; Bron AJ, 2000, CORNEA, V19, P699, DOI 10.1097/00003226-200009000-00015; FEARON ER, 1995, CANCER SURV, V24, P3; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Genini M, 1996, INT J CANCER, V66, P571; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; HEI TK, 1992, CANCER RES, V52, P6305; Hei TK, 2000, INHAL TOXICOL, V12, P141, DOI 10.1080/08958378.2000.11463207; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; Jagirdar J, 1997, ENVIRON HEALTH PERSP, V105, P1197, DOI 10.2307/3433532; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; Kamp DW, 1999, THORAX, V54, P638, DOI 10.1136/thx.54.7.638; Kane AB, 1996, IARC SCI PUBL, P11; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Ni ZY, 2000, MUTAT RES-GEN TOX EN, V468, P87, DOI 10.1016/S1383-5718(00)00043-7; Pass HI, 1996, J CELL BIOCHEM, P142; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; PERDUE TD, 1994, J HISTOCHEM CYTOCHEM, V42, P1061, DOI 10.1177/42.8.8027525; Piao CQ, 2001, ONCOGENE, V20, P7301, DOI 10.1038/sj.onc.1204908; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Salih HR, 2001, EUR J MED RES, V6, P323; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Suzuki M, 2001, INT J MOL MED, V8, P43; WILLEY JC, 1991, CANCER RES, V51, P5370; Wu XF, 1998, INT J CANCER, V79, P490, DOI 10.1002/(SICI)1097-0215(19981023)79:5<490::AID-IJC8>3.3.CO;2-D; Xu A, 1999, CANCER RES, V59, P5922; Zanella CL, 1996, CANCER RES, V56, P5334; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	37	54	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7471	7477		10.1038/sj.onc.1205891	http://dx.doi.org/10.1038/sj.onc.1205891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386809				2022-12-28	WOS:000178618200002
J	Pfeifer, GP; Denissenko, MF; Olivier, M; Tretyakova, N; Hecht, SS; Hainaut, P				Pfeifer, GP; Denissenko, MF; Olivier, M; Tretyakova, N; Hecht, SS; Hainaut, P			Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers	ONCOGENE			English	Review						cigarette smoke; lung cancer; DNA damage; p53; carcinogens	POLYCYCLIC AROMATIC-HYDROCARBONS; LUNG-CANCER; DIOL-EPOXIDE; CIGARETTE-SMOKING; METHYLATED CPG; 4-AMINOBIPHENYL-DNA ADDUCTS; CHEMICAL CARCINOGENESIS; TRANSVERSION MUTATIONS; MOLECULAR EPIDEMIOLOGY; CYTOSINE METHYLATION	It is estimated that cigarette smoking kills over 1000 000 people each year by causing lung cancer as welt as many other neoplasmas. p53 mutations are frequent in tobacco-related cancers and the mutation load is often higher in cancers from smokers than from nonsmokers. In lung cancers, the p53 mutational patterns are different between smokers and nonsmokers with an excess of G to T transversions in smoking-associated cancers. The prevalence of G to T transversions is 30% in smokers' lung cancer but only 12% in lung cancers of nonsmokers. A similar trend exists, albeit less marked, in laryngeal cancers and in head and neck cancers. This type of mutation is infrequent in most other tumors aside from hepatocellular carcinoma. At several p53 mutational hotspots common to all cancers, such as codons 248 and 273, a large fraction of the mutations are G to T events in lung cancers but are almost exclusively G to A transitions in non-tobacco-related cancers. Two important classes of tobacco smoke carcinogens are the polycyclic aromatic hydrocarbons (PAH) and the nicotine-derived nitrosamines. Recent studies have indicated that there is a strong coincidence of G to T transversion hotspots in lung cancers and sites of preferential formation of PAH adducts along the P53 gene. Endogenously methylated CpG dinucleotides are the preferred sites for G to T transversions, accounting for more than 50% of such mutations in lung tumors. The same dinucleotide, when present within CpG-methylated mutational reporter genes, is the target of G to T transversion hotspots in cells exposed to the model PAH compound benzo[a]pyrene-7,8-diol-9,10-epoxide. As summarized here, a number of other tobacco smoke carcinogens also can cause G to T transversion mutations. The available data suggest that p53 mutations in lung cancers can be attributed to direct DNA damage from cigarette smoke carcinogens rather than to selection of pre-existing endogenous mutations.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Sequenom Inc, San Diego, CA 92121 USA; Int Agcy Res Canc, WHO, F-69372 Lyon, France; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	City of Hope; Beckman Research Institute of City of Hope; Sequenom; World Health Organization; International Agency for Research on Cancer (IARC); University of Minnesota System; University of Minnesota Twin Cities	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org; hecht002@umn.edu; hainaut@iarc.fr	Olivier, Magali/G-3728-2010; Hainaut, Pierre/B-6018-2012	Olivier, Magali/0000-0002-8202-342X; Hainaut, Pierre/0000-0002-1303-1610; Hecht, Stephen/0000-0001-7228-1356	NATIONAL CANCER INSTITUTE [R01CA081301, R37CA081301, R01CA084469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA013333] Funding Source: NIH RePORTER; NCI NIH HHS [CA84469, CA 81301] Funding Source: Medline; NIDA NIH HHS [DA 13333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1985, IARC Monogr Eval Carcinog Risk Chem Hum, V36, P101; [Anonymous], 1999, IARC Monogr Eval Carcinog Risks Hum, V71 Pt 1, P109; [Anonymous], 1982, IARC Monogr Eval Carcinog Risk Chem Hum, V29, P93; [Anonymous], 1978, IARC Monogr Eval Carcinog Risk Chem Man, V17, P83; Armstrong RN, 1997, COMPREHENSIVE TOXICO, V3, P307; Arora A, 2001, CARCINOGENESIS, V22, P1173, DOI 10.1093/carcin/22.8.1173; Asami S, 1997, CARCINOGENESIS, V18, P1763, DOI 10.1093/carcin/18.9.1763; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; BIGGER CAH, 1992, P NATL ACAD SCI USA, V89, P368, DOI 10.1073/pnas.89.1.368; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Burchell B, 1997, COMPREHENSIVE TOXICO, V3, P401; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; Casale GP, 2001, CHEM RES TOXICOL, V14, P192, DOI 10.1021/tx000012y; Castelao JE, 2001, JNCI-J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538; Chao A, 2000, JNCI-J NATL CANCER I, V92, P1888, DOI 10.1093/jnci/92.23.1888; Chen JX, 1998, CANCER RES, V58, P2070; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; Chepiga TA, 2000, FOOD CHEM TOXICOL, V38, P949, DOI 10.1016/S0278-6915(00)00086-7; Chung FL, 1999, IARC SCI PUBL, P45; CONNEY AH, 1982, CANCER RES, V42, P4875; Culp SJ, 1997, MUTAT RES-FUND MOL M, V378, P97, DOI 10.1016/S0027-5107(97)00101-2; Culp SJ, 1998, CARCINOGENESIS, V19, P117, DOI 10.1093/carcin/19.1.117; Das A, 1999, CHEM BIOL, V6, P461, DOI 10.1016/S1074-5521(99)80064-7; Delclos K.B., 1997, COMPREHENSIVE TOXICO, V12, P141; DeMarini DM, 2001, CANCER RES, V61, P6679; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DEUTSCHWENZEL RP, 1983, JNCI-J NATL CANCER I, V71, P539; Doll R, 1996, BRIT MED BULL, V52, P35, DOI 10.1093/oxfordjournals.bmb.a011531; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; Feng ZH, 2002, BIOCHEMISTRY-US, V41, P6414, DOI 10.1021/bi020093s; FOILES PG, 1991, CHEM RES TOXICOL, V4, P364, DOI 10.1021/tx00021a017; GEACINTOV NE, 1986, CARCINOGENESIS, V7, P759, DOI 10.1093/carcin/7.5.759; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P413, DOI 10.1021/tx00022a003; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Gupta RC, 1999, MUTAT RES-FUND MOL M, V424, P195, DOI 10.1016/S0027-5107(99)00019-6; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hainaut P, 2001, MUTAGENESIS, V16, P551, DOI 10.1093/mutage/16.6.551; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY N, 1980, BANDURY REPORT 3 A, P93; Hecht S.S., 1999, ANAL DETERMINATION N, P421, DOI DOI 10.1016/B978-044450095-3/50012-7; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HECHT SS, 1986, CANCER RES, V46, P4162; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hoffmann D., 1990, CHEM CARCINOGENESIS, P63, DOI [10.1007/978-3-642-74775-5_3, DOI 10.1007/978-3-642-74775-5_3]; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HusgafvelPursiainen K, 1996, ENVIRON HEALTH PERSP, V104, P553, DOI 10.2307/3432822; Hussain SP, 1998, CANCER RES, V58, P4023; Hussain SP, 2001, CANCER RES, V61, P6350; *IARC, 1974, IARC MON EV CARC RIS, V4, P97; IARC, 1983, IARC MON EV CARC RIS, V32, P211; *IARC, 1986, IARC MON EV CARC RIS, V60, P73; *IARC, 1972, IARC MON EV CARC RIS, V1; IARC, 1974, IARC MON EV CARC RIS, V7, P111; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; *IARC, 1973, IARC MON CARC RISK C, V4, P127; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38, P37; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Koc H, 1999, CHEM RES TOXICOL, V12, P566, DOI 10.1021/tx980265f; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Kozack R, 2000, MUTAT RES-FUND MOL M, V450, P41, DOI 10.1016/S0027-5107(00)00015-4; Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LIN DX, 1994, ENVIRON HEALTH PERSP, V102, P11, DOI 10.2307/3432144; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MCCOY GD, 1979, CANCER RES, V39, P2844; MELCHIOR WB, 1994, CARCINOGENESIS, V15, P889, DOI 10.1093/carcin/15.5.889; MELIKIAN AA, 1988, CANCER RES, V48, P1781; MELIKIAN AA, 1990, CHEM RES TOXICOL, V3, P139, DOI 10.1021/tx00014a009; MILLER JA, 1994, DRUG METAB REV, V26, P1, DOI 10.3109/03602539409029782; Misra RR, 1998, CHEM RES TOXICOL, V11, P211, DOI 10.1021/tx970183b; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nesnow S, 1995, TOXICOLOGY, V105, P403, DOI 10.1016/0300-483X(95)03238-B; Nia AB, 2002, BIOMARKERS, V7, P209, DOI 10.1080/13547500110120000; NIA AB, 2002, IN PRESS CANC RES, V62; Noori P, 2001, CARCINOGENESIS, V22, P1825, DOI 10.1093/carcin/22.11.1825; *NTP, 1986, 289 NTP; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Paschke T, 2000, MUTAGENESIS, V15, P457, DOI 10.1093/mutage/15.6.457; Pauly GT, 2002, CHEM RES TOXICOL, V15, P165, DOI 10.1021/tx0101245; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Pfeifer GP, 1998, ENVIRON MOL MUTAGEN, V31, P197, DOI 10.1002/(SICI)1098-2280(1998)31:3<197::AID-EM1>3.0.CO;2-I; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; PREUSSMANN R, 1984, CHEM CARCINOGENS, V2, P643; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297; Recio L, 2000, Res Rep Health Eff Inst, P49; REZNIKSHULLER H, 1983, COMP RESP TRACTCARCI, P109; RIVENSON A, 1988, CANCER RES, V48, P6912; Rodin SN, 2000, P NATL ACAD SCI USA, V97, P12244, DOI 10.1073/pnas.180320897; Rojas M, 1998, PHARMACOGENETICS, V8, P109; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; Ross JA, 1999, MUTAT RES-FUND MOL M, V424, P155, DOI 10.1016/S0027-5107(99)00016-0; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; Santella RM, 1999, CANCER EPIDEM BIOMAR, V8, P733; SCHULLER HM, 1993, CANCER RES, V53, P2498; See KY, 2000, MUTAT RES-REV MUTAT, V463, P215, DOI 10.1016/S1383-5742(00)00047-8; SELLAKUMAR A, 1974, J NATL CANCER I, V53, P1713; Singer B., 1983, MOL BIOL MUTAGENS CA, P45; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; SNOOK ME, 1978, BEITR TABAKFORSCH, V9, P222; Sodum RS, 1998, CHEM RES TOXICOL, V11, P1453, DOI 10.1021/tx980160c; SOLT DB, 1987, J ORAL PATHOL MED, V16, P294; Spiegelhalder B, 1996, EUR J CANCER PREV, V5, P33, DOI 10.1097/00008469-199609001-00007; Swenberg JA, 1999, IARC SCI PUBL, P29; SWENBERG JA, 1980, CANCER RES, V40, P3398; Szeliga J, 1998, CHEM RES TOXICOL, V11, P1, DOI 10.1021/tx970142f; Tang DL, 2001, CANCER RES, V61, P6708; THORNTONMANNING JR, 1995, CARCINOGENESIS, V16, P1723, DOI 10.1093/carcin/16.8.1723; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tretyakova N, 1997, CARCINOGENESIS, V18, P137, DOI 10.1093/carcin/18.1.137; Vahakangas KH, 2001, CANCER RES, V61, P4350; Vineis P, 2001, CANCER EPIDEM BIOMAR, V10, P1249; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Wang M, 2000, CHEM RES TOXICOL, V13, P1149, DOI 10.1021/tx000118t; Wang MY, 2000, CHEM RES TOXICOL, V13, P1065, DOI 10.1021/tx000095i; Wang MY, 2001, CHEM RES TOXICOL, V14, P1435, DOI 10.1021/tx010097i; Wang MY, 2001, CHEM RES TOXICOL, V14, P423, DOI 10.1021/tx000234w; WEI SJC, 1993, CANCER RES, V53, P3294; Weisenberger DJ, 1999, J BIOL CHEM, V274, P23948, DOI 10.1074/jbc.274.34.23948; WHO, 1997, TOB HLTH GLOB STAT R, P10; WILSON VL, 1989, CARCINOGENESIS, V10, P2149, DOI 10.1093/carcin/10.11.2149; Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792; Yoon JH, 2001, CANCER RES, V61, P7110; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhao CY, 1999, MUTAT RES-FUND MOL M, V424, P117, DOI 10.1016/S0027-5107(99)00013-5; Zhao CY, 2000, CARCINOGENESIS, V21, P107, DOI 10.1093/carcin/21.1.107	143	781	800	5	164	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7435	7451		10.1038/sj.onc.1205803	http://dx.doi.org/10.1038/sj.onc.1205803			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379884				2022-12-28	WOS:000178618000014
J	Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER				Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER			Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer	ONCOGENE			English	Article						methylation; RASSF1A; colorectal cancer; Wilms' tumour	DNA METHYLATION; EPIGENETIC INACTIVATION; H19 LOCUS; EXPRESSION; 3P21.3; LUNG; RAS; CARCINOMA; REGION; WT1	The 3p21.3 tumour suppressor gene (TSG) RASSF1A is inactivated predominantly by promoter methylation and rarely by somatic mutations. Recently we demonstrated that epigenetic inactivation of RASSF1A is frequent in both clear cell and papillary adult renal cell carcinomas (even though 3p21.3 allele loss is rare in papillary tumours). Wilms' tumour is the most common childhood kidney tumour, but relatively little is known about its molecular pathogenesis. Thus TSGs such as WT1, p16(CDKN2a) and p53 are inactivated in only a minority of cases. In view of the involvement of RASSF1A in adult renal cancers we investigated RASSF1A as a candidate Wilms' TSG. We detected RASSF1A hypermethylation in 21 of 39 (54%) primary Wilms' tumours. 3p21.3 allele loss was not detected in nine informative Wilms' tumours (five with RASSF1A methylation). In contrast to RASSF1A, only a minority (10.3%) of Wilms' tumours demonstrated p16 promoter methylation. As chromosome 3p allele loss is frequent in colorectal cancer, we proceeded to investigate RASSF1A promoter methylation in colorectal cancer and detected RASSF1A methylation in 80% (4/5) colorectal cancer cell lines and 45% (13/29) primary colorectal cancers. There was no correlation between RASSF1A and p16 methylation in colorectal cancer. We have demonstrated that RASSF1A inactivation is the most frequent genetic or epigenetic event yet reported in Wilms' tumourigenesis and that allelotyping studies may fail to identify regions containing important TSGs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Anat, Cambridge CB1, England; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Reik, Wolf/I-6794-2012; Schofield, Paul/AAA-9414-2020	MAHER, EAMONN R/0000-0002-6226-6918; Schofield, Paul/0000-0002-5111-7263; Reik, Wolf/0000-0003-0216-9881				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies R, 1999, CANCER RES, V59, p1747S; DAVIES R, 1999, CANCER RES, V59, pS1751; Hao XP, 2000, CANCER RES, V60, P18; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kane MF, 1997, CANCER RES, V57, P808; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lerman MI, 2000, CANCER RES, V60, P6116; LUO XN, 1995, ONCOGENE, V11, P743; Morrissey C, 2001, CANCER RES, V61, P7277; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; Richards FM, 1996, HUM MOL GENET, V5, P639, DOI 10.1093/hmg/5.5.639; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Stirzaker C, 1997, CANCER RES, V57, P2229; Thiagalingam S, 1996, CANCER RES, V56, P2936; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U	35	75	83	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7277	7282		10.1038/sj.onc.1205922	http://dx.doi.org/10.1038/sj.onc.1205922			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370819				2022-12-28	WOS:000178504600017
J	Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM				Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM			Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways	ONCOGENE			English	Article						bile acids; invasion; colorectal cancer	PROTEIN-KINASE-C; COLONIC EPITHELIAL-CELLS; DOWN-REGULATION; ADENOCARCINOMA CELLS; LITHOCHOLIC ACID; NUCLEAR RECEPTOR; CADHERIN/CATENIN COMPLEX; URSODEOXYCHOLIC ACID; CELLULAR INVASION; INDUCED APOPTOSIS	Bile acids are implicated in colorectal carcinogenesis as evidenced by epidemiological and experimental studies. We examined whether bile acids stimulate cellular invasion of human colorectal and dog kidney epithelial cells at different stages of tumor progression. Colon PC/AA/C1, PCmsrc, and HCT-8/E11 cells and kidney MDCKT23 cells were seeded on top of collagen type I gels and invasive cells were counted after 24 h incubation. Activation of the Rac1 and RhoA small GTPases was investigated by pull-down assays. Haptotaxis was analysed with modified Boyden chambers. Lithocholic acid, chenodeoxycholic acid, cholic acid and deoxycholic acid stimulated cellular invasion of SRC-and RhoA-transformed PCmsrc and MDCKT23-RhoAV14 cells, and of HCT-8/E11 cells originating from a sporadic tumor, but were ineffective in premalignant PC/AA/C1 and MDCKT23 cells. Bile acid-stimulated invasion occurred through stimulation of haptotaxis and was dependent on the RhoA/Rho-kinase pathway and signaling cascades using protein kinase C, mitogen-activated protein kinase, and cyclooxygenase-2. Accordingly, BA-induced invasion was associated with activation of the Rac1 and RhoA GTPases and expression of the farnesoid X receptor. We conclude that bile acids stimulate invasion and haptotaxis in colorectal cancer cells via several cancer invasion signaling pathways.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; INSERM, U 452, UFR Med, F-06107 Nice, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Ghent University; Ghent University Hospital; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mareel, MM (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, 1P7,Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@rug.ac.be	Debruyne, Philip/AAU-6685-2021	Debruyne, Philip/0000-0001-5438-9697				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; AZNAVOORIAN S, 1990, J NATL CANCER I, V82, P1485, DOI 10.1093/jnci/82.18.1485; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; Batta AK, 1998, CANCER RES, V58, P1684; BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, P145, DOI 10.1016/0016-5085(93)90846-5; Bracke ME, 1997, EUR J CELL BIOL, V74, P342; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; EARNEST DL, 1994, CANCER RES, V54, P5071; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fujita T, 1998, CANCER RES, V58, P4823; Glinghammar B, 2001, GASTROENTEROLOGY, V120, P401, DOI 10.1053/gast.2001.21188; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halvorsen B, 2000, BIOCHEM J, V349, P189, DOI 10.1042/0264-6021:3490189; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILL MJ, 1971, LANCET, V1, P95; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamano T, 1999, DIS COLON RECTUM, V42, P668, DOI 10.1007/BF02234147; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozoni V, 2000, CARCINOGENESIS, V21, P999, DOI 10.1093/carcin/21.5.999; Kurtz W., 1992, Verdauungskrankheiten, V10, P153; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LATTA RK, 1993, CANCER LETT, V70, P167, DOI 10.1016/0304-3835(93)90227-Z; LEHMANN M, 1994, CANCER RES, V54, P2102; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; McMillan L, 2000, BIOCHEM BIOPH RES CO, V273, P45, DOI 10.1006/bbrc.2000.2899; Moseley R, 1999, TXB GASTROENTEROLOGY, P380; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Owen RW, 1997, SCAND J GASTROENTERO, V32, P76, DOI 10.1080/00365521.1997.11720725; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Rao YP, 1997, J LIPID RES, V38, P2446; REDDY BS, 1981, CANCER RES, V41, P3766; REDDY BS, 1977, CANCER RES, V37, P3228; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlottmann K, 2000, CANCER RES, V60, P4270; Shimao Y, 1999, CLIN EXP METASTAS, V17, P351; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUMMERTON J, 1983, BRIT J SURG, V70, P549, DOI 10.1002/bjs.1800700914; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; VAKAET L, 1991, INVAS METAST, V11, P249; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimber A, 2000, CANCER RES, V60, P672; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	70	69	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6740	6750		10.1038/sj.onc.1205729	http://dx.doi.org/10.1038/sj.onc.1205729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360401				2022-12-28	WOS:000178315800004
J	Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC				Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC			An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia	ONCOGENE			English	Article						point mutation; constitutive activation; helix-helix interaction; asparagine	CELL-SURFACE RECEPTORS; RAS GENE-MUTATIONS; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; POINT MUTATIONS; BETA-SUBUNIT; IN-VIVO; N-RAS; G-CSF; DIFFERENTIATION	To date, constitutively activating point mutations reported in hematopoietic growth factor receptors in patients with acute myeloid leukemia (AML) have been restricted to receptors with intrinsic tyrosine kinase activity such as c-kit and FLT3. We describe here a Thr617Asn mutation in the transmembrane domain of the non-tyrosine kinase receptor for granulocyte colony-stimulating factor (G-CSF) in the blast cells of two out of 555 AML patients examined. The mutant receptor conferred growth factor independence on factor-dependent Ba/F3 cells. In the absence of ligand, immunoblotting showed weak phosphorylation of JAK2, STAT3, ERKs 1 and 2 and the receptor itself, and there was approximately 70% of maximal growth in a proliferation assay. All signals were significantly enhanced in the presence of G-CSF. Retroviral transduction of mutant receptor into primary hematopoietic CD34+ cells induced G-CSF independent myeloid differentiation as assessed by the development of neutrophils and surface expression of CD11b and CD14. These results confirm the importance of the transmembrane domain for receptor function and suggest that introduction of an asparagine residue can cause sufficient stabilization of helix-helix interactions in the absence of ligand to activate downstream signaling pathways involved in directing proliferation and differentiation.	UCL, Dept Haematol, London WC1E 6HX, England	University of London; University College London	Gale, RE (corresponding author), UCL, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	rosemary.gale@ucl.ac.uk	Ashby, Louisa/GRN-9388-2022; SHAKOORI, ABDUL RAUF/Q-9373-2019; Pizzey, Arnold/E-6301-2015	Ashby, Louisa/0000-0001-8247-096X; Pizzey, Arnold/0000-0003-1850-1121				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Alexander WS, 1998, LEUKEMIA RES, V22, P1097, DOI 10.1016/S0145-2126(98)00110-6; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bernard T, 1996, BRIT J HAEMATOL, V93, P527, DOI 10.1046/j.1365-2141.1996.d01-1696.x; BERNSTEIN ID, 1991, BLOOD, V77, P2316; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Byrne JL, 1998, BRIT J HAEMATOL, V100, P256; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dong F, 1998, J IMMUNOL, V161, P6503; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kitamura T, 1998, BLOOD, V92, P2596, DOI 10.1182/blood.V92.7.2596; Kiyoi H, 1999, BLOOD, V93, P3074; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; KOTTARIDIS PD, 2002, IN PRESS BLOOD; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; MOLINEUX G, 1991, BLOOD, V78, P961; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHINJO K, 1995, BRIT J HAEMATOL, V91, P783, DOI 10.1111/j.1365-2141.1995.tb05390.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	41	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5981	5989		10.1038/sj.onc.1205767	http://dx.doi.org/10.1038/sj.onc.1205767			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203110				2022-12-28	WOS:000177671300001
J	Jiang, M; Milner, J				Jiang, M; Milner, J			Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference	ONCOGENE			English	Article						RNA interference; HPV 16; human cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; DOUBLE-STRANDED-RNA; MESSENGER-RNA; P53; PROTEIN; E6; DEGRADATION; INHIBITION	Selective silencing of mammalian gene expression has recently been achieved using short interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation and the process is highly efficient. Here we demonstrate siRNA silencing of pathogenic viral gene expression. As a well characterized model we chose cervical carcinoma cells positive for human papillomavirus type 16. Over 90% of human cervical cancers are positive for papillomavirus and abnormal cell proliferation is driven by co-operative effects of viral E6 and E7 genes. We sought to silence HPV E6 and E7 gene expression using siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk		Jiang, Ming/0000-0003-3361-9881				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; STEELE C, 1993, CANCER RES, V53, P2330; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	26	302	386	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6041	6048		10.1038/sj.onc.1205878	http://dx.doi.org/10.1038/sj.onc.1205878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203116				2022-12-28	WOS:000177671300007
J	Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H				Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H			Increased arythydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; chemotherapy; arylhydrocarbon receptor; cytochrome-P450; cell cycle	ARYL-HYDROCARBON RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR ARNT; HUMAN AH RECEPTOR; D GENE-EXPRESSION; CELL-CYCLE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; POLYCHLORINATED DIBENZOFURANS; ANTITUMORIGENIC ACTIVITY; GLUCOCORTICOID-RECEPTOR	The arylhydrocarbon receptor (AhR) was initially identified as a member of the adaptive metabolic and toxic response pathway to polycyclic aromatic hydrocarbons and to halogenated dibenzo-p-dioxins and dibenzofurans. In the present study, we sought to determine the functional significance of the AhR pathway in pancreatic carcinogenesis. AhR expression was analysed by Northern blotting. The exact site of AhR expression was analysed by in situ hybridization and immunohistochemistry. The effects of TCDD and four selective AhR agonists on pancreatic cancer cell lines were investigated by growth assays, apoptosis assays, and induction of the cyclin-dependent kinase inhibitor p21. There was strong AhR mRNA expression in 14 out of 15 pancreatic cancer samples, weak expression in chronic pancreatitis tissues, and faint expression in all normal pancreata. In pancreatic cancer tissues, AhR mRNA and protein expression were localized in the cytoplasm of pancreatic cancer cells. TCDD and the four AhR agonists inhibited pancreatic cancer cell growth in a dose-dependent manner, and decreased anchorage-independent cell growth. DAPI staining did not reveal nuclear fragmentation and CYP1A1 and was not induced by TCDD and AhR agonists. In contrast, TCDD and AhR agonists induced the expression of the cyclin-dependent kinase inhibitor p21. In conclusion, the relatively non-toxic AhR agonists caused growth inhibition in pancreatic cancer cells with high AhR expression levels via cell cycle arrest. In addition, almost all human pancreatic cancer tissues expressed this receptor at high levels, suggesting that these or related compounds may play a role in the therapy of pancreatic cancer in the future.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, Bern, Switzerland; Univ Bern, Inst Pathol, Inselspital, Bern, Switzerland; Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Ruprecht Karls University Heidelberg; University of Bern; University of Bern; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Andren-Sandberg A, 1999, ANN ONCOL, V10, P131, DOI 10.1023/A:1008377928466; Angus WGR, 1999, CARCINOGENESIS, V20, P947, DOI 10.1093/carcin/20.6.947; ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; Becher H, 1996, CANCER CAUSE CONTROL, V7, P312, DOI 10.1007/BF00052936; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; BUCHLER M, 1991, CANCER-AM CANCER SOC, V68, P1507, DOI 10.1002/1097-0142(19911001)68:7<1507::AID-CNCR2820680707>3.0.CO;2-0; BUCKINGHAM J, 1997, DICT ORGANIC COMPOUN; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Cheung YL, 1999, CANCER LETT, V139, P199, DOI 10.1016/S0304-3835(99)00045-2; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DREISBACH RH, 1987, HDB POISONING PREVEN; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRIESS H, 1992, PANCREAS, V7, P516, DOI 10.1097/00006676-199209000-00002; FRIESS H, 1993, CANCER RES, V53, P2704; GEIGER LE, 1981, TOXICOL APPL PHARM, V59, P125, DOI 10.1016/0041-008X(81)90459-2; Goodman LS., 2018, GOODMAN GILMANS PHAR; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARRIS M, 1989, MOL PHARMACOL, V35, P729; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; Hayes, 1982, PESTICIDES STUDIED M, V247, P3140; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; *IARC WHO, 1987, IARC MON, V1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1987, IARC MON, V1; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; JOHNSON ES, 1992, CRIT REV TOXICOL, V21, P451, DOI 10.3109/10408449209089883; JONES PBC, 1986, J BIOL CHEM, V261, P6647; Kashani M, 1998, PROSTATE, V37, P98; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; Ledirac N, 2000, TOXICOL APPL PHARM, V164, P273, DOI 10.1006/taap.2000.8920; Li W, 1998, BIOCHEM PHARMACOL, V56, P599, DOI 10.1016/S0006-2952(98)00208-1; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; McDougal A, 2001, BREAST CANCER RES TR, V66, P147, DOI 10.1023/A:1010608000074; MORSE MA, 1990, CANCER RES, V50, P2613; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Oikawa K, 2001, CANCER RES, V61, P5707; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1979, CANCER RES, V39, P3341; POLAND AP, 1974, J BIOL CHEM, V249, P5599; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; Ramamoorthy K, 1999, CARCINOGENESIS, V20, P115, DOI 10.1093/carcin/20.1.115; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rininger JA, 1997, CHEMOSPHERE, V34, P1557, DOI 10.1016/S0045-6535(96)00451-1; ROWLANDS C, 1993, CANCER RES, V53, P1802; Roy NK, 1997, ARCH BIOCHEM BIOPHYS, V344, P373, DOI 10.1006/abbi.1997.0238; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sax N. I., 1989, DANGEROUS PROPERTIES; Sittig M, 1985, HDB TOXIC HAZARDOUS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Steenland K, 1999, J NATL CANCER I, V91, P779, DOI 10.1093/jnci/91.9.779; STOEWSAND GS, 1988, CANCER LETT, V39, P199, DOI 10.1016/0304-3835(88)90105-X; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Sun GL, 1997, CANCER CHEMOTH PHARM, V40, P239, DOI 10.1007/s002800050653; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; TAKEUCHI Y, 1993, AM J GASTROENTEROL, V88, P1928; VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; WANG XH, 1992, BIOCHEM PHARMACOL, V43, P1635; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Windholz M., 1983, MERCK INDEX ENCY CHE, Vtenth; Wormke M, 2000, J STEROID BIOCHEM, V72, P197, DOI 10.1016/S0960-0760(00)00030-3; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707	89	109	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6059	6070		10.1038/sj.onc.1205633	http://dx.doi.org/10.1038/sj.onc.1205633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203118				2022-12-28	WOS:000177671300009
J	Mitsiades, CS; Mitsiades, N; Poulaki, V; Schlossman, R; Akiyama, M; Chauhan, D; Hideshima, T; Treon, SP; Munshi, NC; Richardson, PG; Anderson, KC				Mitsiades, CS; Mitsiades, N; Poulaki, V; Schlossman, R; Akiyama, M; Chauhan, D; Hideshima, T; Treon, SP; Munshi, NC; Richardson, PG; Anderson, KC			Activation of NF-kappa B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications	ONCOGENE			English	Article						multiple myeloma; IGF-1; NF-kappa B; IAPs; Apo2L; TRAIL	GROWTH-FACTOR-I; DEXAMETHASONE-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; NUCLEAR TRANSLOCATION; MEDIATED APOPTOSIS; BIOLOGIC SEQUELAE; CANCER CELLS; INDUCTION; EXPRESSION	Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. We have previously shown that Apo2 ligand/TNF-Related apoptosis inducing ligand (Apo2L/TRAIL) induces apoptosis of MM cells, including cells either sensitive or resistant to Dex and cytotoxic drugs, and overcomes the growth and survival effect of IL-6; conversely, NF-kappaB transcriptional activity attenuates their Apo2L/TRAIL-sensitivity. In the current study, we demonstrate that IGF-1 stimulates sustained activation of NF-kappaB and Akt; induces phosphorylation of the FKHRL-1 Forkhead transcription factor; upregulates a series of intracellular anti-apoptotic proteins including FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP; and decreases Apo2L/TRAIL-sensitivity of MM cells. In contrast, IL-6 does not cause sustained NF-kappaB activation, induces less pronounced Akt activation and FKHRL-1 phosphorylation than IGF-1, and increases the expression of only survivin. Forced overexpression of constitutively active Akt in MM-1S cells reduced their sensitivity to Apo2L/TRAIL and to doxorubicin (Doxo). In contrast, the Akt inhibitor IL-6-Hydroxymethylchiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate induced cell death of both Dex- and Doxo-sensitive and -resistant cells; opposed the protective effect of constitutive Akt activity against Apo2L/TRAIL; and abrogated the NF-kappaB activation, increase of anti-apoptotic proteins and protection against Apo2L/TRAIL induced by IGF-1. These findings therefore define an important role of the Akt pathway in modulating tumor cell responsiveness to Apo2L/TRAIL, delineate molecular mechanisms for the survival effects of IGF-1, and characterize differential pathophysiologic sequelae of IGF-1 vs IL-6 on MM cells. Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1.	Harvard Univ, Jerome Lipper Multiple Myeloma Ctr, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Anderson, KC (corresponding author), Harvard Univ, Jerome Lipper Multiple Myeloma Ctr, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021		PHS HHS [P0-1 78378, R0-1 50947] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Feinman R, 1999, BLOOD, V93, P3044; Ge NL, 2000, BLOOD, V96, P2856; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Grundker C, 2000, J CLIN ENDOCR METAB, V85, P3815, DOI 10.1210/jc.85.10.3815; Han YP, 2001, J CELL SCI, V114, P131; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Jelinek DF, 1997, J IMMUNOL, V159, P487; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kolenko V, 1999, J IMMUNOL, V163, P590; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Mitsiades Constantine S., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P348; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades CS, 2000, BLOOD, V96, p756A; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ogawa M, 2000, CANCER RES, V60, P4262; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Poulaki V, 2001, CANCER RES, V61, P4864; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056	44	403	420	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5673	5683		10.1038/sj.onc.1205664	http://dx.doi.org/10.1038/sj.onc.1205664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173037				2022-12-28	WOS:000177463400002
J	Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K				Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K			Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein	ONCOGENE			English	Article						JCU; leader protein; agnoprotein; PML	HUMAN NEUROTROPIC POLYOMAVIRUS; T-ANTIGEN; NUCLEAR-LOCALIZATION; TUMOR-ANTIGEN; VIRUS; SIMIAN-VIRUS-40; AGNOPROTEIN; EXPRESSION; REPLICATION; ATTENUATION	The late region of the human neurotropic JC virus encodes a 71 amino acid protein, named Agnoprotein, whose biological function remains elusive. Here we demonstrate that in the absence of other viral proteins, expression of Agnoprotein can inhibit cell growth by deregulating cell progression through the cell cycle stages. Cells with constitutive expression of Agnoprotein were largely accumulated at the G2/M stage and that decline in the activity of cyclins A and B is observed in these cells. Agnoprotein showed the ability to augment p21 promoter activity in transient transfection assay and a noticeable increase in the level of p21 is detected in cells continuously expressing Agnoprotein. Results from binding studies revealed the interaction of Agnoprotein with p53 through the N-terminal of the Agnoprotein spanning residues 1 - 36. Co-expression of p53 and Agnoprotein further stimulated transcription of the p21 promoter. Thus, the interaction of p53 and Agnoprotein can lead to a higher level of p21 expression and suppression of cell cycle progression during the cell cycle.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96, Philadelphia, PA 19122 USA.	kkhalili@astro.temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ALWINE JC, 1982, J VIROL, V42, P798, DOI 10.1128/JVI.42.3.798-803.1982; Berger JR, 1998, J NEUROVIROL, V4, P59, DOI 10.3109/13550289809113482; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1982, CELL, V29, P183, DOI 10.1016/0092-8674(82)90102-7; HAY N, 1985, MOL CELL BIOL, V5, P1327, DOI 10.1128/MCB.5.6.1327; Ishii N, 1996, J VIROL, V70, P1317, DOI 10.1128/JVI.70.2.1317-1322.1996; KHALILI K, 1988, P NATL ACAD SCI USA, V85, P354, DOI 10.1073/pnas.85.2.354; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOMURA S, 1983, J VIROL, V45, P428, DOI 10.1128/JVI.45.1.428-433.1983; Okada Y, 2001, J NEUROVIROL, V7, P302; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; Rinaldo CH, 1998, J VIROL, V72, P6233, DOI 10.1128/JVI.72.7.6233-6236.1998; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989	27	75	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5574	5581		10.1038/sj.onc.1205744	http://dx.doi.org/10.1038/sj.onc.1205744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165856				2022-12-28	WOS:000177442000007
J	Christman, JK				Christman, JK			5-Azacytidine and 5-aza-2 '-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy	ONCOGENE			English	Review						DNA methylation; 5-azacytidine; DNA methyltransferase; cancer	METASTASIS SUPPRESSOR GENE; HUMAN GASTRIC-CARCINOMA; CPG-ISLAND METHYLATION; HUMAN PROSTATE-CANCER; LEUKEMIA-CELLS HL-60; ACID-DEFINED DIETS; BREAST-CANCER; 5-METHYLCYTOSINE CONTENT; HHAI METHYLTRANSFERASE; TRANSCRIPTIONAL REGULATION	5-Azacytidine was first synthesized almost 40 years ago. It was demonstrated to have a wide range of anti-metabolic activities when tested against cultured cancer cells and to be an effective chemotherapeutic agent for acute myelogenous leukemia. However, because of 5-azacytidine's general toxicity, other nucleoside analogs were favored as therapeutics. The finding that 5-azacytidine was incorporated into DNA and that, when present in DNA, it inhibited DNA methylation, led to widespread use of 5-azacytidine and 5-aza-2'-deoxycytidine (Decitabine) to demonstrate the correlation between loss of methylation in specific gene regions and activation of the associated genes. There is now a revived interest in the use of Decitabine as a therapeutic agent for cancers in which epigenetic silencing of critical regulatory genes has occurred. Here, the current status of our understanding of the mechanism(s) by which 5-azacytosine residues in DNA inhibit DNA methylation is reviewed with an emphasis on the interactions of these residues with bacterial and mammalian DNA (cytosine-C5) methyltransferases. The implications of these mechanistic studies for development of less toxic inhibitors of DNA methylation are discussed.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Christman, JK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Univ Med Ctr, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [R21CA091315] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA091315-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Barletta JM, 1997, CANCER RES, V57, P48; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; BEISLER JA, 1978, J MED CHEM, V21, P204, DOI 10.1021/jm00200a012; BHAGWAT AS, 1987, J BACTERIOL, V169, P1537, DOI 10.1128/jb.169.4.1537-1546.1987; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Brank AS, 2002, PROTEIN EXPRES PURIF, V25, P31, DOI 10.1006/prep.2001.1606; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN J, 1990, CELL GROWTH DIFFER, V1, P383; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551; CHRISTMAN JK, 1995, ADV EXP MED BIOL, V369, P141; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; CHRISTMAN JK, 1977, EUR J BIOCHEM, V81, P53, DOI 10.1111/j.1432-1033.1977.tb11926.x; CHRISTMAN JK, 1985, J BIOL CHEM, V260, P4059; CHRISTMAN JK, 1993, J NUTR BIOCHEM, V4, P672, DOI 10.1016/0955-2863(93)90106-7; CHRISTMAN JK, 1983, CANCER RES, V43, P763; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CIHAK A, 1974, ONCOLOGY-BASEL, V30, P405; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DASKALAKIS M, 1999, BLOOD, V94, P306; DAVIDSON S, 1992, EUR J CANCER, V28A, P362, DOI 10.1016/S0959-8049(05)80054-1; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Ehrlich Melanie, 2000, P273; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 1996, J GASTROEN HEPATOL, V11, P1079, DOI 10.1111/j.1440-1746.1996.tb00040.x; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304; FEINBERG AP, 1988, CANCER RES, V48, P1159; FERGUSON AT, 1995, CANCER RES, V55, P2279; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FLATAU E, 1984, MOL CELL BIOL, V4, P2098, DOI 10.1128/MCB.4.10.2098; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garcia RG, 2001, ANTISENSE NUCLEIC A, V11, P369, DOI 10.1089/108729001753411335; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; GLAZER RI, 1980, MOL PHARMACOL, V17, P111; GLOVER AB, 1987, CANCER TREAT REP, V71, P737; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; HALLE S, 1968, J VIROL, V2, P1228, DOI 10.1128/JVI.2.10.1228-1229.1968; Hartsough MT, 2001, CANCER RES, V61, P2320; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hu JF, 1997, MOL ENDOCRINOL, V11, P1891, DOI 10.1210/me.11.13.1891; Huynh H, 1996, CANCER RES, V56, P4865; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Izbicka E, 1999, ANTICANCER RES, V19, P1285; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantharidis P, 1997, CLIN CANCER RES, V3, P2025; KARON M, 1972, SCIENCE, V178, P62, DOI 10.1126/science.178.4056.62; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kawano S, 1999, BLOOD, V94, P1113; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LANDOLPH JR, 1982, CANCER RES, V42, P817; LAPEYRE JN, 1979, BIOCHEM BIOPH RES CO, V87, P698, DOI 10.1016/0006-291X(79)92015-1; LAPEYRE JN, 1981, CARCINOGENESIS, V2, P873, DOI 10.1093/carcin/2.9.873; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEE TT, 1976, BIOCHEM PHARMACOL, V25, P1737, DOI 10.1016/0006-2952(76)90407-X; Lee YY, 1997, CANCER, V80, P1889, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1889::AID-CNCR3>3.0.CO;2-J; LI LH, 1970, CANCER RES, V30, P2760; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; LOMBARDI B, 1979, INT J CANCER, V23, P565, DOI 10.1002/ijc.2910230419; LU LJW, 1980, CANCER RES, V40, P2701; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; MCGREGOR DB, 1989, CARCINOGENESIS, V10, P2003, DOI 10.1093/carcin/10.11.2003; MENDELSOHN N, 1980, CANCER RES, V40, P3206; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; MITANI H, 1989, CARCINOGENESIS, V10, P1879, DOI 10.1093/carcin/10.10.1879; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; MOMPARLER RL, 1984, MOL PHARMACOL, V25, P436; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Myohanen SK, 1998, CANCER RES, V58, P591; Nelson JB, 1997, CANCER RES, V57, P35; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; OSHAWA K, 1996, J NEUROCHEM, V67, P89; PAUL P, 1982, Kobe Journal of Medical Sciences, V28, P181; PISKALA A, 1964, COLLECT CZECH CHEM C, V29, P2060; Plumb JA, 2000, CANCER RES, V60, P6039; Pogribny IP, 2000, CANCER RES, V60, P588; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato S, 1999, JPN J CANCER RES, V90, P485, DOI 10.1111/j.1349-7006.1999.tb00773.x; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; SHARRARD RM, 1992, BRIT J CANCER, V65, P667, DOI 10.1038/bjc.1992.142; Sheikhnejad G, 1999, J MOL BIOL, V285, P2021, DOI 10.1006/jmbi.1998.2426; Shin JY, 2000, CANCER RES, V60, P262; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; SILVERMAN AL, 1989, CANCER RES, V49, P3468; Singal R, 2000, ANTICANCER RES, V20, P59; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; van der Velden PA, 2001, CANCER RES, V61, P5303; VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474; VESELY J, 1969, COLLECT CZECH CHEM C, V34, P901, DOI 10.1135/cccc19690901; VESELY J, 1978, PHARMACOL THER PT A, V2, P813, DOI 10.1016/0362-5478(78)90016-5; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VISVADER J, 1993, BLOOD, V82, P1493; WAINFAN E, 1989, CANCER RES, V49, P4094; Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s; WEISS JW, 1974, ARCH BIOCHEM BIOPHYS, V160, P119, DOI 10.1016/S0003-9861(74)80016-0; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Xing RH, 1999, INT J CANCER, V81, P443, DOI 10.1002/(SICI)1097-0215(19990505)81:3<443::AID-IJC19>3.0.CO;2-T; Yan PS, 2001, CANCER RES, V61, P8375; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhang XY, 1996, FEBS LETT, V392, P179, DOI 10.1016/0014-5793(96)00810-1; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	146	986	1057	7	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5483	5495		10.1038/sj.onc.1205699	http://dx.doi.org/10.1038/sj.onc.1205699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154409				2022-12-28	WOS:000177197700013
J	Jackson-Grusby, L				Jackson-Grusby, L			Modeling cancer in mice	ONCOGENE			English	Article						embryonic stem cell; gene targeting; mouse model; recombinase; inducible transgene; microarray	EMBRYONIC STEM-CELLS; MULTIPLE INTESTINAL NEOPLASIA; SITE-SPECIFIC RECOMBINATION; TRANSGENIC MICE; MAMMALIAN-CELLS; GENE-EXPRESSION; CHROMOSOMAL TRANSLOCATION; DNA HYPOMETHYLATION; CRE-LOXP; APC GENE	The laboratory mouse is one of the most powerful tools for both gene discovery and validation in cancer genetics. Recent technological advances in engineering the mouse genome with chromosome translocations, latent alleles, and tissue-specific and temporally regulated mutations have provided more exacting models of human disease. The marriage of mouse tumor models with rapidly evolving methods to profile genetic and epigenetic alterations in tumors, and to finely map genetic modifier loci, will continue to provide insight into the key pathways leading to tumorigenesis. These discoveries hold great promise for identifying relevant drug targets for treating human cancer.	MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Jackson-Grusby, L (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Berns A, 1999, CANCER RES, V59, p1773S; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cronin CA, 2001, GENE DEV, V15, P1506, DOI 10.1101/gad.892001; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Diaz V, 2001, J BIOL CHEM, V276, P16257, DOI 10.1074/jbc.M011725200; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eads CA, 2000, CANCER RES, V60, P5021; Eads CA, 2002, CANCER RES, V62, P1296; Eggan K, 2002, NAT BIOTECHNOL, V20, P455, DOI 10.1038/nbt0502-455; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giovannini M, 2000, GENE DEV, V14, P1617; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hasan MT, 2001, GENESIS, V29, P116, DOI 10.1002/gene.1014; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jacoby RF, 1996, CANCER RES, V56, P710; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lei H, 1996, DEVELOPMENT, V122, P3195; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAGY A, 1990, DEVELOPMENT, V110, P815; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Ringrose L, 1997, EUR J BIOCHEM, V248, P903, DOI 10.1111/j.1432-1033.1997.00903.x; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Scheurle D, 2000, CANCER RES, V60, P4037; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Strausberg RL, 2000, TRENDS GENET, V16, P103, DOI 10.1016/S0168-9525(99)01937-X; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	93	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5504	5514		10.1038/sj.onc.1205603	http://dx.doi.org/10.1038/sj.onc.1205603			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154411				2022-12-28	WOS:000177197700015
J	Digweed, M; Demuth, I; Rothe, S; Scholz, R; Jordan, A; Grotzinger, C; Schindler, D; Grompe, M; Sperling, K				Digweed, M; Demuth, I; Rothe, S; Scholz, R; Jordan, A; Grotzinger, C; Schindler, D; Grompe, M; Sperling, K			SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11	ONCOGENE			English	Review						ionizing irradiation; Fanconi anaemia; immortalization	STRAND BREAK REPAIR; FANCONI-ANEMIA; CELLULAR-RESPONSE; BRCA1; FIBROBLASTS; PHOSPHORYLATION; SUSCEPTIBILITY; PROTEINS; COMPLEX; BINDING	The accumulation of DNA repair proteins at the sites of DNA damage can be visualized in mutagenized cells at the single cell level as discrete nuclear foci by immunofluorescent staining. Formation of nuclear foci in irradiated human fibroblasts, as detected by antibodies directed against the DNA repair protein MRE11, is significantly disturbed by the presence of the viral oncogene, SV40 large T-antigen. The attenuation of foci formation was found in both T-antigen immortalized cells and in cells transiently expressing T-antigen, indicating that it is not attributable to secondary mutations but to T-antigen expression itself. ATM-mediated nibrin phosphorylation was not altered, thus the disturbance of MRE11 foci formation by T-antigen is independent of this event. The decrease in MRE11 foci was particularly pronounced in T-antigen immortalized cells from the Fanconi anaemia complementation group FA-D2. FA-D2 cells produce essentially no MRE11 DNA repair foci after ionizing irradiation and have a significantly increased cellular radiosensitivity at low radiation doses. The gene mutated in FA-D2 cells, FANCD2, codes for a protein which also locates to nuclear foci and may, therefore, be involved in MRE11 foci formation, at least in T-antigen immortalized cells. This finding possibly links Fanconi anaemia proteins to the frequently reported increased sensitivity of Fanconi anaemia cells to transformation by SV40. From a practical stand point these findings are particularly relevant to the many studies on DNA repair which exploit the advantages of SV40 immortalized cell lines. The interference of T-antigen with DNA repair processes, as demonstrated here, should be borne in mind when interpreting such studies.	Humboldt Univ, Charite, Inst Humangenet, D-13353 Berlin, Germany; Humboldt Univ, Charite, Klin Strahlenheilkunde, D-13353 Berlin, Germany; Humboldt Univ, Charite, Med Klin, Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, Inst Humangenet, D-97070 Wurzburg, Germany; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Oregon Health & Science University	Digweed, M (corresponding author), Humboldt Univ, Charite, Inst Humangenet, Augustenburger Pl 1, D-13353 Berlin, Germany.		Grötzinger, Carsten/B-6938-2008; Demuth, Ilja/ABD-5352-2021	Grötzinger, Carsten/0000-0001-9872-3087; Demuth, Ilja/0000-0002-4340-2523; Grompe, Markus/0000-0002-6616-4345				Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; DIGWEED M, 2002, IN PRESS CARCINOGENE, V23; DOSIK H, 1970, BLOOD-J HEMATOL, V36, P341, DOI 10.1182/blood.V36.3.341.341; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Lanson NA, 2000, NUCLEIC ACIDS RES, V28, P2882, DOI 10.1093/nar/28.15.2882; Liu JM, 1996, BIOCHEM BIOPH RES CO, V223, P685, DOI 10.1006/bbrc.1996.0956; LUBINIECKI AS, 1980, AM J HEMATOL, V8, P389, DOI 10.1002/ajh.2830080407; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Y, 2000, GENE DEV, V14, P927; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	24	50	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4873	4878		10.1038/sj.onc.1205616	http://dx.doi.org/10.1038/sj.onc.1205616			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118365				2022-12-28	WOS:000176874800001
J	Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP				Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP			Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells	ONCOGENE			English	Article						retinoblastoma protein; UV radiation; apoptosis; DNA damage repair	NUCLEOTIDE EXCISION-REPAIR; MAMMARY EPITHELIAL-CELLS; LIGHT-INDUCED APOPTOSIS; RNA-POLYMERASE-II; ULTRAVIOLET-IRRADIATION; RETINOBLASTOMA PROTEIN; IONIZING-RADIATION; CASPASE ACTIVATION; SUPPRESSOR GENES; E7 PROTEIN	Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. We have previously demonstrated that a human breast cancer cell line, MDA-MB-468, which lacks the retinoblastoma protein (pRb), is particularly sensitive to low doses of ultraviolet (UV) radiation. These cells are 15-20-fold more sensitive to UV radiation than cells with wild-type pRb. In order to understand the mechanisms of the high apoptotic response of MDA-MB-468 cells to UV radiation, we examined the effects of UV on these cells with regards to both membrane-mediated events and DNA damage. We found that MDA-MB-468 cells were resistant to all ligand-induced death receptor signaling. In addition, although UV activated caspase 8 in MDA-MB-468 cells, a peptide inhibitor of caspase 8 failed to inhibit UV-induced apoptosis. We then tested the possibility that nuclear events mediated the enhanced sensitivity to UV-induced apoptosis in these cells. Unlike UV-resistant cells, MDA-MB-468 cells were unable to recover mRNA synthesis after 5 J/m(2) UVC. We also found that the pRb-null DU-145 cells similarly had attenuated recovery of mRNA synthesis after UV radiation. In UV-resistant cells with wild-type pRb, the inactivation of pRb with HPV-16 E7 resulted in significant inhibition in their ability to recover mRNA synthesis and increased levels of apoptosis following UV radiation. Furthermore, pRb-null cells were deficient in repair of UV radiation-induced DNA damage. These data suggest that the sensitivity of MDA-MB-468 cells to UV radiation is due to defects in repair of DNA damage and recovery of mRNA synthesis rather than to membrane death receptor pathways. Inactivation of pRb may contribute to an increased sensitivity to UV radiation by attenuating repair of DNA lesions and recovery of mRNA synthesis following UV radiation.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Radiol, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada	University of Michigan System; University of Michigan; University of Ottawa; Ottawa Hospital Research Institute	Ethier, SP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA.	spethier@umich.edu	McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Boyer SN, 1996, CANCER RES, V56, P4620; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Fan GS, 1997, J BIOL CHEM, V272, P19413, DOI 10.1074/jbc.272.31.19413; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Game JC, 1999, GENETICS, V151, P485; Havre PA, 1998, CANCER RES, V58, P4733; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sartor CI, 1997, CANCER RES, V57, P978; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	43	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4481	4489		10.1038/sj.onc.1205546	http://dx.doi.org/10.1038/sj.onc.1205546			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085226				2022-12-28	WOS:000176476700002
J	Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT				Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT			Patterns of gene promoter methylation in squamous cell cancer of the head and neck	ONCOGENE			English	Article						p16(INK4a); DAP-kinase; RASSF1A; E-Cadherin; hypermethylation; oral cancer; head and neck cancer	TUMOR-SUPPRESSOR GENE; E-CADHERIN EXPRESSION; CPG ISLAND; EPIGENETIC INACTIVATION; LUNG-CANCER; DNA HYPERMETHYLATION; BREAST CANCERS; HIGH-FREQUENCY; CARCINOMAS; RASSF1A	Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16(INK4a), gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16(INK4a) methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16(INK4a) promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Dent & Oral Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.		Peters, Edward S/H-1077-2015; Kelsey, Karl T/I-1252-2014	Peters, Edward S/0000-0003-4928-6532; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [CA78609] Funding Source: Medline; NIDCR NIH HHS [1P01-DE12467-05] Funding Source: Medline; NIEHS NIH HHS [ES08357, ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES008357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Belinsky SA, 1995, TOXICOL LETT, V82-3, P335, DOI 10.1016/0378-4274(95)03486-2; BLOT WJ, 1988, CANCER RES, V48, P3282; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Califano J, 1996, CANCER RES, V56, P2488; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Eguchi K, 1997, CANCER RES, V57, P4913; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lo KW, 2001, CANCER RES, V61, P3877; MAESTRO R, 1993, CANCER RES, V53, P5775; Morrissey C, 2001, CANCER RES, V61, P7277; Nagai MA, 1999, BRAZ J MED BIOL RES, V32, P897, DOI 10.1590/S0100-879X1999000700015; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed AL, 1996, CANCER RES, V56, P3630; Riese U, 1999, INT J MOL MED, V4, P61; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPITZ MR, 1999, HEAD NECK CANC MULTI, P11; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARBROUGH WG, 1994, LARYNGOSCOPE, V104, P1337; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	41	165	173	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4231	4236		10.1038/sj.onc.1205528	http://dx.doi.org/10.1038/sj.onc.1205528			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082610				2022-12-28	WOS:000176174200005
J	Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK				Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK			Protein kinase C delta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression	ONCOGENE			English	Article						tumor promotion; protein kinase C; transgenic mice; ornithine decarboxylase; skin carcinogenesis	PHORBOL ESTER; TRANSGENIC MICE; MOUSE SKIN; PROTEOLYTIC ACTIVATION; IRREVERSIBLE INHIBITOR; INDUCED APOPTOSIS; GENE-EXPRESSION; OKADAIC ACID; DBA/2 MICE; PROMOTION	Protein Kinase Cdelta (PKCdelta), a Call-independent, phospholipid-dependent serine/threonine kinase, is among the PKC isoforms expressed in mouse epidermis. We reported that FVB/N transgenic mice that overexpress (similar to eightfold) PKCdelta protein in basal epidermal cells are resistant to skin tumor formation by the 7,12-dimethylbenz(a)anthracene (DMBA)-initiation and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promotion protocol. However, despite being resistant to skin tumor promotion by TPA, PKCdelta transgenic mice elicited a 3-4-fold increase in TPA-induced epidermal ODC activity and putrescine levels than their wild-type littermates. PKCdelta was observed to be the key component of the TPA signal transduction pathways to the induction of mouse epidermal ODC activity. To determine if TPA-induced ODC activity and associated putrescine levels in PKCdelta transgenic mice contributed to PKCdelta-mediated suppression of skin tumor promotion by TPA, the irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), was used. PKCdelta transgenic mice and their wild-type littermates were initiated with 100 nmol DMBA and then promoted twice weekly with 5 nmol TPA. The experimental group was given 0.5% DFMO in their drinking water, while the control group was given tap water. After 25 weeks, the number of papillomas (> 2 mm) per mouse was counted. The DFMO treatment did not affect the skin tumor multiplicity of PKCdelta transgenic mice. These results indicate that PKCdelta-induced ODC activity is not involved in PKCdelta-mediated tumor suppression. Thus, the signaling pathways via PKCdelta to epidermal ODC induction and skin tumor suppression appear to be independent.	Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, Madison, WI 53792 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; Max Planck Society	Verma, AK (corresponding author), Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, K4-532,, Madison, WI 53792 USA.	akverma@facstaff.wisc.edu	Leitges, Michael/AAN-1953-2021					ALDAZ CM, 1985, CANCER RES, V45, P2753; ARGYRIS TS, 1985, CRC CR REV TOXICOL, V14, P211, DOI 10.3109/10408448509037459; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DIGIOVANNI J, 1984, CARCINOGENESIS, V5, P1493, DOI 10.1093/carcin/5.11.1493; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FISCHER SM, 1988, CANCER RES, V48, P658; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GILMOUR SK, 1987, CANCER RES, V47, P1221; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HIRABAYASHI N, 1988, CARCINOGENESIS, V9, P2215, DOI 10.1093/carcin/9.12.2215; Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.0.CO;2-P; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; IMAMOTO A, 1992, CARCINOGENESIS, V13, P177, DOI 10.1093/carcin/13.2.177; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Jansen AP, 2001, CANCER RES, V61, P808; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOZA RA, 1991, CARCINOGENESIS, V12, P1619, DOI 10.1093/carcin/12.9.1619; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBrien TG, 1997, CANCER RES, V57, P2630; Otieno MA, 2000, CANCER RES, V60, P4391; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Rajesh D, 1999, MOL PHARMACOL, V56, P515, DOI 10.1124/mol.56.3.515; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sawai H, 1997, J BIOL CHEM, V272, P2452; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VERMA AK, 1988, CANCER RES, V48, P1736; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; VERMA AK, 1986, CANCER RES, V46, P6149; VERMA AK, 1995, SKIN CANC MECH HUMAN, P383; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang HQ, 1999, J CELL SCI, V112, P3497; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	56	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3620	3630		10.1038/sj.onc.1205451	http://dx.doi.org/10.1038/sj.onc.1205451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032864				2022-12-28	WOS:000175793700013
J	Cao, Y; Li, H; Deb, S; Liu, JP				Cao, Y; Li, H; Deb, S; Liu, JP			TERT regulates cell survival independent of telomerase enzymatic activity	ONCOGENE			English	Article						telomerase; hTERT; p53; PARP cell survival	CATALYTIC SUBUNIT GENE; LIFE-SPAN; WILD-TYPE; CANCER; P53; INHIBITION; ACTIVATION; END	Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, plays a pivotal role in the maintenance of telomeres and cell proliferation. Here we report that down-regulation of hTERT induces apoptosis independently of telomerase enzymatic activity in human breast cancer cells. Expression of a hTERT mutant lacking telomerase activity rescues the cells with lowered telomerase without inducing cell death. With similar patterns of subcellular distribution to that of the tumor suppressor protein p53 during mitosis, hTERT interacts with p53 and poly(ADP-ribose) polymerase (PARP). Decreasing p53 expression in intact cells worsens, and increasing p53 prevents, cell death induced by lowering hTERT. Thus, hTERT maintains cell survival and proliferation via both telomerase enzymatic activity-dependent telomere lengthening and enzymatic activity-independent intermolecular interactions involving p53 and PARP.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute; Monash University	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, Commercial Rd, Prahran, Vic 3181, Australia.	jun-ping.liu@med.monash.edu.au		Liu, Jun-Ping/0000-0001-7442-2116				Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cao Y, 2001, FASEB J, V15, P96, DOI 10.1096/fj.01-0447fje; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; GREIDER CW, 1995, TELOMERES, P35; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI H, 2001, IN PRESS BIOGERONTOL; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; LIU JP, 2001, ADV CELL AGING GERON, V8, P33; Liu Jun-Ping, 2000, Molecular Cell Biology Research Communications, V3, P129, DOI 10.1006/mcbr.2000.0203; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Saretzki G, 2001, CANCER GENE THER, V8, P827, DOI 10.1038/sj.cgt.7700383; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	42	187	201	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3130	3138		10.1038/sj.onc.1205419	http://dx.doi.org/10.1038/sj.onc.1205419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082628				2022-12-28	WOS:000175373600004
J	Fleischer, A; Ayllon, V; Dumoutier, L; Renauld, JC; Rebollo, A				Fleischer, A; Ayllon, V; Dumoutier, L; Renauld, JC; Rebollo, A			Proapoptotic activity of ITM2B(s), a BH3-only protein induced upon IL-2-deprivation which interacts with Bcl-2	ONCOGENE			English	Article						apoptosis; BH3; ITM2B(s)	CELL-DEATH; CYTOCHROME-C; BH3 DOMAIN; APOPTOSIS; FAMILY; EXPRESSION; SURVIVAL; MITOCHONDRIA; BAD; PHOSPHORYLATION	Growth factor deprivation is a physiological mechanism to induce apoptosis. We used an IL-2-dependent murine T cell line to identify proteins that trigger apoptosis. Here we report the identification, the cloning and characterization of ITM2B(s), a protein induced upon IL-2-deprivation. ITM2B(s), which shares the BH3 domain of Bcl-2 family members, is a cytoplasmic and mitochondrial protein. Expression of ITM2B, induces apoptosis in IL-2-stimulated cells, but not in IL-4-stimulated cells, while overexpression of the long form of the protein is not able to induce apoptosis. In IL-2-stimulated cells, ITM2B(s) interacts with the antiapoptotic protein Bcl-2, and does not interact with the proapoptotic Bad. Mutation of the critical L and D residues within the BH3 domain abolished the ability of ITMBs, to promote apoptosis.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Ludwig Institute for Cancer Research; Universite Catholique Louvain	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Rebollo, Angelita/P-2118-2017; Ayllon, Veronica/L-7069-2014; Fleischer, Aarne/ABE-6966-2020; Renauld, Jean-Christophe/B-7268-2012	Ayllon, Veronica/0000-0002-7322-9282; Fleischer, Aarne/0000-0003-4146-3303; Renauld, Jean-Christophe/0000-0003-1736-2131; Dumoutier, Laure/0000-0002-6645-684X; Rebollo, Angelita/0000-0002-1293-9686				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Cerezo A, 1999, CELL DEATH DIFFER, V6, P87, DOI 10.1038/sj.cdd.4400458; CHINTTENDEN T, 1995, NATURE, V374, P733; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	29	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3181	3189		10.1038/sj.onc.1205464	http://dx.doi.org/10.1038/sj.onc.1205464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082633				2022-12-28	WOS:000175373600009
J	McWilliams, A; MacAulay, C; Gazdar, AF; Lam, S				McWilliams, A; MacAulay, C; Gazdar, AF; Lam, S			Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions	ONCOGENE			English	Review						lung neoplasms; diagnostic imaging; bronchoscopy	POSITRON-EMISSION-TOMOGRAPHY; ATYPICAL ADENOMATOUS HYPERPLASIA; ABERRANT PROMOTER METHYLATION; HIGH-RESOLUTION CT; CARCINOMA IN-SITU; BRONCHIAL EPITHELIUM; GENE-EXPRESSION; VIRTUAL BRONCHOSCOPY; CONFOCAL MICROSCOPY; ONCOGENE MUTATIONS	Current approaches for the therapy of lung cancer, the majority of which being advanced cancers, have failed to impact on long term survival. The key to improvement lies in the combination of early diagnosis and the introduction of novel targeted therapies. In this article we review some of the innovative approaches, both imaging and molecular, that are currently under investigation for early detection. Because lung cancers may arise in the central or peripheral compartments of the lung, newer approaches must target tumours arising in both of these compartments. Specimens available for analysis include sputa and blood. Detection of genetic changes in peripheral blood is a promising avenue being explored by several groups. Molecular techniques discussed include gene mutations, detection of nuclear riboprotein, methylation related silencing of genes and malignancy associated changes. Newer imaging technologies include autofluorescence bronchoscopy, virtual bronchoscopy, optical coherent tomography and confocal microscopy. Although the impact of these new technologies on survival has not been determined, they offer a wide range of exciting new approaches. In time they may completely revamp the present highly conservative and unsuccessful approaches to early diagnosis.	Univ Western Australia, Nedlands, WA 6009, Australia; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; British Columbia Canc Agcy, Lung Tumour Grp, Vancouver, BC V5Z 4E6, Canada	University of Western Australia; University of British Columbia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; British Columbia Cancer Agency	Lam, S (corresponding author), 600 W 10th Ave, Vancouver, BC 4E6, Canada.	slam@bccancer.bc.ca		MacAulay, Calum/0000-0003-4440-2792				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y; Aoki T, 2000, AM J ROENTGENOL, V174, P763, DOI 10.2214/ajr.174.3.1740763; Aquino SL, 1999, CLIN CHEST MED, V20, P725, DOI 10.1016/S0272-5231(05)70251-3; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1978, CANCER-AM CANCER SOC, V42, P483, DOI 10.1002/1097-0142(197808)42:2<483::AID-CNCR2820420216>3.0.CO;2-E; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bota S, 2001, AM J RESP CRIT CARE, V164, P1688, DOI 10.1164/ajrccm.164.9.2012147; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Bury T, 1997, EUR RESPIR J, V10, P2529, DOI 10.1183/09031936.97.10112529; CORTESE DA, 1983, J THORAC CARDIOV SUR, V86, P373; Dawn S K, 2001, Respir Care, V46, P912; Dickensheets DL, 1996, OPT LETT, V21, P764, DOI 10.1364/OL.21.000764; DUHAYLONGSOD FG, 1995, ANN THORAC SURG, V60, P1348, DOI 10.1016/0003-4975(95)00754-9; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1986, J OCCUP ENVIRON MED, V28, P692, DOI 10.1097/00043764-198608000-00031; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Fry WA, 1996, CANCER, V77, P1947, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; GMITRO AF, 1993, OPT LETT, V18, P565, DOI 10.1364/OL.18.000565; Gupta NC, 1996, J NUCL MED, V37, P943; Gupta NC, 2001, CHEST, V120, P521, DOI 10.1378/chest.120.2.521; Haponik EF, 1999, CLIN CHEST MED, V20, P201, DOI 10.1016/S0272-5231(05)70135-0; HEELAN RT, 1984, RADIOLOGY, V151, P289, DOI 10.1148/radiology.151.2.6324279; Henderson Laura-Jane, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P638; Henschke CI, 2001, CANCER, V92, P153, DOI 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Herder GJM, 2001, J CLIN ONCOL, V19, P4271, DOI 10.1200/JCO.2001.19.22.4271; Hibi K, 1998, CANCER RES, V58, P5690; Hirsch FR, 2001, CLIN CANCER RES, V7, P5; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Izatt JA, 1996, IEEE J SEL TOP QUANT, V2, P1017, DOI 10.1109/2944.577331; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KANEKO M, 1997, CHEST, V112, pS62; KERR KM, 1997, PATHOLOGY LUNG TUMOR, P119; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; KOSS LG, 1964, ACTA CYTOL, V8, P104; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; Kurasono Y, 1998, VIRCHOWS ARCH, V432, P207, DOI 10.1007/s004280050157; Lacroix J, 2001, INT J CANCER, V92, P1; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; LAM S, 2000, LUNG CANCER, V29, P145; Lane P, 2001, PROC SPIE, V4251, P192, DOI 10.1117/12.427894; Lane PM, 2000, OPT LETT, V25, P1780, DOI 10.1364/OL.25.001780; Li XD, 2000, OPT LETT, V25, P1520, DOI 10.1364/OL.25.001520; Lonergan Kim, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P472; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Mac Manus MP, 2001, CANCER, V92, P886, DOI 10.1002/1097-0142(20010815)92:4<886::AID-CNCR1397>3.0.CO;2-V; MACAULAY C, 1995, ANAL QUANT CYTOL, V17, P55; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MCWILLIAMS A, 2001, IPA 8 WORLD C PHOT M, P40; MCWILLIAMS A, 2001, CHEST, V120, pS166; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; MELAMED MR, 1982, MORPHOGENESIS LUNG C, V1, P37; MILLER RR, 1990, AM J SURG PATHOL, V14, P904, DOI 10.1097/00000478-199010000-00002; Mori K, 2000, IEEE T MED IMAGING, V19, P103, DOI 10.1109/42.836370; MORI M, 1993, CANCER, V72, P2331, DOI 10.1002/1097-0142(19931015)72:8<2331::AID-CNCR2820720808>3.0.CO;2-E; Mori M, 1998, ULTRASTRUCT PATHOL, V22, P459, DOI 10.3109/01913129809032282; MUHM JR, 1983, RADIOLOGY, V148, P609, DOI 10.1148/radiology.148.3.6308709; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; NASIELL M, 1966, ACTA CYTOL, V10, P421; NASIELL M, 1987, LUNG CARCINOMAS, P207; NG ABP, 1983, ACTA CYTOL, V27, P397; Nieburgs H. E., 1959, T 7 ANN M INT SOC CY, P137; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Oda M, 1998, LUNG CANCER-J IASLC, V22, P23, DOI 10.1016/S0169-5002(98)00070-1; Palcic B., 1994, COMPENDIUM COMPUTERI, P157; Palmisano WA, 2000, CANCER RES, V60, P5954; Patz EF, 2000, CHEST, V117, P1568, DOI 10.1378/chest.117.6.1568; Payne PW, 1997, MAYO CLIN PROC, V72, P697; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; RISSE EKJ, 1988, ACTA CYTOL, V32, P629; RISSE EKJ, 1987, ACTA CYTOL, V31, P159; Ritter JH, 1999, AM J CLIN PATHOL, V111, P587; Rollins AM, 1999, OPT LETT, V24, P1484, DOI 10.1364/OL.24.001484; Rollins AM, 1998, OPT EXPRESS, V3, P219, DOI 10.1364/OE.3.000219; ROSA UW, 1973, CHEST, V63, P203, DOI 10.1378/chest.63.2.203; Sabharwal YS, 1999, APPL OPTICS, V38, P7133, DOI 10.1364/AO.38.007133; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; SACCOMANNO G, 1982, SEMIN RESPIR MED, V4, P156, DOI 10.1055/s-2007-1012480; Seemann MD, 2001, LUNG CANCER-J IASLC, V32, P237, DOI 10.1016/S0169-5002(00)00228-2; SHIBUYA K, 2001, J CLIN EXP MED, V199, P593; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Smithpeter CL, 1998, APPL OPTICS, V37, P2749, DOI 10.1364/AO.37.002749; Sone S, 2001, BRIT J CANCER, V84, P25, DOI 10.1054/bjoc.2000.1531; Sone S, 2000, BRIT J RADIOL, V73, P137, DOI 10.1259/bjr.73.866.10884725; SONKA M, 1994, P SOC PHOTO-OPT INS, V2168, P73, DOI 10.1117/12.174425; Soria JC, 2002, CANCER RES, V62, P351; Summers RM, 1998, RADIOLOGY, V208, P331, DOI 10.1148/radiology.208.2.9680555; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006; Thiberville Luc, 1997, European Respiratory Journal Supplement, V10, p425S; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TOCKMAN MS, 1994, CHEST, V106, pS385, DOI 10.1378/chest.106.6_Supplement.385S; TOCKMAN MS, 1997, CLIN BIOL BASIS LUNG; Toyooka S, 2001, MOL CANCER THER, V1, P61; UMIKER WO, 1957, SURGERY, V41, P705; USUDA K, 1994, CANCER, V74, P2239, DOI 10.1002/1097-0142(19941015)74:8<2239::AID-CNCR2820740806>3.0.CO;2-P; Venmans BJW, 2000, CHEST, V117, P1572, DOI 10.1378/chest.117.6.1572; WAGNIERES G, 2002, FLUORESCENCE BIOMEDI; WHO, 2000, WORLD HLTH REP 2000, P164; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; WOOLNER LB, 1983, ATLAS EARLY LUNG CAN, P107; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Yang ZG, 2001, AM J ROENTGENOL, V176, P1399, DOI 10.2214/ajr.176.6.1761399; Yankelevitz DE, 2000, RADIOL CLIN N AM, V38, P267, DOI 10.1016/S0033-8389(05)70162-7; Yankelevitz DF, 1999, RADIOLOGY, V212, P561, DOI 10.1148/radiology.212.2.r99au33561; Yoshida J, 1998, CHEST, V114, P710, DOI 10.1378/chest.114.3.710; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	131	52	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6949	6959		10.1038/sj.onc.1205831	http://dx.doi.org/10.1038/sj.onc.1205831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362276				2022-12-28	WOS:000178640200009
J	Zabarovsky, ER; Lerman, MI; Minna, JD				Zabarovsky, ER; Lerman, MI; Minna, JD			Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers	ONCOGENE			English	Review						lung cancer; tumor supressor gene; human chromosome 3; deletion mapping; preneoplasia; gene therapy	ABERRANT PROMOTER METHYLATION; HOMOZYGOUS DELETION REGION; RENAL-CELL CARCINOMA; ARGININE-RICH PROTEIN; JAAGSIEKTE SHEEP RETROVIRUS; ACID RECEPTOR BETA-2; FHIT GENE; SHORT ARM; EPIGENETIC INACTIVATION; MICROCELL HYBRIDS	Loss of heterozygosity (LOH) involving several chromosome 3p regions accompanied by chromosome 3p deletions are detected in almost 100% of small (SCLCs) and more than 90% of non-small (NSCLCs) cell lung cancers. In addition, these changes appear early in the pathogenesis of lung cancer and are found as clonal lesions in the smoking damaged respiratory epithelium including histologically normal epithelium as well as in epithelium showing histologic changes of preneoplasia. These 3p genetic alterations lead to the conclusion that the short arm of human chromosome 3 contains several tumor suppressor gene(s) (TSG(s)). Although the first data suggesting that 3p alterations were involved in lung carcinogenesis were published more than 10 years ago, only recently has significant progress been achieved in identifying the candidate TSGs and beginning to demonstrate their functional role in tumor pathogenesis. Some of the striking results of these findings has been the discovery of multiple 3p TSGs and the importance of tumor acquired promoter DNA methylation as an epigenetic mechanism for inactivating the expression of these genes in lung cancer. This progress, combined with the well known role of smoking as an environmental causative risk factor in lung cancer pathogenesis, is leading to the development of new diagnostic and therapeutic strategies which can be translated into the clinic to combat and prevent the lung cancer epidemic. It is clear now that genetic and epigenetic abnormalities of several genes residing in chromosome region 3p are important for the development of lung cancers but it is still obscure how many of them exist and which of the numerous candidate TSGs are the key players in lung cancer pathogenesis. We review herein our current knowledge and describe the most credible candidate genes.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Genomics & Bioinformat, S-17177 Stockholm, Sweden; NCI, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zabarovsky, ER (corresponding author), Karolinska Inst, MTC, Box 280, S-17177 Stockholm, Sweden.	eugzab@ki.se; lerman@mail.ncifcrf.gov; John.Minna@UTSouthwestern.edu	Zabarovsky, Eugene R/A-6645-2010		NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; ADORJAN P, 2002, NUCLEIC ACIDS RES, V30, P1; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2002, P AACR, V42, P614; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; ANGELBORG G, 2002, P AACR, V42; ANGELONI D, 2001, HUMAN LUNG CANC CANC, V23, P169; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Banham AH, 2001, CANCER RES, V61, P8820; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Brambilla E, 2000, AM J PATHOL, V156, P939, DOI 10.1016/S0002-9440(10)64962-0; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Caballero OL, 2001, GENE CHROMOSOME CANC, V32, P119, DOI 10.1002/gcc.1173; CHEN LC, 1994, CANCER RES, V54, P3021; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Daigo Y, 1999, CANCER RES, V59, P1966; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Drumheller T, 1996, J MED GENET, V33, P842, DOI 10.1136/jmg.33.10.842; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Edamatsu H, 2000, GENES CELLS, V5, P849, DOI 10.1046/j.1365-2443.2000.00370.x; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; Fan X, 2001, CANCER GENET CYTOGEN, V128, P97, DOI 10.1016/S0165-4608(01)00398-3; Fong KM, 1997, CANCER RES, V57, P2256; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Fullwood P, 1999, CANCER RES, V59, P4662; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062; Geradts J, 1999, CLIN CANCER RES, V5, P791; Geurts JMW, 1997, CANCER RES, V57, P13; Girard L, 2000, CANCER RES, V60, P4894; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; Greenspan DL, 1997, CANCER RES, V57, P4692; Guo ZM, 2000, INT J CANCER, V86, P518, DOI 10.1002/(SICI)1097-0215(20000515)86:4<518::AID-IJC12>3.0.CO;2-Y; Gure AO, 1998, CANCER RES, V58, P1034; Helland A, 2000, INT J CANCER, V88, P217; Heppell-Parton AC, 1999, CANCER GENET CYTOGEN, V111, P105, DOI 10.1016/S0165-4608(98)00208-8; Hirano A, 2001, CLIN CANCER RES, V7, P876; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikeda T, 2000, ONCOL REP, V7, P323; IMREH S, 1994, GENE CHROMOSOME CANC, V11, P237, DOI 10.1002/gcc.2870110406; Ishii H, 2001, CANCER RES, V61, P1578; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Ji L, 2002, CANCER RES, V62, P2715; Ji L, 1999, CANCER RES, V59, P3333; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Keith RL, 2000, CLIN CANCER RES, V6, P1616; Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kiss H, 2002, EUR J HUM GENET, V10, P52, DOI 10.1038/sj.ejhg.5200758; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Kosaki R, 1999, CANCER RES, V59, P1141; Kuzmin I, 2002, CANCER RES, V62, P3498; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Lee MG, 2001, CANCER RES, V61, P6688; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lerman MI, 2000, CANCER RES, V60, P6116; Li JF, 2002, P NATL ACAD SCI USA, V99, P10724, DOI 10.1073/pnas.132271699; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; Liu NF, 2001, CANCER RES, V61, P5207; Lo KW, 2001, CANCER RES, V61, P3877; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Lott ST, 1998, CANCER RES, V58, P3533; Lounis H, 1998, ONCOGENE, V17, P2359, DOI 10.1038/sj.onc.1202152; Lovell M, 1999, CANCER RES, V59, P2182; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268; Matsumoto S, 2000, CANCER LETT, V152, P63, DOI 10.1016/S0304-3835(99)00431-0; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Morrissey C, 2001, CANCER RES, V61, P7277; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Nelson HH, 1998, CANCER RES, V58, P1804; Orikasa K, 1998, CANCER GENET CYTOGEN, V104, P104, DOI 10.1016/S0165-4608(97)00470-6; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Palmarini M, 1999, J VIROL, V73, P6964, DOI 10.1128/JVI.73.8.6964-6972.1999; Palmisano WA, 2000, CANCER RES, V60, P5954; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; Pifarre A, 1997, BRIT J CANCER, V75, P184, DOI 10.1038/bjc.1997.31; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; RIMESSI P, 1994, ONCOGENE, V9, P3467; Roche J, 1996, ONCOGENE, V12, P1289; ROCHE J, 2002, P AACR, V43; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Sato M, 1998, GENE CHROMOSOME CANC, V23, P367; Schlosshauer PW, 2000, MODERN PATHOL, V13, P1066, DOI 10.1038/modpathol.3880196; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shridhar R, 1996, CANCER RES, V56, P5576; Shridhar V, 1996, ONCOGENE, V12, P1931; Shridhar V, 1997, ONCOGENE, V14, P2213, DOI 10.1038/sj.onc.1201054; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1997, CANCER RES, V57, P5207; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Su TH, 2000, GYNECOL ONCOL, V76, P193, DOI 10.1006/gyno.1999.5659; SUNDARESAN V, 1995, ANN ONCOL, V6, P27, DOI 10.1093/annonc/6.suppl_1.S27; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Sutherland LC, 2001, ONCOGENE, V20, P2713, DOI 10.1038/sj.onc.1204371; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; Tanaka H, 1998, CANCER RES, V58, P3429; Thiagalingam S, 1996, CANCER RES, V56, P2936; Timmer T, 1999, EUR J HUM GENET, V7, P478, DOI 10.1038/sj.ejhg.5200334; Todd MC, 1996, ONCOGENE, V13, P2387; Todd S, 1997, CANCER RES, V57, P1344; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2000, BIOCHEM BIOPH RES CO, V278, P671, DOI 10.1006/bbrc.2000.3870; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tschentscher F, 2001, CANCER RES, V61, P3439; Tse C, 2002, CANCER RES, V62, P542; Tseng JE, 1999, CANCER RES, V59, P4798; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vieten L, 1998, GENE CHROMOSOME CANC, V21, P39, DOI 10.1002/(SICI)1098-2264(199801)21:1<39::AID-GCC6>3.0.CO;2-9; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Waber PG, 1996, ONCOGENE, V12, P365; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wei MH, 1996, CANCER RES, V56, P1487; Werner NS, 2000, CANCER RES, V60, P2780; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wistuba II, 1997, CANCER RES, V57, P3154; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; Wu XF, 1998, CANCER RES, V58, P1605; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; Xiang RH, 2002, CANCER RES, V62, P2637; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; Yang QF, 2001, ANTICANCER RES, V21, P1829; Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7; Yang Y, 2001, P NATL ACAD SCI USA, V98, P1136, DOI 10.1073/pnas.98.3.1136; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; ZHANG LR, 1995, CANCER RES, V55, P428; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	198	293	323	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6915	6935		10.1038/sj.onc.1205835	http://dx.doi.org/10.1038/sj.onc.1205835			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362274				2022-12-28	WOS:000178640200007
J	Wang, DL; Lemon, WJ; You, M				Wang, DL; Lemon, WJ; You, M			Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice	ONCOGENE			English	Article						mouse; linkage disequilibrium; lung tumor; susceptibility; gene mapping	RAS PROTOONCOGENE; CANCER; ASSOCIATION; RELATIVES; RISK; POLYMORPHISMS; GENES	Linkage disequilibrium (LD) has been used to map chromosomal regions regulating quantitative traits, also called quantitative trait loci (QTLs). With the increasing number of available mouse polymorphic genetic markers, LD can be estimated for the purpose of fine-mapping a given QTL or in the identification of novel QTLs. A whole-genome LD analysis was conducted for mapping mouse lung tumor susceptibility QTLs in 25 strains of mice with known susceptibility to lung cancer using 5638 genetic markers. A total of 63 markers were found to be significantly associated with lung tumor susceptibility, many of which were novel QTLs. This study demonstrates the feasibility of using LD to map QTLs on a whole genome level. Further characterization of the newly identified lung tumor susceptibility QTLs may lead to the identification of genes whose human homologue may predispose some individuals to lung cancer.	Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	You, M (corresponding author), Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.	you-1@medctr.osu.edu			NATIONAL CANCER INSTITUTE [P30CA016058, R01CA058554, R01CA078797] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78797, P30CA16058, R01CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPORASO NE, 1992, ENVIRON HEALTH PERSP, V98, P101; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GOFFMAN TE, 1982, JAMA-J AM MED ASSOC, V247, P1020, DOI 10.1001/jama.247.7.1020; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; Herzog CR, 1997, J CELL BIOCHEM, P49; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Johannsson O, 1996, AM J HUM GENET, V58, P441; LI FP, 1988, CANCER RES, V48, P5358; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; LYNCH HT, 1986, CANCER, V57, P1640, DOI 10.1002/1097-0142(19860415)57:8<1640::AID-CNCR2820570833>3.0.CO;2-Q; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1999, GENOME RES, V9, P639; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P69, DOI 10.1016/0895-4356(91)90202-K; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; Ott J., 1999, ANAL HUMAN GENETIC L; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1987, AM J EPIDEMIOL, V126, P237, DOI 10.1093/aje/126.2.237; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1993, LUNG CANCER, P3; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; SUGIMURA H, 1990, CANCER RES, V50, P1857; ToFigueras J, 1996, CANCER EPIDEM BIOMAR, V5, P337; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X	34	11	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6858	6865		10.1038/sj.onc.1205886	http://dx.doi.org/10.1038/sj.onc.1205886			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360413				2022-12-28	WOS:000178315800017
J	Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C				Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C			PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein	ONCOGENE			English	Article						megakaryopoiesis; PLZF; GATA1; Tpo receptor	ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; PURIFIED HEMATOPOIETIC PROGENITORS; NORMAL ADULT HEMATOPOIESIS; PML-RAR-ALPHA; POZ-DOMAIN; HISTONE DEACETYLASE; INTERACTION MOTIF; FUSION PARTNERS	We investigated the expression of the PLZF gene in purified human hematopoietic progenitors induced to unilineage erythroid, granulocytic or megakaryocytic differentiation and maturation in serum-free culture. PLZF is expressed in quiescent progenitors: the expression level progressively rises through megakaryocytic development, whereas it gradually declines in erythroid and granulopoietic culture. To investigate the role of PLZF in megakaryopoiesis, we transduced the PLZF gene into the erythro-megakaryocytic TF1 cell line. PLZF overexpression upmodulates the megakaryocytic specific markers (CD42a, CD42b, CD61, PF4) and induces the thrombopoietin receptor (TpoR). The proximal promoter of the TpoR gene is activated in PLZF-expressing TF1 cells: in this promoter region, a PLZF DNA-binding site was identified by deletion constructs studies. Interestingly, PLZF and GATA1 proteins coimmunoprecipitate in PLZF-expressing TF1 cells: enforced expression of both PLZF and GATA1 in TF1 cells results in increased upregulation of megakaryocytic markers, as compared to exogenous PLZF or GATA1 alone, suggesting a functional role for the PLZF/GATA1 complex. Our data indicate that PLZF plays a significant stimulatory role in megakaryocytic development, seemingly mediated in part by induction of TpoR expression at transcriptional level. This stimulatory effect is potentiated by physical interaction of PLZF and GATA1, which are possibly assembled in a multiprotein transcriptional complex.	Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; Mt Sinai Sch Med, New York, NY USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Istituto Superiore di Sanita (ISS); Icahn School of Medicine at Mount Sinai; Jefferson University	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol, Viale Regina Elena 299, I-00161 Rome, Italy.		Licht, Jonathan/L-4239-2019; Testa, Ugo/J-6472-2016; Quaranta, Maria Teresa/AAC-2134-2019; pagliuca, alfredo/J-3107-2012; Licht, Jonathan/AAL-9184-2020; Pagliuca, Alfredo/AAI-3689-2020; Labbaye, Catherine/J-9930-2016	Testa, Ugo/0000-0001-7900-8942; Quaranta, Maria Teresa/0000-0002-5886-507X; pagliuca, alfredo/0000-0002-8703-2077; Licht, Jonathan/0000-0002-3942-1369; Labbaye, Catherine/0000-0003-1255-4396	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GREGORY RC, 1996, BLOOD, V87, P1763; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1998, CANCER RES, V58, P14; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ivins S, 1998, BLOOD, V92, p308A; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MAOUCHE L, 1991, BLOOD, V78, P2557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; TSANG AH, 1997, CELL, V90, P459; VALTIERI M, 1994, CANCER RES, V54, P4398; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; Vyas P, 1999, BLOOD, V93, P2867; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	61	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6669	6679		10.1038/sj.onc.1205884	http://dx.doi.org/10.1038/sj.onc.1205884			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242665				2022-12-28	WOS:000178202300013
J	Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S				Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S			Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses	ONCOGENE			English	Article						HBx; DHBV; avihepadnavirus; HCC; apoptosis; transactivation	HEPATITIS-B VIRUS; PROGRAMMED CELL-DEATH; OPEN READING FRAME; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; TRANSGENIC MICE; GROUND-SQUIRRELS; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; EMBRYO FIBROBLASTS	Two established activities of the multifunctional human hepatitis B virus X-protein are its transactivating and pro-apoptotic potential. We analysed whether X-proteins from other orthohepadnaviruses and the newly discovered avihepadnaviral X-proteins have similar functions as HBx. Previously, we have shown that HBx suppresses oncogenic transformation of primary rat embryo fibroblasts (REF) by induction of apoptosis. Using this system, we found that the wildtype X-proteins of woodchuck, ground squirrel, arctic squirrel and woolly monkey hepatitis B virus exhibit similar levels of proapoptotic activity as HBx, whereas mutants with carboxyterminal deletions were severely impaired in this activity. A strong correlation between the pro-apoptotic and transactivating abilities of the mammalian X-proteins was found. The newly discovered avihepadnaviral X-like proteins showed similar and Raf-MAPK pathway-dependent transactivating abilities and induced apoptosis in the REF-assay. Our data indicate that the transactivating and pro-apoptotic activities reside in the carboxyterminal half of orthohepadnaviral X and are conserved in avihepadnaviral X-proteins.	JLU Giessen, Inst Med Virol, Giessen, Germany; Robert Koch Inst, D-1000 Berlin, Germany; Heinrich Pette Inst, Hamburg, Germany; Inst Pasteur, Paris, France; SW Fdn Biomed Res, San Antonio, TX 78284 USA	Justus Liebig University Giessen; Robert Koch Institute; Heinrich Pette Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Texas Biomedical Research Institute	Schaefer, S (corresponding author), Univ Rostock, Dept Virol, Schillingallee 70, D-18055 Rostock, Germany.		Pollicino, Teresa/HDN-3708-2022; Hildt, Eberhard/A-1040-2015; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035				Andrisani OM, 1999, INT J ONCOL, V15, P373; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P974; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; Chang SF, 2001, J VIROL, V75, P161, DOI 10.1128/JVI.75.1.161-170.2001; Chang SF, 1999, VIROLOGY, V262, P39, DOI 10.1006/viro.1999.9844; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DANE DS, 1970, LANCET, V1, P695; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1988, P NATL ACAD SCI USA, V85, P6162, DOI 10.1073/pnas.85.16.6162; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Grethe S, 2000, J VIROL, V74, P5377, DOI 10.1128/JVI.74.11.5377-5381.2000; Hu XL, 2000, P NATL ACAD SCI USA, V97, P1661, DOI 10.1073/pnas.97.4.1661; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lanford RE, 2000, J VIROL, V74, P2955, DOI 10.1128/JVI.74.6.2955-2959.2000; Lanford RE, 1998, P NATL ACAD SCI USA, V95, P5757, DOI 10.1073/pnas.95.10.5757; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin B, 2000, INTERVIROLOGY, V43, P185, DOI 10.1159/000025037; MacDonald DM, 2000, J VIROL, V74, P4253, DOI 10.1128/JVI.74.9.4253-4257.2000; MARION PL, 1980, P NATL ACAD SCI-BIOL, V77, P2941, DOI 10.1073/pnas.77.5.2941; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MARION PL, 1984, P NATL ACAD SCI-BIOL, V81, P898, DOI 10.1073/pnas.81.3.898; MASON WS, 1980, J VIROL, V36, P829, DOI 10.1128/JVI.36.3.829-836.1980; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Netter HJ, 1997, J GEN VIROL, V78, P1707, DOI 10.1099/0022-1317-78-7-1707; Norder H, 1996, VIROLOGY, V218, P214, DOI 10.1006/viro.1996.0181; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Pult I, 2001, VIROLOGY, V289, P114, DOI 10.1006/viro.2001.1115; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; SEEGER C, 1984, J VIROL, V51, P367, DOI 10.1128/JVI.51.2.367-375.1984; SEIFER M, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P586; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPRENGEL R, 1988, J VIROL, V62, P3832, DOI 10.1128/JVI.62.10.3832-3839.1988; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Takahashi K, 2000, VIROLOGY, V267, P58, DOI 10.1006/viro.1999.0102; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Testut P, 1996, J VIROL, V70, P4210, DOI 10.1128/JVI.70.7.4210-4219.1996; Tu H, 2001, CANCER RES, V61, P7803; WANG XW, 1995, CANCER RES, V55, P6012; Warren KS, 1999, J VIROL, V73, P7860, DOI 10.1128/JVI.73.9.7860-7865.1999; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	69	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6606	6613		10.1038/sj.onc.1205916	http://dx.doi.org/10.1038/sj.onc.1205916			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242658				2022-12-28	WOS:000178202300006
J	Robertson, KD				Robertson, KD			DNA methylation and chromatin - unraveling the tangled web	ONCOGENE			English	Review						DNA methyltransferase; chromatin; DNA methylation; histone deacetylase; histone methylase; transcriptional repression	MESSENGER-RNA EXPRESSION; RECOMBINANT HUMAN DNA; EMBRYONIC STEM-CELLS; ICF SYNDROME; DE-NOVO; CYTOSINE-5 METHYLTRANSFERASE; HISTONE DEACETYLASE; MAMMALIAN DEVELOPMENT; REPLICATION FOCI; SATELLITE DNA	Methylation of cytosines within the CpG dinucleotide by DNA methyltransferases is involved in regulating transcription and chromatin structure, controlling the spread of parasitic elements, maintaining genome stability in the face of vast amounts of repetitive DNA, and X chromosome inactivation. Cellular DNA methylation is highly compartmentalized over the mammalian genome and this compartmentalization is essential for embryonic development. When the complicated mechanisms that control which DNA sequences become methylated go awry, a number of inherited genetic diseases and cancer may result. Much new information has recently come to light regarding how cellular DNA methylation patterns may be established during development and maintained in somatic cells. Emerging evidence indicates that various chromatin states such as histone modifications (acetylation and methylation) and nucleosome positioning (modulated by ATP-dependent chromatin remodeling machines) determine DNA methylation patterning. Additionally, various regulatory factors interacting with the DNA methyltransferases may direct them to specific DNA sequences, regulate their enzymatic activity, and allow their use as transcriptional repressors. Continued studies of the connections between DNA methylation and chromatin structure and the DNA methyltransferase-associated proteins, will likely reveal that many, if not all, epigenetic modifications of the genome are directly connected. Such studies should also yield new insights into treating diseases involving aberrant DNA methylation.	NCI, Epigenet Gene Regulat & Canc Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Robertson, KD (corresponding author), NCI, Epigenet Gene Regulat & Canc Sect, NIH, Bethesda, MD 20892 USA.	robertk@mail.nih.gov		Robertson, Keith/0000-0002-7508-3328	NATIONAL CANCER INSTITUTE [K22CA084535] Funding Source: NIH RePORTER; NCI NIH HHS [CA84535-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aapola U, 2001, CYTOGENET CELL GENET, V92, P122, DOI 10.1159/000056881; Aguirre-Arteta AM, 2000, CELL GROWTH DIFFER, V11, P551; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bonfils C, 2000, J BIOL CHEM, V275, P10754, DOI 10.1074/jbc.275.15.10754; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cardoso MC, 1999, J CELL BIOL, V147, P25, DOI 10.1083/jcb.147.1.25; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Clapier CR, 2002, NUCLEIC ACIDS RES, V30, P649, DOI 10.1093/nar/30.3.649; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Doherty AS, 2002, DEV BIOL, V242, P255, DOI 10.1006/dbio.2001.0534; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Ehrlich M, 2001, HUM MOL GENET, V10, P2917, DOI 10.1093/hmg/10.25.2917; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001; Feng Q, 2001, GENE DEV, V15, P827; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; FRANCESCHINI P, 1995, EUR J PEDIATR, V154, P840, DOI 10.1007/BF01959794; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Geiman TM, 2000, P NATL ACAD SCI USA, V97, P4772, DOI 10.1073/pnas.97.9.4772; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassan KMA, 2001, HUM GENET, V109, P452; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; JACKSON JP, 2002, NATURE          0317; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jarvis CD, 1996, GENE, V169, P203, DOI 10.1016/0378-1119(95)00843-8; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kal AJ, 2000, GENE DEV, V14, P1058; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin MJ, 2000, FEBS LETT, V469, P101, DOI 10.1016/S0014-5793(00)01254-0; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lyko F, 2000, MECH DEVELOP, V95, P215, DOI 10.1016/S0925-4773(00)00325-7; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Martienssen R, 1999, NAT GENET, V22, P6, DOI 10.1038/8708; Meng GY, 2000, GENE, V242, P59, DOI 10.1016/S0378-1119(99)00477-1; Mertineit C, 1998, DEVELOPMENT, V125, P889; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miniou P, 1997, HUM GENET, V99, P738, DOI 10.1007/s004390050441; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; Raabe EH, 2001, DEV DYNAM, V221, P92, DOI 10.1002/dvdy.1128; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SCHUFFENHAUER S, 1995, HUM GENET, V96, P562, DOI 10.1007/BF00197412; SMEETS DFCM, 1994, HUM GENET, V94, P240; TAGARRO I, 1994, HUM GENET, V93, P383; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Tucker KL, 2001, NEURON, V30, P649, DOI 10.1016/S0896-6273(01)00325-7; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WILKINSON CRM, 1995, NUCLEIC ACIDS RES, V23, P1995; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	135	352	384	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5361	5379		10.1038/sj.onc.1205609	http://dx.doi.org/10.1038/sj.onc.1205609			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154399	Bronze			2022-12-28	WOS:000177197700003
J	Choi, Y; Zhang, J; Murga, C; Yu, H; Koller, E; Monia, BP; Gutkind, JS; Li, WQ				Choi, Y; Zhang, J; Murga, C; Yu, H; Koller, E; Monia, BP; Gutkind, JS; Li, WQ			PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells	ONCOGENE			English	Article						myeloma; PTEN; SHIP; signal transduction	PROTEIN-KINASE-B; INOSITOL PHOSPHATASE SHIP; POLYPHOSPHATE 5-PHOSPHATASE SHIP; FORKHEAD TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; PHOSPHOINOSITIDE 3-KINASE; TUMOR SUPPRESSION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; NEGATIVE REGULATION; GLIOBLASTOMA CELLS	Expression of PTEN tumor suppressor gene has been known to dephosphorylate the phosphatidylinositol 3' kinase (PI3K) products on the 3 prime inositol ring, resulting in reduced Akt activation. Loss of PTEN expression in OPM2 and Delta47 human myeloma lines led to high Akt activity toward insulin-like growth factor I (IGF-I). In contrast, mouse plasma cell tumor (PCT) lines, expressing wild type PTEN, did not respond to IGF-I for Akt activation. We demonstrated here that endogenous PTEN played a negative role in controlling Akt activity in both mouse PCT and NIH3T3 fibroblast lines by using anti-sense oligonucleotides against PTEN. To determine the role of src-homology 2-containing inositol 5' phosphatase (SHIP) in regulating the PI3K/Akt pathway, we manipulated its expression by down-regulation and overexpression in myeloma, PCT and NIH3T3 lines and analysed Akt activation. Our results showed that SHIP, unlike PTEN, did not affect Akt activity in all systems analysed, despite its ability to dephosphorylate a PI3K product. Although SHIP2 expression resulted in suppression of interleukin-6-mediated mitogen-activated protein kinase activation, expression of SHIP and SHIP2 in a PTEN-null myeloma line did not suppress Akt activity. Biologically, expression of only PTEN, but not SHIP and SHIP2, resulted in growth inhibition and increased apoptosis in OPM2 myeloma line. Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, Bethesda, MD USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, E407,3970 Reservoir Rd NW,New Res Bldg, Washington, DC 20007 USA.		Gutkind, J. Silvio/J-1201-2016; Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEL PL, 1997, SCIENCE, V278, P687; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feinman R, 1999, BLOOD, V93, P3044; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kyle RA, 2001, ONCOLOGIST, V6, P119, DOI 10.1634/theoncologist.6-2-119; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MACHAMA T, 1998, J BIOL CHEM, V273, P13375; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potter M, 1997, HEMATOL ONCOL CLIN N, V11, P323, DOI 10.1016/S0889-8588(05)70434-2; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rohrschneider LR, 2000, GENE DEV, V14, P505; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Treon SP, 1999, BLOOD, V93, P1287, DOI 10.1182/blood.V93.4.1287.404k14_1287_1298; Urashima M, 1997, BLOOD, V90, P279; Weng LP, 1999, CANCER RES, V59, P5808; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	68	79	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5289	5300		10.1038/sj.onc.1205650	http://dx.doi.org/10.1038/sj.onc.1205650			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149650				2022-12-28	WOS:000177193900010
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction	ONCOGENE			English	Article						NQO1; ARE; t-BHQ; c-Maf	ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; SUBUNIT GENE; NRF2; PROTEIN; BINDING; FAMILY	Anti-oxidant response element (ARE) and nuclear factors including Nrf2 and small Maf (MafG and MafK) proteins are known to regulate expression and induction of detoxifying enzyme genes including quinone oxidoreductase1 (NQO1). Nrf2 upregulates and small Maf proteins lacking the transcriptional activation domain down regulates ARE-mediated expression and induction. In this report, we have investigated the role of c-Maf (large Mal) containing the transcriptional activation domain in the regulation of ARE-mediated genes expression. The overexpression of c-Maf in human hepatoblastoma (Hep-G2) cells led to the repression of ARE-mediated NQO1 and GST Ya genes expression and induction in response to tert-butyl hydroquinone (t-BHQ). This was in contrast to the role of c-Maf in the activation of Maf recognition element (MARE) mediated p53 gene expression. Deletion of transcriptional activation domain of c-Maf (<^>c-Maf) led to significant loss of MARE-mediated p53 gene expression but had no effect on the repression of ARE-mediated NQO1 gene expression. The overexpression of MafG in Hep-G2 cells repressed both ARE and MARE-mediated genes expression. The co-expression of c-Maf with MafG rescued the MafG repression of MARE but not ARE-mediated gene expression. Band and super shift assays showed the presence of c-Maf in the ARE-nuclear protein complex. Similar assays with in vitro translated proteins revealed that both c-Maf and <^>c-Maf bound to NQO1 gene ARE as homodimers and heterodimers with small Maf but not as heterodimers with Nrf2. Mutational analysis of the NQO1 gene ARE indicated that core ARE sequence is essential for binding of c-Maf leading to repression of NQO1 gene expression. Northern analysis revealed that c-Maf expression increases 2 h after t-BHQ treatment. It reached a plateau at 4 h after t-BHQ treatment. The results together led to the conclusion that c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and induction in response to anti-oxidants.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Matsushima-Hibiya Y, 1998, BIOCHEM BIOPH RES CO, V245, P412, DOI 10.1006/bbrc.1998.8447; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	36	62	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5301	5312		10.1038/sj.onc.1205642	http://dx.doi.org/10.1038/sj.onc.1205642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149651				2022-12-28	WOS:000177193900011
J	Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L				Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L			Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation	ONCOGENE			English	Article						HPV E6; MAGUK; PDZ; MAGI	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; DISCS LARGE PROTEIN; GUANYLATE-KINASE; PDZ DOMAIN; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	The E6 proteins from the high-risk human papillomavirus (HPV) types have previously been shown to target a number of PDZ domain-containing proteins for proteasome-mediated degradation. These include the hDIg tumour suppressor and the MAGI-I protein. In this study we show that high-risk HPV E6 proteins also target the related MAGI-2 and MAGI-3 proteins for degradation. Moreover, we show that the interaction is specific to one PDZ domain, and that co-expression of this domain can protect each of the full-length MAGI proteins from E6-mediated degradation. These data provide clear indicators for the potential design of compounds that could specifically inhibit the interaction of oncogenic HPV E6 proteins with an important class of target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Roche Holding; Genentech; University of California System; University of California Los Angeles	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Sawyers, Charles/G-5327-2016; guccione, ernesto/G-9874-2011					Adey NB, 2000, CANCER RES, V60, P35; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li J, 1998, CANCER RES, V58, P5667; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	56	161	172	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5088	5096		10.1038/sj.onc.1205668	http://dx.doi.org/10.1038/sj.onc.1205668			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140759				2022-12-28	WOS:000176975900007
J	Dallol, A; Forgacs, E; Martinez, A; Sekido, Y; Walker, R; Kishida, T; Rabbitts, P; Maher, ER; Minna, JD; Latif, F				Dallol, A; Forgacs, E; Martinez, A; Sekido, Y; Walker, R; Kishida, T; Rabbitts, P; Maher, ER; Minna, JD; Latif, F			Tumour specific promoter region methylation of the human homologue of the Drosophilia Roundabout gene DUTT1 (ROBO1) in human cancers	ONCOGENE			English	Article						methylation; 3p12 tumour suppressor gene; DUTT1/ROBO1	RENAL-CELL CARCINOMA; SUPPRESSOR GENE; BREAST-CANCER; LUNG-CANCER; CLEAR-CELL; EPIGENETIC INACTIVATION; HOMOZYGOUS DELETION; GUIDANCE RECEPTORS; DNA METHYLATION; CHROMOSOME 3P12	The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) defined the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identified tumour specific promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5' region contains a CpG island, and the poly(A)(+) tail has an atypical 5'-GATAAA-3' signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR-SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RTPCR. Bisulfite sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (-244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC-RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC-RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our findings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region defined by hemi and homozygous deletions and functional analysis.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Leicester, Glenfield Hosp, Breast Canc Res Unit, Leicester, Leics, England; Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; Univ Cambridge, MRC,Mol Oncol Grp, Dept Oncol, MRC Ctr, Cambridge CB2 2QH, England; Univ Birmingham, Sch Med, Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Yokohama City University; MRC Laboratory Molecular Biology; University of Cambridge; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012; Sekido, Yoshitaka/P-9756-2015	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50 CA 70907] Funding Source: Medline; Breast Cancer Now [1999:98] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ANGELONI D, 2000, CANC GENETICS TUMOR; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lerman MI, 2000, CANCER RES, V60, P6116; Lott ST, 1998, CANCER RES, V58, P3533; Lovell M, 1999, CANCER RES, V59, P2182; LUBINSKI J, 1994, CANCER RES, V54, P3710; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300; Mau S, 1996, CANCER RES, V56, P5484; Morrissey C, 2001, CANCER RES, V61, P7277; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Phelps RM, 1996, J CELL BIOCHEM, P32; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; SHUIN T, 1994, CANCER RES, V54, P2852; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Todd S, 1997, CANCER RES, V57, P1344; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616	42	99	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3020	3028		10.1038/sj.onc.1205421	http://dx.doi.org/10.1038/sj.onc.1205421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082532				2022-12-28	WOS:000175262700009
J	Joosten, M; Vankan-Berkhoudt, Y; Tas, M; Lunghi, M; Jenniskens, Y; Parganas, E; Valk, PJ; Lowenberg, B; van den Akker, E; Delwel, R				Joosten, M; Vankan-Berkhoudt, Y; Tas, M; Lunghi, M; Jenniskens, Y; Parganas, E; Valk, PJ; Lowenberg, B; van den Akker, E; Delwel, R			Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites	ONCOGENE			English	Article						leukemia; disease gene; common virus integration site; insertional mutagenesis	PERIPHERAL CANNABINOID RECEPTOR; HUMAN MYELOID-LEUKEMIA; CELL-LINES; N-MYC; GENE; TRANSLOCATION; ACTIVATION; MUTATIONS; NEOPLASMS; NEUROFIBROMATOSIS	The identification of common virus integration sites (cVIS) in retrovirally induced tumors in mice provides a powerful strategy to isolate novel transforming genes. Applying virus LTR-specific inverse-PCR and RT-PCR combined with automated sequencing on CasBr-M Murine Leukemia Virus (MuLV) induced myeloid leukemias, 126 virus integration sites were cloned. Using locus- and LTR-specific primers, a nested-PCR/Southern-blotting procedure was developed on genomic DNA from a large panel of MuLV-induced leukemias, to analyse whether a particular virus insertion represented a cVIS. In fact 39 out of 41 integrations analysed this way appeared to represent a common virus integration. We recognized six previously cloned cVISs, i.e. Evil, Hoxa7, c-Myb, Cb/Evi11, Evi12, and His1 and 33 novel common insertions, designated Cas-Br Virus Integration Site (Casvis). Among this group we found integrations in or near genes encoding nuclear proteins, e.g. Dnmt-2, Nm23-M2, Ctbp1 or Erg, within receptor genes, e.g. Cb2 or mrc1, novel putative signaling or transporter genes, the ringfinger-protein gene Mid1 and a panel of genes encoding novel proteins with unknown function. The finding that 39 out of 41 integrations analysed represented a cVIS, suggests that the majority of the other virus insertions that were not yet analysed by the PCR/Southern-blotting method are located in a cVIS as well and may therefore also harbor novel disease genes.	Erasmus Univ, Inst Hematol, NL-3015 GE Rotterdam, Netherlands; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Erasmus University Rotterdam; St Jude Children's Research Hospital	Delwel, R (corresponding author), Erasmus Univ, Inst Hematol, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	delwel@hema.fgg.eur.nl	Valk, Peter/AAX-2823-2020	Bastiaansen-Jenniskens, Yvonne/0000-0002-2921-1237				BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; Berns A, 1999, CANCER RES, V59, p1773S; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; Cox MC, 2001, LEUKEMIA RES, V25, P349, DOI 10.1016/S0145-2126(00)00136-3; deBoer CJ, 1997, ANN ONCOL, V8, P109, DOI 10.1023/A:1008207005567; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HIRVONEN H, 1993, LEUKEMIA LYMPHOMA, V11, P197, DOI 10.3109/10428199309086996; HOLMES KL, 1986, J IMMUNOL, V137, P679; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; Joosten M, 2000, VIROLOGY, V268, P308, DOI 10.1006/viro.2000.0183; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; OFIR R, 1992, LEUKEMIA RES, V16, P797, DOI 10.1016/0145-2126(92)90159-5; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; SILVER J, 1986, J VIROL, V60, P1156, DOI 10.1128/JVI.60.3.1156-1158.1986; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; Specchia G, 2001, LEUKEMIA RES, V25, P501, DOI 10.1016/S0145-2126(00)00160-0; Tanaka K, 2001, CANCER GENET CYTOGEN, V124, P27, DOI 10.1016/S0165-4608(00)00316-2; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Valk PJM, 1997, NUCLEIC ACIDS RES, V25, P4419, DOI 10.1093/nar/25.21.4419; Valk PJM, 1999, J VIROL, V73, P3595, DOI 10.1128/JVI.73.5.3595-3602.1999; Valk PJM, 1997, J VIROL, V71, P6796, DOI 10.1128/JVI.71.9.6796-6804.1997	33	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7247	7255		10.1038/sj.onc.1205813	http://dx.doi.org/10.1038/sj.onc.1205813			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370816	Bronze			2022-12-28	WOS:000178504600014
J	Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH				Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH			Identification of Src transformation fingerprint in human colon cancer	ONCOGENE			English	Article						Src; colon cancer; expression profiling; microarray	BETA-PROTEIN-PRECURSOR; C-SRC; GENE-EXPRESSION; V-SRC; BINDING PROTEIN; MESSENGER-RNA; SARCOMA VIRUS; ACTIVATION; OVEREXPRESSION; GROWTH	We used a classical rodent model of transformation to understand the transcriptional processes, and hence the molecular and cellular events a given cell undergoes when progressing from a normal to a transformed phenotype. Src activation is evident in 80% of human colon cancer, yet the myriad of cellular processes effected at the level of gene expression has yet to be fully documented. We identified a Src 'transformation fingerprint' within the gene expression profiles of Src-transformed rat 3Y1 fibroblasts demonstrating a progression in transformation characteristics. To evaluate the role of this gene set in human cancer development and progression, we extracted the orthologous genes present on the Affymetrix Hu95A GeneChip(TM) (12k named genes) and compared expression profiles between the Src-induced rodent cell line model of transformation and staged colon tumors where Src is known to be activated. A similar gene expression pattern between the cell line model and staged colon tumors for components of the cell cycle, cytoskeletal associated proteins, transcription factors and lysosomal proteins suggests the need for co-regulation of several cellular processes in the progression of cancer. Genes not previously implicated in tumorigenesis were detected, as well as a set of 14 novel, highly conserved genes with here-to-fore unknown function. These studies define a set of transformation associated genes whose up-regulation has implications for understanding Src mediated transformation and strengthens the role of Src in the development and progression of human colon cancer. Supportive Supplemental Data can be viewed at http:// pga.tigr.org/PGApubs.shtml.	Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Johns Hopkins Canc Ctr, Div Canc Biol, Baltimore, MD 21231 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NCI, Div Clin Sci, Med Branch,Mol Signaling & Oncogenesis Sect, Dept Canc & Cell Biol, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yeatman, TJ (corresponding author), Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA.	yeatman@moffitt.usf.edu; nhlee@tigr.org	Liu, Edison/C-4141-2008	Quackenbush, John/0000-0002-2702-5879	NATIONAL CANCER INSTITUTE [K24CA085429, R01CA077049, U01CA085052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059781] Funding Source: NIH RePORTER; NCI NIH HHS [CA77049-02, CA85429-01, CA85052-A1] Funding Source: Medline; NHLBI NIH HHS [HL59781] Funding Source: Medline; PHS HHS [6120-119-L0-A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akamatsu H, 1996, CANCER RES, V56, P4541; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BYRNE JA, 1995, CANCER RES, V55, P2896; Chew CS, 2000, J CELL SCI, V113, P2035; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Freier S, 1999, GUT, V44, P704, DOI 10.1136/gut.44.5.704; Guo QM, 2000, CANCER RES, V60, P5922; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Iravani S, 1998, LAB INVEST, V78, P365; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Manenti S, 1998, CANCER RES, V58, P1429; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Niinaka Y, 1998, CANCER RES, V58, P2667; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OKAMOTOINOUE M, 1990, J CELL SCI, V96, P631; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SKOTZKO M, 1995, CANCER RES, V55, P5493; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TAKEKURA N, 1990, INT J CANCER, V45, P847, DOI 10.1002/ijc.2910450510; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WICKUS G, 1975, P NATL ACAD SCI USA, V72, P746, DOI 10.1073/pnas.72.2.746; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852; YANO M, 1999, CANC LETT, V22, P45; Yeung KY, 2001, BIOINFORMATICS, V17, P309, DOI 10.1093/bioinformatics/17.4.309; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	73	79	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7256	7265		10.1038/sj.onc.1205900	http://dx.doi.org/10.1038/sj.onc.1205900			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370817				2022-12-28	WOS:000178504600015
J	Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F				Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F			Functional interaction of Sam68 and heterogeneous nuclear ribonucleoprotein K	ONCOGENE			English	Article						Sam68; hnRNP K; RRE; CT element; protein - protein interaction	HUMAN-IMMUNODEFICIENCY-VIRUS; FAMILY TYROSINE KINASES; RNA HELICASE-A; HNRNP-K; BINDING-PROTEIN; MESSENGER-RNA; DOMAIN; SRC; IDENTIFICATION; LOCALIZATION	Sam68 is a target of the c-Src tyrosine kinase. We previously showed that overexpression of Sam68 functionally substitutes for, as well as synergies with, HIV-1 Rev in Rev-response element (RRE)-mediated gene expression and virus replication. Here we describe the identification of heterogeneous nuclear ribonucleoprotein K (hnRNP K) as a protein that specifically interacts with Sam68 in vitro and in vivo. HnRNP K did not bind to RRE-RNA directly, but formed a super complex with Sam68 and RRE in vitro. RNase treatment did not change the strength of binding of hnRNP K to Sam68. We demonstrated that hnRNP K significantly inhibited Sam68-mediated, but not Rev-mediated, RRE-dependent gene expression. We further showed that Sam68, but not a non-functional mutant Sam68p21, inhibited transcriptional activation of CT element by hnRNP K. Interestingly, the Sam68p21 with a single amino acid substitution in the nuclear localization domain exhibited less affinity for hnRNP K in vitro. We propose that the direct interaction of Sam68 and hnRNP K adversely affect the activities of both proteins in signal transduction pathways of both transcriptional and post-transcriptional events.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Wayne State University	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, Stein Clin Res Bldg, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu			NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM05089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Reddy TR, 2000, ONCOGENE, V19, P4071, DOI 10.1038/sj.onc.1203749; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; REICH E, 1962, P NATL ACAD SCI USA, V48, P1238, DOI 10.1073/pnas.48.7.1238; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Weighardt F, 1999, J CELL SCI, V112, P1465; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662	39	32	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7187	7194		10.1038/sj.onc.1205759	http://dx.doi.org/10.1038/sj.onc.1205759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370808				2022-12-28	WOS:000178504600006
J	David-Pfeuty, T; Nouvian-Dooghe, Y				David-Pfeuty, T; Nouvian-Dooghe, Y			Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function	ONCOGENE			English	Article						p14(Arf); cell cycle regulation; tumor suppression; cell morphology; cyclin-dependent kinase	ARF TUMOR-SUPPRESSOR; WILD-TYPE P53; RIBOSOMAL-RNA; P53-DEPENDENT APOPTOSIS; STABILIZES P53; P19(ARF); MDM2; TRANSCRIPTION; INHIBITORS; PROTEINS	The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.	Ctr Univ, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; DURO D, 1995, ONCOGENE, V11, P21; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GAUTIER T, 1992, J CELL SCI, V102, P729; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MAO L, 1995, CANCER RES, V55, P2995; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OConnor PM, 1997, CANCER SURV, V29, P151; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Savino TM, 1999, J CELL SCI, V112, P1889; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6779	6790		10.1038/sj.onc.1205871	http://dx.doi.org/10.1038/sj.onc.1205871			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360404				2022-12-28	WOS:000178315800008
J	Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P				Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P			Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis	ONCOGENE			English	Article						transgenic mouse; v-Ha-RAS; Werner syndrome; TPA; genome instability	X-CHROMOSOME INACTIVATION; MOUSE SKIN; SYNDROME PROTEIN; DNA HELICASE; MULTISTAGE CARCINOGENESIS; REPEAT HYPOTHESIS; LINE-1 ELEMENTS; MICE; RECOMBINATION; EXONUCLEASE	Tg.AC transgenic mice provide a sensitive assay for oncogenic agents and a convenient alternative to the two-stage initiation/promoter model of skin tumorigenesis. Although extensively used, this model has remained in part an enigma since mice that carry the Tg.AC transgene (consisting of v-Ha-Ras driven by an embryonic zeta-globin promoter) would not ordinarily be expected to develop skin and other adult tumors. Cloning and characterizing the inserted transgene has provided an insight into the Tg.AC phenotype. We find that the transgene is inserted into a Line-1 element in such a way as to create extended inverted repeats consisting of both transgene and Line-1 sequences. Such structures would be expected to contribute to the instability of the Tg.AC locus and we suggest that this instability is critical to the Tg.AC phenotype. Further, we strengthen this notion by introducing an inactivating mutation in the murine Wrn gene (a gene important in maintenance of genome stability) and showing that bigenic Tg.AC/ Wrn(Deltahel/Deltahel) mice experience an eightfold increase in inactivating germline mutations at the Tg.AC locus. Similarly, Tg.AC/ Wrn(Deltahel/Deltahel) mice that retain an intact and thus active Tg.AC locus experience a sharp increase in papillomas as compared to Tg.AC/Wrn(+/+), mice. This work demonstrates a genetic interaction between the instability of the multicopy transgene and the Werner Syndrome gene. From this, we conclude that genetic instability remains a key element in this tumor promoter model.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Laval, Ctr Rech Cancerol, CHUQ, Quebec City, PQ G1R 2J6, Canada	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Laval University	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Bishop, Alexander/0000-0002-5742-4387				Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; Berenblum I, 1941, CANCER RES, V1, P807; Bestor TH, 1998, CIBA F SYMP, V214, P187; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Cannon RE, 2000, MOL CARCINOGEN, V29, P229, DOI 10.1002/1098-2744(200012)29:4<229::AID-MC1005>3.0.CO;2-9; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; DIGIOVANNI J, 1993, CARCINOGENESIS, V14, P1831, DOI 10.1093/carcin/14.9.1831; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dunson DB, 2000, TOXICOL SCI, V55, P293, DOI 10.1093/toxsci/55.2.293; Eastin WC, 1998, TOXICOL PATHOL, V26, P461, DOI 10.1177/019262339802600401; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FUKUCHI K, 1990, HUM GENET, V84, P249; Gordenin DA, 1998, MUTAT RES-FUND MOL M, V400, P45, DOI 10.1016/S0027-5107(98)00047-5; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Gulezian D, 2000, TOXICOL PATHOL, V28, P482, DOI 10.1177/019262330002800320; Hansen LA, 1996, CARCINOGENESIS, V17, P1825, DOI 10.1093/carcin/17.9.1825; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Humble MC, 2000, GENOMICS, V70, P292, DOI 10.1006/geno.2000.6384; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lebel M, 2002, CARCINOGENESIS, V23, P213, DOI 10.1093/carcin/23.1.213; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Lyon MF, 2000, P NATL ACAD SCI USA, V97, P6248, DOI 10.1073/pnas.97.12.6248; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; MARASCHIO P, 1986, CLIN GENET, V30, P353; MELARAGNO MI, 1995, MECH AGEING DEV, V78, P117, DOI 10.1016/0047-6374(94)01530-Y; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; OWENS DM, 1995, CANCER RES, V55, P3171; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Thompson KL, 2001, MOL CARCINOGEN, V32, P176, DOI 10.1002/mc.10009; Waldman AS, 1999, GENETICS, V153, P1873; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	56	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6657	6668		10.1038/sj.onc.1205795	http://dx.doi.org/10.1038/sj.onc.1205795			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242664				2022-12-28	WOS:000178202300012
J	Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B				Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B			An atypical caspase-independent death pathway for an immunogenic cancer cell line	ONCOGENE			English	Article						apoptosis; necrosis; caspase-independent; z-VAD; tumor immunology	DENDRITIC CELLS; NUCLEAR TRANSLOCATION; APOPTOTIC CELLS; ACTIVATED DNASE; ANTIGEN; BCL-2; INHIBITION; EXPRESSION; MATURATION; FORM	REGb cell line, a highly immunogenic tumor cell variant isolated from a rat colon cancer, yields regressive tumors when injected into syngeneic hosts. We previously demonstrated that REGb tumor immunogenicity was related to the capacity of releasing dead cells in vivo. Also, in vitro, REGb cell monolayers release dead cells, especially when cultured in serum-free medium. In the current study, we show that the release of dead cells results from an atypical death process associating features of necrosis and apoptosis. In spite of features considered as hallmarks of caspase-dependent apoptosis, including chromatin fragmentation and DNA oligonucleosomal cleavage, caspases are not activated and caspase inhibitors are ineffective to prevent REGb cell death. In contrast with a number of other types of cell death, the spontaneous death of REGb cells in culture depends on de novo protein synthesis as this death is blocked by low doses of the mRNA translation inhibitor cycloheximide. This unusual mode of cell death that associates necrotic and apoptotic features could provide optimal conditions for triggering a specific immune response.	Fac Med & Pharm Dijon, INSERM U517, IFR 100, F-21079 Dijon, France; Inst Gustave Roussy, CNRS UMR 1599, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy	Bonnotte, B (corresponding author), Fac Med & Pharm Dijon, INSERM U517, IFR 100, 7 Blvd Jeanne Arc, F-21079 Dijon, France.		Kroemer, Guido/AAY-9859-2020; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; KROEMER, Guido/B-4263-2013; Bonnotte, Bernard/ABA-2525-2021; REBE, Cédric/AAD-4316-2019	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Bonnotte, Bernard/0000-0002-1098-4598; REBE, Cédric/0000-0001-8831-145X; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Belmokhtar CA, 2000, EXP CELL RES, V254, P99, DOI 10.1006/excr.1999.4737; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Famulski KS, 1999, CELL DEATH DIFFER, V6, P281, DOI 10.1038/sj.cdd.4400495; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Rovere P, 1998, J IMMUNOL, V161, P4467; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Shaif-Muthana M, 2000, CANCER RES, V60, P6441; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Torriglia A, 2000, ANN NY ACAD SCI, V926, P192; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956	25	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6091	6100		10.1038/sj.onc.1205738	http://dx.doi.org/10.1038/sj.onc.1205738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203121				2022-12-28	WOS:000177671300012
J	Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ				Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ			Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action	ONCOGENE			English	Article						tumour necrosis factor-alpha (TNF-alpha); Barrett's oesophagus; cancer; cadherins and catenins	GROWTH-FACTOR RECEPTOR; BETA-CATENIN; CANCER; ESOPHAGUS; CELLS; INFLAMMATION; EXPRESSION; ADENOCARCINOMA; ACTIVATION; REGULATORS	Barrett's metaplasia (BM) is an early lesion in the progression from oesophageal inflammation through dysplasia to the development of Barrett's adenocarcinoma (BA). Previous work indicates that BM and BA are associated with reduced E-cadherin expression and increased cytoplasmic/nuclear pools of its associated protein beta-catenin. beta-catenin participates in Wnt signalling and activates oncogene transcription by complexing with T-cells factors (TCF). One such oncogene is c-myc. We have previously shown that TNF-alpha can down-regulate E-cadherin expression. Here, we assess TNF-alpha expression in Barrett's metaplasia and examine if TNF-alpha can promote beta-catenin mediated transcription of oncogenes in a gastrointestinal model system. Employing immunohistochemistry and Western blot analysis of oesophageal tissue, epithelial expression of TNF-alpha increases with progression along the metaplasia-dysplasia-carcinoma sequence (P<0.001). beta-catenin mediated transcription was then assessed in TNF-alpha stimulated cell lines using the TOPFLASH reporter system whilst c-myc expression was assessed by real time PCR. In a columnar intestinal cell model, TNF-alpha induces c-myc expression which is induced via beta-catenin mediated transcription (P<0.05). This beta-catenin mediated transcription is independent of NF-kappaB activation. Thus, TNF-alpha is up-regulated in the progression of Barrett's oesophagus and beta-catenin mediated transcription of c-myc is a novel pathway whereby elevated levels of TNF-alpha may lead to oncogene transcription and altered biology in gastrointestinal epithelia and metaplasia.	Univ Birmingham, Queen Elizabeth Hosp, Epithelial Lab, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, CRVK Lab, Birmingham B15 2TH, W Midlands, England; Birmingham Heartlands Hosp, Oesophageal Res Lab, Birmingham B9 SS, W Midlands, England; Univ Glasgow, Lister Dept Surg, Histopathol Unit, Glasgow G31 2ER, Lanark, Scotland; Imperial Canc Res Fund, London WC2A 3PN, England; Univ Leicester, Dept Med, Leicester LE1 5WW, Leics, England; Univ Leicester, Dept Oncol, Leicester LE1 5WW, Leics, England	University of Birmingham; University of Birmingham; Heart of England NHS Foundation Trust; University of Glasgow; Cancer Research UK; University of Leicester; University of Leicester	Jankowski, JAZ (corresponding author), Leicester Royal Infirm, Dept Med & Oncol, Mycosal Biol Lab, Leicester LE1 5WW, Leics, England.		Jankowski, Janusz/H-2706-2012; Wright, Nicholas/HHY-7227-2022	Jankowski, Janusz/0000-0003-2130-9181; Wright, Nicholas/0000-0002-5525-3457				Bailey T, 1998, AM J PATHOL, V152, P135; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; COTTAM DW, 1993, INT J ONCOL, V2, P861; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dixon MF, 2001, GUT, V49, P359, DOI 10.1136/gut.49.3.359; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Frommel TO, 1999, MED HYPOTHESES, V52, P27, DOI 10.1054/mehy.1997.0621; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MENKEPLUYMERS MBE, 1992, GUT, V33, P1454, DOI 10.1136/gut.33.11.1454; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; NATHKE I, 1999, MOL PATHOL, V52, P166; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Perry I, 1999, LAB INVEST, V79, P1489; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Schmitz H, 1999, J CELL SCI, V112, P137; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS P, 1997, BRIT J SURG, V84, P110; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	34	141	148	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6071	6081		10.1038/sj.onc.1205731	http://dx.doi.org/10.1038/sj.onc.1205731			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203119				2022-12-28	WOS:000177671300010
J	Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M				Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M			A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression	ONCOGENE			English	Article						Cdkn2a; p16(INK4a); ARF; genetic variants; mouse lung tumors; pulmonary adenoma progression 1; quantitative trait locus	CELL-CYCLE CONTROL; SUPPRESSOR GENE; PLASMACYTOMA SUSCEPTIBILITY; STABILIZES P53; MDM2; P19(ARF); CANCER; P16(INK4A); CDKN2A; MICE	Lung cancer is the leading cause of cancer death among both men and women, accounting for more than 28% of all cancer deaths. In fact, more people die of lung cancer than of colon, breast, and prostate cancers combined. Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in the development of lung cancer. Inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci since genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Papg-1 (pulmonary adenoma progression 1) was previously mapped to a region on mouse chromosome 4. This locus contains a candidate gene, Cdkn2a also referred to as Ink4a/Arf, which dually encodes two established tumor suppressors p16(INK4a) and ARE Cdkn2a became a primary candidate for Papg-1 for two reasons: (1) two haplotypes of mouse Cdkn2a were found to segregate with differential genetic susceptibility to lung tumor progression in mice; and (2) in vitro studies showed that the p16(INK4a) allele from the BALB/cJ mouse had a significantly decreased ability to bind and inhibit CDK6 and to suppress cell growth when compared with the p16(INK4a) allele from the A/J mouse. Here, we report that mice with a heterozygous deficiency for the A/J Cdkn2a allele were significantly more susceptible to lung tumor progression than mice with a heterozygous deficiency for a BALB/cJ Cdkn2a allele, when compared to their respective wild type mice. These results offer strong evidence that naturally occurring variation of p16(INK4a) influences susceptibility to enhance lung tumor progression making it a strong candidate for the lung tumor progression locus, Papg-1.	Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA; Amer Hlth Fdn, Valhalla, NY 10595 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; American Health Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	You, M (corresponding author), Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, 420 W 12th Ave, Columbus, OH 43210 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [R01CA78797, R01CA58554, P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058554, P30CA016058, R01CA078797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERVONT HB, 1938, PUBLIC HLTH REP, V53, P232; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; Herzog CR, 1997, J CELL BIOCHEM, P49; HERZOG CR, 1994, CANCER RES, V54, P4007; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1997, CANCER RES, V57, P4164; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; QUELLE DE, 1995, CELL, V83, P993; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1992, GENET EPIDEMIOL, V9, P261, DOI 10.1002/gepi.1370090405; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIMKIN MB, 1955, ADV CANCER RES, V3, P223, DOI 10.1016/S0065-230X(08)60921-5; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XF, 1997, CANCER, V79, P1527, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1527::AID-CNCR13>3.0.CO;2-#; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	32	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5960	5966		10.1038/sj.onc.1205725	http://dx.doi.org/10.1038/sj.onc.1205725			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185599				2022-12-28	WOS:000177520900019
J	Kawamata, N; Sakajiri, S; Sugimoto, K; Isobe, Y; Kobayashi, H; Oshimi, K				Kawamata, N; Sakajiri, S; Sugimoto, K; Isobe, Y; Kobayashi, H; Oshimi, K			A novel chromosomal translocation t(1;14)(q25;q32) in pre-B acute lymphoblastic leukemia involves the LIM homeodomain protein gene, Lhx4	ONCOGENE			English	Article						inverse PCR; transcriptional factor; immunoglobulin heavy chain gene; RT-PCR; reporter gene assay	CHRONIC MYELOGENOUS LEUKEMIA; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; HOMEOBOX GENES; HOX GENE; EXPRESSION; ACTIVATION; LYMPHOMAS; LOCUS; HLH-2	Chromosome 1q21-25 is one of the hotspots of chromosomal abnormalities including translocations and duplications in hematological malignancies. This would suggest that oncogene(s) reside in this region. We have cloned the junctional sequence of t(1;14)(q25;q32) in preB acute lymphoblastic leukemia cells by an inverse PCR method. A novel sequence was fused to the joining region of the immunoglobulin heavy chain gene. We confirmed this rearrangement by Southern blot analysis, genomic PCR and fluorescence in situ hybridization. We found a coding sequence which is homologous to the mouse Lhx4 cDNA sequence 17 kb from the breakpoint. The human Lhx4 gene encodes 390 amino-acids, including one tandem pair of LIM domains and one homeodomain. The human Lhx4 gene consists of six exons. Lhx4 protein is very homologous to human Lhx3 protein except in the N-terminal region. The transcripts of the Lhx4 gene were not detected in adult multiple tissues analysed by Northern blotting, but were detected in the leukemic cells carrying t(1;14)(q25;q32) by reverse-transcription PCR. The protein expression of Lhx4 in these leukemic cells was confirmed by Western blot analysis. Lhx4 activated the reporter gene carrying the mouse alpha-glycoprotein subunit promoter region, which is regulated by Lhx3. LIM protein and homeodomain protein genes are frequently involved in translocations of hematological malignancies. The Lhx4 gene is deregulated in the leukemic cells and Lhx4 protein may play an important role, possibly as an activator, in leukemogenesis.	Juntendo Univ, Sch Med, Dept Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan; Saitama Canc Ctr, Dept Med, Div Hematol, Ina, Saitama 3620806, Japan	Juntendo University	Kawamata, N (corresponding author), Juntendo Univ, Sch Med, Dept Med, Div Hematol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.			Sugimoto, Keiji/0000-0001-9835-5405				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Buske C, 2000, INT J HEMATOL, V71, P301; Dawid IB, 2001, NEURON, V30, P301, DOI 10.1016/S0896-6273(01)00307-5; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; De Vita VT, 2001, CANC PRINCIPLES PRAC; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Jin L, 1998, ENDOCR PATHOL, V9, P169, DOI 10.1007/BF02782609; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KOBAYASHI H, 1994, BLOOD, V84, P3473; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Liu YB, 2002, BRAIN RES, V928, P147, DOI 10.1016/S0006-8993(01)03243-7; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Machinis K, 2001, AM J HUM GENET, V69, P961, DOI 10.1086/323764; MIKI T, 1994, BLOOD, V83, P217; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nowell PC, 1997, CANCER GENET CYTOGEN, V94, P13, DOI 10.1016/S0165-4608(96)00227-0; Popescu NC, 1997, CANCER GENET CYTOGEN, V93, P10, DOI 10.1016/S0165-4608(96)00262-2; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sloop KW, 1999, MOL ENDOCRINOL, V13, P2212, DOI 10.1210/me.13.12.2212; Sloop KW, 2001, J BIOL CHEM, V276, P36311, DOI 10.1074/jbc.M103888200; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wu HK, 1997, BIOCHEM BIOPH RES CO, V234, P742, DOI 10.1006/bbrc.1997.6592; Wu HK, 1996, ONCOGENE, V12, P1205	35	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4983	4991		10.1038/sj.onc.1205628	http://dx.doi.org/10.1038/sj.onc.1205628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118377				2022-12-28	WOS:000176874800013
J	Sugiyama, T; Shimizu, S; Matsuoka, Y; Yoneda, Y; Tsujimoto, Y				Sugiyama, T; Shimizu, S; Matsuoka, Y; Yoneda, Y; Tsujimoto, Y			Activation of mitochondrial voltage-dependent anion channel by a pro-apoptotic BH3-only protein Bim	ONCOGENE			English	Article						VDAC; Bcl-2; Bim; apoptosis; mitochondria	CYTOCHROME-C RELEASE; BCL-2 FAMILY MEMBERS; PERMEABILITY TRANSITION PORE; CELL-DEATH; YEAST MITOCHONDRIA; INDUCE APOPTOSIS; MAMMALIAN-CELLS; BAX; MEMBRANE; VDAC	Bcl-2 family of proteins regulates apoptosis by controlling mitochondrial membrane permeability. We have previously shown that the voltage-dependent anion channel (VDAC) plays a crucial role in apoptotic changes of the mitochondria and its activity is directly regulated by some Bcl-2 family members, including Bcl-2/Bcl-X-L and Bax/Bak but not Bid. Here, we showed that in isolated mitochondria, Bim induced loss of membrane potential and cytochrome c release like Bax/Bak, with these changes being inhibited by an anti-VDAC antibody. In addition, microinjection of the anti-VDAC antibody significantly reduced Bim-induced apoptosis. Study using purified proteins indicated that Bim directly interacts with the VDAC. Immunoprecipitation analysis revealed that Bim interacts with the VDAC and the interaction is remarkably enhanced during apoptosis. An experiment using liposomes indicated that Bim enhanced VDAC activity, as did Bax/Bak. Furthermore, Bim (but not tBid) was able to induce apoptotic changes of yeast mitochondria in a VDAC-dependent manner, and also induced the lysis of red blood cells, with this effect being inhibited by the anti-VDAC antibody. These results indicate that Bim has an ability to activate directly the VDAC, which plays an important role in apoptosis of mammalian cells.	Osaka Univ, Grad Sch Med, Mol Genet Lab, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Mol Genet Lab, Room B8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Sugiyama, Tomoyasu/0000-0001-5704-6606				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	43	103	126	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4944	4956		10.1038/sj.onc.1205621	http://dx.doi.org/10.1038/sj.onc.1205621			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118373				2022-12-28	WOS:000176874800009
J	Loden, M; Stighall, M; Nielsen, HN; Roos, G; Emdin, SO; Ostlund, H; Landberg, G				Loden, M; Stighall, M; Nielsen, HN; Roos, G; Emdin, SO; Ostlund, H; Landberg, G			The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node	ONCOGENE			English	Article						breast cancer; cell cycle; cyclins; cdk-inhibitors; pRb pathway; proliferation	CELL-CYCLE; RETINOBLASTOMA PROTEIN; TUMOR PROLIFERATION; EXPRESSION; P53; DEREGULATION; P27(KIP1); G(1); MARKERS; FAMILY	In an attempt to identify subtypes of breast cancer and pinpoint patterns of cell cycle regulatory defects associated with clinical behaviour, proliferation and other transformation associated events, a multitude of cell cycle regulatory proteins were analysed in a material of 113 primary breast cancers. Increased proliferation was observed in two different scenarios; (1) with high cyclin D1 and elevated retinoblastoma protein (pRb) phosphorylation, (cyclin D1(high) tumours) or (2) with high cyclin E protein but low cyclin D1 and lack of corresponding pRb phosphorylation (cyclin E high tumours) indicative of an interrupted pRb pathway. Characteristic for cyclin E-high tumours were further defects in p53, p27 and bcl-2, while c-erbB2 overexpression and c-myc amplification was found in both cyclin D1(high) and E-high tumours. Using transfected cell lines overexpressing cyclin E, cyclin E-high and D1(high) tumours were mimicked and the cyclin D1(high) cell line normalized the cyclin E kinase activity by an induction and redirection of p21 and p27 to the cyclin E complex whereas cyclin E-high cell lines obtained increased kinase activity with out redirection or inhibitors. Based on differences in genetic aberrations as well as function of the pRb node we therefore propose a model in which cyclin D1(high) and cyclin E-high tumours represent two alternative mechanisms to inactivate the pRb pathway and thereby achieve unrestrained growth in the tumorogenesis of breast cancer.	Lund Univ, Malmo Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden; Umea Univ, Dept Pathol, S-90187 Umea, Sweden; Umea Univ, Dept Oncol, S-90187 Umea, Sweden; Umea Univ, Dept Surg, S-90187 Umea, Sweden	Lund University; Skane University Hospital; Umea University; Umea University; Umea University	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se						Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BOSARI S, 1995, VIRCHOWS ARCH, V427, P229; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jares P, 1997, J PATHOL, V182, P160; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang GJ, 1997, CLIN CANCER RES, V3, P2329; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	48	89	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4680	4690		10.1038/sj.onc.1205578	http://dx.doi.org/10.1038/sj.onc.1205578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096344				2022-12-28	WOS:000176625100009
J	Clark, PA; Llanos, S; Peters, G				Clark, PA; Llanos, S; Peters, G			Multiple interacting domains contribute to p14(ARF) mediated inhibition of MDM2	ONCOGENE			English	Article						p53; tumour suppressor; INK4a/ARF; MDM2; nucleolus	TUMOR-SUPPRESSOR; NUCLEOLAR LOCALIZATION; P53; ARF; MUTATIONS; LOCUS; DEGRADATION; P16(INK4A); PROMOTES; P19(ARF)	The small basic protein p14(Arf), encoded by one of the alternative transcripts from the human INK4A/ARF locus, interferes with MDM2-mediated ubiquitination of the p53 tumour suppressor protein. The resultant stabilization of p53 leads to increased expression of p53-regulated genes, such as MDM2 itself and the cyclin-dependent kinase inhibitor p21(CIP1). Here we relate physical interactions between p][4111 and MDM2, as determined using synthetic peptides and systematic deletions of p14(Arf), with consequential effects on p53 stabilization and transcriptional activity. The data imply that the amino terminal half of p14(Arf), encoded by the alternative first exon (exon 1beta) contacts MDM2 through multiple domains that can independently impede MDM2-mediated degradation of p53, provided that they are localized in the cell nucleus. As well as identifying previously unrecognized functional domains, our findings offer an explanation for the relative paucity of missense mutations in exon 1beta in human tumours.	London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, 61 Lincolns Inn Fields, London WC2A 3PX, England.	g.peters@cancer.org.uk	, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BATES S, 1994, ONCOGENE, V9, P1633; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	35	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4498	4507		10.1038/sj.onc.1205558	http://dx.doi.org/10.1038/sj.onc.1205558			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085228				2022-12-28	WOS:000176476700004
J	Calvo, KR; Sykes, DB; Pasillas, MP; Kamps, MP				Calvo, KR; Sykes, DB; Pasillas, MP; Kamps, MP			Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1	ONCOGENE			English	Article						Hoxa9; Nup98-HoxA9; Meis1; leukaemia; AML	NUP98/HOXA9 FUSION TRANSCRIPT; CHRONIC MYELOGENOUS LEUKEMIA; HOMEOBOX GENE; DNA-BINDING; NUP98 GENE; T(7-11)(P15-P15); PROTEINS; CELLS; TRANSLOCATION; MICE	The association between acute myeloid leukaemia (AML) and the aberrant expression of Hoxa9 is evidenced by (1) proviral activation of Hoxa9 and Meis1 in BXH-2 murine AML, (2) formation of the chimeric Nup98-HoxA9 transactivator protein as a consequence of the t(7;11) translocation in human AML, and (3) the strong expression of HoxA9 and Meis1 in human AML. In mouse models, enforced retroviral expression of Hoxa9 alone in marrow is not sufficient to cause rapid AML, while co-expression of Meis1 and Hoxa9 induces rapid AML. In contrast, retroviral expression of Nup98-HoxA9 is sufficient to cause rapid AML in the absence of enforced Meis1 expression. Previously, we demonstrated that Hoxa9 could block the differentiation of murine marrow progenitors cultured in granulocyte-macrophage colony-simulating factor (GM-CSF). These progenitors lacked Meis1 expression, could not proliferate in stem cell factor (SCF), but could differentiate into neutrophils when switched into granulocyte colony-simulating factor (G-CSF). Ectopic expression of Meis1 in these Hoxa9 cells suppressed their G-CSF-induced differentiation, permitted proliferation in SCF, and therein offered a potential explanation of cooperative function. Because Meis1 binds N-terminal Hoxa9 sequences that are replaced by Nup98, we hypothesized that Nup98-HoxA9 might consolidate the biochemical functions of both Hoxa9 and MOO on target gene promoters and might evoke their same lymphokine-responsive profile in immortalized progenitors. Here we report that Nup98-HoxA9, indeed mimicks Hoxa9 plus Meis1 coexpression - it immortalizes myeloid progenitors, prevents differentiation in response to GM-CSF, IL-3, G-CSF, and permits proliferation in SCF. Unexpectedly, however, Nup98-Hoxa9 also enforced strong transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes at levels similar to those found in mouse AML's generated by proviral activation of Hoxa9 and Meis1. Using Hoxa9(-/-) marrow, we demonstrate that expression of Hoxa9 is not required for myeloid immortalization by Nup98-HoxA9. Rapid leukaemogenesis by Nup98-HoxA9 may therefore result from both the intrinsic functions of Nup98-HoxA9, as well as of those of coexpressed HOX and MEIS1 genes.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kamps, MP (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Calvo, Katherine/A-8109-2009	Calvo, Katherine/0000-0002-0771-4191	NATIONAL CANCER INSTITUTE [R01CA056876, P30CA023100, T32CA077109] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876, CA77109-01, 5P0CA23100-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HG, 2001, GENE CHROMOSOME CANC, V30, P410, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1108>3.0.CO;2-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 2001, P NATL ACAD SCI USA, V98, P13120, DOI 10.1073/pnas.231115398; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fujino T, 2002, BLOOD, V99, P1428, DOI 10.1182/blood.V99.4.1428; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hatano Y, 1999, BRIT J HAEMATOL, V107, P600, DOI 10.1046/j.1365-2141.1999.01754.x; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Yamamoto K, 2000, BRIT J HAEMATOL, V109, P423, DOI 10.1046/j.1365-2141.2000.02003.x	28	97	104	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4247	4256		10.1038/sj.onc.1205516	http://dx.doi.org/10.1038/sj.onc.1205516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082612				2022-12-28	WOS:000176174200007
J	Qanungo, S; Basu, A; Das, M; Haldar, S				Qanungo, S; Basu, A; Das, M; Haldar, S			2-methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells	ONCOGENE			English	Article						apoptosis; mitochondria; 2-methoxyestradiol; pancreatic cancer	ENDOGENOUS MAMMALIAN METABOLITE; WILD-TYPE P53; ESTROGEN METABOLITE; CYTOCHROME-C; INHIBITS ANGIOGENESIS; BCL2 PHOSPHORYLATION; ACTIVATION; GROWTH; PATHWAY; ARREST	The antiproliferative action of 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite is specific for cancer cells and is mediated by the induction of programmed cell death or apoptosis. But the identity of the downstream effectors of apoptotic signaling induced by 2-ME is not known. In the present study, we explored the effect of 2-ME on apoptosis in a panel of human pancreatic cancer cell lines. We have identified two categories of pancreatic cancer cell lines, which are either sensitive to 2-ME such as MIA PaCa-2, CFPAC-1, PANC-1, or non-sensitive to 2-ME such as Hs 766T. The results presented here indicated that the cell lines responsive to 2-ME could undergo apoptosis either by G2-M arrest (PANC-1) with Bcl-X-L phosphorylation or by the accumulation of tetraploid cells in G1-S region (MIA PaCa-2) without Bcl-2/Bcl-X-L phosphorylation. Furthermore, 2-ME induced apoptosis in pancreatic cancer cells is mitochondria dependent as evident by the release of cytochrome c into the cytosol. 2-ME exposed cells exhibit Bid cleavage that is accompanied by the translocation of Bax into the mitochondria. Also 2-ME could induce phosphorylation of Bcl-X-L in G2-M arrested cells, thus indicating the involvement of various anti- and pro-apoptotic regulators in the signaling cascade. The dissection of differential response of pancreatic cancer cell lines holds promise for future therapeutic intervention.	Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System	Haldar, S (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, R456,Rammelkamp Bldg,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	Shaldar@metrohealth.org			NATIONAL CANCER INSTITUTE [R01CA077328] Funding Source: NIH RePORTER; NCI NIH HHS [CA77328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANDREAS G, 2000, CANCER RES, V60, P2163; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Basu A, 1998, INT J ONCOL, V13, P659; BASU A, 2002, IN PRESS NEOPLASIA, V4; Brady H J, 1999, Results Probl Cell Differ, V23, P127; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Denmeade S R, 1997, Adv Pharmacol, V41, P553, DOI 10.1016/S1054-3589(08)61072-8; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Huober JB, 2000, INT J RADIAT ONCOL, V48, P1127, DOI 10.1016/S0360-3016(00)00767-7; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; KARPINICH NO, 2002, IN PRESS J BIOL CHEM; KATOTAKA M, 1998, CANCER RES, V58, P4761; KHAN P, 1979, J CELL BIOL, V82, P1; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; Lottering ML, 1996, CANCER LETT, V110, P181, DOI 10.1016/S0304-3835(96)04489-8; MacCarthy-Morrogh L, 2000, CANCER RES, V60, P5441; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MARTUCCI CP, 1979, ENDOCRINOLOGY, V105, P1288, DOI 10.1210/endo-105-6-1288; MARTUCCI CP, 1983, CATECHOL ESTROGENS, P115; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schumacher G, 1999, CLIN CANCER RES, V5, P493; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; VANDERHEIDE MG, 2001, NATURE CELL BIOL, V1, pE209; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wassberg E, 1999, UPSALA J MED SCI, V104, P1; Wassberg E, 1999, AM J PATHOL, V154, P395, DOI 10.1016/S0002-9440(10)65286-8; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoubine MN, 1999, INT J ONCOL, V15, P639	60	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4149	4157		10.1038/sj.onc.1205508	http://dx.doi.org/10.1038/sj.onc.1205508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037671	Bronze			2022-12-28	WOS:000176186000009
J	Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E				Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E			Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors	ONCOGENE			English	Article						Apo2L/TRAIL; CPT-11; SN-38; p21; DR4; DR5	APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; IONIZING-RADIATION; ANTITUMOR-ACTIVITY; COMPLEX-FORMATION; CANCER-CELLS; CASPASE 3; DEATH; INDUCTION; P53	Apo2L/TRAIL exhibits enhanced apoptotic activity in tumor xenograft models when used in combination with the topoisomerase 1 inhibitor CPT-11. To investigate the cellular mechanisms involved in this increased tumor-killing activity, a series of in vitro experiments were conducted using the human colon carcinoma cell line (HCT116). Apo2L/TRAIL induced a transient upregulation of DR5 mRNA, while CPT-11 increased both death and decoy receptor expression. Upregulation of decoy receptors by CPT-11 was partially inhibited by co-administration of Apo2L/TRAIL. CPT-11 treatment resulted in accumulation of cells at G(2)M-phase and correlated with a substantial increase in the protein levels of the cyclin-dependent kinase inhibitor p21. However, cells co-treated with CPT-11 and Apo2L/TRAIL, or pretreated with CPT-11 for up to 24 h followed by 2 h Apo2L/TRAIL, resulted in a caspase-dependent degradation of p21, reversal of G(2)-M phase arrest with a concomitant increase in apoptosis. The sequential treatment produced the greatest induction of DR5 and DR4, caspase-3-like cleavage/activation and p21 degradation, as well as increased apoptosis. These data indicate that the up-regulation of Apo2L/TRAIL ligand and its death receptors as well as cleavage of p21 protein in the Apo2L/TRAIL plus CPT-11 treatment contributes to the positive cooperation between these agents in enhancing tumor cell apoptosis.	Genentech Inc, Dept Clin & Expt Pharmacol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept BioAnalyt R&D, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Escandon, E (corresponding author), Genentech Inc, Dept Clin & Expt Pharmacol, 1 DNA Way, San Francisco, CA 94080 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Choi SH, 1998, CANCER LETT, V124, P15, DOI 10.1016/S0304-3835(97)00428-X; Deptala A, 1999, INT J ONCOL, V15, P861; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farczadi E, 1999, NEOPLASMA, V46, P219; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HARPER JW, 1993, CELL, V75, P805; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; McDonald AC, 1998, BRIT J CANCER, V78, P745, DOI 10.1038/bjc.1998.571; Nagane M, 2000, CANCER RES, V60, P847; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sheikh MS, 1998, CANCER RES, V58, P1593; Sparreboom A, 1998, CLIN CANCER RES, V4, P2747; Strasser A, 1999, INT J CANCER, V81, P505, DOI 10.1002/(SICI)1097-0215(19990517)81:4<505::AID-IJC1>3.0.CO;2-J; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; TISHLER RB, 1993, CANCER RES, V53, P2212; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	42	46	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3611	3619		10.1038/sj.onc.1205449	http://dx.doi.org/10.1038/sj.onc.1205449			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032863				2022-12-28	WOS:000175793700012
J	Giovino, GA				Giovino, GA			Epidemiology of tobacco use in the United States	ONCOGENE			English	Review						epidemiology; tobacco use; cigarette smoking	CIGARETTE-SMOKING; TEENAGE SMOKING; INDUSTRY; YOUTH; CARCINOMA; PREVALENCE; CESSATION; CAMPAIGN; HEALTH; IMPACT	Efforts to understand trends in and patterns of lung cancer are well served by studies of trends in and patterns of tobacco use. In the United States, the manufactured cigarette emerged as the tobacco product of choice shortly after the turn of the twentieth century. Lung cancer emerged after years of inhalation of cigarette smoke, first among men and then among women. The massive public health education campaign that began after scientists recognized the dangers of cigarette smoking has contributed to large reductions in cigarette use and subsequent smoking-attributable morbidity and mortality. Since 1965, the prevalence of cigarette smoking among US adults has declined by almost half, with positive trends observed among persons in almost all sociodemographic groups and efforts to reduce disparities recognized as an important goal in public health. An epidemiologic approach to understanding and controlling patterns of tobacco use is proposed. The model focuses on the agent (tobacco products), host (consumer or potential consumer), vector (tobacco companies and other users), and environment (with influences from families, social sources, culture, history, politics, law, and media). Accelerating progress in reducing tobacco use will accelerate reductions in tobacco-attributable morbidity and mortality.	Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Giovino, GA (corresponding author), Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Elm & Carlton St, Buffalo, NY 14263 USA.	Gary.Giovino@RoswellPark.org			NCI NIH HHS [P30 CA16056-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos A, 2000, TOB CONTROL, V9, P3, DOI 10.1136/tc.9.1.3; Anda RF, 1999, JAMA-J AM MED ASSOC, V282, P1652, DOI 10.1001/jama.282.17.1652; BACHMAN J, 1993, MONITORING FUTURE QU; Bachman J. G., 1980, MONITORING FUTURE QU; Bachman JG., 2001, MONITORING FUTURE QU; Bachman JG, 1981, MONITORING FUTURE QU; Balbach ED, 1995, AM J PUBLIC HEALTH, V85, P1650, DOI 10.2105/AJPH.85.12.1650; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; Bondurant, 2001, CLEARING SMOKE ASSES; Burns D. M., 1997, SMOKING TOBACCO CONT, P13; Burton S L, 2000, MMWR Morb Mortal Wkly Rep, V49, P665; *CAL ENV PROT AG, 1997, HLTH EFF EXP ENV TOB; Caraballo RS, 2001, AM J EPIDEMIOL, V153, P807, DOI 10.1093/aje/153.8.807; *CDCP, 1999, BEST PRACT COMP TOB; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P300; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P409; *CDCP, 2001, MMWR SS, V50, P4; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P342; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P986; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1101; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P925; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P869; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1107; Chaloupka FJ, 2002, TOB CONTROL, V11, pI62, DOI 10.1136/tc.11.suppl_1.i62; Chapman S, 1999, AM J PUBLIC HEALTH, V89, P1018, DOI 10.2105/AJPH.89.7.1018; Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142; Cummings KM, 2002, TOB CONTROL, V11, pI5, DOI 10.1136/tc.11.suppl_1.i5; CUMMINGS KM, 2002, TOB CONTROL S1, V11, pI220; CUMMINGS KM, 2002, ONCOGENE REV; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; EVERETTJONES S, 2002, TOB CONTROL, V11, P20; Fant RV, 1999, TOB CONTROL, V8, P387, DOI 10.1136/tc.8.4.387; Farrelly MC, 2002, AM J PUBLIC HEALTH, V92, P901, DOI 10.2105/AJPH.92.6.901; FIORE MC, 2000, TREATING TOBACCO USE; *FTC, 2001, CIG REP 1999; Gfroerer J, 1997, DRUG ALCOHOL DEPEN, V47, P19, DOI 10.1016/S0376-8716(97)00063-X; GIOBINO GA, 1994, MMWR SURV SUM, V43, P31; Giovino G, 2000, PREVALENCE SELECTED; Giovino G A, 1999, Nicotine Tob Res, V1 Suppl 1, pS31, DOI 10.1080/14622299050011571; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HAZAN AR, 1995, AM J PUBLIC HEALTH, V85, P116, DOI 10.2105/AJPH.85.1.116; Hurt RD, 1998, JAMA-J AM MED ASSOC, V280, P1173, DOI 10.1001/jama.280.13.1173; Jacobson PD., 2001, REGULATING TOBACCO, P207; JAMIESON KH, 1998, TAX SPEND LITTLE KID; Johnston L. D., 1997, MONITORING FUTURE QU; JOHNSTON LD, 1986, MONITORING FUTURE QU; KENDRICK JS, 1995, AM J PUBLIC HEALTH, V85, P217, DOI 10.2105/AJPH.85.2.217; Kluger R, 1996, ASHES ASHES AMERICAS; KOZLOWSKI L, 2002, NICOTINE PUBLIC HLTH, V11, pI40; KOZLOWSKI LT, 2000, NICOTINE PUBLIC HLTH; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; Lopez AD, 1994, TOB CONTROL, V3, P242, DOI [DOI 10.1136/TC.3.3.242, 10.1136/tc.3.3.242]; McMahon R J, 1999, Nicotine Tob Res, V1 Suppl 2, pS45; MILLER L, 1954, READERS DIGEST   JUL, P1; MILMORE B K, 1956, Public Health Monogr, V45, P107; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; MURRAY CJL, 1996, INVESTING RES DEV; *NAT CANC POL BOAR, 2000, STAT PROGR RED TOB U; *NCI, 1997, CIGARS HLTH EFFECTS, V9; *NCI, 2000, TOBACCO RES IMPLEMEN; *NCI, 2001, NIH PUBLICATION, V14; *NCI, 2001, RISKS ASSOCIATED SMO, V13; Nelson DE, 1996, PREV MED, V25, P91, DOI 10.1006/pmed.1996.9999; Noland MP, 1996, ADDICT BEHAV, V21, P349; Norr Roy, 1952, READERS DIG, P738; NOVOTNY TE, 1998, CHRONIC DIS EPIDEMIO, P117; Orleans CT, 1993, NICOTINE ADDICTION P, pix; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; Pauly JL, 2002, TOB CONTROL, V11, pI51, DOI 10.1136/tc.11.suppl_1.i51; Pollay RW, 2000, TOB CONTROL, V9, P136, DOI 10.1136/tc.9.2.136; Pollay RW, 2002, TOB CONTROL, V11, pI18, DOI 10.1136/tc.11.suppl_1.i18; POMERLEAU OF, 1993, J CONSULT CLIN PSYCH, V61, P723, DOI 10.1037/0022-006X.61.5.723; Rabin R. L., 2001, REGULATING TOBACCO; Ries LA, 2002, SEER CANC STAT REV 1; RIGOTTI NA, 2001, REGULATING TOBACCO, P143; Saloojee Y, 2000, B WORLD HEALTH ORGAN, V78, P902; SAMET JM, 1999, ENV TOXICANTS HUMAN; SHOPLAND DR, 1995, LUNG CANCER, P1; SILLETT RW, 1978, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6146.1185; SLADE J, 1989, J PSYCHOACTIVE DRUGS, V21, P281, DOI 10.1080/02791072.1989.10472169; SLADE J, 1993, NICOTINE ADDICTION P, P3; SLADE J, 2001, REGULATING TOBACCO, P72; Slovic P., 2001, SMOKING RISK PERCEPT, DOI 10.4135/9781452232652; Smith SS, 1999, PRIMARY CARE, V26, P433, DOI 10.1016/S0095-4543(05)70112-3; *SUBS AB MENT HLTH, 2001, SUMM FIND 2000 NHSDA; Swedrock TL, 1999, TOB CONTROL, V8, P111, DOI 10.1136/tc.8.1.111; Teti TS, 1998, TOB CONTROL, V7, P441, DOI 10.1136/tc.7.4.441; *TOB I, 1991, TIMN01644224424 TOB; TOLLEY HD, 1991, NIH PUBL, P75; TURNER C, 1992, DHHS PUBLICATION; Tyas SL, 1998, TOB CONTROL, V7, P409, DOI 10.1136/tc.7.4.409; *US DEP LAB, 2002, CONS PRIC IND ALL UR; *US FOOD DRUG ADM, 1996, FED REGISTER, V61, P44395; *USDA, 1994, TOB SIT OUTL REP; *USDA, 1989, DHHS PUBLICATION; *USDA, 1988, HLTH CONS SMOK NIC A; *USDA, 1987, TOB SIT OUTL REP; *USDA, 2002, TOB OUTL; *USDA, 1999, TOB SIT; *USDHHS, 1994, PREV TOB US AM YOUNG; *USDHHS, 2001, WOM TOB REP SURG GEN; *USDHHS, 1990, DHHS PUBLICATION; *USDHHS, 1998, TOB US AM US RAC ETH; *USPHS, 1964, PHS PUBLICATION, V1103; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; VONGERNET A, 2000, NICOTINE PUBLIC HLTH; Wakefield M, 2000, TOB CONTROL, V9, P177, DOI 10.1136/tc.9.2.177; Wakefield MA, 2000, BRIT MED J, V321, P333, DOI 10.1136/bmj.321.7257.333; WALLACE JM, 2002, IN PRESS PUB HLTH RE; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WARNER KE, 1985, HEALTH EDUC QUART, V12, P115, DOI 10.1177/109019818501200111; Wayne GF, 2002, TOB CONTROL, V11, pI32, DOI 10.1136/tc.11.suppl_1.i32; Weinstein ND, 1998, ANN BEHAV MED, V20, P135, DOI 10.1007/BF02884459; World Bank, 1999, CURB EP GOV EC TOB C; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; YEE SL, 2001, SURVEILLANCE EVALUAT; 1953, CONSUMER REPORTS, V18, P58; 1954, CONSUMER REPORTS, V19, P54	124	223	224	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7326	7340		10.1038/sj.onc.1205808	http://dx.doi.org/10.1038/sj.onc.1205808			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379876				2022-12-28	WOS:000178618000006
J	Osada, H; Takahashi, T				Osada, H; Takahashi, T			Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer	ONCOGENE			English	Review						tumor suppressor; oncogene; lung cancer	NON-SMALL-CELL; ENDOTHELIAL GROWTH-FACTOR; RETINOBLASTOMA SUSCEPTIBILITY GENE; RECEPTOR TYROSINE KINASES; MESSENGER-RNA EXPRESSION; MITOTIC CHECKPOINT GENES; MYC FAMILY ONCOGENE; IN-VIVO ALTERATIONS; K-RAS MUTATIONS; PROTEIN EXPRESSION	Lung cancer has become the leading cause of cancer death in many economically well-developed countries. Recent molecular biological studies have revealed that overt lung cancers frequently develop through sequential morphological steps, with the accumulation of multiple genetic and epigenetic alterations affecting both tumor suppressor genes and dominant oncogenes. Cell cycle progression needs to be properly regulated, while cells have built-in complex and minute mechanisms such as cell cycle checkpoints to maintain genomic integrity. Genes in the p16INK4A-RB and p14ARF-p53 pathways appear to be a major target for genetic alterations involved in the pathogenesis of lung cancer. Several oncogenes are also known to be altered in lung cancer, leading to the stimulation of autocrine/paracrine loops and activation of multiple signaling pathways. It is widely acknowledged that carcinogens in cigarette smoke are deeply involved in these multiple genetic alterations, mainly through the formation of DNA adducts. A current understanding of the molecular mechanisms of lung cancer pathogenesis and progression is presented in relation to cigarette smoking, an absolute major risk factor for lung cancer development, by reviewing genetic alterations of various tumor suppressor genes and oncogenes thus far identified in lung cancer, with brief summaries of their functions and regulation.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Barr LF, 2000, CANCER RES, V60, P143; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brognard J, 2001, CANCER RES, V61, P3986; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cagle PT, 1997, AM J PATHOL, V150, P393; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CLINE MJ, 1987, CANCER, V60, P2669, DOI 10.1002/1097-0142(19871201)60:11<2669::AID-CNCR2820601116>3.0.CO;2-4; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cooper CA, 1997, J PATHOL, V181, P401, DOI 10.1002/(SICI)1096-9896(199704)181:4<401::AID-PATH799>3.0.CO;2-Y; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Decaussin M, 1999, J PATHOL, V188, P369; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Fontanini G, 1999, BRIT J CANCER, V79, P363, DOI 10.1038/sj.bjc.6690058; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; GAZZERI S, 1990, CANCER RES, V50, P1566; Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Guo QM, 2000, CANCER RES, V60, P5922; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haruki N, 2000, CANCER RES, V60, P4689; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hatanaka H, 2001, CLIN CANCER RES, V7, P1287; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENSEL CH, 1990, CANCER RES, V50, P3067; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HIBI K, 1992, ONCOGENE, V7, P445; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hussain SP, 2001, CANCER RES, V61, P6350; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kajita T, 2001, BRIT J CANCER, V85, P255, DOI 10.1054/bjoc.2001.1882; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KERN JA, 1990, CANCER RES, V50, P5184; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Konishi H, 2002, CANCER RES, V62, P271; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LADANYI M, 1993, CANCER RES, V53, P16; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Lerman MI, 2000, CANCER RES, V60, P6116; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Marrogi AJ, 2000, CLIN CANCER RES, V6, P4739; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuda A, 2001, AM J PATHOL, V158, P87, DOI 10.1016/S0002-9440(10)63947-8; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; MIYASHITA T, 1995, CELL, V80, P293; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Nadav L, 2001, INT J ONCOL, V19, P237; Nagatake M, 1996, CANCER RES, V56, P2718; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Okami K, 1998, CANCER RES, V58, P509; Osada H, 2001, CANCER RES, V61, P8331; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; RACHWAL WJ, 1995, BRIT J CANCER, V72, P56, DOI 10.1038/bjc.1995.277; REISSMANN PT, 1993, ONCOGENE, V8, P1913; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Robles AI, 2001, CANCER RES, V61, P6660; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; RUSCH V, 1993, CANCER RES, V53, P2379; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SHIRAISHI M, 1989, CANCER RES, V49, P6474; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P67, DOI 10.1053/sonc.2001.28557; Sozzi G, 1997, CANCER RES, V57, P2121; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; *STAT INF DEP MIN, 1999, VIT STAT JAP 1999, V3, P398; SUGIO K, 1994, CANCER RES, V54, P5811; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Takahama M, 1999, CLIN CANCER RES, V5, P2506; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; Tani M, 1997, CARCINOGENESIS, V18, P1119, DOI 10.1093/carcin/18.5.1119; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; Tomizawa Y, 1998, CANCER RES, V58, P5478; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tseng JE, 1999, CANCER RES, V59, P4798; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Uchida K, 1996, CANCER RES, V56, P5583; Urban T, 2000, BRIT J CANCER, V82, P412; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang SSQ, 1999, GENE CHROMOSOME CANC, V25, P154, DOI 10.1002/(SICI)1098-2264(199906)25:2<154::AID-GCC11>3.3.CO;2-N; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINER DB, 1990, CANCER RES, V50, P421; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiao L, 2000, CANCER RES, V60, P400; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1991, CANCER RES, V51, P2735; Yamada KM, 2001, J CELL SCI, V114, P2375; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yano T, 2000, EUR J CANCER, V36, P601, DOI 10.1016/S0959-8049(99)00327-5; Yatabe Y, 1998, CANCER RES, V58, P1042; Yi ES, 1997, MODERN PATHOL, V10, P142; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YOKOTA J, 1988, ONCOGENE, V3, P471; YONEDA K, 1993, HUM PATHOL, V24, P1180, DOI 10.1016/0046-8177(93)90213-Z; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan A, 2000, INT J CANCER, V89, P475, DOI 10.1002/1097-0215(20001120)89:6<475::AID-IJC2>3.0.CO;2-T; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	176	157	171	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7421	7434		10.1038/sj.onc.1205802	http://dx.doi.org/10.1038/sj.onc.1205802			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379883				2022-12-28	WOS:000178618000013
J	Wistuba, II; Mao, L; Gazdar, AF				Wistuba, II; Mao, L; Gazdar, AF			Smoking molecular damage in bronchial epithelium	ONCOGENE			English	Article						smoking; preneoplasia; lung cancer	CELL LUNG CANCERS; ABERRANT PROMOTER METHYLATION; BRONCHOALVEOLAR LAVAGE FLUID; FORMER SMOKERS; RESPIRATORY EPITHELIUM; ONCOGENE MUTATIONS; GENE-EXPRESSION; P53 MUTATION; EARLY-STAGE; PATHOGENESIS	Our understanding of the molecular pathology of lung cancer is advancing rapidly with several specific genes and chromosomal regions being identified. Lung cancer appears to require many mutations in both dominant and recessive oncogenes to possess malignant phenotypes. Several genetic and epigenetic changes are common to all lung cancer histologic types, while others appear to be cell type specific. However, specific roles of the genes undergoing mutations and the order of cumulative molecular changes that lead to the development of each lung tumor histologic type remain to be fully elucidated. Recent findings of molecular abnormalities in normal appearing and preneoplastic bronchial epithelium from patients with lung cancer and chronic smokers suggest that genetic changes may serve as biomarkers for early diagnosis, risk assessment and monitoring response to chemoprevention.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Pontificia Univ Catolica Chile, Dept Anat Pathol, Santiago, Chile; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8-106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Betticher DC, 1997, BRIT J CANCER, V75, P1761, DOI 10.1038/bjc.1997.300; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Colby T V, 1998, Adv Anat Pathol, V5, P205, DOI 10.1097/00125480-199807000-00001; Esteller M, 2001, CANCER RES, V61, P3225; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; Girard L, 2000, CANCER RES, V60, P4894; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hanahan D, 2000, NATURE, V406, P573, DOI 10.1038/35020662; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hittelman WN, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P385; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Lang S M, 2000, Eur J Med Res, V5, P341; Lee JJ, 2001, J NATL CANCER I, V93, P1081, DOI 10.1093/jnci/93.14.1081; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NUORVA K, 1993, AM J PATHOL, V142, P725; Palmisano WA, 2000, CANCER RES, V60, P5954; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Smith AL, 1996, BRIT J CANCER, V73, P203, DOI 10.1038/bjc.1996.36; Soria JC, 2002, CANCER RES, V62, P351; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Toyooka S, 2001, MOL CANCER THER, V1, P61; Viallet J, 1996, J CELL BIOCHEM, P228; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1999, CANCER RES, V59, P1973; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Yashima K, 1997, CANCER RES, V57, P2373; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	49	115	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	2002	21	48					7298	7306		10.1038/sj.onc.1205806	http://dx.doi.org/10.1038/sj.onc.1205806			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379874				2022-12-28	WOS:000178618000004
J	Nayak, BK; Das, GM				Nayak, BK; Das, GM			Stabilization of p53 and transactivation of its target genes in response to replication blockade	ONCOGENE			English	Article						p53; transactivation; p21; replication blockade; hydroxyurea; aphidicolin	TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE; DNA-DAMAGE; ARREST; P21; TRANSCRIPTION; COACTIVATORS; CHECKPOINT; MODULATION; APOPTOSIS	Although it is clear that p53 plays a pivotal role in G1/G2 checkpoints to conserve genomic integrity, its role in S phase checkpoint is less well understood. Recently, it has been reported that p53 is transcriptionally impaired even though it is stabilized during replication blockade. However, the mechanisms underlying this phenomenon are not known. In the present study, it has been shown that p53 accumulates and transactivates its target genes such as p21, gadd45 and bax in response to replication blockade in normal and cancer cells. Lack of transcriptional activation under similar conditions in cells lacking p53 shows that p53-target gene activation during replication blockade is indeed p53-dependent. Further, transactivation of p21 in response to replication blockade by hydroxyurea and aphidicolin is similar to that in response to ionizing radiation except that the latter is more immediate compared to the response to replication blockade. These findings suggest that impairment of transcriptionally active p53 in response to replication blockade is not a general phenomenon.	Univ Texas, Hlth Sci Ctr, Dept Surg, Mol Oncol Res Program, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Das, GM (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.		Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093	NCI NIH HHS [R01 CA079911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ji C, 1997, ONCOGENE, V15, P2749, DOI 10.1038/sj.onc.1201441; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	29	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7226	7229		10.1038/sj.onc.1205889	http://dx.doi.org/10.1038/sj.onc.1205889			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370812				2022-12-28	WOS:000178504600010
J	Xie, SH; Lin, H; Sun, T; Arlinghaus, RB				Xie, SH; Lin, H; Sun, T; Arlinghaus, RB			Jak2 is involved in c-Myc induction by Bcr-Abl	ONCOGENE			English	Article						Philadelphia chromosome leukemia; Bcr-Abl oncoprotein; Jak2 tyrosine kinase; c-Myc induction	NF-KAPPA-B; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; STAT5 ACTIVATION; FACTOR-RECEPTOR; KINASE-ACTIVITY; FUSION PROTEIN; MYELOID CELLS	We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of Bcr-Abl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by Bcr-Abl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bbeta is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bbeta. Expression of the SH2-Bbeta R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672, CA 49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Miyamoto N, 2001, LEUKEMIA, V15, P1758, DOI 10.1038/sj.leu.2402260; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Okuda K, 1998, BLOOD, V92, P3848, DOI 10.1182/blood.V92.10.3848.422k44_3848_3856; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHUI K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WilsonRawls J, 1996, CANCER RES, V56, P3426; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	44	111	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7137	7146		10.1038/sj.onc.1205942	http://dx.doi.org/10.1038/sj.onc.1205942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370803				2022-12-28	WOS:000178504600001
J	Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M				Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M			The mechanism involved in the regulation of phospholipase C gamma 1 activity in cell migration	ONCOGENE			English	Article						cell motility; epidermal growth factor; phosphoinositide 3-kinase; phospholipase C; pleckstrin homology domain	FOCAL ADHESION KINASE; C-GAMMA; GROWTH-FACTOR; TUMOR-SUPPRESSOR; ACTIVATION; MOTILITY; DOMAIN; OVEREXPRESSION; IDENTIFICATION; INHIBITION	Activation of the enzyme phospholipase C (PLC) leads to the formation of second messengers inositol 1,4,5-trisphosphate and diacylglycerol. Tyrosine kinase receptors activate this reaction through PLCgamma isoenzymes. PLCgamma activity involves its activation with, and phosphorylation by, receptor tyrosine kinases. Recently, it has been shown that phosphoinositide 3-kinase (PI 3-K) may regulate PLCgamma activity through the interaction of the PI 3-K product phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3) and the PLCgamma pleckstrin homology (PH) domain. In an effort to understand the signalling pathway that involves PI 3-K regulation of PLCgamma, we found that EGF induces a PI 3-K-dependent translocation of PLCgamma1 at the leading edge of migrating cells in a wound healing assay. Similarly, the isolated PH, but not the Src-homology (SH) domains, N-SH2 or SH3, of PLCgamma1, translocates at the leading edge. Our experiments also showed that stable PH PLCgamma1 expression blocks epidermal growth factor (EGF)- and serum-induced cell motility and increases cell adhesion in MDA-MB-231 cells. This may suggest that influence of PI 3-K on PLCgamma1 could be relevant in cell migration, where PLCgamma1 seems to play a key role by modulating a series of events involved in actin polymerization.	Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Univ G DAnnunzio, Dept Drug Sci, Lab Cellular Physiol, I-66100 Chieti, Italy; UCL, Sackler Inst, London WC1E 6JJ, England	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of London; University College London	Falasca, M (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, Via Vestini 1, I-66100 Chieti, Italy.	m.falasca@ucl.ac.uk	Mariggiò, Maria Addolorata/T-9047-2017; Falasca, Marco/S-4020-2016	Mariggiò, Maria Addolorata/0000-0001-5306-7143; Falasca, Marco/0000-0002-9801-7235; Mariggio, Maria Addolorata/0000-0002-3508-8706				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chang JS, 1997, CANCER RES, V57, P5465; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; LI J, 1997, SCIENCE, V275, P1876; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; NOMOTO K, 1995, MOL CARCINOGEN, V12, P146, DOI 10.1002/mc.2940120306; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Price JT, 1999, CANCER RES, V59, P5475; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SODERQUIST AM, 1992, CANCER RES, V52, P4526; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Turner T, 1997, CLIN CANCER RES, V3, P2275; Wells A, 2000, ADV CANCER RES, V78, P31; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	32	86	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6520	6529		10.1038/sj.onc.1205821	http://dx.doi.org/10.1038/sj.onc.1205821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226755				2022-12-28	WOS:000177925300012
J	Johnson, KC; Kissil, JL; Fry, JL; Jacks, T				Johnson, KC; Kissil, JL; Fry, JL; Jacks, T			Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene	ONCOGENE			English	Article						Nf2; merlin; dominant-negative; transformation; contact inhibition	NEUROFIBROMATOSIS TYPE-2 GENE; MERLIN; PRODUCT; PROTEIN; GROWTH; ACTIN; EXPRESSION; COLOCALIZES; MEMBRANE; ADHESION	Mutations in the Nf2 tumor suppressor gene lead to tumor formation in humans and mice and cellular overproliferation phenotypes in Drosophila. The Nf2 encoded protein, merlin, shares close sequence similarity in its amino terminus to members of the band 4.1 family of membrane-cytoskeletal linkers. Similarities between merlin and this family suggest a role for merlin in regulating cytoskeletal function. However, the mechanism of the tumor suppressing activity of merlin is not yet understood. Mutational analysis of Nf2 in flies has led to the identification of a dominant-negative allele, which harbors mutations in the amino terminus of the protein. Here, we report that expression of a murine analog of this amino-terminal mutant of Nf2 leads to complete transformation of NIH3T3 fibroblasts in culture. Cells that express this Nf2 mutant allele display disruptions of the actin cytoskeleton, lack of contact inhibition of growth, and anchorage-independent growth. Finally, fibroblasts that express this mutant Nf2 allele form tumors when injected into nude mice.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu		Fry, Jessica/0000-0003-2748-0334				FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Harwalkar JA, 1998, AM J OTOL, V19, P654; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MCCLATCHEY AI, 2001, GENE DEV, V12, P1121; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sainio M, 1997, J CELL SCI, V110, P2249; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	34	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					5990	5997		10.1038/sj.onc.1205693	http://dx.doi.org/10.1038/sj.onc.1205693			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203111				2022-12-28	WOS:000177671300002
J	Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R				Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R			Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines	ONCOGENE			English	Article						She family proteins; anaplastic lymphoma kinase (ALK); constitutive phosphorylation; neuroblastoma; gene amplification	NON-HODGKINS-LYMPHOMA; PHOSPHOTYROSINE BINDING DOMAIN; RECEPTOR TYROSINE KINASE; HUMAN N-MYC; ADAPTER PROTEIN; MAMMARY TUMORIGENESIS; TRANSFORMING ACTIVITY; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION	She family of docking proteins, ShcA, Shell and ShcC, play roles in cellular signal transduction by binding to phosphotyrosine residues of various activated receptor tyrosine kinases. Both Shell and ShcC proteins are selectively expressed in the neural system of adult mouse tissues. In most of neuroblastoma cells, obvious tyrosine phosphorylation of ShcC was observed, whereas expression of ShcB was considerably low. Phosphoproteins associated with hyperphosphorylated ShcC were purified from neuroblastoma cell lines, and identified by mass-spectrometry. Anaplastic lymphoma kinase (ALK), which turned out to be one of these phosphoproteins, was constitutively activated and associated with the PTB domain of ShcC in three neuroblastoma cells. In vitro kinase assay revealed that ShcC is a potent substrate of the activated ALK kinase. The ALK gene locus was significantly amplified in both of these cell lines, suggesting that gene amplification leads to constitutive activation of the ALK kinase, which results in hyperphosphorylation of ShcC. Constitutive activation of ALK appeared to interfere with signals from other receptor tyrosine kinases. ALK-ShcC signal activation, possibly caused. by co-amplification with the N-myc gene, might give additional effects on malignant tumor progression of neuroblastoma.	Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuo Ku, Tokyo 1040045, Japan; Kirin Brewery Co Ltd, Lab Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Meiji Pharm Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Kirin Brewery Company Limited; Meiji Pharmaceutical University; Kitasato University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, 5-1-1 Tsukuji, Tokyo 1040045, Japan.			Sakai, Ryuichi/0000-0001-6833-1103				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; George RE, 1996, ONCOGENE, V12, P1583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; KUGA N, 1975, GANN, V66, P547; Lai KMV, 2000, GENE DEV, V14, P1132; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LAYFIELD LJ, 1995, J SURG ONCOL, V59, P21, DOI 10.1002/jso.2930590107; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nojiri H, 1999, FEBS LETT, V453, P140, DOI 10.1016/S0014-5793(99)00709-7; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; OLE NJ, 1996, RAPID COMMUN MASS SP, V10, P1371; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, J BIOL CHEM, V269, P32740; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SOUTHERN EM, 1975, J MOL BIOL, V94, P51, DOI 10.1016/0022-2836(75)90404-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGIMOTO T, 1984, J NATL CANCER I, V72, P923; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287	54	91	96	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5823	5834		10.1038/sj.onc.1205735	http://dx.doi.org/10.1038/sj.onc.1205735			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185581				2022-12-28	WOS:000177520900001
J	Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A				Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A			Rare mutations of the DMBT1 gene in human astrocytic gliomas	ONCOGENE			English	Article						DMBT1; mutation; glioblastoma; pilocytic astrocytoma	TUMORS; PTEN; PROGRESSION; EXPRESSION; CANCER	The Deleted in Malignant Brain Tumors I gene (DMBT1) has been proposed as a tumor suppressor gene candidate in human brain tumors, based on the observation of homozygous deletions affecting the DMBT1 region or part of the gene. In order to support this hypothesis, we performed a mutational analysis of the entire coding region of DMBT1, employing SSCP analysis and direct DNA sequencing in a series of 79 astrocytic gliomas. Five somatic mutations were detected. Two mutations, one of which resulted in an amino acid exchange, occurred in glioblastomas. One pilocytic astrocytoma carried two missense mutations and another pilocytic astrocytoma contained a somatic mutation, not affecting the presumed protein. In addition, 21 of the 27 single nucleotide polymorphisms identified in this study have not been recognized previously. The data indicate, that small mutations are not a frequent finding in gliomas.	Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany; Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Charite Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Deimling, A (corresponding author), Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany.		von Deimling, Andreas/F-7774-2013; Mollenhauer, Jan/G-4452-2012	von Deimling, Andreas/0000-0002-5863-540X; Stockhammer, Florian/0000-0002-0525-5956				Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 1999, ONCOGENE, V18, P6233, DOI 10.1038/sj.onc.1203071; Mollenhauer J, 2000, CANCER RES, V60, P1704; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Takeshita H, 1999, JPN J CANCER RES, V90, P903, DOI 10.1111/j.1349-7006.1999.tb00833.x; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wu WG, 1999, CANCER RES, V59, P1846	15	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5956	5959		10.1038/sj.onc.1205733	http://dx.doi.org/10.1038/sj.onc.1205733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185598				2022-12-28	WOS:000177520900018
J	Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P				Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P			Unusual expression of LINE-1 transposable element in the MRL autoimmune lymphoproliferative syndrome-prone strain	ONCOGENE			English	Article						LINE-1; retrotransposon; endogenous retroviruses; Fas; autoimmunity	MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IA ANTIGENS; L1 ELEMENT; CELL; INSERTION; RNA; SEQUENCE; MICE; TRANSCRIPTION	LINE-1 are endogenous mobile genetic elements that have dispersed and accumulated in the genomes of eukaryotes via germline transposition, with up to 100 000 copies in mammalian genomes. LINE- I elements transpose by reverse transcription of their own transcript. Transposition requires synthesis of a full-length, sense-strand transcripts and proteins encoded by open reading frame (ORF) 1 and ORF2. Although severely repressed in most normal tissues, LINE-I occasionally leads to disease by insertional mutagenesis. In the present study, Northern blot and in situ hybridization analyses revealed a template-strand transcription of LINE-I ORF2 (encoding reverse transcriptase, RT) in lymphoid organs and the liver from MRL-+/+ and Fas-deficient MRL/lpr strains and their normal ancestors. While these Sense transcripts are restricted to the nucleus in hepatocytes, they are also found in the cytoplasm in splenocytes. In contrast to transcription, ORF2 translation was detected only in MRL strains, as shown by the cytoplasmic labelling of splenic cells obtained with a monoclonal antibody recognizing the LINE-1 RT. This antibody coprecipitated two proteins of 45 and 12 kDa from MRL/lpr lymphoid organ lysates that were removed by pretreatment with anti-beta2-microglobulin antiserum, suggesting a structural association between a LINE-I product and a major histocompatibility complex class I or class I-like molecule.	CNRS, UPR 9045, Inst Andre Lwoff, F-94801 Villejuif, France; INSERM, U 267, F-94807 Villejuif, France; INSERM, U 131, F-92140 Clamart, France; Univ Paris 11, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bobe, P (corresponding author), CNRS, UPR 9045, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94801 Villejuif, France.	bobe@infobiogen.fr	, BENIHOUD/O-4334-2019	Bobe, Pierre/0000-0002-8835-6786				BEHARKA AA, 1995, P NATL ACAD SCI USA, V92, P6294, DOI 10.1073/pnas.92.14.6294; BOBE P, 1987, IMMUNOGENETICS, V25, P251, DOI 10.1007/BF00404695; BOBE P, 1993, J IMMUNOL, V151, P2813; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; CHVATCHKO Y, 1983, FEBS LETT, V163, P207, DOI 10.1016/0014-5793(83)80820-5; DELARBRE C, 1988, J IMMUNOGENET, V15, P307; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUDLEY JP, 1987, NUCLEIC ACIDS RES, V15, P2581, DOI 10.1093/nar/15.6.2581; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; Herrmann Martin, 1998, Current Opinion in Rheumatology, V10, P347; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; JACKSON M, 1985, NUCLEIC ACIDS RES, V13, P3389, DOI 10.1093/nar/13.9.3389; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Kono D H, 2000, Int Rev Immunol, V19, P367, DOI 10.3109/08830180009055504; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakagawa K, 1996, IMMUNOL REV, V152, P193, DOI 10.1111/j.1600-065X.1996.tb00917.x; NATORI T, 1974, TRANSPLANTATION, V18, P550, DOI 10.1097/00007890-197412000-00015; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PADGETT RW, 1988, NUCLEIC ACIDS RES, V16, P739, DOI 10.1093/nar/16.2.739; PEUCHMAUR M, 1990, AM J PATHOL, V136, P383; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; SCHICHMAN SA, 1992, J MOL BIOL, V224, P559, DOI 10.1016/0022-2836(92)90544-T; SEVERYNSE DM, 1992, MAMM GENOME, V2, P41, DOI 10.1007/BF00570439; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEBER T, 1987, GENE, V53, P105, DOI 10.1016/0378-1119(87)90097-7; Wilson IA, 1998, CURR OPIN IMMUNOL, V10, P67, DOI 10.1016/S0952-7915(98)80034-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	46	19	22	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5593	5600		10.1038/sj.onc.1205730	http://dx.doi.org/10.1038/sj.onc.1205730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165858				2022-12-28	WOS:000177442000009
J	Wang, L; Rudert, WA; Loutaev, I; Roginskaya, V; Corey, SJ				Wang, L; Rudert, WA; Loutaev, I; Roginskaya, V; Corey, SJ			Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation	ONCOGENE			English	Article						Cbl; Jak; STAT; Lyn; G-CSF	COLONY-STIMULATING FACTOR; UBIQUITIN-PROTEIN LIGASES; SRC KINASE LYN; TYROSINE KINASE; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; NEGATIVE REGULATOR; ANTIGEN RECEPTOR; PHOSPHOINOSITIDE 3-KINASE	Engagement of the Granulocyte-Colony-Stimulating Factor (G-CSF) receptor activates non-receptor protein tyrosine kinases Lyn and Jak2. We found that Lyn-deficient DT40 cells that express the G-CSF receptor (DT40GR) do not demonstrate G-CSF-induced mitogenic signaling. Lyn associates with and phosphorylates a small set of molecules, including c-Cbl. c-Cbl is an adaptor involved in cell growth and cytoskeletal reorganization, predominantly in hematopoietic cells. Using yeast two-hybrid analysis, we found that c-Cbl directly couples Lyn to PI 3-kinase. We also found that expression of the c-CblY731F mutant, which uncouples PI 3-kinase, resulted in the inhibition of G-CSF-induced proliferative signaling in DT40GR cells. As a complementary strategy, we sought to analyse the effects of c-Cbl deficiency in DT40GR cells. We isolated, cloned and sequenced the full-length cDNA for chicken c-Cbl and constructed antisense vectors. Antisense inhibition of c-Cbl expression in DT40GR cells led to enhanced Jak-STAT activation following G-CSF stimulation. Yet, this enhancement of Jak-STAT activation was associated with decreased G-CSF-induced PI 3-kinase activity and DNA synthesis. PI 3-kinase activity correlated with DNA synthesis and physiological levels of c-Cbl. Together, these data suggest that physiologic level of c-Cbl provides a growth stimulatory pathway for G-CSF and that enhanced Jak-STAT activation is not sufficient for G-CSF-induced growth.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Hematol Oncol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), MD Anderson Canc Ctr, Dept Pediat, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Erdreich-Epstein A, 1999, J LEUKOCYTE BIOL, V65, P523, DOI 10.1002/jlb.65.4.523; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FELESTEIN J, 1995, PHYLIP PHYLOGENY INF; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Sattler M, 1997, J BIOL CHEM, V272, P10248; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Sinha S, 2001, EXP HEMATOL, V29, P746, DOI 10.1016/S0301-472X(01)00647-6; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Willeke T, 2000, J LEUKOCYTE BIOL, V68, P284; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	55	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5346	5355		10.1038/sj.onc.1205670	http://dx.doi.org/10.1038/sj.onc.1205670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149655				2022-12-28	WOS:000177193900015
J	Danaee, H; Nelson, HH; Karagas, MR; Schned, AR; Ashok, TDS; Hirao, T; Perry, AE; Kelsey, KT				Danaee, H; Nelson, HH; Karagas, MR; Schned, AR; Ashok, TDS; Hirao, T; Perry, AE; Kelsey, KT			Microsatellite instability at tetranucleotide repeats in skin and bladder cancer	ONCOGENE			English	Article						EMAST; ptch; microsatellite instability; p53; skin cancer; bladder cancer	BASAL-CELL CARCINOMA; WILD-TYPE P53; CYCLE CONTROL; HUMAN HOMOLOG; LUNG-CANCER; MUTATIONS; GENE; RADIATION; CARCINOGENESIS; IRRADIATION	Recently, a novel form of MSI has been described that occurs only at tetranucleotide repeat markers. This has been termed elevated microsatellite instability at selected tetranucleotide repeats (EMAST). EMAST has been related to alterations of the p53 gene, and to the nature of the repeat sequence. We initially tested whether loss of heterozygosity (LOH) at the p53 and the patched (ptch) genes was related to EMAST in a series of 61 non-melanoma skin cancer (NMSC) tumors. We then analysed a series of 57 primary bladder cancers for the presence of EMAST, testing whether this was related to mutation or expression of the p53 gene. In both NMSC and bladder tumors we found a high prevalence of EMAST (75.4 and 43.9%). In NMSC the prevalence of EMAST was higher in tumors that had either p53 or ptch LOH, although the difference was not statistically significant. There was a significant association of extensive EMAST (three or more loci) with mutations in p53 among the bladder cancer tumors, but no indication of elevated EMAST in tumors with abnormal p53 staining without mutation. The association of EMAST with p53 mutation was confined to non-invasive disease. Hence, EMAST likely reflects a particular pattern of somatic events that are interactive with p53 mutation, particularly common in skin cancer and limited to non-invasive disease in bladder cancer.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Dartmouth Coll, Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA; Dartmouth Coll, Sch Med, Dept Pathol, Lebanon, NH 03756 USA	Harvard University; Harvard T.H. Chan School of Public Health; Dartmouth College; Dartmouth College	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.		Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [T32CA009078, R01CA057494, R01CA082354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P42ES005947, P42ES007373] Funding Source: NIH RePORTER; NCI NIH HHS [CA82354, CA09078, R01 CA082354, CA57494] Funding Source: Medline; NIEHS NIH HHS [P42ES5947, ES00002, P42ES07373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Ahrendt SA, 2000, CANCER RES, V60, P2488; Boland CR, 1998, CANCER RES, V58, P5248; Chuang YYE, 1999, CANCER RES, V59, P3073; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii K, 1997, BIOCHEM BIOPH RES CO, V240, P269, DOI 10.1006/bbrc.1997.7603; Fujii K, 1999, JPN J CANCER RES, V90, P1351, DOI 10.1111/j.1349-7006.1999.tb00719.x; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karagas MR, 1998, ENVIRON HEALTH PERSP, V106, P1047, DOI 10.1289/ehp.98106s41047; Karagas MR, 1999, INT J CANCER, V81, P555, DOI 10.1002/(SICI)1097-0215(19990517)81:4<555::AID-IJC9>3.0.CO;2-R; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lichter MD, 2000, ARCH DERMATOL, V136, P1007, DOI 10.1001/archderm.136.8.1007; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; NAGASAWA H, 1988, TERATOGEN CARCIN MUT, V8, P25, DOI 10.1002/tcm.1770080104; Nelson HH, 1998, CANCER RES, V58, P1804; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Ren ZP, 1997, AM J PATHOL, V150, P1791; Shen TL, 1999, HUM PATHOL, V30, P284, DOI 10.1016/S0046-8177(99)90006-0; Sidransky D, 1996, ANNU REV MED, V47, P285; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0	31	50	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4894	4899		10.1038/sj.onc.1205619	http://dx.doi.org/10.1038/sj.onc.1205619			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118368				2022-12-28	WOS:000176874800004
J	Liu, RT; Huang, CC; You, HL; Chou, FF; Hu, CCA; Chao, FP; Chen, CM; Cheng, JT				Liu, RT; Huang, CC; You, HL; Chou, FF; Hu, CCA; Chao, FP; Chen, CM; Cheng, JT			Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas	ONCOGENE			English	Article						TSG101; overexpression; immunohistochemistry; in situ hybridization; RT-PCR; human papillary thyroid carcinoma	ABERRANT TRANSCRIPTS; HUMAN-BREAST; PROTEIN; CHROMOSOME-11; CANCERS; ACCUMULATION; CELLS; HETEROZYGOSITY; SUPPRESSOR; FHIT	Functional inactivation of tumor susceptibility gene tsg101 leads to cellular transformation and tumorigenesis in mice. While human TSG101 is located in a region where frequent loss of heterozygosity can be detected in a variety of cancers, no genomic deletion in TSG101 gene has been reported, casting a doubt on the role of TSG101 as a classical tumor suppressor. Some studies have revealed that TSG101 is a frequent target of splicing defects, which correlate with cellular stress and p53 status. Furthermore, recent reports have identified TSG101 as a part of the MDM2/p53 regulatory circuitry, a well-recognized circuitry that upon deregulation results in tumorigenesis. Interestingly, overexpression of tsg101 from an adventitious promoter also leads to neoplastic transformation. On the basis of this information, we have analysed TSG101 gene expression in 20 human papillary thyroid carcinomas (PTCs) by immunohistochemistry and demonstrated that the overexpression of TSG101 protein is closely associated with human PTCs. Further sequence analysis reveals no mutation in cDNA region encoding steadiness box in these PTC specimens, indicating that the upregulation of TSG101 protein is not caused by the alteration of this region. In situ hybridization analysis confirms that overexpression of TSG101 also occurs at the transcriptional level. In addition, semi-quantitative RT-PCR and subsequent Southern hybridization verify that the amounts of TSG101 transcripts are indeed lower in three normal thyroid tissues than in PTC specimens. Here we report the upregulation of TSG101 expression in PTC cells, providing the first evidence of the association of TSG101 overexpression with human tumors and suggesting that upregulation of TSG101 steady-state level might play a role in mediating tumorigenesis of human PTC.	Natl Sun Yat Sen Univ, Dept Sci Biol, Kaohsiung 804, Taiwan; Chang Gung Mem Hosp, Div Metab, Kaohsiung 83305, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 83305, Taiwan; Chang Gung Mem Hosp, Dept Surg, Kaohsiung 833, Taiwan	National Sun Yat Sen University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Cheng, JT (corresponding author), Natl Sun Yat Sen Univ, Dept Sci Biol, Kaohsiung 804, Taiwan.			Hu, Chih-Chi/0000-0001-9024-2932				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Baffa R, 1996, CANCER RES, V56, P268; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chang JG, 1999, BRIT J CANCER, V79, P445, DOI 10.1038/sj.bjc.6690069; Feng GH, 2000, CANCER RES, V60, P1736; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hsu SF, 1998, HYBRIDOMA, V17, P251, DOI 10.1089/hyb.1998.17.251; Jennings T, 1995, EXP MOL PATHOL, V62, P199, DOI 10.1006/exmp.1995.1022; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin PM, 1998, BRIT J HAEMATOL, V102, P753, DOI 10.1046/j.1365-2141.1998.00815.x; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; McIver B, 2000, CLIN ENDOCRINOL, V52, P749, DOI 10.1046/j.1365-2265.2000.01009.x; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Ponting CP, 1997, J MOL MED-JMM, V75, P467; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Turpin E, 1999, ONCOGENE, V18, P7834, DOI 10.1038/sj.onc.1203196; Wang NM, 2000, INT J ONCOL, V16, P75; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; Willeke F, 1998, MOL CARCINOGEN, V23, P195; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699	36	60	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4830	4837		10.1038/sj.onc.1205612	http://dx.doi.org/10.1038/sj.onc.1205612			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101421				2022-12-28	WOS:000176716300012
J	Evans, RL; Poe, BS; Goodrich, DW				Evans, RL; Poe, BS; Goodrich, DW			Nuclear localization is required for induction of apoptotic cell death by the Rb-associated p84N5 death domain protein	ONCOGENE			English	Article						apoptosis; death domain; nucleus; retinoblastoma; Rb	RETINOBLASTOMA GENE-PRODUCT; SUPPRESSION; ACTIVATION; SIGNAL; LIFE; P53	The mechanisms utilized to transduce apoptotic signals that originate from within the nucleus, in response to DNA damage for example, are not well understood. Identifying these mechanisms is important for predicting how tumor cells will respond to genotoxic radiation or chemotherapy. The Rb tumor suppressor protein can inhibit apoptosis triggered by DNA damage, but how it does so is unclear. We have previously characterized a death domain protein, p84N5, that specifically associates with an amino-terminal domain of Rb protein. The p84N5 death domain is required for its ability to trigger apoptotic cell death. Association with Rb protein inhibits p84N5-induced apoptosis suggesting that it may be a mediator of Rb's effects on apoptosis. Unlike other death domain-containing apoptotic signaling proteins, however, p84N5 is localized predominantly within the nucleus of interphase cells. Here we test whether p84N5 requires nuclear localization in order to trigger apoptosis. We identify the p84N5 nuclear localization signal and demonstrate that nuclear localization is required for p84N5-induced apoptosis. To our knowledge, this identifies p84N5 as the first death-domain containing apoptotic signaling protein that functions within the nucleus. By analogy to other death domain containing proteins, p84N5 may play some role in apoptotic signaling within the nucleus. Further, p84N5 is a potential mediator of Rb protein's effects on DNA damage induced apoptosis.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA-70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Doostzadeh-Cizeron J, 2001, J BIOL CHEM, V276, P1127, DOI 10.1074/jbc.M006944200; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	21	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4691	4695		10.1038/sj.onc.1205583	http://dx.doi.org/10.1038/sj.onc.1205583			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096345				2022-12-28	WOS:000176625100010
J	Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C				Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C			The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD	ONCOGENE			English	Article						NF-kappaB; apoptosis; MnSOD; reactive oxygen species	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; SEVERE LIVER DEGENERATION; PROSTATE CARCINOMA-CELLS; ALPHA-INDUCED APOPTOSIS; MICE LACKING; DIHYDRORHODAMINE 123; HYDROGEN-PEROXIDE; DEFICIENT MICE; T-LYMPHOCYTES	Rel/NF-kappaB transcription factors are involved in several physiological processes, including the regulation of apoptosis. These factors were shown to exhibit pro- or anti-apoptotic activities in different cellular models, but at present, the mechanisms underlying these opposite effects are poorly understood. In this study, we show that the constitutive expression of a transcriptionally active member of the Rel/NF-kappaB family, c-Rel, first induces a resistance against TNFalpha-induced apoptosis and later increases the level of spontaneous apoptosis of HeLa cells. Both the anti- and pro-apoptotic effects increase with the level of c-Rel overexpression. The up-regulation by c-Rel of the manganese superoxide dismutase (MnSOD) could explain both the rapid anti-apoptotic effect and the delayed pro-apoptotic one. Indeed, the enzymatic activity of MnSOD is to transform the toxic O-2(.-) in H2O2. Hence, on one hand, its induction helps cells to resist against the apoptogenic burst of O-2 produced upon TNFalpha stimulation, but on the other hand, it leads to a progressive H2O2 accumulation that ultimately results in apoptosis. These results indicate that the anti- and pro-apoptotic effects of Rel/NF-kappaB factors are not necessarily alternative but can occur successively in the same cell, via the up-regulation of the same target gene.	Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, F-59021 Lille, France; Univ Lille 2, IPL, CNRS, UMR 8526,Inst Biol Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Abbadie, C (corresponding author), Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, 1 Rue Calmette,BP 447, F-59021 Lille, France.	corinne.abbadie@ibl.fr	ABBADIE, Corinne/F-4949-2018; Bernard, David/D-6265-2018	ABBADIE, Corinne/0000-0002-8174-2393; monte, didier/0000-0002-0613-6203				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bernard D, 2001, CANCER RES, V61, P2656; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Cusack JC, 2000, CANCER RES, V60, P2323; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gugasyan R, 2000, IMMUNOL REV, V176, P134; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Y, 2000, CANCER RES, V60, P4426; Huguet C, 1997, CELL DEATH DIFFER, V4, P413, DOI 10.1038/sj.cdd.4400259; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1999, FREE RADICAL BIO MED, V26, P1554, DOI 10.1016/S0891-5849(99)00024-6; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qin ZH, 1999, J NEUROSCI, V19, P4023; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudolph D, 2000, GENE DEV, V14, P854; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sohur US, 2000, CANCER RES, V60, P1202; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	57	65	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4392	4402		10.1038/sj.onc.1205536	http://dx.doi.org/10.1038/sj.onc.1205536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080470				2022-12-28	WOS:000176317100005
J	Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM				Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM			R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras	ONCOGENE			English	Article						H-Ras; R-Ras; structure-function; transformation; integrin affinity modulation	NUCLEOTIDE DISSOCIATION STIMULATOR; INTEGRIN CYTOPLASMIC DOMAINS; OUT SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; PLASMA-MEMBRANE; EFFECTOR LOOP; ACTIVATION; CELLS; PATHWAY; PROTEIN	Activated versions of the similar GTPases, H-Ras and R-Ras, have differing effects on biological phenotypes: Activated H-Ras strongly transforms many fibroblast cell lines causing dramatic changes in cell shape and cytoskeletal organization. In contrast, R-Ras transforms fewer cell lines and the transformed cells display only some of the morphological changes associated with H-Ras transformation. H-Ras cells can survive in the absence of serum whereas R-Ras cells seem to die by an apoptotic-like mechanism in response to removal Of serum. H-Ras can suppress integrin activation and R-Ras specifically antagonizes this effect. To map sequences responsible for these differences we have generated and investigated a panel of H-Ras and R-Ras chimeras. We found that the C-terminal 53 amino acids of R-Ras were necessary and sufficient to specify the contrasting biological properties of R-Ras with respect to focus morphology, reactive oxygen species (ROS) production and reversal of H-Ras-induced integrin suppression. Surprisingly, we found chimeras in which the focus formation and integrin-mediated phenotypes were separated, suggesting that different effectors could be involved in mediating these responses. An integrin profile of H-Ras and R-Ras cell pools showed no significant differences; both activated H-Ras and R-Ras expressing cells were found to have reduced beta(1) activity, suggesting that the activity state of the beta(1) subunit is not sufficient to direct an H-Ras transformed cell morphology.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Copenhagen; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Willumsen, BM (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA 61951, CA 76092] Funding Source: Medline; NHLBI NIH HHS [HL 31950, HL 48728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076092, R29CA061951] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chou CC, 1997, N-S ARCH PHARMACOL, V355, P177, DOI 10.1007/PL00004929; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUGHES PE, 2002, IN PRESS MOL CELL BI; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Jasiulionis MG, 1996, CANCER RES, V56, P1682; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIN CS, 1993, CANCER RES, V53, P2950; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang YC, 1999, CLIN CANCER RES, V5, P129; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS G, 1999, DISCOVERY, V1, P11; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	62	16	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4448	4461		10.1038/sj.onc.1205538	http://dx.doi.org/10.1038/sj.onc.1205538			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080475				2022-12-28	WOS:000176317100010
J	Mason, SL; Loughran, O; La Thangue, NB				Mason, SL; Loughran, O; La Thangue, NB			p14(ARF) regulates E2F activity	ONCOGENE			English	Article						E2F; p14(ARF); MDM2; p53	TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; NUCLEOLAR LOCALIZATION; GENE-PRODUCT; P53; MDM2; P19(ARF); DEGRADATION; INHIBITION; PATHWAY	The ARF protein product of the ink4a/arf locus is induced by a variety of oncogenic signals. ARF facilitates growth arrest through the p53 pathway by hindering the down-regulation of p53 activity mediated by MDM2, through the formation of a protein complex with MDM2. Here we have explored the possibility that human p14(LambdaRF) activity is integrated with growth regulating pathways other than p53, and report our results that p14(LambdaRF) can control the activity of the E217 transcription factor. p14(LambdaRF) regulates E2F activity in different cell-types, including p53(-/-)/mdm(-/-) MEFs, thus excluding that the effects of p14(LambdaRF) are indirectly caused through MDM2 modulation. p14(LambdaRF) down-regulates E2F-dependent transcription, and in cells undergoing E2F-dependent apoptosis prompts cell cycle arrest. p14(LambdaRF) possesses multiple binding domains for E2F-1, one of which resides within the N-terminal region and coincides with the regulation of E2F activity. A mutational analysis of p14(LambdaRF) indicates that the E2F-1 and MDM2 binding domains can be distinguished. These results highlight the potential interplay between p14(LambdaRF) and E2F, and establish p14(LambdaRF) as a pleiotrophic regulator of cell growth that acts by targetting at least two key pathways in the control of proliferation, namely E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	N.LaThangue@bio.gla.ac.uk			Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline; MRC [G9400953] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Botz J, 1996, MOL CELL BIOL, V16, P3401; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	46	55	61	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4220	4230		10.1038/sj.onc.1205524	http://dx.doi.org/10.1038/sj.onc.1205524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082609				2022-12-28	WOS:000176174200004
J	von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT			Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells	ONCOGENE			English	Article						proapoptotic genes; Bax; ceramide; mitochondria; DU 145 cells; HCT116 cells	CYTOCHROME-C RELEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ETOPOSIDE-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; HUMAN-MELANOMA CELLS; GENE BAX; CANCER-CHEMOTHERAPY; CASPASE ACTIVATION; MEDIATED APOPTOSIS	The intracellular pathways leading to mitochondrial activation and subsequent cell death in the ceramide-mediated stress response have been intensively studied in recent years. Experimental evidence has been provided that ceramide-induced apoptosis is inhibited by overexpression of antiapoptotic proteins of the Bcl-2 family. However, the direct effect of proapoptotic gene products, e.g. Bax, on ceramide-induced death signalling has not yet been studied in detail. In the present work, we show by measurement of mitochondrial permeability transition, cytochrome c release, activation of caspase-3 and DNA fragmentation that ceramide-induced apoptosis is marginal in Bax-negative DU 145 cells. Reconstitution of Bax by generation of DU 145 cells stably expressing this proapoptotic factor, clearly enhanced ceramide-induced apoptosis at all levels of the mitochondrial signalling cascade. Using the broad-range caspase inhibitor zVAD-fmk and zDEVD-fmk, an inhibitor of caspase-3-like activities, we demonstrate that the ceramide-induced mitochondrial activation in Bax-transfected DU 145 cells is caspase-independent. On the other hand, apoptotic events located downstream of the mitochondria, e.g. DNA fragmentation, were shown to be caspase-dependent. This influence of Bax on ceramide-induced apoptosis was confirmed in another cellular system: whereas Bax-positive HCT116 wild type cells were very sensitive towards induction of cell death by C-2-ceramide, sensitivity of Bax knock-out HCT116 cells was significantly reduced. Thus, we conclude that Bax is a key activator of ceramide-mediated death pathways.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mde-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; Geilen CC, 1997, ARCH DERMATOL RES, V289, P559, DOI 10.1007/s004030050240; Geilen GC, 1997, J BIOL CHEM, V272, P8997, DOI 10.1074/jbc.272.14.8997; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kim HJ, 2001, FEBS LETT, V505, P264, DOI 10.1016/S0014-5793(01)02836-8; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1999, INT J ONCOL, V15, P535; Malisan F, 1999, FEBS LETT, V452, P100, DOI 10.1016/S0014-5793(99)00543-8; Marcelli M, 2000, PROSTATE, V42, P260, DOI 10.1002/(SICI)1097-0045(20000301)42:4<260::AID-PROS3>3.0.CO;2-0; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MIYASHITA T, 1993, BLOOD, V81, P151; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Peltenburg LTC, 2000, Q J NUCL MED, V44, P355; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	62	158	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4009	4019		10.1038/sj.onc.1205497	http://dx.doi.org/10.1038/sj.onc.1205497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037683				2022-12-28	WOS:000175869900007
J	Lin, J; Tang, H; Jin, X; Jia, G; Hsieh, JT				Lin, J; Tang, H; Jin, X; Jia, G; Hsieh, JT			p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3	ONCOGENE			English	Article						p-53; Stat3; prostate cancer; apoptosis	WILD-TYPE P53; EPIDERMAL-GROWTH-FACTOR; SIGNAL TRANSDUCER; SUPPRESSES GROWTH; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; GENE-THERAPY; MUTANT P53; ACTIVATION; CARCINOMA	Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) and mutation of the p53 are both commonly detected in human prostate cancer cells. We sought to investigate whether there is functional regulation of Stat3 by wild-type (wt) p53. Our results demonstrate that expression of wt p53 but not mutant p53 significantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Expression of the p53 downstream target, p21(WAF-1), did not have any inhibitory effect on Stat3 phosphorylation. Wt p53 but not p21(WAF-1) induced dramatic apoptosis in these prostate cancer cells. Expression of wt p53 did not cause a reduction of phosphorylation-independent Stat3 protein and reduction of phosphorylation of three unrelated protein kinases, ERK1, ERK2 (ERK1/2), and AKT. Interestingly, p53-dependent apoptosis occurred in the presence of high levels of phosphorylated AKT and ERK1/2 in both DU145 and Tsu prostate cancer cells. Further, we evaluated a series of established human prostate, breast, and ovarian cancer cell lines and found that all cancer cell lines expressing constitutively active Stat3, only harbor mutated or deleted p53. One implication of these results is that the anti-proliferative activities of p53 may not be compatible with the constitutive Stat3 signal in cancer cells.	Univ Michigan, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA; Huang Si Aesthet Plast Surg Hosp, Beijing, Peoples R China; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lin, J (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA.	linjia@mich.edu	Tang, Hua/K-4948-2016; Lin, Jiayuh/E-3515-2011	Tang, Hua/0000-0002-6685-6165; 				BARTEK J, 1990, ONCOGENE, V5, P893; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELSTNER E, 1995, CANCER RES, V55, P2822; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GarciaOlivares A, 1997, ENVIRONMETRICS, V8, P1, DOI 10.1002/(SICI)1099-095X(199701)8:1<1::AID-ENV230>3.3.CO;2-2; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobberger JW, 1999, CYTOMETRY, V38, P201, DOI 10.1002/(SICI)1097-0320(19991015)38:5<201::AID-CYTO2>3.0.CO;2-F; JOVE R, 2001, 92 AACR ANN M; Katayose D, 1995, CLIN CANCER RES, V1, P889; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lin JY, 2000, CANCER RES, V60, P5895; Lin JY, 2002, CANCER RES, V62, P376; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Tagliaferri P, 1996, CLIN CANCER RES, V2, P207; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAGINUMA Y, 1992, CANCER RES, V52, P4196; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	84	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3082	3088		10.1038/sj.onc.1205426	http://dx.doi.org/10.1038/sj.onc.1205426			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082540				2022-12-28	WOS:000175262700017
J	Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL				Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL			Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells	ONCOGENE			English	Article						Stat3; Bcl-2; chemoresistance	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; FACTOR-I RECEPTOR; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; CARCINOMA CELLS; APOPTOSIS; EXPRESSION; STAT3	Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3-Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.	Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Santander 39008, Spain; Hosp Univ Marques de Valdecilla, Med Oncol Serv, Santander 39008, Spain; Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Ctr Invest Energet Medioambientales & Tecnol, Madrid 28040, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Av Valdecilla S-N, Santander 39008, Spain.	inmflj@humv.es	Segovia, Jose Carlos/L-2922-2014; Real, Pedro J./K-2994-2014; Real, Pedro J./ABH-3493-2021	Segovia, Jose Carlos/0000-0003-4101-6124; Real, Pedro J./0000-0001-7968-5353; Sierra, Angels/0000-0003-1023-3492				Alas S, 2001, CANCER RES, V61, P5137; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Bartucci M, 2001, CANCER RES, V61, P6747; BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruns CJ, 2000, CANCER RES, V60, P2926; Bundred NJ, 2001, ENDOCR-RELAT CANCER, V8, P183, DOI 10.1677/erc.0.0080183; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Ellis PA, 1998, BREAST CANCER RES TR, V48, P107, DOI 10.1023/A:1005933815809; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PRICE JE, 1990, CANCER RES, V50, P717; Sanz C, 2001, EXP HEMATOL, V29, P728, DOI 10.1016/S0301-472X(01)00635-X; Schorr K, 1999, CANCER RES, V59, P2541; Sierra A, 2000, INT J CANCER, V89, P142, DOI 10.1002/(SICI)1097-0215(20000320)89:2<142::AID-IJC7>3.3.CO;2-2; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Sierra A, 1997, LAB INVEST, V77, P357; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu JX, 1996, ANTICANCER RES, V16, P2233; Yarden RI, 2001, J CELL BIOCHEM, P232; Yu DH, 1996, ONCOGENE, V13, P1359; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	44	251	271	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7611	7618		10.1038/sj.onc.1206004	http://dx.doi.org/10.1038/sj.onc.1206004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400004				2022-12-28	WOS:000178756200001
J	Rubin, H				Rubin, H			Selective clonal expansion and microenvironmental permissiveness in tobacco carcinogenesis	ONCOGENE			English	Review						cigarette smoke; initiation; promotion; co-carcinogenesis	TUMOR-PROMOTING AGENTS; POLYCYCLIC AROMATIC-HYDROCARBONS; MOUSE SKIN; PULMONARY METASTASES; OPTICAL ENANTIOMERS; CIGARETTE-SMOKE; PHORBOL ESTERS; NEOPLASTIC TRANSFORMATION; EPIDERMAL HYPERPLASIA; COCARCINOGENIC ACTION	Historically our knowledge about the direct carcinogenic activity of cigarette smoke and its constituents grew from painting experiments on the skin of mice to produce papillomas and carcinomas. The neutral fraction of cigarette smoke condensate had most of the carcinogenic activity in this test and was rich in carcinogenic polycyclic aromatic hydrocarbons (PAHs), the most abundant by far being BP. However, the concentration of BP in the condensate was only about 2% the amount of pure BP required to cause skin tumors. In other fractions there were non-carcinogenic constituents that promoted tumor formation when applied repeatedly to mouse skin that had been initiated by a single subcarcinogenic application of BP. There were also constituents of cigarette smoke that acted as cocarcinogens when applied simultaneously with repeated applications of BP. BP was effective as an initiator at lower concentrations than as a complete carcinogen, and some non-carcinogenic PAHs in the condensate were also active initiators. It was concluded from these studies that cigarette smoke condensate is primarily a tumor-promoting and co-carcinogenic agent with weak activity as a complete carcinogen. A major effect of promoters, and possibly of co-carcinogens, is a diffuse hyperplasia which includes selective expansion of clones carrying endogenous mutations and/or mutations induced by PAHs and other carcinogens such as NNK. The induced mutations as well as damaged cells would occur throughout the exposed region and, along with the hyperplasia, increase the permissiveness of the cellular microenvironment for neoplastic expression of any potential tumor cell in its midst. Since neither the promoters nor co-carcinogens in tobacco smoke are known to interact directly with DNA, their effects can be considered epigenetic processes that act upon genetically altered cells. Examples are cited from studies of experimental skin carcinogenesis, smoking-induced histopathological changes in human lung and spontaneous transformation in cell culture to illustrate the genetic and epigenetic interactions of neoplastic development in general and their significance for smoking-induced lung cancer in particular. Certain dietary modifications that appear to be effective in moderating the promotional phase of animal and human carcinogenesis are suggested for trial in managing lung cancer.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rubin, H (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	hrubin@uclink4.berkeley.edu			NATIONAL LIBRARY OF MEDICINE [G13LM007483] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; ALDAZ CM, 1985, CANCER RES, V45, P2753; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; Andersson DI, 1998, SCIENCE, V282, P1133, DOI 10.1126/science.282.5391.1133; ARMUTH V, 1972, CANCER RES, V32, P2259; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1970, ARCH ENVIRON HEALTH, V21, P754, DOI 10.1080/00039896.1970.10667329; AUERBACH O, 1956, CANCER, V9, P76, DOI 10.1002/1097-0142(195601/02)9:1<76::AID-CNCR2820090106>3.0.CO;2-D; Berenblum I, 1941, CANCER RES, V1, P44; Berenblum I, 1941, CANCER RES, V1, P807; BERENBLUM I, 1949, BRIT J CANCER, V3, P384, DOI 10.1038/bjc.1949.42; BERENBLUM I, 1947, BRIT J CANCER, V1, P379, DOI 10.1038/bjc.1947.35; BERENBLUM I, 1947, BRIT J CANCER, V1, P383, DOI 10.1038/bjc.1947.36; BERENBLUM I, 1974, CARCINOGENESIS BIOL; BERRY DL, 1978, CANCER RES, V38, P2301; Biesele JJ, 1943, J NATL CANCER I, V4, P373; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRAND KG, 1976, CANCER RES, V36, P3681; BROOKES P, 1964, NATURE, V202, P781, DOI 10.1038/202781a0; BROWN JM, 1973, BRIT J RADIOL, V46, P613, DOI 10.1259/0007-1285-46-548-613; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; Burczynski ME, 2000, CANCER RES, V60, P908; BURDETTE WJ, 1955, CANCER RES, V15, P201; BURKHART F, 1997, NY TIMES        0116; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; Cairns J., 1978, CANC SCI SOC; CAIRNS J, 1991, GENETICS, V154, P1427; CARMEL RJ, 1977, CANCER RES, V37, P145; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen JX, 1998, CANCER RES, V58, P2070; CHENG SC, 1988, CARCINOGENESIS, V9, P1721, DOI 10.1093/carcin/9.9.1721; Chow M, 1999, P NATL ACAD SCI USA, V96, P2093, DOI 10.1073/pnas.96.5.2093; Chow M, 2000, CANCER RES, V60, P6510; COOK J. W., 1937, AMER JOUR CANCER, V29, P219; Cook JW, 1933, J CHEM SOC, P395, DOI 10.1039/jr9330000395; CRAMER W., 1942, JOUR NATION CANCER INST, V2, P369; CRAMER W., 1942, JOUR NATION CANCER INST, V2, P379; DAVIES D F, 1960, J Chronic Dis, V11, P579, DOI 10.1016/0021-9681(60)90059-X; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; DRUCKREY H., 1963, ZEIT KREBSFORSCH, V65, P465, DOI 10.1007/BF00525755; DZARLIEVAPETRUSEVSKA RT, 1985, CARCINOGENESIS, V6, P1447, DOI 10.1093/carcin/6.10.1447; Elsasser WM, 1998, REFLECTIONS THEORY O; ESSENBERG JM, 1952, SCIENCE, V116, P561, DOI 10.1126/science.116.3021.561; FRANKFURT OS, 1973, JNCI-J NATL CANCER I, V51, P1861, DOI 10.1093/jnci/51.6.1861; FRANKFURT OS, 1972, JNCI-J NATL CANCER I, V49, P131; Friedewald WF, 1944, J EXP MED, V80, P101, DOI 10.1084/jem.80.2.101; FURSTENBERGER G, 1981, P NATL ACAD SCI-BIOL, V78, P7722, DOI 10.1073/pnas.78.12.7722; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; FURSTENBERGER G, 1983, SCIENCE, V220, P89, DOI 10.1126/science.6828884; FURTH J, 1953, CANCER RES, V13, P477; GELLHORN A, 1958, CANCER RES, V18, P510; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hastings PJ, 2000, CELL, V103, P723, DOI 10.1016/S0092-8674(00)00176-8; Hayward SW, 2001, CANCER RES, V61, P8135; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HECHT SS, 1981, J NATL CANCER I, V66, P163; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HECKER E, 1968, CANCER RES, V28, P2338; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HIEGER I, 1962, BRIT J CANCER, V16, P716, DOI 10.1038/bjc.1962.83; HIEGER I, 1936, AM J CANC, V28, P522; HOLLIDAY R, 1994, DEV GENET, V15, P453, DOI 10.1002/dvg.1020150602; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HUBERMAN E, 1974, INT J CANCER, V13, P326, DOI 10.1002/ijc.2910130308; Hussain SP, 2001, CANCER RES, V61, P6350; IVERSEN OH, 1985, VIRCHOWS ARCH B, V49, P129, DOI 10.1007/BF02912091; KAINA B, 1989, TERATOGEN CARCIN MUT, V9, P331, DOI 10.1002/tcm.1770090602; KAPITULNIK J, 1978, CANCER RES, V38, P354; KATO R, 1969, HEREDITAS-GENETISK A, V61, P1; KATO R, 1968, HEREDITAS-GENETISK A, V59, P120; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENNAWAY E. L., 1930, BRIT MED JOUR, V1, P1044; Krawczak M, 1998, MUTAGENESIS, V13, P319, DOI 10.1093/mutage/13.4.319; KRAWCZAK M, 1995, HUM MUTAT, V5, P48, DOI 10.1002/humu.1380050107; LANKAS GR, 1977, MUTAT RES, V45, P153, DOI 10.1016/0027-5107(77)90053-7; LEE LW, 1989, AM J PATHOL, V135, P63; LEUCHTENBERGER C, 1974, ONCOLOGY-BASEL, V29, P122, DOI 10.1159/000224894; LEVIN W, 1977, CANCER RES, V37, P2721; LEVIN W, 1977, CANCER RES, V37, P3356; Levin W, 1978, POLYCYCLIC HYDROCARB, P189; MACKAY W, 1992, CARCINOGENESIS, V13, P1415, DOI 10.1093/carcin/13.8.1415; MacKenzie I, 1941, J EXP MED, V73, P391, DOI 10.1084/jem.73.3.391; MARX JL, 1978, SCIENCE, V201, P515, DOI 10.1126/science.307276; Melendez-Colon VJ, 1999, CARCINOGENESIS, V20, P1885, DOI 10.1093/carcin/20.10.1885; MILAS L, 1984, CANC INVASTION METAS; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Mottram JC, 1944, J PATHOL BACTERIOL, V56, P181, DOI 10.1002/path.1700560207; NEWBOLD RF, 1979, INT J CANCER, V24, P203, DOI 10.1002/ijc.2910240212; Olumi AF, 1999, CANCER RES, V59, P5002; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; Peacock PR, 1938, BRIT J EXP PATHOL, V19, P315; PELLING JC, 1982, CARCINOGENESIS, V3, P1135, DOI 10.1093/carcin/3.10.1135; PELLING JC, 1984, CANCER RES, V44, P1081; PETRUSEVSKA RT, 1988, CARCINOGENESIS, V9, P1207, DOI 10.1093/carcin/9.7.1207; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Pullinger BD, 1940, J PATHOL BACTERIOL, V50, P463, DOI 10.1002/path.1700500308; Pullinger BD, 1941, J PATHOL BACTERIOL, V53, P287, DOI 10.1002/path.1700530213; RAICK AN, 1972, CANCER RES, V32, P1562; Ralston SL, 1995, CARCINOGENESIS, V16, P2899, DOI 10.1093/carcin/16.12.2899; REDDY AL, 1983, NATURE, V304, P69, DOI 10.1038/304069a0; Rodin SN, 2000, P NATL ACAD SCI USA, V97, P12244, DOI 10.1073/pnas.180320897; RODIN SN, 2002, IN PRESS MUTATION RE; ROE FJC, 1955, BRIT J CANCER, V9, P177, DOI 10.1038/bjc.1955.14; ROE FJC, 1959, BRIT J CANCER, V13, P623, DOI 10.1038/bjc.1959.68; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; Rosenberg SM, 1998, GENETICS, V148, P1559; Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365; RUBIN H, 1995, P NATL ACAD SCI USA, V92, P4843, DOI 10.1073/pnas.92.11.4843; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; RUBIN H, 1960, VIROLOGY, V10, P29, DOI 10.1016/0042-6822(60)90004-0; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Rubin H, 2001, ADV CANCER RES, V83, P159, DOI 10.1016/S0065-230X(01)83006-2; Rubin H, 2001, CANCER RES, V61, P799; RUBIN H, 1994, P NATL ACAD SCI USA, V91, P1039, DOI 10.1073/pnas.91.3.1039; RUBIN H, 1992, P NATL ACAD SCI USA, V89, P977, DOI 10.1073/pnas.89.3.977; RUBIN H, 1994, P NATL ACAD SCI USA, V91, P12076, DOI 10.1073/pnas.91.25.12076; RUBIN H, 1975, P NATL ACAD SCI USA, V72, P3551, DOI 10.1073/pnas.72.9.3551; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SALAMAN MH, 1953, BRIT J CANCER, V7, P472, DOI 10.1038/bjc.1953.49; SETALA K, 1959, J NATL CANCER I, V23, P925; SHUBIK P, 1950, CANCER RES, V10, P13; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; Slaga T J, 1982, Carcinog Compr Surv, V7, P19; SLAGA TJ, 1980, P NATL ACAD SCI-BIOL, V77, P3659, DOI 10.1073/pnas.77.6.3659; SLAGA TJ, 1979, CANCER RES, V39, P67; STOKER M, 1964, VIROLOGY, V24, P165, DOI 10.1016/0042-6822(64)90099-6; TANNENBAUM A, 1959, PHYSIOPATHOLOGY CANC, P517; TERZAGHIHOWE M, 1987, CARCINOGENESIS, V8, P145, DOI 10.1093/carcin/8.1.145; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDUURE.BL, 1970, J NATL CANCER I, V44, P1167; VANDUURE.BL, 1973, JNCI-J NATL CANCER I, V51, P703; VANDUUREN BL, 1976, JNCI-J NATL CANCER I, V56, P1237, DOI 10.1093/jnci/56.6.1237; VANDUUREN BL, 1966, JNCI-J NATL CANCER I, V37, P519; VANDUUREN BL, 1971, JNCI-J NATL CANCER I, V47, P235; VANDUUREN BL, 1975, CANCER RES, V35, P502; VANDUUREN BL, 1980, BANBURY REPORT, V3, P105; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WEISS RA, 1970, EXP CELL RES, V63, P1, DOI 10.1016/0014-4827(70)90326-5; WITHERS HR, 1973, CANCER RES, V33, P1931; WYNDER E L, 1961, Acta Med Scand Suppl, V369, P63; WYNDER EL, 1957, CANCER, V10, P1193, DOI 10.1002/1097-0142(195711/12)10:6<1193::AID-CNCR2820100616>3.0.CO;2-Y; WYNDER EL, 1957, J NATL CANCER I, V19, P361, DOI 10.1093/jnci/19.3.361; WYNDER EL, 1959, CANCER, V12, P1079, DOI 10.1002/1097-0142(195911/12)12:6<1079::AID-CNCR2820120604>3.0.CO;2-I; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; WYNDER EL, 1961, CANCER, V14, P1306, DOI 10.1002/1097-0142(196111/12)14:6<1306::AID-CNCR2820140621>3.0.CO;2-T; WYNDER EL, 1969, CANCER, V24, P289, DOI 10.1002/1097-0142(196908)24:2<289::AID-CNCR2820240212>3.0.CO;2-8; WYNDER EL, 1958, CANCER-AM CANCER SOC, V11, P1140, DOI 10.1002/1097-0142(195811/12)11:6<1140::AID-CNCR2820110609>3.0.CO;2-Z; WYNDER EL, 1957, CANCER-AM CANCER SOC, V10, P255, DOI 10.1002/1097-0142(195703/04)10:2<255::AID-CNCR2820100208>3.0.CO;2-H; YANG NC, 1961, SCIENCE, V134, P386, DOI 10.1126/science.134.3476.386; YAO A, 1994, P NATL ACAD SCI USA, V91, P7712, DOI 10.1073/pnas.91.16.7712; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198	165	38	38	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7392	7411		10.1038/sj.onc.1205800	http://dx.doi.org/10.1038/sj.onc.1205800			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379881	Bronze			2022-12-28	WOS:000178618000011
J	Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O				Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O			Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control	ONCOGENE			English	Article						ErbB; RALT; proteasome; cell cycle; Ras pathways	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; MAMMARY EPITHELIAL-CELLS; EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; NEGATIVE REGULATORS; IN-VIVO; C-CBL; DEGRADATION; DIFFERENTIATION	Over-expression studies have demonstrated that RALT (receptor associated late transducer) is a feedback inhibitor of ErbB-2 mitogenic and transforming signals. In growth-arrested cells, expression of endogenous RALT is induced by mitogenic stimuli, is high throughout mid to late G1 and returns to baseline as cells move into S phase. Here, we show that physiological levels of RALT effectively suppress ErbB-2 mitogenic signals. We also investigate the regulatory mechanisms that preside to the control of RALT expression. We demonstrate that pharmacological ablation of extracellular signal-regulated kinase (ERK) activation leads to blockade of RALT expression, unlike genetic and/or pharmacological interference with the activities of PKC, Src family kinases, p38 SAPK and PI-3K. Tamoxifen-dependent activation of an inducible Raf:ER chimera was sufficient to induce RALT expression. Thus, activation of the Ras-Raf-ERK pathway is necessary and sufficient to drive RALT expression. The RALT protein is labile and was found to accumulate robustly upon pharmacological inhibition of the proteasome. We were able to detect ubiquitin-conjugated RALT species in living cells, suggesting that ubiquitinylation targets RALT for proteasome-dependent degradation. Such an integrated transcriptional and posttranslational control is likely to provide RALT with the ability to fluctuate timely in order to tune ErbB signals.	Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Segatto, O (corresponding author), Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy.		Sala, Gianluca/C-2056-2017; Falcone, Germana/A-3735-2016	Sala, Gianluca/0000-0002-4494-915X; Segatto, Oreste/0000-0003-2561-1142; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flanagan A M, 1998, Curr Opin Hematol, V5, P181, DOI 10.1097/00062752-199805000-00006; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; Greenwood S, 1997, DEVELOPMENT, V124, P4879; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Hughes EA, 1996, J EXP MED, V183, P1569, DOI 10.1084/jem.183.4.1569; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V269, P106, DOI 10.1016/0003-9861(89)90091-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	70	67	72	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6530	6539		10.1038/sj.onc.1205823	http://dx.doi.org/10.1038/sj.onc.1205823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226756				2022-12-28	WOS:000177925300013
J	Fry, AM				Fry, AM			The Nek2 protein kinase: a novel regulator of centrosome structure	ONCOGENE			English	Review						Nek2; centrosome; mitosis; NIMA; Fin1; protein kinase	NIMA-RELATED KINASE; CELL-CYCLE REGULATORS; ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; CHROMATIN CONDENSATION; EXPRESSION PATTERN; MITOTIC REGULATOR; VERTEBRATE CELLS; IN-VIVO; PHOSPHORYLATION	Regulation of the centrosome, the major microtubule organizing centre in an animal cell, is in large part controlled by cell cycle-dependent protein phosphorylation. Along with cyclin dependent kinases, polo kinases and Aurora kinases, NIMA-related kinases are emerging as critical regulators of centrosome structure and function. Nek2 is the most closely related vertebrate protein by sequence to the essential mitotic regulator NIMA of Aspergillus nidulans. Nek2 is highly enriched at the centrosome and functional studies in human and Xenopus systems support a role for Nek2 in both maintenance and modulation of centrosome architecture. In particular, current evidence supports a model in which one function of Nek2 kinase activity is to promote the splitting of duplicated centrosomes at the onset of mitosis through phosphorylation of core centriolar proteins. Recent studies in lower organisms have raised the possibility that kinases related to Nek2 may have conserved functions in MTOC organization, as well as in other aspects of mitotic progression.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	amf5@le.ac.uk		Fry, Andrew/0000-0003-4417-7329				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Cohen PTW, 2002, J CELL SCI, V115, P241; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Francis SE, 2000, CURR TOP DEV BIOL, V49, P105; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2001, METHOD CELL BIOL, V67, P305; Fry AM, 2000, J CELL SCI, V113, P1973; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Fujioka T, 2000, BIOCHEM BIOPH RES CO, V279, P799, DOI 10.1006/bbrc.2000.4021; Graf R, 2002, J CELL SCI, V115, P1919; Graf R, 2000, CURR TOP DEV BIOL, V49, P161; GRALLERT A, 2002, IN PRESS EMBO J; Hagan IM, 2000, CURR TOP DEV BIOL, V49, P133; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jean C, 1999, EUR J CELL BIOL, V78, P549, DOI 10.1016/S0171-9335(99)80020-X; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Krien MJE, 1998, J CELL SCI, V111, P967; Krien MJE, 2002, EMBO J, V21, P1713, DOI 10.1093/emboj/21.7.1713; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Mack GJ, 1998, ARTHRITIS RHEUM, V41, P551; Mahjoub MR, 2002, J CELL SCI, V115, P1759; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2001, J CELL SCI, V114, P3749; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; Pfleger CM, 2000, GENE DEV, V14, P655; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhee K, 1997, DEVELOPMENT, V124, P2167; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; Wai DH, 2002, INT J ONCOL, V20, P441; Whitehead CM, 1999, J CELL BIOCHEM, P192; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Ye XS, 1998, MOL BIOL CELL, V9, P3019, DOI 10.1091/mbc.9.11.3019; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	77	164	176	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6184	6194		10.1038/sj.onc.1205711	http://dx.doi.org/10.1038/sj.onc.1205711			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214248				2022-12-28	WOS:000177840500007
J	Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E				Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E			Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability	ONCOGENE			English	Article						hypoxia; p53-responsive gene; cell viability; stress response	GROWTH ARREST; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-DAMAGE; HYPOXIA; P53; EXPRESSION; PROTEIN; ACTIVATION; APOPTOSIS	cDNA microarray hybridization was used in an attempt to identify novel genes participating in cellular responses to prolonged hypoxia. One of the identified novel genes, designated Hi95 shared significant homology to a p53-regulated GADD family member PA26. In addition to its induction in response to prolonged hypoxia, the increased Hi95 transcription was observed following DNA damage or oxidative stress, but not following hyperthermia or serum starvation. Whereas induction of Hi95 by prolonged hypoxia or by oxidative stress is most likely p53-independent, its induction in response to DNA damaging treatments (gamma- or UV-irradiation, or doxorubicin) occurs in a p53-dependent manner. Overexpression of Hi95 full-length cDNA was found toxic for many types of cultured cells directly leading either to their apoptotic death or to sensitization to serum starvation and DNA damaging treatments. Unexpectedly, conditional overexpression of the Hi95 cDNA in MCF7-tet-off cells resulted in their protection against cell death induced by hypoxia/glucose deprivation or H2O2. Thus, Hi95 gene seems to be involved in complex regulation of cell viability in response to different stress conditions.	Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel; Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Chumakov, PM (corresponding author), Quark Biotech Inc, QBI Enterprises Ltd, Weizmann Sci Pk,POB 4071, IL-70400 Ness Ziona, Israel.	chumakp@ccf.org; elenaf@qbi.co.il	Chumakov, Peter M/E-7731-2014; Budanov, Andrei V/HGD-5487-2022	Budanov, Andrei V/0000-0002-7943-1000; Chumakov, Peter/0000-0002-8078-2908; Gudkov, Andrei/0000-0003-2548-0154				Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI MM, 1980, OBSTET GYNECOL, V55, P728; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Faerman A, 1997, METHOD CELL BIOL, V52, P373, DOI 10.1016/S0091-679X(08)60388-X; Feldser D, 1999, CANCER RES, V59, P3915; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; JONES PA, 1975, CELL, V6, P245, DOI 10.1016/0092-8674(75)90015-X; Kataoka Y, 2000, INT J RADIAT BIOL, V76, P633; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PRICE BD, 1992, CANCER RES, V52, P3814; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sowter HM, 2001, CANCER RES, V61, P6669; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V90, P410, DOI 10.1016/0006-291X(79)91250-6; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhang W, 2001, INT J ONCOL, V18, P749	44	271	291	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6017	6031		10.1038/sj.onc.1205877	http://dx.doi.org/10.1038/sj.onc.1205877			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203114				2022-12-28	WOS:000177671300005
J	Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE				Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE			Interplay between cdk9 and NF-kappa B factors determines the level of HIV-1 gene transcription in astrocytic cells	ONCOGENE			English	Article						HIV-1 transcription; NF-kappa B; cdk9	HUMAN-IMMUNODEFICIENCY-VIRUS; TAR-INDEPENDENT TRANSACTIVATION; RNA-POLYMERASE-II; FACTOR P-TEFB; IN-VITRO; CELLULAR PROTEIN; PUR-ALPHA; CYCLIN T1; ACTIVATION; KINASE	Basal transcription of the HIV-1 genome is controlled by a variety of ubiquitous and inducible regulatory factors, some with the ability to associate with the viral DNA sequences within the promoter spanning the long terminal repeat (LTR). In this report we demonstrate that activation of the HIV-1 promoter through the inducible DNA binding NF-kappaB transcription factors can be affected by cdk9 in human astrocytic cells. Our results show that ectopic expression of cdk9, but not its mutant variant which lacks the domain responsible for its kinase activity, augments transcription of the LTR. Moreover, we demonstrate that induction of the NF-kappaB pathway by PMA, or overexpression of its subunits including p50/p65 have a negative effect on the ability of cdk9 to stimulate viral gene transcription in these cells. Results from band-shift experiments demonstrated significant suppression of p50/p65 association to its DNA target motif by cdk9. Further, data from GST pull-down and combined immunoprecipitation/Western blot analysis of the protein extracts from cells expressing cdk9, p50 and p65 have revealed the interaction of cdk9 with both p50 and p65 in the absence of DNA containing the kappaB motif. All of these observations led us to conclude that the interaction of cdk9 with the NF-kappaB factors can determine the ability of NF-kappaB to modulate HIV-1 gene transcription.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Sbarro Inst Canc Res, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12Th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Hiscott J, 1997, J LEUKOCYTE BIOL, V62, P82, DOI 10.1002/jlb.62.1.82; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; LINDHOLM P F, 1990, New Biologist, V2, P1034; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rostasy K, 2000, J NEUROVIROL, V6, P537, DOI 10.3109/13550280009091954; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	27	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5797	5803		10.1038/sj.onc.1205754	http://dx.doi.org/10.1038/sj.onc.1205754			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173051				2022-12-28	WOS:000177463400016
J	Scarr, RB; Sharp, PA				Scarr, RB; Sharp, PA			PDCD2 is a negative regulator of HCF-1 (C1)	ONCOGENE			English	Article						host cell factor 1 (HCF-1); MYND domain; PDCD2 protein; N-CoR/mSin3A corepressor complexes; cell cycle progression	HERPES-SIMPLEX VIRUS; ACUTE MYELOID-LEUKEMIA; PROGRAMMED CELL-DEATH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACCESSORY FACTOR HCF; DNA-BINDING DOMAIN; OCT-1 POU DOMAIN; VP16-INDUCED COMPLEX; TRANSCRIPTIONAL REGULATION; CONFORMATIONAL ALTERATION	Temperature sensitive mutations in host cell factor 1 (HCF-1) arrest cells in the middle of the G1 phase of the cycle. We have shown that the highly conserved C-terminal WYF domain of HCF-1 protein interacts with the MYND domain of the PDCD2 protein. This interaction is conserved between human HCF-1 and HCF-2 and the C. elegans HCF. Overexpression of PDCD2, which interacts with the N-CoR/mSin3A corepressor complexes, suppresses cotransfected HCF-1 complementation of a temperature lesion in the endogenous HCF-1 protein. Overexpression of domains of either PDCD2 or HCF-1, which should interfere with interactions between these two proteins, enhances the complementation.	MIT, Dept Biol, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sharp, PA (corresponding author), MIT, Dept Biol, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [P01-CA042063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Amiel A, 1999, CANCER GENET CYTOGEN, V112, P53, DOI 10.1016/S0165-4608(98)00255-6; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; D'MELLO SR, 1993, NEUROREPORT, V4, P355, DOI 10.1097/00001756-199304000-00003; FEINSTEIN PG, 1995, GENETICS, V140, P573; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hauptschein RS, 2000, DNA RES, V7, P261, DOI 10.1093/dnares/7.4.261; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KAWAKAMI T, 1995, CYTOGENET CELL GENET, V71, P41, DOI 10.1159/000134058; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Liu Y, 1999, MOL CELL BIOL, V19, P909; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; Misra V, 1996, MOL CELL BIOL, V16, P4404; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Schonemann MD, 1998, ADV EXP MED BIOL, V449, P39; Sowa Y, 1997, CANCER RES, V57, P3145; Stilgenbauer S, 1999, LEUKEMIA, V13, P1331, DOI 10.1038/sj.leu.2401499; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; VAUX DL, 1995, DNA CELL BIOL, V14, P189, DOI 10.1089/dna.1995.14.189; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6	60	44	45	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5245	5254		10.1038/sj.onc.1205647	http://dx.doi.org/10.1038/sj.onc.1205647			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149646				2022-12-28	WOS:000177193900006
J	Hertel, CB; Zhou, XG; Hamilton-Dutoit, SJ; Junker, S				Hertel, CB; Zhou, XG; Hamilton-Dutoit, SJ; Junker, S			Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma	ONCOGENE			English	Article						transcription factors; B cell markers; extinction; Hodgkin lymphoma	HEAVY-CHAIN; T-CELL; GENE-TRANSCRIPTION; ACTIVATOR PROTEIN; ENHANCER ACTIVITY; 3ALPHA ENHANCER; DOWN-REGULATION; TARGET GENES; NF-HB; EXPRESSION	In classical Hodgkin lymphoma the malignant Hodgkin/Reed-Sternberg (HRS) cells characteristically constitute only a small minority of the tumour load. Their origin has been debated for decades, but on the basis of rearrangement and somatic hypermutations of their immunoglubulin (Ig) genes, HRS cells are now ascribed to the B-cell lineage. Nevertheless, phenotypically HRS cells have lost their B cell identity: they usually lack common B cell-specific surface markers such as CD19 and CD79a as well as Ig gene transcripts. Here we demonstrate that Ig promoters as well as both intronic and 3' enhancer sequences are transcriptionally inactive in HRS cell lines. This inactivity correlates with either reduced levels or even a complete lack of several B cell-specific transcription factors required for their expression: Oct-2, OBF-1, PU.1, E47/E12, PAX-5 and EBF. Moreover, we demonstrate that PU.1 and PAX-5 are significantly down-regulated in HRS cells in pathological specimens from primary tumour tissues. However, forced expression of these transcription factors can activate regulatory sequences of silenced B cell marker genes, and in one instance also transcription from a silenced endogenous locus. Thus, HRS cells are dedifferentiated B cells with global down-regulation of B cell-specific genes.	Aarhus Univ, Inst Human Genet, DK-8000 Aarhus, Denmark; Aarhus Univ, Inst Pathol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Junker, S (corresponding author), Aarhus Univ, Inst Human Genet, DK-8000 Aarhus, Denmark.	sjunker@biobase.dk	Dutoit, Stephen Hamilton/E-1815-2013	Hamilton-Dutoit, Stephen/0000-0003-2158-3885				Andersen AST, 1997, MOL IMMUNOL, V34, P97, DOI 10.1016/S0161-5890(97)00017-5; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Birshtein BK, 1997, CURR TOP MICROBIOL, V224, P73; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chang YF, 2000, J NONDESTRUCT EVAL, V19, P1, DOI 10.1023/A:1006671706818; CHEN HM, 1995, ONCOGENE, V11, P1549; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Foss HD, 1999, BLOOD, V94, P3108, DOI 10.1182/blood.V94.9.3108.421a21_3108_3113; Gisler R, 2000, BLOOD, V96, P1457, DOI 10.1182/blood.V96.4.1457.h8001457_1457_1464; Gisler R, 1999, MOL IMMUNOL, V36, P1067, DOI 10.1016/S0161-5890(99)00092-9; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Hsu PL, 1996, LAB INVEST, V74, P395; Jaffe ES, 2001, WHO CLASSIFICATION T; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Junker S, 1997, J CELL SCI, V110, P2579; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Krenacs L, 1998, BLOOD, V92, P1308, DOI 10.1182/blood.V92.4.1308.416k32_1308_1316; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LIEBERMAN TA, 1991, HORMONAL CONTROL REG, P399; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NEURATH MF, 1994, J IMMUNOL, V153, P730; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pettersson S, 1997, IMMUNOBIOLOGY, V198, P236, DOI 10.1016/S0171-2985(97)80044-7; Re D, 2001, CANCER RES, V61, P2080; Rothenberg EV, 2000, CURR OPIN GENET DEV, V10, P370, DOI 10.1016/S0959-437X(00)00098-8; Rudiger T, 1998, AM J SURG PATHOL, V22, P1184, DOI 10.1097/00000478-199810000-00003; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 1996, CURR OPIN IMMUNOL, V8, P160, DOI 10.1016/S0952-7915(96)80053-7; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; STEISHEN CP, 1945, MOL CELL BIOL, P15; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Theil J, 2001, BLOOD, V97, P3191, DOI 10.1182/blood.V97.10.3191; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; Watanabe K, 2000, HISTOPATHOLOGY, V36, P353; WESTON K, 1988, VIROLOGY, V162, P406, DOI 10.1016/0042-6822(88)90481-3	60	97	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					4908	4920		10.1038/sj.onc.1205629	http://dx.doi.org/10.1038/sj.onc.1205629			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118370				2022-12-28	WOS:000176874800006
J	Fusaro, G; Wang, S; Chellappan, S				Fusaro, G; Wang, S; Chellappan, S			Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis	ONCOGENE			English	Article						Rb; E2F; prohibitin; apoptosis; cell cycle	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; REPRESS TRANSCRIPTION; CELL-LINES; E2F-1; P53; PHOSPHORYLATION; PROLIFERATION; RECEPTOR	Prohibitin, a potential tumor suppressor, is known to induce growth suppression and repress E2F-mediated transcription. These growth regulatory functions of prohibitin require a physical interaction with the Rb protein. We now find that prohibitin protects cells from apoptosis mediated by camptothecin, a topoisomerase I inhibitor. Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130. This correlates with an increase in the levels of cyclin E as well as the kinase activity associated with it. Inactivation of Rb leads to the dissociation and release of free E2F. We find also that E2F activity is induced upon camptothecin treatment, but this increase is absent in prohibitin overexpressing cells. It thus appears that prohibitin may be inhibiting apoptosis by downregulating E2F activity when Rb family members are inactive.	H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, Tampa, FL 33612 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University	Chellappan, S (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER; NCI NIH HHS [CA77301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HSEIH JK, 1997, GENE DEV, V11, P1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JUPE ER, 1995, EXP CELL RES, V218, P577, DOI 10.1006/excr.1995.1194; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	40	85	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4539	4548		10.1038/sj.onc.1205551	http://dx.doi.org/10.1038/sj.onc.1205551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085232				2022-12-28	WOS:000176476700008
J	Lundberg, AS; Randell, SH; Stewart, SA; Elenbaas, B; Hartwell, KA; Brooks, MW; Fleming, MD; Olsen, JC; Miller, SW; Weinberg, RA; Hahn, WC				Lundberg, AS; Randell, SH; Stewart, SA; Elenbaas, B; Hartwell, KA; Brooks, MW; Fleming, MD; Olsen, JC; Miller, SW; Weinberg, RA; Hahn, WC			Immortalization and transformation of primary human airway epithelial cells by gene transfer	ONCOGENE			English	Article						transformation; lung cancer; immortalization; ras oncogene	LARGE T-ANTIGEN; TELOMERASE ACTIVITY; RAS ONCOGENE; LIFE-SPAN; NEOPLASTIC TRANSFORMATION; CELLULAR SENESCENCE; CLONAL GROWTH; TUMOR-CELLS; HUMAN-LUNG; IN-VITRO	One critical step in the development of a cancerous cell is its acquisition of an unlimited replicative lifespan, the process termed immortalization. Experimental model systems designed to study cellular transformation ex vivo have relied to date on the in vitro selection of a subpopulation of cells that have become immortalized through treatment with chemical or physical mutagens and the selection of rare clonal variants. In this study, we describe the direct immortalization of primary human airway epithelial cells through the successive introduction of the Simian Virus 40 Early Region and the telomerase catalytic subunit hTERT. Cells immortalized in this way are now responsive to malignant transformation by an introduced H-ras or K-ras oncogene. These immortalized human airway epithelial cells, which have been created through the stepwise introduction of genetic alterations, provide a novel experimental model system with which to study further the biology of the airway epithelial cell and to dissect the molecular basis of lung cancer pathogenesis.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Childrens Hosp, Dept Pathol, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT)	Randell, SH (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.		Stewart, Sheila A/C-5213-2012	Fleming, Mark/0000-0003-0948-4024				Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LECHNER JF, 1981, CANCER RES, V41, P2294; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Olumi AF, 1999, CANCER RES, V59, P5002; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel R R, 1988, Oncogene Res, V3, P401; REDDEL RR, 1988, CANCER RES, V48, P1904; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rich JN, 2001, CANCER RES, V61, P3556; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stoner G D, 1980, Methods Cell Biol, V21A, P15, DOI 10.1016/S0091-679X(08)60756-6; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	44	190	203	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4577	4586		10.1038/sj.onc.1205550	http://dx.doi.org/10.1038/sj.onc.1205550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085236				2022-12-28	WOS:000176476700012
J	Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C				Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C			Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer	ONCOGENE			English	Article						MLN51; breast cancer; SH2; SH3; NLS; coiled-coil	SIGNALING PROTEINS; SH3 DOMAINS; MAMMALIAN-CELLS; FACTOR RECEPTOR; COILED COILS; IDENTIFICATION; CARCINOMA; DNA; LOCALIZATION; PRECURSOR	Metastatic Lymph Node 51 (MLN51) cDNA was isolated by differential screening of a human breast cancer metastasis cDNA library. MLN51 cDNA encodes a novel human protein of 703 residues that shares no significant homology to any known protein. However MLN51 is well conserved between vertebrate and invertebrate species suggesting an important biological function. The amino terminal half of the protein contains a coiled-coil domain and two potential nuclear localization signals (NLS). The carboxy terminal half contains one SH2 and four SH3 binding motifs. The coiled-coil domain promotes MLN51 oligomerization in transfected cells. When transiently expressed, the MLN51 protein is mainly found in the cytoplasm with a weak nuclear staining. However, deletion of the carboxy terminal half of the protein allows the targeting of the protein to the nucleus, demonstrating that the NLSs are functional. MLN51 is ubiquitously expressed in normal tissues. Human breast carcinomas show MLN51 overexpression in malignant epithelial cells. The uncommon association of protein-protein interaction domains often found either in nuclear or in cytoplasmic signaling proteins raises a possible nucleo-cytoplasmic function for MLN51.	Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Tomasetto, C (corresponding author), Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	cat@igbmc.u-strasburg.fr	Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014	Tomasetto, Catherine Laure/0000-0002-1811-5848; Regnier, Catherine/0000-0002-4386-1324				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bieche I, 1996, CANCER RES, V56, P3886; Boyle P, 2000, INT J GYNECOL OBSTET, V70, P263, DOI 10.1016/S0020-7292(00)00298-8; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mayer BJ, 2001, J CELL SCI, V114, P1253; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SHOEMAN RL, 1993, BIOESSAYS, V15, P605, DOI 10.1002/bies.950150906; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000; Yu DL, 2000, CHINESE PHYS LETT, V17, P19, DOI 10.1088/0256-307X/17/1/007; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4422	4434		10.1038/sj.onc.1205611	http://dx.doi.org/10.1038/sj.onc.1205611			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080473				2022-12-28	WOS:000176317100008
J	Blanco, MJ; Moreno-Bueno, G; Sarrio, D; Locascio, A; Cano, A; Palacios, J; Nieto, MA				Blanco, MJ; Moreno-Bueno, G; Sarrio, D; Locascio, A; Cano, A; Palacios, J; Nieto, MA			Correlation of Snail expression with histological grade and lymph node status in breast carcinomas	ONCOGENE			English	Article						Snail; E-cadherin; breast carcinoma; invasive ductal carcinomas; lobular carcinoma	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; NEURAL CREST; IN-SITU; VERTEBRATE DEVELOPMENT; LOBULAR CARCINOMA; GENE-EXPRESSION; BETA-CATENIN; CHICK; TISSUE	Snail is a zinc finger transcription factor that triggers the epithelial-mesenchymal transition (EMT) by directly repressing E-cadherin expression. Snail is required for mesoderm and neural crest formation during embryonic development and has recently been implicated in the EMT associated with tumour progression. In a series of human breast carcinomas, we have analysed the expression of Snail and that of molecules of the E-cadherin/catenin complexes. We have also correlated these data with the pathological features of the tumours. We show that Snail expression inversely correlates with the grade of differentiation of the tumours and that it is expressed in all the infiltrating ductal carcinomas (IDC) presenting lymph node metastases that were analysed. In addition, Snail is expressed in some dedifferentiated tumours with a negative nodal status. Considering that Snail is involved in the induction of the invasive and migratory phenotype in epithelial cells, these results indicate that it is also involved in the progression of breast ductal tumours, where it could additionally serve as a marker of the metastatic potential.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Ctr Nacl Invest Oncol, Programa Patol Mol, Madrid, Spain; Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Nieto, MA (corresponding author), CSIC, Inst Cajal, Doctor Arce 37, E-28002 Madrid, Spain.	anieto@cajal.csic.es	Moreno-Bueno, Gema/K-9354-2016; Locascio, Annamaria/E-8714-2015; Nieto, M. Angela/A-6531-2008; Palacios, Jose/AAV-3765-2020; SARRIO, DAVID/Y-8903-2019	Moreno-Bueno, Gema/0000-0002-5030-6687; Locascio, Annamaria/0000-0001-6956-2157; Nieto, M. Angela/0000-0002-3538-840X; Sarrio, David/0000-0003-4886-8290				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1996, ONCOGENE, V13, P1919; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; GRAU Y, 1984, GENETICS, V108, P347; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; KOHN EC, 1995, CANCER RES, V55, P1856; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Locascio A, 2001, CURR OPIN GENET DEV, V11, P464, DOI 10.1016/S0959-437X(00)00218-5; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; PALACIOS J, 1995, AM J PATHOL, V146, P605; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Ros MA, 1997, DEVELOPMENT, V124, P1821; Sefton M, 1998, DEVELOPMENT, V125, P3111; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Van Diest PJ, 1999, J PATHOL, V187, P383, DOI 10.1002/(SICI)1096-9896(199903)187:4<383::AID-PATH299>3.0.CO;2-H; Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	30	466	502	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3241	3246		10.1038/sj.onc.1205416	http://dx.doi.org/10.1038/sj.onc.1205416			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082640				2022-12-28	WOS:000175373600016
J	Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J				Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J			Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1)	ONCOGENE			English	Article						PGP9.5/UCH-L1; JAB1; p27(Kip1); lung cancer; nuclear localization; yeast two-hybrid system	DEUBIQUITINATING ENZYMES; CELL-CYCLE; CDK INHIBITOR; PROTEIN; P27; DEGRADATION; SPECIFICITY; EXPRESSION; PREDICTOR; COMPLEX	PGP9.5 (UCH-L1) is a member of the ubiquitin C-terminal hydrolase (UCH) family of proteins that is expressed in neuronal tissues. Our previous studies have shown that PGP9.5 was highly expressed in primary lung cancers and lung cancer cell lines. Additionally, the frequency of PGP9.5 over expression increases with tumor stage, indicating that PGP9.5 may play a role in lung cancer tumorigenesis. We used the yeast two-hybrid system to identify proteins that interact with PGP9.5. We show that PGP9.5 interacts with at least three proteins, one of which is JAB1, a Jun activation domain binding protein that can bind to p27(Kip1) and is involved in the cytoplasmic transportation of p27(Kip1) for its degradation. We also show that PGP9.5 is associated with JAB1 in vitro and in vivo; and that both proteins can be a part of a heteromeric complex containing p27(Kip1) in the nucleus in lung cancer cells. Furthermore, under serum-restimulation, nuclear translocation of both PGP9.5 and JAB1 coincides with a reduced level of P27(Kip1) in the nucleus. In contrast, when cells are contact inhibited, both PGP9.5 and JAB1 became more perinuclear and cytoplasmic in localization while p27(Kip1) was present only in the nucleus. Therefore, PGP9.5 may contribute to p27(Kip1) degradation via its interaction and nuclear translocation with JAB1.	NCI, Lab Populat Genet, Ctr Canc Res, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Jen, J (corresponding author), NCI, Lab Populat Genet, Ctr Canc Res, Bldg 41,Rm D702,41 Lib Dr, Bethesda, MD 20892 USA.	jenj@mail.nih.gov	Resto, Vicente/D-9891-2014		NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, J CELL BIOCHEM, P40; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hibi K, 1998, CANCER RES, V58, P5690; Hirano K, 2000, CANCER DETECT PREV, V24, P343; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hommura F, 2000, CLIN CANCER RES, V6, P4073; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; James P, 1996, GENETICS, V144, P1425; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yao J, 2000, INT J CANCER, V89, P213, DOI 10.1002/1097-0215(20000520)89:3<213::AID-IJC1>3.0.CO;2-L	33	95	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3003	3010		10.1038/sj.onc.1205390	http://dx.doi.org/10.1038/sj.onc.1205390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082530	Bronze			2022-12-28	WOS:000175262700007
J	Cummings, KM				Cummings, KM			Programs and policies to discourage the use of tobacco products	ONCOGENE			English	Review						tobacco control; smoking cessation; prevention; nicotine dependence	SMOKING-CESSATION; HEALTH WARNINGS; MEDIA COVERAGE; LOW TAR; CIGARETTE; ADOLESCENTS; MORTALITY; NICOTINE; SMOKERS; CAMPAIGN	The past 50 years has witnessed a dramatic change in attitudes toward and use of tobacco by Americans that has resulted in recent declines in the incidence of lung cancer. Most public health scholars believe that this change has been accelerated by public policy interventions to reduce tobacco use. The research literature suggests that the most potent demand reducing influences on tobacco use have been efforts to increase the financial cost of using tobacco products primarily through taxation, smoke-free policies, comprehensive advertising bans, and paid counter-advertising campaigns. New therapies for treating nicotine dependence and measures to liberalize access to medicinal forms of nicotine have the potential to revolutionize the way societies address the problem of tobacco use in the future. Unfortunately, the economic reality of the tobacco business has hindered public health efforts to curb the use of tobacco products. While government regulation of tobacco products is a worthy goal, capitalism, and not government regulation, most likely holds the greatest potential to rapidly alter the worldwide epidemic of tobacco caused disease. It is up to the public health community to harness the powers of capitalism to speed the development of less dangerous alternatives to the conventional cigarette.	Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cummings, KM (corresponding author), Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Elm & Carlton St, Buffalo, NY 14263 USA.	Michael.Cummings@Roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1981, FED TRAD COMM STAFF; Ayanian JZ, 1999, JAMA-J AM MED ASSOC, V281, P1019, DOI 10.1001/jama.281.11.1019; Bates C, 1999, TOB CONTROL, V8, P225, DOI 10.1136/tc.8.2.225; BLUM A, 1993, TOBACCO USE AM CRISI, P63; Bondurant, 2001, CLEARING SMOKE ASSES; Borland R, 1997, ADDICTION, V92, P1427; Borland R, 1997, Tob Control, V6, P317; BRANDT AM, 1990, DAEDALUS-US, V119, P155; *BROWN WILL TOB CO, 2000, NEW YORK SEN BILL FI; Cecil H, 1996, J APPL SOC PSYCHOL, V26, P502, DOI 10.1111/j.1559-1816.1996.tb02728.x; CHALOUPKA FJ, 2001, TABACCO CONTROL DEV, P237; CHALOUPKA FJ, 2002, TOBACCO CONTROL S1, V11, P62; CONNOLLY GN, 1992, MONOGR NCI, V12, P29; CUMMINGS K, 2002, IN PRESS NICOTINE TO; Cummings KM, 2002, TOB CONTROL, V11, pI110, DOI 10.1136/tc.11.suppl_1.i110; CUMMINGS KM, 2002, IN PRESS ADDICTION; CUMMINGS KM, 2002, TOBACCO CONTROL S1, V11, P5; CUNNINGHAM R, 2002, EVALUATION NEW WARNI; Curry SJ, 1998, NEW ENGL J MED, V339, P673, DOI 10.1056/NEJM199809033391006; DAVIS RM, 1989, JAMA-J AM MED ASSOC, V261, P90, DOI 10.1001/jama.261.1.90; Daynard R., 1994, TOB CONTROL, V3, P59; Daynard RA, 2001, AM J PUBLIC HEALTH, V91, P1967, DOI 10.2105/AJPH.91.12.1967; Dunn W.L., 1972, MOTIVES INCENTIVES C; *EC CONS FIRM ORZ, 2000, TAX BURD TAB HIST CO, V35; Emont SL., 1993, TOB CONTROL, V2, P13, DOI [10.1136/tc.2.1.13, DOI 10.1136/TC.2.1.13]; Evans WN, 1999, AM ECON REV, V89, P728, DOI 10.1257/aer.89.4.728; *FED COMM COMM, 1987, FED COMM COMM REC, V2, P5272; *FED TRAD COMM, 1981, REP TAR NIC CARB MON; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FIORE MC, 2000, TREATING TOBACCO USE; FISCHER PM, 1989, JAMA-J AM MED ASSOC, V261, P84, DOI 10.1001/jama.261.1.84; Fischer PM, 1993, TOB CONTROL, V2, P279, DOI DOI 10.1136/TC.2.4.279; GAJALAKSHMI GK, 2000, TOBACCO CONTROL DEV, P11; HAMILTON JL, 1972, REV ECON STAT, V54, P401, DOI 10.2307/1924567; HARRIS JE, 1997, MMWR-MORBID MORTAL W, V45, P960; Healton C, 2001, AM J PUBLIC HEALTH, V91, P554, DOI 10.2105/AJPH.91.4.554; HEATH AC, 1993, ADDICT BEHAV, V18, P19, DOI 10.1016/0306-4603(93)90005-T; Henningfield J. E., 1993, NICOTINE ADDICTION P, P24; Hieda Y, 1999, PSYCHOPHARMACOLOGY, V143, P150, DOI 10.1007/s002130050930; HO R, 1992, AUST PSYCHOL, V27, P109, DOI 10.1080/00050069208257590; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hughes JR, 1999, TOB CONTROL, V8, P323, DOI 10.1136/tc.8.3.323; *I MED, 1994, GROW TOB FREE; JHA P, 2000, TOBACCO CONTROL DEV, P449; Kennedy GE, 1999, TOB CONTROL, V8, P254, DOI 10.1136/tc.8.3.254; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; King C, 2001, NEW ENGL J MED, V345, P504, DOI 10.1056/NEJMsa003149; Kluger R, 1996, ASHES ASHES AM 100 Y; KOPSTEIN A, 2001, DHHS PUBLICATION; Kozlowski LT, 2001, TOB CONTROL, V10, P201, DOI 10.1136/tc.10.3.201; Leavell NR, 1999, TOB CONTROL, V8, P433, DOI 10.1136/tc.8.4.433; LINTHWAITE P, 1985, HLTH ED J, V44, P218, DOI DOI 10.1177/001789698504400419; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Mahood G, 1999, TOB CONTROL, V8, P356, DOI 10.1136/tc.8.4.356; MALOUFF J, 1992, J PSYCHOL, V126, P371, DOI 10.1080/00223980.1992.10543370; MITCHELL B, 1999, REV DOCUMENTS TOBACC; *NAT CANC I, 1996, MONOGRAPH US DHHS NA, V7; *NAT CANC I, 1993, NIH PUBLICATION US D; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; NOVOTNY TE, 2001, TOBACCO CONTROL DEV, P287; OKEEFE MT, 1971, PUBLIC OPIN QUART, V35, P242, DOI 10.1086/267896; PARKINSON MD, 1992, TOBACCO CONTROL S, V1, pS52; Pierce JP, 2001, TOB CONTROL, V10, P145, DOI 10.1136/tc.10.2.145; PIERCE JP, 1998, JAMA-J AM MED ASSOC, V80, P893; Pollay R., 1994, TOB CONTROL, V3, P130; Pollay R., 1994, TOB CONTROL, V3, P134; Pollay RW, 2000, TOB CONTROL, V9, P136, DOI 10.1136/tc.9.2.136; Pollay RW, 2002, TOB CONTROL, V11, pI18, DOI 10.1136/tc.11.suppl_1.i18; POLLAY RW, 1997, PUBLIC RELAT REV, V16, P27; Proctor R., 1999, NAZI WAR CANC, p[173, 226]; RABIN RL, 1993, SMOKING POLICY LAW P; Rigotti NA, 1997, NEW ENGL J MED, V337, P1044, DOI 10.1056/NEJM199710093371505; Robinson TN, 1997, ARCH PEDIAT ADOL MED, V151, P267, DOI 10.1001/archpedi.1997.02170400053010; Saffer H., 2000, TOBACCO CONTROL POLI, P215; Schauffler HH, 2001, TOB CONTROL, V10, P175, DOI 10.1136/tc.10.2.175; SCHAUFFLER HH, 1993, SMOKING POLICY LAW P, P184; Shiffman S, 1997, Tob Control, V6, P306; Shiffman S, 2001, TOB CONTROL, V10, pI17; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P380, DOI 10.2105/AJPH.90.3.380; Simonich WL, 1991, GOVT ANTISMOKING POL; SLADE J, 1993, NICOTINE ADDICTION P; Slovic P., 2001, SMOKING RISK PERCEPT, DOI 10.4135/9781452232652; Strahan EJ, 1999, ENHANCING EFFECTIVEN; SWAIN PA, 1996, Patent No. 5876727; Sweanor D, 2000, ADDICTION, V95, pS25; THOMPSON S, 2002, STOP MAGAZINE, V9, P26; U.S. Department of Health and Human Services, 2000, RED TOB US REP SURG; *US DHHS, 1989, DHHS PUBL CDC CTR CH; *US DHHS, 1986, DHHS PUBL CDC CTR HL; *US DHHS, 1994, PREV TOB US AM YOUNG; *US EPS, 1992, 600690006F EPA OFF H; WAGNER S, 1971, FED TRAD COMM; WAKEFIELD MA, 2002, IN PRESS AM J PUB HL; Warner KE, 1997, JAMA-J AM MED ASSOC, V278, P1087, DOI 10.1001/jama.278.13.1087; WARNER KE, 1992, AM J PUBLIC HEALTH, V82, P17, DOI 10.2105/AJPH.82.1.17; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WARNER KE, 1986, SELLING SMOKING CIGA; WASSERMAN J, 1991, J HEALTH ECON, V10, P43, DOI 10.1016/0167-6296(91)90016-G; Wayne GF, 2002, TOB CONTROL, V11, pI32, DOI 10.1136/tc.11.suppl_1.i32; Westman E C, 2001, Nicotine Tob Res, V3, P391, DOI 10.1080/14622200126973; Wilkenfeld J, 2000, JNCI-J NATL CANCER I, V92, P90, DOI 10.1093/jnci/92.2.90; Wilson C, 2001, NEW SCI, V172, P28; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; [No title captured]; 1967, FED REG, V29, P530; 1969, FED REG, V34, P7917	107	29	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7349	7364		10.1038/sj.onc.1205810	http://dx.doi.org/10.1038/sj.onc.1205810			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379878				2022-12-28	WOS:000178618000008
J	Hu, YC; Sidransky, D; Ahrendt, SA				Hu, YC; Sidransky, D; Ahrendt, SA			Molecular detection approaches for smoking associated tumors	ONCOGENE			English	Article						molecular detection; tumor; smoking; PCR; mutation; microsatellite instability; methylation	SQUAMOUS-CELL CARCINOMA; BRONCHOALVEOLAR LAVAGE FLUID; BLADDER-CANCER; LUNG-CANCER; MICROSATELLITE ALTERATIONS; PROMOTER HYPERMETHYLATION; CIGARETTE-SMOKING; GENE-MUTATIONS; RAS MUTATIONS; P53 MUTATIONS	Smoking is directly responsible for approximately 90% of lung cancers and is also strongly associated with cancers of the head and neck, esophagus and urinary bladder. Our growing understanding of the molecular changes that underlie cancer progression has contributed to the development of novel molecular approaches for the detection of cancer. In this study, we review a number of recent studies that have used molecular techniques to detect neoplastic DNA from lung, head and neck, esophagus and bladder cancer. The majority of these approaches are based on polymerase chain reaction (PCR) based assays. These PCR-based techniques can detect a few clonal cancer cells containing a specific DNA mutation, microsatellite alteration, or CpG island methylation among an excess background of normal cells. The ability to accurately detect a small number of malignant cells in a wide range of clinical specimens including sputum, saliva, bronchoalveolar lavage fluid, urine, serum, plasma, or tissue has significant implications for screening high-risk individuals (such as cigarette smokers) for cancer.	Univ Rochester, Dept Surg, Rochester, NY 14642 USA; Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA	University of Rochester; Johns Hopkins University; Johns Hopkins Medicine	Ahrendt, SA (corresponding author), Univ Rochester, Dept Surg, 601 Elmwood Ave, Rochester, NY 14642 USA.	steven_ahrendt@urmc.rochester.edu		Ahrendt, Steven/0000-0002-3029-2126				Ahrendt S A, 1999, Surg Oncol Clin N Am, V8, P641; Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Ahrendt SA, 2000, CANCER RES, V60, P3155; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; BLOT WJ, 1988, CANCER RES, V48, P3282; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BURCH JD, 1989, INT J CANCER, V44, P622, DOI 10.1002/ijc.2910440411; Califano J, 1999, J NATL CANCER I, V91, P599, DOI 10.1093/jnci/91.7.599; CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H; Chen XQ, 1996, NAT MED, V2, P1033; CLAVEL J, 1989, INT J CANCER, V44, P605, DOI 10.1002/ijc.2910440408; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Doll R, 1998, Stat Methods Med Res, V7, P87, DOI 10.1191/096228098668199908; Esteller M, 1999, CANCER RES, V59, P67; FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO;2-B; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HARTGE P, 1987, J NATL CANCER I, V78, P1119; Hemstreet GP, 2001, JNCI-J NATL CANCER I, V93, P427, DOI 10.1093/jnci/93.6.427; Hibi K, 2001, CLIN CANCER RES, V7, P3135; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; Miyake H, 1998, INT J CANCER, V79, P560, DOI 10.1002/(SICI)1097-0215(19981218)79:6<560::AID-IJC2>3.0.CO;2-X; MORRISON AS, 1984, J UROLOGY, V131, P650, DOI 10.1016/S0022-5347(17)50559-5; Mourah S, 1998, INT J CANCER, V79, P629, DOI 10.1002/(SICI)1097-0215(19981218)79:6<629::AID-IJC13>3.3.CO;2-T; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NAWROZ H, 1994, CANCER RES, V54, P1152; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Palmisano WA, 2000, CANCER RES, V60, P5954; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Sardi I, 2000, GENE CHROMOSOME CANC, V29, P201, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1031>3.0.CO;2-X; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Sidransky D, 1995, J Natl Cancer Inst Monogr, P27; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Strauss GM, 1997, CHEST, V111, P754, DOI 10.1378/chest.111.3.754; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Taylor JA, 1998, CANCER RES, V58, P3603; Usadel H, 2002, CANCER RES, V62, P371; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611	61	49	51	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7289	7297		10.1038/sj.onc.1205805	http://dx.doi.org/10.1038/sj.onc.1205805			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379873				2022-12-28	WOS:000178618000003
J	Ego, T; Ariumi, Y; Shimotohno, K				Ego, T; Ariumi, Y; Shimotohno, K			The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression	ONCOGENE			English	Article						HTLV-1; Tax; HDAC; HAT; CBP	NF-KAPPA-B; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; DNA METHYLATION; PROTEIN; CREB; ACETYLATION; REPRESSOR; COMPLEX; FAMILY	Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to interact with several transcription factors and regulate their transcriptional activities. The human T-cell leukemia virus type I (HTLV1) Tax oncoprotein activates transcription from its long terminal repeat (LTR) through interaction with cellular factors such as CREB and a transcriptional coactivator CBP/p300. However, little is known about the interaction between Tax and transcriptional repressors. Here, we demonstrate the physical and functional interaction between Tax and HDAC1. We found that HDAC1 represses the trans-activation function of Tax in 293T and MT4 cells. However, this repression was restored by treatment with an HDAC inhibitor, Trichostatin A. We also observed physical interaction between Tax and HDAC1 both in vitro and in vivo. The N-terminal region of HDAC I (amino acid residues 28-97) was required for this binding. Moreover, HDAC1 inhibited the synergistic trans-activation of Tax observed on ectopic expression of CBP. However, this repression was relieved by overexpression of CBP. Thus, HDAC1 is likely to compete with CBP in binding with Tax and functions as a negative regulator for the transcriptional activation by Tax.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SAGGIORO D, 1991, VIROLOGY, V182, P68, DOI 10.1016/0042-6822(91)90649-V; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	30	59	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7241	7246		10.1038/sj.onc.1205701	http://dx.doi.org/10.1038/sj.onc.1205701			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370815				2022-12-28	WOS:000178504600013
J	Robles, AI; Linke, SP; Harris, CC				Robles, AI; Linke, SP; Harris, CC			The p53 network in lung carcinogenesis	ONCOGENE			English	Review						p73; p14(ARF); mutational spectrum; mutational hotspots; tobacco smoke	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; POLYCYCLIC AROMATIC-HYDROCARBONS; CANCER MUTATIONAL HOTSPOTS; TUMOR-SUPPRESSOR P53; KINASE C-ABL; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; MAMMALIAN-CELLS; TRANSCRIPTIONAL TARGET; FUNCTIONAL INTERACTION	The p53 tumor suppressor gene lies at the crossroads of multiple cellular response pathways that control a cell's fate in response to endogenous or exogenous stresses. Positive and negative regulatory loops both upstream and downstream of p53 cooperate to finely tune its functions as a transcription factor, a DNA damage sensor, and possibly, a protein-assembly scaffold. Through this plethora of activities, p53 is a major determinant of cell survival and a safeguard against genetic instability. Functional inactivation of p53 pathways through genetic and epigenetic events affecting the p53 gene itself and/or its interacting partners occur with a high frequency in lung cancer. The p53 mutational spectrum provides molecular evidence of the etiology of lung cancer and supports abundant epidemiological data indicating the role of tobacco smoke in the causation of this disease.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), 37 Convent Dr,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Robles, Ana/0000-0001-5019-4374; Linke, Steven/0000-0001-8584-4947				Agami R, 1999, NATURE, V399, P809; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BENNETT WP, 1993, CANCER RES, V53, P4817; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DeMarini DM, 2001, CANCER RES, V61, P6679; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Gazzeri S, 1998, CANCER RES, V58, P3926; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Goldman R, 2001, CANCER RES, V61, P6367; Gong JG, 1999, NATURE, V399, P806; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hagiwara K, 1999, CANCER RES, V59, P4165; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1974, NATURE, V252, P68, DOI 10.1038/252068a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1998, CANCER RES, V58, P4023; Hussain SP, 2001, CANCER RES, V61, P6350; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; IIZASA T, 1993, CARCINOGENESIS, V14, P1789, DOI 10.1093/carcin/14.9.1789; International Agency for Research on Cancer Tobacco smoking IARC, 1986, IARC MON EV CARC RIS, V38; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY AM, 1977, NATURE, V269, P348, DOI 10.1038/269348a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu G, 2001, CANCER RES, V61, P8718; Mai M, 1998, CANCER RES, V58, P2347; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Mariatos G, 2000, MUTAT RES-FUND MOL M, V456, P59, DOI 10.1016/S0027-5107(00)00110-X; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nicholson SA, 2001, CANCER RES, V61, P5636; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nigro JM, 1997, CANCER RES, V57, P3635; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Robles AI, 2001, ACTA ONCOL, V40, P696; Robles AI, 2001, CANCER RES, V61, P6660; Rodin SN, 2000, P NATL ACAD SCI USA, V97, P12244, DOI 10.1073/pnas.180320897; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sigal A, 2000, CANCER RES, V60, P6788; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SOZZI G, 1992, CANCER RES, V52, P6079; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; Vahakangas KH, 2001, CANCER RES, V61, P4350; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WESTON A, 1993, ENVIRON HEALTH PERSP, V99, P257, DOI 10.2307/3431495; WESTON A, 1992, CANCER EPIDEM BIOMAR, V1, P481; Wiencke JK, 1999, J NATL CANCER I, V91, P614, DOI 10.1093/jnci/91.7.614; Wiesmuller L, 1996, J VIROL, V70, P737; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wolf P, 2001, CANCER RES, V61, P8113; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yoon JH, 2001, CANCER RES, V61, P7110; Yoshikawa H, 1999, ONCOGENE, V18, P3415, DOI 10.1038/sj.onc.1202677; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	119	113	116	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6898	6907		10.1038/sj.onc.1205563	http://dx.doi.org/10.1038/sj.onc.1205563			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362272				2022-12-28	WOS:000178640200005
J	Blagosklonny, MV				Blagosklonny, MV			Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs	ONCOGENE			English	Article						p53; mitosis; G2 arrest; checkpoints; paclitaxel	G(2) ARREST; DNA-DAMAGE; P53; CANCER; UCN-01; KINASE; P21(WAF1/CIP1); APOPTOSIS; PATHWAYS; THERAPY	By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancer-selective strategy for treatment of p53-deficient tumors.	New York Med Coll, Brander Canc Res Inst, Dept Med, Hawthorne, NY 10532 USA	New York Medical College	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, Dept Med, 19 Bradhurst Ave, Hawthorne, NY 10532 USA.							An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1999, LEUKEMIA, V13, P2031, DOI 10.1038/sj.leu.2401623; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li W, 1999, MOL PHARMACOL, V55, P1988; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; Smith APL, 2002, CELL CYCLE, V1, P16, DOI 10.4161/cc.1.1.96; Torres K, 1998, CANCER RES, V58, P3620; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1996, NATURE, V381, P643; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455	26	51	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6249	6254		10.1038/sj.onc.1205793	http://dx.doi.org/10.1038/sj.onc.1205793			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214265				2022-12-28	WOS:000177829000001
J	Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H				Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H			FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins	ONCOGENE			English	Article						cytokine receptor; inflammatory mediators; signal transduction; gene regulation; cytotoxicity	BREAST-CANCER CELLS; ONCOSTATIN-M; DNA METHYLATION; BINDING-PROTEIN; UP-REGULATION; TRANSCRIPTIONAL REPRESSION; GELSOLIN EXPRESSION; TARGETED DISRUPTION; GROWTH-INHIBITION; SIGNAL TRANSDUCER	The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRalpha, OSMRbeta, gp130, or the transcription factor STAT3. FR-specific induction of LIFRalpha occurs independently of de noro protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRalpha. and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines.	INSERM, U463, Inst Biol, F-44035 Nantes 01, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute; Roswell Park Cancer Institute	Blanchard, F (corresponding author), INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44035 Nantes 01, France.		Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA068612, R01CA085580] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 68612, CA 85580] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAJAJ P, 1993, CANCER LETT, V71, P143, DOI 10.1016/0304-3835(93)90109-M; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BHUYAN BK, 1992, CANCER RES, V52, P5687; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; BREITMAN TR, 1990, CANCER RES, V50, P6268; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; CAMERON DJ, 1980, J IMMUNOL, V124, P708; Chen B, 2000, CANCER RES, V60, P3290; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Klouche M, 1999, J IMMUNOL, V163, P4583; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Melki JR, 1999, CANCER RES, V59, P3730; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1432; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; RICHARDS CD, 1994, CYTOKINE, V6, P40, DOI 10.1016/1043-4666(94)90006-X; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Shin JY, 2000, CANCER RES, V60, P262; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; WARE CB, 1995, DEVELOPMENT, V121, P1283; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	60	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6264	6277		10.1038/sj.onc.1205777	http://dx.doi.org/10.1038/sj.onc.1205777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214267				2022-12-28	WOS:000177829000003
J	Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D				Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D			Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation	ONCOGENE			English	Article						thioredoxin reductase; thioredoxin; AP-1; redox; ionizing radiation	NF-KAPPA-B; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; REDOX REGULATION; GENE-EXPRESSION; RETINOID COMBINATION; OXIDATIVE STRESS; DRUG TARGET; CELL-LINES; ACTIVATION	A recently identified class of signaling factors uses critical cysteine motif(s) that act as redox-sensitive 'sulfhydryl switches' to reversibly modulate specific signal transduction cascades regulating downstream proteins with similar redox-sensitive sites. For example, signaling factors such as redox factor-1 (Ref-1) and transcription factors such as the AP-1 complex both contain redox-sensitive cysteine motifs that regulate activity in response to oxidative stress. The mammalian thioredoxin reductase-1 (TR) is an oxidoreductase selenocysteine-containing flavoprotein that also appears to regulate multiple downstream intracellular redox-sensitive proteins. Since ionizing radiation (IR) induces oxidative stress as well as increases AP-1 DNA-binding activity via the activation of Ref-1, the potential roles of TR and thioredoxin (TRX) in the regulation of AP-1 activity in response to IR were investigated. Permanently transfected cell lines that overexpress wild type TR demonstrated constitutive increases in AP-1 DNA-binding activity as well as AP-1-dependent reporter gene expression, relative to vector control cells. In contrast, permanently transfected cell lines expressing a TR gene with the active site cysteine motif deleted were unable to induce AP-1 activity or reporter gene expression in response to IR. Transient genetic overexpression of either the TR wild type or dominant-negative genes demonstrated similar results using a transient assay system. One mechanism through which TR regulates AP-1 activity appears to involve TRX sub-cellular localization, with no change in the total TRX content of the cell. These results identify a novel function of the TR enzyme as a signaling factor in the regulation of AP-1 activity via a cysteine motif located in the protein.	NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Sect Canc Biol, Mallinckrodt Inst Radiol, St Louis, MO USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiol, Iowa City, IA USA; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 606, Japan; Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; University of Iowa; Kyoto University; Kyoto University	Gius, D (corresponding author), NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, 9000 Rockville Pike,Bldg 10,Room B3B69, Bethesda, MD 20892 USA.	giusd@mail.nih.gov	; Hirota, Kiichi/E-9181-2010	Goswami, Prabhat/0000-0002-5700-2096; Spitz, Douglas/0000-0002-1254-8765; Hirota, Kiichi/0000-0003-1110-0827	NATIONAL CANCER INSTITUTE [R01CA078282, R29CA069593, R01CA071401, K08CA072602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78282, CA69593, CA 71401, 1 K08 CA72602-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Berggren M, 1996, ANTICANCER RES, V16, P3459; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Gallegos A, 1996, CANCER RES, V56, P5765; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 2000, BIOCHEM BIOPH RES CO, V275, P825, DOI 10.1006/bbrc.2000.3392; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; Kirkpatrick DL, 1997, ONCOL RES, V9, P351; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Oberley TD, 2001, FREE RADICAL BIO MED, V30, P412, DOI 10.1016/S0891-5849(00)00486-X; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; Powis G, 1998, CHEM-BIOL INTERACT, V112, P23, DOI 10.1016/S0009-2797(97)00148-8; Sasada Tetsuro, 1996, Journal of Toxicological Sciences, V21, P285; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; Wei SJ, 2000, CANCER RES, V60, P6688; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	39	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6317	6327		10.1038/sj.onc.1205749	http://dx.doi.org/10.1038/sj.onc.1205749			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214272				2022-12-28	WOS:000177829000008
J	Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I				Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I			Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells	ONCOGENE			English	Article						Smad4; tumor suppressor gene; TGF-beta; E-cadherin; invasion	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; COLORECTAL-CANCER; GENE; DPC4; MUTATIONS; EXPRESSION; PROTEINS	Smad4 is an intracellular transmitter of TGF-beta signals and its tumor suppressor function is presumed to reside in its capacity to mediate TGF-beta-induced growth inhibition. However, there is accumulating evidence that this hypothesis may be too simple. The roles of TGF-beta in carcinogenesis are complex and also comprise tumor promoting functions particularly in late stage carcinogenesis. Importantly, functional inactivation of Smad4 in colon carcinomas frequently occurs at late stages when tumors acquire invasive and metastatic capabilities. We have previously reported that stable re-expression of Smad4 in SW480 human colon carcinoma cells was adequate to suppress tumor growth in nude mice. However, it did not affect cell growth in vitro nor did it restore TGF-beta responsiveness. Here, we report that Smad4 transcriptionally induced classical cadherins including the invasion suppressor E-cadherin, presumably re-establishing epithelial morphology. Smad4-induced cadherins were able to recruit catenins to the plasma membrane and were functionally active in cell-cell adhesion. These results indicate a novel pathway of Smad4-mediated tumor suppression and suggest that Smad4 in colon cells may be involved in the maintenance of epithelial traits.	Ruhr Univ Bochum, IMBL, Dept Internal Med, D-4630 Bochum, Germany; Univ Cologne, Dept Pathol, Cologne, Germany; State Univ Ghent VIB, Dept Mol Biomed Res, Mol Cell Biol Unit, B-9000 Ghent, Belgium	Ruhr University Bochum; University of Cologne; Flanders Institute for Biotechnology (VIB); Ghent University	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	van Roy, Frans M/C-6123-2009; Reinacher-Schick, Anke C/F-2722-2012	van Roy, Frans M/0000-0003-4358-1039; Berx, Geert/0000-0001-5770-2458				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fink SP, 2001, CANCER RES, V61, P256; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hajra KM, 2002, CANCER RES, V62, P1613; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; KINGSTON P, 1994, RES SOCIAL STRATIFIC, V13, P3; Kitagawa K, 1996, INT J CANCER, V66, P91, DOI 10.1002/(SICI)1097-0215(19960328)66:1<91::AID-IJC16>3.0.CO;2-E; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wilentz RE, 2000, CANCER RES, V60, P2002; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	64	57	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6049	6058		10.1038/sj.onc.1205766	http://dx.doi.org/10.1038/sj.onc.1205766			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203117				2022-12-28	WOS:000177671300008
J	Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F				Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F			Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						FGF-binding proteins; FGF-BP; prostate cancer cells; ribozyme-targeting; prostate tumorigenesis; HBp17	FIBROBLAST-GROWTH-FACTOR; GENE-EXPRESSION; STRUCTURAL CHARACTERIZATION; ANGIOGENIC SWITCH; OVER-EXPRESSION; RETINOIC ACID; TUMOR-GROWTH; RECEPTOR; STIMULATION; CARCINOMA	Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male. Since locally advanced or metastatic prostate tumors are essentially incurable, identification of new target molecules and treatment strategies is of critical importance. Fibroblast growth factor-2 (FGF-2) acts as potent mitogen which is upregulated in prostate cancers modulating cancer cell proliferation and development of an invasive phenotype. Normally it is tightly bound to the extracellular matrix that quenches its biological activity. The FGF-binding proteins (FGF-BP, HBp17) is a secreted protein which is able to mobilize and activate FGF-2 from the extracellular matrix. Here we show that FGF-BP is highly expressed in prostate tumor cells. To study the functional role of FGF-BP, we use a ribozymetargeting approach to selectively deplete FGF-BP in prostate cancer cells achieving a more than 50% reduction of FGF-BP mRNA and protein levels in two mass-transfected cell lines. FGF-BP depletion reduces proliferation of the cells in vitro without changes in cell cycle distribution or apoptosis. Using cDNA microarrays, Northern blotting and RT-PCR, we show a complex pattern of changes in the gene expression profiles upon FGF-BP depletion. Most strikingly, ribozyme-mediated reduction of FGF-BP levels completely abolishes the ability of the highly metastatic PC-3 prostate carcinoma cells to grow tumors in an athymic nude mouse in vivo model which is far beyond the effects of FGF-BP ribozyme targeting observed previously in cells from other tumors in the same model. Taken together, our study identifies FGF-BP as a potential rate-limiting factor for prostate cancer growth and, due to its restricted expression pattern in adults, a potentially attractive target for prostate cancer therapy.	Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; JW Goethe Univ, Dept Med 1, Frankfurt, Germany	Philipps University Marburg; Fred Hutchinson Cancer Center; Goethe University Frankfurt	Aigner, A (corresponding author), Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2000, TOXICOLOGY, V144, P221, DOI 10.1016/S0300-483X(99)00210-3; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Aumuller G, 1999, PROSTATE, V38, P261; BEGUN FP, 1995, J UROLOGY, V153, P839, DOI 10.1016/S0022-5347(01)67732-2; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; CHACKALROY M, 1989, J CLIN INVEST, V84, P43, DOI 10.1172/JCI114167; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Giri D, 1999, CLIN CANCER RES, V5, P1063; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; LAROCCA RV, 1991, J UROLOGY, V145, P393, DOI 10.1016/S0022-5347(17)38351-9; Leung HY, 1996, ONCOGENE, V12, P1833; LiaudetCoopman EDE, 1996, BIOCHEM BIOPH RES CO, V229, P930, DOI 10.1006/bbrc.1996.1904; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Lieberman R, 2001, UROLOGY, V57, P4, DOI 10.1016/S0090-4295(00)00931-6; Martin R, 2000, J HISTOCHEM CYTOCHEM, V48, P1121, DOI 10.1177/002215540004800809; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; Middleman MN, 1996, CANCER TREAT REV, V22, P105, DOI 10.1016/S0305-7372(96)90030-4; MORI H, 1990, PROSTATE, V16, P71, DOI 10.1002/pros.2990160108; NAKAMOTO T, 1992, CANCER RES, V52, P571; NISHI N, 1988, PROSTATE, V13, P39, DOI 10.1002/pros.2990130105; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Ropiquet F, 2000, CANCER RES, V60, P4245; Ropiquet F, 1999, J UROLOGY, V162, P595, DOI 10.1016/S0022-5347(05)68632-6; Shain SA, 1996, CELL GROWTH DIFFER, V7, P573; Stoppler H, 2001, ONCOGENE, V20, P7430, DOI 10.1038/sj.onc.1204957; STORY MT, 1989, PROSTATE, V15, P355, DOI 10.1002/pros.2990150408; Thomas R, 2001, INT J CANCER, V93, P47, DOI 10.1002/ijc.1291; van Bokhoven A, 2001, PROSTATE, V47, P36; Webber MM, 1997, PROSTATE, V30, P58; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; Wellstein A, 1996, BREAST CANCER RES TR, V38, P109, DOI 10.1007/BF01803789; WU DQ, 1991, J BIOL CHEM, V266, P16778; YAGODA A, 1993, CANCER-AM CANCER SOC, V71, P1098, DOI 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	49	31	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5733	5742		10.1038/sj.onc.1205560	http://dx.doi.org/10.1038/sj.onc.1205560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173043				2022-12-28	WOS:000177463400008
J	Redeuilh, G; Attia, A; Mester, J; Sabbah, M				Redeuilh, G; Attia, A; Mester, J; Sabbah, M			Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases	ONCOGENE			English	Article						oestrogen receptor; p21(waf1); cell cycle; coactivators; cyclin-dependent kinases	CREB BINDING-PROTEIN; HISTONE ACETYLTRANSFERASE ACTIVITY; ESTROGEN-RECEPTOR; CELL-CYCLE; NUCLEAR RECEPTORS; BIOLOGICAL-ACTIVITY; P300 COACTIVATOR; DISTINCT ROLES; BREAST-CANCER; D1 EXPRESSION	We have investigated the interaction between the expression of p21(WAF1/CIP1/SDI1), a stoichiometric inhibitor of Cdk, and the transcriptional activity of the oestrogen receptor alpha (ERalpha). Transient transfection experiments demonstrated that the expression of p21(WAF1/CIP1/SDI1) amplified the transcriptional activation by ERalpha. A dominant negative mutant of Cdk2 also enhanced the ERa transcriptional activity, indicating that the underlying mechanism relies on the inhibition of Cdk2 activity and cell cycle arrest. In agreement with this conclusion, experiments with p21(WAF1/CIP1/SDI1) mutants demonstrated that the domain involved in the binding of p21(WAF1/CIP1/SDI1) to Cdks was indispensable for the modulation of ERa activity. In addition, we show that expression of p21(WAF1/CIP1/SDI1) alleviates the block on CBP function mediated by Cdk2 and in turn stimulates transcriptional activation by ERalpha in a CBP-histone acetyltransferase (HAT)-dependent manner. These results suggest a novel mechanism by which p21(WAF1/CIP1/SDI1) functions as an enhancer of ERalpha activity through the modulation of CBP function.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Sabbah, M (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	sabbah@st-antoine.inserm.fr		SABBAH, Michele/0000-0001-5368-9022				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Altucci L, 1996, ONCOGENE, V12, P2315; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Auwerx J, 1999, CELL, V97, P161; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XM, 2000, J NATL CANCER I, V92, P1403, DOI 10.1093/jnci/92.17.1403; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GAGNE D, 1994, J BIOLUM CHEMILUM, V9, P201, DOI 10.1002/bio.1170090314; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMAN T, 1995, CANCER RES, V55, P5187; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	69	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5773	5782		10.1038/sj.onc.1205753	http://dx.doi.org/10.1038/sj.onc.1205753			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173048				2022-12-28	WOS:000177463400013
J	Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R				Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R			Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair	ONCOGENE			English	Article						transcription-coupled nucleotide excision repair; DNA mismatch repair; ligation mediated PCR; cyclobutane pyrimidine dieter	COCKAYNE-SYNDROME; TUMOR-CELLS; UV; INVOLVEMENT; SUNLIGHT; LIGHT; MSH2; PHOTOPRODUCTS; DEFICIENCY; POLYMERASE	The transcription-coupled nucleotide excision repair (TONER) pathway maintains genomic stability by rapidly eliminating helix-distorting DNA adducts, such as UV-induced cyclobutane pyrimidine dimers (CPDs), specifically from the transcribed strands of active genes. DNA mismatch repair (MMR) constitutes yet another critical antimutagenic pathway that removes mispaired bases generated during semiconservative replication. It was previously reported that the human colon adenocarcinoma strains HCT11G and LoVo (bearing homozygous mutations in the MMR genes hMLH1 and hMSH2, respectively), besides manifesting hallmark phenotypes associated with defective DNA mismatch correction, are also completely deficient in TONER of UV-induced CPDs. This revealed a direct mechanistic link between MMR and TONER in human cells, although subsequent studies have either supported, or argued against, the validity of this important notion. Here, the ligation-mediated polymerase chain reaction was used to show at nucleotide resolution that MMR-deficient HCT11G and LoVo retain the ability to excise UV-induced CPDs much more rapidly from the transcribed vs the nontranscribed strands of active genes. Moreover, relative to DNA repair-proficient counterparts, MMR-deficient cells were not more sensitive to the cytotoxic effects of UV, and displayed equal ability to recover mRNA synthesis following UV challenge. These results conclusively demonstrate that hMLH1- and hMSH2-deficient human colon adenocarcinoma cells are fully proficient in TONER.	Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada; Univ Quebec, Cent Hosp, Hop St Francois Assise, Unite Rech Genet Humaine & Mol,Res Ctr, Quebec City, PQ G1L 3L5, Canada; Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1Y 4K7, Canada; Hop Maison Neuve Rosemont, Ctr Rech Guy Bernier, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Fac Med, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Laval University; Laval University; University of Quebec; University of Ottawa; Ottawa Hospital Research Institute; Universite de Montreal; Universite de Montreal	Drobetsky, EA (corresponding author), Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada.	regen.drouin@crsfa.ulaval.ca	Rochette, Patrick/HHN-2300-2022; Therrien, Jean-Philippe/AAW-8912-2021; McKay, Bruce C/I-4081-2013	Therrien, Jean-Philippe/0000-0001-5878-6841; McKay, Bruce C/0000-0002-7921-1331; Rochette, Patrick/0000-0002-0678-8869				Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; AFZAL V, 1995, MUTAGENESIS, V10, P457, DOI 10.1093/mutage/10.5.457; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; Angers M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e83; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; Drouin R, 2001, Methods Mol Biol, V148, P175; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fleck O, 1999, NAT GENET, V21, P314, DOI 10.1038/6838; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KOI M, 1994, CANCER RES, V54, P4308; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; Ljungman M, 1996, ONCOGENE, V13, P823; MAYNE LV, 1982, CANCER RES, V42, P1473; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Reitmair AH, 1997, CANCER RES, V57, P3765; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; Sonneveld E, 2001, ONCOGENE, V20, P538, DOI 10.1038/sj.onc.1204125; Sweder KS, 1996, GENETICS, V143, P1127; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Therrien JP, 2001, CANCER RES, V61, P3781; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174	42	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5743	5752		10.1038/sj.onc.1205641	http://dx.doi.org/10.1038/sj.onc.1205641			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173044				2022-12-28	WOS:000177463400009
J	Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S				Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S			Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array	ONCOGENE			English	Article						cDNA array; RT-PCR; adenocarcinoma; lung cancer	CELL LUNG-CANCER; POLO-LIKE KINASE; TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; MALIGNANT MESOTHELIOMA; HYDROCARBON RECEPTOR; ENDOTHELIAL-CELLS; TISSUE INHIBITOR	No clear patterns in molecular changes underlying the malignant processes in lung cancer of different histological types have been found so far. To identify critical genes in lung cancer progression we compared the expression profile of cancer related genes in 14 pulmonary adenocarcinoma patients with normal lung tissue by using the cDNA array technique. Principal component analyses (PCA) and permutation test were used to detect the differentially expressed genes. The expression profiles of 10 genes were confirmed by semiquantitative real-time RT-PCR. In tumour samples, as compared to normal lung tissue, the up-regulated genes included such known tumour markers as CCNB1, PLK, tenascin, KRT8, KRT19 and TOP2A. The down-regulated genes included caveolin 1 and 2, and TIMP3. We also describe, for the first time, down-regulation of the interesting SOCS2 and 3, DOC2 and gravin. We show that silencing of SOCS2 is not caused by methylation of exon 1 of the gene. In conclusion, by using the cDNA array technique we were able to reveal marked differences in the gene expression level between normal lung and tumour tissue and find possible new tumour markers for pulmonary adenocarcinoma.	Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Finnish Inst Occupat Hlth, Dept Occupat Med, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Aalto University; Finnish Institute of Occupational Health	Knuutila, S (corresponding author), Haartman Inst, Dept Med Genet, POB 21, FIN-00014 Helsinki, Finland.			Wikman, Harriet/0000-0001-6862-0888				Aalto Y, 2001, LEUKEMIA, V15, P1721, DOI 10.1038/sj.leu.2402282; Anbazhagan R, 1999, CANCER RES, V59, P5119; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bjorkqvist AM, 1998, BRIT J CANCER, V77, P260, DOI 10.1038/bjc.1998.42; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; Chen JJW, 2001, CANCER RES, V61, P5223; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Cilley RE, 2000, J PEDIATR SURG, V35, P113, DOI 10.1016/S0022-3468(00)80026-3; Diviani D, 2001, J CELL SCI, V114, P1431; Dohmoto K, 2000, LUNG CANCER-J IASLC, V30, P55, DOI 10.1016/S0169-5002(00)00125-2; Dohr O, 1997, MOL PHARMACOL, V51, P703, DOI 10.1124/mol.51.5.703; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; EVERETT AD, 2001, J BIOL CHEM, V31, P31; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Hand D. J., 2001, ADAPTIVE COMPUTATION; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hellmann GM, 2001, TOXICOL SCI, V61, P154, DOI 10.1093/toxsci/61.1.154; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Huang Y, 2001, LAB INVEST, V81, P863, DOI 10.1038/labinvest.3780295; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Karameris A, 1997, AM J RESP CRIT CARE, V156, P1930, DOI 10.1164/ajrccm.156.6.9612046; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Kellner U, 2000, ONKOLOGIE, V23, P424, DOI 10.1159/000027205; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kishimoto T, 2001, NAT GENET, V28, P4, DOI 10.1038/88244; Kojima S, 2000, BLOOD, V95, P1309; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee IH, 1997, MOL CELLS, V7, P589; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; Nhung N V, 1999, Cesk Patol, V35, P80; Nishihira J, 1998, INT J MOL MED, V2, P17; PENDLETON N, 1994, EUR J CANCER, V1, P93; PINES J, 1992, CIBA F SYMP, V170, P187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; RAZANI B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241; Reeves R, 1995, Prog Cell Cycle Res, V1, P339; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Soria JC, 2000, CANCER RES, V60, P4000; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; Thomas P, 2000, J PATHOL, V190, P150; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tuder RM, 2001, EUR RESPIR J, V17, P1065, DOI 10.1183/09031936.01.00202701; Ueki T, 2000, CANCER RES, V60, P1835; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wilson MJ, 2000, IMMUNOL RES, V22, P21, DOI 10.1385/IR:22:1:21; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wolf M, 2000, CANCER GENET CYTOGEN, V123, P128, DOI 10.1016/S0165-4608(00)00319-8; Xia W, 2001, CANCER RES, V61, P5644; Xiao S, 1997, AM J PATHOL, V150, P901; Ylisirnio S, 2001, CLIN CANCER RES, V7, P1633; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	84	148	164	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5804	5813		10.1038/sj.onc.1205726	http://dx.doi.org/10.1038/sj.onc.1205726			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173052				2022-12-28	WOS:000177463400017
J	Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ				Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ			Several regions of p53 are involved in repression of RNA polymerase III transcription	ONCOGENE			English	Article						p53; repression; RNA polymerase III; TFIIIB; transcription	TATA-BINDING-PROTEIN; WILD-TYPE P53; TUMOR SUPPRESSORS; DNA-BINDING; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; FACTOR-TFIIIB; AMINO-ACIDS; DAMAGED DNA	The tumour suppressor p53 has been shown to regulate RNA polymerase (pol) III transcription both in vitro and in vivo. We have characterized the regions of p53 that contribute to this effect. Repression of pol III transcription in vivo does not require residues 13-19 near the N-terminus of p53 that are highly conserved through evolution. However, amino acids 22 and 23 in the adjacent transactivation domain do contribute to the inhibition of pol III activity. Deletions within the central DNA-binding core domain (residues 102-292) of p53 can entirely abolish the repression function in these assays, despite the fact that pol III templates contain no recognized p53 binding site. Deletion or substitution within the C-terminal domain of p53 can also compromise its ability to repress pol III activity in vitro and in transfected cells. These observations reveal that repression of pol III transcription is a complex function involving multiple regions of p53 extending throughout much of the protein.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England	University of Glasgow; University of York - UK	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN KV, 1992, SCIENCE, V255, P459; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; Molinari M, 1996, ONCOGENE, V13, P2077; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOUSSI T, 1990, ONCOGENE, V5, P945; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; White RJ, 1998, INT J ONCOL, V12, P741; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	65	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5540	5547		10.1038/sj.onc.1205739	http://dx.doi.org/10.1038/sj.onc.1205739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165852				2022-12-28	WOS:000177442000003
J	Bianco, NR; Montano, MM				Bianco, NR; Montano, MM			Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth	ONCOGENE			English	Article						estrogen; estrogen receptor alpha; prothymosin alpha	QUINONE REDUCTASE GENE; TRANSCRIPTIONAL ACTIVATION; LINKER HISTONES; EXPRESSION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION; CLONING; REGION	Prothymosin alpha (PTalpha) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues. Its high conservation in mammals and wide tissue distribution suggest an essential biological role. While the exact mechanism of action of PTalpha remains elusive, the one constant has been its relationship with the proliferative state of the cell and its requirement for cellular growth and survival. Recently PTalpha was found to promote transcriptional activity by sequestering the anticoactivator, REA from the Estrogen Receptor (ER) complex. We now report that Estradiol (E-2) upregulates PTa mRNA and protein expression. Further studies indicate that ERalpha regulates PTa gene transcriptional activity. We have also delimited the region of PTalpha gene promoter involved in ERalpha-mediated transcriptional regulation and identified a novel ERalpha-binding element. Increased intracellular PTalpha expression in the presence of estrogens is accompanied by increased nuclear/decreased cytoplasmic localization. Increased nuclear expression of PTalpha is correlated with increased proliferation as measured by expression of Ki67 nuclear antigen. Conversely, inhibition of nuclear PTalpha expression in breast cancer cells using antisense methodology resulted in the inhibition of E-2-induced breast cancer cell proliferation. Overall these studies underscore the importance of PTalpha in estrogen-induced breast cell proliferation.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44122 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER; NCI NIH HHS [CA80959] Funding Source: Medline; NIGMS NIH HHS [T32 GM08056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; AUSUBEL FM, 1992, SHORT PROTOCALS MOL; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Enkemann SA, 2000, J HISTOCHEM CYTOCHEM, V48, P1341, DOI 10.1177/002215540004801005; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; Garnier M, 1997, J NEUROSCI, V17, P4591; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Loidi L, 1999, LIFE SCI, V64, P2125, DOI 10.1016/S0024-3205(99)00161-7; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Magdalena C, 2000, BRIT J CANCER, V82, P584, DOI 10.1054/bjoc.1999.0968; MANROW RE, 1991, J BIOL CHEM, V266, P3916; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; MOL PC, 1995, MOL CELL BIOL, V15, P6999; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PerezEstevez A, 1997, J BIOL CHEM, V272, P10506; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SZABO P, 1993, HUM GENET, V90, P629; Tsitsilonis OE, 1998, ANTICANCER RES, V18, P1501; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wu CL, 1997, LIFE SCI, V61, P2091, DOI 10.1016/S0024-3205(97)00882-5; ZALVIDE JB, 1992, J BIOL CHEM, V267, P8692; Zhao RB, 2000, GENE DEV, V14, P981	53	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5233	5244		10.1038/sj.onc.1205645	http://dx.doi.org/10.1038/sj.onc.1205645			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149645				2022-12-28	WOS:000177193900005
J	Hoo, LS; Zhang, JYY; Chan, EKL				Hoo, LS; Zhang, JYY; Chan, EKL			Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer	ONCOGENE			English	Article						auto-antigen; auto-antibody; tumor associated antigen; tumor auto-immunity	RNA-BINDING-PROTEINS; CHRONIC LIVER-DISEASE; HEPATITIS-C VIRUS; HEPATOCELLULAR-CARCINOMA; ANTINUCLEAR ANTIBODIES; RISK-FACTORS; SS-A/RO; KH-DOMAIN; AUTOANTIBODIES; AUTOANTIGEN	Recently our laboratory identified a cytoplasmic RNA-binding protein p62 which binds to and regulates the expression of IGF II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90 localized to the cytoplasm in cultured cells and mouse fetal, but not adult liver. Among 11 human gastric cancer tissues examined, p90 was overexpressed in six (55%). Together with other cancer associated auto-antibodies such as anti-p53, anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer may be directly linked to aberrant auto-antigen expression.	Scripps Res Inst, Dept Mol & Expt Med, WM Keck Autoimmune Dis Ctr, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, DNA Core Lab Struct Anal, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Chan, EKL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, WM Keck Autoimmune Dis Ctr, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	echan@scripps.edu	Chan, Edward K. L./B-5671-2009; Zhang, Jianying/F-3798-2010	Chan, Edward K. L./0000-0003-3938-9503; 	NATIONAL CANCER INSTITUTE [R01CA056956] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039645] Funding Source: NIH RePORTER; NCI NIH HHS [CA56956] Funding Source: Medline; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI39645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; Chan EKL, 1994, MANUAL BIOL MARKERS, P1; CHANDLER N, 1998, P 19 ANN C CAN NUCL, V1, P1; Covini G, 1997, J HEPATOL, V26, P1255, DOI 10.1016/S0168-8278(97)80460-6; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fritzler MJ, 2000, J INVEST MED, V48, P28; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; IMAI H, 1993, CANCER-AM CANCER SOC, V71, P26, DOI 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N; Kikuno R, 2000, NUCLEIC ACIDS RES, V28, P331, DOI 10.1093/nar/28.1.331; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lu ML, 2001, AM J PATHOL, V159, P945, DOI 10.1016/S0002-9440(10)61770-1; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; Rattner JB, 1997, CLIN INVEST MED, V20, P308; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Selak S, 1999, J INVEST MED, V47, P311; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; Soussi T, 2000, CANCER RES, V60, P1777; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; Tan EM, 2001, J CLIN INVEST, V108, P1411, DOI 10.1172/JCI200114451; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Wang DR, 1996, J INVEST DERMATOL, V107, P610, DOI 10.1111/1523-1747.ep12584194; Zhang JY, 1998, AM J TROP MED HYG, V59, P947, DOI 10.4269/ajtmh.1998.59.947; Zhang JY, 1998, INT J EPIDEMIOL, V27, P574, DOI 10.1093/ije/27.4.574; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101; Zhang JY, 2001, CLIN IMMUNOL, V100, P149, DOI 10.1006/clim.2001.5048; Zhang JY, 2001, CLIN EXP IMMUNOL, V125, P3, DOI 10.1046/j.1365-2249.2001.01585.x	39	114	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5006	5015		10.1038/sj.onc.1205625	http://dx.doi.org/10.1038/sj.onc.1205625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118381				2022-12-28	WOS:000176874800017
J	Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH				Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH			Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours	ONCOGENE			English	Article						Cre-loxP; Luca region; chromosome 3; deletion; breast cancer; lung cancer	EMBRYONIC STEM-CELLS; FREQUENT EPIGENETIC INACTIVATION; SUPPRESSOR GENE; LUNG-CANCER; ALLELE LOSS; RASSF1A; BREAST; MICE; RECOMBINATION; GENERATION	Chromosomal deletions are a common feature of epithelial tumours and when further defined by homozygous deletions, are often the location of tumour suppressor genes. Deletions within the short arm of chromosome 3 occur very frequently in human carcinomas: a minimal region of loss at 3p21.3 (the Luca) region has been defined by overlapping homozygous deletions in lung and breast cancer cell lines. Using a rapid strategy for Cre-loxP chromosome engineering, a deletion of approximately 370 kb was created in the mouse germline corresponding to the deleted region at 3p21.3. The deletion when homozygous is embryonic lethal. Heterozygotes develop normally despite being haplo-insufficient for twelve genes including the candidate tumour suppressor gene Rassf1. Because damage to 3p21.3 often occurs very early in the sequence of genetic changes that lead to malignancy, particularly in lung and breast cancer, further genetic damage to these mice will provide the opportunity to model multi-step tumorigenesis of these tumours.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Cambridge, Ctr Mrc, Dept Oncol, Cambridge CB2 2QH, England	University of Edinburgh; University of Cambridge	Smith, AJH (corresponding author), Univ Edinburgh, Ctr Genome Res, W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.		Johnstone, Karen/E-2369-2011	Johnstone, Karen/0000-0002-3183-8397				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chung GTY, 1995, ONCOGENE, V11, P2591; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hesketh R., 1997, ONCOGENE TUMOUR SUPP; Justice MJ, 1997, METHODS, V13, P423, DOI 10.1006/meth.1997.0548; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Lee MG, 2001, CANCER RES, V61, P6688; LePage DF, 2000, P NATL ACAD SCI USA, V97, P10471, DOI 10.1073/pnas.97.19.10471; Lerman MI, 2000, CANCER RES, V60, P6116; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mitelman F, 1991, CATALOGUE CHROMOSOME; Morrissey C, 2001, CANCER RES, V61, P7277; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wistuba II, 2000, CANCER RES, V60, P1949; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	27	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4521	4529		10.1038/sj.onc.1205530	http://dx.doi.org/10.1038/sj.onc.1205530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085230				2022-12-28	WOS:000176476700006
J	Alarcon-Vargas, D; Tansey, WP; Ronai, Z				Alarcon-Vargas, D; Tansey, WP; Ronai, Z			Regulation of c-myc stability by selective stress conditions and by MEKK1 requires aa 127-189 of c-myc	ONCOGENE			English	Article						c-myc; stress kinases; MEKK1; protein stability; cytokines; TNF alpha	RECEPTOR-INTERACTING PROTEIN; CELL-LINE; PHOSPHORYLATION; TRANSACTIVATION; STABILIZATION; EXPRESSION; DEGRADATION; ACTIVATION; KINASE; JNK	C-myc availability is central for its ability to serve as a regulator of cell growth and death. Here we study the regulation of c-myc protein stability and identify domains of c-myc that are important for its stabilization in response to stress kinases activated following selective stress conditions. UV-irradiation elicited an increase in c-myc protein levels, which could be attenuated by inhibitors of stress kinases but also by actinomycin D-inhibitor of transcription. Inhibition of protein synthesis results in a noticeable decrease in c-myc levels, further pointing to the short half-life of the protein. However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of C-myc, suggesting that selective stress conditions are required to increase c-myc protein stability. Expression of MEKK1, an upstream regulator of protein kinases that has been implicated in mediating the response to diverse stress conditions, also results in an efficient increase in the half-life of c-myc protein. To map c-myc domains that are responsive to stress kinases, we monitored changes in the level of c-myc deletion mutants following MEKK1 expression. Of the seven c-myc deletion mutants analysed, the domain spanning amino acids 127-189 was found to be required for MEKK1-dependent increase in c-myc stability. In all, the present study identifies a novel domain that is important for the regulation of c-myc stability by stress kinases in response to selective stress conditions.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cold Spring Harbor Laboratory	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419, P01CA013106, F31CA085197] Funding Source: NIH RePORTER; NCI NIH HHS [CA85197, CA13106, CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Dang CV, 1999, MOL CELL BIOL, V19, P1; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Park IC, 1998, CANCER LETT, V125, P17, DOI 10.1016/S0304-3835(97)00450-3; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SETH A, 1991, J BIOL CHEM, V266, P23521; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; WATERS CM, 1991, ONCOGENE, V6, P797; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	45	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4384	4391		10.1038/sj.onc.1205543	http://dx.doi.org/10.1038/sj.onc.1205543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080469				2022-12-28	WOS:000176317100004
J	Simone, C; Bagella, L; Bellan, C; Giordano, A				Simone, C; Bagella, L; Bellan, C; Giordano, A			Physical interaction between pRb and cdk9/cyclinT2 complex	ONCOGENE			English	Article						cdk9; cyclin T2; pRb; phosphorylation	RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; CYCLIN-CDK COMPLEXES; P-TEFB KINASE; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HIV-1 TAT; IN-VITRO; FUNCTIONAL INACTIVATION; MUSCLE DIFFERENTIATION	Cyclin-dependent kinase 9 (cdk9) is a multifunctional kinase with roles in different cellular pathways such as transcriptional elongation, differentiation and apoptosis. Cdk9/cyclin T differs functionally from other cdk/cyclin complexes that regulate cell cycle progression, but maintains structural affinity with those complexes. In addition, previous reports have demonstrated that the cdk9 complex is able to phosphorylate p56/pRb in vitro. In this report we show in vitro and in vivo interaction between cdk9/cyclinT2 and the protein product of the retinoblastoma gene (pRb) in human cell lines. The interaction involves the region composed of residues 129-195 of cdk9, cyctinT2 (1-642 aa) and the C-terminal domain of pRb (835-928 aa). We located the minimal region of cdk9 phosphorylation on the C-terminus of pRb, by identifying the residues between 793 and 834. This region contains at least three proline-directed serines (sp), S795, S807 and S811, which have been reported to be phosphorylated in vivo and which could be targeted by the cdk9 complex. These data suggest that, in logarithmically growing cells, cdk9/cyclin T2 and pRb are located in a nuclear multiprotein complex probably involved in transduction of cellular signals to the basal transcription machinery and that one of these signals could be the cdk9 phosphorylation of pRb.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/L-3903-2013	BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; BAGELLA, Luigi/0000-0003-2815-037X				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; CORBEIL HB, 1995, ONCOGENE, V11, P909; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; De Luca P, 1998, J CELL BIOCHEM, V70, P281, DOI 10.1002/(SICI)1097-4644(19980801)70:2<281::AID-JCB13>3.0.CO;2-Q; DECAPRIO JA, 1998, CELL, V54, P257; DEFALCO G, 2002, IN PRESS CANC BIOL T; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LIS JT, 2000, GENE DEV, V11, P2633; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pan WJ, 2001, CANCER RES, V61, P2885; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Simone C., 2001, FRONT BIOSCI, V6, P1073; Stiegler P, 2001, CRIT REV EUKAR GENE, V11, P59; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4158	4165		10.1038/sj.onc.1205511	http://dx.doi.org/10.1038/sj.onc.1205511			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037672				2022-12-28	WOS:000176186000010
J	Qiao, D; Zeeman, AM; Deng, W; Looijenga, LH; Lin, HF				Qiao, D; Zeeman, AM; Deng, W; Looijenga, LH; Lin, HF			Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas	ONCOGENE			English	Article						hiwi; piwi; spermatogenesis; germline; stem cells; seminoma	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA-IN-SITU; ALKALINE-PHOSPHATASE; STEM-CELLS; CHROMOSOMAL CONSTITUTION; SPERMATOCYTIC SEMINOMA; TESTICULAR CANCER; RNA INTERFERENCE; MESSENGER-RNA	The piwi family genes are highly conserved during evolution and play essential roles in stem cell self-renewal, gametogenesis, and RNA interference in diverse organisms ranging from Drosophila rnelanogaster and C. elegans to Arabidopsis. Here we report the molecular characterization of hiwi, a human member of the piwi gene family. hiwi maps to the long arm of chromosome 12, band 12q24.33, a genomic region that displays genetic linkage to the development of testicular germ cell tumors of adolescents and adults (TGCTs), i.e., seminomas and nonseminomas. In addition, gain of this chromosomal region has been found in some TGCTs. hiwi encodes a 3.6 kb mRNA that is expressed abundantly in the adult testis. It encodes a highly basic 861-amino-acid protein that shares significant homology throughout its entire length with other members of the PIWI family proteins in Drosophila, C. elegans and mammals. In normal human testes, him is specifically expressed in germline cells, with its expression detectable in spermatocytes and round spermatids during spermatogenesis. No expresssion was observed in testicular tumors of somatic origin, such as Sertoli cell and Leydig cell tumors. Enhanced expression was found in 12 out of 19 sampled testicular seminomas-tumors originating from embryonic germ cells with retention of germ cell phenotype. In contrast, no enhanced expression was detected in 10 nonseminomas-testicular tumors that originate from the same precursor cells as seminomas yet have lost their germ cell characteristics. Finally, no enhanced expression was detected in four spermatocytic seminomas-testicular tumors that most likely originate from germ cells capable of partial meiosis. Thus, hind is specifically expressed in both normal and malignant spermatogenic cells in a maturation stage-dependent pattern, in which it might function in germ cell proliferation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Erasmus Univ, Josephine Nefkens Inst, Univ Hosp Rotterdam Daniel, Pathol Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands	Duke University; Erasmus University Rotterdam; Erasmus MC	Lin, HF (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, POB 3709, Durham, NC 27710 USA.	h.lin@cellbio.duke.edu	Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Zeeman, Anne-Marie/0000-0002-0157-4669	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042012, R01HD033760] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33760, HD42012] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brabender J, 2001, J GASTROINTEST SURG, V5, P174, DOI 10.1016/S1091-255X(01)80031-7; Burke A, 1993, J UROL PATHOL, V1, P21; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Cox DN, 2000, DEVELOPMENT, V127, P503; COX DN, 1999, FUNCTION DROSOPHILA; deJong B, 1997, CANCER GENET CYTOGEN, V95, P88, DOI 10.1016/S0165-4608(96)00273-7; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; DeMeyts ER, 1996, J PATHOL, V178, P166; DENG W, 2002, IN PRESS DEV CELL; GONDOS B, 1993, EUR UROL, V23, P68; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; JORGENSEN N, 1995, LAB INVEST, V72, P223; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Lau YFC, 2000, CYTOGENET CELL GENET, V91, P160, DOI 10.1159/000056838; Lin HF, 1997, DEVELOPMENT, V124, P2463; Looijenga L, 1998, APMIS, V106, P71; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 1999, INT J CANCER, V83, P809, DOI 10.1002/(SICI)1097-0215(19991210)83:6<809::AID-IJC20>3.0.CO;2-0; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Meng XJ, 2001, CANCER RES, V61, P3267; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; NICHOLSON PW, 1995, BRIT J CANCER, V71, P421, DOI 10.1038/bjc.1995.86; Ogawa T, 1998, CANCER GENET CYTOGEN, V100, P36, DOI 10.1016/S0165-4608(97)00004-6; Oosterhuis JW, 1997, CANCER GENET CYTOGEN, V95, P96, DOI 10.1016/S0165-4608(96)00275-0; OOSTERHUIS JW, 1993, EUR UROL, V23, P245; OOSTERHUIS JW, 1993, EUR UROL, V23, P16; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; RADFORD DM, 1990, CANCER RES, V50, P6146; Roelofs H, 1999, J PATHOL, V189, P236; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; Ross MH., 1995, HISTOLOGY TEXT ATLAS, V3; Rothe M, 2000, AM J PATHOL, V157, P1597, DOI 10.1016/S0002-9440(10)64797-9; Schmidt A, 1999, GENETICS, V151, P749; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Sharp PA, 2000, SCIENCE, V287, P2431, DOI 10.1126/science.287.5462.2431; Shigenari A, 1998, CANCER RES, V58, P5079; SKAKKEBAEK NE, 1972, LANCET, V2, P516; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Stoop H, 2001, LAB INVEST, V81, P919, DOI 10.1038/labinvest.3780302; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; [No title captured]	50	240	264	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3988	3999		10.1038/sj.onc.1205505	http://dx.doi.org/10.1038/sj.onc.1205505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037681				2022-12-28	WOS:000175869900005
J	Jacobsen, K; Groth, A; Willumsen, BM				Jacobsen, K; Groth, A; Willumsen, BM			Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation	ONCOGENE			English	Article						oncogene; inducible ras; saturation density; reversible transformation	NIH 3T3 CELLS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSION; GENE-EXPRESSION; ONCOGENIC RAS; LAC OPERATOR; INK4A LOCUS; C-RASH; ACTIVATION	The Ras oncogene transforms cultured murine fibroblasts into malignant, focus-forming cells, whose lack of contact inhibition is evidenced by high saturation densities. In order to investigate the reversibility of Ras transformation, as well as the kinetics of Ras-induced changes, cell lines that conditionally express oncogenic Ras were constructed. Both focus formation and increased saturation density were inducible and fully reversible. In exponentially growing cells, oncogenic Ras-expression had no effect on proliferation rates, Erk phosphorylation, or the level of cyclin D1, and Ras-induction did not confer serum-independent growth. As expected, growth to high density in uninduced cells led to quiescence with a low level of cyclin D1 and no active Erk; in this setting, Ras induction prevented full downregulation of cyclin D1 and inactivation of Erk. Our results show that Ras expression to a level sufficient for transformation leads to relatively subtle effects on known downstream targets, and that the focus formation and increased saturation density growth induced by Ras is not a result of growth factor independence.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark	University of Copenhagen	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark.	bmw@biobase.dk	Willumsen, Berthe M/H-1903-2012; Groth, Anja/AAH-5386-2019	Willumsen, Berthe M/0000-0002-2277-6999; Groth, Anja/0000-0003-0577-1771				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHUNG HH, 1992, BIOCHIM BIOPHYS ACTA, V1129, P278, DOI 10.1016/0167-4781(92)90504-S; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FILMUS J, 1994, ONCOGENE, V9, P3627; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Harvey J J, 1971, Int Rev Exp Pathol, V10, P265; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; JACOBSEN KD, 1995, J MOL BIOL, V252, P289, DOI 10.1006/jmbi.1995.0496; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SIMONS PJ, 1967, NATURE, V214, P897, DOI 10.1038/214897a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; Villalonga P, 2000, ONCOGENE, V19, P690, DOI 10.1038/sj.onc.1203341; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZAVADA J, 1970, NATURE, V225, P24, DOI 10.1038/225024a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	54	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3058	3067		10.1038/sj.onc.1205423	http://dx.doi.org/10.1038/sj.onc.1205423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082537				2022-12-28	WOS:000175262700014
J	Brownson, RC; Figgs, LW; Caisley, LE				Brownson, RC; Figgs, LW; Caisley, LE			Epidemiology of environmental tobacco smoke exposure	ONCOGENE			English	Article						environmental tobacco smoke; lung neoplasms; socioeconomic level; tobacco smoke pollution	LUNG-CANCER RISK; PASSIVE SMOKING; NONSMOKING WOMEN; PUBLICATION BIAS; GENETIC SUSCEPTIBILITY; INVOLUNTARY SMOKING; LIFETIME EXPOSURE; HEALTH; POPULATION; GSTM1	The health hazards due to exposure to environmental tobacco smoke (ETS) are increasingly established. ETS contains thousands of chemicals including 43 known carcinogens. One of the most important known health effects of ETS exposure is lung cancer in non-smokers, based on epidemiologic evidence and knowledge of the uptake and metabolism of ETS. Epidemiologic studies need to carefully take into account confounding and potential errors in exposure assessment. More research is needed to understand the genetic factors that influence ETS-induced lung cancer. Studies of the patterns of ETS exposure suggest higher rates of exposure in people employed as blue collar workers, in service occupations, earning lower incomes, and among the less educated. Certain racial/ethnic groups (e.g. Blacks, American Indians) may be at higher risk of ETS exposure. Despite substantial progress in protecting individuals from ETS exposure, additional efforts are needed in improving and enforcing policies to reduce exposure.	St Louis Univ, Sch Publ Hlth, Salus Ctr, Dept Community Hlth, St Louis, MO 63104 USA; St Louis Univ, Sch Publ Hlth, Salus Ctr, Prevent Res Ctr, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Brownson, RC (corresponding author), St Louis Univ, Sch Publ Hlth, Salus Ctr, Dept Community Hlth, 3545 Lafayette Ave, St Louis, MO 63104 USA.	brownson@slu.edu						AKIBA S, 1986, CANCER RES, V46, P4804; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; BAST RC, 2000, CANC MED; Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; Boffetta P, 1998, J NATL CANCER I, V90, P1440, DOI 10.1093/jnci/90.19.1440; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brownson RC, 1998, EPIDEMIOL REV, V20, P218, DOI 10.1093/oxfordjournals.epirev.a017982; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; BROWNSON RC, 1993, INT J EPIDEMIOL, V22, P804, DOI 10.1093/ije/22.5.804; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; BUTLER TL, 1988, RELATIONSHIP PASSIVE; *CA EPA, 1997, HLTH EFF EXP ENV TOB; Cardenas VM, 1997, CANCER CAUSE CONTROL, V8, P57, DOI 10.1023/A:1018483121625; CDC, NAT REP HUM EXP ENV; CORREA P, 1983, LANCET, V2, P595; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338, DOI 10.1093/oxfordjournals.aje.a115340; CUMMINGS KM, 1989, AM J EPIDEMIOL, V130, P122, DOI 10.1093/oxfordjournals.aje.a115303; Curtin F, 1998, AM J EPIDEMIOL, V148, P1040; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Dresler CM, 2000, LUNG CANCER-J IASLC, V30, P153, DOI 10.1016/S0169-5002(00)00163-X; ERIKSEN MP, 1988, ANNU REV PUBL HEALTH, V9, P47, DOI 10.1146/annurev.pu.09.050188.000403; Fontenot J. P., 1991, PROF ANIM SCI, V7, P1; Gao Y, 1999, MUTAT RES-GEN TOX EN, V444, P441, DOI 10.1016/S1383-5718(99)00092-3; GARFINKEL L, 1985, J NATL CANCER I, V75, P463; Gealy R, 1999, CANCER EPIDEM BIOMAR, V8, P297; Gerlach K K, 1997, Tob Control, V6, P199; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; HIRAYAMA T, 1984, PREV MED, V13, P680, DOI 10.1016/S0091-7435(84)80017-1; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; Hou SM, 2001, CANCER EPIDEM BIOMAR, V10, P133; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; JINOT J, 1994, J CLIN EPIDEMIOL, V47, P339, DOI 10.1016/0895-4356(94)90154-6; Jockel KH, 1998, EPIDEMIOLOGY, V9, P672; Johnson KC, 2001, INT J CANCER, V93, P902, DOI 10.1002/ijc.1416; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; KABAT GC, 1995, AM J EPIDEMIOL, V142, P141, DOI 10.1093/oxfordjournals.aje.a117612; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; Kawachi I, 1996, AM J EPIDEMIOL, V144, P909; KOLONEL LN, 1977, AM J EPIDEMIOL, V106, P476, DOI 10.1093/oxfordjournals.aje.a112494; KOO LC, 1987, INT J CANCER, V39, P162, DOI 10.1002/ijc.2910390207; Kreuzer M, 2000, AM J EPIDEMIOL, V151, P241, DOI 10.1093/oxfordjournals.aje.a010199; LAM TH, 1987, BRIT J CANCER, V56, P673, DOI 10.1038/bjc.1987.264; Lee CH, 2000, INT J EPIDEMIOL, V29, P224, DOI 10.1093/ije/29.2.224; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; LEFCOE NM, 1983, CHEST, V84, P90, DOI 10.1378/chest.84.1.90; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; LERCHEN ML, 1986, AM J EPIDEMIOL, V123, P481, DOI 10.1093/oxfordjournals.aje.a114263; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Liu G, 2001, CANCER RES, V61, P8718; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; Malats N, 2000, CANCER EPIDEM BIOMAR, V9, P827; MATANOSKI G, 1995, AM J EPIDEMIOL, V142, P149, DOI 10.1093/oxfordjournals.aje.a117613; McLaughlin J K, 1990, Epidemiology, V1, P408, DOI 10.1097/00001648-199009000-00013; *NAT HLTH MED RES, 1997, HLTH EFF PASS SMOK; NRC (National Research Council), 1986, ENV TOB SMOK MEAS EX; Nyberg F, 1998, EPIDEMIOLOGY, V9, P301, DOI 10.1097/00001648-199805000-00015; Nyberg F, 1997, EPIDEMIOLOGY, V8, P304, DOI 10.1097/00001648-199705000-00013; ONEILL I, 1987, ENV CARCINOGENS METH, V9; PERSHAGEN G, 1987, AM J EPIDEMIOL, V125, P17, DOI 10.1093/oxfordjournals.aje.a114504; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; PRON GE, 1988, AM J EPIDEMIOL, V127, P267, DOI 10.1093/oxfordjournals.aje.a114802; QING L, 1993, AM J EPIDEMIOL, V137, P145, DOI 10.1093/oxfordjournals.aje.a116654; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Rapiti E, 1999, LUNG CANCER-J IASLC, V23, P183, DOI 10.1016/S0169-5002(99)00013-6; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; REPACE JL, 1993, NICOTINE ADDICTION P, P129; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SCHOTTENFELD D, 1997, CANC EPIDEMIOLOGY PR; SHIMIZU H, 1988, TOHOKU J EXP MED, V154, P389, DOI 10.1620/tjem.154.389; SIDNEY S, 1989, AM J EPIDEMIOL, V129, P1305, DOI 10.1093/oxfordjournals.aje.a115250; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; STAMATAKIS KA, 2002, J WOMENS HLTH GENDER; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; Stucker I, 1999, INT J EPIDEMIOL, V28, P829, DOI 10.1093/ije/28.5.829; SVENSSON C, 1989, ACTA ONCOL, V28, P623, DOI 10.3109/02841868909092282; US Department of Health and Human Services, 1986, HLTH CONS INV SMOK R; *USEPA, 1992, RESP HLTH EFF PASS S; Vahakangas KH, 2001, CANCER RES, V61, P4350; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; Vine M. F., 1990, BIOL MARKERS EPIDEMI, P196; Wang JS, 1999, BIOTECHNOL BIOENG, V62, P402, DOI 10.1002/(SICI)1097-0290(19990220)62:4<402::AID-BIT3>3.3.CO;2-M; Wang LD, 2000, INT J CANCER, V88, P139, DOI 10.1002/1097-0215(20001001)88:1&lt;139::AID-IJC22&gt;3.0.CO;2-L; WELLS AJ, 1988, BRIT MED J, V296, P1128, DOI 10.1136/bmj.296.6629.1128-a; Whitlock G, 1998, TOB CONTROL, V7, P276, DOI 10.1136/tc.7.3.276; WU AH, 1985, JNCI-J NATL CANCER I, V74, P747; Zaridze D, 1998, INT J CANCER, V75, P335, DOI 10.1002/(SICI)1097-0215(19980130)75:3<335::AID-IJC1>3.0.CO;2-3; Zhong LJ, 1999, CANCER CAUSE CONTROL, V10, P607, DOI 10.1023/A:1008962025001	94	38	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7341	7348		10.1038/sj.onc.1205809	http://dx.doi.org/10.1038/sj.onc.1205809			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379877				2022-12-28	WOS:000178618000007
J	Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD				Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD			Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells	ONCOGENE			English	Article						ErbB-2; cell cycle; cdk inhibitors; cdk2; luminal epithelial	PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; CANCER CELLS; INDUCED APOPTOSIS; CDK INHIBITORS; MESSENGER-RNA; D1 EXPRESSION; KINASE; P27(KIP1); GROWTH	Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours overexpress the ErbB-2 receptor. Herein, a non-transformed, immortalized cell system was used to investigate the effects of ErbB-2 overexpression in luminal epithelial cells. The phenotypic consequence of ErbB-2 overexpression is a shortening of the G1 phase of the cell cycle and early S phase entry, which leads to hyperproliferation. We show that this effect was mediated through the up-regulation of cdk6 and cyclins D1 and E, and enhanced degradation and relocalization of P27(Kip1). These changes were effected predominantly through enhanced MAPK signalling, resulting in cdk2 hyperactivation. PI3K signalling also participated in cell cycle progression, since PI3K and MAPK coordinately regulated changes in cyclin D1 and cdk6 expression. Cdk4 activity was not required for cell cycle progression in these cells, and was constitutively inhibited through its association with p16(INK4A). MAPK-dependent induction of p21(Cip1) was also necessary for G1 phase progression, although its degradation by the proteasome was required for S phase entry. These data provide new insights into the complex molecular mechanisms underlying mitogenic cell cycle control in luminal epithelial cells, the cell type relevant to primary breast cancer, and show how ErbB-2 overexpression subverts this normal control.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Breast Canc Lab, Dept Surg, Royal Free & Univ Coll Med Sch, London W1W 7EJ, England	Ludwig Institute for Cancer Research; University of London; University College London	Timms, JF (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	jtimms@ludwig.ucl.ac.uk	Timms, John/A-1556-2010	Timms, John/0000-0002-4507-835X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	64	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6573	6586		10.1038/sj.onc.1205847	http://dx.doi.org/10.1038/sj.onc.1205847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242655				2022-12-28	WOS:000178202300003
J	Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH				Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH			Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo	ONCOGENE			English	Article						receptor tyrosine kinase; transgenic mice; lung tumors; type II cells	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; TRANSGENIC MICE; PULMONARY ADENOCARCINOMAS; C GENE; MOUSE; ACTIVATION; OVEREXPRESSION; IDENTIFICATION; CARCINOMA	RON, a member of the MET proto-oncogene family, has been implicated in the progression of certain epithelial cancers. The purpose of this study was to determine the oncogenic potential of RON in vivo in lung epithelial cells. Transgenic mice were established using surfactant protein C promoter to express human RON in the distal lung epithelial cells. These mice were born normal but developed multiple lung tumors with distinct morphology and growth patterns. Tumors appeared as a single mass in the lung around 2 months of age and gradually developed into multiple nodules located mostly in the peripheral portions of the lung. A transition from early adenomas to later adenocarcinomas was observed. Morphologically, tumors were characterized as cuboidal epithelial cells with a type 11 cell phenotype, grew along the alveolar walls, and projected into the alveolar septa. RON was highly expressed and constitutively activated in tumors. These results indicate that overexpression of human wild-type RON causes the formation of lung tumors with unique biological characteristics in vivo. This model provides opportunities to study the role of RON in the pathogenesis of lung tumors and to elucidate the mechanisms underlying this distinct lung tumor.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Sch Med, Dept Med, Div Pulm Sci & Crit Care,CU Canc Ctr, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310003, Peoples R China	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail Box 4000, Denver, CO 80204 USA.				NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; HOGAN B, 1996, MANIPULATING MOUSE E; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	30	46	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6382	6386		10.1038/sj.onc.1205783	http://dx.doi.org/10.1038/sj.onc.1205783			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214279				2022-12-28	WOS:000177829000015
J	Duensing, S; Munger, K				Duensing, S; Munger, K			Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability	ONCOGENE			English	Review						HPV; centrosomes; genomic instability; cervical cancer	E7 ONCOPROTEIN; TYPE-16 E7; GENETIC INSTABILITY; CELL-LINE; HUMAN KERATINOCYTES; E6 ONCOPROTEIN; DNA ANEUPLOIDY; EXPRESSION; PROTEIN; PROLIFERATION	The majority of human cancers are genomically unstable, often with gains or losses of whole chromosomes. In high-risk human papillomavirus (HPV)-associated cervical neoplasia, the two HPV-encoded oncoproteins E6 and E7 have been implicated in mitotic infidelity by their ability to induce centrosome-related mitotic disturbances. However, the mechanisms by which HPV E6 and E7 subvert centrosome homeostasis are strikingly different. Whereas the E7 oncoprotein rapidly drives centrosome duplication errors in cells that appear phenotypically normal, expression of the HPV E6 oncoprotein results in an accumulation of supernumerary centrosomes in multinucleated cells. The primary centrosome duplication defect in HPV E7 expressing cells may be linked to the ability of E7 to disrupt regulatory nodes that govern both the host cell division cycle machinery and the initiation of centrosome duplication. Most importantly, the E7 oncoprotein has been shown to dysregulate cdk2 activity, a major determinant for the initiation of centrosome duplication. HPV-induced centrosome abnormalities, multipolar mitoses, and aneuploidy often occur at early stages during cervical carcinogenesis and increase with malignant conversion. These findings suggest that HPV oncoprotein-induced chromosomal instability increases the risk for genetic changes that may ultimately facilitate carcinogenic progression.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Res Bldg,D2-537,200 Longwood Ave, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA66980, R01 CA81135] Funding Source: Medline; NIDCR NIH HHS [P01 DE00275] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081135, R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BIBBO M, 1989, AM J CLIN PATHOL, V92, P261, DOI 10.1093/ajcp/92.3.261; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Bulten J, 1998, AM J PATHOL, V152, P495; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Flores ER, 1999, VIROLOGY, V262, P344, DOI 10.1006/viro.1999.9868; FU YS, 1981, GYNECOL ONCOL, V12, pS220, DOI 10.1016/0090-8258(81)90076-7; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gisselsson D., 2001, RING CHROMOSOMES VIC; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hittelman WN, 2001, ANN NY ACAD SCI, V952, P1; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; JONES HW, 1967, OBSTET GYNECOL, V30, P790; Kashyap V, 1998, CANCER LETT, V123, P47, DOI 10.1016/S0304-3835(97)00396-0; Katich SC, 2001, ONCOGENE, V20, P543, DOI 10.1038/sj.onc.1204130; Kessis TD, 1996, ONCOGENE, V13, P427; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Larson AA, 1997, CANCER RES, V57, P4171; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lowy DR, 2001, FIELDS VIROLOGY, P2231; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; MUNGER K, 1989, J VIROL, V63, P4417; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; Poignee M, 2001, CANCER RES, V61, P7118; REID R, 1984, CANCER-AM CANCER SOC, V53, P943, DOI 10.1002/1097-0142(19840215)53:4<943::AID-CNCR2820530421>3.0.CO;2-X; Rihet S, 1996, J CLIN PATHOL, V49, P892, DOI 10.1136/jcp.49.11.892; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; Skyldberg B, 2001, MODERN PATHOL, V14, P279, DOI 10.1038/modpathol.3880303; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; Southern SA, 1997, CANCER RES, V57, P4210; Southern SA, 2001, CANCER RES, V61, P4858; Steinbeck RG, 1997, ACTA ONCOL, V36, P3, DOI 10.3109/02841869709100723; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; *WHO, 1995, IARC MONOGR EVAL CAR, V64, P35; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	74	101	107	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6241	6248		10.1038/sj.onc.1205709	http://dx.doi.org/10.1038/sj.onc.1205709			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214255				2022-12-28	WOS:000177840500014
J	Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J				Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J			Functional interaction between human papillomavirus type 18 E2 and poly(ADP-ribose) polymerase 1	ONCOGENE			English	Article						PARP; HPV; transcriptional activation	CALCIUM-INDUCED DIFFERENTIATION; HUMAN KERATINOCYTES; ADP-RIBOSYLATION; TRANSCRIPTIONAL REPRESSOR; CELL-DIFFERENTIATION; MAMMALIAN-CELLS; E7 ONCOPROTEIN; E6 ONCOPROTEIN; EARLY PROMOTER; HELA-CELLS	Human papillomavirus E2 protein is a transcription factor of viral gene expression and DNA replication. Here we show that PARP is a positive regulator of the E2 protein of human papillomavirus type 18 (HPV-18). PARP interacted with the COOH terminal region of HPV-18 E2 in vitro. The E2 interaction domain within PARP is located in the NH2-terminal zinc finger motif and the BRCT motif included in the automodification domain. Overexpression of either wild type or the NH2-terminal region of PARP containing zinc finger and BRCT stimulated E2-dependent transcription. Gel retardation assay indicates that PARP augments DNA binding activity of E2 in vitro. We also show that PARP-1 is recruited to E2-dependent promoter in vivo using ChIP assay. These results suggest that PARP serves a transcriptional co-activator in E2-dependent transcription by interacting directly with the HPV E2 protein.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Strasbourg 1, UPR 9003, CNRS,Ecole Super Biotechnol, Lab Convent Commissariat Energie Atom, F-67400 Illkirch Graffenstaden, France	Korea Advanced Institute of Science & Technology (KAIST); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011; Kim, Karam/K-1412-2018; Schreiber, Valérie/M-5007-2016; Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	Lee, Daeyoup/0000-0003-2006-1823; Kim, Karam/0000-0002-1886-5163; Schreiber, Valérie/0000-0003-0507-639X; KIM, JIN WOO/0000-0003-0767-1918				Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; di Fagagna FD, 1999, NAT GENET, V23, P76; FERRO AM, 1984, J BIOL CHEM, V259, P547; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, J BIOL CHEM, V277, P6483, DOI 10.1074/jbc.M105085200; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Masutani M, 2001, MUTAT RES-FUND MOL M, V477, P111, DOI 10.1016/S0027-5107(01)00112-9; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; OHASHI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7132, DOI 10.1073/pnas.81.22.7132; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Pugh B F, 1995, Methods Mol Biol, V37, P349; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5877	5885		10.1038/sj.onc.1205723	http://dx.doi.org/10.1038/sj.onc.1205723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185587				2022-12-28	WOS:000177520900007
J	Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M				Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M			Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition	ONCOGENE			English	Article						HPV; E6; G1/S transition	CELL-CYCLE REGULATION; RETINOBLASTOMA-PROTEIN; E7 ONCOPROTEIN; INHIBITOR P27(KIP1); GROWTH ARREST; GENE-PRODUCT; S-PHASE; C-MYC; BINDING; PATHWAY	In this study we show that E6 of human papillomavirus has the ability to deregulate the cell cycle G1/S transition. In rodent immortalized fibroblasts (NIH3T3) serum deprivation or over-expression of the cyclin-dependent kinase inhibitors, p16(INK4a) or p27(KIP1), leads to G1 cell cycle arrest. HPV16 E6 overcomes the antiproliferative signals, gaining the ability to drive serum-deprived and p16(INK4a) or p27(KIP1) over-expressing cells into S phase. E6 protein from the benign HPV type 1 displays a similar activity to HPV16 E6 to deregulate the G1/S transition. Thus, this activity appears to be conserved between E6 proteins from non-oncogenic and oncogenic HPV types. Furthermore, we show that HPV16 E6 is not able to circumvent a G1 arrest imposed by pRb mutant in which all CDK phosphorylation sites have been mutated. These data indicate that the viral protein acts upstream of pRb and its mechanism in promoting cell cycle progression is dependent on pRb phosphorylation. In summary, this study describes a novel biological function of HPV E6 and shows that the S phase entry, required for viral DNA replication, is not exclusively controlled by E7, but that E6 also is involved in this event.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alunni-Fabbroni M, 2000, ONCOGENE, V19, P2277, DOI 10.1038/sj.onc.1203570; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; TOMMASINO M, 1997, E7 PROTEIN HUMAN PAP; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zwerschke W, 2000, ADV CANCER RES, V78, P1	30	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5665	5672		10.1038/sj.onc.1205617	http://dx.doi.org/10.1038/sj.onc.1205617			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173036				2022-12-28	WOS:000177463400001
J	Esteller, M				Esteller, M			CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future	ONCOGENE			English	Review						CpG island; DNA methylation; tumor suppressor genes	HUMAN CANCER-CELLS; HMLH1 PROMOTER HYPERMETHYLATION; POLYMERASE-CHAIN-REACTION; METHYLATION-SPECIFIC PCR; HUMAN BREAST-CANCER; DNA METHYLATION; LUNG-CANCER; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; PROSTATE-CANCER	We have come a long way since the first reports of the existence of aberrant DNA methylation in human cancer. Hypermethylation of CpG islands located in the promoter regions of tumor suppressor genes is now firmly established as an important mechanism for gene inactivation. CpG island hypermethylation has been described in almost every tumor type. Many cellular pathways are inactivated by this type of epigenetic lesion: DNA repair (hMLH1, MGMT), cell cycle (p16(INK4a), p15(INK4b), p14(ARF)), apoptosis (DAPK), cell adherence (CDH1, CDH13), detoxification (GSTP1), etc... However, we still know little of the mechanisms of aberrant methylation and why certain genes are selected over others. Hypermethylation is not an isolated layer of epigenetic control, but is linked to the other pieces of the puzzle such as methyl-binding proteins, DNA methyltransferases and histone deacetylase, but our understanding of the degree of specificity of these epigenetic layers in the silencing of specific tumor suppressor genes remains incomplete. The explosion of user-friendly technologies has given rise to a rapidly increasing list of hypermethylated genes. Careful functional and genetic studies are necessary to determine which hypermethylation events are truly relevant for human tumorigenesis. The development of CpG island hypermethylation profiles for every form of human tumors has yielded valuable pilot clinical data in monitoring and treating cancer patients based in our knowledge of DNA methylation. Basic and translational will both be needed in the near future to fully understand the mechanisms, roles and uses of CpG island hypermethylation in human cancer. The expectations are high.	Ctr Natl Invest Oncol, Mol Pathol Program, Canc Epigenet Lab, E-28029 Madrid, Spain		Esteller, M (corresponding author), Ctr Natl Invest Oncol, Mol Pathol Program, Canc Epigenet Lab, E-28029 Madrid, Spain.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BAYLIN SB, 1986, CANCER RES, V46, P2917; Bianco T, 1999, HUM MUTAT, V14, P289, DOI 10.1002/(SICI)1098-1004(199910)14:4<289::AID-HUMU3>3.0.CO;2-A; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cairns P, 2001, CLIN CANCER RES, V7, P2727; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Corn PG, 1999, CANCER RES, V59, P3352; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Dobrovic A, 1997, CANCER RES, V57, P3347; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Ehrlich Melanie, 2000, P273; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Esteller M, 2001, CANCER RES, V61, P2816; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2002, J NATL CANCER I, V94, P26; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fleisher AS, 1999, CANCER RES, V59, P1090; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Goessl C, 2000, CANCER RES, V60, P5941; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Grady WM, 2001, CANCER RES, V61, P900; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HEDELFANK I, 2001, NEW ENGL J MED, V343, P539; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jarrard DF, 1998, CANCER RES, V58, P5310; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Liang GN, 2000, CANCER RES, V60, P4907; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Myohanen SK, 1998, CANCER RES, V58, P591; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NGUYEN CT, 2001, NUCLEIC ACIDS RES, V93, P1465; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Palmisano WA, 2000, CANCER RES, V60, P5954; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Plumb JA, 2000, CANCER RES, V60, P6039; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 1999, CLIN CANCER RES, V5, P2450; SCHWARTSMANN G, 1997, LEUKEMIA S1, V11, P28; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Stirzaker C, 1997, CANCER RES, V57, P2229; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyota M, 2000, CANCER RES, V60, P4044; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Wijermans PW, 1997, LEUKEMIA, V11, P1, DOI 10.1038/sj.leu.2400526; Wolf P, 2001, CANCER RES, V61, P8113; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Xu XL, 2001, CANCER RES, V61, P7943; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yuan YF, 2001, CANCER RES, V61, P5558; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	119	912	993	3	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5427	5440		10.1038/sj.onc.1205600	http://dx.doi.org/10.1038/sj.onc.1205600			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154405				2022-12-28	WOS:000177197700009
J	Slater, DJ; Hilgenfeld, E; Rappaport, EF; Shah, N; Meek, RG; Williams, WR; Lovett, BD; Osheroff, N; Autar, RS; Ried, T; Felix, CA				Slater, DJ; Hilgenfeld, E; Rappaport, EF; Shah, N; Meek, RG; Williams, WR; Lovett, BD; Osheroff, N; Autar, RS; Ried, T; Felix, CA			MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site	ONCOGENE			English	Article						MLL; SEPTIN6; complex translocation; infant leukaemia; spectral karyotype; DNA topoisomerase II	ACUTE LYMPHOBLASTIC-LEUKEMIA; PARTNER GENE; MYELODYSPLASTIC SYNDROME; DROSOPHILA-TRITHORAX; HUMAN HOMOLOG; FUSES MLL; 11Q23; AF-4; IDENTIFICATION; SEPTINS	We examined the MLL translocation in two cases of infant AML with X chromosome disruption. The G-banded karyotype in the first case suggested t(X;3)(q22;p21)ins(X;11)(q22;q13q25). Southern blot analysis showed one MLL rearrangement. Panhandle PCR approaches were used to identify the MLL fusion transcript and MLL genomic breakpoint junction. SEPTIN6 from chromosome band Xq24 was the partner gene of MLL. MLL exon 7 was joined in-frame to SEPTIN6 exon 2 in the fusion transcript. The MLL genomic breakpoint was in intron 7; the SEPTIN6 genomic breakpoint was in intron 1. Spectral karyotyping revealed a complex rearrangement disrupting band 11q23. FISH with a probe for MLL confirmed MLL involvement and showed that the MLL-SEPTIN6 junction was on the der(X). The MLL genomic breakpoint was a functional DNA topoisomerase 11 cleavage site in an in vitro assay. In the second case, the karyotype revealed t(X;11)(q22;q23). Southern blot analysis showed two MLL rearrangements. cDNA panhandle PCR detected a transcript fusing MLL exon 8 in-frame to SEPTIN6 exon 2. MLL and SEPTIN6 are vulnerable to damage to form recurrent translocations in infant AML. Identification of SEPTIN6 and the SEPTIN family members hCDCrel and MSF as partner genes of MLL suggests a common pathway to leukaemogenesis.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA; NCI, Div Genet, Bethesda, MD 20892 USA; Geisinger Med Ctr, Div Hematol Oncol, Dept Pediat, Danville, PA 17822 USA; Alfred I Dupont Inst, Dept Hematol Oncol, Dept Pediat, Wilmington, DE 19899 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Geisinger Medical Center; Nemours Alfred I. duPont Hospital for Children; Vanderbilt University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902B,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Rappaport, Eric/GRO-4051-2022		NATIONAL CANCER INSTITUTE [R01CA080175, R01CA085469, R01CA077683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA77683, CA85469, CA80175] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYTON PM, 2001, TRANSCRIPTION FACTOR; Beites CL, 2001, METHOD ENZYMOL, V329, P499; BERNARD OA, 1994, ONCOGENE, V9, P1039; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; Eguchi M, 2001, GENE CHROMOSOME CANC, V32, P212, DOI 10.1002/gcc.1185; Felix CA, 1999, MOL DIAGN, V4, P269, DOI 10.1016/S1084-8592(99)80002-2; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Felix CA, 1998, J PEDIAT HEMATOL ONC, V20, P299, DOI 10.1097/00043426-199807000-00004; FELIX CA, 2000, HEMATOLOGY 2000 ED P, P294; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HURET JL, 2001, ATLAS GENET CYTOGENE; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; Macville M, 1997, HISTOCHEM CELL BIOL, V108, P299, DOI 10.1007/s004180050169; MAHMOUD HH, 1995, MED PEDIATR ONCOL, V24, P77, DOI 10.1002/mpo.2950240203; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nakata Y, 1999, LEUKEMIA RES, V23, P85, DOI 10.1016/S0145-2126(98)00131-3; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Ono R, 2002, CANCER RES, V62, P333; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Pegram LD, 2000, BLOOD, V96, P4360; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; PRASAD R, 1993, CANCER RES, V53, P5624; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Ross JA, 1998, INT J CANCER, V78, P26; Roulston Diane, 1997, P325; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Russell SEH, 2000, CANCER RES, V60, P4729; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Smith MA, 1999, J CLIN ONCOL, V17, P569, DOI 10.1200/JCO.1999.17.2.569; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; SUPER HJG, 1994, BLOOD, V83, P641; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1999, CANCER RES, V59, P4261; Taki T, 1996, ONCOGENE, V13, P2121; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tatsumi K, 2001, GENE CHROMOSOME CANC, V30, P230, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1084>3.0.CO;2-J; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; Woods WG, 1996, BLOOD, V87, P4979, DOI 10.1182/blood.V87.12.4979.bloodjournal87124979	72	47	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4706	4714		10.1038/sj.onc.1205572	http://dx.doi.org/10.1038/sj.onc.1205572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096348				2022-12-28	WOS:000176625100013
J	Wunderlich, M; Berberich, SJ				Wunderlich, M; Berberich, SJ			Mdm2 inhibition of p53 induces E2F1 transactivation via p2l	ONCOGENE			English	Article						Mdm2; E2F1; p53; p21	TRANSCRIPTION FACTOR E2F-1; RING-FINGER DOMAIN; P53-INDEPENDENT APOPTOSIS; DNA-DAMAGE; P53-MEDIATED TRANSACTIVATION; RETINOBLASTOMA PROTEIN; CELL-LINE; S-PHASE; EXPRESSION; DIFFERENTIATION	The transcription factor E2F1 functions as a key regulator for both cell-cycle progression and apoptosis. Mdm2, a major cellular regulator of the p53 tumor suppressor protein, is also closely involved in cell cycle and apoptosis. In addition to regulation of p53, Mdm2 has been reported to stimulate E2F1 transactivation by a mechanism that remains unclear. Here we examined how overexpression of Mdm2 alters E2F1/DP1 transactivation. Using a set of cell lines with differing p53 and Rb status we determined that Mdm2 induction of E2F1 transactivation was p53-dependent, resulting from release of repression by p53. While Mdm2 association with p53 was required to increase E2F1 transactivation, Mdm2 mediated degradation of p53 was not. p53 repression of E2F1 transactivation required a functional DNA binding and transactivation domain. Consistent with Mdm2 activation of E2F1 via an inhibition of p53 transactivation we demonstrate a concomitant reduction in p21 protein levels with Mdm2 overexpression. Furthermore, E2F1 repression by an Rb-phosphorylation mutant could not be reversed by Mdm2 overexpression. Mdm2 was also unable to enhance E2F1 transactivation in Mouse embryo fibroblasts lacking p21. Taken together, these results suggest that Mdm2 activation of E2F1 occurs through the repression of p53-dependent transcription of p21, a p53-target gene and cyclin dependent kinase inhibitor.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hywy, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R01CA064430, R29CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430-09, R01 CA064430, CA64430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin JY, 2000, CANCER RES, V60, P5895; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	41	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4414	4421		10.1038/sj.onc.1205541	http://dx.doi.org/10.1038/sj.onc.1205541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080472				2022-12-28	WOS:000176317100007
J	Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF				Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF			Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines	ONCOGENE			English	Article						epigenetic; tumor suppressor gene; pediatric tumor	LUNG-CANCER PATIENTS; CPG ISLAND; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; HUMAN NEOPLASIA; BREAST CANCERS; HYPERMETHYLATION; 3P21.3; DNA; EXPRESSION	Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16(Ink4a), MGMT, GSTP1, RASSF1A, APC, DAPK, RARbeta, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and nonmalignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P=0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2'deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Childrens Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Amer Type Culture Collect, Manassas, VA 20110 USA; Univ Siena, Dept Ophthalmol, I-53100 Siena, Italy	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Siena	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Tomlinson, Gail/AAR-9776-2020		NCI NIH HHS [U01CA8497102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen B, 1998, AM J PATHOL, V152, P1071; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davidoff A M, 2001, Semin Pediatr Surg, V10, P106, DOI 10.1053/spsu.2001.24700; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Loeb LA, 2001, CANCER RES, V61, P3230; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 1999, LEUKEMIA, V13, P884, DOI 10.1038/sj.leu.2401437; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Takita J, 2000, MED PEDIATR ONCOL, V35, P541, DOI 10.1002/1096-911X(20001201)35:6<541::AID-MPO9>3.0.CO;2-T; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	33	165	177	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4345	4349		10.1038/sj.onc.1205446	http://dx.doi.org/10.1038/sj.onc.1205446			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082624				2022-12-28	WOS:000176174200019
J	Lambert, S; Lopez, BS				Lambert, S; Lopez, BS			Inactivation of the RAD51 recombination pathway stimulates UV-induced mutagenesis in mammalian cells	ONCOGENE			English	Article						mammalian RAD51; recombination; mutagenesis; DNA repair; UV-C	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; SPONTANEOUS MUTATION; DNA-POLYMERASES; REPAIR; RADIATION; CYCLE; P53	We have examined the impact of the RAD51 recombination pathway on recombination and mutagenesis induced by UV-C in mammalian cells. We used hamster CHO cell lines that express different forms of Rad51 protein, resulting in stimulation or inhibition of spontaneous gene conversion. Spontaneous mutagenesis was affected by none of the RAD51 forms. The wild-type mouse MmRAD51 affects neither UV-induced recombination nor UV-induced mutagenesis. In contrast, the dominant negative SMRAD51 strongly impairs UV-induced recombination while it stimulates UV-induced mutagenesis. Our results show that a defect in the RAD51 gene conversion pathway reveals (a) mutagenic alternative pathway(s) to repair UV-damage, in mammalian cells.	Dept Radiobiol & Radiopathol, Direct Sci Vivant, CEA, CNRS,UMR217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), Dept Radiobiol & Radiopathol, Direct Sci Vivant, CEA, CNRS,UMR217, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; lambert, sarah/0000-0002-1403-3204				BHATTACHARYYA NP, 1990, MUTAT RES, V234, P31, DOI 10.1016/0165-1161(90)90028-M; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; KADYK LC, 1992, GENETICS, V132, P387; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Luria SE, 1943, GENETICS, V28, P491; QUAH SK, 1980, GENETICS, V96, P819; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sambrook J., 2002, MOL CLONING LAB MANU; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	20	21	21	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4065	4069		10.1038/sj.onc.1205535	http://dx.doi.org/10.1038/sj.onc.1205535			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037689				2022-12-28	WOS:000175869900013
J	Mikkers, H; Allen, J; Berns, A				Mikkers, H; Allen, J; Berns, A			Proviral activation of the tumor suppressor E2 alpha contributes to T cell lymphomagenesis in E mu Myc transgenic mice	ONCOGENE			English	Article						E2A; lymphoma; MuLv; c-Myc; transgene	MURINE LEUKEMIA-VIRUS; DNA-BINDING PROTEINS; ZINC-FINGER PROTEIN; LOOP-HELIX PROTEINS; C-MYC; TRANSCRIPTION FACTOR; E2A; GENE; PROGRESSION; APOPTOSIS	The basic helix-loop-helix factor E2A plays an important role in the development of B and T lymphocytes. In addition, E2a has been implicated as a gene with tumor suppressor activity, since mice deficient for E2a succumb to T cell lymphomas. We have performed retroviral tagging in EmuMyc transgenic mice to identify genes that contribute to lymphomagenesis. The EmuMyc transgenic mouse is a well-established model of a common translocation in human B cell lymphomas. Analyses of the proviral insertion sites in the MuLV-induced lymphomas revealed that a number of T cell lymphomas carried proviral insertions in the promoter region of E2a. These proviral insertions yield hybrid viral-E2a mRNAs resulting in a marked rise in E2A protein levels. The proviral insertions in E2a were predominantly of clonal origin indicating that E2a insertions are early events in these T cell lymphomas. The primary oncogenic effect of E2A is likely to be associated with enhancement of transcription of the c-Myc transgene via binding to the regulatory immunoglobulin enhancers. The results herein thus provide the first evidence that in a specific setting E2A overexpression can contribute to T-lymphomagenesis. This implies that E2a contains oncogenic features in addition to the previously described tumor suppressive properties.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; HSU B, 1995, ONCOGENE, V11, P175; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MIKKERS H, 2002, IN PRESS NATURE GENE; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhao F, 2001, MOL CELL BIOL, V21, P6346, DOI 10.1128/MCB.21.18.6346-6357.2001; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	51	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6559	6566		10.1038/sj.onc.1205930	http://dx.doi.org/10.1038/sj.onc.1205930			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242653				2022-12-28	WOS:000178202300001
J	Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA				Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA			Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas	ONCOGENE			English	Article						head and neck squamous cell carcinomas; frizzled; beta-catenin; apoptosis	BETA-CATENIN; EXPRESSION; PATTERN; ESTABLISHMENT; GENES; LMX1	The diverse receptor-ligand pairs of the Wnt and frizzled (Fz) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. Hence, we investigated the expression and function of five Writ (Wnt-1, 5a, 7a, 10b, 13) and two Fz (Fz-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC). In comparison to normal bronchial or oral epithelial cells, all the HNSCC had markedly increased mRNA levels of Wnt-1, 7a, 10b, and 13, as well as Fz-2. Moreover, the levels of Wnt-1, 10b, and Fz-2 proteins were also markedly increased in HNSCC, relative to normal epithelial cells. Treatment of one HNSCC cell line (SNU 1076) with anti-Wnt-1 antibodies reduced the activity of the Wnt/Fz dependent transcription factor LEF/TCF, and diminished the expression of cyclin D1 and beta-catenin proteins. Blocking Wnt-1 signaling also inhibited proliferation and induced apoptosis in these cells. These results show that HNSCC cell lines often overexpress one or more Wnt and Fz genes, and suggest that the growth and survival of a subset of HNSCC may depend on the Wnt/Fz pathway. Hence, the Writ and Fz receptors may be possible targets for immunotherapy therapy of this common cancer.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; NCI, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Carson, DA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcarson@ucsd.edu	Lu, desheng/E-4822-2013; Rhee, Chae-Seo/D-5904-2012	Lu, desheng/0000-0002-3616-6657; Lu, Desheng/0000-0002-0314-5649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kim SY, 1997, ACTA OTO-LARYNGOL, V117, P775, DOI 10.3109/00016489709113477; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; PARR BA, 1993, DEVELOPMENT, V119, P247; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Whiteside TL, 1998, CLIN CANCER RES, V4, P1135; YASUMURA S, 1993, CANCER RES, V53, P1461; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5	22	166	192	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6598	6605		10.1038/sj.onc.1205920	http://dx.doi.org/10.1038/sj.onc.1205920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242657				2022-12-28	WOS:000178202300005
J	Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T				Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T			Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571	ONCOGENE			English	Article						BCR/ABL; PI-3k; STI571; wortmannin; combination therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DNA-BINDING ACTIVITY; BCR-ABL; CELL-LINES; CONSTITUTIVE ACTIVATION; CLINICAL RESISTANCE	BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome (Ph-1)-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL). STI571 (Gleevec), a novel anti-leukemia drug targeting BCR/ABL kinase can induce remissions of the Ph-1-positive leukemias. STI571 was recently combined with the standard cytostatic drugs to achieve better therapeutic results and to overcome emerging drug resistance mechanisms. We decided to search for a more specific partner compound for ST1571. Our previous studies showed that a signaling protein phosphatidylinositol-3 kinase (PI-3k) is essential for the growth of CML cells, but not of normal hematopoietic cells (Blood, 86:726,1995). Therefore the anti-Ph-1-leukemia effect of the combination of BCR/ABL kinase inhibitor ST1571 and PI-3k inhibitor wortmannin (WT) or LY294002 (LY) was tested. We showed that ST1571 + WT exerted a synergistic effect against the Ph-1-positive cell lines, but did not affect the growth of Ph-1-negative cell line. Moreover, the combinations of STI571+WT or STI571+LY were effective in the inhibition of clonogenic growth of CML-chronic phase and CML-blast crisis patient cells, while sparing normal bone marrow cells. Single colony RT-PCR assay showed that colonies arising from the mixture of CML cells and normal bone marrow cells after treatment with STI571+WT were selectively depleted of BCR/ABL-positive cells. Biochemical analysis of the CML cells after the treatment revealed that combination of ST1571 + WT caused a more pronounced activation of caspase-3 and induced massive apoptosis, in comparison to ST1571 and WT alone. In conclusion, combination of ST1571 + WT or ST1571 + LY may represent a novel approach against the Ph-1-positive leukemias.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Bio Life Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.	tskorski@astro.temple.edu	Klejman, Agata/AAC-1844-2021	Klejman, Agata/0000-0001-6083-9957	NCI NIH HHS [CA87300] Funding Source: Medline; NIDDK NIH HHS [K01 DK02896] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chai SK, 1997, J IMMUNOL, V159, P4720; Clift RA, 1996, BONE MARROW TRANSPL, V17, pS1; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DHUT S, 1990, LEUKEMIA, V4, P745; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gordon MY, 1999, LEUKEMIA, V13, pS65, DOI 10.1038/sj.leu.2401281; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gratwohl A, 1996, BONE MARROW TRANSPL, V17, pS7; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nielsen M, 1996, J IMMUNOL, V157, P5350; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Silver RT, 1999, BLOOD, V94, P1517; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; Slupianek A, 2001, CANCER RES, V61, P2194; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; TALPAZ M, 1987, CANCER, V59, P664, DOI 10.1002/1097-0142(19870201)59:3+<664::AID-CNCR2820591316>3.0.CO;2-Y; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; Van Etten RA, 2001, BLOOD CELL MOL DIS, V27, P201, DOI 10.1006/bcmd.2000.0370; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yu CR, 2002, CANCER RES, V62, P188	85	126	132	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5868	5876		10.1038/sj.onc.1205724	http://dx.doi.org/10.1038/sj.onc.1205724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185586				2022-12-28	WOS:000177520900006
J	Orlovsky, K; Theodor, L; Malovani, H; Chowers, Y; Nir, U				Orlovsky, K; Theodor, L; Malovani, H; Chowers, Y; Nir, U			Gamma interferon down-regulates Fer and induces its association with inactive Stat3 in colon carcinoma cells	ONCOGENE			English	Article						Fer; gamma interferon; Stat3; colon carcinoma	TYROSINE KINASE FER; PROSTATE-CANCER CELLS; IFN-GAMMA; ACTIVATION; PROTEIN; GENE; PHOSPHORYLATION; TRANSCRIPTION; BINDING; ENCODES	Gamma interferon (IFN-gamma) is a regulator of cell growth, which suppresses the proliferation of HT-29 colon carcinoma cells. Here we show that in HT-29 cells IFN-gamma transiently increased the cellular level of the tyrosine kinase Fer, whose functioning was found to be essential for the proliferation of malignant cell-lines. The transient elevation in the level of Fer, was followed by its down-regulation, an effect which was most prominent after 6-8 h of IFN-gamma treatment. Up- and down-regulation of Fer was paralleled by the activation and subsequent deactivation of Stat3, which is a potent oncogene and a putative substrate of the tyrosine kinase Fer. Moreover, IFN-gamma induced the association of Fer and Stat3 and the newly formed complex was most stable at the down-regulated states of the two proteins. Formation of the Fer/Stat3 complex was accompanied by an attenuation in cell-cycle progression and accumulation of cells in the G1 phase. Thus, Fer and Stat3 are two proliferation-promoting factors whose down-regulation could contribute to the cytostatic activity of IFN-gamma in colon carcinoma cells.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Chaim Sheba Med Ctr, Dept Gastroenterol, IL-52621 Tel Hashomer, Israel	Bar Ilan University; Chaim Sheba Medical Center	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.			Chowers, Yehuda/0000-0001-5130-845X				Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kominsky SL, 2000, CANCER RES, V60, P3904; LETWIN K, 1988, ONCOGENE, V3, P621; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TRINCHIERI G, 1984, LAB INVEST, V50, P489; VANMOORSELAAR RJA, 1991, PROSTATE, V18, P331, DOI 10.1002/pros.2990180407; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200	33	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4997	5001		10.1038/sj.onc.1205624	http://dx.doi.org/10.1038/sj.onc.1205624			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118379				2022-12-28	WOS:000176874800015
J	Kubista, M; Rosner, M; Kubista, E; Bernaschek, G; Hengstschlager, M				Kubista, M; Rosner, M; Kubista, E; Bernaschek, G; Hengstschlager, M			Brca1 regulates in vitro differentiation of mammary epithelial cells	ONCOGENE			English	Article						Brca1; differentiation; mammary epithelial cells; breast cancer	SUPPRESSOR GENE BRCA1; BREAST-CANCER; DNA-DAMAGE; NEURONAL DIFFERENTIATION; NUCLEAR PHOSPHOPROTEIN; TUMOR-FORMATION; EXPRESSION; MOUSE; CYCLE; VARIANT	Murine Breal is widely expressed during development in different tissues. Why alterations of BRCA1 lead specifically to breast and ovarian cancer is currently not clarified. Here we show that Brca1 protein expression is upregulated during mammary epithelial differentiation of HC11 cells, during differentiation of C2C12 myoblasts into myotubes and during neuronal differentiation of N1E-115 cells. Ectopic overexpression of BRCA1 and downregulation of endogenous Brca1 expression specifically affect the regulation of mammary epithelial cell differentiation. Accelerated mammary epithelial cell differentiation upon high ectopic BRCA1 expression is not a consequence of the anti-proliferative capacity of this tumor suppressor and independent of functional p53. Overexpression of the BRCA1 variant lacking the large central exon 11 has no effects on mammary epithelial cell differentiation. These data provide new insights into the cellular role of Brca1.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chen YM, 1996, CANCER RES, V56, P3168; Daniel DC, 1999, CELL TISSUE RES, V298, P481, DOI 10.1007/s004410050070; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERLO GR, 1994, ONCOGENE, V9, P443; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	40	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4747	4756		10.1038/sj.onc.1205580	http://dx.doi.org/10.1038/sj.onc.1205580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101413				2022-12-28	WOS:000176716300004
J	Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y				Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y			Transformation of Ba/F3 cells and rat-1 cells by ETV6/ARG	ONCOGENE			English	Article						translocation; tyrosine kinase; ETV6/ARG; transforming activity	CHRONIC MYELOMONOCYTIC LEUKEMIA; PROTEIN-TYROSINE KINASE; ETV6-NTRK3 GENE FUSION; ABL-RELATED GENE; ENCODES; TEL; OLIGOMERIZATION; DOMAIN; BETA; BCR	ETV6/ARG, a novel fusion gene composed of the ETV6 HLH oligomerization domain and most of sequences of the ARG protein tyrosine, was recently identified in human leukemia cells. The presence of the ETV6/ARG translocation raises the possibility that the resulting fusion protein functions as an oncogene. However, the transforming activity of the ETV6/ARG protein has not been determined and its contribution to leukemogenesis is therefore unknown. Here we address this question by analysing the oncogenic activity of ETV6/ARG in hematopoietic and fibroblast cells. It is demonstrated that expression of ETV6/ARG confers IL3-independent growth to Ba/F3 cells and anchorage independent growth to Rat-1 fibroblasts. It is also shown that multiple signaling molecules, including PI3K, SHC, ras-GAP and CRK-L, are tyrosine phosphorylated in Ba/F3 cells that express ETV6/ARG. Analysis of four different types of ETV6/ARG transcripts previously identified in the AML-M3 leukemia cell line HT93A suggest that ETV6 HLH domain is required for oncogenic activity. Based upon these results it is concluded that ARG can be activated as an oncogene in human malignancy and that the ETV6/ARG oncoprotein triggers some of the same signaling pathways associated with activated ABL oncogenes.	Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Tokyo 1620052, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Mol Therapy, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Funct Genomics, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Sch Int Hlth, Dept Human Genet, Tokyo 1130033, Japan; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	National Center for Global Health & Medicine - Japan; Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo; University of Tokyo; Fox Chase Cancer Center	Sato, Y (corresponding author), Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Toyama 1-21-1, Tokyo 1620052, Japan.	ysato@ri.imcj.go.jp			NCI NIH HHS [CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057273, R55CA057273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Iijima Y, 2000, BLOOD, V95, P2126; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mysliwiec T, 1996, ONCOGENE, V12, P631; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEREGO R, 1991, ONCOGENE, V6, P1899; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; WANG N, 1993, FOCUS, V3, P3	23	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4374	4383		10.1038/sj.onc.1205544	http://dx.doi.org/10.1038/sj.onc.1205544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080468				2022-12-28	WOS:000176317100003
J	Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L				Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L			Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5 ' end of the BRCA1 gene	ONCOGENE			English	Article						BRCA1; splice mutation; real time RT-PCR; breast cancer	OVARIAN-CANCER; MESSENGER-RNA; BREAST; IDENTIFICATION; EXPRESSION	We report two novel mutations in the splice sites of BRCA1 exon 5: IVS5+3A>G, a Belgian founder mutation, and IVS3-6T>G, identified in one family with a strong family history of breast cancer. Real-time RT-PCR showed that IVS3-6T>G leads to a fivefold increase of the BRCA1-Deltaex5 (isoform with an in frame skip of exon 5) ratio to the total BRCA1 expression level. lVS5+3A>G results in a 10-fold increase of the BRCA1-Delta22ntex5 ratio (isoform with an out of frame skip of the last 22 nucleotides of exon 5) and a twofold increase of the BRCA1-Deltaex5 ratio. These altered ratios are most likely to result from increased expression of the alternative transcripts, although we cannot completely rule out a small decrease of the total BRCA1 expression level due to highly variable BRCA1 levels in cultured cell lines. In order to explore the functional significance of the isoforms, we evaluated their prevalence in normal tissues and cancer cell lines. The BRCA1-Delta22ntex5 ratio was significantly higher in an ovarian cancer cell line compared to normal ovarian tissue. Our findings suggest that revealing the defects caused by some splice mutations requires accurate quantitative methods. We hypothesize that disruption of alternative transcript ratios of BRCA1 may be a dominant mechanism affecting predisposition to hereditary breast and/or ovarian cancer.	Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, B-9000 Ghent, Belgium; Clin Univ St Luc, Ctr Genet Humaine, B-1200 Brussels, Belgium	Ghent University; Ghent University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Messiaen, L (corresponding author), Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, OK5,Pintelaan 185, B-9000 Ghent, Belgium.	Ludwine.Messiaen@rug.ac.bc	Vandesompele, Jo/W-3411-2018; Claes, Kathleen/AFR-6830-2022	Vandesompele, Jo/0000-0001-6274-0184; Claes, Kathleen/0000-0003-0841-7372				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Claes K, 1999, DIS MARKERS, V15, P69, DOI 10.1155/1999/241046; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Pummi K, 2000, ARCH DERMATOL RES, V292, P422, DOI 10.1007/s004030000155; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vandenbroucke I I, 2001, Nucleic Acids Res, V29, pE68, DOI 10.1093/nar/29.13.e68; VANDESOMPELE, 2002, IN PRESS; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	23	29	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4171	4175		10.1038/sj.onc.1205520	http://dx.doi.org/10.1038/sj.onc.1205520			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037674				2022-12-28	WOS:000176186000012
J	Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C				Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C			Gastrin mediated cholecystokinin-2 receptor activation induces loss of cell adhesion and scattering in epithelial MDCK cells	ONCOGENE			English	Article						epithelial cells; cell adhesion; Gastrin; CCK-2R; catenin; migration; cancer	CADHERIN-CATENIN COMPLEX; HEPATOCYTE GROWTH-FACTOR; HUMAN COLORECTAL-CANCER; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; B/GASTRIN RECEPTOR; P120 CATENIN; BETA-CATENIN; PROTEIN INTERACTIONS	The presence of gastrin and CCK-2/gastrin receptors in human preneoplastic and neoplastic lesions of pancreas and colon suggests a role in cancer development. Gastrin's growth-promoting action has been established, but a role in cellular morphogenetic processes promoting tumor invasion has been elusive. Our aim was (i) to investigate whether activation of the CCK-2R affects cellular morphology, intercellular adhesion and motility, as crucial parameters of epithelial differentiation, and (ii) to identify the signaling pathways and mechanisms implicated. Madin-Darby Canine Kidney (MDCK) cells were chosen to generate an epithelial non-tumorigenic model system expressing human CCK-2R. Epithelial differentiation and motility were analysed upon CCK-2R activation using immunocytochemistry and invasion assays. The functionality of adhesion complexes and activity of signaling proteins was determined with biochemical techniques. CCK-2R activation induced cell dissociation and enhanced invasion, preceded by decreased membrane localization of adherens junction molecules and nuclear accumulation of beta-catenin. Concomitantly, and requiring the activation of several signaling pathways, catenins were shifted from the cytoskeletal to the cytoplasmic fraction, suggesting the detachment of the cytoskeleton from the adherens complex. These data represent the first evidence for the CCK-2R, regulating cell-cell and cell-substrate adhesion and support a role for CCK-2R in the progression of carcinoma.	CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bierkamp, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, 1 Av Jean Poulhes, F-31403 Toulouse, France.		SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019; Kowalski-Chauvel, Aline/O-9212-2014	SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827; 				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; Ding WQ, 2002, CANCER RES, V62, P947; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirata M, 1996, FEBS LETT, V383, P241, DOI 10.1016/0014-5793(96)00245-1; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Saillan-Barreau C, 1998, GASTROENTEROLOGY, V115, P988, DOI 10.1016/S0016-5085(98)70271-9; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; SEVA C, 1990, DIGESTION, V46, P166, DOI 10.1159/000200381; Skoudy A, 1996, INT J CANCER, V68, P14, DOI 10.1002/(SICI)1097-0215(19960927)68:1<14::AID-IJC3>3.0.CO;2-#; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Taniguchi T, 1996, ONCOGENE, V12, P1357; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Todisco A, 2001, AM J PHYSIOL-GASTR L, V280, pG298, DOI 10.1152/ajpgi.2001.280.2.G298; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	53	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7656	7670		10.1038/sj.onc.1205999	http://dx.doi.org/10.1038/sj.onc.1205999			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400008				2022-12-28	WOS:000178756200005
J	Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y				Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y			Involvement of nectin in the localization of junctional adhesion molecule at tight junctions	ONCOGENE			English	Article						nectin; JAM; cadherin; adherens junctions; tight junctions	CELL-CELL-ADHESION; KIDNEY EPITHELIAL-CELLS; SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC DOMAIN; ADHERENS JUNCTIONS; ALPHA-CATENIN; DESMOPLAKIN ORGANIZATION; SPATIAL REGULATION	Junctional adhesion molecule (JAM) is a Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at tight junctions (TJs). Claudin is a key cell-cell adhesion molecule that forms TJ strands at TJs. JAM is associated with claudin through their cytoplasmic tail-binding protein, ZO-1. JAM is furthermore associated with Par-3, a cell polarity protein which forms a ternary complex with Par-6 and atypical protein kinase C. Nectin is another Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at adherens junctions (AJs). Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. We show here that nectin is furthermore involved in the localization of JAM at TJs. During the formation of the junctional complex consisting of AJs and Us in Madin-Darby canine kidney (MDCK) cells, JAM was recruited to the nectin-based cell-cell adhesion sites. This recruitment of JAM was inhibited by nectin inhibitors, which inhibited the trans-interaction of nectin. Microbeads coated with the extracellular fragment of nectin, that interacted with cellular nectin, also recruited JAM to the bead-MDCK cell contact sites. Furthermore, when cadherin-deficient L fibroblasts stably expressing both exogenous JAM and nectin (nectin-JAM-L cells) were co-cultured with L fibroblasts expressing only nectin (nectin-L cells), JAM was concentrated at the cell-cell adhesion sites between nectin-JAM-L and nectin-L cells without the trans-interaction of JAM. Analyses of the localization and immunoprecipitation of JAM revealed that it was associated with nectin through afadin and ZO-1. These results suggest that nectin has a role in the localization of JAM at Us in the process of the formation of the junctional complex in epithelial cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Kyoto Univ, Fac Med, Dept Geriatr Med, Kyoto 6068501, Japan	Osaka University; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018; Ikeda, Wataru/V-8531-2019	Fukuhara, Atsunori/0000-0002-6289-3778; Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; AOKI J, 1994, J BIOL CHEM, V269, P8431; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 2000, J CELL SCI, V113, P2363; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127	78	102	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7642	7655		10.1038/sj.onc.1205875	http://dx.doi.org/10.1038/sj.onc.1205875			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400007				2022-12-28	WOS:000178756200004
J	Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G				Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G			Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors	ONCOGENE			English	Article						FRA6F; fragile sites; chromosome 6q21; senescence; human tumors; schizophrenia	IMMORTAL HUMAN FIBROBLASTS; EPITHELIAL OVARIAN-CANCER; 2 DISTINCT REGIONS; CHROMOSOME 6Q; HOMOZYGOUS DELETIONS; MULTIPLE REGIONS; INTEGRATION SITE; HUMAN HOMOLOG; BROAD REGION; ALLELIC LOSS	The common fragile site FRA6GF, located at 6q21, is an extended region of about 1200 kb, with two hot spots of breakage each spanning about 200 kb. Transcription mapping of the FRA6F region identified 19 known genes, 10 within the FRA6F interval and nine in a proximal or distal position. The nucleotide sequence of FRA6F is rich in repetitive elements (LINE1 and LINE2, Alu, MIR, MER and endogenous retroviral sequences) as well as in matrix attachment regions (MARs), and shows several DNA segments with increased helix flexibility. We found that tight clusters of stem-loop structures were localized exclusively in the two regions with greater frequency of breakage. Chromosomal instability at FRA6F probably depends on a complex interaction of different factors, involving regions of greater DNA flexibility and MARs. We propose an additional mechanism of fragility at FRA6F, based on stem-loop structures which may cause delay or arrest in DNA replication. A senescence gene likely maps within FRA6F, as suggested by detection of deletion and translocation breakpoints involving this fragile site in immortal human-mouse cell hybrids and in SV40-immortalized human fibroblasts containing a human chromosome 6 deleted at q21. Deletion breakpoints within FRA6F are common in several types of human leukemias and solid tumors, suggesting the presence of a tumor suppressor gene in the region. Moreover, a gene associated to hereditary schizophrenia maps within FRA6F. Therefore, FRA6F may represent a landmark for the identification and cloning of genes involved in senescence, leukemia, cancer and schizophrenia.	Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Sanger Ctr, Hinxton CB10 1SA, Cambs, England; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Med, Rochester, MN 55905 USA	University of Ferrara; University of Ferrara; Wellcome Trust Sanger Institute; Mayo Clinic	Barbanti-Brodano, G (corresponding author), Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Negrini, Massimo/J-2377-2016; Mungall, Andrew J./U-7067-2018	Negrini, Massimo/0000-0002-0007-1920; Mungall, Andrew J./0000-0002-0905-2742				Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bell DW, 1997, CANCER RES, V57, P4057; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; Cao QH, 1997, GENOMICS, V43, P1, DOI 10.1006/geno.1997.4815; Chen CH, 1998, HUM GENET, V103, P702, DOI 10.1007/s004390050894; Cooney KA, 1996, CANCER RES, V56, P4150; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Egeli U, 2000, HEAD NECK-J SCI SPEC, V22, P591, DOI 10.1002/1097-0347(200009)22:6<591::AID-HED8>3.0.CO;2-C; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.0.CO;2-V; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jackson A, 1998, GENOMICS, V50, P34, DOI 10.1006/geno.1998.5270; Karayianni E, 1999, CYTOGENET CELL GENET, V86, P263, DOI 10.1159/000015356; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Mangelsdorf M, 2000, CANCER RES, V60, P1683; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mishmar D, 1999, AM J HUM GENET, V64, P908, DOI 10.1086/302299; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2000, GENE, V252, P217, DOI 10.1016/S0378-1119(00)00231-6; Morelli C, 1997, CANCER RES, V57, P4153; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; Morelli C, 1997, CYTOGENET CELL GENET, V79, P97, DOI 10.1159/000134691; Paige AJW, 2000, CANCER RES, V60, P1690; PAPPAS GJ, 1995, GENOMICS, V25, P124, DOI 10.1016/0888-7543(95)80117-5; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Simonic I, 1996, HUM GENET, V97, P524; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Smith DI, 1998, INT J ONCOL, V12, P187; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tunca B, 2000, CANCER GENET CYTOGEN, V119, P139, DOI 10.1016/S0165-4608(99)00228-9; Tunca B, 2000, CANCER LETT, V152, P201, DOI 10.1016/S0304-3835(00)00334-7; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	66	65	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7266	7276		10.1038/sj.onc.1205573	http://dx.doi.org/10.1038/sj.onc.1205573			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370818				2022-12-28	WOS:000178504600016
J	Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W				Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W			Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21	ONCOGENE			English	Article						phosphorylation; radiation; p53; p21; Mdm-2; TAF(II)31; hydrogen bond	DAMAGE-INDUCED PHOSPHORYLATION; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; ONCOPROTEIN MDM2; DNA-BINDING; IN-VITRO; PROTEIN; KINASE; DEGRADATION	Analyses of five wild-type p53 containing cell lines revealed lineage specific differences in phosphorylation of Thr18 after treatment with ionizing (IR) or ultraviolet (UV) radiation. Importantly, Thr18 phosphorylation correlated with induction of the p53 downstream targets p21(Waf1/Cip1) (p21) and Mdm-2, suggesting a transactivation enhancing role. Thr18 phosphorylation has been shown to abolish side-chain hydrogen bonding between Thr18 and Asp21, an interaction necessary for stabilizing alpha-helical conformation within the transactivation domain. Mutagenesis-derived hydrogen bond disruption attenuated the interaction of p53 with the transactivation repressor Mdm-2 but had no direct effect on the interaction of p53 with the basal transcription factor TAF(II)31. However, prior incubation of p53 mutants with Mdm-2 modulated TAF(II)31 interaction with p53, suggesting Mdm-2 blocks the accessibility of p53 to TAF(II)31. Consistently, p53-null cells transfected with hydrogen bond disrupting p53 mutants demonstrated enhanced endogenous p21 expression, whereas p53/Mdm-2-double null cells exhibited no discernible differences in p21 expression. We conclude disruption of intramolecular hydrogen bonding between Thr18 and Asp21 enhances p53 transactivation by modulating Mdm-2 binding, facilitating TAF(II)31 recruitment.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Uesugi, Motonari/AAM-9777-2020		NATIONAL CANCER INSTITUTE [R29CA067987] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; COLLINS A, 1987, INT J RADIAT BIOL, V51, P971, DOI 10.1080/09553008714551271; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Jabbur JR, 2001, INT J MOL MED, V7, P163; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Mayo LD, 1997, CANCER RES, V57, P5013; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scolnick DM, 1997, CANCER RES, V57, P3693; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	85	37	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7100	7113		10.1038/sj.onc.1205856	http://dx.doi.org/10.1038/sj.onc.1205856			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370832				2022-12-28	WOS:000178424900013
J	el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A				el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A			BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells	ONCOGENE			English	Article						BTG2(TIS21/PC3); PC12 cells; cell differentiation; apoptosis	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; PC3/BTG/TOB FAMILY; CELLULAR-RESPONSE; TOB/BTG1 FAMILY; MESSENGER-RNA; GENE; PC3; EXPRESSION; MEMBER	The p53-transcriptional target, BTG2(TIS21/PC3), was previously identified as an antiproliferative gene. However, the precise biological functions of the protein product remain to be elucidated. BTG(2TIS21/PC3) expression is induced in vivo during neurogenesis, and the gene is transiently expressed in vitro in rat pheochromocytoma PC12 cells after induction of neuronal differentiation by addition of nerve growth factor (NGF). These observations suggest that BTG2(TIS21/PC3) is functionally significant during the neuronal differentiation process. To test this hypothesis, a vector that expressed BTG2(TIS21/PC3) under the control of an inducible promoter was introduced into PC12 cells. Growth arrest and differentiation in response to NGF were greatly enhanced by BTG2(TIS21/PC3) overexpression. Furthermore, an antisense oligonucleotide complementary to BTG2(TIS21/PC3) mRNA, which was able to inhibit endogenous BTG2(TIS21/PC3) expression, triggered programmed cell death in differentiated PC12 cells. These observations confirm that BTG2(TIS21/PC3) expression promotes neuronal differentiation and that it is required for survival of terminally differentiated cells.	INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, F-69008 Lyon, France; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Fac Pharm Lyon, Dept Genet Mol & Biochim Clin, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; New York University; New York University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, 28 Rue Laennec, F-69008 Lyon, France.	puisieux@lyon.fnclcc.fr		PUISIEUX, Alain/0000-0002-9938-3798				ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; Cimato TR, 1997, J CELL BIOL, V138, P1089, DOI 10.1083/jcb.138.5.1089; Corrente G, 2002, NEUROREPORT, V13, P417, DOI 10.1097/00001756-200203250-00011; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Malatesta P, 2000, MECH DEVELOP, V90, P17, DOI 10.1016/S0925-4773(99)00224-5; Marz P, 1997, EUR J NEUROSCI, V9, P2765, DOI 10.1111/j.1460-9568.1997.tb01705.x; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VINORES SA, 1981, J NEUROCHEM, V37, P597; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Zhu JH, 1998, CANCER RES, V58, P5061	32	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6772	6778		10.1038/sj.onc.1205888	http://dx.doi.org/10.1038/sj.onc.1205888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360398				2022-12-28	WOS:000178315800007
J	Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S				Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S			IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells	ONCOGENE			English	Article						IL-6; STAT3; MEK kinase; phosphorylation	SIGNAL TRANSDUCER GP130; JAK-TYK KINASES; TYROSINE KINASE; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERLEUKIN-6 FAMILY; PROTEIN-KINASES; IN-VIVO; INHIBITOR; ASSOCIATION	Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jakl phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37,Room 1D-18, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KUMAR G, 1994, J IMMUNOL, V153, P4436; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nosaka T, 2000, INT J HEMATOL, V71, P309; Ogata A, 1997, J IMMUNOL, V159, P2212; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Treon S P, 1998, Curr Opin Hematol, V5, P42; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YANG YP, 1995, HUM GENE THER, V6, P1203, DOI 10.1089/hum.1995.6.9-1203; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	38	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6791	6800		10.1038/sj.onc.1205815	http://dx.doi.org/10.1038/sj.onc.1205815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360405				2022-12-28	WOS:000178315800009
J	Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND				Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND			BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains	ONCOGENE			English	Article						BRCA; acetyl-CoA carboxylase; BRCT; GST pull-down	COENZYME-A CARBOXYLASE; BREAST-CANCER CELLS; NUCLEAR-LOCALIZATION SIGNAL; POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; OVARIAN-CANCER; MURINE BRCA1	Germ-line alterations in BRCA1 are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 is a 220-kDa protein that contains a tandem of two BRCA1 C-Terminal (BRCT) domains. Among missense and nonsense BRCA1 mutations responsible for family breast cancer, some are located into the BRCT tandem of BRCA1 coding sequence. In an attempt to understand how BRCT is critical for BRCA1 function, we search for partners of this BRCT tandem of BRCA1. Using a glutathione-S-transferase (GST) pull-down assay with murine cells, we isolated only one major BRCA1-interacting protein, further identified as Acetyl Coenzyme A (CoA) Carboxylase a (ACCA). We showed that this interaction is conserved through murine and human species. We also delineated the minimum interacting region as being the whole tandem of BRCT domains. We demonstrated that BRCA1 interacts in vitro and in vivo with ACCA. This interaction is completely abolished by five distinct germline BRCA1 deleterious mutations affecting the BRCT tandem of BRCA1. Interestingly, ACCA originally known as a rate-limiting enzyme for fatty acids biosynthesis, has been recently shown to be over-expressed in breast cancers and considered as a potential target for anti-neoplastic therapy. Furthermore, our observation is making a bridge between the genetic factors involved in susceptibility to breast and ovarian cancers, and environmental factors such as nutrition considered as key elements in the etiology of those cancers.	Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, F-69373 Lyon 08, France; CEN Grenoble, DBMS, Lab Chim Prot, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA	Venezia, ND (corresponding author), Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; BACHELIER R, 2001, VIRCHOWS ARCH, V40, P261; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brownsey RW, 1997, BIOCHEM SOC T, V25, P1232, DOI 10.1042/bst0251232; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carroll KK, 1998, LIPIDS, V33, P1055, DOI 10.1007/s11745-998-0305-8; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Deng CX, 2000, BIOESSAYS, V22, P728; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moncur JT, 1998, P NATL ACAD SCI USA, V95, P6989, DOI 10.1073/pnas.95.12.6989; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTESANO R, 1997, IN VIVO CELL DEV BIO, V34, P468; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patterson RE, 1999, J AM DIET ASSOC, V99, P1412, DOI 10.1016/S0002-8223(99)00341-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1996, CANCER RES, V56, P2745; Riboli E, 2001, J NUTR, V131, p170S, DOI 10.1093/jn/131.1.170S; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruderman N, 2001, SCIENCE, V291, P2558, DOI 10.1126/science.1060277; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Saitoh S, 1996, J CELL BIOL, V134, P949, DOI 10.1083/jcb.134.4.949; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; STOLL BA, 1995, ANN ONCOL, V6, P245, DOI 10.1093/oxfordjournals.annonc.a059153; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Tomlinson GE, 1998, CANCER RES, V58, P3237; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	80	75	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6729	6739		10.1038/sj.onc.1205915	http://dx.doi.org/10.1038/sj.onc.1205915			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360400				2022-12-28	WOS:000178315800003
J	He, Q; Luo, XQ; Huang, Y; Sheikh, MS				He, Q; Luo, XQ; Huang, Y; Sheikh, MS			Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells	ONCOGENE			English	Article						NSAIDs; TRAIL/Apo2L; death receptor 5; Bax; caspases; colon cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYTOCHROME-C; COLORECTAL-CANCER; DEATH RECEPTORS; GENE-EXPRESSION; IN-VIVO; LIGAND; COLON; MECHANISMS; RELEASE	The nonsteroidal anti-inflammatory drugs (NSAIDs) are believed to mediate their anticancer effects by inducing apoptosis but the molecular mechanisms of their apoptotic effects remain largely unknown. Here we report that two different NSAIDs, sulindac sulfide and SC-'236 engage the death receptor 5 (DR5) and mitochondrial pathways to mediate apoptosis in human colon cancer cells. We show that sulindac sulfide and SC-'236-induced apoptosis is coupled with upregulation of DR5, caspase 8 activation and Bid cleavage. Thus, a cross talk appears to exist between the DR5 and mitochondrial pathways during apoptosis induced by these NSAIDs. We further show that sulindac sulfide and SC-'236-induced DR5 upregulation occurs independent of the COX inhibitory effects of these NSAIDs. Using Bax-proficient (Bax+/-) and Bax-deficient (Bax-/-) HCT116 human colon cancer cells, we further demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac sulfide and SC-'236. For example, sulindac sulfide upregulates DR5 in both Bax-deficient and proficient cells, but Apo2L/TRAIL efficiently potentiates sulindac sulfide-induced apoptosis as well as activation of caspase-8, -9 and -3 only in Bax-proficient cells. SC-'236 also upregulates DR5 in both Bax-proficient and Bax-deficient cells but Apo2L/TRAIL potentiates SC-'236- mediated apoptosis and caspases-8 and -3 activation in both Bax-proficient and Bax-deficient cells. Further, in Bax-deficient cells, neither sulindac sulfide nor SC-'236 in combination with Apo2L/TRAIL effectively promotes the release of cytochrome c from mitochondria into cytosol and caspase-9 activation. Collectively, our results suggest that unlike sulindac sulfide, SC-'236 in combination with Apo2L/TRAIL can overcome Bax deficiency to induce apoptosis. These results have important clinical implications in that the tumors harboring Bax mutations are likely to develop resistance to sulindac but not to SC-'236-like NSAIDs. In conclusion, the data presented herein form the basis of future in-depth studies to further explore the utility of Apo2L/TRAIL and NSAIDs, in combination, as a novel cancer preventive/therapeutic strategy.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Huang Y, 2001, CANCER RES, V61, P6918; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LANCASTER T, 1994, DIGEST DIS, V12, P170, DOI 10.1159/000171450; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch HT, 1999, J MED GENET, V36, P801; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 2002, CANCER RES, V62, P1583; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2000, GENE DEV, V14, P2060; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	46	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6032	6040		10.1038/sj.onc.1205897	http://dx.doi.org/10.1038/sj.onc.1205897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203115				2022-12-28	WOS:000177671300006
J	Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F				Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F			CAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner	ONCOGENE			English	Article						retinal pigment epithelium; signal transduction	MAP KINASE ERK; SIGNALING PATHWAYS; ACTIVE-TRANSPORT; PROTEIN; PHOSPHORYLATION; ACTIVATION; RAF-1; COMPLEXITY; SECRETION; REQUIRES	Retinal pigmented epithelial (RPE) cell integrity is critical to the maintenance of retina functions and RPE cells do not proliferate in adults. The activation of RPE results in cell proliferation which may be associated with proliferative retinopathy and choroidal melanoma. Mitogen-activated protein kinase (MAPK) is believed to be a key participant in the response to mitogenic stimuli. We therefore investigated the involvement of the extracellular signal-regulated protein kinase (ERK) I and 2 during the induction of RPE cell proliferation. After foetal calf serum (FCS) stimulation activation of the Ras/Raf/ERK signalling pathway was detected by Western blotting and immunochemistry, with specific anti-phosphosignalling protein antibodies. Pharmacological and antisense (AS) oligonucleotide (ODN) strategies were used to analyse the signalling involved in FCS-induced RPE cell proliferation. Activation of the small G protein Ras and, to a lesser extent of Raf-1, the kinase directly downstream from Ras, was necessary to FCS-induced cell proliferation. MEK1/2 and ERK1/2 were activated during cell proliferation. Inhibition of MEK1/2 with UO 126 completely abolished ERK1/2 activation and reduced cell proliferation by 33-43%. ERK1/2 depletion by an AS ODN approach reduced cell proliferation by 27-33%, confirming the role of ERK1/2 in the FCS stimulation of RPE cells. We also investigated the role of PKA/cAMP, one of the major inhibitory pathways of ERK1/2. PKA blockade did not modify ERK1/2 activation or cell proliferation. In contrast, agents that increased cAMP concentration, abolished RPE proliferation, and MEK/ERK activation. Moreover, inhibition of the cAMP-activated small G protein Rap1, partially reversed the inhibitory effects of cAMP on cell proliferation and MEK/ERK activation. The requirement for Ras and ERK1/2, the lack of ERK1/2 regulation by PKA and the cAMP/Rap1 counter-regulatory pathway for ERK-mediated cell proliferation suggest complex regulation of signalling in RPE cells. These data may have important implications for the development of more selective models for retinal anti-proliferative therapies.	CNRS, Ctr Biomed Cordeliers, INSERM U450, F-75006 Paris, France; Univ Klinikum Hamburg Eppendorf, Dept Ophthalmol, Cornea Bank Transplantat Lab, D-20246 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Hamburg; University Medical Center Hamburg-Eppendorf	Mascarelli, F (corresponding author), CNRS, Ctr Biomed Cordeliers, INSERM U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mascarelli, Frederic/L-8916-2018; Valtink, Monika/I-1507-2013	Valtink, Monika/0000-0003-3205-1876				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Bryckaert M, 2000, ONCOGENE, V19, P4917, DOI 10.1038/sj.onc.1203872; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231; Zubilewicz A, 2001, INVEST OPHTH VIS SCI, V42, P488	27	53	55	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6101	6112		10.1038/sj.onc.1205765	http://dx.doi.org/10.1038/sj.onc.1205765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203122	Bronze			2022-12-28	WOS:000177671300013
J	Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A				Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A			pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation	ONCOGENE			English	Article						apoptosis; gamma-radiation; pRb2/p130; glioblastoma; p73; Bcl-2; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN NEUROBLASTOMA-CELLS; GROWTH IN-VIVO; KINASE C-ABL; INDUCED APOPTOSIS; DNA-DAMAGE; TISSUE TRANSGLUTAMINASE; TUMOR-CELLS; PROTEIN; CYCLE	This study shows that in the glioblastoma hamster cell line HJC12 the retinoblastoma family member pRb2/p130 enhances gamma-radiation-induced cell death. In HJC12 cells the tetracycline-regulated expression of pRb2/p130 increased the percentage of gamma-radiation-induced apoptotic cells from 27 to 47%. pRb2/p130 overexpression was associated with the downregulation of the anti-apoptotic factor Bcl-2 and the upregulation of the steady-state protein levels of the pro-apoptotic transcription factor p73. In particular, RT-PCR showed a significant increase in the expression of the p73delta isoform when pRb2/p130 was overexpressed. The ability of pRb2/p130 to modulate apoptosis was not associated with its role in mediating G0/G1 arrest during cell cycle progression. Our data suggest a role for pRb2/p130 in glioblastoma gamma-radiation-induced cell death, indicating that the antitumoral action of pRb2/p130 can regulate both inhibition of cell cycle progression and induction of cell death.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillo Faccial, I-80131 Naples, Italy; Univ Roma Tor Vergata, Dipartimento Med Interna, I-00133 Rome, Italy; Univ Roma Tor Vergata, Biochim Lab, IDI, IRCCS,Dipartimento Med Sperimentale & Sci Biochim, I-00133 Rome, Italy; Temple Univ, Ctr Neuro Virol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; University of Naples Federico II; University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		TERRINONI, Alessandro/J-1533-2012; Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	TERRINONI, Alessandro/0000-0002-7442-2252; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X	NCI NIH HHS [5 T32 CA09137, P01-CA56309, R01 CA60999/01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309, R01CA060999, T32CA009137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 1999, NATURE, V399, P809; An B, 1996, CANCER RES, V56, P438; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Berry DE, 1996, ONCOGENE, V12, P1809; Bowen C, 1998, CANCER RES, V58, P3275; CHOISYROSSI C, 1999, CELL DEATH DIFFER, V5, P1162; Claudio PP, 2000, CANCER RES, V60, P372; CLAUDIO PP, 1994, CANCER RES, V54, P5555; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Debatin KM, 1997, BIOCHEM SOC T, V25, P405, DOI 10.1042/bst0250405; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fan GS, 1996, ONCOGENE, V12, P1909; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong JG, 1999, NATURE, V399, P806; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOST C, 1997, NATURE, V38, P191; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; RAY GV, 1995, INT J ONCOL, V7, P801; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhivotovsky B, 1997, J CELL BIOCHEM, V64, P43, DOI 10.1002/(SICI)1097-4644(199701)64:1<43::AID-JCB7>3.3.CO;2-S	47	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5897	5905		10.1038/sj.onc.1205750	http://dx.doi.org/10.1038/sj.onc.1205750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185589				2022-12-28	WOS:000177520900009
J	Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK				Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK			WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma	ONCOGENE			English	Article						WAVE3; neuroblastoma; actin polymerization	NEURO-BLASTOMA; MOLECULAR CHARACTERIZATION; NEUROBLASTOMA; FAMILY; REGION; RETINOBLASTOMA; BREAKPOINT; MUTATION; DELETION; CANCER	Neuroblastoma (Nb) is a malignancy of the sympathetic nervous system which affects children in their first decade. It is the most common extra-cranial solid tumor in children with an incidence of approximately 1 in 8 - 10 000 live births annually and accounts for approximately 10% of all children's cancers. Ganglioneuroblastoma is a relatively benign form of Nb and consists of a mixture of fibrils, mature and maturing ganglion cells, as well as undifferentiated neuroblasts. During routine cytogenetic analysis of patients with different manifestations of neuroblastoma we have identified one patient with ganglioneuroblastoma that carries an apparently balanced t(1:13)(q21:q12) reciprocal translocation. Positional cloning of the translocation breakpoint on chromosome 13 resulted in the mapping of the breakpoint between coding exon 2 and exon 3 of WAVE3, a member of WASP gene family. Although the breakpoint region on chromosome I was localized to within 2 kb of genomic sequence, no gene was found to be interrupted on this chromosome. The WAVE3 transcript is mainly expressed in the nervous system and, like all the members of the WASP gene family, WAVE3 is a key element in actin polymerization and cytoskeleton organization. WAVE3, therefore, is important for cell differentiation and motility and its expression is lost in a number of low grade and stage 4S tumors. From analysis of its expression pattern and function, WAVE3 is a candidate tumor suppressor gene, at least in some forms of neuroblastoma.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Roswell Park Cancer Institute; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 16056-26] Funding Source: Medline; NINDS NIH HHS [NS35791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson J, 2001, BRIT J CANCER, V85, P493, DOI 10.1054/bjoc.2001.1979; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Castleberry RP, 1999, J PEDIAT HEMATOL ONC, V21, P178, DOI 10.1097/00043426-199905000-00004; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; DANGIO GJ, 1971, LANCET, V1, P1046; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; Fryns JP, 1996, GENET COUNSEL, V7, P73; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; Kitamura E, 2000, ONCOGENE, V19, P5772, DOI 10.1038/sj.onc.1203978; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; LANCIOTTI M, 1992, CELL MOL NEUROBIOL, V12, P225, DOI 10.1007/BF00712928; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; MICHALSKI AJ, 1993, GENOMICS, V18, P141, DOI 10.1006/geno.1993.1439; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MITCHELL CD, 1991, BRIT MED BULL, V47, P136, DOI 10.1093/oxfordjournals.bmb.a072452; MITCHELL CD, 1989, ONCOGENE, V4, P253; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; NAGANO H, 1980, JPN J HUM GENET, V25, P39, DOI 10.1007/BF01876544; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; PONZONI M, 1991, CELL MOL NEUROBIOL, V11, P397, DOI 10.1007/BF00711421; RICCARDI VM, 1978, PEDIATRICS, V61, P604; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Roberts T, 1998, CANCER GENET CYTOGEN, V100, P10, DOI 10.1016/S0165-4608(97)00013-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER WG, 1984, CANCER GENET CYTOGEN, V11, P153, DOI 10.1016/0165-4608(84)90109-2; Sossey-Alaoui K, 1999, GENOMICS, V60, P330, DOI 10.1006/geno.1999.5924; Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takenawa T, 2001, J CELL SCI, V114, P1801; Van Roy N, 1997, EUR J CANCER, V33, P1974, DOI 10.1016/S0959-8049(97)00319-5; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; XU Y, 1994, ISMB, V2, P376; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	42	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5967	5974		10.1038/sj.onc.1205734	http://dx.doi.org/10.1038/sj.onc.1205734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185600				2022-12-28	WOS:000177520900020
J	Srivenugopal, KS; Ali-Osman, F				Srivenugopal, KS; Ali-Osman, F			The DNA repair protein, O-6-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein	ONCOGENE			English	Article						MGMT; DNA repair; ubiquitin; proteasome; alkylating agents	PROTEASOME-MEDIATED DEGRADATION; GLUTATHIONE-S-TRANSFERASE; POSITIVE CANCER-CELLS; HUMAN TUMOR-CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; PROMOTER HYPERMETHYLATION; MOLECULAR-BASIS; BETA-CATENIN; P53 PROTEIN; K-RAS	We have previously shown that O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein that protects tissues against toxic and carcinogenic effects of alkylating agents, is degraded through ubiquitination-dependent proteolysis. Here, we investigated the role of the human papillomavirus (HPV) E6 protein in MGMT degradation. In three pairs of isogenic human tumor cell lines in which a member of each pair expressed the E6 protein through stable transfection (HCT116/HCT116-E6, MCF7/MCF7-E6, and RKO/RKO-E6), we found a consistent 40-55% reduction in the MGMT protein level and its activity in all E6-expressing cells compared with the parent cells (P = <0.05). E6 expression did not, however, alter the levels of MGMT mRNA. Addition of the recombinant MGMT (rMGMT) protein to extracts of HCT116/E6 cells resulted in the binding of E6 to MGMT. Further, the purified E6 protein promoted the degradation of rMGMT in rabbit reticulocyte lysates. Immunoprecipitation assays showed the presence of a ternary protein complex between MGMT, E6, and the cellular ubiquitin-ligase E6-associated protein (E6-AP). Transient transfection of the p53-null H1299 lung tumor cells with an E6 construct also down-regulated the MGMT. The MGMT protein also showed structural features that are compatible for interaction with the E6, and E6-AP components. Collectively, these data suggest that the oncogenic E6 proteins enhance the ubiquitin-dependent proteolysis of MGMT.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Box 64, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NCI NIH HHS [CA-74321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali-Osman F., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P572; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Boyer SN, 1996, CANCER RES, V56, P4620; BRENT T P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P421; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; BUTZ K, 1995, ONCOGENE, V10, P927; Chen C, 1999, CARCINOGENESIS, V20, P699, DOI 10.1093/carcin/20.4.699; CHEN JY, 1993, ONCOGENE, V8, P2159; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dolan ME, 1997, CLIN CANCER RES, V3, P837; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Esteller M, 2000, CANCER RES, V60, P2368; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GERSON SL, 1995, HEMATOL ONCOL CLIN N, V9, P431, DOI 10.1016/S0889-8588(18)30103-5; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris LC, 1996, CANCER RES, V56, P2029; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUSSAIN SP, 1994, ONCOGENE, V9, P13; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; KEISS TD, 1993, P NATL ACAD SCI USA, V90, P3988; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Maki CG, 1996, CANCER RES, V56, P2649; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3; SKHEDY D, 1994, FEBS LETT, V348, P126; Srivenugopal KS, 2002, CANCER LETT, V181, P87, DOI 10.1016/S0304-3835(01)00823-0; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; WAJNBERG EF, 1989, FEBS LETT, V243, P141, DOI 10.1016/0014-5793(89)80116-4; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Wolf P, 2001, CANCER RES, V61, P8113; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhang QW, 2001, J PHARMACOL EXP THER, V298, P141; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	59	66	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5940	5945		10.1038/sj.onc.1205762	http://dx.doi.org/10.1038/sj.onc.1205762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185595				2022-12-28	WOS:000177520900015
J	Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D				Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D			Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators	ONCOGENE			English	Article						microtubules; mitosis; breast cancer; mRNA processing; Sm proteins; TACC proteins	CHROMOSOME ARM 8P; COILED-COIL; TUMOR-SUPPRESSOR; GENE FAMILY; CYCLIN B1; PROTEIN; EXPRESSION; SM; CPEB; INTERACTS	The three human TACC genes encode a family of proteins that are suspected to play a role in carcinogenesis. Their function is not precisely known; a Xenopus TACC protein called Maskin is involved in translational control, while the Drosophila D-TACC associates with microtubules and centrosomes. We have characterized the human TACC1 gene and its products. The TACC1 gene is located in region p12 of chromosome 8; its mRNA is ubiquitously expressed and encodes a protein with an apparent molecular mass of 125 kDa, which is cytoplasmic and mainly perinuclear. We show that TACC1 mRNA gene expression is down-regulated in various types of tumors. Using immunohistochemistry of tumor tissue-microarrays and sections, we confirm that the level of TACC1 protein is down-regulated in breast cancer. Finally, using the two-hybrid screen in yeast, GST pull-downs and co-immunoprecipitations, we identified two potential binding partners for TACC1, LSM7 and SmG. They constitute a conserved subfamily of Sm-like small proteins that associate with U6 snRNPs and play a role in several aspects of mRNA processing. We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes.	Dept Mol Oncol, INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Pathol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Atelier Bioimagerie, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Dept Mol Oncol, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017; ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	Ginestier, Christophe/0000-0002-7477-3837; ADELAIDE, José JA/0000-0003-4364-9857; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Conte, Nathalie/0000-0002-1010-3121				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kelley JR, 2000, SURGERY, V128, P353, DOI 10.1067/msy.2000.107605; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	46	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5619	5630		10.1038/sj.onc.1205658	http://dx.doi.org/10.1038/sj.onc.1205658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165861				2022-12-28	WOS:000177442000012
J	Smiraglia, DJ; Plass, C				Smiraglia, DJ; Plass, C			The study of aberrant methylation in cancer via restriction landmark genomic scanning	ONCOGENE			English	Review						DNA methylation; RLGS; cancer; genomic scanning; hypomethylation	ACUTE MYELOID-LEUKEMIA; CPG-ISLAND METHYLATION; CTCF-BINDING SITES; DNA METHYLATION; CELL-LINES; HEPATOCELLULAR-CARCINOMA; 2-DIMENSIONAL ELECTROPHORESIS; PROMOTER HYPERMETHYLATION; 5-METHYLCYTOSINE CONTENT; TRANSGENIC MICE	Restriction landmark genomic scanning (RLGS) has been used to study DNA methylation in cancer for nearly a decade. The strong bias of RLGS for assessing the methylation state of CpG islands genome wide makes this an attractive technique to study both hypo- and hypermethylation of regions of the genome likely to harbor genes. RLGS has been used successfully to identify regions of hypomethylation, candidate tumor suppressor genes, correlations between hypermethylation events and clinical factors, and quantification of hypermethylation in a multitude of malignancies. This review will examine the major uses of RLGS in the study of aberrant methylation in cancer and discuss the significance of some of the findings.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Smiraglia, DJ (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.	Smiraglia.1@postbox.acs.ohio-state.edu	Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Smiraglia, Dominic/0000-0001-8852-1510; 	NIDCR NIH HHS [DE13123-02] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akama TO, 1997, CANCER RES, V57, P3294; ASAKAWA J, 1995, ELECTROPHORESIS, V16, P241, DOI 10.1002/elps.1150160140; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello J F, 2000, Brain Tumor Pathol, V17, P49, DOI 10.1007/BF02482735; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 1997, CANCER RES, V57, P1250; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; HIROTSUNE S, 1992, CANCER RES, V52, P3642; HIROTSUNE S, 1993, BIOCHEM BIOPH RES CO, V194, P1406, DOI 10.1006/bbrc.1993.1981; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; KAWAI J, 1994, MOL CELL BIOL, V14, P7421, DOI 10.1128/MCB.14.11.7421; Kim YS, 2000, INT J ONCOL, V17, P297; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Konishi N, 1997, PATHOL INT, V47, P735, DOI 10.1111/j.1440-1827.1997.tb04451.x; Konishi N, 1996, CELL MOL BIOL, V42, P1129; Kuick R, 1996, GENETICS, V144, P307; KUO KC, 1980, NUCLEIC ACIDS RES, V8, P4763, DOI 10.1093/nar/8.20.4763; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; Nagai H, 1998, CANCER, V82, P454, DOI 10.1002/(SICI)1097-0142(19980201)82:3<454::AID-CNCR5>3.0.CO;2-P; NAGAI H, 1994, CANCER RES, V54, P1545; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Nagai H, 1999, GENE, V237, P15, DOI 10.1016/S0378-1119(99)00322-4; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nakamura M, 1997, J NEURO-ONCOL, V35, P113, DOI 10.1023/A:1005712308061; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; Okazaki Y, 1996, NAT GENET, V13, P87, DOI 10.1038/ng0596-87; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; OKUIZUMI H, 1995, ELECTROPHORESIS, V16, P253, DOI 10.1002/elps.1150160141; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1999, ONCOGENE, V18, P3159, DOI 10.1038/sj.onc.1202651; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rosas SLB, 2001, CANCER RES, V61, P939; Rouillard JM, 2001, GENOME RES, V11, P1453, DOI 10.1101/gr.181601; Rush LJ, 2002, BLOOD, V99, P1874, DOI 10.1182/blood.V99.5.1874; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHIRMACHER P, 1991, AM J PATHOL, V139, P231; SHIBATA H, 1995, ELECTROPHORESIS, V16, P210, DOI 10.1002/elps.1150160136; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Suzuki H, 1994, DNA Res, V1, P245, DOI 10.1093/dnares/1.5.245; Tada A, 1998, ONCOL REP, V5, P1137; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Tateno M, 2001, CANCER RES, V61, P1144; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; WATANABE S, 1995, ELECTROPHORESIS, V16, P218, DOI 10.1002/elps.1150160137; Wimmer K, 1996, ELECTROPHORESIS, V17, P1741, DOI 10.1002/elps.1150171112; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357; Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005	110	57	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5414	5426		10.1038/sj.onc.1205608	http://dx.doi.org/10.1038/sj.onc.1205608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154404				2022-12-28	WOS:000177197700008
J	Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B				Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B			ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene	ONCOGENE			English	Article						spectrin; ankyrin; cytoskeleton; neuronal stem cells; gene structure	CENTRAL-NERVOUS-SYSTEM; MEMBRANE SKELETON; EPITHELIAL-CELLS; MESSENGER-RNA; ERYTHROCYTE SPECTRIN; MOLECULAR-CLONING; LIVER DEVELOPMENT; NEURAL CELLS; IN-VITRO; IDENTIFICATION	Spectrins play a pivotal role in axonal transport, neurite extension, the organization of synaptic vesicles, as well as for protein sorting in the Golgi apparatus and cell membrane. Among spectrins there is great variability in sequence composition, tissue distribution, and function, with two known genes encoding the alpha-chain, and at least five encoding the beta-chain. It remains unclear as to whether novel beta-spectrins such as elf1-4 are distinct genes or alpha-G-spectrin isoforms. The role for ELF in the developing nervous system has not been identified to date. In this study we demonstrate the genomic structure of elf-3, as well as the expression of ELF in the developing mouse brain using a peptide specific antibody against its distinctive amino-terminal end. Full genomic structural analyses reveal that elf-3 is composed of 31 exons spanning similar to67 kb, and confirm that elf and mouse brain beta-G-spectrin share multiple exons, with a complex form of exon/intron usage. In embryonic stages, E9-12, anti-ELF localized to the primary brain vesicular cells that also labeled strongly with anti-nestin but not anti-vimentin. At E12-14, anti-ELF localized to axonal sprouts in the developing neuroblasts of cortex and purkinje cell layer of the cerebellum, as well as in cell bodies in the diencephalon and metencephalon. Double labeling identified significant co-localization of anti-ELF, nestin and dystrophin in sub ventricular zone cells and in stellate-like cells of the developing forebrain. These studies define clearly the expression of ELF, a new isoform of beta-G-spectrin in the developing brain. Based on its expression pattern, ELF may have a role in neural stem cell development and is a marker of axonal sprouting in mid stages of embryonic development.	Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; DVAMC, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Childrens Hosp, Philadelphia, PA 19104 USA; NHGRI, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Georgetown University	Mishra, L (corresponding author), Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lopamishra@yahoo.com		Mishra, Lopa/0000-0002-6850-0808	NIDDK NIH HHS [1R01 DK56111, 1R03 DK53861, 1R01 DK 58637] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111, R03DK053861] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BIRKENMEIER CS, 1988, P NATL ACAD SCI USA, V85, P8121, DOI 10.1073/pnas.85.21.8121; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Chen YW, 2001, J MOL NEUROSCI, V17, P59, DOI 10.1385/JMN:17:1:59; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAVIS J, 1983, J BIOL CHEM, V258, P7757; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Doetsch F, 1997, J NEUROSCI, V17, P5046; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Emery A, 1988, DUCHENNE MUSCULAR DY; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GLENNEY JR, 1983, J CELL BIOL, V96, P1491, DOI 10.1083/jcb.96.5.1491; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Hayes NVL, 2000, J CELL SCI, V113, P2023; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; JOOSTEN EAJ, 1989, NEUROSCIENCE, V31, P439, DOI 10.1016/0306-4522(89)90386-2; JUNG D, 1991, NEUROSCI LETT, V124, P87, DOI 10.1016/0304-3940(91)90828-H; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1998, J NEUROCHEM, V71, P2585; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MARINPADILLA M, 1985, J COMP NEUROL, V235, P82, DOI 10.1002/cne.902350107; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1999, MAMM GENOME, V10, P62, DOI 10.1007/s003359900944; Mishra L, 1998, INT J DEV BIOL, V42, P221; MOON RT, 1987, BIOESSAYS, V7, P159, DOI 10.1002/bies.950070405; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; MORROW JS, 1997, HDB PHYSIOL 14, P485; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Ohara O, 1998, MOL BRAIN RES, V57, P181, DOI 10.1016/S0169-328X(98)00068-0; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Sakaguchi G, 1998, BIOCHEM BIOPH RES CO, V248, P846, DOI 10.1006/bbrc.1998.9067; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; Sikorski AF, 2000, BRAIN RES, V852, P161, DOI 10.1016/S0006-8993(99)02253-2; SIMAN R, 1987, J NEUROSCI, V7, P55; SOBUE K, 1990, NEUROSCI RES, pS80, DOI 10.1016/0921-8696(90)90035-2; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Stabach PR, 2000, J BIOL CHEM, V275, P21385, DOI 10.1074/jbc.C000159200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; TAKASHIMA S, 1981, BRAIN RES, V225, P1, DOI 10.1016/0006-8993(81)90314-0; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; WINKELMANN JC, 1988, BLOOD, V72, P328; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zarnescu DC, 1999, J CELL BIOL, V146, P1075, DOI 10.1083/jcb.146.5.1075; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681; ZIMMER WE, 1991, BRAIN RES BULL, V27, P187, DOI 10.1016/0361-9230(91)90066-S	85	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5255	5267		10.1038/sj.onc.1205548	http://dx.doi.org/10.1038/sj.onc.1205548			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149647				2022-12-28	WOS:000177193900007
J	Herrant, M; Luciano, F; Loubat, A; Auberger, P				Herrant, M; Luciano, F; Loubat, A; Auberger, P			The protective effect of phorbol esters on Fas-mediated apoptosis in T cells. Transcriptional and postranscriptional regulation	ONCOGENE			English	Article						apoptosis; phorbol esters; cDNA arrays; death and survival genes	PROTEIN-KINASE-C; EXPRESSION INDUCES APOPTOSIS; MYC EXPRESSION; ENDOTHELIAL-CELLS; DOWN-MODULATION; GROWTH ARREST; KNOCKOUT MICE; DEATH; ACTIVATION; PATHWAY	Phorbol esters are tumor promoters that bind and activate both conventional and new Protein kinase C (PKC) isoforms. In various circumstances, PKC-dependent signaling pathways can promote cell survival and protect against cell death. This was first analysed in Jurkat T cells where Phorbol Myristate Acetate (PMA) was found to inhibit Fas-mediated apoptosis as judged by DiOC6(3) staining, caspase activation and DNA fragmentation, indicating that PMA exerts its protective effect upstream or at the mitochondrial level in these cells. PMA activated most of the main kinase pathways in T cells such as PKCs, p42/44MAPK, p38MAPK and p90Rsk but not JNK and Akt. A pharmacological approach allowed us to identify that nPKCs are both necessary and likely sufficient to promote T cell survival. Besides this post-transcriptional regulation, nPKCs may also regulate apoptosis at the transcriptional level. cDNA arrays were used to identify a set of genes whose expression was modulated in death versus survival conditions. Following PMA treatment, expression of Mcl-l and Bcl-x increased while that of cMyc was significantly reduced. Moreover, survivin expression decreased upon CH11 or PMA treatment. cMyc, survivin and Bcl-x modulation seems to be regulated at the transcriptional level while decrease in Mcl-1 protein in CH11-treated cells resulted especially from a caspase-dependent proteolysis. Taken together, our data demonstrate that PMA-mediated inhibition of apoptosis is a complex process that is integrated at both the transcriptional and post-transcriptional level and point out to the potential role of Mcl-1, Bcl-x, c-Myc and survivin in this process.	Fac Med, IFR 50, INSERM, U526,Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; Fac Med, IFR 50, INSERM, U364, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med, IFR 50, INSERM, U526,Equipe Labellisee Ligue Natl Contre Canc, Ave Valombrose, F-06107 Nice 2, France.		KHATIB, Abdel-Majid/A-9948-2015; luciano, frederic/P-6264-2016; AUBERGER, Patrick/G-1491-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; luciano, frederic/0000-0001-9253-4998; AUBERGER, Patrick/0000-0002-2481-8275				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Nagata S, 1998, J HUM GENET, V43, P2, DOI 10.1007/s100380050029; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Oberg F, 2001, LEUKEMIA, V15, P217, DOI 10.1038/sj.leu.2402025; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tiberio L, 2001, CELL DEATH DIFFER, V8, P967, DOI 10.1038/sj.cdd.4400909; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Wu M, 1996, MOL CELL BIOL, V16, P5015; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	62	41	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4957	4968		10.1038/sj.onc.1205689	http://dx.doi.org/10.1038/sj.onc.1205689			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118374				2022-12-28	WOS:000176874800010
J	Zink, D; Mayr, C; Janz, C; Wiesmuller, L				Zink, D; Mayr, C; Janz, C; Wiesmuller, L			Association of p53 and MSH2 with recombinative repair complexes during S phase	ONCOGENE			English	Article						BRCA1-associated surveillance complex; Rad50; Rad51; replication-associated homologous recombination; tumor suppressor	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE MSH2; HUMAN RAD51 PROTEIN; LARGE-T-ANTIGEN; MISMATCH REPAIR; DNA-DAMAGE; CELL-CYCLE; IN-VIVO; REPLICATION FIDELITY	Our previous recombination and biochemical analyses have led to the hypothesis that the tumor suppressor p53 monitors homologous recombination, a function which was previously attributed to the mismatch repair protein MSH2. Here, we show that a certain fraction of p53 is concentrated within discrete nuclear foci of cells synchronized in G1 phase, a pattern which becomes even more pronounced in S phase, especially after gamma-ray treatment. p53 foci show some colocalization with MSH2 within distinct foci during G1 phase, while dots formed by BRCA1 display an independent localization pattern. In S phase nuclei, p53 foci almost completely colocalize with MSH2 foci and associate with the recombination surveillance factor BRCA1 in irradiated S phase cells. These p53 and MSH2 foci also show significant overlaps with foci of the recombination enzymes Rad50 and Rad51, which for the first time unveiled recombination-related functions of p53 in replicating cells. During S phase, p53 and MSH2 are maximally active in binding to early recombination intermediates, and coexist within the same nuclear DNA-protein complexes. Our data suggest that p53 is linked similarly to homologous recombination as MSH2 and provide further evidence for the new concept of a dual role of p53 in the regulation of growth and repair.	Univ Ulm, Frauenklin & Poliklin, D-89075 Ulm, Germany; LMU Munchen, Inst Anthropol & Human Genet, D-80336 Munich, Germany	Ulm University; University of Munich	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Eils R, 1996, J CELL BIOL, V135, P1427, DOI 10.1083/jcb.135.6.1427; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Lambert S, 1999, MUTAT RES-DNA REPAIR, V433, P159, DOI 10.1016/S0921-8777(99)00004-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; SCHIRMBECK R, 1989, J VIROL, V63, P2308, DOI 10.1128/JVI.63.5.2308-2316.1989; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100; Wang Y, 2000, GENE DEV, V14, P927; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	66	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4788	4800		10.1038/sj.onc.1205614	http://dx.doi.org/10.1038/sj.onc.1205614			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101417				2022-12-28	WOS:000176716300008
J	Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME				Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME			Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1	ONCOGENE			English	Article						MIC-1; glioma; anoxia; p53; HIF-1	TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; WILD-TYPE P53; RECEPTOR NUCLEAR TRANSLOCATOR; BONE MORPHOGENETIC PROTEIN; TUMOR ANGIOGENESIS; GENE-EXPRESSION; MAMMALIAN-CELLS; MEMBER; HYPOXIA	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression. p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis. In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the fet-On system for p53 in the LN-Z308 glioblastoma cell line. The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling. Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines. MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway. Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected. In the present experimental model MIC-1 may exert its anti-tumorigenic properties via a paracrine mechanism mediated by host cells in vivo. Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.	Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Pathol, Expt Oncol Lab, CH-1011 Lausanne, Switzerland; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ S Wales, Sydney, NSW 2010, Australia; Prizer Cent Res, Groton, CT USA; Emory Univ, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; St Vincents Hospital Sydney; University of New South Wales Sydney; Emory University; Emory University	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Fairlie, Walter/M-8401-2015; Hegi, Monika/O-4796-2015	Fairlie, Walter/0000-0002-2498-1160; Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; BONNEKOH B, 1989, ARCH DERMATOL RES, V281, P487, DOI 10.1007/BF00510085; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Detmer K, 1999, BLOOD CELL MOL DIS, V25, P310, DOI 10.1006/bcmd.1999.0259; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fairlie WD, 2001, BIOCHEMISTRY-US, V40, P65, DOI 10.1021/bi001064p; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kessler R, 2000, CANCER RES, V60, P1403; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Strelau J, 2000, J NEUROSCI, V20, P8597; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405	43	139	154	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4212	4219		10.1038/sj.onc.1205610	http://dx.doi.org/10.1038/sj.onc.1205610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082608				2022-12-28	WOS:000176174200003
J	Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K				Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K			Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia	ONCOGENE			English	Article						beta-catenin; prostate; neoplasia; metaplasia	COLORECTAL-CANCER; APC GENE; MAMMARY-GLAND; MICE; CELLS; EXPRESSION; MUTATIONS; POLYPOSIS; ACTIVATION; CARCINOMA	The present study documents that stabilization of beta-catenin is sufficient to induce lesions reminiscent of prostate intraepithelial neoplasia (PIN). Such lesions were present in all compound mutant mice and all prostate acini expressing stabilized beta-catenin. High grade PIN-like lesions resembling early human prostate cancer were detected as early as 10 weeks of age. Surprisingly, stabilization of beta-catenin in other secretory epithelia including salivary, preputial, harderian, and mammary glands induced extensive squamous metaplasia and keratinization associated with terminal differentiation of the target cells, but failed to cause neoplastic transformation. Epidermal hyperplasia, hair follicle cysts, and odontomas were also observed. The prostatic lesions exhibited upregulation of c-myc, increased rate of cellular proliferation, loss of the Na-K-Cl co-transporter NKCC1, and expression of androgen receptor. Basal cell markers such as p63 and keratin 5 were not expressed by the masses of PIN-like lesions, but were present in small foci of proliferating beta-catenin expressing basal cells. Our observations indicate that beta-catenin stabilization is a crucial event for the initiation of PIN-like lesions, but induces squamous metaplasia rather than tumorigenesis in secretory epithelia other than the prostate.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Khazaie, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Klein, Ludger/G-8785-2011	Klein, Ludger/0000-0003-2054-071X				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Davies G, 2000, J UROLOGY, V163, P985, DOI 10.1016/S0022-5347(05)67869-X; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hayward SW, 1996, ACTA ANAT, V155, P81; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; IOZZO RV, 1995, CANCER RES, V55, P3495; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; LAU W, 2001, NAT GENET, V28, P3; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; LUONGO C, 1994, CANCER RES, V54, P5947; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULHOLLAND DJ, 2002, J BIOL CHEM, V20, P20; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Rashid MG, 2001, CANCER RES, V61, P489; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sparks AB, 1998, CANCER RES, V58, P1130; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUNDBERG JP, 2000, COLON CANC STUDY SEC; SUZUKI H, 1994, JPN J CANCER RES, V85, P847, DOI 10.1111/j.1349-7006.1994.tb02957.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; YANG F, 2002, J BIOL CHEM, V15, P15	47	88	92	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4099	4107		10.1038/sj.onc.1205562	http://dx.doi.org/10.1038/sj.onc.1205562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037666				2022-12-28	WOS:000176186000004
J	Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y				Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y			Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas	ONCOGENE			English	Article						colon cancer; adenoma-carcinoma sequence; cDNA microarray; expression profile	CDNA MICROARRAY; CANCER-CELLS; HYPOXIA; IDENTIFICATION; CARCINOGENESIS; RIBOSOME	Most colon cancers are thought to develop through the 'adenoma-to-carcinoma sequence' model. To elucidate the mechanisms underlying this pathway, we analysed gene-expression profiles of 20 colorectal tumors (nine adenomas and 11 differentiated adenocarcinomas) by means of a cDNA microarray representing 23 040 genes coupled with laser-capture micro dissection. A two-dimensional hierarchical clustering analysis of expression profiles of the 20 tumors correctly separated the carcinoma group from the adenoma group. Furthermore we identified 51 genes whose expression was commonly up-regulated, 376 that were commonly down-regulated in both types of tumors as opposed to normal colonic epithelium and 50 whose expression levels were significantly different between adenomas and carcinomas. On the basis of expression profiles of the 50 discriminating genes, we established a scoring system to separate adenomas from carcinomas. Application of this scoring system for evaluating five additional colorectal tumors correctly predicted their histological features. The genome-wide information reported here should contribute to a more profound understanding of colorectal tumorigenesis, particularly of adenoma-carcinoma progression, and provide indicators for developing novel strategies to diagnose, treat, and ultimately prevent colorectal carcinomas.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Afshari CA, 1999, CANCER RES, V59, P4759; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CHU FF, 1993, J BIOL CHEM, V268, P2571; Denko N, 2000, CLIN CANCER RES, V6, P480; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hoeren FU, 1998, GENETICS, V149, P479; Kallioniemi OP, 2001, ANN MED, V33, P142, DOI 10.3109/07853890109002069; Kitahara O, 2001, CANCER RES, V61, P3544; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Maguire BA, 2001, CELL, V104, P813, DOI 10.1016/S0092-8674(01)00278-1; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; Notterman DA, 2001, CANCER RES, V61, P3124; Ogiso Y, 1999, BIOCHEM BIOPH RES CO, V258, P448, DOI 10.1006/bbrc.1999.0635; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815	22	157	172	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4120	4128		10.1038/sj.onc.1205518	http://dx.doi.org/10.1038/sj.onc.1205518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037668				2022-12-28	WOS:000176186000006
J	Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O				Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O			Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX; double fusion; double translocation	SYT; GENES; SSX; TRANSLOCATION; IDENTIFICATION; TRANSCRIPT; PROTEINS; VARIANT; TUMORS	The chromosomal translocation t(X;18)(p11.2;q11.2) is tightly linked to the tumorigenesis of synovial sarcoma. Through this translation the SYT gene on chromosome 18 is fused with a testis/cancer antigen gene on the X chromosome, generating either a SYT-SSX1, SYT-SSX2, or less often a SYT-SSX4 fusion gene. It has been anticipated that the individual synovial sarcoma carries only one of these variants, however, in this study we demonstrated that SYT-SSX1 and SYT-SSX2 coexist in a significant proportion of the cases. From 121 SYT-SSX positive primary tumors, co-expression of SYT-SSX1 and SYT-SSX2 was seen in 12 cases (10%), which were characterized in further detail both at the RNA, DNA and chromosomal level. In all 12 cases the SYT-SSX1 and SYT-SSX2 fusions resulted in identical SYT-SSX fusion transcripts. However, at the genomic level the translocations were different, and most likely occurred between variable intronic sites in the target genes. By interphase FISH analyses of 10 cases SYT-SSX2 translocations were found to be the most abundant in all but one of the cases, in which SYT-SSX1 was predominating. The findings reveal a new heterogenous feature of synovial sarcoma, accounting for approximately 10% of all cases, which may shed light on the molecular genetic mechanisms behind translocations in general, and on the etiology of synovial sarcoma in particular.	Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, CCK L801, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Stockholm Soder Hosp, SE-11883 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lund University; Skane University Hospital	Larsson, C (corresponding author), Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden.	Catharina.Larsson@cmm.ki.se	Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Brodin B, 2001, GENE, V268, P173, DOI 10.1016/S0378-1119(01)00412-7; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nilsson G, 1999, CANCER RES, V59, P3180; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Panagopoulos I, 2001, GENE CHROMOSOME CANC, V31, P362, DOI 10.1002/gcc.1155; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sreekantaiah C, 1998, CYTOGENET CELL GENET, V82, P13, DOI 10.1159/000015056; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981	21	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4181	4190		10.1038/sj.onc.1205569	http://dx.doi.org/10.1038/sj.onc.1205569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037676				2022-12-28	WOS:000176186000014
J	Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y				Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y			HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas	ONCOGENE			English	Article						CpG island; DNA methylation; HOX gene	DNA METHYLATION; EXPRESSION; COMPLEX	CpG island methylation results in the silencing of the associated gene and is an important step in tumorigenesis. Following a comprehensive isolation of CpG islands that were methylated in human lung adenocarcinoma, we found that in cancer cells de novo CpG island methylation generally occurred in a sporadic manner. However, some methylated CpG islands appeared to cluster in discrete chromosomal regions. In this study, we have investigated the methylation status of CpG islands located at such chromosomal loci. We have found that many CpG islands at the HOXA and HOXD loci were methylated in human lung adenocarcinoma. The de novo methylation of these CpG islands was also observed in patient's DNA from noncancerous portions of lung tissue. These results indicate the presence of specific chromosomal regions that are susceptible to de novo methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Golpon HA, 2001, AM J PATHOL, V158, P955, DOI 10.1016/S0002-9440(10)64042-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kappen C, 1996, AM J RESP CELL MOL, V15, P156, DOI 10.1165/ajrcmb.15.2.8703471; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 2002, IN PRESS ONCOGENE, V21; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426	19	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3659	3662		10.1038/sj.onc.1205453	http://dx.doi.org/10.1038/sj.onc.1205453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032868				2022-12-28	WOS:000175793700017
J	Sugiyama, K; Sugiura, K; Hara, T; Sugimoto, K; Shima, H; Honda, K; Furukawa, K; Yamashita, S; Urano, T				Sugiyama, K; Sugiura, K; Hara, T; Sugimoto, K; Shima, H; Honda, K; Furukawa, K; Yamashita, S; Urano, T			Aurora-B associated protein phosphatases as negative regulators of kinase activation	ONCOGENE			English	Article						Aurora-B; historic H3; protein phosphatase; okadaic acid; substrate specificity	HISTONE H3 PHOSPHORYLATION; MITOTIC CHROMOSOME CONDENSATION; CATALYTIC SUBUNIT; SIGNALING PATHWAY; CENTRAL SPINDLE; CELL-DIVISION; IDENTIFICATION; CYTOKINESIS; MITOSIS; COMPLEX	The human serine/threonine kinase Aurora-B is structurally related to the protein kinase Ip11p from S cerevisiae and aurora from Drosophila melanogaster, which are key regulators of mitosis. The present study shows that human Aurora-B is activated by okadaic acid and forms complexes with the protein serine/threonine phosphatase type I (PP1) or PP2A, but not with PP5. These data identified Aurora-B associated protein phosphatases as negative regulators of kinase activation. We then used a series of substrates based on a histone H3 phosphorylation site (residues 5-15) to determine the substrate specificity of human Aurora-B. We found that this enzyme is an arginine-directed kinase that can phosphorylate histone H3 at serines 10 and 28 in vitro, suggesting that human Aurora-B is a mitotic histone H3 kinase.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Osaka Prefecture Univ, Div Appl Biochem, Grad Sch Agr & Biol Sci, Sakai, Osaka 5998531, Japan; Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Nagoya University; Nagasaki University; Osaka Metropolitan University; Hokkaido University	Urano, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4660065, Japan.	turano@med.nagoya-u.ac.jp	Yamashita, Shunichi/GVS-9508-2022; Sugiura, Kazumitsu/M-8913-2014	Sugiura, Kazumitsu/0000-0002-5207-4592; Yamashita, Shunichi/0000-0001-6399-6261; Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	42	128	130	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3103	3111		10.1038/sj.onc.1205432	http://dx.doi.org/10.1038/sj.onc.1205432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082625				2022-12-28	WOS:000175373600001
J	Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP				Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP			Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation	ONCOGENE			English	Article						cell cycle; CDC25B; pEg3; kinase; human cells	MITOTIC INDUCER; HELA-CELLS; MITOSIS; LOCALIZATION; TYROSINE; HOMOLOG; 14-3-3-PROTEINS; THREONINE-14; ACTIVATION; TRANSITION	The pEg3 protein is a member of the evolutionarily conserved KIN1/PAR-1/MARK kinase family which is involved in cell polarity and microtubule dynamics. In Xenopus, pEg3 has been shown to be a cell cycle dependent kinase whose activity increases to a maximum level during mitosis of the first embryonic cell division. CDC25B is one of the three CDC25 phosphatase genes identified in human. It is thought to regulate the G2/M progression by dephosphorylating and activating the CDK/cyclin complexes. In the present study we show that the human pEg3 kinase is able to specifically phosphorylate CDC25B in vitro. One phosphorylation site was identified and corresponded to serine 323. This residue is equivalent to serine 216 in human CDC25C which plays an important role in the regulation of phosphatase during the cell cycle and at the G2 checkpoint. pEg3 is also able to specifically associate with CDC25B in vitro and in vivo. We show that the ectopic expression of active pEg3 in human U2OS cells induces an accumulation of cells in G2. This effect is counteracted by overexpression of CDC25B. Taken together these results suggest that pEg3 is a potential regulator of the G2/M progression and may act antagonistically to the CDC25B phosphatase.	Univ Rennes 1, IFR 97, CNRS, UMR 6061, F-35043 Rennes, France; Univ Toulouse 3, CNRS, UMR 5088, LBCMCP, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tassan, JP (corresponding author), Univ Rennes 1, IFR 97, CNRS, UMR 6061, 2 Ave Professeur Leon Bernard,CS34317, F-35043 Rennes, France.		DUCOMMUN, Bernard/B-3208-2008; BALDIN, Véronique/Y-8397-2019	BALDIN, Véronique/0000-0001-8523-0494; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blot J, 2002, DEV BIOL, V241, P327, DOI 10.1006/dbio.2001.0525; Cans C, 1999, ANTICANCER RES, V19, P1241; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NAGATA A, 1991, NEW BIOL, V3, P959; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	38	84	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7630	7641		10.1038/sj.onc.1205870	http://dx.doi.org/10.1038/sj.onc.1205870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400006				2022-12-28	WOS:000178756200003
J	Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK				Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK			Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes	ONCOGENE			English	Article						beta-catenin; LEF/TCF; target genes; oncogenic transformation	ANCHORAGE-INDEPENDENT GROWTH; NEOPLASTIC TRANSFORMATION; COLORECTAL-CANCER; C-MYC; WNT; IP6; TRANSCRIPTION; ACTIVATION; EXPRESSION; CELLS	Genetic analysis of beta-catenin-induced oncogenic transformation in chicken embryo fibroblasts (CEF) revealed the following prerequisites for oncogenicity: (1) removal of the N terminal phosphorylation sites targeted by glycogen synthase kinase 3beta (GSK3beta), (2) retention of the N terminal transactivation domain, and (3) retention of the armadillo repeats. The C terminal transactivation domain played an ancillary role in the transformation of CEF. There was a rough correlation between the transforming activity of various beta-catenin constructs and their transactivation of the TOPFLASH reporter. Expression levels of the candidate target genes of beta-catenin-LEF, cyclin D1 and myc were not correlated with each other or with the transforming activity of beta-catenin constructs. A new target gene, coding for inositol hexakisphosphate kinase 2 (IP6K2) was identified. Its expression showed concordance with the transforming activity of beta-catenin constructs.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Freiburg, Inst Mol Med & Zellforsch, Freiburg, Germany	Scripps Research Institute; University of Freiburg	Aoki, M (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	maoki@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Hecht, Andreas/0000-0003-2262-2575	NCI NIH HHS [CA 78230, CA79616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078230, R01CA079616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Dahmen RP, 2001, CANCER RES, V61, P7039; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nagasawa Y, 1999, CANCER RES, V59, P3539; Norbis F, 1997, J MEMBRANE BIOL, V156, P19, DOI 10.1007/s002329900183; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3671; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vucenik I, 1998, ANTICANCER RES, V18, P4091; Vucenik I, 1998, ANTICANCER RES, V18, P4083; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	43	27	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					6983	6991		10.1038/sj.onc.1205796	http://dx.doi.org/10.1038/sj.onc.1205796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370820				2022-12-28	WOS:000178424900001
J	Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T				Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T			High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas	ONCOGENE			English	Article						p53 mutation; protein-truncating mutation; liver metastasis; colorectal carcinoma	PROGNOSTIC-SIGNIFICANCE; ADENOMATOUS POLYPOSIS; TERM SURVIVAL; KI-RAS; CANCER; OVEREXPRESSION; ACCUMULATION; EXPRESSION; DOMAIN; BREAST	To clarify the significance of p53 mutations in liver metastasis of colorectal carcinogenesis, the characteristics of p53 mutations from 51 liver metastases and 76 primary invasive carcinomas without liver metastasis (Dukes' A, B and C) were compared. The frequency of tumors with p53 mutations was 61% (31 out of 51) in the liver metastases, and 51% (39 out of 76) in the primary carcinomas without liver metastasis. Approximately 90% of the informative cases having p53 mutation showed 17pLOH. Mutations detected within exons 4-10 of the p53 gene included missense, nonsense, frameshift, inframe deletion, and inframe insertion mutations. Out of the tumors with p53 mutations, we found that the percentage of tumors with protein-truncating mutations (nonsense and frameshift mutations) was extremely higher in liver metastases (16 out of 31, 52%) than in primary carcinomas without liver metastasis (5 out of 39, 13%) (P=0.0005). The present results suggest that protein-truncating mutations of the p53 gene are more relevant than missense mutations as one of the prognostic factors in liver metastasis of colorectal carcinomas.	Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				AUVINEN A, 1994, BRIT J CANCER, V70, P293, DOI 10.1038/bjc.1994.295; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOH HS, 1995, CANCER RES, V55, P5217; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTMANN A, 1995, ONCOGENE, V10, P681; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; Lanza G, 1996, AM J CLIN PATHOL, V105, P604; Lim BHG, 1996, INT J CANCER, V69, P200, DOI 10.1002/(SICI)1097-0215(19960621)69:3<200::AID-IJC9>3.0.CO;2-3; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYAKI M, 1994, CANCER RES, V54, P3011; MORRIN M, 1994, GUT, V35, P1627, DOI 10.1136/gut.35.11.1627; MULDER JWR, 1995, BRIT J CANCER, V71, P1257, DOI 10.1038/bjc.1995.243; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SAITOH S, 1994, ONCOGENE, V9, P2869; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Smith DR, 1996, BRIT J CANCER, V74, P216, DOI 10.1038/bjc.1996.340; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	22	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6689	6693		10.1038/sj.onc.1205887	http://dx.doi.org/10.1038/sj.onc.1205887			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242668				2022-12-28	WOS:000178202300016
J	Shreeram, S; Sparks, A; Lane, DP; Blow, JJ				Shreeram, S; Sparks, A; Lane, DP; Blow, JJ			Cell type-specific responses of human cells to inhibition of replication licensing	ONCOGENE			English	Article						replication licensing; geminin; Cdt1	S-PHASE PROGRESSION; DNA-REPLICATION; MCM PROTEINS; IN-VIVO; CHECKPOINT; CYCLE; CHROMATIN; ORIGINS; COMPLEXES; DAMAGE	Replication origins are 'licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1. Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin. Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines. Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation. U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint. Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approximately normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint. Geminin also induced apoptosis in both these cell lines. In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis. A 'licensing checkpoint' may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing. These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anticancer target.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Lane, David/0000-0003-0551-3545	Cancer Research UK [A2335] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Miura M, 1999, METH MOL B, V113, P577; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stoeber K, 2001, J CELL SCI, V114, P2027; Sun W, 2000, J CELL SCI, V113, P683; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; WOODWARD A, 2002, IN PRESS CHEMTRACTS	47	153	161	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6624	6632		10.1038/sj.onc.1205910	http://dx.doi.org/10.1038/sj.onc.1205910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242660	Green Accepted			2022-12-28	WOS:000178202300008
J	Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR				Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR			Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency	ONCOGENE			English	Article						Apc; Tcf-1; mammary; acanthoma; cre	BETA-CATENIN; CYCLIN D1; BREAST-CANCER; GENE; EXPRESSION; GLAND; PROTEIN; TARGET; TUMORIGENESIS; HYPERPLASIA	Apc (adenomatous polyposis colt) encodes a tumour suppressor gene that is mutated in the majority of colorectal cancers. Recent evidence has also implicated Apc mutations in the aetiology of breast tumours. Ape is a component of the canonical Wnt signal transduction pathway, of which one target is Tcf-1. In the mouse, mutations of both Ape and Tcf-1 have been implicated in mammary tumorigenesis. We have conditionally inactivated Apc in both the presence and absence of Tcf-1 to examine the function of these genes in both normal and neoplastic development. Mice harbouring mammary-specific mutations in Apc show markedly delayed development of the mammary ductal network. During lactation, the mice develop multiple metaplastic growths which, surprisingly, do not spontaneously progress to neoplasia up to a year following their induction. However, additional deficiency of Tcf-1 completely blocks normal mammary development and results in acanthoma.	Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Biomed Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Inst Canc Res, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Med Ctr, Ctr Biomed Genet, Utrecht, Netherlands; Univ Med Ctr, Dept Immunol, Utrecht, Netherlands	Cardiff University; University of Edinburgh; University of Edinburgh; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Clarke, AR (corresponding author), Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales.	ClarkeAR@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Noda, Tetsuo/B-1667-2016; Mason, John O/A-1926-2010	Mason, John O/0000-0002-0489-2400; Shibata, Hiroyuki/0000-0003-3581-3506; Naughton, Catherine/0000-0002-9576-5983; Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010	Biotechnology and Biological Sciences Research Council [G06054] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Bukholm IK, 2000, J PATHOL, V190, P15; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ho KYK, 1999, HISTOPATHOLOGY, V35, P249; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Midgley CA, 1997, J PATHOL, V181, P426; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Moser AR, 2001, CANCER RES, V61, P3480; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 2000, GENE DEV, V14, P1837; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	51	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6446	6457		10.1038/sj.onc.1205892	http://dx.doi.org/10.1038/sj.onc.1205892			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226748				2022-12-28	WOS:000177925300005
J	Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI				Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI			Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling	ONCOGENE			English	Article						VEGF; KDR; Shc; Sck; angiogenesis	FACTOR RECEPTOR KDR; PHOSPHOTYROSINE INTERACTION DOMAIN; TYROSINE KINASE; PERMEABILITY FACTOR; ADAPTER PROTEIN; SH2 DOMAINS; FOCAL ADHESIONS; DNA-SYNTHESIS; TUMOR-GROWTH; IN-VIVO	Sek, a member of the She family of cell signaling proteins, has only been studied in neuronal cells, though previous studies have demonstrated its expression in tissues other than brain. Using RT-PCR and RNase protection assays, we detected Sek mRNA expression in endothelial cells, and Sek protein was detected by Western blotting using polyclonal and monoclonal antibodies targeting the Sek CH1 domain. Immunohistochemistry protocols demonstrate that Sck is expressed in KDR and PECAM positive cells found in the mouse retina, mouse heart and human umbilical chord. Treatment of human umbilical vein endothelial (HUVE) cells with vascular endothelial growth factor (VEGF) leads to the recruitment of Sck to the KDR VEGF receptor and an enhanced Sek tyrosine phosphorylation. Sek is recruited to KDR tyrosine 1175, as coimmunoprecipitation of KDR and Sek is not observed in VEGF-treated porcine aortic endothelial cells expressing a receptor mutated at this autophosphorylation site. The Sek and She SH2 domains, and not the PTB domain, mediates its interactions with KDR, as recombinant Sek SH2 domain binds to a tyrosine phosphorylated KDR 1175-derived synthetic peptide, but not to a peptide synthesized without tyrosine phosphate. Recombinant PLCgamma, SH2 domain also interacts with the phosphotyrosine 1175 containing peptide. VEGF-induced MAPK activation is dependent upon PLCgamma activity, and chimeric proteins consisting of the She or Sek SH2 domains fused with a cellular internalization sequence attenuated this activation. Taken together, these results demonstrate that Sck is expressed in vascular endothelial cells, and participates in VEGF-induced signal transduction.	Albert Einstein Coll Med, Div Cardiol, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Div Cardiol, Dept Med, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [R01 CA86289-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lai KMV, 2000, GENE DEV, V14, P1132; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yoshiji H, 1996, CANCER RES, V56, P2013; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6307	6316		10.1038/sj.onc.1205781	http://dx.doi.org/10.1038/sj.onc.1205781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214271				2022-12-28	WOS:000177829000007
J	Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK				Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK			Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis	ONCOGENE			English	Article						E2F-1; PKR; apoptosis; gene therapy; adenovirus	NF-KAPPA-B; TRANSCRIPTION FACTOR E2F-1; TUMOR-SUPPRESSOR P53; DNA-BINDING; CELLULAR ACTIVATOR; C-MYC; GENE; EXPRESSION; INDUCTION; INITIATION	The transcription factor E2F-1 induces cell cycle progression at the G1/S checkpoint, and deregulation of E2F-1 provokes apoptosis in a wide variety of malignant cells. To date only p14(ARF) and p73, a p53 homologue, have been identified as E2F-1-inducible genes capable of mediating an apoptotic response. Here we show that adenovirus-mediated E2F-1 overexpression in cancer cells induces expression and autophosphorylation of the double-stranded RNA-dependent protein kinase PKR leading to phosphorylation of its downstream target, the alpha-subunit of the eukaryotic translation initiation factor 2 (eIF-2alpha) and to apoptotic cell death. This PKR-dependent apoptosis occurs in cell lines with mutated p53 and in cell lines with mutated p53 and p73, and is significantly reduced by the chemical inhibition of PKR activation. Further, PKR-/- mouse embryo fibroblasts, but not PKR+/+ mouse embryo fibroblasits, demonstrate significant resistance to E2F-1-induced apoptosis. We conclude that an important pathway of E2F-1-mediated apoptosis is dependent on PKR activation and does not require p53 or p73.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Jikei Univ, Dept Surg, Sch Med, Tokyo 105, Japan; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Jikei University; University of Miami	Hunt, KK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA.	khunt@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GUSELLA GL, 1995, J IMMUNOL, V154, P345; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tanaka H, 2000, GENE, V246, P373, DOI 10.1016/S0378-1119(00)00080-9; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wong AHT, 2001, J BIOL CHEM, V276, P13727, DOI 10.1074/jbc.M011240200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshikawa H, 1999, ONCOGENE, V18, P3415, DOI 10.1038/sj.onc.1202677; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	58	34	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6278	6288		10.1038/sj.onc.1205761	http://dx.doi.org/10.1038/sj.onc.1205761			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214268				2022-12-28	WOS:000177829000004
J	Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K				Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K			Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma	ONCOGENE			English	Article						human telomerase reverse transcriptase; auto-antigen; hepatocellular carcinoma	CHRONIC LIVER-DISEASE; CELLS; CANCER; AUTOANTIBODIES; MALIGNANCIES; BREAST	Human telomerase reverse transcriptase, hTERT, is the catalytic component of human telomerase. Expression of hTERT confers telomerase activity, indicating that hTERT is the rate-limiting component of human telomerase. Here we report the detection of anti-hTERT auto-antibodies in the sera derived patients with hepatocellular carcinoma using recombinant, purified hTERT as an antigen in an enzyme linked immunosorbent assay (ELISA). The levels of anti-hTERT antibodies in serum correlated with progression to hepatocellular carcinoma. In contrast, we detected only low levels of anti-hTERT auto-antibodies in the sera derived from 18 normal volunteers. The observation of hTERT auto-antibodies in the sera derived from cancer patients suggests that such auto-antibodies constitute novel and specific tumor marker.	Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Grad Sch Med, Dept Biol Mol, Div Mol Oncol,Canc Res Inst, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Kanazawa University	Kaneko, S (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.							Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Covini G, 1997, HEPATOLOGY, V25, P75; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; IMAI H, 1992, AM J PATHOL, V140, P859; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; IMAI H, 1993, CANCER-AM CANCER SOC, V71, P26, DOI 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamoto M, 1999, CANCER, V85, P245, DOI 10.1002/(SICI)1097-0142(19990101)85:1<245::AID-CNCR37>3.0.CO;2-9; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NELSON DS, 1977, PATHOLOGY, V9, P155, DOI 10.3109/00313027709085253; Nouso K, 1996, CANCER, V78, P232, DOI 10.1002/(SICI)1097-0142(19960715)78:2<232::AID-CNCR7>3.0.CO;2-N; Saeboe-Larssen S, 2002, J IMMUNOL METHODS, V259, P191, DOI 10.1016/S0022-1759(01)00506-3; SCHATTNER A, 1983, CANCER-AM CANCER SOC, V52, P2156, DOI 10.1002/1097-0142(19831201)52:11<2156::AID-CNCR2820521130>3.0.CO;2-2; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; Treon SP, 2000, SEMIN ONCOL, V27, P598; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Vonderheide RH, 2001, CANCER RES, V61, P8366; WASSERMAN J, 1975, CLIN EXP IMMUNOL, V19, P417; WINTER SF, 1992, CANCER RES, V52, P4168	26	24	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5946	5950		10.1038/sj.onc.1205788	http://dx.doi.org/10.1038/sj.onc.1205788			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185596				2022-12-28	WOS:000177520900016
J	Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM				Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM			Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hypermethylation; breast cancer	NONPOLYPOSIS COLORECTAL-CANCER; IN-SITU; PROMOTER HYPERMETHYLATION; ENDOMETRIAL CARCINOMAS; CELL-LINES; GASTRIC CARCINOMAS; HIGH-FREQUENCY; COLON-CANCER; TUMOR-CELLS; DNA	Breast cancer is the most common cancer in women, but its pathogenesis is still unclear. Microsatellite instability (MSI) has been identified in breast cancer cells, suggesting an association with mismatch repair defects. To test this hypothesis, we investigated MSI, protein expression of hMSH2 and hMLH1, as well as genetic and epigenetic modifications of these two genes in 32 sporadic breast tumors. MSI was identified in 15 cases. Immunohistochemistry analysis revealed that all MSI cases but one had lower than normal expression of hMSH2 (nine cases), hMLH1 (12 cases), or both (seven cases). In tumors with MSI, both genetic and epigenetic modifications of these mismatch repair genes were also identified. Eight cases harbored mutations or polymorphisms in hMSH2 and hMLH1, and 10 exhibited hypermethylation in the promoter region of hMLH1. These results suggest that both genetic and epigenetic alterations of hMSH2 and especially of h-MLH1 contribute to genomic instability and tumorigenesis in sporadic breast cancer.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Suite MS 117,800 Rose St, Lexington, KY 40536 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALDAZ CM, 1995, CANCER RES, V55, P3976; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I; Boland CR, 1998, CANCER RES, V58, P5248; CONTEGIACOMO A, 1995, INT J CANCER, V64, P264, DOI 10.1002/ijc.2910640409; CUI J, 1998, CHUNG HUA I HSUEH I, V15, P348; Cunningham JM, 1998, CANCER RES, V58, P3455; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; Friedrich M, 1999, HISTOCHEM J, V31, P717, DOI 10.1023/A:1003996431044; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89; Grady WM, 2001, CANCER RES, V61, P900; Gurin CC, 1999, CANCER RES, V59, P462; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hosoya N, 1998, JPN J CANCER RES, V89, P33, DOI 10.1111/j.1349-7006.1998.tb00476.x; Jonsson M, 1995, EUR J CANCER, V31A, P2330, DOI 10.1016/0959-8049(95)00447-5; Kane MF, 1997, CANCER RES, V57, P808; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1999, CANCER RES, V59, P159; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1999, J MED GENET, V36, P801; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Paulson TG, 1996, CANCER RES, V56, P4021; Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X; Rush EB, 1997, ANN SURG ONCOL, V4, P310, DOI 10.1007/BF02303580; Salvesen HB, 2000, CLIN CANCER RES, V6, P3607; Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Shen KL, 2000, J SURG ONCOL, V74, P100, DOI 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O; Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Toyama T, 1996, CANCER LETT, V108, P205, DOI 10.1016/S0304-3835(96)04414-X; Toyama T, 1996, INT J CANCER, V68, P447, DOI 10.1002/(SICI)1097-0215(19961115)68:4<447::AID-IJC8>3.0.CO;2-0; Vasen HFA, 2001, AM J HUM GENET, V68, P1533, DOI 10.1086/320610; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Weber TK, 1997, CANCER RES, V57, P3798; YEE CJ, 1994, CANCER RES, V54, P1641; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	57	72	84	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5696	5703		10.1038/sj.onc.1205683	http://dx.doi.org/10.1038/sj.onc.1205683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173039				2022-12-28	WOS:000177463400004
J	Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O				Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O			The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11. 2; q11.2) and the cell cycle machinery	ONCOGENE			English	Article						cyclin A; cyclin D1; SYT-SSX; synovial sarcoma	SYT; SSX; CANCER; OVEREXPRESSION; PROLIFERATION; TRANSLOCATION; PROGNOSIS; PROTEINS; GENES	A recent large multi-centre study convincingly confirmed previous observations that the SYT-SSX1 fusion type, compared to SYT-SSX2, of synovial sarcoma is associated with a worse clinical outcome. Apart from the clinical impact, this fact also suggests (1) that the SYT-SSX fusion gene may influence molecular mechanisms involved in tumour growth and progression; and (2) that the SYT-SSX1 fusion type has a stronger influence on these mechanisms than SYT-SSX2. The nature of the underlying mechanisms is, however, still unknown. In this study we made use of the SYT-SSX1 vs SYT-SSX2 concept to investigate whether major, tumour relevant, and growth regulatory proteins (e.g. cyclins and cyclin-dependent kinases) may be involved. Using Western blotting analysis on 74 fresh, fusion variant-typed, tumour samples from localized synovial sarcoma, we found a significant correlation between SYT-SSX1 and high expression of cyclin A (P=0.003) and D1 (P=0.025). Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.	Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430072, Peoples R China; Karolinska Hosp, Dept Orthoped, Stockholm, Sweden; Stockholm Soder Hosp, Dept Orthoped, Stockholm, Sweden; Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England; Royal Marsden NHS Trust, Dept Pathol, London, England; Canc Res Inst, Mol Cytogenet Team, Sutton, Surrey, England; Norwegian Radium Hosp, Dept Pathol, Canc Res Inst, Oslo, Norway; Norwegian Radium Hosp, Dept Tumor Biol, Canc Res Inst, Oslo, Norway	Karolinska Institutet; Karolinska University Hospital; Wuhan University; Karolinska Institutet; Karolinska University Hospital; Royal Orthopaedic Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oslo; University of Oslo	Larsson, O (corresponding author), Karolinska Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Shipley, Janet/0000-0001-6748-8678				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SH, 1998, CLIN CANCER RES, V4, P2377; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; Mishina T, 2000, CLIN CANCER RES, V6, P11; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nilsson G, 1999, CANCER RES, V59, P3180; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shamma A, 1998, INT J ONCOL, V13, P455; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; XIE Y, 2002, IN PRESS CANC RES, V62	27	34	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5791	5796		10.1038/sj.onc.1205700	http://dx.doi.org/10.1038/sj.onc.1205700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173050				2022-12-28	WOS:000177463400015
J	Lee, DCW; Chan, KW; Chan, SY				Lee, DCW; Chan, KW; Chan, SY			RET receptor tyrosine kinase isoforms in kidney function and disease	ONCOGENE			English	Article						RET; GDNF; kidney; mIMCD3; polycystic kidney disease	URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; CELL-LINE; NEUROTROPHIC FACTOR; MOUSE KIDNEY; PROTOONCOGENE; EXPRESSION; GDNF; BINDING; EMBRYOGENESIS	The RET proto-oncogene encodes two major isoforms, RET9 and RET51, which differ at the carboxyl-terminal. Loss-of-function mutations in RET result in gut aganglionosis while gain of function mutations result in cancer syndromes. From studies on transgenic mice, RET9 is important for early development of the kidney and the enteric nervous system. Little is known about the function of RET isoforms in later life. Here we report the expression of RET isoforms and its signalling complex, GDNF and GFRalpha1, in foetal and adult human kidneys. We found their expression in both the developing and the adult renal collecting system. We further show that only RET51 but not RET9 could promote the survival and tubulogenesis of mIMCD3 (mouse inner medullary collecting duct) cells in collagen gel. Our results agree with the hypothesis that RET51 signalling is related to differentiation events in later kidney organogenesis. In addition, it may also have a function in the adult kidney. We further extend our study by showing increased RET and GDNF expression in collecting duct cysts of polycystic kidney patients. This suggests that GDNF/RET signalling may contribute to proliferation of the collecting duct epithelium in an autocrine/paracrine manner.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Ctr Human Dev & Birth Defects, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.			Chan, Siu Yuen/0000-0001-7262-1293				Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brenner BM, 1996, BRENNER RECTORS KIDN; Chan SY, 1998, ONCOGENE, V17, P661, DOI 10.1038/sj.onc.1201970; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Fisher CE, 2001, DEVELOPMENT, V128, P4329; Grimm L, 1998, HUM MOL GENET, V7, P1873, DOI 10.1093/hmg/7.12.1873; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLTHOFER H, 1981, LAB INVEST, V45, P391; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Lanoix J, 1996, ONCOGENE, V13, P1153; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; O'Rourke DA, 1999, AM J PHYSIOL-RENAL, V276, pF581, DOI 10.1152/ajprenal.1999.276.4.F581; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Sainio K, 1997, DEVELOPMENT, V124, P4077; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885	36	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5582	5592		10.1038/sj.onc.1205741	http://dx.doi.org/10.1038/sj.onc.1205741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165857				2022-12-28	WOS:000177442000008
J	Turker, MS				Turker, MS			Gene silencing in mammalian cells and the spread of DNA methylation	ONCOGENE			English	Article						DNA methylation; methylation spreading; silencing	DE-NOVO METHYLATION; CPG-ISLAND METHYLATION; DENOVO METHYLATION; APRT GENE; PREIMPLANTATION DEVELOPMENT; DROSOPHILA-MELANOGASTER; CYTOSINE METHYLATION; CARCINOMA-CELLS; HISTONE CODE; IN-VIVO	Aberrant gene silencing in mammalian cells is associated with promoter region methylation, but the sequence of these two events is not clear. This review will consider the possibility that gene silencing is not a single event, but instead a series of events that begins with a dramatic drop in transcription potential and ends with its complete cessation. This transition will be portrayed as a chaotic process that ensues when transcription levels drop and DNA methylation begins spreading haltingly towards the diminished promoter. According to this view, silencing is stabilized when the promoter region is 'captured' by the spread of DNA methylation near or into its transcription factor binding sites.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NCI NIH HHS [R01 CA92114] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092114] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Arnaud P, 2000, MOL CELL BIOL, V20, P3434, DOI 10.1128/MCB.20.10.3434-3441.2000; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; COOPER GE, 1993, SOMAT CELL MOLEC GEN, V19, P221, DOI 10.1007/BF01233070; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hanel ML, 2001, MOL CELL BIOL, V21, P2384, DOI 10.1128/MCB.21.7.2384-2392.2001; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; HASSE A, 1994, J BIOL CHEM, V269, P1821; Hejnar J, 2001, P NATL ACAD SCI USA, V98, P565, DOI 10.1073/pnas.98.2.565; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liang GN, 2000, CANCER RES, V60, P4907; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Melki JR, 2000, BLOOD, V95, P3208; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; MONK M, 1987, DEVELOPMENT, V99, P371; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nosaka K, 2000, CANCER RES, V60, P1043; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6; SILVA AJ, 1993, DEV BIOL, V156, P391, DOI 10.1006/dbio.1993.1086; Song SH, 2001, CANCER RES, V61, P4628; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Turker MS, 1999, SEMIN CANCER BIOL, V9, P329, DOI 10.1006/scbi.1999.0133; TURKER MS, 1989, J BIOL CHEM, V264, P11632; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	66	171	179	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5388	5393		10.1038/sj.onc.1205599	http://dx.doi.org/10.1038/sj.onc.1205599			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154401				2022-12-28	WOS:000177197700005
J	Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E				Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E			Base excision repair of adenine/8-oxoguanine mispairs by an aphidicolin-sensitive DNA polymerase in human cell extracts	ONCOGENE			English	Article						DNA repair; oxidative damage; mammalian cell extracts; base excision repair; 8oxo G/A mismatch	TRANSCRIPTION-COUPLED REPAIR; MISMATCH-CONTAINING DNA; RETRACTED ARTICLE. SEE; THYMINE DIMER BYPASS; COLI MUTY GENE; ESCHERICHIA-COLI; HUMAN HOMOLOG; SUBCELLULAR-LOCALIZATION; GLYCOSYLASE DETERMINES; SUBSTRATE-SPECIFICITY	Replication of DNA containing 8-oxo-7,8-dihydroguanine (8oxoG) can generate 8oxoG/A base pairs which, if uncorrected, lead to G-->T transversions. It is generally accepted that the repair of these promutagenic base pairs in human cells is initiated by the MutY DNA glycosylase homolog (hMYH). Here we provide biochemical evidence that human cell extracts perform base excision repair (BER) on both DNA strands of an 8oxoG/A mismatch. At early repair times the specificity of nucleotide incorporation indicates a preferential insertion of C opposite 8oxoG leading to the formation of 8oxoG/C pairs. This is followed by repair synthesis on the opposite DNA strand that is consistent with hOGG1-mediated correction of 8oxoG/C to G/C. Repair synthesis on either strand is completely inhibited by aphidicolin suggesting that a replicative DNA polymerase is involved in the gap filling. This is the first demonstration that repair of 8oxoG/A base pairs is by two BER events likely mediated by Poldelta/epsilon. We suggest that the Poldelta/epsilon-mediated BER is the general mode of repair when BER lesions are formed at replication forks.	Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy; Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms, Herts, England; Inst Gustave Roussy, Grp Reparat ADN, UMR 1772 CNRS, F-94805 Villejuif, France	Istituto Superiore di Sanita (ISS); Cancer Research UK; UNICANCER; Gustave Roussy	Dogliotti, E (corresponding author), Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, Via Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Fortini, Paola/K-1197-2018; Parlanti, Eleonora/AAC-5978-2021	Fortini, Paola/0000-0001-6206-8498; 				AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leadon SA, 1997, CANCER RES, V57, P3784; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Tissier A, 2000, GENE DEV, V14, P1642; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; WEISER T, 1991, J BIOL CHEM, V266, P10420; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5204	5212		10.1038/sj.onc.1205561	http://dx.doi.org/10.1038/sj.onc.1205561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149642				2022-12-28	WOS:000177193900002
J	Zeng, JZ; Wang, HY; Chen, ZJ; Ullrich, A; Wu, MC				Zeng, JZ; Wang, HY; Chen, ZJ; Ullrich, A; Wu, MC			Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma	ONCOGENE			English	Article						differential expression; cancer-related protein; proline-rich motif; antisense technology; metastasis; tumor marker	EUKARYOTIC MESSENGER-RNAS; GROWTH-FACTOR-ALPHA; C-MYC; PROTEIN EXPRESSION; DNA METHYLATION; HIGH-FREQUENCY; SH3 DOMAINS; MUTATIONS; HETEROZYGOSITY; HEPATITIS	To gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a similar to80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event frequently (89.2%) in HCCs and correlated significantly with the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time- and dose-dependent manner. Furthermore, HuH-7 cells harboring the HCCA1 antisense expression clone displayed a remarkably reduced efficiency in colony formation. Together, these data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.	Secondary Mil Med Univ, Int Corp Lab Signal Transduct, Eastern Hepatobiliary Surg Inst, Shanghai 200438, Peoples R China; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Naval Medical University; Max Planck Society	Wang, HY (corresponding author), Secondary Mil Med Univ, Int Corp Lab Signal Transduct, Eastern Hepatobiliary Surg Inst, 225 Changhai Rd, Shanghai 200438, Peoples R China.		Wang, Hongyang/B-1340-2010	Zeng, Jin-Zhang/0000-0003-1252-2351				Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; Chen TC, 2000, CANCER LETT, V153, P169, DOI 10.1016/S0304-3835(00)00366-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; COLLIER JD, 1992, J HEPATOL, V14, P377, DOI 10.1016/0168-8278(92)90186-S; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; De Petro G, 1998, CANCER RES, V58, P2234; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Duffy MJ, 2001, CLIN CHEM, V47, P624; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Ferrell L, 2000, MODERN PATHOL, V13, P679, DOI 10.1038/modpathol.3880119; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Hsu HC, 1997, CANCER RES, V57, P5179; Huang GT, 1999, HEPATO-GASTROENTEROL, V46, P1923; Hui AM, 1999, SCAND J GASTROENTERO, V34, P737; Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2; Ince N, 1999, NEW ENGL J MED, V340, P798, DOI 10.1056/NEJM199903113401009; Johnson P J, 2001, Clin Liver Dis, V5, P145, DOI 10.1016/S1089-3261(05)70158-6; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keck CL, 1999, CANCER GENET CYTOGEN, V111, P37, DOI 10.1016/S0165-4608(98)00210-6; KENMOCHI K, 1987, LIVER, V7, P18; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; King KL, 1998, J GASTROEN HEPATOL, V13, P273, DOI 10.1111/j.1440-1746.1998.01555.x; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kondoh N, 1999, CANCER RES, V59, P4990; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Miyake H, 2000, CANCER RES, V60, P3058; Musso O, 1997, J HEPATOL, V26, P593, DOI 10.1016/S0168-8278(97)80425-4; OGATA N, 1991, HEPATOLOGY, V13, P31, DOI 10.1002/hep.1840130106; Ponder KP, 1996, FASEB J, V10, P673, DOI 10.1096/fasebj.10.7.8635684; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shi YZ, 2000, BRIT J CANCER, V83, P50; Shimizu Y, 1999, INT J CANCER, V82, P187, DOI 10.1002/(SICI)1097-0215(19990719)82:2&lt;187::AID-IJC6&gt;3.0.CO;2-1; Tahara K, 1999, CANCER, V85, P1234, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.3.CO;2-Z; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; Takeda S, 1996, ONCOGENE, V12, P1589; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Teeguarden JG, 2000, MOL CARCINOGEN, V28, P51, DOI 10.1002/(SICI)1098-2744(200005)28:1<51::AID-MC7>3.0.CO;2-3; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wang HY, 1996, ONCOGENE, V12, P2555; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zimmermann U, 1997, HEPATOLOGY, V26, P1492; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	59	23	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4932	4943		10.1038/sj.onc.1205652	http://dx.doi.org/10.1038/sj.onc.1205652			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118372				2022-12-28	WOS:000176874800008
J	La Rocca, SA; Vannucchi, S; Pompili, M; Pinney, DF; Emerson, CP; Grossi, M; Tato, F				La Rocca, SA; Vannucchi, S; Pompili, M; Pinney, DF; Emerson, CP; Grossi, M; Tato, F			Selective repression of myoD transcription by v-Myc prevents terminal differentiation of quail embryo myoblasts transformed by the MC29 strain of avian myelocytomatosis virus	ONCOGENE			English	Article						Myc; qmyoD; myogenic differentiation; cell transformation	MUSCLE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; NORMAL-CELLS; DNA-BINDING; MECHANISMS; EXPRESSION; GENE; ONCOGENES; PROMOTER; PROTEINS	We have investigated the mechanism by which expression of the v-myc oncogene interferes with the competence of primary quail myoblasts to undergo terminal differentiation. Previous studies have established that quail myoblasts transformed by myc oncogenes are severely impaired in the accumulation of mRNAs encoding the myogenic transcription factors Myf-5, MyoD and Myogenin. However, the mechanism responsible for such a repression remains largely unknown. Here we present evidence that v-Myc selectively interferes with quail myoD expression at the transcriptional level. Cis-regulatory elements involved in the auto-activation of qmyoD are specifically targeted in this unique example of transrepression by v-Myc, without the apparent participation of Myc-specific E-boxes or InR sequences. Transiently expressed v-Myc efficiently interfered with MyoD-dependent transactivation of the qmyoD regulatory elements, while the myogenin promoter was unaffected. Finally, we show that forced expression of MyoD in v-myc-transformed quail myoblasts restored myogenin expression and promoted extensive terminal differentiation. These data suggest that transcriptional repression of qmyoD is a major and rate-limiting step in the molecular pathway by which v-Myc severely inhibits terminal differentiation in myogenic cells.	Univ Roma La Sapienza, Sezione Sci Microbiol, Ist Pasteur,Dipartimento Biol Cellulare & Svilupp, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Pennsylvania	Grossi, M (corresponding author), Dipartimento Biol Cellulare & Sviluppo, Sezione Microbiol, Via Sardi 70, I-00185 Rome, Italy.		la rocca, severina anna/D-8028-2011; Grossi, Milena/D-2955-2009					ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; CROUCH DH, 1993, ONCOGENE, V8, P1849; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOLKENTIN JD, 1996, CURR OPIN GENE DEV, V6, P455; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; PINNEY DF, 1995, DEV BIOL, V170, P21, DOI 10.1006/dbio.1995.1192; POLLERBERG GE, 1995, J NEUROSCI RES, V41, P427, DOI 10.1002/jnr.490410402; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	23	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4838	4842		10.1038/sj.onc.1205586	http://dx.doi.org/10.1038/sj.onc.1205586			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101422				2022-12-28	WOS:000176716300013
J	Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J				Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J			Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain	ONCOGENE			English	Article						c-kit; EGFP; signal transduction; PI3-kinase; Src	STEM-CELL-FACTOR; GREEN FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; RECEPTOR TYROSINE KINASE; SRC FAMILY KINASES; PHOSPHATIDYLINOSITOL 3'-KINASE; ADAPTER PROTEIN; LIPID RAFTS; MAST-CELLS; ACTIVATION	In order to investigate activation and internalization of e-kit we created a functional c-kit-EGFP chimera by inserting EYFP (enhanced yellow fluorescent protein) within the extracellular domain of e-kit immediately downstream of the signal sequence, SS-EYFP-kit. This location was chosen because the C-terminal fusion of EGFP to c-kit unexpectedly caused constitutive activation of the c-kit tyrosine kinase. As analysed in fixed cells and by real time imaging in vivo, SCF induced activation led to internalization of the fusion construct and translocation to punctate structures resembling vesicles. Analysis of the internalization process by time lapse imaging revealed high mobility and discontinuous movement of these vesicles and their predominantly radial tracks. Two subsets of vesicles were observed: Traffic of the majority of vesicles was directed from the periphery to the center of the cell and most likely represents the internalization of activated receptor molecules via the endosomal pathway. However, some vesicular structures were observed to move towards the periphery of the cell and probably contain newly synthesized protein to replace internalized receptor molecules. The calculated velocity of moving vesicles ranged from 0.05 to 0.2 mum per se. Vesicle formation upon SCF induced dimerization of the receptor was strictly dependent on kinase activity of e-kit. Treatment of cells with phenylarsine oxide, an agent blocking receptor internalization, prior to SCF stimulation resulted in abrogation of the translocation of the chimera to vesicles whereas accumulation of vesicles was observed when cells were treated with proteasome inhibitors. Cholesterol depletion of the cell membrane by methyl-beta-cyclodextrin resulted in dose dependent reduction of receptor internalization indicating that c-kit may be present in lipid rafts or that intact lipid rafts are required for efficient internalization of the receptor. Using the induction of vesicular structures as a sign of efficient internalization of the receptor analysis of mutant e-kit constructs deficient either in activation of PI3-Kinase or Src revealed that internalization of e-kit is dependent on recruitment of Src but not PI3-Kinase.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Munster, Dept Internal Med A, D-4400 Munster, Germany	Technical University of Munich; University of Munich; University of Munster	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.		Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Broudy VC, 1999, BLOOD, V94, P1979; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; Coutinho S, 2000, BLOOD, V96, P618; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Feng YQ, 1999, BIOCHEMISTRY-US, V38, P4553, DOI 10.1021/bi982224o; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KANUKURA Y, 1994, LEUKEMIA S1, V8, pS18; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Krystal GW, 1998, CANCER RES, V58, P4660; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LANGLEY KE, 1993, BLOOD, V81, P656; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li Q, 1996, CANCER RES, V56, P4343; LIU L, 1994, J BIOL CHEM, V269, P16774; Longley BJ, 1997, P NATL ACAD SCI USA, V94, P9017, DOI 10.1073/pnas.94.17.9017; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MIYAZAWA K, 1994, BLOOD, V83, P137; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Shimizu YJ, 1996, J IMMUNOL, V156, P3443; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YEE NS, 1994, J BIOL CHEM, V269, P31991	40	52	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4508	4520		10.1038/sj.onc.1205559	http://dx.doi.org/10.1038/sj.onc.1205559			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085229				2022-12-28	WOS:000176476700005
J	Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A				Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A			HMGA1 and HMGA2 protein expression in mouse spermatogenesis	ONCOGENE			English	Article						HMGA proteins; testis; spermatogenesis; fertility	IFN-BETA GENE; SERTOLI CELLS; HMGI(Y) PROTEINS; TRANSGENIC MICE; MESSENGER-RNA; DNA-BINDING; PROMOTER; RECEPTOR; I(Y); IDENTIFICATION	The high-mobility group A (HMGA) nonhistone chromosomal proteins HMGA1 and HMGA2 play a role in determining chromatin structure and in regulating the transcription of several genes. High levels of these proteins are characteristic of rapidly dividing cells in embryonic tissue and in tumors. The aim of this study was to determine the role of HMGA1 and HMGA2 throughout mouse spermatogenesis. Northern blot analysis and immunocytochemistry showed HMGA1 and HMGA2 expression during the progression from spermatocyte to spermatid. Interestingly, Western blot analysis with antibodies against the HMGA1 gene product revealed only the HMG1c isoform (27 kDa) in the testis; HMGA1a and HMGA1b were undetectable. These three isoforms are encoded by the HMGA1 gene through alternative splicing. Finally, few spermatids and complete absence of spermatozoa were observed in the testes of HMGA2-null mice, which suggests that the HMGA2 gene plays a critical role in male fertility.	Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy; Univ Roma Tor Vergata, Sezione Anat, Dipartimento Biol Cellulare & Sanita Publ, Rome, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Sannio, Fac Sci MM FF NN, Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; Magna Graecia University of Catanzaro; University of Sannio	Chieffi, P (corresponding author), Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Battista, Sabrina/AAY-2981-2020; Di Agostino, Silvia/H-1121-2018; Fedele, Monica/C-1417-2015; Tramontano, Donatella/AAS-1740-2020; Pierantoni, Giovanna Maria/O-7527-2015; Di Agostino, Silvia/S-8566-2019; Chiariotti, Lorenzo/AAC-5262-2022; Chieffi, Paolo/ABA-7892-2020; Barchi, Marco/Q-9378-2019	Battista, Sabrina/0000-0001-5899-9759; Di Agostino, Silvia/0000-0003-3730-1125; Fedele, Monica/0000-0002-9171-1312; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Barchi, Marco/0000-0003-1104-6234; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; chieffi, paolo/0000-0001-8483-5635; Fusco, Alfredo/0000-0003-3332-5197; Tramontano, Donatella/0000-0002-9308-034X				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Albanesi C, 1996, DEVELOPMENT, V122, P1291; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOOCKFOR FR, 1991, ENDOCRINOLOGY, V129, P256, DOI 10.1210/endo-129-1-256; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; CHUBB C, 1985, ENDOCRINOLOGY, V117, P338, DOI 10.1210/endo-117-1-338; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DEKRETSER DM, 1995, BASIC ENDOCRINOLOGY, P2307; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; GERARD N, 1991, MOL CELL ENDOCRINOL, V82, pR13, DOI 10.1016/0303-7207(91)90019-O; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LEGER H, 1995, MOL CELL BIOL, V15, P3738; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; OKUDA Y, 1994, ENDOCRINE, V2, P1163; Pero R, 2001, AM J PATHOL, V159, P1225, DOI 10.1016/S0002-9440(10)62508-4; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J., 2002, MOL CLONING LAB MANU; Sette C, 1997, DEVELOPMENT, V124, P2267; Sharpe RM, 1994, REGULATION SPERMATOG, P1363; TAMIMI Y, 1993, CANCER RES, V53, P5512; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; vanWert JM, 1998, BIOL REPROD, V59, P704, DOI 10.1095/biolreprod59.3.704; WISNIEWSKI J, 1993, EUR J BIOCHEM, V212, P137, DOI 10.1111/j.1432-1033.1993.tb17643.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	85	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2002	21	22					3644	3650		10.1038/sj/onc/1205501	http://dx.doi.org/10.1038/sj/onc/1205501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032866				2022-12-28	WOS:000175793700015
J	Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A				Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A			Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas	ONCOGENE			English	Article						transgenic mice; HMGA2; pituitary adenomas; Pit-1; tumorigenesis	EXPRESS HIGH-LEVELS; GROUP PROTEIN GENE; NEOPLASTIC TRANSFORMATION; MESENCHYMAL TUMORS; HMGI(Y) PROTEINS; C GENE; CELLS; LIPOMAS; FAMILY; REARRANGEMENTS	Overexpression of the HMGA2 gene is a common feature of neoplastic cells both in experimental and human models. Intragenic and extragenic HMGA2 rearrangements responsible for HMGA2 gene overexpression have been frequently detected in human benign tumours of mesenchymal origin. To better understand the role of HMGA2 overexpression in human tumorigenesis, we have generated transgenic mice carrying the HMGA2 gene under the transcriptional control of the cytomegalovirus promoter. High expression of the transgene was demonstrated in all the mouse tissues analysed, whereas no expression of the endogenous HMGA2 gene was detected in the same tissues from wild-type mice. In this study, two indipendent lines of transgenic mice have been generated. By 6 months of age, 85% of female animals of both transgenic lines developed pituitary adenomas secreting prolactin and growth hormone. The transgenic males developed the same phenotype with a lower penetrance (40%) and a longer latency period (about 18 months). Therefore, these data demonstrate that the overexpression of HMGA2 leads to the onset of mixed growth hormone/prolactin cell pituitary adenomas. These transgenic mice may represent an important tool for the study of this kind of neoplasia.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Harbor UCLA Med Ctr, Natl Hormone & Pituitary Program, Torrance, CA 90509 USA; Thomas Jefferson Univ, Jefferson Med Coll, Image Ctr, Philadelphia, PA 19107 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Fac Med & Chirurg Catanzaro, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Jefferson University; Fox Chase Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Jefferson University; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; visone, rosa/K-7910-2016; Battista, Sabrina/AAY-2981-2020; Young, Richard A/F-6495-2012; Baldassarre, Gustavo/K-1350-2016; Pierantoni, Giovanna Maria/O-7527-2015	Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Young, Richard A/0000-0001-8855-8647; Baldassarre, Gustavo/0000-0002-9750-8825; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197; VISONE, Rosa/0000-0002-4993-0220; Kenyon, Lawrence/0000-0002-3719-9565	NCI NIH HHS [P30 CA 56036, P01 CA 76259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, P30CA056036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BAUER K, 1990, ENDOCRINOLOGY, V127, P1224, DOI 10.1210/endo-127-3-1224; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Finelli P, 2000, INT J CANCER, V86, P344, DOI 10.1002/(SICI)1097-0215(20000501)86:3<344::AID-IJC7>3.0.CO;2-8; FINELLI P, 2002, IN PRESS CANC RES; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; PellegriniBouiller I, 1997, HORM RES, V47, P251, DOI 10.1159/000185472; Rogalla P, 1996, AM J PATHOL, V149, P775; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Spady TJ, 1999, ENDOCRINE, V11, P217, DOI 10.1385/ENDO:11:3:217; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TSOKOS M, 1987, AM J PATHOL, V128, P484; Weil RJ, 1998, CANCER RES, V58, P4715; Wood LJ, 2000, CANCER RES, V60, P4256; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	173	178	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3190	3198		10.1038/sj.onc.1205428	http://dx.doi.org/10.1038/sj.onc.1205428			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082634				2022-12-28	WOS:000175373600010
J	Guan, BX; Yue, P; Lotan, R; Sun, SY				Guan, BX; Yue, P; Lotan, R; Sun, SY			Evidence that the human death receptor 4 is regulated by activator protein 1	ONCOGENE			English	Article						DR4; AP-1; death receptors; gene expression; apoptosis	APOPTOSIS-INDUCING LIGAND; LUNG-CARCINOMA CELLS; FAS LIGAND; IN-VIVO; TRAIL; AP-1; EXPRESSION; INDUCTION; CANCER; AGENTS	Death receptor 4 (DR4; also called TRAIL-RI), a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Although several chemotherapeutic agents were reported to induce DR4 expression, the mechanism of this effect remains largely unknown. To begin to understand its regulation, we cloned a 1.8 Kb 5'-flanking region of the human DR4 gene and identified several putative binding sites for transcription factors including activator protein I (AP-1). Among the three putative AP-1 binding sites, the site located at -350/-344 is functionally active as evidenced by a combination of electrophoretic mobility shift and luciferase reporter assays. The AP-1 activator phorbol 12-myristate 13-acetate (TPA) enhanced the binding of this DR4 AP-1 binding site to protein(s) in a nuclear extract from TPA-treated cells, increased luciferase activity of a reporter construct containing this site and induced DR4 expression at the transcription level. These results indicate that AP-1 regulates DR4 expression via the AP-1 binding site located at -350/-344. AP-1 has been implicated in many critical cellular processes including apoptosis, and is a major target of the c-Jun NH3-terminal kinase signaling pathway that is activated by many anticancer drugs. Therefore, our findings may increase the understanding of the mechanisms underlying AP-1-mediated apoptosis as well as drug-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Fan MY, 2001, CANCER RES, V61, P4450; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fricker J, 1999, MOL MED TODAY, V5, P374, DOI 10.1016/S1357-4310(99)01555-5; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nagane M, 2000, CANCER RES, V60, P847; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ozoren N, 2000, INT J ONCOL, V16, P917; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sambrook J., 1989, MOL CLONING LAB MANU, P79, DOI DOI 10.17221/2151-JFS; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin MS, 2001, CANCER RES, V61, P4942; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1997, CANCER RES, V57, P4931; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247	39	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3121	3129		10.1038/sj.onc.1205430	http://dx.doi.org/10.1038/sj.onc.1205430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082627				2022-12-28	WOS:000175373600003
J	Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD				Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD			WISP3 is a novel tumor suppressor gene of inflammatory breast cancer	ONCOGENE			English	Article						WISP3; breast cancer; tumor suppressor gene; angiogenesis	FACTOR-BINDING PROTEIN; IMMEDIATE-EARLY GENE; MAMMARY EPITHELIAL-CELLS; TISSUE GROWTH-FACTOR; RHOC GTPASE; IGF-I; FAMILY; CYR61; EXPRESSION; SENESCENCE	Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with a 5-year disease-free survival of less than 45%. Little is known about the genetic alterations that result in IBC. In our previous work, we found that WISP3 was specifically lost in human IBC tumors when compared to stage-matched, non-IBC tumors. We hypothesize that WISP3 has tumor suppressor function in the breast and that it may be a key genetic alteration that contributes to the unique IBC phenotype. The full-length WISP3 cDNA was sequenced and cloned into an expression vector. The resulting construct was introduced in to the SUM149 cell line that was derived from a patient with IBC and lacks WISP3 expression. In soft agar, stable WISP3 transfectants formed significantly fewer colonies than the controls. Stable WISP3 transfectants lost their ability to invade and had reduced angiogenic potential. WISP3 transfection was effective in suppressing in vivo tumor growth in nude mice. Mice bearing WISP3 expressing tumors had a significantly longer survival than those with vector-control transfectant tumors. Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis.	Univ Michigan, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kleer, CG (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Univ Hosp 2G332, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu	Pan, Quintin/E-3808-2011		NATIONAL CANCER INSTITUTE [R01CA077612, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 46592, R01 CA 77612] Funding Source: Medline; NCRR NIH HHS [M01 RR 00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Byun D, 2001, J ENDOCRINOL, V169, P135, DOI 10.1677/joe.0.1690135; ETHIER SP, 1993, CANCER RES, V53, P627; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Lee BJ, 1924, SURG GYNECOL OBSTET, V39, P580; Li WX, 1996, MOL PATHOL, V49, P91; LIVANT DL, 1995, CANCER RES, V55, P5085; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Merajver SD, 1997, J CLIN ONCOL, V15, P2873, DOI 10.1200/JCO.1997.15.8.2873; NISSANOV J, 1995, LAB INVEST, V73, P734; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sprenger CC, 1999, CANCER RES, V59, P2370; SWAIN SM, 1987, CANCER RES, V47, P3889; Tsugu A, 2000, AM J PATHOL, V157, P919, DOI 10.1016/S0002-9440(10)64605-6; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xu LF, 2000, GENE DEV, V14, P585	30	118	120	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3172	3180		10.1038/sj.onc.1205462	http://dx.doi.org/10.1038/sj.onc.1205462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082632				2022-12-28	WOS:000175373600008
J	Shields, PG				Shields, PG			Molecular epidemiology of smoking and lung cancer	ONCOGENE			English	Review						genetic susceptibilities; polymorphisms; carcinogenesis; biomarkers; environmental tobacco smoke	DNA ADDUCT LEVELS; ENVIRONMENTAL TOBACCO-SMOKE; POLYCYCLIC AROMATIC-HYDROCARBONS; SQUAMOUS-CELL CARCINOMA; LOW-YIELD CIGARETTES; P53 GENE-MUTATIONS; WHITE BLOOD-CELLS; S-TRANSFERASE M1; PASSIVE SMOKING; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE NNK	Lung cancer is the single most common cause of death, and almost all of it is due to tobacco smoking. Before the widespread use of cigarettes in this century, lung cancer was a rare illness. Tobacco smoke is a complex mixture of numerous mutagens and carcinogens. Over the last 40 years, the type of cigarettes most frequently used has been changing, namely the increased use of low tar and nicotine cigarettes. This has been accompanied by an increased risk of lung cancer due to a smokers' need to maintain blood nicotine levels, which in turn causes the need for smoking more cigarettes per day and deeper inhalation. This phenomena has led to the increasing rates of lung adenocarcinoma, compared to squamous cell carcinoma. It also probably explains, in part, the greater risk of lung cancer in women compared to men (in addition to some biological differences). The study of lung cancer involves many types of biomarkers, including those that measure exposure, the biologically effective dose and harm. The use of these has allowed us to understand many parts of lung carcinogenesis. Genetic susceptibilities play a large role in lung cancer risk. They govern smoking behavior (affecting dopamine reward mechanisms due to nicotine and nicotine metabolism), carcinogen metabolism and detoxification, DNA repair, cell cycle control and other cellular responses. The need for the study of lung cancer is highlighted by the need to improve cessation rates and reduce exposure among persons who cannot quit smoking, for better prevention strategies for former smokers and an understanding of environmental tobacco smoke risk.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Shields, PG (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Res Bldg,W315,3970 Reservoir Rd NW, Washington, DC 20007 USA.	pgs2@georgetown.edu	Shields, Peter G/I-1644-2012					Atawodi SE, 1998, CANCER EPIDEM BIOMAR, V7, P817; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; BADAWI AF, 1995, CANCER RES, V55, P5230; Bailar JC, 1999, NEW ENGL J MED, V340, P958, DOI 10.1056/NEJM199903253401211; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Benowitz NL, 1998, J PHARMACOL EXP THER, V287, P958; BENOWITZ NL, 1986, JAMA-J AM MED ASSOC, V256, P241; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Brockmoller J, 1998, TOXICOL LETT, V103, P173, DOI 10.1016/S0378-4274(98)00304-X; Brownson RC, 1998, EPIDEMIOL REV, V20, P218, DOI 10.1093/oxfordjournals.epirev.a017982; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; Brunnemann KD, 1996, CRIT REV TOXICOL, V26, P121, DOI 10.3109/10408449609017926; BURNEY LE, 1959, JAMA-J AM MED ASSOC, V171, P1829, DOI 10.1001/jama.1959.73010310005016; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CORNFIELD J, 1959, J NATL CANCER I, V22, P173; DARBY SC, 1988, BRIT J CANCER, V58, P825, DOI 10.1038/bjc.1988.319; Djordjevic MV, 2000, JNCI-J NATL CANCER I, V92, P106, DOI 10.1093/jnci/92.2.106; Djordjevic MV, 1997, PREV MED, V26, P435, DOI 10.1006/pmed.1997.0184; DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; EBERT RV, 1983, JAMA-J AM MED ASSOC, V250, P2840, DOI 10.1001/jama.250.20.2840; Ernster VL, 1996, ANNU REV PUBL HEALTH, V17, P97; FISCHER S, 1990, CARCINOGENESIS, V11, P723, DOI 10.1093/carcin/11.5.723; FISCHER S, 1989, CARCINOGENESIS, V10, P1511; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; GRITZ ER, 1983, PHARMACOL BIOCHEM BE, V18, P457, DOI 10.1016/0091-3057(83)90469-0; Haldorsen T, 1999, INT J EPIDEMIOL, V28, P1032, DOI 10.1093/ije/28.6.1032; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HARRIS CC, 1974, NATURE, V252, P68, DOI 10.1038/252068a0; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; Hou SM, 1999, CARCINOGENESIS, V20, P437, DOI 10.1093/carcin/20.3.437; IARC, 1986, IARC MON EV CARC RIS, V38; Kaiser U, 1996, INT J CANCER, V67, P357, DOI 10.1002/(SICI)1097-0215(19960729)67:3<357::AID-IJC9>3.0.CO;2-Q; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kim JH, 1998, CARCINOGENESIS, V19, P1847, DOI 10.1093/carcin/19.10.1847; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Kondo K, 1996, J SURG ONCOL, V61, P20, DOI 10.1002/(SICI)1096-9098(199601)61:1<20::AID-JSO6>3.3.CO;2-#; Kure EH, 1996, CARCINOGENESIS, V17, P2201, DOI 10.1093/carcin/17.10.2201; Lee P N, 1998, Stat Methods Med Res, V7, P137, DOI 10.1191/096228098669795194; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; Lerman C, 1998, HEALTH PSYCHOL, V17, P56, DOI 10.1037/0278-6133.17.1.56; LEVI F, 1987, EUR J CANCER CLIN ON, V23, P1025, DOI 10.1016/0277-5379(87)90353-1; Lewis DFV, 1997, DRUG METAB REV, V29, P1055, DOI 10.3109/03602539709002243; Lodovici M, 1998, CHEM-BIOL INTERACT, V116, P199, DOI 10.1016/S0009-2797(98)00091-X; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; Mollerup S, 1999, CANCER RES, V59, P3317; MUSTONEN R, 1993, CARCINOGENESIS, V14, P151, DOI 10.1093/carcin/14.1.151; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; Nyberg F, 1997, EPIDEMIOLOGY, V8, P304, DOI 10.1097/00001648-199705000-00013; OKADA T, 1994, PHARMACOGENETICS, V4, P333, DOI 10.1097/00008571-199412000-00006; Palmisano WA, 2000, CANCER RES, V60, P5954; Parsons WD, 1998, CANCER EPIDEM BIOMAR, V7, P257; Pastorelli R, 1998, CANCER EPIDEM BIOMAR, V7, P703; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PERERA FP, 1987, J NATL CANCER I, V78, P887; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Poli P, 1999, TOXICOL LETT, V108, P267, DOI 10.1016/S0378-4274(99)00098-3; Prescott E, 1998, INT J EPIDEMIOL, V27, P27, DOI 10.1093/ije/27.1.27; RENNARD SI, 1990, EUR RESPIR J, V3, P752; REPACE JL, 1990, RISK ANAL, V10, P27, DOI 10.1111/j.1539-6924.1990.tb01017.x; RISCH HA, 1994, SCIENCE, V263, P1206, DOI 10.1126/science.8122096; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; ROBERTSON IGC, 1988, POLYNUCLEAR AROMATIC, P799; Rojas M, 1998, PHARMACOGENETICS, V8, P109; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; RYBERG D, 1994, CANCER RES, V54, P5801; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Sabol SZ, 1999, HEALTH PSYCHOL, V18, P7, DOI 10.1037/0278-6133.18.1.7; Schoket B, 1998, CARCINOGENESIS, V19, P841, DOI 10.1093/carcin/19.5.841; Scott FM, 1997, CLIN CANCER RES, V3, P479; SETO H, 1993, ARCH ENVIRON CON TOX, V24, P498, DOI 10.1007/BF01146169; Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453; SHIELDS PG, 1998, MED WORKPLACE APPL B, P253; Shimada T, 1996, CANCER RES, V56, P2979; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; SIDNEY S, 1995, ARCH INTERN MED, V155, P727, DOI 10.1001/archinte.155.7.727; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SMITH TJ, 1995, CANCER RES, V55, P5566; SMITH TJ, 1992, CANCER RES, V52, P1757; SORSA M, 1984, ENVIRON RES, V33, P312, DOI 10.1016/0013-9351(84)90029-X; Speit G, 1999, METH MOL B, V113, P203; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; STERN SJ, 1993, J CELL BIOCHEM, P129; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; Sunyer J, 1996, AM J EPIDEMIOL, V144, P734; Takagi Y, 1998, BRIT J CANCER, V77, P1568, DOI 10.1038/bjc.1998.258; TANG DL, 1995, CANCER EPIDEM BIOMAR, V4, P341; Tang DL, 1998, CARCINOGENESIS, V19, P1949, DOI 10.1093/carcin/19.11.1949; Tang DL, 2001, CANCER RES, V61, P6708; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; TIANO HF, 1994, CARCINOGENESIS, V15, P2859, DOI 10.1093/carcin/15.12.2859; TRICKER AR, 1991, CARCINOGENESIS, V12, P257, DOI 10.1093/carcin/12.2.257; TWEEDIE RL, 1992, BRIT J CANCER, V66, P700, DOI 10.1038/bjc.1992.341; *US DEP HLTH, 2000, FTC CIG TEST METH DE, P238; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012; van Delft JHM, 1998, CRIT REV TOXICOL, V28, P477, DOI 10.1080/10408449891344254; VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WADA M, 1993, BLOOD, V82, P3163; WIENCKE JK, 1995, CANCER RES, V55, P4910; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; XUE KX, 1992, INT J CANCER, V50, P702, DOI 10.1002/ijc.2910500506; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; Zaridze D.G., 1991, IARC SCI PUBL, V105, P485; ZEISE L, 1997, EPA REPORT	120	120	134	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6870	6876		10.1038/sj.onc.1205832	http://dx.doi.org/10.1038/sj.onc.1205832			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362269				2022-12-28	WOS:000178640200002
J	Schneider, E; Kartarius, S; Schuster, N; Montenarh, M				Schneider, E; Kartarius, S; Schuster, N; Montenarh, M			The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H	ONCOGENE			English	Article						protein kinase CK-2; cyclin dependent kinases; phosphorylation regulation	CDK-ACTIVATING KINASE; RING FINGER PROTEIN; TRANSCRIPTION FACTOR; IN-VITRO; P53; TFIIH; CAK; COMPLEX; SUBUNIT; MAT1	Cyclin dependent kinases are regulated by phosphorylation and dephosphorylation of the catalytic cdk subunits, by assembly with specific cyclins and by specific inhibitor molecules. Recently, it turned out that cyclins are also phosphoproteins, which means that they are also potential targets for a regulation by phosphorylation and dephosphorylation. Here, we show that cyclin H was phosphorylated by protein kinase CK2. Like most other CK2 substrates cyclin H was much better phosphorylated by the CK2 holoenzyme than by the alpha-subunit alone. By using point mutants derived from the cyclin H sequence we mapped the CK2 phosphorylation site at threonine 315 at the C-terminal end of cyclin H. Phosphorylation at this position had no influence on the assembly of the cyclin H/cdk7/Mat1 complex. However, phosphorylation at amino acid 315 of cyclin H turned out to be critical for a full cyclin H/cdk7/Mat1 kinase activity when the CTD peptide of RNA polymerase II or cdk2 was used as a substrate.	Univ Saarland, D-66424 Homburg, Germany	Saarland University	Montenarh, M (corresponding author), Univ Saarland, Bldg 44, D-66424 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; ANGIOLILLO A, 1993, MOL CELL BIOCHEM, V125, P65, DOI 10.1007/BF00926836; APPEL K, 1995, ONCOGENE, V11, P1971; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gotz C, 1996, ONCOGENE, V13, P391; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x	30	34	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5031	5037		10.1038/sj.onc.1205690	http://dx.doi.org/10.1038/sj.onc.1205690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140753				2022-12-28	WOS:000176975900001
J	Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A				Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A			Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers	ONCOGENE			English	Article						pancreatic cancer; bile duct cancer; K-RAS; pancreatic intraepithelial neoplasia	GENE-MUTATIONS; ONCOGENE ACTIVATION; ADENOCARCINOMA; PROGRESSION; CARCINOMAS; CODON-12; PATHWAYS	Recent studies on small series of pancreatic cancer (PC) with foci of pancreatic intraepithelial neoplasia (PanIN), a putative precursor lesion, have shown that multiple K-RAS mutations may coexist in the same neoplastic pancreas. To see whether mutant-K-RAS polyclonality is a common and specific feature of pancreatic carcinogenesis, we investigated a unselected series of periampullary cancers (41 pancreatic, 13 biliary and two ampullary adenocarcinomas). After hemi-nested polymerase chain reaction (PCR), mutations identified with single strand conformation polymorphism (SSCP) were confirmed by allele-specific PCR and sequencing. K-RAS codon 12 was mutated in 34 (83%) pancreatic cancers and in 11 (85%) biliary cancers. Multiple distinct K-RAS mutations were found in 16 PC (39% of all cases, 47% of those with mutated K-RAS) and in eight biliary cancers (62 and 72%, respectively). In PC, multiple K-RAS mutations were more frequent (P<0.001) in cancers with (nine of 12, 75%) than in those without detectable PanIN (seven of 29, 24%). Individual precursor lesions of the same neoplastic pancreas were found to harbor distinct mutations. Results show that multiple K-RAS mutations are frequent both in PC with associated PanIN and in biliary cancers, and indicate that clonally distinct precursor lesions of PC might variably contribute to tumor development.	Ist Clin Humanitas, Div Gastroenterol, I-20089 Milan, Italy; Univ Milan, Dept Internal Med, I-20121 Milan, Italy; Ist Clin Humanitas, Dept Pathol, Res Lab, I-20089 Milan, Italy; Osped San Raffaele, Dept Surg, I-20132 Milan, Italy; Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA	IRCCS Humanitas Research Hospital; University of Milan; IRCCS Humanitas Research Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California San Diego	Malesci, A (corresponding author), Ist Clin Humanitas, Div Gastroenterol, Via Manzoni 56, I-20089 Milan, Italy.		Piemonti, Lorenzo/P-7605-2017; Laghi, Luigi/GZM-5831-2022; Bianchi, Paolo/E-7592-2013	Piemonti, Lorenzo/0000-0002-2172-2198; Laghi, Luigi/0000-0003-4187-1059; Bianchi, Paolo/0000-0001-5786-5644; zerbi, alessandro/0000-0002-9176-0448				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; CALDAS C, 1994, CANCER RES, V54, P3568; CUBILLA AL, 1976, CANCER RES, V36, P2690; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; LEVI S, 1991, CANCER RES, V51, P3497; Moskaluk CA, 1997, CANCER RES, V57, P2140; MOTOJIMA K, 1991, ANN SURG, V214, P657, DOI 10.1097/00000658-199112000-00003; Rozenblum E, 1997, CANCER RES, V57, P1731; Sherratt EJ, 1996, BIOTECHNIQUES, V20, P430; SUGANO K, 1993, LAB INVEST, V68, P361; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; TADA M, 1993, CANCER RES, V53, P2472; Urrutia R, 1996, GASTROENTEROLOGY, V110, P306, DOI 10.1053/gast.1996.v110.agast960306; WATANABE M, 1994, GASTROENTEROLOGY, V107, P1147, DOI 10.1016/0016-5085(94)90240-2; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; YANAGISAWA A, 1993, CANCER RES, V53, P953; Yashiro M, 2001, CANCER RES, V61, P2676; Zhu D, 1997, CANCER RES, V57, P2485	23	57	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4301	4306		10.1038/sj.onc.1205533	http://dx.doi.org/10.1038/sj.onc.1205533			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082617				2022-12-28	WOS:000176174200012
J	Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A				Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A			Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells	ONCOGENE			English	Article						MAPK; TRAIL; apoptosis; MCF-7 cells; mitochondria	CYTOCHROME-C; TUMOR-CELLS; IN-VIVO; T-CELLS; DEATH; CASPASE-3; BCL-2; CHEMOTHERAPY; SENSITIVITY; LYMPHOCYTES	We studied the role of the mitogen-activated protein kinase (MAPK) pathway in the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in breast tumor MCF-7 cells. We found that addition of a protein kinase C (PKC) activator to MCF-7 cultures prevented TRAIL-induced apoptosis, by inhibiting a step downstream of both caspase-8 activation and BID cleavage. TRAIL-induced translocation of Bax from cytosol to mitochondria, release of cytochrome c from mitochondria and activation of caspase-9 were all inhibited by PKC activation. PKC-mediated prevention of mitochondrial apoptotic events; and apoptosis was found to be dependent on the MAPK pathway. Since TRAIL is a ligand of potential use in antineoplastic clinical trials, our findings may provide relevant information in cancer therapy.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.		Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jarvis WD, 1999, INVEST NEW DRUG, V17, P227, DOI 10.1023/A:1006328303451; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	34	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4323	4327		10.1038/sj.onc.1205523	http://dx.doi.org/10.1038/sj.onc.1205523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082620				2022-12-28	WOS:000176174200015
J	Piu, F; Magnani, M; Ader, ME				Piu, F; Magnani, M; Ader, ME			Dissection of the cytoplasmic domains of cytokine receptors involved in STAT and Ras dependent proliferation	ONCOGENE			English	Article						cytokine receptor; proliferation; STAT; Ras	COLONY-STIMULATING FACTOR; FACTOR G-CSF; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; THROMBOPOIETIN RECEPTOR; TYROSINE-PHOSPHORYLATION; MUSCARINIC RECEPTORS; HEMATOPOIETIC-CELLS; DISTINCT REGIONS; BETA-CHAIN	Cytokine receptors have different signaling requirements which ultimately lead to various physiological responses. In an effort to precisely characterize the molecular determinants involved in the proliferative response mediated by cytokines, we examine dose-dependent proliferation of the betac (GM-CSF, IL-3, IL-5) and homodimeric (G-CSF, TPO) cytokine receptors. Here we report that all cytokine receptors tested activate mostly STAT3 and STAT5. While STAT3 had a positive effect on betac cytokine receptor dependent proliferation, STAT5 was strongly inhibitory. Similarly, G-CSF and TPO lead to activation of STAT3 and STAT5 but, unlike the betac cytokine receptors, both stimulated cellular growth. On the other hand, Ras activation was necessary for all receptor mediated proliferation with the exception of G-CSF R. Truncated mutants of the receptors intracellular domains were used to delineate the functional domains involved in JAK/STAT and Ras activation linked to cellular growth. For instance, we revealed a critical role for the specific alpha subunit of the betac receptors in triggering receptor activation, STAT3 stimulation and proliferation, while Ras activation originates from the distal intracellular portion of the betac subunit. Finally, we showed that proximal STAT activation is the triggering event of G-CSF and TPO receptor function.	ACADIA Pharmaceut Inc, Signal Transduct Grp, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, Signal Transduct Grp, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com	Magnani, Mauro/A-1919-2008					Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Downward J, 1996, CANCER SURV, V27, P87; Doyle SE, 1998, BLOOD, V92, P867; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Kasper B, 1999, INT J HEMATOL, V70, P241; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Porteu F, 1996, MOL CELL BIOL, V16, P2473; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RONCO LV, 1994, J BIOL CHEM, V269, P277; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; WEISS M, 1993, BLOOD, V82, P3298; Wilks AF, 1996, CANCER SURV, V27, P139; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yoshimura A, 1998, Curr Opin Hematol, V5, P171, DOI 10.1097/00062752-199805000-00004	54	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3579	3591		10.1038/sj.onc.1205444	http://dx.doi.org/10.1038/sj.onc.1205444			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032860				2022-12-28	WOS:000175793700009
J	Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM				Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM			Aplidin (TM) induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta	ONCOGENE			English	Article						Aplidin (TM); oxidative damage; JNK; p38; caspascs; PKC-delta	N-TERMINAL KINASE; SIGNAL-REGULATED KINASE; CELL-DEATH; GAMMA-RADIATION; GLUTATHIONE; CASPASES; DIDEMNIN; ALPHA; BCL-2; ERK	Aplidin(TM), a new antitumoural drug presently in phase II clinical trials, has shown both in vitro and in vivo activity against human cancer cells. Aplidin(TM) effectively inhibits cell viability by triggering a canonical apoptotic program resulting in alterations in cell morphology, caspase activation, and chromatin fragmentation. Pro-apoptotic concentrations of Aplidin(TM) induce early oxidative stress, which results in a rapid and persistent activation of both JNK and p38 MAPK and a biphasic activation of ERK. Inhibition of JNK and p38 MAPK blocks the apoptotic program induced by Aplidin(TM), demonstrating its central role in the integration of the cellular stress induced by the drug. JNK and p38 MAPK activation results in downstream cytochrome c release and activation of caspases -9 and -3 and PARP cleavage, demonstrating the mediation of the mitochondrial apoptotic pathway in this process. We also demonstrate that protein kinase C delta (PKC-delta) mediates the cytotoxic effect of Aplidin(TM), and that it is concomitantly processed and activated late in the apoptotic process by a caspase mediated mechanism. Remarkably, cells deficient in PKC-delta show enhanced survival upon drug treatment as compared to its wild type counterpart. PKC-delta thus appears as an important component necessary for full caspase cascade activation and execution of apoptosis, which most probably initiates a positive feedback loop further amplifying the apoptotic process.	PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Ctr Citrometria Flujo, E-28040 Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cell Biol, Fukuoka 8128582, Japan	PharmaMar; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Kyushu University; Kyushu University	Sanchez-Puelles, JM (corresponding author), PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain.	jmspuelles@pharmamar.com	Losada, Alejandro/AAW-8589-2021; Munoz, Alberto/O-6393-2014; Cuadrado, Ana/AAA-9277-2019; Alvarez-Barrientos, Alberto/L-9299-2014; Cuadrado, Ana/HGU-4777-2022; Sanchez-Puelles, Jose Maria/E-4159-2018	Munoz, Alberto/0000-0003-3890-4251; Cuadrado, Ana/0000-0002-9752-5932; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Sanchez-Puelles, Jose Maria/0000-0002-4283-4885				Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; ANTHONEY A, 2000, J CLIN ONCOL S, V19, pA734; ARMAND JP, 2001, P AM SOC CLIN ONCOL, V20; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOWMAN A, 2001, P AM SOC CLIN ONCOL, V20; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROGGINI M, 2000, P 11 NCI EORTC AACR; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CIRUELOS EM, 2002, P AM SOC CLIN ONCOL, V20; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Crews CM, 1996, P NATL ACAD SCI USA, V93, P4316, DOI 10.1073/pnas.93.9.4316; CREWS CM, 1994, J BIOL CHEM, V269, P15411; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Ding W, 2000, TOXICOL APPL PHARM, V162, P93, DOI 10.1006/taap.1999.8829; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERBA E, 1999, P AACR NCI EORTC INT; FAIRCLOTH G, 1999, P AM ASS CANC RES, V40; FAIRCLOTH G, 1998, P AM ASS CANC RES, V39; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Grubb DR, 2001, ONCOGENE, V20, P4085, DOI 10.1038/sj.onc.1204545; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Huang CS, 1999, CANCER RES, V59, P3053; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; KOJI U, 1999, J BIOL CHEM, V274, P2234; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Krupinski J, 2000, NEUROBIOL DIS, V7, P332, DOI 10.1006/nbdi.2000.0310; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUROUN JA, 2001, P AM SOC CLIN ONCOL, V20; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Miyanishi K, 2001, GASTROENTEROLOGY, V121, P865, DOI 10.1053/gast.2001.27982; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Persons DL, 1999, CLIN CANCER RES, V5, P1007; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rinehart KL, 2000, MED RES REV, V20, P1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; STEMPKA L, 1998, ASBMB S PROT KIN C C; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Whelan R D, 1989, Cancer Commun, V1, P359; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Yu WP, 2001, CANCER RES, V61, P6569; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	77	122	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7533	7544		10.1038/sj.onc.1205972	http://dx.doi.org/10.1038/sj.onc.1205972			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386816				2022-12-28	WOS:000178618200009
J	Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A				Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A			High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice	ONCOGENE			English	Article						patched-knockout mice; X-rays; medulloblastoma; LOH	CELL CARCINOMA SYNDROME; HUMAN HOMOLOG; GORLIN SYNDROME; UNITED-STATES; PATCHED GENE; MUTATIONS; CANCER; P53	Individuals affected with the Gorlin syndrome inherit a germ-line mutation of the patched (Ptc1) developmental gene and, analogously to Ptc1 heterozygous mice, show an increased susceptibility to spontaneous tumor development. Human and mouse Ptc1 heterozygotes (Ptc1(+/-)) are also hypersensitive to ionizing radiation (IR)-induced tumorigenesis in terms of basal cell carcinoma (BCC) induction. We have analysed the involvement of Ptc1 in the tumorigenic response to a single dose of 3 Gy X-rays in neonatal and adult Ptc1 heterozygous and wild type mice. We report that irradiation dramatically increased the incidence of medulloblastoma development (51%) over the spontaneous rate (7%) in neonatal but not adult Ptc1 heterozygotes, indicating that medulloblastoma induction by IR is subjected to temporal restriction. Analysis of Ptc1 allele status in the tumors revealed loss of the wild type allele in 17 of 18 medulloblastomas from irradiated mice and in two of three spontaneous medulloblastomas. To our knowledge, irradiated newborn Ptc1(+/-) heterozygous mice constitute the first mouse model of IR-induced medulloblastoma tumorigenesis, providing a useful tool to elucidate the molecular basis of medulloblastoma development.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; GSF Munich, Natl Res Ctr, Inst Pathol, Munich, Germany; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Goettingen, Inst Human Genet, Gottingen, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Gottingen	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Atkinson, Michael J/E-5537-2011; Atkinson, Michael/AAU-5127-2020	Atkinson, Michael J/0000-0003-3358-2089; Atkinson, Michael/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Chidambaram A, 1996, CANCER RES, V56, P4599; COREY R, 1997, CANCER RES, V57, P842; Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; LACOMBE D, 1990, Genetic Counseling, V1, P273; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Unden AB, 1996, CANCER RES, V56, P4562; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wicking C, 1997, AM J HUM GENET, V60, P21; Xie JW, 1997, CANCER RES, V57, P2369; ZURAWEL RH, 1997, CANCER RES, V577, P842; ZURAWEL RH, 2000, GENES CHROMOSOMES CA, V28	24	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7580	7584		10.1038/sj.onc.1205973	http://dx.doi.org/10.1038/sj.onc.1205973			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386820				2022-12-28	WOS:000178618200013
J	Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H				Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H			Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer	ONCOGENE			English	Article						oncogene; amplification; quantitative PCR; therapy	TRANSCRIPTION-PCR ASSAY; P53 GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; C-MYC; MULTIVARIATE-ANALYSIS; MONOCLONAL-ANTIBODY; CARCINOMAS; CHEMOTHERAPY; EXPRESSION	Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.	Hop St Louis, Serv Biochim B, F-75475 Paris 10, France; Hop St Louis, CNRS, UPR9051, F-75475 Paris 10, France; UPRES, Fac Sci Pharmaceut & Biol, Genet Mol Lab, JE 2195, F-75006 Paris, France; Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, F-92210 St Cloud, France; Hop St Louis, Serv Anat Pathol, F-75475 Paris 10, France; Hop St Louis, INSERM, ERM 0220, F-75475 Paris 10, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Hop St Louis, Serv Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr	Vidaud, Michel/O-7346-2017; Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				BERTHEAU P, 2002, IN PRESS LANCET; Bieche I, 1999, CANCER RES, V59, P2759; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Bieche I, 1999, CLIN CHEM, V45, P1148; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang S, 1998, CANCER, V82, P2366; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COLES C, 1992, CANCER RES, V52, P5291; Cuny M, 2000, CANCER RES, V60, P1077; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Degeorges A, 1998, BREAST CANCER RES TR, V47, P47, DOI 10.1023/A:1005824216444; Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P5, DOI 10.1089/cbr.1999.14.5; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P303; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; GARCIA I, 1989, CANCER RES, V49, P6675; Gradishar WJ, 1996, SEMIN SURG ONCOL, V12, P352; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUERIN M, 1988, ONCOGENE RES, V3, P21; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kerangueven F, 1997, CANCER RES, V57, P5469; Nakopoulou LL, 1996, J PATHOL, V179, P31, DOI 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sainsbury JRC, 2000, BRIT MED J, V321, P745, DOI 10.1136/bmj.321.7263.745; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Sjostrom J, 1998, BRIT J CANCER, V78, P812, DOI 10.1038/bjc.1998.584; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Turpin E, 1999, ONCOGENE, V18, P7834, DOI 10.1038/sj.onc.1203196; *UICC, 1909, TNM CLASS MAL TUM, P123; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincent-Salomon A, 2000, EUR J CANCER, V36, P586, DOI 10.1016/S0959-8049(99)00339-1; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	43	61	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7593	7597		10.1038/sj.onc.1205932	http://dx.doi.org/10.1038/sj.onc.1205932			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386822				2022-12-28	WOS:000178618200015
J	Yu, Y; Feig, LA				Yu, Y; Feig, LA			Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells	ONCOGENE			English	Article						breast cancer; Ral; R-Ras	GTP-BINDING PROTEINS; TAMOXIFEN RESISTANCE; C-SRC; RECEPTOR; ACTIVATION; GROWTH; SPECIFICITY; ALPHA; RAP1; EGF	A key step in the progression of breast cancer is the conversion of cells front an estrogen-dependent to an estrogen-independent state. Yet the molecular mechanisms underlying this transition in the control of cell proliferation of breast cancer cells remain poorly understood. A potential role for Ras-related GTPases in this process was suggested by the finding that BCAR3/AND-34, a protein isolated on the basis of its ability to convert MCF-7 and ZR-75 breast cancer cell lines to estrogen independence and tamoxifen resistance, is a guanine nucleotide exchange factor with the potential to activate the Ras-related Ral, R-Ras and Rap GTPases. In this study we investigated the potential contribution of these GTPases to the generation of estrogen-independence in MCF-7 cells. We found that elevated R-Ras but not Ral or Rap activity was sufficient to induce estrogen-independent proliferation of MCF-7 cells. The effect of R-Ras was dependent upon its ability to constitutively activate the AKT kinase. Interestingly, although AKT was also constitutively activated when estrogen-independent proliferation was induced by overexpression of EGF receptors, this mechanism of hormone independence did not require AKT activation. In contrast, EGF receptors did require Ral activation to induce estrogen-independent proliferation, while Ral activation was not required for estrogen-induced proliferation of MCF-7 cells. These findings suggest that Ral activity takes on a significant role in controlling cell proliferation of breast cancer cells when progression to estrogen-independence is associated with over-expression of EGF receptor family members. Moreover, because R-Ras promotes hormone-independent growth in a manner distinct from EGF receptors, it may participate in the conversion of breast cancer cells to estrogen independence when over-expression of EGF receptor family members is not involved.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA047391] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; OHTSUKA T, 1996, J BIOL CHEM, V271, P1253; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tian XJ, 2002, EMBO J, V21, P1327, DOI 10.1093/emboj/21.6.1327; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	39	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7557	7568		10.1038/sj.onc.1205961	http://dx.doi.org/10.1038/sj.onc.1205961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386818				2022-12-28	WOS:000178618200011
J	Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA				Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA			Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers	ONCOGENE			English	Article						BRCA1; estrogen receptor; methylation; breast cancer	SPORADIC BREAST; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; DNA METHYLATION; BRCA1; CARCINOMAS; EXPRESSION; TUMORS; PROMOTER; MUTATIONS	A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-alpha (ERalpha). Previous investigation suggests that methylation of CpGs within the ERa promoter mediates repression of gene expression in some ERalpha-negative breast cancers. To determine if methylation of CpGs within the ERalpha promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERalpha gene in 40 ERalpha-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P < 0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERa gene in BRCA1-linked breast cancers.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden	Dartmouth College; Dartmouth College; Dartmouth College; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cleveland Clinic Foundation; Lund University; Skane University Hospital	Arrick, BA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.			Robson, Mark/0000-0002-3109-1692	NCI NIH HHS [CA77772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archey WB, 1999, CANCER RES, V59, P2292; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; Berns EMJJ, 2001, BRIT J CANCER, V85, P538, DOI 10.1054/bjoc.2001.1937; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; FERGUSON AT, 1995, CANCER RES, V55, P2279; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Penolazzi L, 2000, BBA-GENE STRUCT EXPR, V1492, P560, DOI 10.1016/S0167-4781(00)00145-7; PIVA R, 1990, BRIT J CANCER, V61, P270, DOI 10.1038/bjc.1990.50; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Tomlinson GE, 1998, CANCER RES, V58, P3237; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; YAICH L, 1992, CANCER RES, V52, P77; Yang XW, 2000, CANCER RES, V60, P6890; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	34	29	32	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7034	7041		10.1038/sj.onc.1205844	http://dx.doi.org/10.1038/sj.onc.1205844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370825				2022-12-28	WOS:000178424900006
J	Leu, TH; Maa, MC				Leu, TH; Maa, MC			Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397	ONCOGENE			English	Article						Src; FAK; tyrosine kinase; tyrosol phosphorylation	PROTEIN-TYROSINE KINASE; ACTIVATION LOOP PHOSPHORYLATION; MAP KINASE; IN-VIVO; BINDING; SITE; SRC; REQUIREMENT; ASSOCIATION; FIBRONECTIN	Tyr-397 phosphorylation is important for focal adhesion kinase (FAK)-mediated signalling. In vitro FAK immunocomplex kinase experiments demonstrated that both FAK Tyr-576/577 and Tyr-863 phosphorylation regulated FAK Tyr-397 phosphorylation. While the former increased the intermolecular transphosphorylation activity of FAK, the latter was crucial for its cis-phosphorylation. This observation was further supported by the reduced complex formation between Src and 3F-FAK (576F/577F/863F-FAK) as compared to that between Src and 576F/577F-FAK or Src and 863F-FAK. Regulation of cis- and transphosphorylation activities of FAK by such a differential tyrosyl phosphorylation mechanism is unprecedented. Furthermore, in fibronectin-stimulated cells, both Tyr-576/577 and Tyr-863 phosphorylation could enhance FAK Tyr-397 phosphorylation. This observation implies that integrin-mediated FAK Tyr-397 phosphorylation was also regulated through both FAK cis- and transphosphorylation mechanisms.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786	25	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					6992	7000		10.1038/sj.onc.1205904	http://dx.doi.org/10.1038/sj.onc.1205904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370821				2022-12-28	WOS:000178424900002
J	Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R				Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R			Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin	ONCOGENE			English	Article						E1a; PI3k; Akt; downregulation; insulin; cisplatin	PROTEIN-KINASE-B; ADENOVIRUS E1A; OVARIAN-CANCER; CELL-GROWTH; INSULIN; ACTIVATION; EXPRESSION; GENE; PHOSPHORYLATION; SUPPRESSION	In order to investigate the molecular mechanisms implicated in the induction of chemo sensitivity by adenovirus E1a gene expression, we decided to investigate which signal transduction pathways could be affected by the E1a gene in Human Normal Fibroblast (IMR90). No effect was observed in SAPK pathways (p38MAPK and JNK), but E1a was able to affect the Akt activation mediated by insulin. This result was confirmed by transient transfection experiments performed in Cos-7 cells and also observed in other transformed cell lines such as A431. Furthermore, E1a expression induces a decrease in the basal status of Akt activity. Finally we demonstrated that E1a is able to block the Akt activation mediated by cisplatin and correlates with a sensitive phenotype. In summary, our data demonstrate that specific inhibition of the PI3K/Akt pathway mediates some of the biological properties of E1a such as induction of chemosensitivity.	Clin Puerta Hierro, Unidad Patol Mol, Madrid 28035, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Clin Puerta Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Prieto, Ricardo/AAZ-7221-2021; Sanchez-Prieto, Ricardo/AAY-4271-2021; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Ramon y Cajal, Santiago/H-4955-2016; Javier, Hernandez Losa/C-1173-2008; Sanchez-Prieto, Ricardo/B-6877-2008; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Ramon y Cajal, Santiago/0000-0002-3867-1390; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Fernandez-Soria, Victor Manuel/0000-0002-4225-8697				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Brognard J, 2001, CANCER RES, V61, P3986; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hayakawa J, 2000, CANCER RES, V60, P5988; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; See RH, 1998, MOL CELL BIOL, V18, P4012, DOI 10.1128/MCB.18.7.4012; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shao RP, 2001, CANCER RES, V61, P7413; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; TEODORO JG, 1995, ONCOGENE, V11, P467; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	26	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7131	7136		10.1038/sj.onc.1205934	http://dx.doi.org/10.1038/sj.onc.1205934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370836				2022-12-28	WOS:000178424900017
J	Kaye, FJ				Kaye, FJ			RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer	ONCOGENE			English	Article						retinoblastoma; cyclin dependent kinase; pl6INK4; p27Kipl; lung cancer; neuroendocrine	RETINOBLASTOMA SUSCEPTIBILITY GENE; SMALL-CELL CARCINOMA; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; RAS ONCOGENE MUTATIONS; N-MYC GENE; P16(INK4) PROTEIN; IN-VIVO; EXPRESSION; LINES	The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.	Natl Naval Med Res Inst, NCI Navy Oncol, Bethesda, MD 20889 USA; NCI, Genet Branch, Canc Res Ctr, NIH, Bethesda, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Natl Naval Med Res Inst, NCI Navy Oncol, Bldg 8,Room 5101, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	kaye, frederic/E-2437-2011					Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bockhorn M, 2000, EXP CLIN ENDOCR DIAB, V108, P49; Cagle PT, 1997, AM J PATHOL, V150, P393; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 2000, CANCER RES, V60, P372; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Easton J, 1998, CANCER RES, V58, P2624; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1995, MOL GENETICS CANC, P1; GAZDAR AF, 1985, SCIENCE, V229, P679, DOI 10.1126/science.2992083; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gray SG, 2001, CANCER RES, V61, P5950; Grimison B, 2000, CELL GROWTH DIFFER, V11, P507; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARVEY M, 1995, CANCER RES, V55, P1146; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirsch FR, 2002, SEMIN ONCOL, V29, P51, DOI 10.1053/sonc.2002.31523; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; JOHNSON BE, 1988, CANCER RES, V48, P5163; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kaye F, 2001, MOL GENETICS CANC, P387; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Kleinerman RA, 2000, JNCI-J NATL CANCER I, V92, P2037, DOI 10.1093/jnci/92.24.2037; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Momparler RL, 2001, LUNG CANCER, V34, pS111; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; OOKAWA K, 1993, ONCOGENE, V8, P2175; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUGIO K, 1994, CANCER RES, V54, P5811; Tomizawa Y, 1998, JPN J CLIN ONCOL, V28, P192, DOI 10.1093/jjco/28.3.192; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	90	111	117	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6908	6914		10.1038/sj.onc.1205834	http://dx.doi.org/10.1038/sj.onc.1205834			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362273				2022-12-28	WOS:000178640200006
J	De Vos, J; Thykjaer, T; Tarte, K; Ensslen, M; Raynaud, P; Requirand, G; Pellet, F; Pantesco, V; Reme, T; Jourdan, M; Rossi, JF; Orntoft, T; Klein, B				De Vos, J; Thykjaer, T; Tarte, K; Ensslen, M; Raynaud, P; Requirand, G; Pellet, F; Pantesco, V; Reme, T; Jourdan, M; Rossi, JF; Orntoft, T; Klein, B			Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays	ONCOGENE			English	Article						myeloma; plasma cell; DNA microarray; c-myc; abl; cystathionine beta synthase	HUMAN MULTIPLE-MYELOMA; DOWN-SYNDROME; C-MYC; CYTOSINE-ARABINOSIDE; IN-VITRO; S-PHASE; IDENTIFICATION; LEUKEMIA; CANCER; CDNA	The DNA microarray technology enables the identification of the large number of genes involved in the complex deregulation of cell homeostasis taking place in cancer. Using Affymetrix microarrays, we have compared the gene expression profiles of highly purified malignant plasma cells from nine patients with multiple myeloma (MM) and eight myeloma cell lines to those of highly purified nonmalignant plasma cells (eight samples) obtained by in vitro differentiation of peripheral blood B cells. Two unsupervised clustering algorithms classified these 25 samples into two distinct clusters: a malignant plasma cell cluster and a normal plasma cell cluster. Two hundred and fifty genes were significantly up-regulated and 159 down-regulated in malignant plasma samples compared to normal plasma samples. For some of these genes, an overexpression or downregulation of the encoded protein was confirmed (cyclin D1, c-myc, BMI-1, cystatin c, SPARC, RB). Two genes over-expressed in myeloma cells (ABL and cystathionine beta synthase) code for enzymes that could be a therapeutic target with specific drugs. These data provide a new insight into the understanding of myeloma disease and prefigure that the development of DNA microarray could help to develop an 'a la carte' treatment in cancer disease.	CHU Montpellier, INSERM, U475, F-34000 Montpellier, France; CHU Montpellier, Serv Hematol & Oncol Med, F-34000 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34000 Montpellier, France; Mol Diagnost Lab, Dept Clin Biochem, DK-8200 Aarhus N, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier 5, France.		De Vos, John/A-5703-2010	De Vos, John/0000-0003-1880-4130				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Cornford PA, 2000, CANCER RES, V60, P7099; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; HIRST M, 1994, J BIOL CHEM, V269, P23830; Huang HT, 2000, CANCER RES, V60, P6868; Jego G, 1999, BLOOD, V94, P701, DOI 10.1182/blood.V94.2.701.414k16_701_712; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V91, P664; KANTARJIAN H, 1984, EUR J CANCER CLIN ON, V20, P227, DOI 10.1016/0277-5379(84)90188-3; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1991, BLOOD, V78, P1198; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pellat-Deceunynck C, 2000, EUR J IMMUNOL, V30, P803, DOI 10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P; PETTERSSON M, 1992, BLOOD, V79, P495; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Rao PH, 1998, BLOOD, V92, P1743; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tanaka K, 2001, BBA-MOL BASIS DIS, V1536, P1, DOI 10.1016/S0925-4439(01)00026-6; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Taub JW, 2000, CANCER RES, V60, P6421; Taub JW, 1999, BLOOD, V94, P1393; Taub JW, 1996, BLOOD, V87, P3395, DOI 10.1182/blood.V87.8.3395.bloodjournal8783395; Thykjaer T, 2001, CANCER RES, V61, P2492; van Golen KL, 2000, CANCER RES, V60, P5832; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	47	135	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6848	6857		10.1038/sj.onc.1205868	http://dx.doi.org/10.1038/sj.onc.1205868			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360412				2022-12-28	WOS:000178315800016
J	Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y				Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y			Ku affects the ATM-dependent S phase checkpoint following ionizing radiation	ONCOGENE			English	Article						ku; ATM; S phase checkpoint; ionizing radiation	DOUBLE-STRAND BREAKS; DNA END BINDING; PROTEIN-KINASE; V(D)J RECOMBINATION; ATAXIA-TELANGIECTASIA; REPAIR; DAMAGE; CELLS; INVOLVEMENT; SENSITIVITY	Following exposure to genotoxic stress, proliferating cells actively slow down DNA replication through an S phase checkpoint to provide time for repair. The ATM-dependent pathway plays an important role in the S phase checkpoint response following ionizing irradiation. We report that there is a stronger S phase checkpoint response in irradiated Ku80(-/-) cells as compared with their wild-type counterparts, which has no relationship to DNA-dependent protein kinase (DNA-PK) activity but correlates with a higher ATM activity and with more ATM bound to chromatin DNA in such cells. Wortmannin, a nonspecific inhibitor of ATM, not only reduces the higher activity of ATM kinase, but also abolishes the stronger S phase checkpoint response in Ku80(-/-) cells. Furthermore, a specific ATM antisense oligonucleotide abolishes the stronger S checkpoint response in Ku80(-/-) cells and renders these cells practically indistinguishable from Ku80(+/+) cells for this endpoint. These results in aggregate indicate that the stronger S checkpoint in irradiated Ku80(-/-) cells is due to the higher ATM kinase activity.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; Univ Essen Gesamthsch, Sch Med, Inst Med Radiat Biol, D-45122 Essen, Germany	Jefferson University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Duisburg Essen	Wang, Y (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,B1,1020 Sansom St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 56909, CA 50519, CA76203, T32-CA09137, P30-CA56036] Funding Source: Medline; NIA NIH HHS [AG18949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, T32CA009137, R37CA050519, R29CA076203, R01CA056909, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Dibiase SJ, 2000, CANCER RES, V60, P1245; DYCK EV, 1999, NATURE, V401, P728; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; WANG Y, 1992, CANCER RES, V52, P508; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	32	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6377	6381		10.1038/sj.onc.1205782	http://dx.doi.org/10.1038/sj.onc.1205782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214278				2022-12-28	WOS:000177829000014
J	Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N				Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N			Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells	ONCOGENE			English	Article						apoptosis; caspases; doxorubicin; caspase-8; neuroblastoma	DRUG-INDUCED APOPTOSIS; WILD-TYPE P53; CHEMOTHERAPEUTIC DRUGS; CANCER-THERAPY; PATHWAYS; FAS; MITOCHONDRIA; EXPRESSION; RESISTANCE; TRIGGERS	Death induced by doxorubicin (dox) in neuroblastoma (NB) cells was originally thought to occur via the Fas pathway, however since studies suggest that caspase-8 expression is silenced in most high stage NB tumors, it is more probable that dox-induced death occurs via a different mechanism. Caspase-8 silenced N-type invasive NB cell tines LAN-1 and IMR-32 were investigated for their sensitivity to dox, and compared to S-type noninvasive SH-EP NB cells expressing caspase-8. All cell lines had similar sensitivities to dox, independently of caspase-8 expression. Dox induced caspase-3, -7, -8 and -9 and Bid cleavage in S-type cells and death was blocked by caspase inhibitors but not by oxygen radical scavenger BHA. In contrast, dox-induced death in N-type cells was caspase-independent and was inhibited by BHA. Dox induced a drop in mitochondrial membrane permeability in all cell lines. Dox-induced death in S-type cells gave rise to apoptotic nuclei, whereas in N-type cells nuclei were non-apoptotic in morphology. Transfection of SH-EP cells with a dominant negative FADD mutant inhibited TRAIL-induced death, but had no effect on dox-induced apoptosis. These results suggest that S-type cells undergo apoptosis after dox treatment independently of death receptors, whereas N-type cells are killed by a caspase-independent mechanism.	CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Gross, N (corresponding author), CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland.		Mühlethaler-Mottet, Annick/H-2848-2019	Mühlethaler-Mottet, Annick/0000-0001-8274-0907				Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Ferreira CG, 2000, CANCER RES, V60, P7133; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldman SC, 1996, AM J PATHOL, V148, P1381; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Kataoka T, 1998, J IMMUNOL, V161, P3936; LaQuaglia MP, 1996, J PEDIATR SURG, V31, P315, DOI 10.1016/S0022-3468(96)90025-1; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McKenzie PP, 1999, CLIN CANCER RES, V5, P4199; Miyazaki K, 2001, J BIOCHEM-TOKYO, V129, P963, DOI 10.1093/oxfordjournals.jbchem.a002944; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Oue T, 1996, J PEDIATR SURG, V31, P251, DOI 10.1016/S0022-3468(96)90009-3; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spix C, 2001, EUR J CANCER, V37, P722, DOI 10.1016/S0959-8049(01)00003-X; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	28	40	42	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6132	6137		10.1038/sj.onc.1205879	http://dx.doi.org/10.1038/sj.onc.1205879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203125				2022-12-28	WOS:000177671300016
J	Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro	ONCOGENE			English	Article						extracellular signal regulated kinase; invasion; gliomas; stable transfectants; MMP-9	ACTIVATED PROTEIN-KINASE; HUMAN GLIOBLASTOMA CELLS; IV COLLAGENASE GENE; TRANSCRIPTION FACTOR; GELATINASE-B; C-JUN; HA-RAS; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INVASIVENESS	We previously showed that enhanced expression of MMP-9, an endopeptidase that digests basement-membrane type IV collagen, is related to tumor progression in vitro and in vivo; antisense-MMP-9 stably transfected clones were less invasive than untransfected parental cells and did not form tumors in nude mice. In this study, we examined the role of ERK-1 in the regulation of MMP-9 production and the invasive behavior of the human glioblastoma cell line SNB19, in which ERK1 is constitutively activated. SNB19 cells were stably transfected with mt-ERK, a vector encoding ERK-1 cDNA in which the conserved lysine at codon 71 was changed to arginine, thus impairing the catalytic efficiency of this enzyme. Gelatin zymography showed reduced levels of MMP-9 in the mt-ERK-transfected cell lines relative to those in vector-transfected and parental control cells. Reductions in MMP-9 protein mRNA levels were also detected in the mt-ERK-transfected cells by Western and Northern blotting. The mt-ERK-transfected cells were much less invasive than parental or vector control cells in a Matrigel invasion assay and in a spheroid coculture assay. Thus an ERK-dependent signaling pathway seems to regulate MMP-9 mediated glioma invasion in SNB19 cells; interfering with this pathway could be developed into a therapeutic approach, which aims at a reduction of cancer cell invasion.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76350, CA75557, CA-85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL S, 1995, ONCOGENE, V11, P427; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Forsyth PA, 1998, J NEURO-ONCOL, V36, P21, DOI 10.1023/A:1005879027267; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Genersch E, 2000, J CELL SCI, V113, P4319; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Simon C, 1998, CANCER RES, V58, P1135; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOZERI O, 1992, ONCOGENE, V7, P2259; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	38	92	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5601	5608		10.1038/sj.onc.1205646	http://dx.doi.org/10.1038/sj.onc.1205646			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165859				2022-12-28	WOS:000177442000010
J	Tsou, JA; Hagen, JA; Carpenter, CL; Laird-Offringa, IA				Tsou, JA; Hagen, JA; Carpenter, CL; Laird-Offringa, IA			DNA methylation analysis: a powerful new tool for lung cancer diagnosis	ONCOGENE			English	Article						lung cancer; methylation; CpG island; diagnosis; hypermethylation	TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; CPG-ISLAND METHYLATION; CELL-LINES; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; EPIGENETIC INACTIVATION; ADVANCED-STAGE; EARLY EVENT; DAP-KINASE; HYPERMETHYLATION	Carcinoma of the lung is the most common cause of cancer death worldwide. The estimated 5-year survival ranges from 6-16%, depending on the cell type. The best opportunity for improving survival of lung cancer patients is through early detection, when curative surgical resection is possible. Although the subjects at increased risk for developing carcinoma of the lung (long-term smokers) can be identified, only 10-20% of this group will ultimately develop the disease. Screening tests of long-term smokers employed to date (radiography and sputum cytology) have not been successful in reducing lung cancer mortality. The application of molecular markers specific for lung cancer offers new possibilities for early detection. Hypermethylation of CpG islands in the promoter regions of genes is a common phenomenon in lung cancer, as demonstrated by the analysis of the methylation status of over 40 genes from lung cancer tumors, cell lines, patient sputum and/or serum. Determination of the methylation patterns of multiple genes to obtain complex DNA methylation signatures promises to provide a highly sensitive and specific tool for lung cancer diagnosis. When combined with the development of non-invasive methods to detect such signatures, this may provide a viable method to screen subjects at risk for lung cancer.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Laird-Offringa, IA (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, NOR 6420,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	ilaird@hsc.usc.edu	Carpenter, Catherine L/E-5834-2015; Offringa, Ite/R-4101-2019	Carpenter, Catherine L/0000-0001-8334-4084; 				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; [Anonymous], 1999, CANC INCIDENCE SURVI; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Belinsky SA, 1998, EXP LUNG RES, V24, P463, DOI 10.3109/01902149809087381; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BLACK WC, 1999, CANC SCREENING THEOR, P327; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eguchi K, 1997, CANCER RES, V57, P4913; Elias AD, 1997, CHEST, V112, pS251, DOI 10.1378/chest.112.4_Supplement.251S; Ellis JRC, 2001, BRIT J RADIOL, V74, P478, DOI 10.1259/bjr.74.882.740478; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Feng G, 2001, CANCER RES, V61, P7999; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; FLATAU E, 1983, CANCER RES, V43, P4901; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GAMOU S, 1988, JPN J CANCER RES, V79, P989, DOI 10.1111/j.1349-7006.1988.tb00065.x; GANDERTON RH, 1995, EUR J CANCER, V31A, P1697, DOI 10.1016/0959-8049(95)00351-I; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Herman JG, 1996, CANCER RES, V56, P722; Hou M, 1999, INT J CANCER, V84, P609, DOI 10.1002/(SICI)1097-0215(19991222)84:6<609::AID-IJC12>3.0.CO;2-Q; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Issa JPJ, 1996, CANCER RES, V56, P3655; Jang SJ, 2001, CANCER RES, V61, P7959; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LEON SA, 1977, CANCER RES, V37, P646; Marcus PM, 2001, J CLIN ONCOL, V19, p83S; Markl IDC, 2001, CANCER RES, V61, P5875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nagatake M, 1996, CANCER RES, V56, P1886; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Ng CSH, 2002, J SURG ONCOL, V79, P101, DOI 10.1002/jso.10046; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Osada H, 2001, CANCER RES, V61, P8331; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Palmisano WA, 2000, CANCER RES, V60, P5954; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; ROBERTSON KD, 2001, ONCOGENE, V30, P3189; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Seike M, 2000, CLIN CANCER RES, V6, P4307; SIEGMUND KD, 2002, IN PRESS METHODS; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Stirzaker C, 1997, CANCER RES, V57, P2229; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Tanaka H, 1998, INT J CANCER, V79, P111, DOI 10.1002/(SICI)1097-0215(19980417)79:2<111::AID-IJC2>3.0.CO;2-W; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, MOL CANCER THER, V1, P61; TRAVIS WD, 1996, LUNG CANC PRINCIPLES, P361; Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268; Usadel H, 2002, CANCER RES, V62, P371; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wain J C, 1986, Curr Surg, V43, P489; Ward AM, 2001, ANN CLIN BIOCHEM, V38, P633, DOI 10.1258/0004563011901055; *WHO, 1982, WORLD HLTH ORG; Williams M D, 2001, Cancer Treat Res, V105, P31; Wolf P, 2001, CANCER RES, V61, P8113; Woodson K, 2001, CANCER EPIDEM BIOMAR, V10, P69; Xu XL, 2001, CANCER RES, V61, P7943; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	100	210	224	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5450	5461		10.1038/sj.onc.1205605	http://dx.doi.org/10.1038/sj.onc.1205605			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154407				2022-12-28	WOS:000177197700011
J	Zou, TT; Selaru, FM; Xu, Y; Shustova, V; Yin, J; Mori, Y; Shibata, D; Sato, F; Wang, SM; Olaru, A; Deacu, E; Liu, TC; Abraham, JM; Meltzer, SJ				Zou, TT; Selaru, FM; Xu, Y; Shustova, V; Yin, J; Mori, Y; Shibata, D; Sato, F; Wang, SM; Olaru, A; Deacu, E; Liu, TC; Abraham, JM; Meltzer, SJ			Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon	ONCOGENE			English	Article						colon cancer; cDNA microarrays; cluster analysis; gene filtering	TRANSCRIPTIONAL PROGRAM; EXPRESSION PATTERNS; RECEPTOR; BREAST; CELLS; FIBROBLASTS; CARCINOMA; SUBTYPES; MITOGEN; TUMORS	In order to discover global gene expression patterns characterizing subgroups of colon cancer, microarrays were hybridized to labeled RNAs obtained from seventeen colonic specimens (nine carcinomas and eight normal samples). Using a hierarchical agglomerative method, the samples grouped naturally into two major clusters, in perfect concordance with pathological reports (colon cancer versus normal colon). Using a variant of the unpaired t-test, selected genes were ordered according to an index of importance. In order to confirm microarray data, we performed quantitative, real-time reverse transcriptase - polymerase chain reaction (TaqMan RT-PCR) on RNAs from 13 colorectal tumors and 13 normal tissues (seven of which were matched normal-tumor pairs). RT-PCR was performed on the gro1, B-factor, adlican, and endothelin converting enzyme-1 genes and confirmed microarray findings. Two hundred and fifty genes were identified, some of which were previously reported as being involved in colon cancer. We conclude that cDNA microarraying, combined with bioinformatics tools, can accurately classify colon specimens according to current histopathological taxonomy. Moreover, this technology holds promise of providing invaluable insight into specific gene roles in the development and progression of colon cancer. Our data suggests that a large-scale approach may be undertaken with the purpose of identifying biomarkers relevant to cancer progression.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Div Surg Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Room N3W62,22 S Green St, Baltimore, MD 21201 USA.			Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA85069, CA95323] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085069, R01CA095323, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SI, 2000, AM J RESP CELL MOL, V22, P422, DOI 10.1165/ajrcmb.22.4.3795; Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; American Cancer Society, 2000, CANC FACTS FIG; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Elek J, 2000, IN VIVO, V14, P173; GRAMMATICO P, 1995, WORLD J SURG, V19, P350, DOI 10.1007/BF00299156; Ikeda Y, 2001, ONCOLOGY-BASEL, V61, P168, DOI 10.1159/000055369; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; MELTZER SJ, 1989, EXP MOL PATHOL, V51, P264, DOI 10.1016/0014-4800(89)90024-5; Nicke B, 1999, GUT, V45, P51, DOI 10.1136/gut.45.1.51; PATEL KV, 1995, BRIT J CANCER, V71, P442, DOI 10.1038/bjc.1995.90; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson S, 2001, NEUROSURGERY, V48, P864, DOI 10.1097/00006123-200104000-00035; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Sogawa K, 1997, CANCER LETT, V112, P263, DOI 10.1016/S0304-3835(96)04589-2; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stewart LV, 1997, EXP CELL RES, V233, P321, DOI 10.1006/excr.1997.3569; Takakura S, 2001, INT J ONCOL, V18, P817; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang QD, 2000, ANTICANCER RES, V20, P75	31	120	136	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4855	4862		10.1038/sj.onc.1205613	http://dx.doi.org/10.1038/sj.onc.1205613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101425				2022-12-28	WOS:000176716300016
J	Korus, M; Mahon, GM; Cheng, L; Whitehead, IP				Korus, M; Mahon, GM; Cheng, L; Whitehead, IP			p38 MAPK-mediated activation of NF-kappa B by the RhoGEF domain of Bcr	ONCOGENE			English	Article						Bcr; RhoGEF; Dbl proteins; NF-kappa B; p38 MAPK	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; RAC SIGNALING PATHWAYS; GTP-BINDING PROTEINS; DBL HOMOLOGY DOMAIN; C-ABL PROTEIN; PHILADELPHIA-CHROMOSOME; CELL-CYCLE; FOCAL ADHESIONS	The oncogenic fusion protein p210 Bcr-Abl is causally associated with virtually all cases of chronic myelogenous leukemia. The wild-type Bcr product has several recognizable structural and functional motifs including a domain that contains guanine nucleotide exchange activity for Rho family GTPases (DH/PH domain). Although this domain is retained within p210 Bcr-Abl, it has no known signaling activities in vivo. Here we report that a fragment of Bcr that encodes the isolated DH/PH domain is a potent activator of the NF-kappaB transcription factor. Within the context of full length Bcr, this activity is regulated by proximal flanking sequences that suppress the DH/PH domain encoded guanine nucleotide exchange activity. NF-kappaB activation by Bcr is not mediated by nuclear translocation, but rather by p38 mitogen-activated protein kinase (MAPK)-dependent modification of the RelA/p65 transactivation domain. Although we were able to demonstrate that Bcr can function as an exchange factor for Cdc42 in vivo, NF-kappaB activation appears to occur via a Cdc42-independent mechanism. These studies constitute direct evidence that the Bcr RhoGEF domain can function in vivo, and identify a new signaling activity that may contribute to the transforming potential of p210 Bcr-Abl.	Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Newark, NJ 07103 USA.				NATIONAL CANCER INSTITUTE [R29CA077493] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kin Y, 2001, J BIOL CHEM, V276, P39462, DOI 10.1074/jbc.M105484200; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Leung T, 1996, MOL CELL BIOL, V16, P5313; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Maru Y, 1999, BIOCHEM BIOPH RES CO, V260, P309, DOI 10.1006/bbrc.1999.0822; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RON D, 1991, NEW BIOL, V3, P372; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; WHITEHEAD JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, pF1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	63	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4601	4612		10.1038/sj.onc.1205678	http://dx.doi.org/10.1038/sj.onc.1205678			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096337				2022-12-28	WOS:000176625100002
J	Vooijs, M; te Riele, H; van der Valk, M; Berns, A				Vooijs, M; te Riele, H; van der Valk, M; Berns, A			Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells	ONCOGENE			English	Article						Rb; p107; Trp53; conditional knockout; retinoblastoma; photoreceptor cells	SITE-SPECIFIC RECOMBINATION; HUMAN PITUITARY-TUMORS; TRANSGENIC MICE; MOUSE RETINA; CRE RECOMBINASE; MUTANT MICE; RB; P53; DIFFERENTIATION; MUTATIONS	The retinoblastoma suppressor gene product Rb has been assigned a critical role in cell cycle regulation, the induction of differentiation, and inhibition of oncogenic transformation. Inheritance of a mutant RB allele in humans is responsible for bilateral retinoblastoma, a malignant tumor of the retina. Trilateral retinoblastoma (TRB) is a rare variant of familial retinoblastoma in which, in addition to retinal tumors, tumors develop from the pineal gland, an organ ontologically related to the retina. Germline inactivation of Rb in mice leads to mid-gestational lethality with defects in erythropoeisis and neurogenesis. This embryonic lethality prohibits the analysis of Rb function in selected cell types at later stages of development or in the adult. Here, we describe the Cre-LoxP mediated somatic inactivation of Rb in a subset of neuroendocrine cells, including photoreceptor cells. We observed neuroendocrine tumors of the pineal and pituitary gland. These tumors invariably showed inactivation of Rb and Trp53. Remarkably, loss of Rb in photoreceptor cells does not lead to retinoblastoma or any phenotypic changes, not even when photoreceptor cells are made deficient in Rb, p107 and Trp53. Our results highlight the important differences that exist in tumor susceptibility between mice and man (e.g pineal gland) and question the photoreceptor cell origin of human retinoblastoma.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl	Vooijs, Marc/K-3522-2019					Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Claudio PP, 2000, CANCER RES, V60, P372; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gallie BL, 1999, CANCER RES, V59, p1731S; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GONZALEZFERNANDEZ F, 1992, AM J PATHOL, V141, P363; Griep AE, 1998, INVEST OPHTH VIS SCI, V39, P2723; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBIEC FA, 1977, CANCER-AM CANCER SOC, V39, P2048, DOI 10.1002/1097-0142(197705)39:5<2048::AID-CNCR2820390522>3.0.CO;2-9; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MARGO C, 1983, ARCH OPHTHALMOL-CHIC, V101, P1519, DOI 10.1001/archopht.1983.01040020521003; Marino S, 2000, GENE DEV, V14, P994; Metzger D, 1999, CURR OPIN BIOTECH, V10, P470, DOI 10.1016/S0958-1669(99)00012-9; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NORK TM, 1995, ARCH OPHTHALMOL-CHIC, V113, P791, DOI 10.1001/archopht.1995.01100060117046; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBANUSMAANDAG EC, 1994, EMBO J, V13, P4260; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tsumanuma I, 1995, Noshuyo Byori, V12, P39; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F; WOLOSCHAK M, 1994, CANCER, V74, P693, DOI 10.1002/1097-0142(19940715)74:2<693::AID-CNCR2820740223>3.0.CO;2-P; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1985, DEV BRAIN RES, V21, P229, DOI 10.1016/0165-3806(85)90211-1	53	58	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4635	4645		10.1038/sj.onc.1205575	http://dx.doi.org/10.1038/sj.onc.1205575			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096340				2022-12-28	WOS:000176625100005
J	Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M				Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M			Constitutive activation of NF-kappa B in Ki-ras-transformed prostate epithelial cells	ONCOGENE			English	Article						Kirsten-ras (Ki-Ras); nuclear factor-kappa B; I-kappa B (I kappa,B); I kappa B kinase (IKK)	KINASE COMPLEX; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; INCONTINENTIA PIGMENTI; LIVER DEGENERATION; DEFICIENT MICE; ERK ACTIVITY; BETA; ONCOGENE; PROTEIN	The signaling pathway responsible for the activation of nuclear factor-kappaB (NF-kappaB) by oncogenic forms of Ras remains unclear. Both, the transactivation and DNA binding activities of NF-kappaB, were increased in 267B1 human prostate epithelial cells transformed by viral Kirsten-ras (267B1/Ki-ras cells) compared with those in the parental cells. This increased NF-kappaB activity was attributed to a heterodimeric complex of p50 and p65 subunits. Although the abundance of the inhibitor protein IkappaBbeta was higher in 267B1/Ki-ras cells than in 267B1 cells, an electrophoretic mobility-shift assay suggested that IkappaBalpha is responsible for the activation of NF-kappaB in the former cells. Consistent with this notion, the phosphorylation of IkappaBalpha appeared increased in 267B1/Ki-ras cells, and the proteasome inhibitor I abolished the constitutive activation of NF-kappaB in these cells. The expression of dominant negative mutants of either NIK (NF-kappaB-inducing kinase) or IKKbeta (IkappaB kinase beta) inhibited the activity of NF-kappaB in 267B1/Ki-ras cells. Furthermore, chemical inhibitors specific for Ras activation, sulindac sulfide and farnesytranferase inhibitor 1, markedly reduced IkappaBalpha phosphorylation and NF-kappaB activation in the Ki-ras-transformed cells while transfection of these cells with NIK or IKKbeta counteracted the inhibitory effect on NF-kappaB activation. These results suggest that oncogenic Ki-Ras induces transactivation of NF-kappaB through the NIK-IKKbeta-IkappaBalpha pathway.	Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA; Univ Texas, SW Med Ctr, Dept Med, Harold Simmons Canc Ctr, Dallas, TX 75235 USA	Georgetown University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jung, M (corresponding author), Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Janssen YMW, 1999, METHOD ENZYMOL, V300, P363; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin YB, 1998, INT J COMMUN SYST, V11, P1; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILLS NE, 1995, CANCER RES, V55, P1444; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Ozes ON, 1999, NATURE, V401, P82; PARDA DS, 1993, PROSTATE, V23, P91, DOI 10.1002/pros.2990230202; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SUKUMAR S, 1991, MOL CARCINOGEN, V4, P362, DOI 10.1002/mc.2940040507; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4490	4497		10.1038/sj.onc.1205547	http://dx.doi.org/10.1038/sj.onc.1205547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085227				2022-12-28	WOS:000176476700003
J	Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F				Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F			Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer	ONCOGENE			English	Article						erbA; thyroid receptor genes; thyroid hormone; breast cancer; mutation	MOUSE MAMMARY-GLANDS; C-ERBA-BETA; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; V-ERBA; ESTROGEN; TUMORS; AMPLIFICATION; MUTATIONS; PROMOTER	The relation between thyroid status and diseases and cancer is unclear. No detailed analysis of thyroid hormone receptor (TR) expression in human breast cancer has been reported. We have analysed the expression and mutational status of the TRalpha1, encoded by the c-erbA proto-oncogene, TRbeta1 and TRbeta2 isoforms in 70 sporadic breast cancers. Alterations in the RNA level of TRbeta1, TRalpha1, or both were found in a number of patients. No expression of TRbeta2 RNA was detected. Western blotting analysis confirmed the differences in expression at the protein level in those cases where sufficient tumor sample was available. Additionally, tumor-specific truncated TRbeta1 RNA was found in six patients. Strikingly, three transcripts shared the same breakpoint. Only one tumor carried the corresponding deletion at the genomic DNA level, suggesting that the remaining abnormal TR[11 transcripts are aberrant splicing products. Though no significant correlation was found between TRbeta1 alteration and any clinical parameter, it showed a tendency to associate with early age of onset (<50 years). Our results reveal specific alterations in the expression of TRbeta and TRalpha genes in a subset of breast cancer patients, suggesting that deregulation of thyroid hormone target genes may be involved in the generation of this neoplasia.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.	felixbv@stnet.es	Munoz, Alberto/O-6393-2014; Gonzalez-Sancho, Jose/AAA-6010-2019	Munoz, Alberto/0000-0003-3890-4251; Gonzalez-Sancho, Jose/0000-0001-5875-1964				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARBUTHNOT P, 1989, ANTICANCER RES, V9, P885; Armitage P., 1987, STAT METHODS MED RES; Ballinger SW, 1996, CANCER RES, V56, P5692; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BURKE RE, 1978, CANCER RES, V38, P3769; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CERBON MA, 1981, CANCER RES, V41, P4167; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CIDLOWSKI JA, 1975, ENDOCRINOLOGY, V97, P59, DOI 10.1210/endo-97-1-59; Collingwood TN, 1998, EMBO J, V17, P4760, DOI 10.1093/emboj/17.16.4760; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DOBROVIC A, 1988, CANCER RES, V48, P682; Dressel U., 2001, NUCL RECEPTORS DIS, P59; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V166, P155, DOI 10.1016/S0303-7207(00)00328-2; FEI ZL, 1992, ENDOCRINOLOGY, V130, P1145; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; FUTREAL PA, 1994, CANCER RES, V54, P1791; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gonzalez-Sancho JM, 1999, MOL CARCINOGEN, V24, P99, DOI 10.1002/(SICI)1098-2744(199902)24:2<99::AID-MC4>3.0.CO;2-#; GUERNSEY DL, 1993, CANCER J - FRANCE, V6, P253; HEDLEY AJ, 1981, LANCET, V1, P131; HOUDEBINE LM, 1978, BIOCHIMIE, V60, P809, DOI 10.1016/S0300-9084(78)80027-3; HuberGieseke T, 1997, ONCOLOGY, V54, P214; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x; Lukas J, 2001, CANCER RES, V61, P3212; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MARTINEZ L, 1995, EUR J ENDOCRINOL, V132, P673, DOI 10.1530/eje.0.1320673; Martinez MB, 2000, CANCER CHEMOTH PHARM, V45, P93, DOI 10.1007/s002800050016; McCabe CJ, 1999, J CLIN ENDOCR METAB, V84, P649, DOI 10.1210/jc.84.2.649; Munoz A, 1997, EUR J ENDOCRINOL, V137, P433, DOI 10.1530/eje.0.1370433; Nogueira CR, 1996, J STEROID BIOCHEM, V59, P271, DOI 10.1016/S0960-0760(96)00117-3; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SELLITTI DF, 1983, CANCER RES, V43, P1030; SINGH DV, 1969, J ENDOCRINOL, V45, P579, DOI 10.1677/joe.0.0450579; SMALLRIDGE RC, 1980, CLIN RES, V28, pA421; Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335; Smyth PPA, 1996, J CLIN ENDOCR METAB, V81, P937, DOI 10.1210/jc.81.3.937; Strain JJ, 1997, NUTR CANCER, V27, P48, DOI 10.1080/01635589709514500; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; Vasudevan N, 2001, MOL BRAIN RES, V95, P9, DOI 10.1016/S0169-328X(01)00165-6; Vasudevan N, 2001, J NEUROENDOCRINOL, V13, P779, DOI 10.1046/j.1365-2826.2001.00693.x; VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409; VONDERHAAR BK, 1986, ENDOCRINOLOGY, V119, P580, DOI 10.1210/endo-119-2-580; VONDERHAAR BK, 1977, ENDOCRINOLOGY, V100, P1423, DOI 10.1210/endo-100-5-1423; WALLIN G, 1992, THYROID, V2, P307, DOI 10.1089/thy.1992.2.307; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Yokoe T, 1997, ANTICANCER RES, V17, P695; Zhu YS, 1996, P NATL ACAD SCI USA, V93, P12587, DOI 10.1073/pnas.93.22.12587	63	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4307	4316		10.1038/sj.onc.1205534	http://dx.doi.org/10.1038/sj.onc.1205534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082618				2022-12-28	WOS:000176174200013
J	Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K				Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K			Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells	ONCOGENE			English	Article						A3 adenosine receptor; IB-MECA; cAMP; Wnt pathway; GSK-3 beta	A3 ADENOSINE RECEPTOR; GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; BETA-CATENIN; PHOSPHORYLATION; TELOMERASE; ACTIVATION; INSULIN; MUSCLE; CAMP	The A3 adenosine receptor, A3AR, belongs to the family of Gi proteins, which upon induction, suppresses the formation of cAMP and its downstream effectors. Recent studies have indicated that activation of A3AR by its agonist, IB-MECA, results in growth inhibition of malignant cells. Here we demonstrate the ability of IB-MECA to decrease the levels of protein kinase A, a downstream effector of cAMP, and protein kinase B/Akt in melanoma cells. Examination of glycogen synthase kinase 3beta, GSK-3beta, whose phosphorylation is controlled by protein kinase A and B, showed a substantial decrease in the levels of its phosphorylated form and an increase in total GSK-3beta levels in IB-MECA treated melanoma cells. This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3beta in the cells. Evaluation of beta-catenin, a key component of Wnt signaling pathway which, upon phosphorylation by GSK-3beta rapidly ubiquitinates, showed a substantial decrease in its level after IB-MECA treatment. Accordingly, the level of beta-catenin responsive cell growth regulatory genes including c-myc and cyclin D1 was severely declined upon treatment of the cells with IB-MECA. These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists.	Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel; Can Fite Biopharma Ltd, Kiryat Matalon, Petach Tikva, Israel; Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishman, P (corresponding author), Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel.	pfishman@post.tau.ac.il	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				AUSUBEL F, 1989, CURRENT PROTOCOLS MO, P342; Bar-Yehuda S, 2001, NEOPLASIA, V3, P125, DOI 10.1038/sj.neo.7900138; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fishman P, 1998, CANCER RES, V58, P3181; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fishman P, 2000, EUR J CANCER, V36, P1452, DOI 10.1016/S0959-8049(00)00130-1; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; McEwen DG, 2000, CURR BIOL, V10, pR562, DOI 10.1016/S0960-9822(00)00611-4; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; OHANA G, 2000, J CELLULAR PHYSL, V186, P19; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; STILES GL, 1990, CLIN RES, V38, P10; Zhao ZH, 2000, BBA-MOL BASIS DIS, V1500, P280, DOI 10.1016/S0925-4439(99)00111-8	27	92	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4060	4064		10.1038/sj.onc.1205531	http://dx.doi.org/10.1038/sj.onc.1205531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037688				2022-12-28	WOS:000175869900012
J	Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS				Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS			Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis	ONCOGENE			English	Article						mitochondria; apoptosis; TRAIL; cytochrome c; Bax	FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C; TUMORICIDAL ACTIVITY; CRYSTAL-STRUCTURE; NECROSIS; LIGAND; RECEPTOR; EXPRESSION; TRANSLOCATION; SENSITIVITY	Mitochondrion is one of the master players in both apoptosis and necrosis. We studied the role of mitochondrial function in TRAIL-induced apoptosis. TRAIL killed SK-Hep1 cells with characteristic features of apoptosis such as DNA fragmentation, sub-G1 ploidy peak and cytochrome c translocation. In contrast, mitochondrial DNA-deficient SK-Hep1 rho(0) cells were resistant to TRAIL. Dissipation of mitochondrial potential or cytochrome e translocation did not occur in rho(0) cells after TRAIL treatment. TRAIL induced translocation of Bax subsequent to the cleavage of Bid in parental cells. However, Bax translocation was absent in rho(0) cells, accounting for the failure of cytochrome c release in rho(0) cells. Forced expression of Bax induced caspase-3 activity in rho(0) cells. Incubation of rho(0) cells with ADP+Pi to increase intracellular ATP restored sensitivity to TRAIL. Despite different sensitivity to TRAIL, parental cells and rho(0) cells did not show significant difference in susceptibility to agonistic anti-Fas antibody, TNF-alpha or staurosporine. Our results indicate that TRAIL-induced apoptosis is dependent on intact mitochondrial function and susceptibility of mitochondrial DNA-deficient cells to apoptosis depends on the type of apoptotic stimuli. Tumor cells with mitochondrial mutations or dysfunction might have the ability to evade tumor surveillance imposed by TRAIL in vivo.	Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, Seoul 135710, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Natl Inst Hlth, Div Metab Dis, Dept Biomed Sci, Eunpyung Ku, Seoul 122710, South Korea; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Pohang University of Science & Technology (POSTECH); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Juntendo University; Gwangju Institute of Science & Technology (GIST); Yonsei University	Lee, MS (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, 50 Irwon Dong, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Pak, Youngmi Kim/AAI-1091-2020; Oh, Byung-Ha/C-2061-2011; Lee, Myung Shik/C-9606-2011	Pak, Youngmi Kim/0000-0001-7424-3484; Lee, Myung-Shik/0000-0003-3292-1720				ALBERTS B, 1994, GARLAND PUB INC NEW, V3, P568; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kayagaki N, 1999, J IMMUNOL, V163, P1906; KERR JFR, 1995, METHOD CELL BIOL, V46, P1; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RUBIN BY, 1988, CANCER RES, V48, P6006; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, CANCER RES, V56, P2161; SKOWRONEK P, 1992, BIOCHEM BIOPH RES CO, V187, P991, DOI 10.1016/0006-291X(92)91295-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thomas WD, 1998, J IMMUNOL, V161, P2195; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wuchter C, 2001, LEUKEMIA, V15, P921, DOI 10.1038/sj.leu.2402131; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	57	60	65	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3139	3148		10.1038/sj.onc.1205406	http://dx.doi.org/10.1038/sj.onc.1205406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082629				2022-12-28	WOS:000175373600005
J	Lerman, C; Niaura, R				Lerman, C; Niaura, R			Applying genetic approaches to the treatment of nicotine dependence	ONCOGENE			English	Review						genetics; smoking; nicotine; treatment	SEROTONIN TRANSPORTER GENE; SUSTAINED-RELEASE BUPROPION; DOPAMINE-RECEPTOR GENE; TRYPTOPHAN-HYDROXYLASE GENE; RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; CIGARETTE-SMOKING; NASAL SPRAY; TRANSDERMAL NICOTINE; DEPRESSIVE SYMPTOMS	To advance the science of tobacco control, an enhanced understanding of the bio-behavioral basis of nicotine addiction is needed. In this study, we provide an overview of data from investigations of genetic factors in smoking behavior, discuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessation treatment. The evidence to date is very consistent with respect to the significance of genetic contributions to smoking behavior. However, attempts to elucidate the role of specific genetic variants have met with mixed success. Explanations for the lack of consistency in the results of genetic association studies include biases in ascertainment, ethnic admixture, lack of attention to co-variates or modifiers of genetic risk, and the need for more refined phenotypes. As the field of genetics and smoking research progresses, increasing attention is being devoted to gene - environment interactions, with particular attention to the identification of genetic variants that may modify the effects of pharmacological treatment for smoking. With advances in molecular biology and genomics technology, individualized tailoring of smoking cessation therapy to genotype is within our grasp. Such research has the potential to improve treatment outcome, thereby reducing morbidity and mortality from smoking-related disease.	Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Brown Med Sch, Ctr Behav Med, Providence, RI 02903 USA; Brown Med Sch, Ctr Prevent Med, Providence, RI 02903 USA	University of Pennsylvania; University of Pennsylvania; Brown University; Brown University	Lerman, C (corresponding author), Univ Penn, Dept Psychiat, 3535 Mkt St,Suite 4100, Philadelphia, PA 19104 USA.	clerman@mail.med.upenn.edu	Niaura, Raymond/AAE-7319-2019	Niaura, Raymond/0000-0002-0856-3540	NCI NIH HHS [P50CA084719, R01 CA63562, P50 CA84718] Funding Source: Medline; NHLBI NIH HHS [R01 HL32318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063562, P50CA084718, P50CA084719] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; [Anonymous], 1991, JAMA, V266, P3133; Arinami T, 2000, EUR J PHARMACOL, V410, P215, DOI 10.1016/S0014-2999(00)00816-5; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395; Audrain J., 1998, J APPL BIOBEHAV RES, V3, P29, DOI DOI 10.1111/J.1751-9861.1998.TB00042.X; Balfour DJK, 2001, INT J CLIN PRACT, V55, P53; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Bierut LJ, 2000, AM J MED GENET, V90, P299, DOI 10.1002/(SICI)1096-8628(20000214)90:4<299::AID-AJMG7>3.0.CO;2-Y; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; Blondal T, 1997, EUR RESPIR J, V10, P1585, DOI 10.1183/09031936.97.10071585; Borrelli B, 1996, J CLIN PSYCHIAT, V57, P534; Bowles SV, 1999, PSYCHOSOM MED, V61, P104, DOI 10.1097/00006842-199901000-00117; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; *CDC, 1994, 43 CDC; *CDCP, 2000, 49 CDCP; CEPEDABENITO A, 1993, J CONSULT CLIN PSYCH, V61, P822, DOI 10.1037/0022-006X.61.5.822; CHASSIN L, 1986, DEV PSYCHOL, V22, P327, DOI 10.1037/0012-1649.22.3.327; Choi WS, 1997, AM J PREV MED, V13, P385, DOI 10.1016/S0749-3797(18)30159-4; CINCIRIPINI PM, 1995, J CLIN PSYCHOPHARM, V15, P182, DOI 10.1097/00004714-199506000-00006; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; CLONINGER CR, 1994, CURR OPIN NEUROBIOL, V4, P266, DOI 10.1016/0959-4388(94)90083-3; COHEN SJ, 1989, J AM DENT ASSOC, V118, P41, DOI 10.14219/jada.archive.1989.0018; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CONRAD KM, 1992, BRIT J ADDICT, V87, P1711; DALE LC, 1995, JAMA-J AM MED ASSOC, V274, P1353, DOI 10.1001/jama.274.17.1353; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; DAVID S, 2001, PRESENTATION SOC RES; Ebstein RP, 1997, MOL PSYCHIATR, V2, P472, DOI 10.1038/sj.mp.4000333; Eissenberg T, 2000, DRUG ALCOHOL DEPEN, V59, pS41; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; Fiore M C, 2000, Respir Care, V45, P1200; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FLAY BR, 1983, PEDIATRIC ADOLESCENT, P132; Flory JD, 1999, MOL PSYCHIATR, V4, P93, DOI 10.1038/sj.mp.4000466; FRIEDMAN LS, 1985, ADDICT BEHAV, V10, P1, DOI 10.1016/0306-4603(85)90048-6; GILBERT DG, 1995, BEHAV GENET, V25, P133, DOI 10.1007/BF02196923; Glassman AH, 2001, LANCET, V357, P1929, DOI 10.1016/S0140-6736(00)05064-9; Hall SM, 1996, J CONSULT CLIN PSYCH, V64, P1003, DOI 10.1037/0022-006X.64.5.1003; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; Heath AC, 1999, BEHAV GENET, V29, P395, DOI 10.1023/A:1021670703806; HEATH AC, 1993, ADDICT BEHAV, V18, P19, DOI 10.1016/0306-4603(93)90005-T; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; Hiatt RA, 1999, CANCER EPIDEM BIOMAR, V8, P957; HILLEMAN DE, 1994, J CLIN PHARMACOL, V34, P222, DOI 10.1002/j.1552-4604.1994.tb03989.x; HJALMARSON A, 1994, ARCH INTERN MED, V154, P2567, DOI 10.1001/archinte.154.22.2567; Hu S, 2000, MOL PSYCHIATR, V5, P181, DOI 10.1038/sj.mp.4000690; Hughes J R, 1999, Nicotine Tob Res, V1, P169, DOI 10.1080/14622299050011281; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; HUGHES JR, 1986, BEHAV THER, V17, P335, DOI 10.1016/S0005-7894(86)80066-1; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Hutchison KE, 2002, J ABNORM PSYCHOL, V111, P134, DOI 10.1037//0021-843X.111.1.134; JORENBY DE, 1995, JAMA-J AM MED ASSOC, V274, P1347, DOI 10.1001/jama.274.17.1347; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Jorm AF, 2000, AM J MED GENET, V96, P331, DOI 10.1002/1096-8628(20000612)96:3<331::AID-AJMG19>3.0.CO;2-0; Kandel DB, 2001, DRUG ALCOHOL DEPEN, V64, P233, DOI 10.1016/S0376-8716(01)00126-0; Kendler KS, 1999, PSYCHOL MED, V29, P299, DOI 10.1017/S0033291798008022; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Killen JD, 1996, J CONSULT CLIN PSYCH, V64, P1060, DOI 10.1037/0022-006X.64.5.1060; King G, 1997, SOC SCI MED, V45, P1075, DOI 10.1016/S0277-9536(97)00035-X; King TK, 1997, ANN BEHAV MED, V19, P301, DOI 10.1007/BF02892295; Lando HA, 1996, AM J PUBLIC HEALTH, V86, P1786, DOI 10.2105/AJPH.86.12.1786; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; Lerman C, 2000, MOL PSYCHIATR, V5, P189, DOI 10.1038/sj.mp.4000672; Lerman C, 1998, CANCER EPIDEM BIOMAR, V7, P253; Lerman C, 2001, AM J MED GENET, V105, P518, DOI 10.1002/ajmg.1476; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LIPKUS IM, 1994, HEALTH PSYCHOL, V13, P149, DOI 10.1037/0278-6133.13.2.149; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; Madden PAF, 1999, BEHAV GENET, V29, P423, DOI 10.1023/A:1021674804714; Malhotra AK, 1996, MOL PSYCHIATR, V1, P388; Manuck SB, 1999, BIOL PSYCHIAT, V45, P603, DOI 10.1016/S0006-3223(98)00375-8; Masse LC, 1997, ARCH GEN PSYCHIAT, V54, P62; McKinney EF, 2000, PHARMACOGENETICS, V10, P483, DOI 10.1097/00008571-200008000-00001; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; Niaura R, 2001, PSYCHOL ADDICT BEHAV, V15, P13, DOI 10.1037/0893-164X.15.1.13; NIAURA R, 2002, IN PRESS J CONSULT C; NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; Noble EP, 1998, AM J MED GENET, V81, P257, DOI 10.1002/(SICI)1096-8628(19980508)81:3<257::AID-AJMG10>3.0.CO;2-E; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; Ockene Judith K., 1993, Annals of Behavioral Medicine, V15, P135; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; Paoletti P, 1996, EUR RESPIR J, V9, P643, DOI 10.1183/09031936.96.09040643; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1500, DOI 10.2105/AJPH.80.12.1500; Perkins KA, 1996, EXP CLIN PSYCHOPHARM, V4, P166, DOI 10.1037/1064-1297.4.2.166; Perkins KA, 1999, PHARMACOL BIOCHEM BE, V64, P295, DOI 10.1016/S0091-3057(99)00085-4; Perkins KA, 2001, CNS DRUGS, V15, P391, DOI 10.2165/00023210-200115050-00005; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; Pickworth WB, 1996, J PHARMACOL EXP THER, V279, P450; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Pierce JP, 1999, TOB CONTROL, V8, P37, DOI 10.1136/tc.8.1.37; Piper M E, 2001, Nicotine Tob Res, V3, P291; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; Pomerleau C S, 1992, J Subst Abuse, V4, P143, DOI 10.1016/0899-3289(92)90014-O; Pomerleau CS, 1999, J ADDICT DIS, V18, P13, DOI 10.1300/J069v18n03_02; Pomerleau OF, 1998, PSYCHONEUROENDOCRINO, V23, P115, DOI 10.1016/S0306-4530(97)00074-7; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI 10.1001/jama.284.6.699; Royce JM, 1997, SOC SCI MED, V44, P359, DOI 10.1016/S0277-9536(96)00149-9; Sabol SZ, 1999, HEALTH PSYCHOL, V18, P7, DOI 10.1037/0278-6133.18.1.7; Sargent JD, 2000, TOB CONTROL, V9, P163, DOI 10.1136/tc.9.2.163; SCHNEIDER NG, 1995, ADDICTION, V90, P1671, DOI 10.1046/j.1360-0443.1995.901216719.x; Schneider NG, 1996, CLIN PHARMACOL THER, V60, P568, DOI 10.1016/S0009-9236(96)90153-8; Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453; Shiffman S, 2000, PSYCHOPHARMACOLOGY, V148, P33, DOI 10.1007/s002130050022; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; Silverman MA, 2000, AM J MED GENET, V96, P646, DOI 10.1002/1096-8628(20001009)96:5<646::AID-AJMG10>3.3.CO;2-N; Son BK, 1997, AM J EPIDEMIOL, V145, P110; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; Stallings MC, 1996, J PERS SOC PSYCHOL, V70, P127, DOI 10.1037/0022-3514.70.1.127; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Sullivan P F, 1999, Nicotine Tob Res, V1 Suppl 2, pS51; Sullivan PF, 2001, AM J MED GENET, V105, P479, DOI 10.1002/ajmg.1433; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268; *TRIP, 1998, NAT CANC I TOB RES I; True WR, 1999, ARCH GEN PSYCHIAT, V56, P655, DOI 10.1001/archpsyc.56.7.655; *US DHHS, 1998, SURG GEN REP; VANDENBERGH D, 2002, IN PRESS NICOTINE TO; Vandenbergh DJ, 1997, MOL PSYCHIATR, V2, P417, DOI 10.1038/sj.mp.4000309; Voorhees CC, 1996, PREV MED, V25, P277, DOI 10.1006/pmed.1996.0057; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Walton R, 2001, TRENDS MOL MED, V7, P70, DOI 10.1016/S1471-4914(01)01915-3; Wetter DW, 1999, J CONSULT CLIN PSYCH, V67, P555, DOI 10.1037/0022-006X.67.4.555; Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6	137	52	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7412	7420		10.1038/sj.onc.1205801	http://dx.doi.org/10.1038/sj.onc.1205801			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379882				2022-12-28	WOS:000178618000012
J	Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J				Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J			Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo	ONCOGENE			English	Article						tumor angiogenesis; Eph receptor tyrosine kinase; ephrin; soluble Eph receptor; vascular window model	ENDOTHELIAL GROWTH-FACTOR; SKIN WINDOW CHAMBERS; TYROSINE KINASE; CELL-ADHESION; MOUSE; EXPRESSION; EPHRINS; GENE; MORPHOGENESIS; LIGAND	The Eph family of receptor tyrosine kinases and their ligands, known as ephrins, play a crucial role in vascular development during embryogenesis. The function of these molecules in adult angiogenesis has not been well characterized. Here, we report that blocking Eph A class receptor activation inhibits angiogenesis in two independent tumor types, the RIP-Tag transgenic model of angiogenesis-dependent pancreatic islet cell carcinoma and the 4T1 model of metastatic mammary adenocarcinoma. Ephrin-A1 ligand was expressed in both tumor and endothelial cells, and EphA2 receptor was localized primarily in tumor-associated vascular endothelial cells. Soluble EphA2-Fc or EphA3-Fc receptors inhibited tumor angiogenesis in cutaneous window assays, and tumor growth in vivo. EphA2-Fc or EphA3-Fc treatment resulted in decreased tumor vascular density, tumor volume, and cell proliferation, but increased cell apoptosis. However, EphA2-Fc had no direct effect on tumor cell growth or apoptosis in culture, yet inhibited migration of endothelial cells in response to tumor cells, suggesting that the soluble receptor inhibited blood vessel recruitment by the tumor. These data provide the first functional evidence for Eph A class receptor regulation of pathogenic angiogenesis induced by tumors and support the function of A class Eph receptors in tumor progression.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98122 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Amersham Pharmacia Corp, St Louis, MO 63198 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@mcmail.vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036400] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047078] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA09592, 2P30CA68485] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07751-06] Funding Source: Medline; NICHD NIH HHS [HD36400] Funding Source: Medline; NIDDK NIH HHS [DK47078] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOMAA S, 1993, J CANCER RES CLIN, V119, P288, DOI 10.1007/BF01212727; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brekken RA, 1998, CANCER RES, V58, P1952; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Daniel TO, 1996, KIDNEY INT, V50, pS73; DANKORT DL, 1996, TRANSGENIC MODELS BR; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Goede V, 1998, ANTICANCER RES, V18, P2199; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; Kuehn R, 1999, PANCREAS, V18, P96, DOI 10.1097/00006676-199901000-00012; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Prewett M, 1999, CANCER RES, V59, P5209; PREZIOSI R, 1995, J COMP PATHOL, V113, P301, DOI 10.1016/S0021-9975(05)80117-3; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; ROCKWELL S, 1977, INT J RADIAT BIOL, V31, P153, DOI 10.1080/09553007714550171; ROCKWELL S, 1978, BRIT J CANCER, V37, P212; ROCKWELL S, 1981, CANCER RES, V41, P527; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1996, ANGIOGENESIS BREAST; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301	58	272	302	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7011	7026		10.1038/sj.onc.1205679	http://dx.doi.org/10.1038/sj.onc.1205679			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370823				2022-12-28	WOS:000178424900004
J	Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y				Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y			Localization of p0071-interacting proteins, plakophilin-related armadillo-repeat protein-interacting protein (PAPIN) and ERBIN, in epithelial cells	ONCOGENE			English	Article						p0071; catenin; ERBIN; ErbB2; PAPIN; PDZ	DOMAIN-CONTAINING PROTEIN; BASOLATERAL PDZ PROTEIN; GUANYLATE KINASE; SCAFFOLDING MOLECULE; BETA-CATENIN; JUNCTIONS; MAGI-1; MEMBER; DENSIN-180; CLONING	PAPIN has six PDZ domains and interacts with p0071, a catenin-related protein. Recent studies have revealed that catenins determine the subcellular localization of some PDZ proteins. We have examined whether the localization of PAPIN is determined by p0071 in epithelial cells. PAPIN was localized not only on the lateral membrane but also on the apical membrane, where p0071 was absent. The targeting to both membranes was mediated by the middle region of PAPIN and did not require the p0071-interacting PDZ domain. In cells that came into contact, PAPIN was diffusely distributed on the plasma membrane, while p0071 was concentrated at immature cell-cell contacts. When epithelial cells were exposed to the low concentration of calcium, p0071 was internalized, whereas PAPIN remained on the plasma membrane. We also confirmed that the interaction with p0071 was not essential for the membrane targeting of ERBIN, a recently identified p0071- and ErbB2-binding protein. PAPIN, p0071, and ERBIN formed a complex in 293T cells. Furthermore, ERBIN and ErbB2 were colocalized with PAPIN on the lateral membrane. These findings suggest that PAPIN, p0071, and ERBIN come to the cell-cell contacts independently and interact with each other on the lateral membrane.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Gastroenterol, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@med.tmd.ac.jp						Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Chaib H, 2001, CANCER RES, V61, P2390; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nishimura W, 2002, J NEUROSCI, V22, P757, DOI 10.1523/JNEUROSCI.22-03-00757.2002; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Tsukita S, 1996, CELL STRUCT FUNCT, V21, P381, DOI 10.1247/csf.21.381; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	29	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7042	7049		10.1038/sj.onc.1205852	http://dx.doi.org/10.1038/sj.onc.1205852			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370826				2022-12-28	WOS:000178424900007
J	Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V				Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V			Falkor, a novel cell growth regulator isolated by a functional genetic screen	ONCOGENE			English	Article						Falkor; GSE; MEF; cisplatin	SMOOTH-MUSCLE; DNA-DAMAGE; EXPRESSION; PROTEIN; SM-20; P53; IDENTIFICATION; APOPTOSIS; FAMILY; PROLIFERATION	A novel cell growth regulator, named Falkor, was identified using a functional approach to mammalian gene cloning, the Genetic Supressor Elements (GSE) method. In this screen, expression of the C-terminal domain of Falkor conferred cells with resistance to cisplatin-induced growth arrest. Expression of the C-terminus of Falkor, but not of the full-length protein, enhanced cell growth both following genotoxic stress and under normal conditions suggesting a general role for this protein in cell growth control. This effect of the C-terminus fragment was abrogated by over-expression of the full-length Falkor, suggesting that the fragment counteracts the function of the full-length protein. Falkor is encoded by a 2-kb mRNA which is present at different levels in various tissues, and is localized in the nucleus of cells. The C-terminal domain of Falkor, isolated from the GSE library, has significant homology to a known human and rat cell growth regulator, SM-20, and to the C. elegans protein EGL-9, recently shown to modify the Hypoxia Inducible Factor-la. The homology suggests that these proteins share a functional domain that is conserved among a family of growth regulation proteins.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Weizmann Institute of Science; Cleveland Clinic Foundation	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Peles, Elior/0000-0002-3325-0597; Gudkov, Andrei/0000-0003-2548-0154; Erez, Neta/0000-0001-6506-9074				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARAVIND L, 2001, GENOME BIOL, V2; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KASTAN MB, 1991, CANCER RES, V51, P6304; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Seth P, 2002, ONCOGENE, V21, P836, DOI 10.1038/sj.onc.1205113; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wei YF, 1996, NUCLEIC ACIDS RES, V24, P931, DOI 10.1093/nar/24.5.931	23	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6713	6721		10.1038/sj.onc.1205867	http://dx.doi.org/10.1038/sj.onc.1205867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360397				2022-12-28	WOS:000178315800001
J	Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J				Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J			A new locus for resistance to gamma-radiation-induced thymic lymphoma identified using inter-specific consomic and inter-specific recombinant congenic strains of mice	ONCOGENE			English	Article						mouse thymic lymphomas; tumor resistance genes; inter-specific consomic (ICS); recombinant congenic (IRCS) strains	SUSCEPTIBILITY; TUMORS; MOUSE; GENE; IRRADIATION; SUPPRESSOR; MUTATION; MODELS	Mice of the C57BL/6J inbred strain develop thymic lymphomas at very high frequency after acute gamma-irradiation, while mice of several inbred strains derived from the wild progenitor of the Mus spretus species and their F1 hybrids with C57BL/6J appear extremely resistant. Analysis of the genetic determinism of the gamma-radiation-induced thymic lymphoma (RITL) resistance with the help of inter-specific consomic strains (ICS), which carry a single introgressed Mus spretus chromosome on a C57BL/6J genetic background, provide significant evidence for the existence of a thymic lymphoma resistance (Tlyr1) locus on chromosome 19. The subsequent analysis of the backcross progeny resulting from a cross between consomic mice heterozygous for the Mus spretus chromosome 19 and C57BL/6J mice, together with the study of inter-specific recombinant congenic strains (IRCS), suggest that this Tlyr1 locus maps within the D19Mit60-D19Mit40 chromosome interval. In addition to the discovery of a new locus controlling RITL development, our study emphasizes the value of ICS and IRCS for the genetic analysis of cancer predisposition.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Univ La Laguna, Fac Med, Dept Anat Patol, Tenerife 38071, Spain	Autonomous University of Madrid; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad de la Laguna	Santos, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		Salido, Eduardo C/I-2232-2015; Santos, Javier/ABF-5755-2021; Arozena, Abraham Acevedo/L-6584-2018; Arnau Diaz-Llanos, Maria Rosa/L-8442-2018	Salido, Eduardo C/0000-0001-9599-9854; Santos, Javier/0000-0002-4168-6251; Arozena, Abraham Acevedo/0000-0001-6127-7116; Arnau Diaz-Llanos, Maria Rosa/0000-0002-2941-1626				Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Mori N, 2000, J RADIAT RES, V41, P367, DOI 10.1269/jrr.41.367; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RICHIE ER, 1985, CANCER RES, V45, P2802; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Szymanska H, 1999, INT J CANCER, V83, P674, DOI 10.1002/(SICI)1097-0215(19991126)83:5<674::AID-IJC18>3.0.CO;2-M; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wielowieyski A, 1999, MAMM GENOME, V10, P623, DOI 10.1007/s003359901057; YAMADA Y, 1994, J EXP MED, V180, P2155, DOI 10.1084/jem.180.6.2155; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	24	31	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6680	6683		10.1038/sj.onc.1205846	http://dx.doi.org/10.1038/sj.onc.1205846			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242666	Bronze			2022-12-28	WOS:000178202300014
J	Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K				Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K			The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases	ONCOGENE			English	Article						Src; transcription; historic deacetylase; butyrate; Trichostatin A	LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; ADENOCARCINOMA CELL-LINE; COLON-CANCER; SODIUM-BUTYRATE; C-SRC; TRICHOSTATIN-A; TRANSCRIPTIONAL ACTIVATION; DIETARY FIBER; BREAST-CANCER	Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa nonreceptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast;and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.	Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonham K, 2000, J BIOL CHEM, V275, P37604, DOI 10.1074/jbc.M004882200; BONHAM K, 1993, ONCOGENE, V8, P1973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; DArgenio G, 1996, GASTROENTEROLOGY, V110, P1727, DOI 10.1053/gast.1996.v110.pm8964397; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Espinos E, 1999, MOL CELL BIOL, V19, P3474; FOSS FM, 1989, ONCOGENE RES, V5, P13; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mariadason JM, 2000, CANCER RES, V60, P4561; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2001, CLIN CANCER RES, V7, P759; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Rajala RVS, 2000, BIOCHEM BIOPH RES CO, V273, P1116, DOI 10.1006/bbrc.2000.3066; REDDY BS, 1995, CRIT REV FOOD SCI, V35, P175, DOI 10.1080/10408399509527698; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Sowa Y, 1999, CANCER RES, V59, P4266; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	55	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6340	6347		10.1038/sj.onc.1205787	http://dx.doi.org/10.1038/sj.onc.1205787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214274				2022-12-28	WOS:000177829000010
J	Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR				Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR			Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background	ONCOGENE			English	Article						mismatch repair; p53; tumorigenesis; microsatellite instability; apoptosis	FEMALE EMBRYONIC LETHALITY; MURINE SMALL-INTESTINE; CELL-CYCLE CHECKPOINT; WILD-TYPE P53; MISMATCH REPAIR; P53-DEFICIENT MICE; COLORECTAL-CANCER; DNA-DAMAGE; IONIZING-RADIATION; MUTATION FREQUENCY	In colorectal tumorigenesis, loss of function of the mismatch repair genes is closely associated with genomic instability at the nucleotide level whereas p53 deficiency has been linked with gross chromosomal instability. We have addressed the contribution of these two forms of genetic instability to tumorigenesis using mice mutant for Msh2 and p53. As previously reported, deficiency of both genes leads to rapid lymphomagenesis Here we show that heterozygosity for p53 also markedly reduces survival on an Msh2 null background. We characterized the patterns of genomic instability in a small set of tumours and showed that, as predicted p53 deficiency predisposes to aneuploidy and Msh2 deficiency leads to microsatellite instability (MSI). However, heterozygosity for p53 in the absence of Msh2 resulted in increased MSI and not aneuploidy. This implied role for p53 in modulating MSI was confirmed using a large cohort of primary fibroblast clones. The differences observed were highly significant (P < 0.01) in both the fibroblast clones (which all retained p53 functionality) and the tumours, a proportion of which retained p53 functionality. Our results therefore demonstrate a dose sensitive role for p53 in the maintenance of genomic integrity at the nucleotide level.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	Cardiff University; University of Edinburgh; Netherlands Cancer Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Bubb VJ, 1996, ONCOGENE, V12, P2641; CARDER P, 1993, ONCOGENE, V8, P1397; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Cranston A, 1999, MAMM GENOME, V10, P1020, DOI 10.1007/s003359901151; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DONCHOWER LA, 1992, NATURE, V356, P215; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Gong JG, 1999, NATURE, V399, P806; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HAWN MT, 1995, CANCER RES, V55, P3721; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; OZBUN MA, 1993, CANCER RES, V53, P1646; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Toft NJ, 1998, NAT GENET, V18, P17, DOI 10.1038/ng0198-17; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VINDELOV LL, 1983, CYTOMETRY, V3, P321; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6299	6306		10.1038/sj.onc.1205727	http://dx.doi.org/10.1038/sj.onc.1205727			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214270				2022-12-28	WOS:000177829000006
J	Xia, WL; Mullin, RJ; Keith, BR; Liu, LH; Ma, H; Rusnak, DW; Owens, G; Alligood, KJ; Spector, NL				Xia, WL; Mullin, RJ; Keith, BR; Liu, LH; Ma, H; Rusnak, DW; Owens, G; Alligood, KJ; Spector, NL			Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways	ONCOGENE			English	Article						tyrosine kinase; EGFR; erbB2; Erk1/2; AKT; tumor xenograft	GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; INTERMOLECULAR ASSOCIATION; MONOCLONAL-ANTIBODY; TGF-ALPHA; PROTEIN; ERBB-2; CELLS	Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clinical activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.	GlaxoSmithKline, Dept Discovery Med, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline, Dept Discovery Med, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	ns85812@gsk.com						Albanell J, 2001, CANCER RES, V61, P6500; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Brognard J, 2001, CANCER RES, V61, P3986; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1989, ONCOGENE, V4, P831; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANES PW, 1994, ONCOGENE, V9, P3601; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1996, ONCOGENE, V12, P1117; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pulverer BJ, 1991, NATURE, V363, P83; QIAN XL, 1995, ONCOGENE, V10, P211; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Rusnak DW, 2001, CANCER RES, V61, P7196; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Tenzer A, 2001, CANCER RES, V61, P8203; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	48	541	565	7	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6255	6263		10.1038/sj.onc.1205794	http://dx.doi.org/10.1038/sj.onc.1205794			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214266				2022-12-28	WOS:000177829000002
J	Fukasawa, K				Fukasawa, K			Centrosome - Introduction	ONCOGENE			English	Editorial Material						centrosome; cancer; chromosome instability	P53; INSTABILITY; ORGANIZATION; TUMORS; MICE		Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, 3125 Eden Ave,POB 670521, Cincinnati, OH 45267 USA.							Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Pihan GA, 1998, CANCER RES, V58, P3974; SCHATTEN H, 1986, CELL MOTIL CYTOSKEL, V6, P163, DOI 10.1002/cm.970060215; VOROBJEV IA, 1987, INT REV CYTOL, V106, P227, DOI 10.1016/S0074-7696(08)61714-3; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890	11	24	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6140	6145		10.1038/sj.onc.1205771	http://dx.doi.org/10.1038/sj.onc.1205771			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214242				2022-12-28	WOS:000177840500001
J	Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H				Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H			Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation	ONCOGENE			English	Article						cancer; tolerance; glucose deprivation; AMP-activated protein kinase (AMPK)	SOLID TUMORS; ANGIOGENESIS; GLUCOSE; METABOLISM; EXPRESSION; GROWTH; GENE; INHIBITION; METASTASIS; THERAPY	As tumors grow and invade beyond their homeostatic limits, the tumor cells are subjected to insufficient nutrient and oxygen supplies because of excessive demand for nutrition and oxygen, and insufficient vascularization. We therefore hypothesized that tolerance to nutrient deprivation as well as angiogenesis may be critical in some malignancies, including pancreatic cancers, which are seen to be a hypovascular tumor. In this study, we assessed the effect of AMP-activated protein kinase (AMPK), which plays a major role in protecting cells from metabolic stresses, on tumor biology under nutrient-deprived condition. Whereas hepatic cancer cells had mostly died within 48 h during glucose deprivation, most pancreatic cancer cells survived more than 48 h. The tolerance to glucose deprivation tended to correlate with the cells level of expression of AMPK alpha1 and alpha2. The introduction of AMPK antisense RNA expression vectors into pancreas cancer cell lines, PANC-1 and AsPC-1, significantly diminished their tolerance to glucose deprivation, and the stable transfection of AMPK antisense into PANC-1 cells inhibited tumor growth in nude mice. These findings indicate that AMPK expression contributes to tolerance to nutrient starvation in cancer cells. We propose AMPK as a new target for therapeutic strategies to suppress tumor growth and invasion.	Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan; Chiba Univ, Sch Med, Dept Surg 1, Chiba 2608677, Japan	National Cancer Center - Japan; Chiba University	Esumi, H (corresponding author), Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan.	hesumi@east.nec.go.jp						AGUAN K, 1994, GENE, V149, P345, DOI 10.1016/0378-1119(94)90174-0; Barinaga M, 1997, SCIENCE, V275, P482, DOI 10.1126/science.275.5299.482; Brown JM, 1998, CANCER RES, V58, P1408; CARLING D, 1994, J BIOL CHEM, V269, P11442; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Hockel M, 1999, CANCER RES, V59, P4525; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Izuishi K, 2000, CANCER RES, V60, P6201; Koito K, 1997, AM J ROENTGENOL, V169, P1263, DOI 10.2214/ajr.169.5.9353439; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1996, ONCOGENE, V13, P2699; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yu X, 2000, BIOCHEM BIOPH RES CO, V276, P564, DOI 10.1006/bbrc.2000.3508	33	174	180	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6082	6090		10.1038/sj.onc.1205737	http://dx.doi.org/10.1038/sj.onc.1205737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203120				2022-12-28	WOS:000177671300011
J	Zambrano, A; Villarreal, LP				Zambrano, A; Villarreal, LP			A monoclonal antibody specific for BK virus large T-antigen (clone BK.T-1) also binds the human Ku autoantigen	ONCOGENE			English	Article						BK virus; large T antigen; Ku proteins; antibodies	DNA; INFECTION; GROWTH; P70	A monoclonal antibody directed against the BK virus large T-antigen (clone BK.T-1) has previously been used to evaluate BKV-T antigen (BKV-TAg) expression. However, our experience showed a consistent reactivity to uninfected human, but not rodent cells and tissues. Using immunoprecipitation, Western analysis, amino acid sequencing and end-point dilution analysis, we analysed the BK.T-1 antibody reactivity and identified the bound cellular protein. The results clearly show that the antibody recognizes the large subunit (Ku86) of the Ku autoantigen, the regulatory component of the DNA-PKcs. We also demonstrated that the antibody retained its original reactivity in BKV-TAg transformed hamster kidney cells. The cross-reaction of the BK.T-1 antibody suggests a possible similarity between BKV-TAg and Ku86, but makes the antibody unsuitable for studies of BKV large T-antigen in the human cells.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Villarreal, LP (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Room 3232, Irvine, CA 92697 USA.	lpvillar@uci.edu	Zambrano, Alberto/A-1580-2013; Zambrano, Alberto/Q-6188-2019	Zambrano, Alberto/0000-0001-5677-2999; Zambrano, Alberto/0000-0001-5677-2999				CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Flaegstad T, 1999, CANCER RES, V59, P1160; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MARSHALL J, 1991, ONCOGENE, V6, P1673; MENEGUZZI G, 1981, VIROLOGY, V111, P139, DOI 10.1016/0042-6822(81)90660-7; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1978, VIROLOGY, V85, P137, DOI 10.1016/0042-6822(78)90418-X; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	16	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5725	5732		10.1038/sj.onc.1205692	http://dx.doi.org/10.1038/sj.onc.1205692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173042				2022-12-28	WOS:000177463400007
J	Regl, G; Neill, GW; Eichberger, T; Kasper, M; Ikram, MS; Koller, J; Hintner, H; Quinn, AG; Frischauf, AM; Aberger, F				Regl, G; Neill, GW; Eichberger, T; Kasper, M; Ikram, MS; Koller, J; Hintner, H; Quinn, AG; Frischauf, AM; Aberger, F			Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma	ONCOGENE			English	Article						Basal Cell Carcinoma; hedgehog signalling; GLI genes; cell proliferation	EXPRESSING SONIC HEDGEHOG; PATCHED SIGNALING PATHWAY; TRANSCRIPTION FACTOR; FLOOR PLATE; HUMAN HOMOLOG; HUMAN SKIN; GENE; MICE; INDUCTION; ACTIVATION	Transgenic mouse models have provided evidence that activation of the zinc-finger transcription factor GLI1 by Hedgehog (Hh)-signalling is a key step in the initiation of the tumorigenic programme leading to Basal Cell Carcinoma (BCC). However, the downstream events underlying Hh/GLI-induced BCC development are still obscure. Using in vitro model systems to analyse the effect of Hh/GLI-signalling in human keratinocytes, we identified a positive feedback mechanism involving the zinc finger transcription factors GLI1 and GLI2. Expression of GLI1 in human keratinocytes induced the transcriptional activator isoforms GL12alpha and GL12beta. Both isoforms were also shown to be expressed at elevated levels in 21 BCCs compared to normal skin. Detailed time course experiments monitoring the transcriptional response of keratinocytes either to GLI1 or to GLI2 suggest that GLI1 is a direct target of GLI2, while activation of GLI2 by GLI1 is likely to be indirect. Furthermore, expression of either GLI2 or GLI1 led to an increase in DNA-synthesis in confluent human keratinocytes. Taken together, these results suggest an important role of the positive GLI1-GLI2 feedback loop in Hh-mediated epidermal cell proliferation.	Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Univ London Queen Mary Coll, St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res, London, England; St Johann Hosp, Dept Dermatol, A-5020 Salzburg, Austria	Salzburg University; University of London; Queen Mary University London	Aberger, F (corresponding author), Salzburg Univ, Inst Genet, Hellbrunner Str 34, A-5020 Salzburg, Austria.		Kasper, Maria/Q-6318-2016; Aberger, Fritz/B-6357-2012; Neill, Graham/C-9008-2012	Aberger, Fritz/0000-0003-2009-6305; Kasper, Maria/0000-0002-6117-2717				Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Green J, 1998, BRIT J DERMATOL, V139, P911; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Tanimura A, 1998, J VIROL, V72, P3958, DOI 10.1128/JVI.72.5.3958-3964.1998; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	48	165	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5529	5539		10.1038/sj.onc.1205748	http://dx.doi.org/10.1038/sj.onc.1205748			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165851				2022-12-28	WOS:000177442000002
J	Fiore, E; Fusco, C; Romero, P; Stamenkovic, I				Fiore, E; Fusco, C; Romero, P; Stamenkovic, I			Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity	ONCOGENE			English	Article						ICAM-1; MMP-9; tumor; proteases; cytotoxicity	INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; RAT EMBRYO CELLS; L-SELECTIN CD62L; SERUM LEVELS; METASTATIC PHENOTYPE; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; IV COLLAGENASE	Shedding of intercellular adhesion molecule 1 (ICAM-1) is believed to play a role in tumor cell resistance to cell-mediated cytotoxicity. However, the mechanism whereby ICAM-1 is shed from the surface of tumor cells remains unclear. In this study, we have addressed the possibility that matrix metalloproteinases are implicated in ICAM-1 shedding. Our observations suggest a functional relationship between ICAM-1 and matrix metalloproteinase 9 (MMP-9) whereby ICAM-1 provides a cell surface docking mechanism for proMMP-9, which, upon activation, proteolytically cleaves the extracellular domain of ICAM-1 leading to its release from the cell surface. MMP-9-dependent shedding of ICAM-1 is found to augment tumor cell resistance to natural killer (NK) cell-mediated cytotoxicity. Taken together, our observations propose a mechanism for ICAM-1 shedding from the cell surface and provide support for MMP involvement in tumor cell evasion of immune surveillance.	Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02129 USA; Inst Univ Pathol, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Ludwig Institute for Cancer Research	Stamenkovic, I (corresponding author), Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA.		Romero, Pedro/S-6015-2017	Romero, Pedro/0000-0002-9688-2882	NCI NIH HHS [CA55735] Funding Source: Medline; NIGMS NIH HHS [GM48614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTOMONTE M, 1993, CANCER RES, V53, P3343; Aoudjit F, 1998, J IMMUNOL, V160, P2967; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Becker J C, 1995, Recent Results Cancer Res, V139, P205; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Fonsatti E, 1997, BRIT J CANCER, V76, P1255, DOI 10.1038/bjc.1997.545; GONG JH, 1994, LEUKEMIA, V8, P652; Grothey A, 1998, BRIT J CANCER, V77, P801, DOI 10.1038/bjc.1998.130; Gu B, 1998, BLOOD, V92, P946; Guo HM, 2000, CANCER RES, V60, P888; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HARNING R, 1991, CANCER RES, V51, P5003; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Huang HY, 1998, J CLIN ENDOCR METAB, V83, P1721, DOI 10.1210/jc.83.5.1721; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mitsiades N, 2000, CANCER RES, V60, P4122; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIZZOLO G, 1993, BRIT J HAEMATOL, V84, P161, DOI 10.1111/j.1365-2141.1993.tb03040.x; Sanchez-Rovira P, 1998, EUR J CANCER, V34, P394, DOI 10.1016/S0959-8049(97)10033-8; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Toth M, 1997, CANCER RES, V57, P3159; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	49	174	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5213	5223		10.1038/sj.onc.1205684	http://dx.doi.org/10.1038/sj.onc.1205684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149643				2022-12-28	WOS:000177193900003
J	Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR				Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR			NATH, a novel gene overexpressed in papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid carcinoma; overexpression; NATH	N-TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; TETRATRICOPEPTIDE REPEAT; TPR DOMAIN; E-CADHERIN; IN-VIVO; C-MET; EXPRESSION; PROTEIN; IDENTIFICATION	In this study a replica cDNA screening (RCS) approach to identify genes differentially expressed in papillary thyroid carcinomas (PTC) was used, as compared to non-neoplastic thyroid tissues. RCS is based on hybridization of radioactively labeled cDNA probes made from the biopsies to replica membranes with 15000 clones from a PTC cDNA library. Among the genes overexpressed in PTC, and especially in clinically aggressive tumors with histologic evidence of poorly differentiated or undifferentiated areas, a novel gene named NATH was found. NATH has two mRNA species, 4.6 and 5.8 kb, both harboring the same open reading frame encoding a putative protein of 866 amino acids. The NATH protein is; homologous to yeast N-acetyltransferase (NAT)1 and to mouse NARG1 (mNAT1) and contains four tetratricopeptide repeat (TPR) domains, suggesting that NATH may be part of a multiprotein complex. Overlapping RT-PCR fragments from several PTC biopsies confirmed the NATH mRNA sequence. Northern blots, semiquantitative RT-PCR experiments, TaqMan real-time RT-PCR experiments, and in situ hybridization verified the overexpression of NATH mRNA localized to tumor cells in PTC biopsies. NATH was expressed at a low level in most human adult tissues, including the normal thyroid gland. Increased NATH expression was seen especially in a Burkitt lymphoma cell line and in adult human testis. Recombinant in vitro expression showed that NATH protein was located mainly in the cytoplasm, and was present as a single protein band of the expected 105 kDa molecular weight. Heterologous expression of NATH in the papillary carcinoma cell line (NPA) and 293 cells did not alter the cellular proliferation rate. The biological function of NATH remains to be elucidated, but the overexpression in classic PTC and especially in poorly differentiated or undifferentiated components may indicate a function in the progression of papillary thyroid carcinomas.	Univ Bergen, Dept Biol Mol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Med Genet & Mol Med, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Biol Mol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543				Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Nigris F, 1998, CANCER RES, V58, P4745; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gounalaki N, 2000, FEBS LETT, V473, P37, DOI 10.1016/S0014-5793(00)01480-0; Haugen DRF, 1996, CANCER RES, V56, P1184; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Kurozumi K, 1998, WORLD J SURG, V22, P1237, DOI 10.1007/s002689900551; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LEE FJS, 1990, J BIOL CHEM, V265, P11576; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nishida T, 2002, AM J SURG, V183, P80, DOI 10.1016/S0002-9610(01)00843-1; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Powell DJ, 1998, CANCER RES, V58, P5523; Resnick MB, 1998, MODERN PATHOL, V11, P735; Ryu S, 1997, CANCER LETT, V121, P189, DOI 10.1016/S0304-3835(97)00353-4; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Shuja S, 1999, THYROID, V9, P569, DOI 10.1089/thy.1999.9.569; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; Takano T, 1998, BRIT J CANCER, V78, P221, DOI 10.1038/bjc.1998.468; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; Trovato M, 1998, THYROID, V8, P125, DOI 10.1089/thy.1998.8.125; vonWasielewski R, 1997, CANCER RES, V57, P2501	44	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5056	5068		10.1038/sj.onc.1205687	http://dx.doi.org/10.1038/sj.onc.1205687			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140756				2022-12-28	WOS:000176975900004
J	Gunduz, M; Ouchida, M; Fukushima, K; Ito, S; Jitsumori, Y; Nakashima, T; Nagai, N; Nishizaki, K; Shimizu, K				Gunduz, M; Ouchida, M; Fukushima, K; Ito, S; Jitsumori, Y; Nakashima, T; Nagai, N; Nishizaki, K; Shimizu, K			Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers	ONCOGENE			English	Article						loss of heterozygosity; ING3; tumor suppressor gene; reduced expression; ING family; head and neck cancer	HUMAN-CHROMOSOME 7Q31.1; SQUAMOUS-CELL; FREQUENT LOSS; HETEROZYGOSITY; P33(ING1); PROTEIN; REGION; DNA	Loss of heterozygosity (LOH) has been frequently detected at chromosome 7q31 region in human head and neck squamous cell carcinomas (HNSCC) and many other cancers, suggesting the existence of tumor suppressor genes (TSG). We analysed LOH at 7q3I region in 49 HNSCC by using six polymorphic microsatellite markers and found allelic deletion in 48% (22/46) of the informative cases. We detected two preferentially deleted regions, one is around D7S643 and the other around D7S486. When we redefined the map of 7q31 region according to the contiguous sequences, a recently identified gene, ING3, was found in the proximity of D7S643. ING3 protein harbors the PHD domain highly homologous among ING family proteins, in which we previously found mutations in a related gene, ING1. As only one missense mutation of the ING3 gene was found in HNSCC, we examined the expression level. Reverse-transcription-PCR analysis demonstrated decreased or no expression of ING3 mRNA in 50% of primary tumors as compared with that of matched normal samples. Especially, about 63% of tongue and larynx tumors showed the decrease and a tendency of higher mortality was observed in cases with decreased ING3 expression. All these findings suggest a possibility that the ING3 gene functions as a TSG in a subset of HNSCC.	Okayama Univ, Grad Sch Med & Dent, Dept Mol Genet, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Otolaryngol, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Oral Pathol, Okayama 7008558, Japan	Okayama University; Okayama University; Okayama University	Shimizu, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Mol Genet, Shikata 2-5-1, Okayama 7008558, Japan.	shinke47@md.okayama-u.ac.jp						BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Bieche I, 1997, CLIN CANCER RES, V3, P1009; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gunduz M, 2000, CANCER RES, V60, P3143; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kohno T, 1999, CANCER RES, V59, P4170; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Latil A, 1995, CLIN CANCER RES, V1, P1385; Lin JC, 1996, ONCOGENE, V13, P2001; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Tanino M, 1999, MOL CARCINOGEN, V26, P286; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Wang F, 1998, CHINESE MED J-PEKING, V111, P671; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang JS, 1998, ONCOGENE, V17, P789, DOI 10.1038/sj.onc.1201996	32	107	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4462	4470		10.1038/sj.onc.1205540	http://dx.doi.org/10.1038/sj.onc.1205540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080476				2022-12-28	WOS:000176317100011
J	Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G				Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G			Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones	ONCOGENE			English	Article						c-Myc; telomerase; tumorigenicity; apoptosis; melanoma	TELOMERASE REVERSE-TRANSCRIPTASE; NORMAL HUMAN-CELLS; CATALYTIC SUBUNIT; IN-VITRO; ANTISENSE OLIGODEOXYNUCLEOTIDES; HUMAN FIBROBLASTS; TRANSGENIC MICE; TUMOR-CELLS; LIFE-SPAN; GENE	c-Myc is involved in the control of telomerase activity through its ability to induce the expression of the catalytic subunit of the enzyme, the human telomerase reverse transcriptase (hTERT). Our aim was to study whether telomerase plays a critical role in c-Myc-dependent tumorigenicity of melanoma cells. By using M14-derived clones, expressing low levels of c-Myc, we demonstrated that the down-regulation of c-Myc reduced cell proliferation rate, cloning efficiency and tumorigenicity and increased the apoptotic rate. Decreased tumorigenic potential correlated with reduced hTERT gene expression, telomerase activity and telomere shortening. Introduction of wild-type hTERT into these cells increased their proliferation rate and partially re-established their tumorigenic potential, at early passages, even though the apoptotic rate of the population remained unaltered. After several in vitro passages, hTERT-mediated cell proliferation made the tumorigenic potential of the c-Myc low-expressing clones comparable to that of the M14 parental line. Over-expression of the mutant biologically inactive hTERT did not drive cells to proliferate. In conclusion, our results demonstrate that the reconstitution of high levels of telomerase activity reverses the low tumorigenicity due to low c-Myc expression.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy; Regina Elena Inst Canc Res, Clin & Pathol Labs, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy.	zupi@ifo.it	Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/K-8673-2016; Scarsella, Marco/AAA-1486-2020; Leonetti, Carlo/B-2860-2018; Del Bufalo, Donatella/AAC-1594-2021	Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Leonetti, Carlo/0000-0002-3526-7827; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Citro G, 1998, CANCER RES, V58, P283; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3011	3019		10.1038/sj.onc.1205415	http://dx.doi.org/10.1038/sj.onc.1205415			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082531				2022-12-28	WOS:000175262700008
J	Chan, AS; Thorner, PS; Squire, JA; Zielenska, M				Chan, AS; Thorner, PS; Squire, JA; Zielenska, M			Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between Rhabdomyosarcoma subtypes	ONCOGENE			English	Article						rhabdomyosarcoma; non-coding transcripts; chromosome 12q21; alternative splicing; novel gene	CANCER; SEQUENCES; CDNA; IGF2; RNA; H19	Rhabdomyosarcoma (RMS) is a malignant soft tissue tumor showing varying degrees of skeletal muscle differentiation. Two major histologic subtypes exist, alveolar and embryonal, each with associated molecular genetic changes. We have used Representational Difference Analysis (RDA) to compare gene expression between the two RMS subtypes and have identified the novel gene NCRMS (non-coding RNA in RMS) that has increased expression in the alveolar subtype relative to the embryonal subtype. Multiple alternatively spliced forms of NCRMS were identified through library screening, RACE, and comparison to human expressed sequence tags (ESTs). Northern blot analysis indicated the transcript size to be 1.25 kb in alveolar RMS. There was no sequence homology to any of the known genes in GenBank, but extensive homology to ESTs from various species. Comparison to human genomic sequences identified at least 11 exons mapping to chromosomal region 12q21. Differential expression of NCRMS was noted between various tumor types. Since NCRMS RNA possesses limited potential for protein coding, yet with conserved sequences between different species, it is likely that NCRMS is a functional non-coding RNA. Known genes in its proximity include myogenic regulators Myf5 and Myf6, growth factor Igf1, and another potential differentially expressed gene (ATP2B1) in RMS isolated by RDA.	Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Ontario Canc Inst, Dept Pathol Oncol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Zielenska, M (corresponding author), Hosp Sick Children, Dept Paediat Lab Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	m.zielenska@utoronto.ca	Squire, Jeremy A/A-9352-2012; Squire, Jeremy A/F-4437-2012	Squire, Jeremy A/0000-0002-9863-468X; 				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Anderson John, 1999, Neoplasia (New York), V1, P340, DOI 10.1038/sj.neo.7900052; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Dagher R, 1999, Oncologist, V4, P34; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Lucas S, 1998, CANCER RES, V58, P743; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Srivastava M, 2000, GENE DEV, V14, P1186; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302	20	42	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3029	3037		10.1038/sj.onc.1205460	http://dx.doi.org/10.1038/sj.onc.1205460			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082533				2022-12-28	WOS:000175262700010
J	De Juan, C; Iniesta, P; Gonzalez-Quevedo, R; Moran, A; Sanchez-Pernaute, A; Torres, AJ; Balibrea, JL; Diaz-Rubio, E; Cruces, J; Benito, M				De Juan, C; Iniesta, P; Gonzalez-Quevedo, R; Moran, A; Sanchez-Pernaute, A; Torres, AJ; Balibrea, JL; Diaz-Rubio, E; Cruces, J; Benito, M			Genomic organization of a novel glycosylphosphatidylinositol MAM gene expressed in human tissues and tumors	ONCOGENE			English	Article						novel gene; GPI motif; MAM domain; adhesion molecule; cancer	CARCINOEMBRYONIC ANTIGEN; NEURITE OUTGROWTH; MESSENGER-RNA; CELL; SUPERFAMILY; DOMAIN; MEMBER; FAMILY; LUNG; LAMP	We report the genomic organization of a novel human gene mapped to chromosome 6p21, encoding a putative glycosylphosphatidylinositol (GPI) anchored protein containing a MAM (meprin, A5 antigen, protein tyrosine phosphatase mu) domain, that we have termed as GPIM (GPI and MAM) protein. GPIM gene consists of an 8.9 kb transcript composed of 17 coding exons spanning about 65.5 kb of genomic DNA. The deduced polypeptide consists of 955 amino acids and exhibits structural features found in different types of cell adhesion molecules (CAMs), such as the presence of immunoglobulin domains, the presence of a MAM domain or the capacity to anchor to the cell membrane by a GPI motif. Expression analysis in normal human tissues revealed that this gene is expressed as a 5 kb and 9.5 kb mRNA. Furthermore, the smaller transcript is highly expressed in some human cancer cell lines, as well as in different primary tumors (lung, colon, uterus, stomach and breast). Interestingly, the gene was higher expressed in several tumor tissues analysed as compared to their corresponding normal tissues. Thus, GPIM is a novel gene codifying a protein with structural features characteristics of some CAMs, which might be involved in the tumor progression.	Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Hosp Univ San Carlos, Serv Cirugia, Madrid 28040, Spain; Hosp Univ San Carlos, Serv Oncol, Madrid 28040, Spain	Complutense University of Madrid; Autonomous University of Madrid	Benito, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	benito@farm.ucm.es	Sánchez-Pernaute, Andrés/J-9588-2016; Benito, Manuel/J-5637-2014	Benito, Manuel/0000-0002-7218-406X; Sanchez-Pernaute, Andres/0000-0002-0226-286X; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; De Juan C, 1999, INT J CANCER, V84, P344, DOI 10.1002/(SICI)1097-0215(19990820)84:4<344::AID-IJC2>3.0.CO;2-D; Funatsu N, 1999, J BIOL CHEM, V274, P8224, DOI 10.1074/jbc.274.12.8224; Ilantzis C, 1997, LAB INVEST, V76, P703; JIANG WP, 1992, J BIOL CHEM, V267, P9185; Jones DR, 1998, INT J BIOCHEM CELL B, V30, P313, DOI 10.1016/S1357-2725(97)00144-1; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; KOZAK M, 1986, CELL, V6, P563; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; Pimenta AF, 1996, GENE, V170, P189, DOI 10.1016/0378-1119(96)84698-1; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Takayama M, 1999, EXP NEPHROL, V7, P295; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wilson DJA, 1996, J CELL SCI, V109, P3129; YOSHIHARA Y, 1994, NEURON, V13, P415, DOI 10.1016/0896-6273(94)90357-3; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	21	15	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3089	3094		10.1038/sj.onc.1205383	http://dx.doi.org/10.1038/sj.onc.1205383			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082541				2022-12-28	WOS:000175262700018
J	Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S				Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S			c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis	ONCOGENE			English	Article						c-Myc; dihydrofolate reductase; genomic instability; polyploidy; apoptosis	GENE AMPLIFICATION; P53 MUTATIONS; CYCLE ARREST; TRANSFORMATION; TUMORIGENESIS; CHECKPOINT; LYMPHOMA; EXPRESSION; REDUCTASE; COOPERATE	Overexpression of c-Myc in tumors is usually associated with cell proliferation and increased susceptibility to apoptosis. Concomitantly, c-Myc contributes to tumorigenesis by its ability to destabilize the cellular genome. Here, we examined whether c-Myc induces genomic instability and apoptosis in c-Myc-activated cells. Wildtype Myc (wt-Myc) and two mutated Myc myc box II proteins (mt-Myc) were overexpressed in IL3-dependent murine Ba/F3 cells. As expected, wt-Myc triggered apoptosis in absence of IL3. Standard karyotyping, spectral karyotyping, and fluorescent in situ hybridization (FISH) were performed before and after c-Myc activation. Structural and numerical genomic instability was detected 48 h after wt-Myc activation and included gene amplification, the formation of extrachromosomal elements (EEs), chromosome breakage, deletions, increased aneuploidy, and polyploidization. Interestingly, some cells simultaneously displayed genomic instability and apoptosis. Both wt- and mt-Myc proteins were equally potent promoters of genomic instability. However, only wt-Myc simultaneously induced genomic instability and apoptosis. Mt-Myc proteins failed to induce apoptosis, thereby generating a strong imbalance towards the survival of genomically unstable cells.	CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Inst Etud & Transfert Genes, F-25030 Besancon, France; Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden	CancerCare Manitoba Foundation; Karolinska Institutet	Mai, S (corresponding author), CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.		Mai, Sabine/E-5667-2017; DALSTEIN, Véronique/P-5250-2016	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA KG, 1992, CANCER RES, V52, P4273; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; *COMM STAND GEN NO, 1969, MOUSE NEWS LETT, V17, P481; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CELL, V65, P113; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; ORMEROD MG, 1990, PRACTICAL APPROACH, P69; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WANG HC, 1971, NATURE, V235, P52; WIENER F, 2000, TECHNICAL TIPS ONLIN, V1, P8; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410	31	34	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2981	2990		10.1038/sj/onc/1205274	http://dx.doi.org/10.1038/sj/onc/1205274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082528				2022-12-28	WOS:000175262700005
J	Thun, MJ; Henley, SJ; Calle, EE				Thun, MJ; Henley, SJ; Calle, EE			Tobacco use and cancer: an epidemiologic perspective for geneticists	ONCOGENE			English	Review						tobacco; cancer; genetic epidemiology	SQUAMOUS-CELL CARCINOMA; N-ACETYLTRANSFERASE 2; REPAIR GENE XRCC1; LUNG-CANCER; CIGARETTE-SMOKING; HISTOLOGIC-CHANGES; BREAST-CANCER; BRONCHIAL EPITHELIUM; BLADDER-CANCER; MOLECULAR EPIDEMIOLOGY	Much of what is known about the deleterious effects of tobacco use on health was learned from epidemiologic studies over the last half century. These studies establish unequivocally that tobacco use, particularly manufactured cigarette smoking, causes most cancers of the lung, oropharynx, larynx, and esophagus in the USA, and approximately one-third of all cancers of the pancreas, kidney, urinary bladder and uterine cervix. More recent evidence also implicates smoking with cancers of the stomach, liver and colorectum. While over half of the estimated 440 000 smoking-attributable deaths that occur annually in the USA involve non-malignant cardiovascular and respiratory conditions, smoking-attributable cancers are more recognized and feared. Geneticists increasingly study tobacco use as a model for environmental carcinogenicity. Tobacco-exposed populations provide opportunities to characterize the somatic mutations that give rise to specific cancers and to identify the inherited genetic traits that confer susceptibility or resistance. Studies to identify the genetic determinants of addiction may be particularly important. Future research to identify other susceptibility factors, such as genes that modify carcinogen metabolism or DNA repair, will need to be substantially larger and to quantify lifetime tobacco exposure with more precision than have past studies in order to distinguish gradations in risk due to exposure from those caused by genetic susceptibility. This review considers: (a) the epidemiology of tobacco use; (b) cancers presently classified as smoking-attributable by the US Surgeon General; (c) the magnitude of the epidemic of cancers and other diseases caused by tobacco use; (d) selected issues in the epidemiology of lung cancer; and (e) the interface of genetics and epidemiology in understanding, preventing, and treating tobacco-attributable disease.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Thun, MJ (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd, Atlanta, GA 30329 USA.	Mthun@cancer.org	Henley, Jane/A-4698-2010	Henley, S Jane/0000-0002-2420-306X				Ahsan H, 1997, CANCER EPIDEM BIOMAR, V6, P779; Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494; AUERBACH O, 1986, DIGEST DIS SCI, V31, P1014, DOI 10.1007/BF01300252; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1965, ARCH ENVIRON HEALTH, V11, P4, DOI 10.1080/00039896.1965.10664163; AUERBACH O, 1970, CANCER-AM CANCER SOC, V25, P92, DOI 10.1002/1097-0142(197001)25:1<92::AID-CNCR2820250114>3.0.CO;2-E; AUERBACH O, 1964, AM REV RESPIR DIS, V90, P867; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; BENOWITZ N, 2001, 025074 NIH US DEP HL; Benowitz NL, 2002, J NATL CANCER I, V94, P108, DOI 10.1093/jnci/94.2.108; Bergen AW, 1999, JNCI-J NATL CANCER I, V91, P1365, DOI 10.1093/jnci/91.16.1365; BERKSON J, 1958, J AM STAT ASSOC, V53, P28, DOI 10.2307/2282563; BERKSON J, 1955, P STAFF M MAYO CLIN, V30, P319; BEST E. W. R., 1961, Canadian Journal of Public Health, V52, P99; Brockton N, 2000, AM J EPIDEMIOL, V151, P846; BROWNSON RC, 1992, EPIDEMIOLOGY, V3, P61, DOI 10.1097/00001648-199201000-00012; BURNS D, 1997, CIGARETTE SMOKING BE; Califano J, 1999, CLIN CANCER RES, V5, P1862; Califano J, 1996, CANCER RES, V56, P2488; Califano J, 2000, CLIN CANCER RES, V6, P347; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Castelao JE, 2001, JNCI-J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1217; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P300; CLEMMESEN J, 1965, STAT STUDIES AETIOLO; Cohn BA, 1996, J NATL CANCER I, V88, P1867, DOI 10.1093/jnci/88.24.1867; Cooper EA, 1932, J HYG-CAMBRIDGE, V32, P293; Corrao MA, 2000, B WORLD HEALTH ORGAN, V78, P884; CORRAO MA, 2000, TOBACCO CONTROL COUN; COSMA G, 1993, CANCER EPIDEM BIOMAR, V2, P53; CROFTS F, 1993, CARCINOGENESIS, V14, P1729, DOI 10.1093/carcin/14.9.1729; CRONINGER AB, 1958, CANCER RES, V18, P1263; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Djordjevic MV, 2000, JNCI-J NATL CANCER I, V92, P106, DOI 10.1093/jnci/92.2.106; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1957, BRIT J CANCER, V11, P43, DOI 10.1038/bjc.1957.6; Doll R, 1998, Stat Methods Med Res, V7, P87, DOI 10.1191/096228098668199908; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Doll R, 1996, BRIT MED BULL, V52, P35, DOI 10.1093/oxfordjournals.bmb.a011531; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; Eberhardt MS, 2001, URBAN RURAL HLTH CHA; ENGELBRETH-HOLM J., 1957, ACTA PATH ET MICROBIOL SCAND, V41, P267; FORD B, 1994, SMOKE SCREEN GUIDE P; FRAUMENI JF, 1974, J NATL CANCER I, V52, P659, DOI 10.1093/jnci/52.3.659; GAFFNEY M, 1988, J NATL CANCER I, V80, P925, DOI 10.1093/jnci/80.12.925; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1233; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Giovannucci E, 2001, CANCER EPIDEM BIOMAR, V10, P725; GLANTZ SA, 1996, CIGARETTE PAPERS, P1; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; GUERIN M, 1957, Bull Assoc Fr Etud Cancer, V44, P387; Guo ZM, 2001, CLIN CANCER RES, V7, P1963; HAENSZEL W, 1956, 463 PHS; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; HARRIS RE, 1993, INT J EPIDEMIOL, V22, P592, DOI 10.1093/ije/22.4.592; Heath AC, 1995, BEHAV GENETIC APPROA, P45; Hecht SS, 2000, J NATL CANCER I, V92, P782, DOI 10.1093/jnci/92.10.782; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Henningfield J. E., 1993, NICOTINE ADDICTION P, P24; Hickey K, 2001, EPIDEMIOL REV, V23, P115, DOI 10.1093/oxfordjournals.epirev.a000776; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; Houlston RS, 1999, CANCER EPIDEM BIOMAR, V8, P675; IARC, 1987, IARC MON EV CARC RIS, V1-42; International Agency for Research on Cancer Tobacco smoking IARC, 1986, IARC MON EV CARC RIS, V38; KAHN HA, 1966, MONOGR NAT CANCER I, V19, P1; King TE, 1999, NEW ENGL J MED, V341, P1231, DOI 10.1056/NEJM199910143411612; KREYBERG L, 1962, ACTA PATHOL MIC SC, P11; Lagergren J, 2000, INT J CANCER, V85, P340; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361; Landi M T, 1999, IARC Sci Publ, P173; Lang M, 1999, IARC Sci Publ, P13; LAW CH, 1976, INT J CANCER, V17, P304, DOI 10.1002/ijc.2910170305; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; LEITCH A, 1928, 5 ANN REPORT BRIT EM, P26; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; LUBIN JH, 1984, JNCI-J NATL CANCER I, V73, P383, DOI 10.1093/jnci/73.2.383; MABRY M, 1998, GENETIC BASIC HUMAN, P671; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; Martin GC, 1999, J AM DENT ASSOC, V130, P945, DOI 10.14219/jada.archive.1999.0335; MATTSON ME, 1987, AM J PUBLIC HEALTH, V77, P425, DOI 10.2105/AJPH.77.4.425; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P537, DOI 10.1016/0895-4356(91)90217-W; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MILLS CA, 1950, CANCER RES, V10, P539; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Montague M, 1997, FOCUS EXCEPT CHILD, V30, P1; MOOLGAVKAR SH, 1990, RISK ANAL, V10, P323, DOI 10.1111/j.1539-6924.1990.tb01053.x; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; NOVOTNY TE, 1988, AM J PUBLIC HEALTH, V78, P1187, DOI 10.2105/AJPH.78.9.1187; OSANN KE, 1993, INT J CANCER, V54, P44, DOI 10.1002/ijc.2910540108; PASSEY RD, 1929, 6 REPORT BRIT EMPIRE, P85; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Perneger TV, 2001, J NATL CANCER I, V93, P1600, DOI 10.1093/jnci/93.21.1600; Peto R, 1985, IARC Sci Publ, P43; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Peto R, 1994, MORTALITY SMOKING DE; PIKE MC, 1965, LANCET, V1, P665; Prescott E, 1998, EPIDEMIOLOGY, V9, P79, DOI 10.1097/00001648-199801000-00016; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Richie JP, 1997, CANCER EPIDEM BIOMAR, V6, P783; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; ROFFO A. H., 1931, ZEITSCHR KREBSFORSCH, V33, P321, DOI 10.1007/BF01792286; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P7; RYBERG D, 1994, CANCER RES, V54, P5801; SCHREK R, 1950, CANCER RES, V10, P49; SHIELDS PG, 1993, CANCER EPIDEM BIOMAR, V2, P481; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; Sidransky D, 1995, J Natl Cancer Inst Monogr, P27; SILVERMAN S, 1998, ORAL CANC, P25; SLADE J, 1993, NICOTINE ADDICTION P, P3; Smith SS, 1999, PRIMARY CARE, V26, P433, DOI 10.1016/S0095-4543(05)70112-3; SOMMERING S, 1995, MORBIS VASORUM ABSOR; Spivack SD, 1997, CRIT REV TOXICOL, V27, P319, DOI 10.3109/10408449709089898; Stellman SD, 2001, CANCER EPIDEM BIOMAR, V10, P1193; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125; Stewart JH, 2001, CANCER-AM CANCER SOC, V91, P2476, DOI 10.1002/1097-0142(20010615)91:12<2476::AID-CNCR1283>3.0.CO;2-Z; Strange R C, 1999, IARC Sci Publ, P231; Straub RE, 1999, MOL PSYCHIATR, V4, P129, DOI 10.1038/sj.mp.4000518; STRONG LC, 1996, CANC EPIDEMIOLOGY PR, P559; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUGIURA K, 1956, Gan, V47, P243; Taioli E, 1998, CARCINOGENESIS, V19, P813, DOI 10.1093/carcin/19.5.813; Thun M. J, 1997, MONOGRAPH, V8; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Thun MJ, 1998, TOB CONTROL, V7, P223, DOI 10.1136/tc.7.3.223; Thun MJ, 2000, CANCER EPIDEM BIOMAR, V9, P861; Thun MJ, 1997, NATL CANCER I MONOGR, P305; Tredaniel J, 1997, INT J CANCER, V72, P565, DOI 10.1002/(SICI)1097-0215(19970807)72:4<565::AID-IJC3>3.0.CO;2-O; *US DEP HHS, 1988, RED HLTH CONS SMOK 2; *US DEP HHS, 1990, DHHS PUBLICATION; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R; US Public Health Service, 1964, SMOK HLTH REP ADV CO; *USDA, 2001, USDA COMM EC DIV RES; Wakai K, 2001, JPN J CANCER RES, V92, P821, DOI 10.1111/j.1349-7006.2001.tb01167.x; Weinberg CR, 1999, J NATL CANCER I, V91, P1985, DOI 10.1093/jnci/91.23.1985; Westra WH, 1998, J NATL CANCER I, V90, P1500, DOI 10.1093/jnci/90.20.1500; Wu-Williams AH, 1994, EPIDEMIOLOGY LUNG CA, P71; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; WYNDER EL, 1955, CANCER RES, V15, P445; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; ZANG EA, 1992, CANCER, V70, P69, DOI 10.1002/1097-0142(19920701)70:1<69::AID-CNCR2820700112>3.0.CO;2-A	163	156	159	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7307	7325		10.1038/sj.onc.1205807	http://dx.doi.org/10.1038/sj.onc.1205807			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379875				2022-12-28	WOS:000178618000005
J	Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G				Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G			The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/SH2-catalytic domain linker interactions	ONCOGENE			English	Article						Fyn; Lck; substrate specificity; T cells; Sam68	PROTEIN-TYROSINE KINASE; SH3 DOMAIN; MICE LACKING; LIPID RAFTS; C-SRC; CRYSTAL-STRUCTURE; BINDING-PROTEIN; KH-DOMAIN; ACTIVATION; FAMILY	Sam68 phosphorylation correlates with Fyn but not Lck expression in T cells. This substrate has been used here to explore the possible basis of the specificity of Fyn versus Lck. We show that this specificity is not based on a spatial segregation of the two kinases, since a chimeric Lck molecule containing the membrane anchoring domain of Fyn does not phosphorylate Sam68. Moreover, a Sam68 molecule targeted to the plasma membrane by the farnesylation signal of c-Ha-Ras remains poorly phosphorylated by Lck. In T cells, Fyn appears to be the active Src kinase in rafts, but Sam68 is not expressed in rafts, and its distinct phosphorylation by Fyn and Lck is not affected by raft dispersion. The Fyn/Lck specificity does not reflect a higher kinase activity of Fyn in general, as both Fyn and Lck are similarly recognized by an anti-active Src antibody. Both also strongly phosphorylate another Src substrate in vivo. Mainly, Lck phosphorylates Sam68 when the interaction between the SH3 domain and the SH2-catalytic domain linker is altered in heterologous Src molecules or after mutating key residues in the linker that increase the accessibility of the SH3 domain. Thus, the distinct potential of Fyn and Lck to phosphorylate Sam68 is likely controlled by the interaction of the kinase SH3 domain with the linker and Sam68, possibly on a competitive binding basis.	Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France; Inst J Paoli I Calmettes, Lab Labellise Ligue Natl Contre Canc, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM U119, F-13009 Marseille, France; Univ London Imperial Coll Sci Technol & Med, Sect Cell & Mol Biol, Div Biomed Sci, Fac Med, London SW7 2AZ, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Imperial College London	Bismuth, G (corresponding author), Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France.		Feuillet, Vincent/P-4988-2017; COLLETTE, Yves/F-2270-2013	Feuillet, Vincent/0000-0003-1898-2527; COLLETTE, Yves/0000-0001-5359-7099; Harriague, Julie/0000-0001-6824-9169				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jabado N, 1998, J IMMUNOL, V161, P2798; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; Lang V, 1999, J IMMUNOL, V162, P7224; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607	58	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7205	7213		10.1038/sj.onc.1205929	http://dx.doi.org/10.1038/sj.onc.1205929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370810				2022-12-28	WOS:000178504600008
J	Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR				Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR			Elevated mutant frequencies and predominance of G : C to A : T transition mutations in Msh6(-/-) small intestinal epithelium	ONCOGENE			English	Article						DNA mismatch repair; Msh6; lacI; transgenic shuttle-phage; small intestinal epithelium; Big Blue (TM)	DNA MISMATCH REPAIR; MSH2 DEFICIENT MICE; TRANSGENIC MICE; IN-VIVO; HUMAN-CELLS; GENE PMS2; CANCER; RODENTS; MOUSE; BETA	The DNA mismatch repair (MMR) system is primarily responsible for purging newly synthesized DNA of errors incurred during semi-conservative replication. Lesion recognition is initially carried out by one of two heterodimeric protein complexes, MutSalpha, or MutSbeta. While the former, comprised of MSH2 and MSH6, recognizes mispairs as well as short (1-2 nucleotide) insertions/deletions (IDLs), the latter, made up of MSH2 and MSH3, is primarily responsible for recognizing 2-6 nucleotide IDLs. As most of the functional information on these heterodimers is derived from in vitro studies, it was of interest to study the in vivo consequences of a lack of MutSalpha To this end, Big Blue(TM) mice, that carry a lacI(+) transgenic lambda shuttle-phage mutational reporter, were crossed with Msh6(-/-)mice to evaluate the specific contribution of MutSalpha to genome integrity. Consistent with the importance of MutSalpha in lesion surveillance, small intestine epithelial cell DNA derived from lacI(+) Msh6(-/-) mice exhibited striking increases (average of 41-fold) in spontaneous mutant frequencies. Furthermore, the lacI gene mutation spectrum was dominated by G:C to A:T transitions, highlighting the critical importance of the MutSalpha complex in suppressing this frequently observed type of spontaneous mutation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Calgary; Yeshiva University; Albert Einstein College of Medicine	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.				NATIONAL CANCER INSTITUTE [R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CANCER RES, V59, P5068; Kuraguchi M, 2001, CANCER RES, V61, P7934; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Monroe JJ, 2001, MUTAT RES-FUND MOL M, V476, P1, DOI 10.1016/S0027-5107(01)00081-1; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; PROVOST GS, 1993, MUTAT RES, V288, P133; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Skopek T, 1998, MUTAT RES-FUND MOL M, V400, P77, DOI 10.1016/S0027-5107(98)00040-2; Umar A, 1998, GENETICS, V148, P1637; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Zhang SL, 2001, ENVIRON MOL MUTAGEN, V37, P141, DOI 10.1002/em.1021	43	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7126	7130		10.1038/sj.onc.1205861	http://dx.doi.org/10.1038/sj.onc.1205861			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370835				2022-12-28	WOS:000178424900016
J	Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S				Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S			Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase	ONCOGENE			English	Article						FGF-2; uPA; endothelial cells; L6 myoblasts; PI3-kinase; Ras	FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR-BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; HIGH-AFFINITY; EXPRESSION; DIFFERENTIATION; ANGIOGENESIS; INHIBITION	Activation of phosphoinositide 3-kinase (PI3-kinase) is involved in many cellular responses. FGF-2 is one of the potent inducers of urokinase-type plasminogen activator (uPA) production in endothelial cells. However, little is known about the molecular mechanisms underlying FGF-2-mediated uPA production. Here we examined the signal transduction pathways involved in the regulation of uPA production by FGF-2-treatment. FGF-2 potently upregulated uPA production in murine brain capillary endothelial cells (IBE cells), as well as porcine aortic endothelial (PAE) cells and L6 myoblasts ectopically expressing FGFR1. PI3-kinase inhibitors, wortmannin and LY294002, both enhanced FGF-2-dependent uPA production by these cells. Stable expression of activated mutant p110alpha catalytic subunit of PI3-kinase into IBE cells decreased FGF-2-mediated uPA production, suggesting that PI3-kinase exhibited the negative regulatory effect on uPA production. No increase in FGF-2-induced PI3-kinase activity was observed in proteins immunoprecipitated by anti-phosphotyrosine antibody. Although stable expression of deleted mutant p85alpha regulatory subunit, which lacks association with p110 catalytic subunit, in IBE cells showed no dominant negative effect, transient expression of dominant negative Ras inhibited FGF-2-mediated PI3-kinase activation. These results suggest that only activated Ras contributed the FGF-2-mediated PI3-kinase activation. In cells stably expressing mutant p85a subunit, FGF-2 efficiently induced uPA production. Taken together, activation of PI3-kinase by FGF-2 is Ras-dependent and results in down-regulation of uPA production.	Nagasaki Univ, Dept Urol, Nagasaki 8528051, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, Nagasaki 8528051, Japan	Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Dept Urol, 1-7-1 Sakamoto, Nagasaki 8528051, Japan.	shigeruk@net.nagasaki-u.ac.jp						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Giuliani R, 1999, J CELL SCI, V112, P2597; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7027	7033		10.1038/sj.onc.1205736	http://dx.doi.org/10.1038/sj.onc.1205736			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370824				2022-12-28	WOS:000178424900005
J	Sekhar, KR; Yan, XX; Freeman, ML				Sekhar, KR; Yan, XX; Freeman, ML			Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2	ONCOGENE			English	Article						Nrf2; INrf2; ubiquitin; proteasome	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; SUBUNIT GENE; INDUCIBLE EXPRESSION; CATALYTIC SUBUNIT; GLUTATHIONE; PROTEIN; DOMAIN	INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway. Nrf2 co-immunoprecipitated with a HA tagged ubiquitin polymer and accumulated in cells expressing inactive ubiquitin activating enzyme El. Inhibition of proteasome activity resulted in accumulation of Nrf2. The rate of Nrf2 degradation, measured under conditions where the majority of Nrf2 was not tethered, exhibited a T-1/2 of approximately 3 h. Over-expression of human INrf2, KIAA0132, blocked Nrf2 conjugation to the ubiquitin polymer and blocked Nrf2 degradation. These results suggest that association of Nrf2 with INrf2 inhibits ubiquitin-proteasome degradation of Nrf2. Maintaining the majority of Nrf2 in a tethered form, resistant to ubiquitin-proteasome dependent degradation, allows a pool of Nrf2 to be available for rapid Nrf2/ARE-dependent gene transcription following stress mediated release from INrf2. Further, the observation that free Nrf2 is degraded by the ubiquitin proteasome pathway provides a potential mechanism by which ARE-dependent gene transcription is attenuated after induction.	Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA	Vanderbilt University	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Konjeti, Sekhar/0000-0003-2930-0739; Freeman, Michael/0000-0003-1881-366X	NCI NIH HHS [R01 CA038079, CA-38079] Funding Source: Medline; NIEHS NIH HHS [P30ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA038079, R01CA038079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; McMahon M, 2001, CANCER RES, V61, P3299; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wolf CR, 2001, P NATL ACAD SCI USA, V98, P2941, DOI 10.1073/pnas.071042698; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497	26	111	113	12	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6829	6834		10.1038/sj.onc.1205905	http://dx.doi.org/10.1038/sj.onc.1205905			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360409				2022-12-28	WOS:000178315800013
J	Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ				Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ			The function of multiple I kappa B : NF-kappa B complexes in the resistance of cancer cells to Taxol-induced apoptosis	ONCOGENE			English	Article						apoptosis; gene expression; NF-kappa B; I kappa B; bcl-xl	PRECURSOR NF-KAPPA-B1; KINASE COMPLEX; MICE LACKING; ACTIVATION; ALPHA; PHOSPHORYLATION; INHIBITION; EXPRESSION; PROTEINS; PATHWAY	The Rel/NF-kappaB transcription factors play a key role in the regulation of apoptosis and in tumorigenesis by controlling the expressions of specific genes. To determine the role of the constitutive activity of RelA in tumorigenesis, we generated pancreatic tumor cell lines that express a dominant negative mutant Of IkappaBalpha (IkappaBalphaM). In this report, we show that the inhibition of constitutive NF-kappaB activity, either by ectopic expression Of IkappaBalphaM or by treating the cells with a proteasome inhibitor PS-341 which blocks intracellular degradation Of IBalpha proteins, downregulates the expression of bcl-xl. We identified two putative NF-kappaB binding sites (kappaB/A and B) in the bcl-xl promoter and found that these two sites interact with different NF-kappaB proteins. p65/p50 heterodimer interacts with kappaB/A site whereas p50/p50 homodimer interacts with kappaB/B. The bcl-xl promoter reporter gene assays reveal that NF-kappaB dependent transcriptional activation is mainly mediated by kappaB/A site, indicating that bcl-xl is one of the downstream target genes regulated by RelA/ p50. Both IkappaBalphaM and PS-341 completely abolish NF-kappaB DNA binding activity; however, PS-341, but not ectopic expression Of IkappaBalphaM, sensitized cells to apoptosis induced by Taxol. This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation Of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells. These results demonstrate the important function of various NF-kappaB/IkappaB complexes in regulating anti-apoptotic genes in response to apoptotic stimuli, and they raise the possibility that NF-kappaB:IkappaBalpha and NF-kappaB:IkappaBbeta complexes are regulated by different upstream activators, and that NF-kappaB plays a key role in pancreatic tumorigenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Bern, Inselspital, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bern; University Hospital of Bern; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; Schmidt, Christian/0000-0002-1260-9732	NCI NIH HHS [CA73675, CA75517, CA78778] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075517, P01CA078778, R29CA073675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; Gilmore TD, 1996, ONCOGENE, V13, P1367; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Ishikawa H, 1996, ONCOGENE, V13, P255; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jordan MA, 1996, CANCER RES, V56, P816; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Sambrook J., 1989, MOL CLONING; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	41	142	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6510	6519		10.1038/sj.onc.1205848	http://dx.doi.org/10.1038/sj.onc.1205848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226754				2022-12-28	WOS:000177925300011
J	Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK				Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK			Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus	ONCOGENE			English	Article						oesophageal cancer; transcript map; tylosis	PALMOPLANTAR KERATODERMA; CHROMOSOME 17Q; N-ACETYLTRANSFERASE; HUMAN GENOME; ALLELIC LOSS; EXPRESSION; CARCINOMA; TUMORS; MAP; IDENTIFICATION	The locus for a syndrome of focal palmoplantar keratoderma (Tylosis) associated with squamous cell oesophageal cancer (TOC) has been mapped to chromosome 17q25, a region frequently deleted in sporadic squamous cell oesophageal tumours. Further haplotype analysis described here, based on revised maps of marker order, has reduced the TOC minimal region to a genetic interval of 2 cM limited by the microsatellite markers D17S785 and D17S751. Partial sequence data and complete physical maps estimate the actual size of this region to be only 0.5 Mb. This analysis allowed the exclusion of proposed candidate tumour suppressor genes including MLL septin-like fusion (MSF), survivin, and deleted in multiple human cancer (DMC1). Computer analysis of sequence data from the minimal region identified 13 candidate genes and the presence of 50-70 other 'gene fragments' as ESTs and/or predicted exons and genes. Ten of the characterized genes were assayed for mutations but no disease-specific alterations were identified in the coding and promoter sequences. This region of chromosome 17q25 is, therefore, relatively gene-rich, containing 13 known and possibly as many as 50 predicted genes. Further mutation analysis of these predicted genes, and others possibly residing in the region, is required in order to identify the elusive TOC locus.	Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Liverpool L69 3GN, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L7 8XP, Merseyside, England; Univ London, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; Queen Mary University London	Risk, JM (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Edwards Bldg,Daulby St, Liverpool L69 3GN, Merseyside, England.	j.m.risk@liverpoool.ac.uk	Field, John K./AAD-5674-2020; McRonald, Fiona/B-4005-2009; Kelsell, David P/F-8767-2011	Field, John K./0000-0003-3951-6365; Kelsell, David/0000-0002-9910-7144; McRonald, Fiona/0000-0001-7226-9461				Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847; Brown LM, 2001, AM J EPIDEMIOL, V153, P114, DOI 10.1093/aje/153.2.114; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Franceschi S, 2000, INT J CANCER, V86, P626, DOI 10.1002/(SICI)1097-0215(20000601)86:5&lt;626::AID-IJC4&gt;3.0.CO;2-Y; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Fukino K, 1999, GENE CHROMOSOME CANC, V24, P345, DOI 10.1002/(SICI)1098-2264(199904)24:4<345::AID-GCC8>3.0.CO;2-Q; Geylan YS, 2001, NEOPLASMA, V48, P108; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; HOWELEVANS W, 1958, Q J MED, V27, P413; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Iwaya T, 1998, GASTROENTEROLOGY, V114, P1206, DOI 10.1016/S0016-5085(98)70426-3; Jones J, 2002, INT J ONCOL, V20, P697; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kuhlenbaumer G, 1999, GENOMICS, V62, P242, DOI 10.1006/geno.1999.5991; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li FZ, 1999, CANCER RES, V59, P3143; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Protopopov A, 2000, CYTOGENET CELL GENET, V88, P312, DOI 10.1159/000015516; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; RISK JM, 2002, IN PRESS BIOTECHNIQU; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Shibuta K, 2001, AM J GASTROENTEROL, V96, P3419; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; Sureau A, 1997, NUCLEIC ACIDS RES, V25, P4513, DOI 10.1093/nar/25.22.4513; Taniguchi A, 1998, BIOCHEM BIOPH RES CO, V243, P177, DOI 10.1006/bbrc.1998.8078; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	45	33	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6395	6402		10.1038/sj.onc.1205768	http://dx.doi.org/10.1038/sj.onc.1205768			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214281				2022-12-28	WOS:000177829000017
J	Winey, M; Huneycutt, BJ				Winey, M; Huneycutt, BJ			Centrosomes and checkpoints: the MPS1 family of kinases	ONCOGENE			English	Review						MPS1 kinase; spindle pole body (SPB); centrosome; spindle assembly checkpoint	SPINDLE POLE BODY; DUPLICATION GENE MPS1; PROTEIN-KINASE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; MITOTIC CHECKPOINT; ASSEMBLY CHECKPOINT; COMPONENT SPC110P; MITOSIS; COMPLEX		Univ Colorado, MCD Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Winey, M (corresponding author), Univ Colorado, MCD Biol, 347 UCB, Boulder, CO 80309 USA.				NIGMS NIH HHS [GM51312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Brady DM, 2000, CURR BIOL, V10, P675, DOI 10.1016/S0960-9822(00)00515-7; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; Chial HJ, 1999, BIOL CELL, V91, P439, DOI 10.1016/S0248-4900(99)80085-9; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DONALDSON A, 1995, J CELL BIOL, V132, P887; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fraschini R, 2001, MOL GENET GENOMICS, V266, P115, DOI 10.1007/s004380100533; FRIEDMAN D, 1995, J CELL BIOL, V132, P903; Friedman DB, 2001, J BIOL CHEM, V276, P17958, DOI 10.1074/jbc.M010461200; Gillett ES, 2001, DEV CELL, V1, P162, DOI 10.1016/S1534-5807(01)00032-6; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HE X, 1997, J CELL SCI, V111, P1635; HOGG D, 1994, ONCOGENE, V9, P89; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jones MH, 2001, P NATL ACAD SCI USA, V98, P13675, DOI 10.1073/pnas.241417098; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LINDBERG RA, 1993, ONCOGENE, V8, P351; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; MILLS GB, 1992, J BIOL CHEM, V267, P16000; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Pereira G, 1998, MOL BIOL CELL, V9, P775, DOI 10.1091/mbc.9.4.775; POCH O, 1994, MOL GEN GENET, V243, P641, DOI 10.1007/BF00279573; Schramm C, 2000, EMBO J, V19, P421, DOI 10.1093/emboj/19.3.421; Schutz AR, 1998, MOL BIOL CELL, V9, P759, DOI 10.1091/mbc.9.4.759; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sundberg HA, 1997, MOL BIOL CELL, V8, P2575, DOI 10.1091/mbc.8.12.2575; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	53	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6161	6169		10.1038/sj.onc.1205712	http://dx.doi.org/10.1038/sj.onc.1205712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214245				2022-12-28	WOS:000177840500004
J	Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E				Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E			Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis	ONCOGENE			English	Article						cathepsin-D; cancer; proliferation; angiogenesis; apoptosis	BREAST-CANCER CELLS; CARCINOMA; GROWTH; METASTASIS; PROTEASE; MATRIX	Cathepsin-D is an independent marker of poor prognosis in human breast cancer. We previously showed that human wild-type cathepsin-D, as well as its mutated form devoid of proteolytic activity stably transfected in 3Y1-Ad12 cancer cells, stimulated tumor growth. To investigate the mechanisms by which human cathepsin-D and its catalytically-inactive counterpart promoted tumor growth in vivo, we quantified the expression of proliferating cell nuclear antigen, the number of blood vessels and of apoptotic cells in M-AM tumor xenografts. We first verified that both human wild-type and mutated cathepsin-D were expressed at a high level in cathepsin-D xenografts, whereas no human cathepsin-D was detected in control xenografts. Our immunohistochemical studies then revealed that both wild-type cathepsin-D and catalytically-inactive cathepsin-D, increased proliferating cell nuclear antigen expression and tumor angiogenesis. Interestingly, wild-type cathepsin-D significantly inhibited tumor apoptosis, whereas catalytically-inactive cathepsin-D did not. We therefore propose that human. cathepsin-D stimulates tumor growth by acting-directly or indirectly-as a mitogenic factor on both cancer and endothelial cells independently of its catalytic activity. Our overall results provide the first mechanistic evidences on the essential role of cathepsin-D at multiple tumor progression steps, affecting cell proliferation, angiogenesis and apoptosis.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France; CHU A Villeneuve, Biol Cellulaire Lab, F-34295 Montpellier 5, France; Ctr Hosp Luxembourg 4, Lab Hemato Cancerol, L-1210 Luxembourg, Luxembourg	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Luxembourg Hospital Center	Liaudet-Coopman, E (corresponding author), Univ Montpellier 1, INSERM, U540, 60 rue Navacelles, F-34090 Montpellier, France.		Berchem, Guy/C-9364-2014; Liaudet-Coopman, Emmanuelle/N-4744-2017	Berchem, Guy/0000-0003-0157-2257; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BARRETT AJ, 1970, BIOCHEM J, V117, P601, DOI 10.1042/bj1170601; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Gonzalez-Vela MC, 1999, HISTOPATHOLOGY, V34, P35; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; Morikawa W, 2000, J BIOL CHEM, V275, P38912, DOI 10.1074/jbc.M005402200; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Tsukuba T, 2000, MOL CELLS, V10, P601, DOI 10.1007/s100590000019; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	24	181	195	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5951	5955		10.1038/sj.onc.1205745	http://dx.doi.org/10.1038/sj.onc.1205745			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185597				2022-12-28	WOS:000177520900017
J	Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA				Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA			A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions	ONCOGENE			English	Article						p53 gene; yeast functional assay; p53 expression; mutational hotspots; enhanced transactivation; Xpc mice	NUCLEOTIDE EXCISION-REPAIR; WILD-TYPE P53; IN-VIVO; HUMAN CANCER; CELL-LINES; IONIZING-RADIATION; GENE-EXPRESSION; TERMINAL DOMAIN; DEFICIENT MICE; BAX PROMOTER	A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122-->L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc-/-) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122-->L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122-->L allele in p53-/- mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122-->L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122-->L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122-->L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122-->L mutant allele in the Xpc-/- background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Dept Pathol, Lab Mol Pathol, SW Med Ctr, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233,Mail Drop D3-01,TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Resnick@NIEHS.NIH.GOV	Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brash DE, 1998, CANCER SURV, V32, P69; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Cheo DL, 2000, CANCER RES, V60, P1580; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCallum DE, 1996, ONCOGENE, V13, P2575; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Rodin SN, 1998, INT J MOL MED, V1, P191; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Takeuchi S, 1998, CANCER RES, V58, P641; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhao RB, 2000, GENE DEV, V14, P981	66	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5704	5715		10.1038/sj.onc.1205779	http://dx.doi.org/10.1038/sj.onc.1205779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173040				2022-12-28	WOS:000177463400005
J	Baudry, D; Faussillon, M; Cabanis, MO; Rigolet, M; Zucker, JM; Patte, C; Sarnacki, S; Boccon-Gibod, L; Junien, C; Jeanpierre, C				Baudry, D; Faussillon, M; Cabanis, MO; Rigolet, M; Zucker, JM; Patte, C; Sarnacki, S; Boccon-Gibod, L; Junien, C; Jeanpierre, C			Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour	ONCOGENE			English	Article						Wilms' tumour; expression profiling; WTI splicing; prognosis	ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; SUPPRESSOR WT1; FUNCTIONAL INTERACTION; TISSUE INHIBITOR; SEX; PROTOONCOGENE; METASTASIS; MUTATIONS; INDUCTION	Wilms' tumour (WT) or nephroblastoma is the most frequent kidney cancer in children. In a previous study, we reported alterations to WTI transcription in 90% of WT tested, with decreased exon 5 +/- isoform ratio being the most frequent alteration (56% of WT). We now report an approach based on cDNA profiling of tumour pools to identify genes likely to be dysregulated in association with a decreased WTI exon 5 +/- ratio. We compared the expression profiles of pools of tumours classified according to whether this isoform imbalance was present (five tumours) or not (four tumours), using Atlas Cancer cDNA expression arrays. Fourteen of 588 genes tested displayed specific up-regulation (CCND2, PCNA, N-MYC, E2F3, TOP2A, PAK1, DCC and PCDH2) or down-regulation (VEGF, IGFBP5, TIMP3, ARHB, C-FOS and CD9) in the pool of tumours with decreased exon 5 +/- ratio. These results were validated by RT-PCR analysis of four genes (CCND2, PCNA, VEGF and IGFBP5). We extended the analysis of VEGF expression to 51 tumours by real-time RTPCR and ascertained differential expression of this gene associated with WTI expression pattern. Moreover, our results suggest that the VEGF expression level may be of prognosis relevance for relapsed patients.	Univ Paris 05, Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Inst Curie, F-75248 Paris, France; Inst Gustave Roussy, F-94805 Villejuif, France; Hop Necker Enfants Malad, Clin Chirurg Infantile, F-75743 Paris 15, France; Hop Armand Trousseau, Serv Anat Pathol, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Jeanpierre, C (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France.	jeanpierre@necker.fr	Sarnacki, Sabine/I-2692-2017; Jeanpierre, cecile/H-3770-2017; BLUTEAU, Dominique/AAH-8113-2021	Sarnacki, Sabine/0000-0003-4304-5578; Jeanpierre, cecile/0000-0002-3463-5907; BLUTEAU, Dominique/0000-0002-6530-2363				Bachman KE, 1999, CANCER RES, V59, P798; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Baudry D, 2000, CLIN CANCER RES, V6, P3957; Celiker MY, 2001, ONCOGENE, V20, P4337, DOI 10.1038/sj.onc.1204508; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DECLERCK YA, 1992, CANCER RES, V52, P701; Englert C, 1997, CANCER RES, V57, P1429; Granzen B, 2001, ANTICANCER RES, V21, P771; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Humbert PO, 2000, GENE DEV, V14, P690; Jeanpierre C, 1998, NUCLEIC ACIDS RES, V26, P271, DOI 10.1093/nar/26.1.271; Kayton ML, 1999, J PEDIATR SURG, V34, P743, DOI 10.1016/S0022-3468(99)90367-6; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim CJ, 1996, PATHOL INT, V46, P137, DOI 10.1111/j.1440-1827.1996.tb03589.x; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Linderholm BK, 2001, CANCER RES, V61, P2256; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menke A, 1998, KIDNEY INT, V53, P1512, DOI 10.1046/j.1523-1755.1998.00935.x; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NISEN PD, 1986, CANCER RES, V46, P6217; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; Rigolet M, 2001, PEDIATR NEPHROL, V16, P1113, DOI 10.1007/s004670100040; Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80008-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STANTON BR, 1992, BRAIN PATHOL, V2, P71; Wagner KJ, 2001, BIOCHEM BIOPH RES CO, V287, P977, DOI 10.1006/bbrc.2001.5693; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; WANG ZY, 1995, ONCOGENE, V10, P1243; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432; Zhang XH, 1999, ANTICANCER RES, V19, P1641	40	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5566	5573		10.1038/sj.onc.1205752	http://dx.doi.org/10.1038/sj.onc.1205752			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165855				2022-12-28	WOS:000177442000006
J	Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S				Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S			BRCA2 and Smad3 synergize in regulation of gene transcription	ONCOGENE			English	Article						BRCA2; Smad3; transcription	GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR; CANCER; PROMOTER; PROTEINS; ONCOPROTEIN; FAMILY; COOPERATION; INDUCTION; MUTATIONS	Smad3 is an essential component in the intracellular signaling of transforming growth factor-beta (TGFbeta), which is a potent inhibitor of tumor cell proliferation. BRCA2 is a tumor suppressor involved in early onset of breast, ovarian and prostate cancer. Both Smad3 and BRCA2 possess transcription activation domains. Here, we show that Smad3 and BRCA2 interact functionally and physically. We found that BRCA2 forms a complex with Smad3 in vitro and in vivo, and that both MH1 and MH2 domains of Smad3 contribute to the interaction. TGFbeta1 stimulates interaction of endogenous Smad3 and BRCA2 in non-transfected cells. BRCA2 co-activates Smad3-dependent transcriptional activation of luciferase reporter and expression of plasminogen activator inhibitor-1 (PAM). Smad3 increases the transcriptional activity of BRCA2 fused to the DNA-binding domain (DBD) of Gal4, and reciprocally, BRCA2 co-activates DBD-Gal4-Smad3. Thus, our results show that BRCA2 and Smad3 form a complex and synergize in regulation of transcription.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Ukrainian Acad Sci, Inst Cell Biol, UA-79005 Lvov, Ukraine; Hiroshima Univ, Sch Med, Dept Ophthalmol, Minami Ku, Hiroshima 7348551, Japan	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Cell Biology of NASU; Hiroshima University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Stoika, Rostyslav/0000-0001-5719-2187				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LAIHO M, 1987, J BIOL CHEM, V262, P17467; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nordling M, 1998, CANCER RES, V58, P1372; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	32	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5660	5664		10.1038/sj.onc.1205732	http://dx.doi.org/10.1038/sj.onc.1205732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165866				2022-12-28	WOS:000177442000017
J	Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL				Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL			Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer	ONCOGENE			English	Article						cervical cancer; tumor suppressor gene; chromosome 11q13; loss of heterozygosity; fluorescence in situ hybridization; homozygous deletion	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; HELA-CELLS; FRAGILE SITE; HOMOZYGOUS DELETIONS; ENDOCRINE TUMORS; UTERINE CERVIX; BAND 11Q13; FHIT GENE; MEN1	Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines using chromosome 11 specific probes showed deletion and translocation of 11q13 sequences in five out of eight cell lines. Fluorescence in situ hybridization (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 sequences in the HeLa cells. In order to determine whether 11q13 deletions occur in primary cervical tumors, we analysed 36 tumors using 20 different microsatellite and RFLP markers. Semi automated fluorescein based allelotyping was performed to identify loss of heterozygosity (LOH) in tumors. The results showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near MEN1, the second near D11S913, and the third near INT2 locus were observed. The smallest region of deletion overlap at the D11S913 locus was localized to a 300 Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) probes, confirmed allelic deletion in the tumors. PCR analysis further identified homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore that a putative cervical cancer tumor suppressor gene exists within the 300 kb of chromosome 11q13.	Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, Los Angeles, CA 90073 USA; Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Indiana Univ, Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA; Univ Calif Irvine, Calif Coll Med, Dept Radiat Oncol, Irvine, CA 92697 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Calif Irvine, Calif Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; City Hope Natl Med Ctr, Dept Anat Pathol, Duarte, CA 91010 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California Irvine; City of Hope	Srivatsan, ES (corresponding author), Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, 10H2,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	esrivats@ucla.edu	Pack, Svetlana D./C-2020-2014; Jesudasan, Rachel/AHE-4743-2022	Pack, Svetlana D./0000-0003-3256-6626; Jesudasan, Rachel/0000-0001-9459-832X	NATIONAL CANCER INSTITUTE [R01CA019401, R55CA039312, R37CA019401, R01CA039312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER; NCI NIH HHS [CA39312, CA19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Bednarek AK, 2001, CANCER RES, V61, P8068; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Greenspan DL, 1997, CANCER RES, V57, P4692; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guru SC, 1997, GENOMICS, V42, P436, DOI 10.1006/geno.1997.4783; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; Ishii H, 2001, CANCER RES, V61, P1578; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JESUDASAN RA, 1994, ANTICANCER RES, V14, P1727; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Macville M, 1999, CANCER RES, V59, P141; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; MISRA BC, 1989, AM J HUM GENET, V45, P565; MITRA AB, 1994, CANCER RES, V54, P4481; MONK BJ, 1994, DIAGN MOL PATHOL, V3, P283, DOI 10.1097/00019606-199412000-00012; Muliokandov MR, 1996, CANCER RES, V56, P197; OCADIZ R, 1987, CANCER RES, V47, P4173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Prezant TR, 1998, J CLIN ENDOCR METAB, V83, P1388, DOI 10.1210/jc.83.4.1388; Pulido HA, 2000, CANCER RES, V60, P6677; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RIOU G, 1988, ONCOGENE, V3, P329; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIPRASHVILI Z, 1997, CANCER RES, V57, P5207; Sozzi G, 1997, CANCER RES, V57, P5207; SREEKANTAIAH C, 1987, GYNECOL ONCOL, V28, P337, DOI 10.1016/0090-8258(87)90181-8; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; Srivatsan ES, 2000, GENE CHROMOSOME CANC, V29, P157, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1024>3.0.CO;2-P; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Tanaka C, 1998, J CLIN ENDOCR METAB, V83, P2631, DOI 10.1210/jc.83.8.2631; Venugopalan M, 1998, CANCER GENET CYTOGEN, V104, P124, DOI 10.1016/S0165-4608(97)00461-5; Wang EH, 1998, CANCER RES, V58, P4417; Wood TF, 1996, GENOMICS, V38, P166, DOI 10.1006/geno.1996.0612; Zhuang ZP, 1997, CANCER RES, V57, P4682; ZHUANG ZP, 1995, CANCER RES, V55, P467	55	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5631	5642		10.1038/sj.onc.1205698	http://dx.doi.org/10.1038/sj.onc.1205698			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165862				2022-12-28	WOS:000177442000013
J	Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY				Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY			Regulation of FGF8 expression by the androgen receptor in human prostate cancer	ONCOGENE			English	Article						FGF8; prostate cancer; androgen receptor; gene promoter	FIBROBLAST GROWTH FACTOR-8; OVER-EXPRESSION; DNA-BINDING; MAMMARY; ACTIVATION; CLONING; CELLS; FIBROBLAST-GROWTH-FACTOR-8; COACTIVATOR; INTEGRATION	Fibroblast growth factor 8 (FGF8) has been shown to play a key role in prostate carcinogenesis. It was initially cloned as an androgen induced protein in mouse mammary cancer SC3 cells. In this study, we examined if FGF8 was also regulated by the androgen receptor in human prostate cancer. FGF8b protein expression in resected clinical prostate cancer correlated closely with expression of the androgen receptor (AR). In the androgen sensitive CWR22 prostate xenograft, we observed up-regulation of FGF8b immunoreactivity in testosterone supplemented mice while castration markedly reduced its signal. Furthermore, FGF8b protein expression in AR positive LNCaP cells was similarly enhanced by androgens. The proximal promoter of the human FGF8 gene was cloned into a luciferase reporter construct (FGF8.luc). FGF8.luc activity in AR positive LNCaP and SC3 cells was increased 2.5-fold by androgens. In AR negative DU145 cells, maximal induction of FGF8.luc required both cotransfection of the AR and the presence of androgens. The anti-androgen bicalutamide completely abolished AR mediated FGF8.luc induction. Deletion constructs from FGF8.luc have further defined an active promoter region and an androgen responsive region. Nucleotide analysis of this androgen responsive region has revealed putative androgen response elements. Finally, using ChIP assays we confirmed in vivo interaction between the AR and the androgen responsive region of the FGF8 promoter. Taken together these data provide first evidence that expression of the mitogen FGF8 in prostate cancer is, at least in part, regulated by the androgen receptor at the transcriptional level.	Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.Y.Leung@ncl.ac.uk		Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Bower M, 1997, SEMIN CANCER BIOL, V8, P3, DOI 10.1006/scbi.1997.0055; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Greenwood M, 2000, HIST TODAY, V50, P3; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Koivisto PA, 1999, J PATHOL, V189, P219, DOI 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F; KOUHARA H, 1994, ONCOGENE, V9, P455; Kuriki K, 2000, CELL MOL BIOL, V46, P1147; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; Merrill RM, 1996, J NATL CANCER I, V88, P1683, DOI 10.1093/jnci/88.22.1683; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Myers RB, 1999, J UROLOGY, V161, P945, DOI 10.1016/S0022-5347(01)61826-3; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Song ZG, 2000, CANCER RES, V60, P6730; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Tanaka S, 2001, DIGEST DIS SCI, V46, P1016, DOI 10.1023/A:1010753826788; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; White RD, 1997, EUR UROL, V31, P1; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yoshiura K, 1997, AM J MED GENET, V72, P354, DOI 10.1002/(SICI)1096-8628(19971031)72:3<354::AID-AJMG21>3.3.CO;2-C	43	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5069	5080		10.1038/sj.onc.1205663	http://dx.doi.org/10.1038/sj.onc.1205663			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140757				2022-12-28	WOS:000176975900005
J	Arnott, CH; Scott, KA; Moore, RJ; Hewer, A; Phillips, DH; Parker, P; Balkwill, FR; Owens, DM				Arnott, CH; Scott, KA; Moore, RJ; Hewer, A; Phillips, DH; Parker, P; Balkwill, FR; Owens, DM			Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway	ONCOGENE			English	Article						inflammation; skin; keratinocyte; matrix metalloproteinase; carcinogenesis	PROTEIN-KINASE-C; NF-KAPPA-B; TNF-ALPHA; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; DOWN-REGULATION; PHORBOL ESTER; SKIN TUMORS; MOUSE KERATINOCYTES; TYROSINE KINASE	Tumour necrosis factor-alpha (TNF-alpha) deficient mice (TNF-alpha(-/-) mice) are resistant to skin carcinogenesis. Cellular signalling via the transcription factor complex AP-1 is thought to play a key role in tumour promotion. The induction of a specific subset of AP-1 responsive genes thought to be important for tumour development, namely GM-CSF, MMP-9 and MMP-3, was suppressed in TNF-alpha(-/-) compared to wild-type mouse skin in response to the tumour promotor TPA. The differential induction of these genes correlated with a temporal shift in AP-1 activation and c-Jun expression in TNF-alpha(-/-) compared to wild-type epidermis. The major receptor for TPA-induced signalling in basal keratinocytes, PKCalpha, was also differentially regulated in wild-type compared with TNF-alpha(-/-) epidermis. A marked delay in TPA-induced intracellular translocation and downregulation of PKCalpha was observed in TNF-alpha(-/-) epidermis, which correlated with the deregulated TPA-induced AP-1 activation and c-Jun expression. The frequency of DNA adduct formation and c-Ha-ras mutations was the same in wild-type and TNF-alpha(-/-) epidermis after DMBA treatment, suggesting that TNF-alpha was not involved in tumour initiation. These data suggest that the pro-inflammatory cytokine TNF-alpha is a critical mediator of tumour promotion, acting via a PKCalpha- and AP-1-dependent pathway. This may be one mechanism by which chronic inflammation increases susceptibility to cancer.	Univ London, Barts & London Sch Med & Dent, Canc Res UK Translat Oncol Lab, John Vane Sci Ctr, London EC1M 6BQ, England; Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; Canc Res UK, Prot Phosphorylat Lab, London WC2A 3PX, England; Canc Res UK, Keratinocyte Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK	Balkwill, FR (corresponding author), Univ London, Barts & London Sch Med & Dent, Canc Res UK Translat Oncol Lab, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Balkwill, Frances/0000-0002-5587-9759; Phillips, David/0000-0001-8509-3485	NCI NIH HHS [CA75638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bogovski P, 1994, IARC Sci Publ, P1; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; Goodell AL, 1996, J INVEST DERMATOL, V107, P354, DOI 10.1111/1523-1747.ep12363325; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HANSEN LA, 1990, CANCER RES, V50, P5740; Hulboy DL, 2001, MOL CELL BIOL, V21, P5478, DOI 10.1128/MCB.21.16.5478-5487.2001; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOMORI A, 1993, CANCER RES, V53, P1982; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; Mann A, 2001, CANCER RES, V61, P2311; MILLS KJ, 1992, CARCINOGENESIS, V13, P1113, DOI 10.1093/carcin/13.7.1113; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; MOSER GJ, 1992, CANCER RES, V52, P631; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Pazzaglia S, 2001, MOL CARCINOGEN, V30, P111, DOI 10.1002/1098-2744(200102)30:2<111::AID-MC1019>3.0.CO;2-L; Piscaglia F, 1999, BIOCHEM PHARMACOL, V58, P157, DOI 10.1016/S0006-2952(99)00066-0; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Suganuma M, 1999, CANCER RES, V59, P4516; Suganuma M, 1996, CANCER RES, V56, P3711; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang HQ, 1999, J CELL SCI, V112, P3497; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhong SP, 2001, CANCER RES, V61, P4084	59	136	144	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4728	4738		10.1038/sj.onc.1205588	http://dx.doi.org/10.1038/sj.onc.1205588			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101411				2022-12-28	WOS:000176716300002
J	Grant, DS; Yenisey, C; Rose, RW; Tootell, M; Santra, M; Iozzo, RV				Grant, DS; Yenisey, C; Rose, RW; Tootell, M; Santra, M; Iozzo, RV			Decorin suppresses tumor cell-mediated angiogenesis	ONCOGENE			English	Article						decorin proteoglycan; angiogenesis; migration, attachment; vascular endothelial cell growth factor	GROWTH-FACTOR-RECEPTOR; HEPARAN-SULFATE PROTEOGLYCANS; CAPILLARY ENDOTHELIAL-CELLS; CYCLIN-DEPENDENT KINASES; PROTEIN CORE; GENE-EXPRESSION; COLLAGEN FIBRILLOGENESIS; RIBONUCLEASE INHIBITOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION	The progressive growth of most neoplasms is dependent upon the establishment of new blood vessels, a process regulated by tumor-secreted factors and matrix proteins. We examined the in vitro and in vivo angiogenic ability of conditioned media obtained from fibrosarcoma, carcinoma, and osteosarcoma cells and their decorin-transfected counterparts. Human endothelial cells were investigated in vitro by evaluating three essential steps of angiogenesis: migration, attachment, and differentiation. On the whole, wild-type tumor cell-secretions enhanced endothelial cell attachment, migration, and differentiation, whereas their decorin-expressing forms inhibited these processes. Similarly, decorin-containing media suppressed endothelial cell sprouting in an ex vivo aortic ring assay. Since angiogenesis is an important component of tumor expansion, the growth rate of these cells as tumor xenografts was examined by implantation in nude mice. In vivo, the decorin-expressing tumor xenografts grew at markedly lower rates and showed a significant suppression of neovascularization. Immunohistochemical, Northern and Western blot analyses indicated that the decorin-expressing cells produced vascular endothelial growth factor (VEGF) at markedly reduced rates vis-a-vis their wild-type counterparts. Specificity of this process was confirmed by experiments where addition of recombinant decorin to the wild-type tumor cells caused 80-95% suppression of VEGF mRNA and protein. These results provide a novel mechanism of action for decorin, and indicate that decorin could adversely affect in vivo tumor growth by suppressing the endogenous tumor cell production of a powerful angiogenic stimulus.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112; Yenisey, Cigdem/0000-0001-7693-641X	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; ADANY R, 1990, J BIOL CHEM, V265, P11389; ALBINI A, 1987, CANCER RES, V47, P3239; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Balsari A, 1999, LAB INVEST, V79, P897; BIANCO P, 1993, DERMATAN SULPHATE PR, P193; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; Ghiselli G, 2001, BIOCHEM J, V359, P153, DOI 10.1042/0264-6021:3590153; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1987, AM J PATHOL, V128, P78; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454	65	177	185	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4765	4777		10.1038/sj.onc.1205595	http://dx.doi.org/10.1038/sj.onc.1205595			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101415				2022-12-28	WOS:000176716300006
J	Ren, SX; Cai, HR; Li, ML; Furth, PA				Ren, SX; Cai, HR; Li, ML; Furth, PA			Loss of Stat5a delays mammary cancer progression in a mouse model	ONCOGENE			English	Article						Stat5a; mammary cancer; mouse model; SV40 T antigen, apoptosis	TRANSCRIPTION FACTORS; BREAST-CANCER; GLAND DEVELOPMENT; CELL-SURVIVAL; GROWTH-FACTOR; ACTIVATION; PROLACTIN; EXPRESSION; MICE; SIGNALS	A genetic study was conducted to determine if activated Stat5a contributes to mammary carcinogenesis and to evaluate the mechanism. Similar to human breast cancers, a proportion of mammary adenocarcinomas in the WAP-TAg transgenic mouse model demonstrate constitutive Stat5a/b and Stat3 activation. Stat5a activation is linked to mammary epithelial cell survival and differentiation, and proliferation in hematopoetic cell lineages. Breeding WAP-TAg mice to mice carrying germ-line deletions of the Stat5a gene generated mice with reduced levels of Stat5a. Hemizygous loss of the Stat5a allele significantly reduced levels of Stat5a expression without altering mammary gland development or transgene expression levels. In comparison to mice carrying two wild-type Stat5a alleles, hemizygous loss of the Stat5a allele reduced the number of mice with palpable tumors at 7 months of age (67% from 100%, P<0.05), resulted in smaller tumors at 7 months of age (3.8 cm(3) from 7.6 cm(3), P=0.003), delayed first tumor appearance (208 days from 188 days, P=0.01), and increased the apoptotic index in the adenocarcinomas (4.3+0.3 from 1.2+0.2, P=0.016). Neither cell proliferation nor differentiation in the cancers was altered. Decreasing Stat5a activation levels could be a therapeutic approach for reducing survival of breast cancer cells.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore	Furth, PA (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20007 USA.	paf3@georgetown.edu						Berclaz G, 2001, INT J ONCOL, V19, P1155; Birkenkamp KU, 2001, LEUKEMIA, V15, P1923, DOI 10.1038/sj.leu.2402317; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gallego MI, 2001, DEV BIOL, V229, P163, DOI 10.1006/dbio.2000.9961; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gouilleux-Gruart V, 1997, LEUKEMIA LYMPHOMA, V28, P83, DOI 10.3109/10428199709058334; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Hennighausen L, 1997, J MAMMARY GLAND BIOL, V2, P365, DOI 10.1023/A:1026347313096; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kieslinger M, 2000, GENE DEV, V14, P232; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Schaber JD, 1998, CANCER RES, V58, P1914; Shang YF, 1999, ONCOGENE, V18, P6725, DOI 10.1038/sj.onc.1203084; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162	35	94	97	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4335	4339		10.1038/sj.onc.1205484	http://dx.doi.org/10.1038/sj.onc.1205484			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082622				2022-12-28	WOS:000176174200017
J	Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA				Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA			Global genome repair of 8-oxoG in hamster cells requires a functional CSB gene product	ONCOGENE			English	Article						oxidative DNA damage; repair; DNA instability; Cockayne syndrome	BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; POLYMERASE-II TRANSCRIPTION; COCKAYNE-SYNDROME PATIENTS; RETRACTED ARTICLE. SEE; RNA-POLYMERASE; MITOCHONDRIAL REPAIR; FACTOR CSB/ERCC6; ACIDIC REGION	Cockayne syndrome (CS) is an autosomal recessive human disease characterized by UV-sensitivity as well as neurological and developmental abnormalities. Two complementation groups have been established, designated CS-A and CS-B. Traditionally, CSA and CSB have been ascribed a function in the transcription-coupled repair (TCR) pathway of nucleotide excision repair (NER) that efficiently removes bulky lesions from the transcribed strand of RNA polymerase 11 transcribed genes. To assess the role of the CSB protein in the repair of the highly mutagenic base lesion 7,8-dihydro-8-oxoguanine (8-oxoG), we have investigated the removal of this lesion using an in vitro incision approach with cell extracts as well as an in vivo approach with a modified protocol of the gene-specific repair assay, which allows the measurement of base lesion repair in intragenomic sequences. Our results demonstrate that the integrity of the CSB protein is pivotal for processes leading to incision at the site of 8-oxoG and that the global genome repair (GGR) of this lesion requires a functional CSB gene product in vivo.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	Stevnsner, Tinna/0000-0003-1007-0427				Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Anson RM, 1999, METH MOL B, V113, P257; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1999, BIOCHIMIE, V81, P155, DOI 10.1016/S0300-9084(99)80048-0; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Grishko VI, 1997, MUTAT RES-DNA REPAIR, V384, P73, DOI 10.1016/S0921-8777(97)00017-7; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HTUN H, 1992, METHOD ENZYMOL, V212, P272; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; Kung HC, 1997, J BIOL CHEM, V272, P9227; Le Page F, 1999, BIOCHIMIE, V81, P147, DOI 10.1016/S0300-9084(99)80047-9; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Sunesen M, 2000, NUCLEIC ACIDS RES, V28, P3151, DOI 10.1093/nar/28.16.3151; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; THORSLUND T, 2002, IN PRESS DNA REPAIR; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; Woods CG, 1998, ARCH DIS CHILD, V78, P178, DOI 10.1136/adc.78.2.178	57	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3571	3578		10.1038/sj.onc.1205443	http://dx.doi.org/10.1038/sj.onc.1205443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032859				2022-12-28	WOS:000175793700008
J	Appl, H; Klempnauer, KH				Appl, H; Klempnauer, KH			Targeted disruption of c-myb in the chicken pre B-cell line DT40	ONCOGENE			English	Article						c-myb; DT40 cells; homologous recombination; pre B-cell; Pdcd4	V-MYB; MIM-1 GENE; C/EBP-BETA; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; PDCD4 GENE; NF-M; EXPRESSION; ONCOGENE	The c-myb proto-oncogene is highly expressed in a wide variety of immature hematopoietic cells and plays a key role in the development of the hematopoietic system. c-myb and its retroviral counterpart v-myb encode transcription factors which have been implicated in the regulation of certain target genes. Targeting of c-myb in mouse embryonic stem cells by homologous recombination has provided clear evidence that c-myb is necessary for the proper development of most myeloid lineages of the hematopoietic system as well as of T-lymphocytes. Here we have explored the function of c-myb in the B-lymphoid lineage. We have used the chicken DT40 cells, a pre B-cell line which shows extremely high efficiencies of homologous recombination, as a model system to disrupt c-myb. DT40 cells lacking a functional c-myb gene are viable and show only minor perturbations of their growth parameters, indicating that c-myb is not an essential gene in these cells. We have used the c-myb null DT40 cells to analyse the expression of genes which have been previously been identified as myb target genes. Neither c-myc nor bcl-2, two putative myb targets, showed altered expression in the cells lacking c-myb. However, expression of the Pdcd4 gene, a myb target gene originally identified in a myelomonocytic cell line expressing a conditional form of v-myb, was diminished in the absence of c-myb. The c-myb knock-out cells described here should provide a useful model system for the identification and characterization of c-myb target genes in B-lymphoid cells.	Westfal Wilhelms Univ, Inst Biochem, D-48143 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Westfal Wilhelms Univ, Inst Biochem, Wilhelm Klemm Str 2, D-48143 Munster, Germany.	klempna@uni-muenster.de						Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PRESS RD, 1995, ONCOGENE, V11, P525; QUEVA C, 1992, DEVELOPMENT, V114, P125; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sitzmann J, 1995, ONCOGENE, V11, P2273; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	50	18	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3076	3081		10.1038/sj.onc.1205427	http://dx.doi.org/10.1038/sj.onc.1205427			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082539				2022-12-28	WOS:000175262700016
J	Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ				Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ			Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes	ONCOGENE			English	Article						apoptosis; human skin; keratinocytes; p53; psoriasis; senescence	NF-KAPPA-B; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL TARGET; ULTRAVIOLET-RADIATION; CELLULAR SENESCENCE; MOUSE SKIN; DNA; EXPRESSION; INDUCTION; PROTEIN	The carcinogenic effects of sunlight in human epidermis may be thwarted by either: transient growth arrest and repair of DNA photodamage in keratinocytes (KCs); elimination of KCs with damaged DNA via apoptosis; or by stimulating a senescence switch whereby KCs become irreversibly growth arrested. Using normal human skin organ cultures and living epidermal equivalents, we demonstrate that in the proliferative basal layer, removal of KCs via apoptosis had a rapid onset (beginning within 2 h) following UV-light exposure generating progressively greater numbers of KCs with thymine dimers as the dose of UV-light was increased; involved induction of Apaf-1, activation of caspase-3, and was dependent on p53 activation as addition of a p53 chemical inhibitor blocked the apoptotic response. Suprabasal layer KCs underwent apoptosis at much later time points (> 8 h). KCs in the basal layer repaired DNA damage more rapidly than KCs in suprabasal layers. Steady state levels of p53 increased in irradiated cells, and the increase was accompanied by phosphorylation of serine 9 and serine 15, but not serine 6 residues. By contrast, cultured KCs undergoing spontaneous replicative senescence were resistant to UV-induced apoptosis. Senescent KCs constitutively contained low levels of p53, which were neither increased nor phosphorylated or acetylated after UV-exposure and possessed minimal DNA binding activity, indicative of functional inactivation. Furthermore, treatment of senescent KCs with DNA damaging agent adriamycin did not result in activation of latent p53 or apoptosis. When KCs within psoriatic plaques were examined, they resembled senescent KCs in that they expressed p53, which was not phosphorylated or acetylated. Thus, UV-light induces DNA damage in human epidermal KCs triggering p53 activation, and subsequent apoptosis involving distinct cell layers and kinetics. However, the lack of p53 activation as seen in senescent KCs and psoriatic plaques, is associated with a relative resistance of KCs to UV-induced apoptosis. In conclusion, the sensitivity and resistance of KCs to apoptosis depends not only on the location within various layers of epidermis and levels of p53, but may also involve p53 activation via post-translational modifications.	Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA; Loyola Univ, Ctr Med, Dept Radiat Oncol, Maywood, IL USA	Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA.	Bnickol@lumc.edu	Choubey, Divaker/A-4771-2008		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307, R01AR040065] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47307, AR 40065] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Campbell T, 1998, EXOT PET PRACT, V3, P1; Campisi J, 2000, IN VIVO, V14, P183; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1996, CANC MED, P307; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALL PA, 1993, ONCOGENE, V8, P203; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubilus J, 1996, IN VITRO TOXICOL, V9, P157; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Li G, 1996, AM J PATHOL, V148, P1113; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris RJ, 1997, CANCER RES, V57, P3436; NAKAMURA H, 1994, DEV HYDROB, V91, P3; Nickoloff B J, 2001, J Invest Dermatol, V117, P1; Nickoloff BJ, 2001, J CUTAN PATHOL, V28, P57, DOI 10.1034/j.1600-0560.2001.280201.x; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Ponten F, 2001, JNCI-J NATL CANCER I, V93, P128, DOI 10.1093/jnci/93.2.128; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Qin JZ, 2001, J INVEST DERMATOL, V117, P898, DOI 10.1046/j.0022-202x.2001.01477.x; REES JL, 1995, J INVEST DERMATOL, V104, P883, DOI 10.1111/1523-1747.ep12606149; Robles AI, 2001, CANCER RES, V61, P6660; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; SPANDAU DF, 1994, ONCOGENE, V9, P1861; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; Terui T, 2001, CURR OPIN ALLERGY CL, V1, P461, DOI 10.1097/01.all.0000011061.54491.2e; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; Yaar M, 1998, J Investig Dermatol Symp Proc, V3, P47; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	60	82	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2991	3002		10.1038/sj.onc.1205404	http://dx.doi.org/10.1038/sj.onc.1205404			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082529	Bronze			2022-12-28	WOS:000175262700006
J	Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY				Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY			Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers	ONCOGENE			English	Article						microsatellite instability; promoter methylation; mismatch repair gene mutation; colorectal cancer; HNPCC	MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; YOUNG-PATIENTS; COLON-CANCER; CELL-LINES; MUTATIONS; METHYLATION; EXPRESSION; TUMORS; GENE	High-frequency microsatellite instability (MSI-H) results from deficiency in nucleotide mismatch repair. It contributes significantly to carcinogenesis in the human colorectal mucosa. Here we study 41 colorectal and three other HNPCC-related cancers with MSI-H to provide comprehensive information on the mechanisms of inactivation of the two major proteins involved, hMLH1 and hMSH2. Seventeen of the patients had family histories meeting the criteria for Bethesda grades 1, 2 or 3. Of these familial cases, 14 (83%) had early-onset disease, defined on the basis of diagnosis prior to the age of 50, but in three the disease was of late onset (>50 years). A second subset of 20 patients had early onset disease without family history. The remaining seven patients were selected to allow comparisons with sporadic, late-onset disease, the molecular basis of which has been extensively reported elsewhere. We stratified the tumours initially on the basis of hMLH1 or hMSH2 protein deficiency, detected by immunohistochemistry, and then by analysis of germline and somatic mutation, mRNA transcription, loss of heterozygosity (LOH) at the hMLH1 and hMSH2 loci, and methylation status in two regions of the hMLH1 promoter. The functional significance of several of these changes in the MSI-H tumours was confirmed by comparisons with 16 tumours with low-frequency microsatellite instability and 56 tumours with stable microsatellites. As anticipated, patients with family histories usually showed germline mutation of hMSH2 or hMLH1. In many cases the residual normal allele was silenced in their tumours by loss of heterozygosity (LOH). The small subset of late-onset, sporadic cases confirmed the preponderance in this group of biallelic hMLH1 promoter methylation. In the early-onset, apparently sporadic subset there were 11 tumours with hMLH1 deficiency, five with hMSH2 deficiency and four with no detectable abnormality in expression of either protein. These showed a complex mixture of lesions, including germline and somatic mutations, promoter methylation, LOH, suppression of wild-type RNA by as yet undiscovered mechanisms, or no detectable abnormality in any of these parameters. Evidence is presented to indicate that methylation in proximal region of the hMLH1 promoter is a more reliable correlate of transcriptional silencing in colorectal cancers than methylation in upstream region. These observations have significant implications for management of patients with MSI-H tumours.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Cambridge	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Chung, Lap Ping/C-4258-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.0.CO;2-1; Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376; Cunningham JM, 1998, CANCER RES, V58, P3455; Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shin KH, 2002, CANCER RES, V62, P38; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	22	60	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7585	7592		10.1038/sj.onc.1205968	http://dx.doi.org/10.1038/sj.onc.1205968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386821				2022-12-28	WOS:000178618200014
J	Chou, AH; Howard, BD				Chou, AH; Howard, BD			Inhibition by Wnt-1 or Wnt-3a of nerve growth factor-induced differentiation of PC12 cells is reversed by bisindolylmaleimide-I but not by several other PKC inhibitors	ONCOGENE			English	Article						bisindolylmaleimide-I; protein kinase C; signaling	PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3; SIGNALING PATHWAY; PHEOCHROMOCYTOMA CELLS; INT-1 PROTOONCOGENE; COLON-CARCINOMA; ACTIVATION; MOUSE; EXPRESSION; POTENT	Wnt-1 and Wnt-3a exhibit redundancy in neural crest development. We have found that they do not produce the same effects on PC12 cells, which were obtained from the adrenal medulla, a neural crest derivative. However, both Wnt-1 or Wnt-3a inhibit nerve growth factor (NGF)-induced neurite outgrowth. The inhibition is reversed by the protein kinase C (PKC) inhibitor, bisindolylmaleimide-I, but it did not reverse Wnt-l-induced activation of the canonical Writ pathway. The Wnt-1 inhibitory effect was not reversed by several other PKC inhibitors, by phorbol ester-induced down-regulation of PKC, or by pertussis toxin, which is known to inhibit another Writ signaling pathway, the Wnt/Ca2+ pathway. We suggest that bisindolylmaleimide-I acts by affecting either a pathway downstream from Lef-1/Tcf in the canonical pathway or a Writ signaling pathway other than the canonical pathway. In either case, the bisindolylmaleimide-I sensitivity of this pathway should aid in its identification.	Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Howard, BD (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA.							ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; EDREICHEPSTEIN A, 1998, GROWTH FACTORS, V15, P149; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Ito Y, 1997, J NEUROCHEM, V69, P729; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J., 2002, MOL CLONING LAB MANU; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRACHTE GJ, 1995, AM J PHYSIOL-CELL PH, V268, pC978, DOI 10.1152/ajpcell.1995.268.4.C978; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	35	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6348	6355		10.1038/sj.onc.1205791	http://dx.doi.org/10.1038/sj.onc.1205791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214275				2022-12-28	WOS:000177829000011
J	Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Isolation of HELAD1, a novel human helicase gene up-regulated in colorectal carcinomas	ONCOGENE			English	Article						helicase; APC; HELAD1; colon cancer	DEAD BOX PROTEIN; BETA-CATENIN; DNA HELICASE; HEPATOCELLULAR CARCINOMAS; XERODERMA-PIGMENTOSUM; CYCLIN D1; CELL; MUTATIONS; TARGET; APC	To investigate the mechanisms of colorectal carcinogenesis, we searched for genes regulated by adenomatous polyposis coli gene product (APC) and identified a novel gene, termed HELAD1 (helicase, APC down-regulated 1). A recombinant polypeptide representing the ATPases associated with cellular activities (AAA) domain of the HELAD1 product showed 3' to 5' helicase activity and exonuclease activity in vitro. HELAD1 was abundantly expressed in 16 of 20 colon cancers examined but hardly detectable in corresponding non-cancerous mucosae. Treatment of colon-cancer cells with antisense oligonucleotides suppressed its expression and induced apoptosis. These data revealed an importance of HELAD1 in colorectal carcinogenesis and suggest that suppression of HELAD1 may be a promising therapeutic strategy.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Dept Surg 2, Sch Med, Mizuho Ku, Nagoya, Aichi 4678601, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Nagoya City University; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Shimokawa, Takashi/AAA-5870-2020; Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Shimokawa, Takashi/0000-0001-6549-9277; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Fujita M, 2001, CANCER RES, V61, P7722; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEKIMI S, 1993, J NEUROSCI, V13, P4254; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; Kawasoe T, 2000, CANCER RES, V60, P3354; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lin YM, 2001, CANCER RES, V61, P6345; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neuwald AF, 1999, GENOME RES, V9, P27; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ono K, 2000, CANCER RES, V60, P5007; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seto M, 1995, GENE, V166, P293, DOI 10.1016/0378-1119(95)00559-5; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Xu LF, 2000, GENE DEV, V14, P585; Yamada T, 2000, CANCER RES, V60, P4761; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6387	6394		10.1038/sj.onc.1205751	http://dx.doi.org/10.1038/sj.onc.1205751			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214280				2022-12-28	WOS:000177829000016
J	Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY				Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY			Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway	ONCOGENE			English	Article						gastric cancer; apoptosis; protein kinase C; cyclo-oxygenase-2; cancer prevention	COLON-CANCER CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUG; KAPPA-B ACTIVITY; CYCLOOXYGENASE-2 INHIBITOR; EPITHELIAL-CELLS; COLORECTAL-CANCER; PROSTAGLANDIN E-2; SULINDAC SULFIDE; CARCINOMA CELLS; PHORBOL ESTER	Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal cancers. Recently, a similar protective effect has been demonstrated by the specific cyclo-oxygenase-2 (COX-2) inhibitors. However, the exact mechanism that accounts for the anti-proliferative effect of specific COX-2 inhibitors is still not fully understood, and it is still controversial whether these protective effects are predominantly mediated through the inhibition of COX-2 activity and prostaglandin synthesis. Identification of molecular targets regulated by COX-2 inhibitors could lead to a better understanding of their pro-apoptotic and anti-neoplastic activities. In the present study, we investigated the effect and the possible molecular target of a COX-2-specific inhibitor SC-236 on gastric cancer. We showed that SC-236 induced apoptosis in gastric cancer cells. However, this effect was not dependent on COX-2 inhibition. SC-236 down-regulated the protein expression and kinase activity of PKC-beta(1), increased the expression of PKCdelta and PKCeta, but did not alter the expression of other PKC isoforms in AGS cells. Moreover, exogenous prostaglandins or PGE(2) receptor antagonists could not reverse the inhibition effect on PKCbeta(1) by SC-236, which suggested that this effect occurred through a mechanism independent of cyclo-oxygenase activity and prostaglandin synthesis. Overexpression of PKCbeta(1) attenuated the apoptotic response of AGS cells to SC-236 and was associated with overexpression of p21(wafl/cip1). Inhibition of PKQ1-mediated overexpression of p21(wafl/cip1) partially reduced the anti-apoptotic effect of PKCbeta(1). The down-regulation of PKCbeta(1) provides an explanation for COX-independent apoptotic effects of specific COX-2 inhibitor in cultured gastric cancer cells. We also suggest that PKCbeta(1) act as survival mediator in gastric cancer, and its down-regulation by COX-2 inhibitor SC-236 may provide new target for future treatment of gastric cancer.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Rui Jin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Hong Kong; University of Hong Kong; Columbia University	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.		Wong, Benjamin Chun Yu/C-4436-2009; Wong, Benjamin Chun Yu/ABB-1962-2020; jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961				Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cesaro P, 2001, INT J CANCER, V93, P179, DOI 10.1002/ijc.1314; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Frey MR, 1997, J BIOL CHEM, V272, P9424; Goldberg Y, 1996, ONCOGENE, V12, P893; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; JUN C, 1997, J IMMUNOL, V162, P3395; KARGMAN SL, 1995, CANCER RES, V55, P3785; Kawamori T, 1998, CANCER RES, V58, P409; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kunikata T, 2001, J PHYSIOLOGY-PARIS, V95, P157, DOI 10.1016/S0928-4257(01)00021-3; Li M, 2001, CLIN CANCER RES, V7, P1010; LI Y, 1999, J BIOL CHEM, V271, P27025; Livneh E, 1996, ONCOGENE, V12, P1545; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheng HM, 1998, CANCER RES, V58, P362; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Sugibayashi R, 2001, ONCOGENE, V20, P1220, DOI 10.1038/sj.onc.1204206; Teicher BA, 2001, ANTICANCER RES, V21, P3175; Teicher BA, 2001, CANCER CHEMOTH PHARM, V48, P473, DOI 10.1007/s002800100372; Teicher BA, 2001, IN VIVO, V15, P185; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tucker ON, 1999, CANCER RES, V59, P987; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wilson KT, 1998, CANCER RES, V58, P2929; Won JS, 1998, MOL BRAIN RES, V60, P203, DOI 10.1016/S0169-328X(98)00182-X; YASUI W, 1985, JPN J CANCER RES, V76, P1168; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, BRIT J CANCER, V79, P393, DOI 10.1038/sj.bjc.6690062; Zhu GH, 1999, DIGEST DIS SCI, V44, P2020, DOI 10.1023/A:1026670301787	66	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6113	6122		10.1038/sj.onc.1205778	http://dx.doi.org/10.1038/sj.onc.1205778			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203123				2022-12-28	WOS:000177671300014
J	Nathrath, MH; Kuosaite, V; Rosemann, M; Kremer, M; Poremba, C; Wakana, S; Yanagi, M; Nathrath, WBJ; Hofler, H; Imai, K; Atkinson, MJ				Nathrath, MH; Kuosaite, V; Rosemann, M; Kremer, M; Poremba, C; Wakana, S; Yanagi, M; Nathrath, WBJ; Hofler, H; Imai, K; Atkinson, MJ			Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man	ONCOGENE			English	Article						osteosarcoma; allelic imbalance; LOH; synteny relationship; inbred mouse strains	REPRESENTATIONAL DIFFERENCE ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; RADIATION HYBRID MAP; MUTATION SPECTRUM; OSTEO-SARCOMA; DNA-SEQUENCES; CDK4 GENE; RETINOBLASTOMA; P53; HETEROZYGOSITY	We have performed a comparative study of allelic imbalances in human and murine osteosarcomas to identify genetic changes critical for osteosarcomagenesis. Two adjacent but discrete loci on mouse chromosome 9 were found to show high levels of allelic imbalance in radiation-induced osteosarcomas arising in (BALB/c x CBA/CA) F1 hybrid mice. The syntenic human chromosomal regions were investigated in 42 sporadic human osteosarcomas. For the distal locus (OSS1) on mouse chromosome 9 the syntenic human locus was identified on chromosome 6q14 and showed allelic imbalance in 77% of the cases. Comparison between the human and mouse syntenic regions narrowed the locus down to a 4 Mbp fragment flanked by the marker genes ME1 and SCL35A1 For the proximal locus (OSS2) on mouse chromosome 9, a candidate human locus was mapped to chromosome 15q21 in a region showing allelic imbalance in 58% of human osteosarcomas. We have used a combination of synteny and microsatellite mapping to identify two potential osteosarcoma suppressor gene loci. This strategy represents a powerful tool for the identification of new genes important for the formation of human tumors.	GFS Natl Res Ctr Environm & Hlth, Inst Pathol, D-85764 Neuherberg, Germany; Tech Univ Munich, Dept Pediat, D-80804 Munich, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; RIKEN, Genomics Sci Ctr, Mouse Funct Genomics Res Grp, Yokohama, Kanagawa 2240804, Japan; Municipal Hosp Munchen Harlaching, Inst Pathol, D-81545 Munich, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany	Technical University of Munich; Technical University of Munich; Heinrich Heine University Dusseldorf; RIKEN; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nathrath, MH (corresponding author), GFS Natl Res Ctr Environm & Hlth, Inst Pathol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Rosemann, Michael/AAX-8082-2020; Atkinson, Michael/AAU-5127-2020; Atkinson, Michael J/E-5537-2011; Rosemann, Michael/O-2449-2015	Rosemann, Michael/0000-0002-5855-065X; Atkinson, Michael/0000-0003-3358-2089; Atkinson, Michael J/0000-0003-3358-2089; Rosemann, Michael/0000-0002-5855-065X				Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Balsara BR, 1999, CANCER RES, V59, P450; Belchis DA, 1996, DIAGN MOL PATHOL, V5, P214, DOI 10.1097/00019606-199609000-00011; Bernues M, 1999, CANCER GENET CYTOGEN, V112, P42, DOI 10.1016/S0165-4608(98)00248-9; BIEGEL JA, 1989, CANCER GENET CYTOGEN, V38, P89, DOI 10.1016/0165-4608(89)90169-6; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Bridge JA, 1997, CANCER GENET CYTOGEN, V95, P74, DOI 10.1016/S0165-4608(96)00306-8; Brinkschmidt C, 1998, Verh Dtsch Ges Pathol, V82, P184; Chen JR, 2001, MOL CELL ENDOCRINOL, V177, P43, DOI 10.1016/S0303-7207(01)00456-7; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6; Fuchs N, 1998, ANN ONCOL, V9, P893, DOI 10.1023/A:1008391103132; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; GOSSNER W, 1976, RECENT RES CANCER, V54, P36; Goto A, 1998, JPN J CANCER RES, V89, P539, DOI 10.1111/j.1349-7006.1998.tb03295.x; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Kraus F, 2001, MECH DEVELOP, V100, P83, DOI 10.1016/S0925-4773(00)00494-9; Kruzelock RP, 1997, CANCER RES, V57, P106; LADANYI M, 1993, CANCER RES, V53, P16; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; LUZ A, 1991, RADIAT ENVIRON BIOPH, V30, P225, DOI 10.1007/BF01226625; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nellissery MJ, 1998, AM J HUM GENET, V63, P817, DOI 10.1086/302019; Park WS, 2000, CANCER RES, V60, P70; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76; Reardon DA, 1999, GENE CHROMOSOME CANC, V24, P230, DOI 10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C; Simons A, 1999, GENE CHROMOSOME CANC, V26, P115, DOI 10.1002/(SICI)1098-2264(199910)26:2<115::AID-GCC3>3.0.CO;2-E; Simons A, 1997, GENE CHROMOSOME CANC, V20, P196, DOI 10.1002/(SICI)1098-2264(199710)20:2<196::AID-GCC10>3.0.CO;2-P; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; TARKKANEN M, 1995, CANCER RES, V55, P1334; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	43	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5975	5980		10.1038/sj.onc.1205764	http://dx.doi.org/10.1038/sj.onc.1205764			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185601				2022-12-28	WOS:000177520900021
J	Zhuang, SM; Wiseman, RW; Soderkvist, P				Zhuang, SM; Wiseman, RW; Soderkvist, P			Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice	ONCOGENE			English	Article						Trp53; Hras1; Catnb; 1,3-butadiene; mammary adenocarcinomas	TUMOR-SUPPRESSOR GENE; SOMATIC MUTATIONS; RAS GENES; CYCLIN D1; K-RAS; EXPRESSION; CANCER; MOUSE; ACTIVATION; P53	DNAs from 1,3-butadiene-induced mammary adenocarcinomas of B6C3F1 mice were examined for mutations in the Trp53 gene, the ras gene family and several components of the Wnt signaling pathway, including beta-catenin (Catnb), Ape and Axin. Trp53 mutations were detected in 41% (7 out of 17) of tumors. Each tumor with a Trp53 mutation also exhibited loss of the wildtype Trp53 allele, supporting the importance of Trp53 inactivation during development of these tumors. Analyses of the Hras1, Kras2 and Nras proto-oncogenes revealed Hras1 mutations in 53% (9 out of 17) of tumors. Seven of these mutations were a G-C transversion in Hras1 codon 13, consistent with a 1,3-butadiene-specific Kras2 mutation previously reported in several other tumor types. Mutation screens in Catnb exon 2, the Ape mutation cluster region and the Catnb-binding domain of the Axin gene identified Catnb missense mutations in 3 out of 17 (18%) tumors. In total, mutations of the Trp53, Hras] and/or Catnb genes were identified in 15 out of 17 1,3-butadiene-induced mammary adenocarcinomas. These results indicate that multiple genetic pathways are disrupted in chemically induced mammary tumors, and that studies in mouse models may help to understand the etiology of human breast cancers.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden; NIEHS, Lab Womens Hlth, Res Triangle Pk, NC 27709 USA	Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zhuang, SM (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.	shizh@mcb.liu.se		Zhuang, Shi-Mei/0000-0002-2512-3942				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BOS JL, 1989, CANCER RES, V49, P4682; Dashwood RH, 1998, CANCER RES, V58, P1127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; GOODROW T, 1990, CANCER RES, V50, P4818; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Melnick RL, 2001, CHEM-BIOL INTERACT, V135, P27, DOI 10.1016/S0009-2797(01)00213-7; MELNICK RL, 1990, CANCER RES, V50, P6592; Meng QX, 2000, MUTAT RES-GEN TOX EN, V464, P169, DOI 10.1016/S1383-5718(99)00157-6; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; *NAT TOX PROGR, 2000, 9 REP CARC, P14; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Osborne RJ, 2000, CANCER RES, V60, P3706; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Rubinfeld B, 1997, CANCER RES, V57, P4624; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sills RC, 2001, CHEM-BIOL INTERACT, V135, P373, DOI 10.1016/S0009-2797(01)00179-X; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOR A, 1986, LAB INVEST, V55, P603; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Zhuang SM, 1997, CANCER RES, V57, P2710	39	15	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5643	5648		10.1038/sj.onc.1205649	http://dx.doi.org/10.1038/sj.onc.1205649			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165863				2022-12-28	WOS:000177442000014
J	Ferrigno, O; Lallemand, F; Verrecchia, F; L'Hoste, S; Camonis, J; Atfi, A; Mauviel, A				Ferrigno, O; Lallemand, F; Verrecchia, F; L'Hoste, S; Camonis, J; Atfi, A; Mauviel, A			Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling	ONCOGENE			English	Article						TGF-beta; Smad signaling; Src/Yes; Smad7; gene expression and regulation	GROWTH-FACTOR-BETA; SH3 DOMAIN; APOPTOSIS; RECEPTOR; IDENTIFICATION; DEGRADATION; STRAP; BINDS; CELLS	Members of the TGF-beta family of growth factors signal from the cell surface through serine/threonine kinase receptors. Intracellular propagation of the signal occurs by phosphorylation of intracellular proteins of the Smad family. Smad7 belongs to the subclass of inhibitory Smads that function as antagonists of TGF-beta signaling. A yeast two-hybrid screen of a human placental cDNA expression library using full-length mouse Smad7 as bait identified Yes-Associated Protein (YAP65) as a novel Smad7-interacting protein. The association of Smad7 with YAP65 was confirmed using co-expressed tagged proteins in COS-7 cells. Deletion of the PY motif of Smad7 reduced but did not abolish YAP65-Smad7 association, suggesting the existence of several interacting domains. We demonstrate that YAP65 potentiates the inhibitory activity of Smad7 against TGF-beta-induced, Smad3/4-dependent, gene transactivation. Furthermore, YAP65 augments the association of Smad7 to activated TGF-beta receptor type I (TbetaRI), whereas YAP65(1-301), which exerts a dominant-negative effect against Smad7-driven inhibition of TGF-beta signaling, reduces these interactions. Together, these data provide the first evidence that YAP65 is a Smad7 partner that facilitates the recruitment of the latter to activated TbetaRI, and enhances the inhibitory activity of Smad7 against TGF-beta signaling.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75475 Paris 10, France; Hop St Antoine, INSERM, U482, F-75571 Paris, France; Inst Curie, INSERM, U528, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mauviel, A (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Verrecchia, Franck/G-5535-2018; ferrigno, olivier/GSN-8581-2022; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; ferrigno, olivier/0000-0001-7544-4384; Mauviel, Alain/0000-0002-0438-2793				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	23	164	171	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4879	4884		10.1038/sj.onc.1205623	http://dx.doi.org/10.1038/sj.onc.1205623			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118366	Green Submitted			2022-12-28	WOS:000176874800002
J	Vecsey-Semjen, B; Becker, KT; Sinski, A; Blennow, E; Vietor, I; Zatlouka, K; Beug, H; Wagner, E; Huber, LA				Vecsey-Semjen, B; Becker, KT; Sinski, A; Blennow, E; Vietor, I; Zatlouka, K; Beug, H; Wagner, E; Huber, LA			Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers	ONCOGENE			English	Article						colon cancer; cell line; Wnt signaling; APC; E-cadherin; p53	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; BETA-CATENIN; GASTRIC-CANCER; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; RAPID DETECTION; CYCLIN D1; APC GENE; C-MYC	A major obstacle to obtaining more detailed insights into the diversity of phenotypic and molecular changes occurring in colon cancer cells is the lack of low-passage colon cancer cell lines, which would still closely reflect the phenotype of the colon cancer cells in vivo. Here, we characterize eight novel, low passage number human colon carcinoma cell lines, originating from colorectal cancers extensively characterized in the clinics. All cell lines closely resemble the original tumors with respect to phenotype, markers and detectable genetic changes. Cell morphology and marker expression is highly variable, ranging from fully polarized cells correctly expressing all basolateral epithelial markers, to cells with mesenchymal characteristics and a complete loss; of polarity due to delocalization or loss of junction complex proteins. The alterations in phenotype and epithelial marker expression correspond to changes already detectable in the primary tumor in vivo. Seven of the cell lines show chromosomal instability, while one cell line is characterized by microsatellite instability. p53 associated with K-ras mutations were detected in three cell, lines. Hitherto non-described E-cadherin mutations were found at both alleles in one cell line whereas in another cell line the E-cadherin protein was down-regulated. A stabilizing beta-catenin mutation (S45F) appears in the same cell line that carried the mutated E-cadherin gene. Six cell lines carried APC mutations, which in five of the lines led to an activated beta-catenin/Tcf/LEF signaling pathway.. In accordance with beta-catenin/Tcf/LEF activation, the cell lines show increased migration and invasiveness. Our results show that the characterized, low-passage cell lines mirror the diversity of the individual tumors from which they were derived. Through molecular analyses of these cell lines we demonstrate that tumorgenicity events are much more diverse in human colon cancer than expected, despite the common origin of the tumors from a small patient group with similar tumor grading and clinical prognosis.	IMP, Res Inst Mol Pathol, Vienna, Austria; Tech Univ Munich, Dept Pathol, D-8000 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Boehringer Ingelheim Austria GmbH, Live Vaccine Div, Vienna, Austria; Karolinska Hosp, Dept Clin Genet, S-10401 Stockholm, Sweden; Graz Univ, Inst Pathol, Graz, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Boehringer Ingelheim; Karolinska Institutet; Karolinska University Hospital; University of Graz	Wagner, E (corresponding author), IMP, Res Inst Mol Pathol, Vienna, Austria.	ernst.wagner@cup.uni-muenchen.de; huber@nt.imp.univie.ac.at	Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Huber, Lukas Alfons/AAM-3499-2021; Becker, Karl-Friedrich/D-3636-2015	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Huber, Lukas Alfons/0000-0003-1116-2120; Becker, Karl-Friedrich/0000-0002-6801-4498				ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker K F, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU14>3.0.CO;2-Z; Becker KF, 1996, TRENDS GENET, V12, P250, DOI 10.1016/S0168-9525(96)90032-3; BECKER KF, 2002, IN PRESS J PATHOL; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CHANTRET I, 1994, J CELL SCI, V107, P213; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dietmaier W, 1997, CANCER RES, V57, P4749; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Guerrero S, 2000, CANCER RES, V60, P6750; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han AC, 2000, ARCH PATHOL LAB MED, V124, P1147; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANDFORD H, 1890, T PATHOLOGICAL SOC L, V41, P133; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Hartmann C, 1999, INT J ONCOL, V15, P975; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hsu MY, 2000, J CELL SCI, V113, P1535; JEN J, 1994, CANCER RES, V54, P5523; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KAHN S, 1987, ANTICANCER RES, V7, P639; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; Klein G, 1998, ADV CANCER RES, V72, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lochter A, 1999, MATRIX BIOL, V18, P455, DOI 10.1016/S0945-053X(99)00036-0; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mo YY, 1996, CANCER RES, V56, P2633; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagase H, 1996, JPN J CANCER RES, V87, P1025, DOI 10.1111/j.1349-7006.1996.tb03104.x; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oh JH, 1999, INT J CANCER, V81, P902, DOI 10.1002/(SICI)1097-0215(19990611)81:6<902::AID-IJC11>3.0.CO;2-T; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pricolo VE, 1996, AM J SURG, V171, P41, DOI 10.1016/S0002-9610(99)80071-3; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sadot E, 1998, J NEUROCHEM, V70, P428; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vietor I, 2001, EMBO REP, V2, P306, DOI 10.1093/embo-reports/kve066; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Yamamoto H, 2001, CANCER RES, V61, P3139; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x	77	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4646	4662		10.1038/sj.onc.1205577	http://dx.doi.org/10.1038/sj.onc.1205577			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096341				2022-12-28	WOS:000176625100006
J	Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P				Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P			The tumor suppressor activity of SOCS-1	ONCOGENE			English	Article						SOCS-1; Tel-Jak; KIT; BCR-ABL; tyrosine kinase	KINASE-ACTIVITY; NEGATIVE REGULATION; LYMPHOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; BOX MOTIF; C-CBL; PROTEIN; INDUCTION; DOMAIN; JAK2	SOCS-1 is an inducible SH2-containing inhibitor of Jak kinases and as such can potently suppress cytokine signaling. SOCS-1 deficient mice die within the first three weeks of life from a myeloproliferative disorder driven by excessive interferon signaling. We report here that SOCS-I inhibits proliferation signals induced by a variety of oncogenes active within the hematopoietic system. Ectopic expression of SOCS-I abolished proliferation mediated by a constitutively active form of the KIT receptor, TEL-JAK2, and v-ABL, and reduced metastasis from BCR-ABL transformed cells. SOCS-1, however, did not interfere with v-SRC or RASV12 mediated cellular transformation. A mutant form of SOCS-I unable to bind through its SH2 domain to tyrosine phosphorylated proteins could still inhibit KIT, but not TEL-JAK2, indicating multiple mechanisms for SOCS-1-mediated tumor suppression. We show that the steady state levels of TEL-JAK2 and to a greater extent v-ABL are diminished in the presence of SOCS-1. Lastly, we show that SOCS-1 -/- fibroblasts are more sensitive than wild type fibroblasts to either spontaneous or oncogene-induced transformation. These data suggest that loss-of-function of SOCS-1 may collaborate with a variety of hematopoietic oncogenes to facilitate tumor progression.	Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; INSERM, U119, F-13009 Marseille, France	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rottapel, R (corresponding author), Princess Margaret Hosp, Rm 10-116,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rottapel@oci.utoronto.ca; sepulveda@marseille.inserm.fr	De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Ilangumaran, Subburaj/0000-0002-7563-576X; Rottapel, Robert/0000-0002-6024-5558				Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rottapel R, 2000, FR MOLEC B, V29, P246; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	108	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4351	4362		10.1038/sj.onc.1205537	http://dx.doi.org/10.1038/sj.onc.1205537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080466				2022-12-28	WOS:000176317100001
J	Taylor, A; Shang, F; Nowell, T; Galanty, Y; Shiloh, Y				Taylor, A; Shang, F; Nowell, T; Galanty, Y; Shiloh, Y			Ubiquitination capabilities in response to neocarzinostatin and H2O2 stress in cell lines from patients with ataxia-telangiectasia	ONCOGENE			English	Article						ATM; ataxia-telangiectasia; ubiquitination; oxidative stress; aging	LENS EPITHELIAL-CELLS; AGE-RELATED DECLINE; OXIDATIVE STRESS; CONJUGATING ENZYMES; ACTIVATING ENZYME; PROTEIN OXIDATION; REDOX REGULATION; GENE-PRODUCT; EYE LENS; ATM	The human genetic disorder ataxia-telangiectasia (A-T) is due to lack of functional ATM, a protein kinase which is involved in cellular responses to DNA double strand breaks (DSBs) and possibly other oxidative stresses, as well as in regulation of several fundamental cellular functions. Studies regarding responses in A-T cells to the induction of DSBs utilize ionizing radiation or radiomimetic chemicals, such as neocarzinostatin (NCS), which induce DNA DSBs. This critical DNA lesion activates many defense systems, such as the cell cycle checkpoints. The cell cycle is also regulated through a timed and coordinated degradation of regulatory proteins via the ubiquitin pathway. Our recent studies indicate that the ubiquitin pathway is influenced by the cellular redox status and that it is the major cellular pathway for removal of oxidized proteins. Accordingly, we hypothesized that the absence of a functional ATM protein might involve perturbations to the ubiquitin pathway as well. We show here that upon treatment with NCS, there was a transient 50-70% increase in endogenous ubiquitin conjugates in A-T and wt lymphoblastoid cells. Ubiquitin conjugation capabilities per se and levels of substrates for conjugation were also similarly enhanced in wt and A-T cells upon NCS treatment. We also compared the ubiquitination response in A-T and wt cells using H2O2 as the stress, in view of preexisting evidence of the effects of H2O2 on ubiquitination capabilities in other types of cells. As with NCS treatment, there was an approximate to45% increase in endogenous ubiquitin conjugates by 2-4 h after exposure to H2O2. Both cell types showed a rapid 50-150% increase in de novo formed I-125-ubiquitin conjugates. As compared with wt cells, unexposed A-T cells had higher endogenous levels of conjugates and enhanced conjugation capability. However, A-T cells mounted a more muted ubiquitination response to the stress. The enhanced ubiquitin conjugation in unstressed A-T cells and attenuated ability of these cells to respond to stress are consistent with the A-T cells being under oxidative stress and with their having an 'aged' phenotype. The indication that ubiquitin conjugate levels and ubiquitin conjugation capabilities are enhanced upon oxidative stress without significant changes in GSSG/GSH ratios indicates that assays of ubiquitination provide a sensitive measure of cellular stress. The data also add support to the impression that potentiated ubiquitination response to mild oxidative stress is a generalizable phenomenon.	Tufts Univ, JM Human Nutr Res Ctr Aging, USDA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel	Tufts University; United States Department of Agriculture (USDA); Tel Aviv University; Sackler Faculty of Medicine	Taylor, A (corresponding author), Tufts Univ, JM Human Nutr Res Ctr Aging, USDA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	ataylor@hnrc.tufts.edu		Galanty, Yaron/0000-0001-7167-9004	NEI NIH HHS [EY013250] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013250] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; APPLEGATE LA, 1994, J INVEST DERMATOL, V102, P762, DOI 10.1111/1523-1747.ep12377610; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; EDO K, 1991, CHEM PHARM BULL, V39, P170; EISENHAUER DA, 1988, EXP EYE RES, V46, P579, DOI 10.1016/S0014-4835(88)80014-9; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; Haas AL, 1997, FASEB J, V11, P1257; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JABBEN M, 1989, PLANT PHYSIOL, V90, P380, DOI 10.1104/pp.90.2.380; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kamsler A, 2001, CANCER RES, V61, P1849; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lenton KJ, 2000, AM J CLIN NUTR, V71, P1194; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; Okada S, 2000, J GASTROENTEROL, V35, P407, DOI 10.1007/s005350050370; Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1997, CANCER SURV, V29, P285; Rybczynska M, 1996, BBA-LIPID LIPID MET, V1302, P231, DOI 10.1016/0005-2760(96)00067-7; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; SHILOH Y, 1982, BIOCHIM BIOPHYS ACTA, V721, P485, DOI 10.1016/0167-4889(82)90105-7; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Smith D, 1999, J NUTR, V129, P1229, DOI 10.1093/jn/129.6.1229; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TAYLOR A, 1995, MECH AGEING DEV, V79, P33, DOI 10.1016/0047-6374(94)01541-S; TAYLOR A, 1991, IN VITRO CELL DEV B, V27, P287, DOI 10.1007/BF02630905; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; Taylor A., 1999, CRC MOD NUT, V1st, P53; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277	60	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4363	4373		10.1038/sj.onc.1205557	http://dx.doi.org/10.1038/sj.onc.1205557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080467				2022-12-28	WOS:000176317100002
J	Morris, M; Hepburn, P; Wynford-Thomas, D				Morris, M; Hepburn, P; Wynford-Thomas, D			Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function	ONCOGENE			English	Article						senescence; CDK4; CDK6; p53; fibroblast	HUMAN-DIPLOID FIBROBLASTS; KINASE INHIBITOR P16; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; DNA-SYNTHESIS; GENE-TRANSFER; HUMAN-CELLS; RB; IMMORTALIZATION; P21	Replicative senescence is thought to be a significant barrier to human tumorigenesis, which in human fibroblasts, and many other cell types, can be overcome experimentally by combined loss of function of p53 and Rb 'pathways'. To avoid the confounding pleiotropic effects of HPVE7 frequently used in such studies, here we have employed retroviral vectors over-expressing CDK4 or CDK6 as a more representative model of naturally-occurring mutations targeting the Rb pathway. We show that these can extend fibroblast lifespan by similar to10 population doublings, ending in a viable senescence-like state which contrasts with the apoptotic end-stage seen with E7. Compared with 'normal' senescence, this growth arrest was, in most cases, not accompanied by any further increase in p21(Wafl) levels but with up to a 19-fold increase in p16(Ink4a). Surprisingly however, this could not explain arrest, since expression of mutant CDK4 and/or CDK6, incapable of binding p16(Ink4a) did not confer any greater lifespan extension than the wild-type CDKs. Subsequent abrogation of p53 function by a second vector, encoding HPVE6, downregulated p21(Wafl) and conferred a second lifespan extension, ending in a crisis-like state, consistent with full escape from senescence. These data: (i) point to a back-up 'senescence' mechanism distinct from induction of p21(wafl) or p16(Ink4a) and (ii) provide an in vitro model of clonal evolution through successive dysfunction of Rb and p53 pathways in a relevant human cell context.	Cardiff Univ, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Cardiff Univ, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	KingTD@Cardiff.ac.uk	Morris, Mark/C-6413-2008	Morris, Mark/0000-0002-0700-355X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Costello JF, 1997, CANCER RES, V57, P1250; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Grignani F, 1998, CANCER RES, V58, P14; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kanoe H, 1998, ANTICANCER RES, V18, P2317; LI Y, 1994, CANCER RES, V54, P6078; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Parry D, 1999, MOL CELL BIOL, V19, P1775; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pilotti S, 1998, J PATHOL, V185, P188; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; WynfordThomas D, 1996, BIOL SIGNAL, V5, P139	54	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4277	4288		10.1038/sj.onc.1205492	http://dx.doi.org/10.1038/sj.onc.1205492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082615				2022-12-28	WOS:000176174200010
J	Talukder, AH; Wang, RA; Kumar, R				Talukder, AH; Wang, RA; Kumar, R			Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells	ONCOGENE			English	Article						HER2; heregulin; GADD153; differentiation; mammary epithelial cells	FACTOR CHOP GADD153; BINDING PROTEIN; REGULATED EXPRESSION; POINT MUTATION; GROWTH-FACTORS; DNA-BINDING; HEREGULIN; DIFFERENTIATION; STRESS; GENE	Heregulin-beta1 (HRG), a combinatorial ligand for human epidermal growth factor receptor 3 (HER3) and HER4, is a regulatory polypeptide having distinct biological effects, such as growth stimulation, differentiation, invasiveness, and migration in mammary epithelial cells. The mechanism underlying the diverse functions of HRG is not well established but is believed to depend on induced changes in the expression of specific cellular gene products, their modification, or both. Here, we identified the basic leucine zipper transcription factor, the growth-arrest and DNA-damage 153 (GADD153)/ CCAAT-enhancer binding protein (C/EBP) homologous protein (CHOP) as one of the HRG-inducible genes. We demonstrated that HRG stimulation of mammary epithetial cells induces the expression of GADD153 mRNA and protein and transcription of GADD153 promoter. The transcriptional activity of the GADD153 promoter as well as transcription from the C/EBP-activating transcription factor (ATF) composite motif in the GADD153 promoter was also stimulated by HRG-inducible ATF-4 and activated HER2 but not wild-type HER2. GADD153 expression was upregulated by the lactogenic hormones insulin and progesterone and associated with differentiation of normal mammary epithelial cells. Consistent with its role as transcriptional modifier, GADD153 stimulated transcription of beta-casein promoter activity in a STAT5a-sensitive manner in mammary epithelial cells. Analysis of mouse mammary gland development revealed that GADD153 expression was predominantly restricted in the early lactating stages. Because cyclic AMP responsive element and ATF binding sites are present in a variety of growth-regulating cellular genes, these findings suggest that stimulation of GADD153 expression and its transactivating functions may constitute an important mechanism of regulation of putative genes having diverse functions during cell growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Brian/HGA-9535-2022	Wang, Rui-An/0000-0003-2320-1211	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA080066, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Krane IM, 1996, ONCOGENE, V12, P1781; Kumar R, 1996, CLIN CANCER RES, V2, P1215; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SLAMON DJ, 1987, SCIENCE, V235, P77; Talukder AH, 2001, J BIOL CHEM, V276, P5636, DOI 10.1074/jbc.M006824200; Talukder AH, 2000, CANCER RES, V60, P276; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2000, MOL CELL BIOL, V20, P9092, DOI 10.1128/MCB.20.23.9092-9101.2000; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4289	4300		10.1038/sj.onc.1205529	http://dx.doi.org/10.1038/sj.onc.1205529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082616				2022-12-28	WOS:000176174200011
J	Kahana, O; Micksche, M; Witz, IP; Yron, I				Kahana, O; Micksche, M; Witz, IP; Yron, I			The focal adhesion kinase (P125(FAK)) is constitutively active in human malignant melanoma	ONCOGENE			English	Article						melanoma; anchorage independence; integrins; FAK; phosphorylation; cytoskeleton	DEPENDENT TYROSINE PHOSPHORYLATION; C-TERMINAL DOMAIN; PROTEIN-KINASE; CELL-LINES; SIGNAL-TRANSDUCTION; T-CELLS; EXPRESSION; GENE; SRC; OVEREXPRESSION	Malignant melanoma cells show high aggressiveness and metastatic potential. Tumor cells as they become more metastatic, gradually lose their dependence on both adhesion and serum. Thus, in the process of tumor progression cells undergo series of changes that allow them to adapt to different tissue milieu. This implies that during this process, points on the integrin pathway may become constitutively activated. In the present study we investigated the possible role of FAK, being one of the key members of the integrin-signaling pathway, in the multi-step progression towards a malignant phenotype in human melanoma. In our study we show that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation. Indeed, in all melanoma cells tested and not in nevus and neuroblastoma cells, we observed various degrees of constitutive activation of FAK. Our results also suggest that FAK constitutive activation is regulated at least in part by the cytoskeleton, implying that steps along the integrin signaling pathway involving FAK could be among the oncogenic mechanisms that operate in melanoma and may account for the highly aggressive, anchorage independent phenotype of this tumor.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Univ Vienna, Inst Canc Res, Dept Appl & Expt Oncol, Vienna, Austria	Tel Aviv University; Tel Aviv University; University of Vienna	Yron, I (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO;2-E; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Flinn HM, 1996, J CELL SCI, V109, P1133; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1983, J IMMUNOL, V131, P334; HYNES RO, 1992, CELL, V69, P1; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388	44	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					3969	3977		10.1038/sj.onc.1205472	http://dx.doi.org/10.1038/sj.onc.1205472			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037679				2022-12-28	WOS:000175869900003
J	Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS				Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS			Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappa B dimerization	ONCOGENE			English	Article						NF-kappa B; tamoxifen; tumor control; MnSOD; tumor suppressor gene	MANGANESE SUPEROXIDE-DISMUTASE; BREAST-CANCER-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; SUBUNIT; OVEREXPRESSION; SUPPRESSION; ACTIVATION; INDUCTION; RECEPTOR	Manganese superoxide dismutase (MuSOD) has been shown to suppress the development of cancer. Tamoxifen (TAM), a nonsteroidal anti-estrogen that is widely used in chemotherapy, is known to be a modulator of antioxidant status. However, the mechanism by which TAM mediates antioxidant enzyme induction remains unclear. In this study we investigated TAM enhancement of MnSOD induction by TNF-alpha. The results show that co-treatment with TAM and TNF-alpha increases the MnSOD promoter/enhancer driven luciferase activity, MnSOD mRNA and protein levels. Interestingly, co-treatment with TAM and TNF-a drastically decreases the binding activity of the p50/p50 homodimer and increases that of the p50/p65 heterodimer compared to TNF-alpha alone. This change in DNA binding could not be attributed to a decrease in the level of p50, its precursor, p105, or its inhibitors. Furthermore, TAM did not enhance degradation of IkappaB-alpha. These results suggest that p50/p50 homodimer may act as an inhibitory complex of MnSOD expression. Modulation of the DNA binding activity in favor of the p50/p65 complex may enhance NF-kappaB mediated induction of MnSOD by TAM. These findings reveal a potential novel mechanism for the induction of the human MnSOD gene.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand	University of Kentucky; Mahidol University	Clair, DKS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 361 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL-03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059835, R29CA049797, R01CA049797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GOLDENBERG GJ, 1982, CANCER RES, V42, P5147; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LI JJ, 1995, ONCOGENE, V10, P1989; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NEGRINI M, 1994, CANCER RES, V54, P1331; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; TAYLOR CM, 1984, CANCER RES, V44, P1409; THANGARAJU M, 1994, CANCER, V74, P78, DOI 10.1002/1097-0142(19940701)74:1<78::AID-CNCR2820740114>3.0.CO;2-L; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082	40	30	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3603	3610		10.1038/sj.onc.1205448	http://dx.doi.org/10.1038/sj.onc.1205448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032862				2022-12-28	WOS:000175793700011
J	Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K				Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K			Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells	ONCOGENE			English	Article						polo-like kinase; antisense; anticancer activity; xenograft	PROTEIN-KINASE; PHASE-I; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; PLK EXPRESSION; C-ALPHA; CYCLE; DROSOPHILA; OLIGODEOXYNUCLEOTIDE	A central role for polo-like kinases (PLK) in regulating several stages of mitotic progression has been born out in several species. Overexpression of PLK1 is observed in the majority of hitherto analysed human tumors. PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas. In order to define the role of PLK1 for mitotic progression of human cells and for neoplastic cell growth, phosphorothioate antisense oligonucleotides (ASOs) were tested to selectively downregulate PLK1 expression in MDA-MB-435 (breast cancer), HeLa S3 (cervical carcinoma) and A549 (non-small cell lung cancer) cells. ASOs were identified which suppress PLK1 mRNA and protein in a dose-dependent and sequence-specific manner. This approach also led to reduced PLK1 serine/threonine kinase activity. Downregulation of cellular PLK1 levels in cancer cells altered cell cycle progression moderately with an elevated percentage (20-30%) of cells in G(2)/M. Furthermore, cells with reduced PLK1 protein gained a rounded phenotype with multiple centrosomes. Moreover, ASO treatment resulted in potent antiproliferative effects in cell culture. Considerable antitumor activity was observed in vivo against A549 cells. This study suggests that antisense inhibitors targeted against PLK1 at well tolerated doses may be considered as a cancer therapeutic agent.	Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.	Stebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, pVII, DOI 10.1089/oli.1.1998.8.vii; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; CROOKE ST, 1994, CLIN PHARMACOL THER, V56, P641, DOI 10.1038/clpt.1994.189; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HARTWELL LH, 1973, GENETICS, V74, P267; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Knecht R, 1999, CANCER RES, V59, P2794; Kuss B, 1999, ANN ONCOL, V10, P495, DOI 10.1023/A:1026416314887; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; SHARON G, 1990, GENETICS, V125, P475; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yuan JP, 1997, AM J PATHOL, V150, P1165; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3	39	147	158	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3162	3171		10.1038/sj.onc.1205412	http://dx.doi.org/10.1038/sj.onc.1205412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082631				2022-12-28	WOS:000175373600007
J	Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK				Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK			Functional characterization of multiple domains involved in the subcellular localization of the hematopoietic Pbx interacting protein (HPIP)	ONCOGENE			English	Article						hematopoietic Pbx interacting protein; cellular localization; nuclear import; nuclear export; microtubules	NUCLEAR EXPORT SIGNAL; IN-VIVO; GENE-EXPRESSION; CELLS CAUSES; HOX; BINDING; CRM1; OVEREXPRESSION; PREP1; ASSOCIATION	We have previously reported the cloning of the Hematopoietic Pbx Interacting Protein (HPIP), a novel protein discovered through its interaction with Pbx1. HPIP is expressed in early hematopoietic precursors, can bind all members of the Pbx family and can inhibit the transcriptional activation of the oncogene E2A-Pbx. To further understand the function of HPIP, we have analysed its cellular localization and characterized its functional localization domains. Using fluorescence microscopy to follow the distribution of different HPIP sequences fused to GFP, we found that HPIP localizes predominantly to cytoskeletal fibers but has the potential ability to shuttle between the nucleus and the cytosol. The cytoskeletal localization of HPIP is mediated by an N-terminal leucine rich region (between as 190-218) and can be disrupted by the microtubule destabilizing drug vincristine. The HPIP C-terminal domain (aa 443731) bears a nuclear export activity that is blocked by the CRM1 inhibitor Leptomycin B. In addition, we found two basic amino acid regions located between as 485505 and as 695-720 that contain nuclear import activities attenuated by nuclear export. These observations support a model in which the constitutive attachment of HPIP to the cytoskeleton could be modified by changes in functional domains implicated in nuclear export, import and cytoskeleton binding sequences, allowing the molecule to shuttle between the nucleus and the cytosol.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.			Humphries, Richard/0000-0003-0540-7005; Lansdorp, Peter/0000-0001-7435-1071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065430] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CORSETTI MT, 1995, J CELL SCI, V108, P187; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; LEE KK, 2002, J BIOL CHEM, V22, P22; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	33	28	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6766	6771		10.1038/sj.onc.1205784	http://dx.doi.org/10.1038/sj.onc.1205784			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360403				2022-12-28	WOS:000178315800006
J	Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D				Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D			Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families	ONCOGENE			English	Article						BRCA1 mutations; rearrangements; breast-ovarian cancer	KB DELETION; COMBED DNA; IDENTIFICATION; MUTATIONS; REGION; INDIVIDUALS; DUPLICATION; SEQUENCE; LIES	Genetic linkage data have shown that alterations of the BRCA1 gene are responsible for the majority of hereditary breast-ovarian cancers. However, BRCA1 germline mutations are found much less frequently than expected, especially as standard PCR-based mutation detection approaches focus on point and small gene alterations. In order to estimate the contribution of large gene rearrangements to the BRCA1 mutation spectrum, we have extensively analysed a series of 120 French breast-ovarian cancer cases. Thirty-eight were previously found carrier of a BRCA1 point mutation, 14 of a BRCA2 point mutation and one case has previously been reported as carrier of a large BRCA1 deletion. The remaining 67 cases were studied using the BRCA1 bar code approach on combed DNA which allows a panoramic view of the BRCA1 region. Three additional rearrangements were detected: a recurrent 23.8 kb deletion of exons 8-13, a 17.2 kb duplication of exons 3-8 and a 8.6 kb duplication of exons 18-20. Thus, in our series, BRCA1 large rearrangements accounted for 3.3% (4/120) of breast-ovarian cancer cases and 9.5% (4/42) of the BRCA1 gene mutation spectrum, suggesting that their screening is an important step that should be now systematically included in genetic testing surveys.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; CHU Arnaud Villeneuve, Montpellier, France; Ctr Antoine Lacassagne, F-06054 Nice, France; CHU Dupuytren, Limoges, France; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Jean Perrin, Clermont Ferrand, France; Hop Charles Nicolle, Rouen, France; Ctr Paul Strauss, Strasbourg, France; Inst Jean Godinot, Reims, France; Inst Curie, INSERM, U509 Pathol Mol Canc, F-75248 Paris 05, France; Inst Pasteur, ADN, Biophys Lab, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montpellier; CHU de Montpellier; UNICANCER; Centre Antoine Lacassagne; CHU Limoges; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Jean Perrin; CHU de Rouen; UNICANCER; Centre Paul Strauss; UNICANCER; Institut Jean Godinot; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	, bignon/Y-3243-2019	GAD (LAPITEAU), Sophie/0000-0002-3158-6791				Armour JAL, 2000, NUCLEIC ACIDS RES, V28, P605, DOI 10.1093/nar/28.2.605; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Brown MA, 1996, ONCOGENE, V12, P2507; Bruder CEG, 2001, HUM MOL GENET, V10, P271, DOI 10.1093/hmg/10.3.271; Carson N, 1999, AM J HUM GENET, V65, pA287; Charbonnier F, 2000, CANCER RES, V60, P2760; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gad S, 2001, J MED GENET, V38, P388, DOI 10.1136/jmg.38.6.388; Gad S, 2001, GENE CHROMOSOME CANC, V31, P75, DOI 10.1002/gcc.1120; Laurendeau I, 1999, CLIN CHEM, V45, P982; Mazoyer S, 2000, AM J HUM GENET, V67, P207, DOI 10.1086/302974; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 1999, ONCOGENE, V18, P4160, DOI 10.1038/sj.onc.1202754; Nordling M, 1998, CANCER RES, V58, P1372; Pages S, 2001, BRIT J CANCER, V84, P482, DOI 10.1054/bjoc.2000.1627; Payne SR, 2000, GENE CHROMOSOME CANC, V29, P58, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1008>3.0.CO;2-F; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1999, AM J HUM GENET, V64, P300, DOI 10.1086/302211; Puget N, 1997, CANCER RES, V57, P828; Puget N, 1999, CANCER RES, V59, P455; Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Serova O, 1996, AM J HUM GENET, V58, P42; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Wang T, 2001, GENE CHROMOSOME CANC, V31, P91, DOI 10.1002/gcc.1110; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057	34	73	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6841	6847		10.1038/sj.onc.1205685	http://dx.doi.org/10.1038/sj.onc.1205685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360411				2022-12-28	WOS:000178315800015
J	Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB				Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB			MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage	ONCOGENE			English	Article						apoptosis; serine threonine kinases; signal transduction; death receptors; caspases; MAPK	FAS LIGAND EXPRESSION; DECOY RECEPTORS; PROTEIN-KINASE; CANCER-CELLS; MUTATIONS; GENES; INVOLVEMENT; RESISTANCE; INDUCTION; CASPASES	MEK kinase 1 (MEKK1) induces apoptosis through the activation of caspases. The mechanism for MEKK1-induced apoptosis involves caspase-mediated cleavage of MEKK1, releasing a pro-apoptotic 91 kDa kinase fragment that serves to further amplify caspase activation in a feedback loop. Both cleavage of MEKK1 and increased expression of death receptor 4 (DR4, TRAILR1) and death receptor 5 (DR5, TRAILR2) occur following exposure of cells to genotoxins. Overexpression of kinase inactive MEKK1 inhibits MEKK1-mediated apoptosis and effectively blocks death receptor upregulation following etoposide treatment. Herein, we investigate the role of death receptor activation and the ability of AKT/PKB (AKT) to inhibit cell death in MEKK1-induced apoptosis. We show that by preventing DR4 and DR5 activation through expression of decoy receptor 1 (DcR1) and dominant negative FADD, we inhibit MEKK1-induced apoptosis. Furthermore, expression of 91 kDa MEKK1 increased DR4 and FAS mRNA and protein levels. MEKK1-induced apoptosis is amplified by blocking PI-3 kinase activation and overexpression of AKT blocked both MEKK1-induced apoptosis and caspase activation. AKT overexpression also prevented the cleavage of endogenous MEKK1 by genotoxins. AKT did not, however, block MEKK1-induced JNK activation, showing that regulation of the JNK pathway by MEKK1 is independent of its role in regulation of apoptosis. Thus, MEKK1-induced apoptosis requires TRAIL death receptor activation and is blocked by AKT through inhibition of MEKK1 cleavage.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Colorado, Dept Pharmacol, Denver, CO 80262 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Manitoba; University of Colorado System; University of Colorado Denver	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Asselin E, 2001, CANCER RES, V61, P1862; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Lin H, 2001, BIOCHEM J, V353, P299, DOI 10.1042/0264-6021:3530299; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 2001, CANCER RES, V61, P4942; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	36	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6649	6656		10.1038/sj.onc.1205819	http://dx.doi.org/10.1038/sj.onc.1205819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242663				2022-12-28	WOS:000178202300011
J	Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F				Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F			The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro	ONCOGENE			English	Article						topoisomerase I; p53; DNA damage; repair; recombination; genomic instability	DOUBLE-STRAND BREAKS; INDUCED DNA-DAMAGE; WILD-TYPE; COVALENT COMPLEXES; TERMINAL DOMAIN; REPLICATING DNA; T-ANTIGEN; REPAIR; CAMPTOTHECIN; CELLS	Previous studies have shown that human topoisomerase I interacts directly with the tumor-suppressor protein p53. In the past few years it has repeatedly been suggested that topoisomerase I and p53 may play a joint role in the response to genotoxic stress. This led to the suggestion that p53 and human topoisomerase I may cooperate in the process of DNA repair and/or apoptosis. Recently we have demonstrated that a human topoisomerase I cleavage complex can be recognized by an additional topoisomerase I molecule and thereby form a so-called double cleavage complex. The double cleavage complex creates an about 13 nucleotides long single-stranded gap that may provide an entry site for recombinational repair events. Here we demonstrate that p53 stimulates both the DNA relaxation activity as well as the formation of the human topoisomerase I double cleavage complex by at least a factor of six. Stimulation of topoisomerase I activity by p53 is mediated via the central part of topoisomerase I. We also show that human, bovine, and murine p53 stimulate human topoisomerase I relaxation activity equally well. From these results it is conceivable that p53's stimulatory activity on topoisomerase I may play a role in DNA recombination and repair as well as in apoptosis.	Inst Mol Biotechnol, Dept Biochem, D-07745 Jena, Germany; Aarhus Univ, Dept Biol Mol & Struct, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark	Aarhus University	Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Germany.		Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X; Hartmann, Hella/0000-0002-7133-7474; Stevnsner, Tinna/0000-0003-1007-0427				Albor A, 1998, CANCER RES, V58, P2091; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YA, 1997, CANCER RES, V57, P5584; Christiansen K, 1999, BBA-GENE STRUCT EXPR, V1489, P249, DOI 10.1016/S0167-4781(99)00198-0; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEQUIEDT F, 1995, DNA SEQUENCE, V5, P261, DOI 10.3109/10425179509030977; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FROSINA G, 1992, CARCINOGENESIS, V13, P1371, DOI 10.1093/carcin/13.8.1371; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; Labourier E, 1998, NUCLEIC ACIDS RES, V26, P2955, DOI 10.1093/nar/26.12.2955; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sigal A, 2000, CANCER RES, V60, P6788; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; SQUIRES S, 1991, J CELL SCI, V100, P883; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; STEWART AF, 1990, CELL, V60, P141; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Subramanian D, 1998, CANCER RES, V58, P976; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; TSAO YP, 1993, CANCER RES, V53, P5908; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	50	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6614	6623		10.1038/sj.onc.1205912	http://dx.doi.org/10.1038/sj.onc.1205912			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242659				2022-12-28	WOS:000178202300007
J	Budram-Mahadeo, V; Morris, PJ; Latchman, DS				Budram-Mahadeo, V; Morris, PJ; Latchman, DS			The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1)	ONCOGENE			English	Article						Brn-3a; p53; neuronal cells; apoptosis; cell-cycle arrest	NEURONAL DEATH; SYMPATHETIC NEURONS; GROWTH-FACTOR; EXPRESSION; BCL-2; ACTIVATION; PROMOTER; SURVIVAL; OUTGROWTH; DISTINCT	We have previously shown that the anti-apoptotic transcription factor, Brn-3a and the pro-apoptotic p53 factor have antagonistic effects on the promoter of the gene encoding the anti-apoptotic Bcl-2 protein, with p53 abolishing activation by Brn-3a. Here we demonstrate that this antagonism is also observed on the gene encoding the pro-apoptotic Bax protein with Brn-3a abolishing the ability of p53 to activate the Bax promoter and induce Bax protein expression. In contrast, Brn-3a and p53 cooperative to induce maximal activation of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21(CIP1/Waf1). These differential effects of Brn-3a on p53-inducible genes involved in apoptosis or growth arrest are paralleled by its effects on these processes themselves. Thus, we show that Brn-3a antagonises the anti-apoptotic effect of p53 but co-operates with p53 to induce cell cycle arrest. The potential role of Brn-3a in determining the outcome of enhanced p53 levels is discussed.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Budram-Mahadeo, V (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guildord St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; EL DW, 1993, CELL, V75, P817; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; Johnson MD, 1999, J NEUROSCI, V19, P2996; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Railson JE, 2001, J MOL CELL CARDIOL, V33, P1209, DOI 10.1006/jmcc.2001.1384; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Sieber-Blum M, 1998, BIOCHEM CELL BIOL, V76, P1039, DOI 10.1139/bcb-76-6-1039; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950	33	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6123	6131		10.1038/sj.onc.1205842	http://dx.doi.org/10.1038/sj.onc.1205842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203124	Bronze			2022-12-28	WOS:000177671300015
J	Guil, S; Darzynkiewicz, E; Bach-Elias, M				Guil, S; Darzynkiewicz, E; Bach-Elias, M			Study of the 2719 mutant of the c-H-ras oncogene in a bi-intronic alternative splicing system	ONCOGENE			English	Article						splicing; H-ras; 2719 H-ras mutant; CBC; mini-exon; terminal exon	SITE-DIRECTED MUTAGENESIS; SR PROTEINS; IN-VITRO; U1 SNRNP; EXPRESSION; MODULATION	C-H-ras proto-oncogene forms part of the signal transduction pathway of numerous external stimuli. This proto-oncogene is regulated by alternative splicing within its intron D due to the presence of the alternative intron D exon (IDX). The alternative splicing produces mRNA which encodes for the putative p19 protein, that lacks transforming potential. Herein, we demonstrated that SR proteins regulate the intron D splicing. Moreover, we studied the 2719 mutation of H-ras which has higher transforming potential than Ile12 and Val12 H-ras mutants and is also known to affect the 5' splice site of the IDX. However, here we show that the 2719 mutant can still be spliced when the upstream 5' splice-site is blocked. During these later studies, additionally, we generated a short 11 nucleotides 5' terminal exon that was fully defined and spliced in a bi-intronic pre-mRNA. The definition of this mini-exon was also addressed in this work.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Warsaw, Dept Biophys, Inst Expt Phys, PL-02089 Warsaw, Poland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Warsaw	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C-Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015	Guil, Sonia/0000-0002-2257-3331				Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Huang MY, 1997, ONCOL RES, V9, P611; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu L, 1996, Methods Mol Biol, V57, P13	16	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5649	5653		10.1038/sj.onc.1205722	http://dx.doi.org/10.1038/sj.onc.1205722			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165864				2022-12-28	WOS:000177442000015
J	Ehrlich, M				Ehrlich, M			DNA methylation in cancer: too much, but also too little	ONCOGENE			English	Review						DNA methylation; cancer; satellite DNA; LINE-1; imprinting; MAGE genes	HUMAN BREAST-CANCER; HUMAN HEPATOCELLULAR-CARCINOMA; EMBRYONIC STEM-CELLS; MOUSE-LIVER TUMORS; REPETITIVE DNA; SATELLITE DNA; 5-METHYLCYTOSINE CONTENT; ICF SYNDROME; CPG-ISLAND; IMMUNODEFICIENCY SYNDROME	Cancer-associated DNA hypomethylation is as prevalent as cancer-linked hypermethylation, but these two types of epigenetic abnormalities usually seem to affect different DNA sequences. Much more of the genome is generally subject to undermethylation rather than overmethylation. Genomic hypermethylation in cancer has been observed most often in CpG islands in gene regions. In contrast, very frequent hypomethylation is seen in both highly and moderately repeated DNA sequences in cancer, including heterochromatic DNA repeats, dispersed retrotransposons, and endogenous retroviral elements. Also, unique sequences, including transcription control sequences, are often subject to cancer-associated undermethylation. The high frequency of cancer-linked DNA hypomethylation, the nature of the affected sequences, and the absence of associations with DNA hypermethylation are consistent with an independent role for DNA undermethylation in cancer formation or tumor progression. Increased karyotypic instability and activation of tumor-promoting genes by cis or trans effects, that might include altered heterochromatin-euchromatin interactions, may be important consequences of DNA hypomethylation which favor oncogenesis. The relationship of DNA hypomethylation to tumorigenesis is important to be considered in the light of cancer therapies involving decreasing DNA methylation. Inducing DNA hypomethylation may have short-term anticancer effects, but might also help speed tumor progression from cancer cells surviving the DNA demethylation chemotherapy.	Tulane Univ, Sch Med, Dept Biochem, Human Genet Program SL31, New Orleans, LA 70122 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70122 USA	Tulane University; Tulane University	Ehrlich, M (corresponding author), Tulane Univ, Sch Med, Dept Biochem, Human Genet Program SL31, New Orleans, LA 70122 USA.	ehrlich@tcs.tulane.edu			NATIONAL CANCER INSTITUTE [R01CA081506] Funding Source: NIH RePORTER; NCI NIH HHS [CA81506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin Stephen B., 2000, P293; BEDFORD MT, 1987, CANCER RES, V47, P5274; Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8; BRITOBABAPULLE V, 1981, CANCER GENET CYTOGEN, V4, P215, DOI 10.1016/0165-4608(81)90015-7; CARR BI, 1984, CARCINOGENESIS, V5, P1583, DOI 10.1093/carcin/5.12.1583; Casau AE, 1999, J VIROL, V73, P9976, DOI 10.1128/JVI.73.12.9976-9983.1999; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Cho M, 2001, BRIT J CANCER, V85, P563, DOI 10.1054/bjoc.2001.1951; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cui HM, 2001, CANCER RES, V61, P4947; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; DANTE R, 1992, ANTICANCER RES, V12, P559; De Backer O, 1999, CANCER RES, V59, P3157; DENDA A, 1985, CARCINOGENESIS, V6, P145, DOI 10.1093/carcin/6.1.145; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Dupressoir A, 1997, ONCOGENE, V14, P2951, DOI 10.1038/sj.onc.1201148; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2001, HUM MOL GENET, V10, P2917, DOI 10.1093/hmg/10.25.2917; Ehrlich Melanie, 2000, P273; EPSTEIN ND, 1987, NUCLEIC ACIDS RES, V15, P2327, DOI 10.1093/nar/15.5.2327; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1988, CANCER RES, V48, P1159; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Gotzinger N, 1996, J GEN VIROL, V77, P2983, DOI 10.1099/0022-1317-77-12-2983; GUTEKUNST KA, 1993, J ACQ IMMUN DEF SYND, V6, P541; Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Herbst H, 1996, AM J PATHOL, V149, P1727; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; ISSA JP, 2000, ALTERATIONS CANC GUI, P311; Jang SJ, 2001, CANCER RES, V61, P7959; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jurgens B, 1996, CANCER RES, V56, P5698; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B; KONDO M, 1995, ONCOGENE, V10, P1193; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; LAPEYRE JN, 1979, BIOCHEM BIOPH RES CO, V87, P698, DOI 10.1016/0006-291X(79)92015-1; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; LEIBMOSCH C, 1993, GENOMICS, V18, P261, DOI 10.1006/geno.1993.1464; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lin CH, 2001, CANCER RES, V61, P4238; LU LJW, 1983, CANCER LETT, V19, P231, DOI 10.1016/0304-3835(83)90159-3; Malik K, 2000, CANCER RES, V60, P2356; Malik K, 2000, BRIT J CANCER, V83, P1583, DOI 10.1054/bjoc.2000.1549; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; MIKI Y, 1992, CANCER RES, V52, P643; MIKOVITS JA, 1990, J EXP MED, V171, P1705, DOI 10.1084/jem.171.5.1705; Miniou P, 1997, HUM GENET, V99, P738, DOI 10.1007/s004390050441; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; O'Neill RJW, 2001, MAMM GENOME, V12, P256, DOI 10.1007/s003350010270; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; POGRIBNY IP, 1995, CANCER RES, V55, P1894; POIRIER LA, 1994, DRUG METAB REV, V26, P185, DOI 10.3109/03602539409029790; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Robertson KD, 2000, CURR TOP MICROBIOL, V249, P21; Rothberg PG, 1997, MOL CARCINOGEN, V19, P69, DOI 10.1002/(SICI)1098-2744(199707)19:2<69::AID-MC1>3.0.CO;2-G; RUBIN CM, 1994, NUCLEIC ACIDS RES, V22, P5121, DOI 10.1093/nar/22.23.5121; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Santourlidis S, 1999, PROSTATE, V39, P166; Sasaki H, 2000, J BIOCHEM, V127, P711, DOI 10.1093/oxfordjournals.jbchem.a022661; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.0.CO;2-5; SHARRARD RM, 1992, BRIT J CANCER, V65, P667, DOI 10.1038/bjc.1992.142; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shiraishi M, 1999, BIOL CHEM, V380, P81, DOI 10.1515/BC.1999.010; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; Takacs M, 1998, BIOL CHEM, V379, P417, DOI 10.1515/bchm.1998.379.4-5.417; Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; TANAKA Y, 1995, INT J CANCER, V60, P554, DOI 10.1002/ijc.2910600421; Tao LH, 2000, CANCER LETT, V158, P185, DOI 10.1016/S0304-3835(00)00518-8; THOMAS GA, 1992, CARCINOGENESIS, V13, P1039, DOI 10.1093/carcin/13.6.1039; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Thoraval D, 1996, P NATL ACAD SCI USA, V93, P4442, DOI 10.1073/pnas.93.9.4442; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Tycko Benjamin, 2000, P333; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; WAHLFORS J, 1992, BLOOD, V80, P2074; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955; Yuan LM, 1999, CANCER RES, V59, P3215; ZHANG XY, 1985, NUCLEIC ACIDS RES, V13, P4837, DOI 10.1093/nar/13.13.4837; ZHANG XY, 1987, NUCLEIC ACIDS RES, V15, P9429, DOI 10.1093/nar/15.22.9429	124	1129	1225	1	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5400	5413		10.1038/sj.onc.1205651	http://dx.doi.org/10.1038/sj.onc.1205651			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154403				2022-12-28	WOS:000177197700007
J	Widschwendter, M; Jones, PA				Widschwendter, M; Jones, PA			DNA methylation and breast carcinogenesis	ONCOGENE			English	Review						breast cancer; DNA methylation; carcinogenesis; prevention; early detection	MAMMARY EPITHELIAL-CELLS; RETINOIC ACID RECEPTOR; GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; INTERCELLULAR-ADHESION MOLECULE-1; MANGANESE SUPEROXIDE-DISMUTASE; HISTONE DEACETYLASE INHIBITION; PROSTASIN SERINE-PROTEASE; MESSENGER-RNA EXPRESSION; NORMAL HUMAN FIBROBLASTS	Knowledge about breast carcinogenesis has accumulated during the last decades but has barely been translated into strategies for early detection or prevention of this common disease. Changes in DNA methylation have been recognized as one of the most common molecular alterations in human neoplasia and hypermethylation of gene-promoter regions is being revealed as one of the most frequent mechanisms of loss of gene function. The heritability of methylation states and the secondary nature of the decision to attract or exclude methylation support the idea that DNA methylation is adapted for a specific cellular memory. According to Hanahan and Weinberg, there are six novel capabilities a cell has to acquire to become a cancer cell: limitless replicative potential, self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, sustained angiogenesis and tissue invasion and metastasis. This review highlights how DNA-methylation contributes to these features and offers suggestions about how these changes could be prevented, reverted or used as a 'tag' for early detection of breast cancer or, preferably, for detection of premalignant changes.	Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California	Widschwendter, M (corresponding author), Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, 1441 Eastlake Ave,MS 8302L, Los Angeles, CA 90089 USA.	Martin.Widschwendter@uibk.ac.at		Widschwendter, Martin/0000-0002-7778-8380	NCI NIH HHS [1R01 CA 83867-01, 1R01 CA 82422-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083867, R01CA082422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Ahuja N, 1998, CANCER RES, V58, P5489; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566; Arnold JM, 2001, BRIT J CANCER, V85, P1351, DOI 10.1054/bjoc.2001.2075; ARTEAGA CL, 1988, CANCER RES, V48, P3898; Bachman KE, 1999, CANCER RES, V59, P798; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bender CM, 1998, CANCER RES, V58, P95; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bottinger EP, 1997, CANCER RES, V57, P5564; Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen B, 2000, CANCER RES, V60, P3290; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chodosh LA, 1999, CANCER RES, V59, p1765S; Clarke RB, 1997, CANCER RES, V57, P4987; Clarke RB, 1997, BREAST CANCER RES TR, V45, P121, DOI 10.1023/A:1005805831460; Cohn BA, 2001, J NATL CANCER I, V93, P1133, DOI 10.1093/jnci/93.15.1133; Conway KE, 2000, CANCER RES, V60, P6236; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dammann R, 2001, CANCER RES, V61, P3105; Daniels R, 1997, HUM REPROD, V12, P2251, DOI 10.1093/humrep/12.10.2251; Dekker G, 2001, LANCET, V357, P209, DOI 10.1016/S0140-6736(00)03599-6; Devereux TR, 1999, CANCER RES, V59, P6087; Dhar S, 2001, CLIN CANCER RES, V7, P3393; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Du Y, 2001, CANCER RES, V61, P8094; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Fabian CJ, 2001, BREAST CANCER RES, V3, P99, DOI 10.1186/bcr279; FALETTE NS, 1990, CANCER RES, V50, P3974; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Ginger MR, 2001, MOL ENDOCRINOL, V15, P1993, DOI 10.1210/me.15.11.1993; GOING JJ, 1988, AM J PATHOL, V130, P193; Goyal J, 1998, CANCER RES, V58, P4782; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Gustafsson JA, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960-0760(00)00130-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Hartsough MT, 2001, CANCER RES, V61, P2320; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Heimann R, 1998, CANCER RES, V58, P2766; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hori, 1999, Breast Cancer, V6, P79, DOI 10.1007/BF02966912; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; Hui R, 2000, CLIN CANCER RES, V6, P2777; Huschtscha LI, 1998, CANCER RES, V58, P3508; Ingvarsson S, 2001, SEMIN CANCER BIOL, V11, P361, DOI 10.1006/scbi.2001.0391; Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jia TL, 1999, CANCER RES, V59, P742; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KAMEL OW, 1989, AM J PATHOL, V134, P107; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kay PH, 1998, ANTICANCER RES, V18, P1709; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kishimoto T, 2001, NAT GENET, V28, P4, DOI 10.1038/88244; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kress C, 2001, FEBS LETT, V494, P135, DOI 10.1016/S0014-5793(01)02328-6; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kyo S, 1999, CANCER RES, V59, P5917; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; LEE XH, 1995, EXP CELL RES, V218, P296, DOI 10.1006/excr.1995.1158; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; LELLE RJ, 1987, J CANCER RES CLIN, V113, P73, DOI 10.1007/BF00389970; LEONE A, 1993, ONCOGENE, V8, P2325; Li B, 2001, CANCER RES, V61, P8014; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Li ZK, 2001, FREE RADICAL BIO MED, V30, P260, DOI 10.1016/S0891-5849(00)00468-8; Liang G, 2002, CANCER RES, V62, P961; Lin CH, 2001, CANCER RES, V61, P4238; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; LIPPMAN ME, 1990, PROG CLIN BIOL RES, V354, P147; Liu ML, 2001, LEUKEMIA RES, V25, P441, DOI 10.1016/S0145-2126(00)00148-X; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Macleod D, 1998, MOL CELL BIOL, V18, P4433, DOI 10.1128/MCB.18.8.4433; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mehta RG, 2000, EUR J CANCER, V36, P1275, DOI 10.1016/S0959-8049(00)00100-3; MEYER JS, 1982, CANCER, V50, P746, DOI 10.1002/1097-0142(19820815)50:4<746::AID-CNCR2820500420>3.0.CO;2-A; MEYER JS, 1977, HUM PATHOL, V8, P67, DOI 10.1016/S0046-8177(77)80066-X; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Miettinen OS, 2002, LANCET, V359, P404, DOI 10.1016/S0140-6736(02)07592-X; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Moinfar F, 2000, CANCER RES, V60, P2562; MOSCOW JA, 1995, CANCER RES, V55, P3790; Munster PN, 2001, CANCER RES, V61, P8492; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A; Norton JD, 2000, J CELL SCI, V113, P3897; Ogawa Y, 1998, CLIN CANCER RES, V4, P31; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pagliuca A, 2000, CANCER RES, V60, P1376; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; POLEDNAK AP, 1983, J REPROD MED, V28, P314; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Rexer BN, 2001, CANCER RES, V61, P7065; Ristimaki A, 2002, CANCER RES, V62, P632; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; Shang YF, 1999, ONCOGENE, V18, P6725, DOI 10.1038/sj.onc.1203084; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495; SILVA JM, 1999, CANCER RES, V59, P3521; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974; THOMPSON WD, 1989, JNCI-J NATL CANCER I, V81, P1571, DOI 10.1093/jnci/81.20.1571; Thor AD, 2001, CLIN CANCER RES, V7, P2415; Tollefsbol TO, 2001, MED HYPOTHESES, V56, P630, DOI 10.1054/mehy.2000.1241; Toyooka KO, 2001, CANCER RES, V61, P4556; Troisi R, 1998, EPIDEMIOLOGY, V9, P641, DOI 10.1097/00001648-199811000-00014; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; URIA JA, 1994, CANCER RES, V54, P2091; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; WILSON VL, 1983, SCIENCE, V220, P1054; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925; Xu XC, 1997, CANCER RES, V57, P4992; Xu XL, 2001, CANCER RES, V61, P7943; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yuan YF, 2001, CANCER RES, V61, P5558; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZHANG M, 1995, CANCER RES, V55, P2537; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	240	358	392	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5462	5482		10.1038/sj.onc.1205606	http://dx.doi.org/10.1038/sj.onc.1205606			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154408				2022-12-28	WOS:000177197700012
J	Godthelp, BC; Artwert, F; Joenje, H; Zdzienicka, MZ				Godthelp, BC; Artwert, F; Joenje, H; Zdzienicka, MZ			Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1	ONCOGENE			English	Article						Fanconi anemia; MMC; Rad51 foci; nuclear accumulation; homologous recombination	PROTEIN; GENE; RECOMBINATION; REPAIR; COMPLEX; CLONING; BRCA2; CDNA	Fanconi anemia is a hereditary cancer susceptibility disorder characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to DNA cross-linking agents such as mitomycin C. This phenotype suggests a possible role for the Fanconi anemia proteins in the repair of DNA lesions induced by these agents, but the molecular mechanism underlying the defect in this disorder has not yet been identified. Here, we show that amongst eight so far identified complementation groups of Fanconi anemia, only fibroblasts derived from group D1 are defective in the formation of nuclear Rad51 foci after X-ray irradiation or mitomycin C treatment. This indicates that the FANCD1 gene product is uniquely involved in the assembly and/or stabilization of the Rad51 complex. Since DNA damage-induced Rad51 nuclear foci are thought to reflect repair of DNA double-strand breaks by homologous recombination, our results suggest that FANCD1 is likely to be involved in homologous recombination-dependent repair.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, NL-2333 AL Leiden, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Ludwik Rydygier Univ Med Sci, Dept Mol Cell Genet, Bydgoszcz, Poland	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Nicolaus Copernicus University	Zdzienicka, MZ (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	M.Z.Zdzienicka@LUMC.nl						Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Yuan SSF, 1999, CANCER RES, V59, P3547	29	73	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5002	5005		10.1038/sj.onc.1205656	http://dx.doi.org/10.1038/sj.onc.1205656			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118380				2022-12-28	WOS:000176874800016
J	Sasaki, S; Nakamura, T; Arakawa, H; Mori, M; Watanabe, T; Nagawa, H; Croce, CM				Sasaki, S; Nakamura, T; Arakawa, H; Mori, M; Watanabe, T; Nagawa, H; Croce, CM			Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer	ONCOGENE			English	Article						inhibitor of apoptosis protein; TNF-alpha; induced apoptosis; cleavage by caspase-3; Ring Finger domain; esophageal cancer	APOPTOSIS INHIBITORY PROTEIN; CELL-DEATH; BACULOVIRUS GENE; FAMILY; IAP; CASPASES; HOMOLOGS; MOTIF; TID1	hTID1, a human homologue of Drosophila tumor suppressor, I(2)tid regulates the release of cytochrome c from mitochondria and subsequent alteration of caspase-3 activity on apoptosis induced by exogenous stimuli, such as tumor necrosis factor-alpha, and mitomycin C. To search for an interacting molecule with hTid1, we applied two-hybrid yeast screening and isolated a novel gene, which encodes a 46 kDa protein of 373 residues. Within the deduced amino acid sequence, a region showing homology to the Ring Finger domain of X-linked inhibitor of apoptosis protein was identified and the gene was designated as hRFI, standing for human Ring Finger homologous to IAP type. A 2.0 kb hRFI transcript was ubiquitously expressed in all human tissues as well as several cancer cell lines examined. Northern blot analysis showed that in 70% (14 out of 20) of esophageal cancer patients, expression of hRFI in cancerous regions was two or more times higher than in the corresponding normal tissues. HeLa cells transfected with hRFI construct exhibited a tendency to resist TNF-alpha induced apoptosis, suggesting an anti-apoptotic function of the hRFI product. Finally, hRFI protein was shown to be cleaved within the DEDD sequence spanning residues 230 - 233 by caspase-3 during the apoptotic induction.	Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Technol,Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Surg, Oita 8740838, Japan	University of Tokyo; Jefferson University; University of Tokyo; Kyushu University	Sasaki, S (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Young, Richard A/F-6495-2012; Arakawa, Hirofumi/L-3459-2013	Young, Richard A/0000-0001-8855-8647; Arakawa, Hirofumi/0000-0001-6077-0638				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; KOZAK M, 1983, MICROBIOL REV, V47, P1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Merup M, 1997, EUR J HAEMATOL, V58, P174; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X	25	27	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					5024	5030		10.1038/sj.onc.1205627	http://dx.doi.org/10.1038/sj.onc.1205627			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118383				2022-12-28	WOS:000176874800019
J	Andersen, H; Mahmood, S; Tkach, V; Cohn, M; Kustikova, O; Grigorian, M; Berezin, V; Bock, E; Lukanidin, E; Tulchinsky, E				Andersen, H; Mahmood, S; Tkach, V; Cohn, M; Kustikova, O; Grigorian, M; Berezin, V; Bock, E; Lukanidin, E; Tulchinsky, E			The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials	ONCOGENE			English	Article						c-Fos; Fra-1; Fra-2; cell shape; transcription	IN-VITRO; C-FOS; FRA-1 GENE; AP-1; TRANSFORMATION; EXPRESSION; REQUIRES; PHOSPHORYLATION; ACTIVATION; TRANSITION	Numerous studies have revealed distinct functions of Fos proteins in different mouse tissues and cell lines. Here, we perform a direct comparison of the features of exogenous c-Fos, Fra-1 and Fra-2 proteins expressed in murine tumor cells of epithelial origin, CSMLO. Although transactivation potential of c-Fos is much stronger than that of Fra-1 and Fra-2, all three proteins are capable of modulating transcription of target genes. Moreover, there is a certain degree of specificity in the induction of the transcription of AP-1-responsive genes by different Fos proteins. For instance, c-Fos and Fra-1 but not Fra-2 activated genes of the urokinase system. Additionally, not only a strong transcriptional activator c-Fos, but also Fra-1 induced morphological alterations in CSMLO cells. N-terminal domain of Fra-1 was required for this function. On the other hand, Fra-2 failed to change morphology of CSMLO cells. We therefore conclude that c-Fos, Fra-1 and Fra-2 differently activate transcription of target genes and induce morphological changes in epithelioid carcinoma cells in a manner not directly linked to their transactivation potentials.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen 0, Denmark; Univ Copenhagen, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark	Danish Cancer Society; University of Copenhagen	Tulchinsky, E (corresponding author), Leicester Gen Hosp, Div Urol, Clin Sci Unit, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021	Cohn, Martin/0000-0002-2988-3009				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Debinski W, 2001, MOL MED, V7, P598, DOI 10.1007/BF03401866; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JEHN J, 1991, P NATL ACAD SCI USA, V88, P5077; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lepekhin EA, 2001, METH MOL B, V161, P85; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zajchowski DA, 2001, CANCER RES, V61, P5168	31	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4843	4848		10.1038/sj.onc.1205590	http://dx.doi.org/10.1038/sj.onc.1205590			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101423				2022-12-28	WOS:000176716300014
J	Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH				Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH			Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus	ONCOGENE			English	Article						erythroleukemia; receptor; tyrosine kinase; Stk; Fv2; signal transduction	MULTIFUNCTIONAL DOCKING SITE; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR; CELL-TRANSFORMATION; MET PROTOONCOGENE; POINT MUTATIONS; TRUNCATED FORM; TYROSINE; INDUCTION; GENE	During the initial stage of Friend virus-induced erythro-leukemia in mice, interaction of the viral protein gp55 with the erythropoietin receptor, and other host factors, drives the expansion of erythroid precursor cells. Recently, we demonstrated that the Friend virus susceptibility locus, Fv2, which is required for the expansion of infected cells, encodes a naturally occurring, N-terminally truncated form of the Stk receptor tyrosine kinase (Sf-Stk). Here we show that in vitro expression of Sf-Stk confers Friend virus sensitivity to erythroid progenitor cells from Fv2(rr) mice. Furthermore, our data reveal that Sf-Stk kinase activity and Y436, but not Y429, are required for Epo-independent colony formation following Friend virus infection. Introduction of a mutation that results in failure to bind Grb2 abrogates the ability of Sf-Stk to induce colonies in response to Friend virus, while the Grb2 binding site from EGFR restores this response. Consistent with the ability of Grb2 to recruit SOS and Gab1, the Ras/MAPK and PI3K pathways are activated by Sf-Stk, and both of these pathways are required for gp55-mediated erythroblast proliferation. These data clearly demonstrate a requirement for signaling through Sf-Stk in the Epo-independent expansion of Friend virus-infected cells, and suggest a pivotal role for Grb2 in this response.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; St Jude Children's Research Hospital	Correll, PH (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu			NCI NIH HHS [R01 CA084214-01, R01 CA084214-05, R01 CA084214-03, R01 CA084214-04, R01 CA084214, R01 CA084214-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL66471, R01 HL066471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084214] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BONDURANT MC, 1985, J GEN VIROL, V66, P83, DOI 10.1099/0022-1317-66-1-83; CLARKE BJ, 1975, P NATL ACAD SCI USA, V72, P3556, DOI 10.1073/pnas.72.9.3556; Correll Pamela H., 1997, Genes and Function, V1, P69; DANDREA AD, 1992, CANCER SURV, V15, P19; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu QP, 1999, J IMMUNOL, V163, P6606; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; ZHEN Z, 1994, ONCOGENE, V9, P1691	38	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3562	3570		10.1038/sj.onc.1205442	http://dx.doi.org/10.1038/sj.onc.1205442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032858				2022-12-28	WOS:000175793700007
J	Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL				Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinase B/Akt pathways	ONCOGENE			English	Article						Muc4; ErbB2; tyrosine phosphorylation; apoptosis; p27(kip); signaling	SURFACE SIALOMUCIN COMPLEX; RECEPTOR TYROSINE KINASE; GLYCOPROTEIN COMPLEX; SIGNALING NETWORK; MOLECULAR-CLONING; OCULAR SURFACE; RAT MUC4; GROWTH; LOCALIZATION; CELLS	Muc4/sialomucin complex (SMC) is a multifunctional glycoprotein complex which can repress apoptosis in transfected tumor cells. Its transmembrane subunit acts as an intramembrane ligand for the receptor tyrosine kinase ErbB2 to induce the phosphorylation of ErbB2 and, by acting synergistically with the ErbB3 ligand neuregulin, can potentiate the phosphorylation of ErbB2 and ErbB3. In the present study we show that Muc4/SMC alone robustly induces the phosphorylation of ErbB2 to enhance the tyrosine phosphate epitope (Tyr1248) recognized by anti-phospho-ErbB2. Although this tyrosine phosphorylation has been implicated in cell transformation, it does not activate any of the three mitogen-activated protein kinases (MAPKs) or protein kinase B/Akt of the phosphatidyl inositol 3-kinase pathway. Instead, Muc4/SMC expression induces up-regulation of the cell cycle inhibitor p27(kip), consistent with the expression of Muc4/SMC in differentiated, rather than proliferative, epithelial cells. Interestingly, a combination of Muc4/SMC and neuregulin down-regulate p27(kip) and activate protein kinase B/Akt. These observations suggest that Muc4/SMC acts as a regulator of differentiation by inducing a limited phosphorylation of ErbB2 and a modulator of proliferation when acting synergistically with neuregulin to induce a more extensive phosphorylation on both ErbB2 and ErbB3.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, R-124,POB 016960, Miami, FL 33101 USA.	Kcarrawa@med.miami.edu		Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Idris N, 2001, J CELL PHYSIOL, V189, P162, DOI 10.1002/jcp.10012; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Klapper LN, 2000, ADV CANCER RES, V77, P25; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li P, 2001, TISSUE CELL, V33, P111, DOI 10.1054/tice.2000.0162; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pflugfelder SC, 2000, INVEST OPHTH VIS SCI, V41, P1316; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; RICCI A, 1995, ONCOGENE, V11, P1519; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Weed DT, 2001, OTOLARYNG HEAD NECK, V124, P127, DOI 10.1067/mhn.2001.112575; WU K, 1994, J BIOL CHEM, V269, P11950; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	106	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7524	7532		10.1038/sj.onc.1205970	http://dx.doi.org/10.1038/sj.onc.1205970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386815				2022-12-28	WOS:000178618200008
J	Plug-Demaggio, AW; McDougall, JK				Plug-Demaggio, AW; McDougall, JK			The human papillomavirus type 16 E6 oncogene induces premature mitotic chromosome segregation	ONCOGENE			English	Article						genetic instability; chromosome segregation; HPV 16 E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN KERATINOCYTES; GENOMIC INSTABILITY; SPINDLE CHECKPOINT; MAMMALIAN-CELLS; ONCOPROTEINS; P53; DEGRADATION; PROGRESSION; DISRUPTION	Expression of the human papillomavirus type 16 E6 and E7 oncogenes initiates and maintains abnormal cell replication, by interacting with the p53 and retinoblastoma (Rb) gene products. Subsequent changes in host cell gene expression, as a consequence of genetic instability, can result in progression to invasive carcinoma. In addition to previously described effects of these viral oncogenes on centrosome synthesis, primarily associated with the expression of E7, the results described herein demonstrate that the E6 oncogene can induce premature chromosome segregation in human cells.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	McDougall, JK (corresponding author), Univ Washington, Dept Pathol, 1959 Pacific St NE, Seattle, WA 98195 USA.	jmcdouga@fhcrc.org			NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burger MPM, 1997, INT J GYNECOL PATHOL, V16, P10, DOI 10.1097/00004347-199701000-00002; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; MANTOVANI F, 2001, SEMIN CANCER BIOL, V9, P387; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MUNGER K, 1989, J VIROL, V63, P4417; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; THERMAN E, 1984, CANCER GENET CYTOGEN, V11, P185, DOI 10.1016/0165-4608(84)90113-4; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; VANLEEUWEN AM, 1995, VIRCHOWS ARCH, V427, P139, DOI 10.1007/BF00196518; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	28	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7507	7513		10.1038/sj.onc.1205903	http://dx.doi.org/10.1038/sj.onc.1205903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386813				2022-12-28	WOS:000178618200006
J	Wiencke, JK				Wiencke, JK			DNA adduct burden and tobacco carcinogenesis	ONCOGENE			English	Review						DNA adducts; tobacco; risk assessment; molecular epidemiology	GLUTATHIONE-S-TRANSFERASE; LUNG-CANCER RISK; WHITE BLOOD-CELLS; POLYCYCLIC AROMATIC-HYDROCARBONS; COKE-OVEN WORKERS; BENZO<A>PYRENE DIOL-EPOXIDE; REPAIR GENE XRCC1; NUCLEOTIDE EXCISION-REPAIR; HPRT MUTANT FREQUENCY; BLADDER-CANCER	DNA adducts associated with tobacco smoking could provide a marker of biologically effective dose of tobacco carcinogens and improve individual cancer risk prediction. A significant number of clinical and epidemiologic studies have reported associations of increased DNA adduct levels with the occurrence of the prevalent tobacco related cancers including cancer of the lung, head and neck, and bladder. The inducibility of DNA adducts following in vitro treatments using blood lymphocytes also appears to be a risk factor in the development of lung and head and neck cancer. Corroborative evidence pointing to the importance of DNA adducts in tobacco carcinogenesis include numerous studies showing associations of tobacco smoke exposure with the induction of DNA adducts in humans in vivo. Further effort is necessary, however, to more fully characterize the dose - response relationship between smoking and DNA adducts in exposed target and surrogate tissues. The relationship between gene polymorphisms thought to modify tobacco-related cancer risk and DNA adduct levels is complex. Results of some DNA adduct studies (both in vitro and in vivo) appear inconsistent with the epidemiologic findings. This is evident for polymorphisms involving both carcinogen metabolism (e.g. GSTP1) and DNA repair (e.g. XRCC1). Molecular studies of human tumors suggest associations of p53 mutation with DNA adducts and have revealed correlations of DNA adduct levels with somatic alterations (e.g. 3p21 LOH) that are thought to occur at the very earliest stages of tobacco carcinogenesis. More research is needed to assess the relationship between endogenous sources of DNA adducts and tobacco smoke exposure and the relative oncogenic effects of chemically stable versus unstable DNA adducts. Many potentially fruitful new avenues of cancer research are emerging that integrate DNA adduct analyses with assessments of smoking, genetics, diet and ambient air quality. These investigations aim to understand the multifactorial nature of interindividual variability in response to tobacco carcinogens. As these trends continue a variety of innovative study designs and approaches will become important in human populations.	Univ Calif San Francisco, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wiencke, JK (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA.	wiencke@itsa.ucsf.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006717] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06717] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDROV K, 1992, CANCER RES, V52, P6248; Andreassen A, 1996, MUTAT RES-GENET TOX, V368, P275; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Arnould JP, 1999, HUM EXP TOXICOL, V18, P314, DOI 10.1191/096032799678840174; Arnould JP, 2000, PATHOL BIOL, V48, P548; Banaszewski J, 2000, EUR ARCH OTO-RHINO-L, V257, P149, DOI 10.1007/s004050050212; Bartsch H, 1998, RECENT RES CANCER, V154, P86; Bartsch H, 2001, ADV EXP MED BIOL, V500, P675; Binkova B, 1998, MUTAT RES-GEN TOX EN, V416, P67, DOI 10.1016/S1383-5718(98)00061-8; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; BODELL WJ, 1989, CHEM RES TOXICOL, V2, P312, DOI 10.1021/tx00011a008; Bonassi S, 2001, MUTAT RES-FUND MOL M, V480, P349, DOI 10.1016/S0027-5107(01)00194-4; Bucci F, 1998, ANTICANCER RES, V18, P2669; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Butkiewicz D, 2000, ENVIRON MOL MUTAGEN, V35, P99, DOI 10.1002/(SICI)1098-2280(2000)35:2<99::AID-EM4>3.0.CO;2-2; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Carmichael P L, 1998, Arch Toxicol Suppl, V20, P199; Casale GP, 2001, CHEM RES TOXICOL, V14, P192, DOI 10.1021/tx000012y; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Chen HJC, 1998, CHEM RES TOXICOL, V11, P1474, DOI 10.1021/tx980107o; Chen L, 1996, CHEM RES TOXICOL, V9, P897, DOI 10.1021/tx960004a; Cheng L, 2000, CARCINOGENESIS, V21, P1527, DOI 10.1093/carcin/21.8.1527; Cheng YW, 2001, ENVIRON MOL MUTAGEN, V37, P304, DOI 10.1002/em.1037; Cheng YW, 2000, EUR J CANCER, V36, P1381, DOI 10.1016/S0959-8049(00)00131-3; Coles B, 2000, CANCER LETT, V156, P167, DOI 10.1016/S0304-3835(00)00458-4; Coles BF, 2000, CANCER RES, V60, P573; CUZICK J, 1995, J NATL CANCER I, V87, P861, DOI 10.1093/jnci/87.12.861; David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2; Devanesan PD, 1996, CHEM RES TOXICOL, V9, P1113, DOI 10.1021/tx9600513; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; Duell EJ, 2002, JNCI-J NATL CANCER I, V94, P297, DOI 10.1093/jnci/94.4.297; Endo C, 2000, SURG TODAY, V30, P695, DOI 10.1007/s005950070079; Fennell TR, 2000, CANCER EPIDEM BIOMAR, V9, P705; Fields WR, 1998, MOL PHARMACOL, V54, P298, DOI 10.1124/mol.54.2.298; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; Garner RC, 1998, MUTAT RES-FUND MOL M, V402, P67; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; Godschalk RWL, 2001, PHARMACOGENETICS, V11, P389, DOI 10.1097/00008571-200107000-00003; Goldman R, 2001, CANCER RES, V61, P6367; Grant DJ, 2000, MOL CARCINOGEN, V29, P198, DOI 10.1002/1098-2744(200012)29:4<198::AID-MC1001>3.0.CO;2-K; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; GRZYBOWSKA E, 1993, CARCINOGENESIS, V14, P2523, DOI 10.1093/carcin/14.12.2523; Grzybowska E, 2000, MUTAT RES-GEN TOX EN, V469, P271, DOI 10.1016/S1383-5718(00)00090-5; Gupta RC, 1999, MUTAT RES-FUND MOL M, V424, P195, DOI 10.1016/S0027-5107(99)00019-6; Hardie LJ, 2000, CARCINOGENESIS, V21, P167, DOI 10.1093/carcin/21.2.167; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; Hecht SS, 2001, TOXICOLOGY, V166, P31, DOI 10.1016/S0300-483X(01)00436-X; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; Helleberg H, 2001, MUTAGENESIS, V16, P333, DOI 10.1093/mutage/16.4.333; Hemminki K, 2001, INT J CANCER, V92, P923, DOI 10.1002/ijc.1273; Hemminki K, 2000, REGUL TOXICOL PHARM, V32, P264, DOI 10.1006/rtph.2000.1431; Hirao T, 2001, CANCER RES, V61, P612; Hoque A, 2001, CANCER CAUSE CONTROL, V12, P627, DOI 10.1023/A:1011277600059; Hou SM, 2001, CANCER EPIDEM BIOMAR, V10, P133; Hu X, 1999, CANCER RES, V59, P2358; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Jacobson JS, 2000, CANCER EPIDEM BIOMAR, V9, P1303; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; Josyula S, 2000, INT J ONCOL, V17, P811; Kadlubar FF, 1998, MUTAT RES-FUND MOL M, V405, P125, DOI 10.1016/S0027-5107(98)00129-8; Kantarci OH, 2002, MAYO CLIN PROC, V77, P17, DOI 10.4065/77.1.17; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kihara M, 1999, CANCER LETT, V137, P53, DOI 10.1016/S0304-3835(98)00337-1; Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7; Kure EH, 1996, CARCINOGENESIS, V17, P2201, DOI 10.1093/carcin/17.10.2201; Kyrtopoulos SA, 2001, MUTAT RES-GEN TOX EN, V496, P207, DOI 10.1016/S1383-5718(01)00222-4; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; Leuratti C, 1998, CARCINOGENESIS, V19, P1919, DOI 10.1093/carcin/19.11.1919; Li DH, 2001, CANCER RES, V61, P1445; Li DH, 2002, MUTAT RES-GEN TOX EN, V513, P37, DOI 10.1016/S1383-5718(01)00291-1; Li DH, 2001, INT J CANCER, V93, P436, DOI 10.1002/ijc.1347.abs; Lodovici M, 1998, CHEM-BIOL INTERACT, V116, P199, DOI 10.1016/S0009-2797(98)00091-X; London SJ, 1997, CANCER RES, V57, P5001; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Martone T, 1998, INT J CANCER, V75, P512, DOI 10.1002/(SICI)1097-0215(19980209)75:4<512::AID-IJC4>3.0.CO;2-W; Marzilli LA, 2001, METH MOL B, V162, P395; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Melendez-Colon VJ, 1999, CARCINOGENESIS, V20, P1885, DOI 10.1093/carcin/20.10.1885; MelendezColon VJ, 1997, P NATL ACAD SCI USA, V94, P13542, DOI 10.1073/pnas.94.25.13542; Melikian AA, 1999, ONCOL REP, V6, P1371; Melikian AA, 1999, CANCER LETT, V146, P127, DOI 10.1016/S0304-3835(99)00203-7; Misra RR, 2001, CANCER LETT, V164, P161, DOI 10.1016/S0304-3835(01)00384-6; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; Moller L, 1996, CARCINOGENESIS, V17, P61, DOI 10.1093/carcin/17.1.61; Moller P, 1998, MUTAT RES-REV MUTAT, V410, P271, DOI 10.1016/S1383-5742(97)00041-0; Mollerup S, 1999, CANCER RES, V59, P3317; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; MOONEY LA, 1995, CANCER EPIDEM BIOMAR, V4, P627; Motykiewicz G, 1998, TOXICOL LETT, V96-7, P195, DOI 10.1016/S0378-4274(98)00072-1; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; Nath RG, 1998, CANCER RES, V58, P581; Nelson HH, 2002, CANCER RES, V62, P152; Nelson HH, 1998, CANCER RES, V58, P1804; Ni JS, 1998, ANAL BIOCHEM, V264, P222, DOI 10.1006/abio.1998.2835; Nia AB, 2000, ENVIRON MOL MUTAGEN, V36, P127, DOI 10.1002/1098-2280(2000)36:2<127::AID-EM7>3.0.CO;2-G; Nia AB, 2000, CARCINOGENESIS, V21, P1335, DOI 10.1093/carcin/21.7.1335; Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004; Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9; Ozawa S, 1999, CARCINOGENESIS, V20, P991, DOI 10.1093/carcin/20.6.991; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Pan G, 1998, CARCINOGENESIS, V19, P1963, DOI 10.1093/carcin/19.11.1963; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23; Pavanello S, 1999, CARCINOGENESIS, V20, P431, DOI 10.1093/carcin/20.3.431; Pavanello S, 2000, MUTAT RES-REV MUTAT, V463, P285, DOI 10.1016/S1383-5742(00)00051-X; PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713; Peluso M, 2000, CARCINOGENESIS, V21, P183, DOI 10.1093/carcin/21.2.183; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PERERA F, 1992, ENVIRON HEALTH PERSP, V98, P133, DOI 10.2307/3431259; PERERA F, 1989, CANCER RES, V49, P4446; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Petruzzelli S, 1998, CANCER RES, V58, P4122; Phillips DH, 2000, ENVIRON MOL MUTAGEN, V35, P222, DOI 10.1002/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E; Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Piipari R, 2000, INT J CANCER, V86, P610, DOI 10.1002/(SICI)1097-0215(20000601)86:5<610::AID-IJC2>3.0.CO;2-M; Povey AC, 2000, TOXICOL PATHOL, V28, P405, DOI 10.1177/019262330002800308; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Reddy MV, 2000, REGUL TOXICOL PHARM, V32, P256, DOI 10.1006/rtph.2000.1430; Ren Q, 2000, DRUG METAB DISPOS, V28, P1352; Risch A, 2001, PHARMACOGENETICS, V11, P757, DOI 10.1097/00008571-200112000-00003; Roberts KP, 2000, ELECTROPHORESIS, V21, P799, DOI 10.1002/(SICI)1522-2683(20000301)21:4<799::AID-ELPS799>3.3.CO;2-M; Rojas M, 2000, CARCINOGENESIS, V21, P35, DOI 10.1093/carcin/21.1.35; Rojas M, 2001, CARCINOGENESIS, V22, P1015, DOI 10.1093/carcin/22.7.1015; Rojas M, 1998, PHARMACOGENETICS, V8, P109; Romano G, 1999, CANCER EPIDEM BIOMAR, V8, P91; RYBERG D, 1994, CANCER RES, V54, P5801; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Saha BK, 2001, CELL MOL LIFE SCI, V58, P1141, DOI 10.1007/PL00000928; SAVELA K, 1991, CARCINOGENESIS, V12, P503, DOI 10.1093/carcin/12.3.503; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; Schoket B, 2001, MUTAT RES-FUND MOL M, V482, P57, DOI 10.1016/S0027-5107(01)00210-X; Schoket B, 1998, CARCINOGENESIS, V19, P841, DOI 10.1093/carcin/19.5.841; SCHOKET B, 1993, IARC SCI PUBL, V124, P315; SETO H, 1993, ARCH ENVIRON CON TOX, V24, P498, DOI 10.1007/BF01146169; SHIELDS PG, 1993, CANCER RES, V53, P3486; Shinozaki R, 1999, ARCH ENVIRON HEALTH, V54, P79, DOI 10.1080/00039899909602240; Shinozaki R, 1998, CYTOMETRY, V31, P300, DOI 10.1002/(SICI)1097-0320(19980401)31:4<300::AID-CYTO10>3.0.CO;2-U; Soni M, 1998, TOXICOLOGY, V126, P155, DOI 10.1016/S0300-483X(98)00010-9; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Sundberg K, 2002, CHEM RES TOXICOL, V15, P170, DOI 10.1021/tx015546t; Szeliga J, 1998, CHEM RES TOXICOL, V11, P1, DOI 10.1021/tx970142f; Szyfter K, 1999, MUTAT RES-GEN TOX EN, V445, P259, DOI 10.1016/S1383-5718(99)00131-X; Szyfter K, 1999, ACTA BIOCHIM POL, V46, P275, DOI 10.18388/abp.1999_4161; TALASKA G, 1994, CANCER LETT, V84, P93, DOI 10.1016/0304-3835(94)90362-X; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; Tan WG, 2001, J CHROMATOGR A, V924, P377, DOI 10.1016/S0021-9673(01)00987-6; TANG DL, 1995, CANCER EPIDEM BIOMAR, V4, P341; Tang DL, 1998, CARCINOGENESIS, V19, P1949, DOI 10.1093/carcin/19.11.1949; Tang DL, 2001, CANCER RES, V61, P6708; Thier R, 2001, MUTAT RES-FUND MOL M, V482, P41, DOI 10.1016/S0027-5107(01)00208-1; Thurston SW, 2000, BIOMETRICS, V56, P139, DOI 10.1111/j.0006-341X.2000.00139.x; Timbrell JA, 1998, TOXICOLOGY, V129, P1, DOI 10.1016/S0300-483X(98)00058-4; Topinka J, 2000, MUTAT RES-GEN TOX EN, V469, P83, DOI 10.1016/S1383-5718(00)00061-9; Turteltaub KW, 1998, TOXICOL LETT, V103, P435, DOI 10.1016/S0378-4274(98)00344-0; Uno S, 2001, BIOCHEM BIOPH RES CO, V289, P1049, DOI 10.1006/bbrc.2001.6110; Vainio H, 1998, TOXICOL LETT, V103, P581, DOI 10.1016/S0378-4274(98)00252-5; van Delft JHM, 1998, CRIT REV TOXICOL, V28, P477, DOI 10.1080/10408449891344254; Van Delft JHM, 1998, ANN OCCUP HYG, V42, P105, DOI 10.1016/S0003-4878(97)00055-0; Van Delft JHM, 2001, ANN OCCUP HYG, V45, P395, DOI 10.1016/S0003-4878(00)00065-X; van Lieshout EMM, 1999, CANCER RES, V59, P586; VAN SF, 1998, FASEB J, V12, P1409; Viezzer C, 1999, MUTAT RES-FUND MOL M, V431, P259, DOI 10.1016/S0027-5107(99)00169-4; VINEIS P, 1992, ENVIRON HEALTH PERSP, V98, P95, DOI 10.2307/3431253; Vineis P, 1996, Ann Ist Super Sanita, V32, P21; Vineis P, 2000, MUTAT RES-REV MUTAT, V463, P103; Vulimiri SV, 2000, MOL CARCINOGEN, V27, P34, DOI 10.1002/(SICI)1098-2744(200001)27:1<34::AID-MC6>3.3.CO;2-7; Wang MY, 1998, CANCER RES, V58, P38; Wang Y, 1998, IND HEALTH, V36, P337, DOI 10.2486/indhealth.36.337; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wei QY, 2000, J NATL CANCER I, V92, P1764; Whyatt RM, 1998, CARCINOGENESIS, V19, P1389, DOI 10.1093/carcin/19.8.1389; Whyatt RM, 2000, CANCER EPIDEM BIOMAR, V9, P207; Whyatt RM, 2001, CANCER EPIDEM BIOMAR, V10, P581; Wiencke J., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P562; Wiencke JK, 1999, J NATL CANCER I, V91, P614, DOI 10.1093/jnci/91.7.614; WIENCKE JK, 1995, CANCER RES, V55, P4910; WIENCKE JK, 2002, ENV HLTH PERSPEC JUN; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Williams M D, 2001, Cancer Treat Res, V105, P31; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Xing JZ, 2001, METH MOL B, V162, P419; Yang K, 1998, MUTAT RES-FUND MOL M, V422, P285, DOI 10.1016/S0027-5107(98)00210-3; Yang SC, 2000, CHEM RES TOXICOL, V13, P1046, DOI 10.1021/tx0000419; Yi P, 1998, CHEM RES TOXICOL, V11, P1032, DOI 10.1021/tx9800497; Yueh MF, 2001, CARCINOGENESIS, V22, P943, DOI 10.1093/carcin/22.6.943; Zhang J, 2000, INT ARCH OCC ENV HEA, V73, P127, DOI 10.1007/s004200050018; Zhou GD, 2000, MUTAT RES-FUND MOL M, V447, P137, DOI 10.1016/S0027-5107(99)00211-0; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	196	119	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7376	7391		10.1038/sj.onc.1205799	http://dx.doi.org/10.1038/sj.onc.1205799			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379880				2022-12-28	WOS:000178618000010
J	Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC				Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC			Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line	ONCOGENE			English	Article						BAG-1 isoforms; apoptosis; Bcl-2; Bax; p53; caspase-3	ENHANCED EXPRESSION; ENDOCERVICAL CELLS; CHAPERONE ACTIVITY; PROTEIN BAG-1; RECEPTOR; BCL-2; ACTIVATION; RESISTANCE; GENES; RAP46	BAG-1 protein can be expressed as four isoforms of 50, 46, 33 and 29 kDa with different subcellular localizations, which may have different functions in antiapoptosis, but the exact mechanism remains unclear. We constructed BAG-1 full length and deletion mutated plasmids in a pCR3.1 vector and established stable transfections of BAG-I isoforms in low BAG-1 expressing C33A cells. Treatment of the transfected cells with cisplatin, staurosporine, paclitaxel and doxorubicine showed that BAG-1 p50, p46 and p33 isoforms enhanced the resistance to apoptosis. BAG-I p50, p46 and p33 exhibited different degrees of apoptosis inhibition in the transfected cells and BAG-I p46 isoform had the most pronounced effect on anti-apoptosis. BAG-I p29 failed to protect the transfected cells from apoptosis. Resistance to apoptosis by BAG-1 isoforms was correlated with decreased caspase-3 activation. We also detected the expression of Bax, Bak, p53, Bcl-2, BCl-X-L, AIF and MRP1 by Western blots. Bcl-2 protein expression was significantly increased in p50, p46 and p33 transfected cells, while the expression of Bax, Bak, p53, BCl-X-L and MRP1 was essentially unchanged. These in vitro results suggest that distinct isoforms of BAG-1 have different anti-apoptotic functions and their functions may be correlated to increased Bcl-2 expression.	Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Mem Univ Newfoundland, Fac Med, St John, NF A1B 3V6, Canada	University of Miami; Memorial University Newfoundland	Tang, SC (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.	stang@med.miami.edu						Adachi M, 1998, LEUKEMIA LYMPHOMA, V30, P483, DOI 10.3109/10428199809057561; Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Crocoll A, 2000, MECH DEVELOP, V91, P355, DOI 10.1016/S0925-4773(99)00284-1; Ding ZH, 2000, BIOCHEM BIOPH RES CO, V270, P415, DOI 10.1006/bbrc.2000.2432; Ding ZH, 2000, INT J CANCER, V87, P818, DOI 10.1002/1097-0215(20000915)87:6<818::AID-IJC10>3.0.CO;2-M; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Niyaz Y, 2001, J CELL SCI, V114, P1839; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Takahashi N, 2001, BIOCHEM BIOPH RES CO, V286, P807, DOI 10.1006/bbrc.2001.5473; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Terada S, 1997, CYTOTECHNOLOGY, V25, P17, DOI 10.1023/A:1007954103572; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	40	35	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7050	7059		10.1038/sj.onc.1205845	http://dx.doi.org/10.1038/sj.onc.1205845			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370827				2022-12-28	WOS:000178424900008
J	Giaccone, G				Giaccone, G			Clinical impact of novel treatment strategies	ONCOGENE			English	Review						lung cancer; targeted therapy; growth hormones	CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; P53 GENE-TRANSFER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; K-RAS MUTATIONS; HUMAN-BREAST; MATRIX METALLOPROTEINASES; ANTITUMOR-ACTIVITY; PHASE-I	Following two decades of research on the biology of cancer and in particular of lung cancer, we have now a large number of molecular targets that can be utilized to create specific medicines against these cancers. Non-small cell lung cancer represents numerically the most important solid tumor in Western world, and is poorly affected by current therapies, where surgery represents almost the only curative therapy for about 25% of patients who are resectable at diagnosis. An abundant number of targeted therapies are being investigated in NSCLC. Among them are the metalloproteinase inhibitors, several tyrosine kinase inhibitors and several attempts of gene replacement have also been made. Promising results have so far been obtained with some of these approaches, and the outcome of large randomized studies is awaited. Small cell lung cancer (SCLC) represents about 20% of lung carcinomas, and several of the novel approaches that are being attempted for NSCLC, are also being investigated for SCLC. All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future.	Free Univ Amsterdam, Med Ctr, Div Med Oncol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Giaccone, G (corresponding author), Free Univ Amsterdam, Med Ctr, Div Med Oncol, 1117 Boelelaan, NL-1081 HV Amsterdam, Netherlands.	G.Giaccone@vumc.nl	Giaccone, Giuseppe/E-8297-2017	Giaccone, Giuseppe/0000-0002-5023-7562				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Adlard JW, 2000, ANTI-CANCER DRUG, V11, P787, DOI 10.1097/00001813-200011000-00002; Albelda SM, 1997, CHEST, V111, pS144, DOI 10.1378/chest.111.6_Supplement.144S; Albelda SM, 2000, ANN INTERN MED, V132, P649, DOI 10.7326/0003-4819-132-8-200004180-00008; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; Askari FK, 1996, NEW ENGL J MED, V334, P316, DOI 10.1056/NEJM199602013340508; Averbuch SD, 2002, CLIN CANCER RES, V8, P1; BAILEY HH, 2001, P AN M AM SOC CLIN, V20, pA79; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 2001, CLIN CANC RES S, V7, pA630; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; BLAESE RM, 1994, EUR J CANCER, V30A, P1190, DOI 10.1016/0959-8049(94)90482-0; Blanke CD., 2001, P AN M AM SOC CLIN, V20, p1a; Bos M, 1997, CLIN CANCER RES, V3, P2099; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; CAMACHO LH, 2001, P AN M AM SOC CLIN, V20, pA79; Carbone DP, 1997, SEMIN ONCOL, V24, P388; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHEN C, 1995, CANCER RES, V55, P4230; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Clarke MR, 1997, HUM PATHOL, V28, P54, DOI 10.1016/S0046-8177(97)90279-3; COHEN RB, 2000, P AN M AM SOC CLIN, V19, pA474; CONRY RM, 1995, GENE THER, V2, P59; DANG T, 2001, P AN M AM SOC CLIN, V20, pA332; DEVORE RF, 2000, P AN M AM SOC CLIN, V19, P485; Dickler MN, 1999, CLIN CANCER RES, V5, P2773; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ESCUDIER B, 2000, LUNG CANCER S1, V29, P184; Eskens FALM, 2001, J CLIN ONCOL, V19, P1167, DOI 10.1200/JCO.2001.19.4.1167; FAN Z, 1993, CANCER RES, V53, P4637; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FIGLIN RA, 2001, P AN M AM SOC CLIN, V20, pA276; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fong TAT, 1999, CANCER RES, V59, P99; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Frederiksen KS, 1999, LUNG CANCER, V23, P191, DOI 10.1016/S0169-5002(99)00012-4; Gatzemeier U., 2001, European Journal of Cancer, V37, pS50, DOI 10.1016/S0959-8049(01)80665-1; Giatromanolaki A, 1996, ANTICANCER RES, V16, P3819; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORDON MS, 1998, P AN M AM SOC CLIN, V17, P210; Grant SC, 1999, CLIN CANCER RES, V5, P1319; Guddo F, 1999, HUM PATHOL, V30, P788, DOI 10.1016/S0046-8177(99)90139-9; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 1998, ANTICANCER RES, V18, P775; HIDALGO M, 2001, P AN M AM SOC CLIN, V20, pA71; HOLDEN SN, 2001, P AN M AM SOC CLIN, V20, pA80; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Johnson DH, 2001, P AN M AM SOC CLIN, V20, p315a; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KERN JA, 1990, CANCER RES, V50, P5184; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; Kim YC, 1998, LUNG CANCER-J IASLC, V22, P181, DOI 10.1016/S0169-5002(98)00086-5; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Kris MG, 2000, LUNG CANCER, V29, P72; KRUG LM, 2001, P AN M AM SOC CLIN, V20, pA333; KUBBA S, 2000, P AN M AM SOC CLIN, V19, pA487; Kuenen BC, 2002, J CLIN ONCOL, V20, P1657, DOI 10.1200/JCO.20.6.1657; LANGER CJ, 2001, P AN M AM SOC CLIN, V20, pA315; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LoRusso PM, 1996, INVEST NEW DRUG, V14, P349; MARGOLIN K, 1999, P AN M AM SOC CLIN, V18, pA435; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; NEGORO S, 2001, P AN M AM SOC CLIN, V20, pA324; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nemunaitis J, 1998, AM J CLIN ONCOL-CANC, V21, P155, DOI 10.1097/00000421-199804000-00013; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Nguyen DM, 1997, CANCER GENE THER, V4, P191; NIE ZR, 1995, CANCER RES, V55, P4760; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; O-Charoenrat P, 2000, INT J CANCER, V86, P307, DOI 10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1002/bjs.1800840206; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, P1514; PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA310; PICCARTGEBHART MJ, 2001, P AN M AM SOC CLIN, V20, pA80; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Rizvi NA, 1999, CLIN CANCER RES, V5, P1658; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; ROSEN L, 1999, P AN M AM SOC CLIN, V18, pA161; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SALGIA R, 2000, LUNG CANCER S1, V29, P186; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schiller JH, 2001, J CLIN ONCOL, V19, P448, DOI 10.1200/JCO.2001.19.2.448; Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHAWVER LK, 1999, AM SOC CLIN ONCOLOGY, P29; Shepherd FA, 2001, P AN M AM SOC CLIN, V20, p4a; SHIN DM, 2001, P AN M AM SOC CLIN, V20, pA82; Singhal S, 1998, Surg Oncol Clin N Am, V7, P505; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; SMYLIE M, 2001, P AN M AM SOC CLIN, V20, pA307; Soriano AF, 1999, CANCER RES, V59, P6178; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Stewart AK, 1999, HUM GENE THER, V10, P2037; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V33, P515, DOI 10.1007/s002800050093; Thomas DA, 2000, CURR OPIN ONCOL, V12, P564, DOI 10.1097/00001622-200011000-00009; Traxler P, 1999, CLIN CANCER RES, V5, p3750S; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tsubouchi Y, 2000, ANTICANCER RES, V20, P2867; VERSLYPE C, 2001, P AN M AM SOC CLIN, V20, pA171; VERWEIJ J, 2001, P AN M AM SOC CLIN, V20, pA81; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WINQUIST E, 2001, P AN M AM SOC CLIN, V20, pA197; Wolff H, 1998, CANCER RES, V58, P4997; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU DH, 1994, CANCER RES, V54, P3260; YUEN A, 2001, P AN M AM SOC CLIN, V20, pA309; Zou YY, 1998, J NATL CANCER I, V90, P1130, DOI 10.1093/jnci/90.15.1130; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	135	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6970	6981		10.1038/sj.onc.1205565	http://dx.doi.org/10.1038/sj.onc.1205565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362278	Bronze			2022-12-28	WOS:000178640200011
J	Takahashi, T				Takahashi, T			Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application	ONCOGENE			English	Editorial Material						lung cancer; molecular pathogenesis; clinical application			Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001					0	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6868	6869		10.1038/sj.onc.1205830	http://dx.doi.org/10.1038/sj.onc.1205830			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362268				2022-12-28	WOS:000178640200001
J	Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C				Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C			The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit	ONCOGENE			English	Article						high molecular form of FGF-2; DNA repair; NHEJ; DNA-PK; radioresistance	FIBROBLAST-GROWTH-FACTOR; DOUBLE-STRAND BREAKS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; GENE-EXPRESSION; MESSENGER-RNA; KU-PROTEIN; IN-VITRO; REPAIR; WORTMANNIN	We previously reported that overexpression of the 24 kDa basic fibroblast factor (or FGF-2) isoform provides protection from the cytotoxic effect of ionizing radiation (IR). DNA double-strand breaks (DSB), the IR-induced lethal lesions, are mainly repaired in human cells by non-homologous end joining system (NHEJ). NHEJ reaction is dependent on the DNA-PK holoenzyme (composed of a regulatory sub-unit, Ku, and a catalytic sub-unit, DNA-PKcs) that assembles at sites of DNA damage. We demonstrated here that the activity of DNA-PK was increased by twofold in two independent radioresistant cell lines, HeLa 3A and CAPAN A3, overexpressing the 24 kDa FGF-2. This increase was associated with an overexpression of the DNA-PKcs without modification of Ku expression or activity. This overexpression was due to an up-regulation of the DNA-PKcs gene transcription by the 24 kDa FGF-2 isoform. Finally, HeLa 3A cells exhibited the hallmarks of phenotypic changes associated with the overexpression of an active DNA-PKcs. Indeed, a faster repair rate of DSB and sensitization to IR by wortmannin was observed in these cells. Our results represent the characterization of a new mechanism of control of DNA repair and radioresistance in human tumor cells dependent on the overproduction of the 24 kDa FGF-2 isoform.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Toulas, C (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Toulas, Christine/P-3838-2014; salles, bernard/B-8531-2008; Ader-Perarnau, Isabelle/F-7160-2017; MULLER, Catherine/M-2185-2018; Moyal, Elizabeth/A-9802-2015; FAVRE, Gilles/K-9189-2014; MULLER, Catherine/E-2060-2011	Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CohenJonathan E, 1997, CANCER RES, V57, P1364; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Estival A., 2001, International Journal of Molecular Medicine, V8, pS88; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimoto M, 1997, DNA Res, V4, P151, DOI 10.1093/dnares/4.2.151; FUKS Z, 1994, CANCER RES, V54, P2582; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grein S, 1999, MOL CELL BIOCHEM, V191, P121, DOI 10.1023/A:1006806226764; Guo CH, 1999, MOL CELL BIOCHEM, V191, P135, DOI 10.1023/A:1006881405383; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MIMORI T, 1986, J BIOL CHEM, V261, P375; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Price BD, 1996, CANCER RES, V56, P246; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6471	6479		10.1038/sj.onc.1205838	http://dx.doi.org/10.1038/sj.onc.1205838			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226750				2022-12-28	WOS:000177925300007
J	Santoni-Rugiu, E; Duro, D; Farkas, T; Mathiasen, IS; Jaattela, M; Bartek, J; Lukas, J				Santoni-Rugiu, E; Duro, D; Farkas, T; Mathiasen, IS; Jaattela, M; Bartek, J; Lukas, J			E2F activity is essential for survival of Myc-overexpressing human cancer cells	ONCOGENE			English	Article						Myc; E2F; human cancer cells; survival	TUMOR-SUPPRESSOR PATHWAY; CYCLIN-DEPENDENT KINASES; C-MYC; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; PRB/E2F PATHWAY; S-PHASE; EPITHELIAL-CELLS; BETA-TRANSCRIPT; DNA-REPLICATION	Effective cell cycle completion requires both Myc and E2F activities. However, whether these two activities interact to regulate cell survival remains to be tested. Here we have analysed survival of inducible c-Myc-overexpressing cell lines derived from U2OS human osteosarcoma cells, which carry wild-type pRb and p53 and are deficient for p16 and ARF expression. Induced U2OS-Myc cells neither underwent apoptosis spontaneously nor upon reconstitution of the ARF-p53 axis and/or serum-starvation. However, they died massively when concomitantly exposed to inhibitors of EN activity, including a constitutively active pRb (RbDeltacdk) mutant, p16, a stable p27 (p27T187A) mutant, a dominant-negative (dn) CDK2, or dnDP-1. Similar apoptotic effect was observed upon down-modulation of endogenous E2Fs through overexpression of E2F binding site oligonucleotides in U2OS-Myc cells, upon expression of RbDeltacdk or dnDP-1 in the Myc-amplified HL-60 (ARF-; p53-) human leukemia cells, and upon cotransfection of Myc and RbDeltacdk in SAOS-2 (ARF+; p53-) human osteosarcoma cells but not in human primary fibroblasts. Consistent with these results, a dnp53 mutant did not abrogate the Myc-induced apoptotic phenotype, which instead strictly depended on caspase-3-like proteases and on Myc transcriptional activity. Our data indicate that in contrast to normal cells, Myc-overexpressing human cancer cells need E2F activity for their survival, regardless of their ARF and p53 status, a notion that may have important implications for antineoplastic treatment strategies.	Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen E, Denmark; Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Santoni-Rugiu, E (corresponding author), Rigshosp, Dept Pathol, Frederik D Vs Vej 11, DK-2100 Copenhagen O, Denmark.		Jäättelä, Marja/AAT-7932-2021; Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Jäättelä, Marja/0000-0001-5950-7111; Santoni-Rugiu, Eric/0000-0002-2283-3535; Farkas, Thomas/0000-0003-1903-6081; Lukas, Jiri/0000-0001-9087-506X				Amundadottir LT, 1996, ONCOGENE, V13, P757; Asadi F. K., 1995, International Urology and Nephrology, V27, P67; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bowen C, 1998, CANCER RES, V58, P3275; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURO D, 1995, ONCOGENE, V11, P21; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gazzeri S, 1998, CANCER RES, V58, P3926; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li Q, 1999, MOL CELL BIOL, V19, P5339; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Mangano R, 1998, ONCOGENE, V17, P2771, DOI 10.1038/sj.onc.1202434; Markl IDC, 1998, CANCER RES, V58, P5348; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mathiasen IS, 1999, CANCER RES, V59, P4848; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; O'Connor L, 2000, CURR OPIN CELL BIOL, V12, P257, DOI 10.1016/S0955-0674(99)00084-8; Packham G, 1996, ONCOGENE, V13, P461; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; QUELLE DE, 1995, CELL, V83, P993; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VONHOFF DD, 1990, J CLIN INVEST, V85, P1887, DOI 10.1172/JCI114650; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	81	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6498	6509		10.1038/sj.onc.1205828	http://dx.doi.org/10.1038/sj.onc.1205828			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226753				2022-12-28	WOS:000177925300010
J	Versteege, I; Medjkane, S; Rouillard, D; Delattre, O				Versteege, I; Medjkane, S; Rouillard, D; Delattre, O			A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle	ONCOGENE			English	Article						hSNF5; INI1; SWI/SNF; malignant rhabdoid tumour; cell cycle; chromatin	SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; RHABDOID TUMORS; SWI/SNF FAMILY; HUMAN CANCER; S-PHASE; C-MYC; MUTATIONS; GENE; RB	The hSNF5/INI1 gene encodes a member of the SWI/ SNF chromatin remodelling complexes. It was recently identified as a tumour suppressor gene mutated in sporadic and hereditary Malignant Rhabdoid Tumours (MRT). However, the role of hSNF5/INI1 loss-of-function in tumour development is still unknown. Here, we show that the ectopic expression of wild-type hSNF5/ INI1, but not that of truncated versions, leads to a cell cycle arrest by inhibiting the entry into S phase of MRT cells. This G1 arrest is associated with down-regulation of a subset of E2F targets including cyclin A, E2F1 and CDC6. This arrest can be reverted by coexpression of cyclin D1, cyclin E or viral E1A, whereas it cannot be counteracted by pRB-binding deficient E1A mutants. Moreover, hSNF5/INI1 is not able to arrest cells lacking a functional pRB. These observations suggest that the hSNF5/INI1-induced G1 arrest is dependent upon the presence of a functional pRB. However, the observation that a constitutively active pRB can efficiently arrest MRT cells indicates that hSNF5/INI1, at the difference of the ATPase subunits of the SWI/SNF complex, is dispensable for pRB function. Altogether, these data show that hSNF5/INI1 is a potent regulator of the entry into S phase, an effect that may account for its tumour suppressor role.	Inst Curie, Lab Pathol Mol Canc, INSERM, U509, F-75248 Paris 05, France; Inst Curie, UMR 147, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM, U509, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr		Medjkane, Souhila/0000-0001-7973-7707; delattre, olivier/0000-0002-8730-2276				Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 1999, CANCER RES, V59, P74; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Savla J, 2000, JNCI-J NATL CANCER I, V92, P648, DOI 10.1093/jnci/92.8.648; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	43	132	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6403	6412		10.1038/sj.onc.1205841	http://dx.doi.org/10.1038/sj.onc.1205841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226744				2022-12-28	WOS:000177925300001
J	Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H				Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H			Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway	ONCOGENE			English	Article						proliferation; EMT; Ras mutants; PI3K; collagen gels; breast cancer	NIH 3T3 CELLS; HORMONE-INDEPENDENT PROLIFERATION; BREAST-CANCER CELLS; MAP KINASE KINASE; CYCLIN D1; E-CADHERIN; MAMMARY TUMORIGENESIS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; CARCINOMA-CELLS	Carcinogenesis by oncogenic Ras and Her-2 involves enhanced proliferation of epithelial cells in vivo. However, hyperproliferation induced by these oncogenes, or their downstream pathways in vitro has mainly been studied in cultured, fibroblastic cell lines. Here, we demonstrate that oncogenic Ha-Ras or constitutively active Her-2 cause increased proliferation and cyclin D1 upregulation in fully polarized, mammary epithelial cells (EpH4), if cultivated as organotypic structures in three-dimensional collagen/ matrigel matrices. Under standard culture conditions, however, these oncogenes failed to induce hyperproliferation. Using both specific low molecular weight inhibitors and Ras-effector - specific mutants, we dissected signaling pathways downstream of oncogenic Ras (PI3K, Mek1/ MAPK) with respect to (i) hyperproliferation in collagen gels and tumorigenesis in mice and (ii) epithelial/ mesenchymal transition (EMT). We show that the Ras-activated PI3K pathway is required to induce rapid tumor growth and enhanced proliferation of EpH4 cells in collagen gels, but fails to cause EMT in vitro and in vivo. On the other hand, Ras-dependent activation of the Mek1/ MAPK pathway in EpH4 cells (previously shown to cause EMT and metastasis) did not induce hyperproliferation in collagen gels and caused only slow tumor growth. Our data thus indicate that Ras-dependent signaling through the PI3K- and MAPK pathways fulfil distinct, but complementary functions during carcinogenesis.	Inst Mol Pathol, A-1030 Vienna, Austria; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cancer Research UK	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Janda, Elzbieta/AFQ-7061-2022; Downward, Julian/A-3251-2012; Janda, Elzbieta/AAD-5126-2022; Gruenert, Stefan/T-7755-2019; Gruenert, Stefan/B-7598-2016	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297; Downward, Julian/0000-0002-2331-4729				Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; De Vita G, 2000, CANCER RES, V60, P3916; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FILMUS J, 1994, ONCOGENE, V9, P3627; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lenferink AEG, 2001, CANCER RES, V61, P6583; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Montesano R, 1998, IN VITRO CELL DEV-AN, V34, P468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ojakian GK, 1997, J CELL SCI, V110, P2781; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Putz E, 1999, CANCER RES, V59, P241; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Treinies I, 1999, MOL CELL BIOL, V19, P321; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	46	64	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5148	5159		10.1038/sj.onc.1205661	http://dx.doi.org/10.1038/sj.onc.1205661			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140765				2022-12-28	WOS:000176975900013
J	Li, L; Cleary, S; Mandarano, MA; Long, WW; Birchmeier, C; Jones, FE				Li, L; Cleary, S; Mandarano, MA; Long, WW; Birchmeier, C; Jones, FE			The breast proto-oncogene, HRG alpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland	ONCOGENE			English	Article						heregulin; neuregulin; mammary gland development; lactogenesis; epithelial proliferation; lobuloalveoli	GROWTH-FACTOR; DIFFERENTIATION FACTOR; RNA SURVEILLANCE; TRANSGENIC MICE; HEREGULIN; EXPRESSION; REVEALS; CELLS; MORPHOGENESIS; AMPHIREGULIN	Members of the EGF family of growth factors play critical roles during normal and neoplastic breast development. EGF family member HRGalpha is the only HRG1 isoform expressed in the mouse mammary gland and our previous experiments suggest that HRG1 has a unique role in mammary development. To determine the function of HRGalpha activity during mouse mammary gland development, we generated a HRGalpha-deficient mouse strain. Unlike mice with HRG1 or isoform specific HRGbeta gene deletions, HRGalpha-null mice survive to adulthood. HRGalpha-deficient mice display pronounced defects in mammary gland lobuloalveolar development at 17 days of pregnancy and 3 days post-partum. Terminal and lateral ductal alveoli were condensed and alveolar outgrowth during pregnancy was severely impaired. A dramatic reduction in beta-casein expression accompanied defective alveolar development in the HRGalpha-null mice, as determined by in situ hybridization and Northern blot analysis of HRGalpha-deficient mammary glands at 3 days post-partum. Expression of the milk-protein genes WAP and alpha-lactalbumin was not adversely affected. In situ incorporation of BrdU demonstrated that epithelial proliferation was significantly curtailed in mammary glands of HRGalpha-deficient mice at 17 days post-coitus and 3 days postpartum. These results demonstrate that HRGalpha is an important mammary gland mitogen regulating alveolar development and lactogenesis.	Tulane Univ, Sch Med, Hlth Sci Ctr, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA; Max Delbruck Ctr Mol Med, Dept Med Genet, D-13122 Berlin, Germany; Univ Scranton, Inst Mol Biol & Med, Scranton, PA 18510 USA; Univ Scranton, Dept Biol, Scranton, PA 18510 USA	Tulane University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Scranton; University of Scranton	Jones, FE (corresponding author), Tulane Univ, Sch Med, Hlth Sci Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.				NCI NIH HHS [1R01CA95783-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Krane IM, 1996, ONCOGENE, V12, P1781; Le XF, 2000, CANCER RES, V60, P3522; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Torres RM, 1997, LAB PROTOCOLS CONDIT; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	27	73	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4900	4907		10.1038/sj.onc.1205634	http://dx.doi.org/10.1038/sj.onc.1205634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118369				2022-12-28	WOS:000176874800005
J	Gu, J; Zhang, LD; Huang, XF; Lin, TY; Yin, M; Xu, K; Ji, L; Roth, JA; Fang, BL				Gu, J; Zhang, LD; Huang, XF; Lin, TY; Yin, M; Xu, K; Ji, L; Roth, JA; Fang, BL			A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo	ONCOGENE			English	Article						hTERT promoter; Bax; apoptosis; tumor targeting; adenovirus	TELOMERASE ACTIVITY; CANCER CELLS; OVARIAN-CANCER; TRANSGENE EXPRESSION; HEMATOPOIETIC-CELLS; PROSTATE-CANCER; LUNG-CANCER; BONE-MARROW; PROMOTER; THERAPY	Using a binary adenoviral system, we recently showed that the human telomerase reverse transcriptase (hTERT) promoter induces tumor-specific Bax gene expression. However, the strong cytotoxicity of Bax and other pro-apoptotic genes to packaging 293 cells has so far hindered construction of the desired single adenoviral vectors expressing toxic genes. We report here the construction of a single bicistronic adenoviral vector for tumor-specific Bax expression. The vector (Ad/gBax) utilizes the Tet-Off system and expresses a GFP/Bax fusion protein for easy detection. The hTERT promoter drives the expression of tTA, a transactivator capable of binding to TRE (tetracycline-responsive element) in the absence of tetracycline, which in turn induces expression of the GFP-Bax gene. The addition of tetracycline in 293 cells blocks the binding of tTA to TRE and substantially inhibits GFP-Bax expression and toxicity, thus allowing the packaging and production of Ad/gBax. Our data show that Ad/gBax could drive the high expression of GFP-Bax in tumor cells but not in normal cells and mouse tissues. Furthermore, the expression of GFP-Bax fusion protein elicited tumor-specific apoptosis in a variety of human cancer cells in vitro and in vivo at a level comparable to that induced by the binary system. Thus, Ad/gBax may become a potent therapeutic agent for the treatment of cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.		Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NCI NIH HHS [CA78778-01A1, CA 16672, 2P50-CA70970-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andriani F, 2001, JNCI-J NATL CANCER I, V93, P1314, DOI 10.1093/jnci/93.17.1314; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen L, 1995, J CLIN INVEST, V96, P2775, DOI 10.1172/JCI118347; Feldman E, 1997, STEM CELLS, V15, P386, DOI 10.1002/stem.150386; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Kagawa S, 2001, CANCER RES, V61, P3330; Kagawa S, 2000, CANCER RES, V60, P1157; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2001, CANCER RES, V61, P5796; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nishimura S, 2001, CANCER RES, V61, P7009; OSAKI T, 1994, CANCER RES, V54, P5258; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Pataer A, 2000, CANCER RES, V60, P788; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sakakura C, 1997, SURG TODAY, V27, P90, DOI 10.1007/BF01366949; Shariat SF, 2001, CANCER RES, V61, P2562; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tai YT, 1999, CANCER RES, V59, P2121; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; VILE RG, 1993, CANCER RES, V53, P962; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zhang W, 1996, CLIN CANCER RES, V2, P799	27	44	52	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4757	4764		10.1038/sj.onc.1205582	http://dx.doi.org/10.1038/sj.onc.1205582			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101414				2022-12-28	WOS:000176716300005
J	Oh, IH; Eaves, CJ				Oh, IH; Eaves, CJ			Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity	ONCOGENE			English	Article						dominant negative STAT3; stem cells; hematopoiesis; gp-130; self-renewal	ADULT BONE-MARROW; SELF-RENEWAL; INTERLEUKIN-6 FAMILY; QUANTITATIVE ASSAY; IN-VITRO; ACTIVATION; DIFFERENTIATION; GP130; EXPANSION; CYTOKINES	STAT3 is a key downstream signaling intermediate of gp130, a receptor previously shown to activate hematopoietic stem cell (HSC) self-renewal divisions. These findings prompted us to investigate if the STAT3 pathway is important to HSC activity in vivo. Initial semi-quantitative RT-PCR analyses showed STAT3 to be expressed at slightly higher levels in primitive subsets of both human and murine adult bone marrow cells. To test the effect of abrogating STAT3 activity in HSCs, primitive murine fetal liver cells were transduced at high efficiency with either a bicistronic dominant-negative (dn) or wild-type (wt) STAT3-IRES-GFP retrovirus. Dn STAT3-transduced HSCs showed markedly and permanently reduced in vivo lympho-myeloid reconstituting ability relative to co-transplanted non-transduced HSCs or HSCs transduced with a control (GFP-only) vector. In contrast, the activity of dn STAT3-transduced cells with short term in vivo (CFU-S) or in vitro (CFC) proliferation potential was not affected. Overexpression of wt-STAT3 had very little effect on either HSCs or shorter term progenitors. These findings suggest HSCs express non-limiting levels of STAT3 which, nevertheless, play an important stage-specific and non-redundant role in maintaining the function of HSCs stimulated to divide in adult marrow tissue.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Eaves, CJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave,10th Ave, Vancouver, BC V5Z 1L3, Canada.							Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; Chakraborty A, 1996, BLOOD, V88, P2442, DOI 10.1182/blood.V88.7.2442.bloodjournal8872442; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Hennemann B, 2000, HUM GENE THER, V11, P43, DOI 10.1089/10430340050016148; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LEMIEUX ME, 1995, BLOOD, V86, P1339, DOI 10.1182/blood.V86.4.1339.bloodjournal8641339; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Oh IH, 2000, BLOOD, V96, P4160, DOI 10.1182/blood.V96.13.4160.h8004160_4160_4168; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rebel V I, 1996, J Hematother, V5, P25, DOI 10.1089/scd.1.1996.5.25; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; SZILVASSY SJ, 2001, METHODS MOL MED HEMA, P167; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thomas TE, 1999, METHODS, V17, P202, DOI 10.1006/meth.1998.0731; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	36	49	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4778	4787		10.1038/sj.onc.1205592	http://dx.doi.org/10.1038/sj.onc.1205592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101416				2022-12-28	WOS:000176716300007
J	Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K				Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K			TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor	ONCOGENE			English	Article						tumor stroma targeting; tumor associated proteases; TNFR2 signaling; juxtatropic membrane TNF like action	FACTOR-ALPHA; FACTOR RECEPTOR; STROMAL FIBROBLASTS; PROTEIN; CANCER; CELLS; INVOLVEMENT; VASCULATURE; EXPRESSION; THERAPY	We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TINE TNF-Selectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@po.uni-stuttgart.de						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brocks B, 2001, MOL MED, V7, P461, DOI 10.1007/BF03401851; Christ O, 2001, CLIN CANCER RES, V7, P985; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; De Petro G, 1998, CANCER RES, V58, P2234; DeFeo-Jones D, 2000, NAT MED, V6, P1248, DOI 10.1038/81351; Eggermont A M, 2001, Curr Oncol Rep, V3, P359, DOI 10.1007/s11912-001-0090-8; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gasparri A, 1999, CANCER RES, V59, P2917; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Huang PS, 2001, CURR OPIN GENET DEV, V11, P104, DOI 10.1016/S0959-437X(00)00164-7; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mersmann M, 2001, INT J CANCER, V92, P240, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1170>3.3.CO;2-L; Nooijen PTGA, 1998, CANCER RES, V58, P4880; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; ROSENBLUM MG, 1995, CANCER IMMUNOL IMMUN, V40, P322, DOI 10.1007/BF01519633; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Scherf U, 1996, CLIN CANCER RES, V2, P1523; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9	31	24	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4257	4265		10.1038/sj.onc.1205193	http://dx.doi.org/10.1038/sj.onc.1205193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082613				2022-12-28	WOS:000176174200008
J	Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ				Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ			Maspin sensitizes breast carcinoma cells to induced apoptosis	ONCOGENE			English	Article						tumor suppressor; serpin; staurosporine; caspases; maspin/PAI-1 chimera; PAI-1/maspin chimera; cell motility	TUMOR-NECROSIS-FACTOR; MAMMARY EPITHELIAL-CELLS; ALPHA-INDUCED APOPTOSIS; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; POLY(ADP-RIBOSE) POLYMERASE; THYMOSIN BETA-10; PROTEIN-KINASE; CANCER CELLS; SERPIN	Maspin, a novel serine protease inhibitor (serpin), suppresses the growth and metastasis of breast tumor in vivo. However, the underlying molecular mechanism is unclear. In the current study, we report the first evidence that endogenous maspin expression in mammary carcinoma cells MDA-MB-435 enhanced staurosporine (STS)-induced apoptosis as judged by the increased fragmentation of DNA, increased protcolytic inactivation of poly-[ADP-ribose]-polymerase (PARP), as well as the increased activation of caspase-8 and caspase-3. In parallel, recombinant maspin did not directly regulate the proteolytic activities of either caspase-3 or caspase-8 in vitro. Consistent with this result, maspin expressing normal mammary epithelial cells underwent more rapid STS-induced apoptosis as compared to breast carcinoma cells. Interestingly, maspin transfectant cells did not undergo spontaneous apoptosis in the absence of STS. Moreover, neither purified maspin protein added from outside nor endogenous maspin secreted to the cell culture media sensitized cells to STS-induced apoptosis. To investigate the structural determinants of maspin in its apoptosis-sensitizing effect, MDA-MB-435 cells were also transfected with maspin/PAI-1 and PAI-1/maspin chimeric constructs resulting from swapping the N-terminal and the C-terminal domains between maspin and PAI-1 (plasminogen activator inhibitor type 1). The resulting stable transfectant clones expressing maspin/PAI-1 and PAI-1/maspin, respectively, did not undergo spontaneous apoptosis, and were similarly inhibited as maspin transfectant cells in motility assay. Interestingly, however, expression of both maspin/PAI-1 and PAI-1/maspin in MDA-MB-435 cells failed to sensitize these cells to STS-induced apoptosis. Taken together, our evidence provides now insights into the complex molecular mechanisms of maspin that may suppress breast tumor progression not only at the step of invasion and motility, but also by regulating tumor cell apoptosis. The sensitizing effect of maspin on apoptosis is to be contrasted by the pro-survival effect of several other serpins.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Biliran H, 2001, CANCER RES, V61, P8676; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Bromme HJ, 1996, MOL CELL BIOCHEM, V164, P261; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lawrence DA, 1997, ADV EXP MED BIOL, V425, P99; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; McGowen R, 2000, CANCER RES, V60, P4771; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Schleef RR, 2000, J BIOL CHEM, V275, P26385, DOI 10.1074/jbc.C000389200; Seftor REB, 1998, CANCER RES, V58, P5681; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	45	108	111	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4089	4098		10.1038/sj.onc.1205507	http://dx.doi.org/10.1038/sj.onc.1205507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037665				2022-12-28	WOS:000176186000003
J	Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A				Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A			Activation of MyoD-dependent transcription by cdk9/cyclin T2	ONCOGENE			English	Article						cdk9; cyclins; MyoD; muscle differentiation; phosphorylation	RNA-POLYMERASE-II; P-TEFB KINASE; CARBOXY-TERMINAL DOMAIN; MUSCLE GENE-EXPRESSION; HELIX-LOOP-HELIX; CELL-CYCLE; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; MADS-BOX	Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as cdk2 and cdk4. Serum withdrawal promotes muscle-specific gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks, cdk9 is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase It. While ectopic expression of cdk2 together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of cdk9 and its associated cyclin (cyclin T2a) strengthens MyoD-dependent transcription and stimulates myogenic differentiation in both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of cdk9 activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal cdk9-binding region of MyoD mapping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of muscle differentiation includes the direct enzymatic activity of the kinase on MyoD.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Univ Naples 2, Sch Med, Inst Topog Anat, I-80138 Naples, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena; Universita della Campania Vanvitelli; Sapienza University Rome; Salk Institute	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; BELLAN, CRISTIANA/L-3903-2013; BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018	Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; BELLAN, CRISTIANA/0000-0001-6119-9007; BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; BAGELLA, Luigi/0000-0003-2815-037X; Puri, Pier Lorenzo/0000-0003-4964-0095	Telethon [TCP00081] Funding Source: Medline	Telethon(Fondazione Telethon)		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lis JT, 2000, GENE DEV, V14, P792; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MCLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SARTORELLI V, 2001, FRONT BIOSCI, V6, pD1073; SIMONE C, 2001, FRONT BIOSCI, V6, pD1024; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	100	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4137	4148		10.1038/sj.onc.1205493	http://dx.doi.org/10.1038/sj.onc.1205493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037670				2022-12-28	WOS:000176186000008
J	Weber, HO; Samuel, T; Rauch, P; Funk, JO				Weber, HO; Samuel, T; Rauch, P; Funk, JO			Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways	ONCOGENE			English	Article						INK4a/ARF; p53; p21; 14-3-3 sigma; DNA tumor virus	P19(ARF) TUMOR-SUPPRESSOR; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; MDM2; P14(ARF); CANCER; P21; P16(INK4A); PRODUCT	The tumor suppressor ARF is transcribed from the INK4a/ARF locus in partly overlapping reading frames with the CDK inhibitor p16(Ink4a). ARF is able to antagonize the MDM2-mediated ubiquitination and degradation of p53, leading to either cell cycle arrest or apoptosis, depending on the cellular context. However, recent data point to additional p53-independent functions of mouse p19(ARF). Little is known about the dependency of human p14(ARF) function on p53 and its downstream genes. Therefore, we analysed the mechanism of p14(ARF)-induced cell cycle arrest in several human cell types. Wild-type HCT116 colon carcinoma cells (p53(+/+)p21(CIP1+/+) 14-3-3sigma(+/+)), but not p53(-/-) counterparts, underwent G(1) and G(2) cell cycle arrest following infection with a p14(ARF)-adenovirus. In p21(CIP1-/-) cells, p14(ARF) did not induce G(1) or G(2) arrest, while 14-3-3sigma(-/-) counterparts were mainly arrested in G(1), pointing to essential roles of p21(CIP1) in G(1) and G(2) arrest and cooperative roles of p21 and 14-3-3sigma in ARF-mediated G(2) arrest. Our data demonstrate a strict p53 and p21(CIP1) dependency of p14(ARF)-induced cell cycle arrest in human cells.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	University of Erlangen Nuremberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.							Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERMEKING H, 1997, MOL CELL, V1, P1; Herzinger T, 1995, ONCOGENE, V11, P2051; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Modestou M, 2001, CANCER RES, V61, P3145; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	52	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3207	3212		10.1038/sj.onc.1205429	http://dx.doi.org/10.1038/sj.onc.1205429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082636				2022-12-28	WOS:000175373600012
J	Masuda, A; Takahashi, T				Masuda, A; Takahashi, T			Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis	ONCOGENE			English	Review						chromosome instability; cell cycle checkpoint; DNA double-strand break; telomere; lung cancer	STRAND BREAK REPAIR; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-PAPILLOMAVIRUS TYPE-16; MOLECULAR CYTOGENETIC ANALYSIS; SPINDLE ASSEMBLY CHECKPOINT; FLOW CYTOMETRIC ANALYSIS; CYCLIN-E OVEREXPRESSION; SMALL-CELL-CARCINOMA; END-JOINING PATHWAY; DNA-LIGASE-IV	Chromosomal abnormality is one of the hallmarks of neoplastic cells, and the persistent presence of chromosome instability (CIN) has been demonstrated in human cancers, including lung cancer. Recent progress in molecular and cellular biology as well as cytogenetics has shed light on the underlying mechanisms and the biological and clinical significance of chromosome abnormalities and the CIN phenotype. Chromosome abnormalities can be classified broadly into numerical (i.e., aneuploidy) and structural alterations (e.g., deletion, translocation, homogenously staining region (HSR), double minutes (DMs)). However, both alterations usually occur in the same cells, suggesting some overlap in their underlying mechanisms. Missegregation of chromosomes may result from various causes, including defects of mitotic spindle checkpoint, abnormal centrosome formation and failure of cytokinesis, while structural alterations of chromosomes may be caused especially by failure in the repair of DNA double-strand breaks (DSBs) due to the impairment of DNA damage checkpoints and/or DSB repair systems. Recent studies also suggest that telomere erosion may be involved. The consequential acquisition of the CIN phenotype would give lung cancer cells an excellent opportunity to efficiently alter their characteristics so as to be more malignant and suitable to their microenvironment, thereby gaining a selective growth advantage.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bieche I, 2000, CLIN CANCER RES, V6, P452; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Boveri T, 1914, FRAGE ENTSTEHUNG MAL; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brown R, 1999, FRACTALS, V7, P277, DOI 10.1142/S0218348X99000281; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney JP, 1999, CURR OPIN IMMUNOL, V11, P443, DOI 10.1016/S0952-7915(99)80074-0; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dennis TR, 1999, CANCER GENET CYTOGEN, V113, P134, DOI 10.1016/S0165-4608(99)00023-0; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dobashi Y, 1998, AM J PATHOL, V153, P963, DOI 10.1016/S0002-9440(10)65638-6; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FAN SJ, 1995, CANCER RES, V55, P1649; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukuda T, 2001, CANCER RES, V61, P23; Fukuse T, 2000, CANCER RES, V60, P242; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; Girard L, 2000, CANCER RES, V60, P4894; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HAGAG N, 1990, ONCOGENE, V5, P1481; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harley CB, 1997, CANCER SURV, V29, P263; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haruki N, 2000, CANCER RES, V60, P4689; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; HEIM S, 1989, ADV CANCER RES, V52, P1; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; HIRANO T, 1994, AM J PATHOL, V144, P296; HIYAMA K, 1995, ONCOGENE, V10, P937; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; JACKSONYORK GL, 1991, CANCER, V68, P374, DOI 10.1002/1097-0142(19910715)68:2<374::AID-CNCR2820680227>3.0.CO;2-2; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Khan SH, 1998, CANCER RES, V58, P396; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Konishi H, 2002, CANCER RES, V62, P271; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Latil A, 2000, INT J CANCER, V89, P172; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsuoka S, 2001, CANCER RES, V61, P5362; Matzke MA, 1999, BIOESSAYS, V21, P761, DOI 10.1002/(SICI)1521-1878(199909)21:9&lt;761::AID-BIES7&gt;3.0.CO;2-C; McClintock B, 1938, GENETICS, V23, P315; McClintock B, 1941, GENETICS, V26, P234; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Michelland S, 1999, CANCER GENET CYTOGEN, V114, P22, DOI 10.1016/S0165-4608(99)00035-7; Mishina T, 2000, CLIN CANCER RES, V6, P11; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigro S, 1996, INT J CANCER, V67, P871; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; NUORVA K, 1993, AM J PATHOL, V142, P725; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; OUD PS, 1989, CANCER, V64, P1304, DOI 10.1002/1097-0142(19890915)64:6<1304::AID-CNCR2820640623>3.0.CO;2-K; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Petersen I, 1997, CANCER RES, V57, P2331; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; POWELL SN, 1995, CANCER RES, V55, P1643; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Sagawa Y, 2001, CANCER LETT, V168, P45, DOI 10.1016/S0304-3835(01)00501-8; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shivapurkar N, 1999, CANCER RES, V59, P3576; SHU HB, 1995, J CELL BIOL, V130, P1137, DOI 10.1083/jcb.130.5.1137; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Suzuki H, 2000, CANCER RES, V60, P4353; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TESTA JR, 1992, CANCER RES, V52, pS2702; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; Ullmann R, 2001, HUM PATHOL, V32, P1059, DOI 10.1053/hupa.2001.28248; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Viren MMT, 1997, MED ONCOL, V14, P35, DOI 10.1007/BF02990943; Volm M, 1997, BRIT J CANCER, V75, P1774, DOI 10.1038/bjc.1997.302; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu WG, 1998, CANCER RES, V58, P4082; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yamaguchi T, 2001, CANCER RES, V61, P8256; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	192	114	122	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6884	6897		10.1038/sj.onc.1205566	http://dx.doi.org/10.1038/sj.onc.1205566			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362271				2022-12-28	WOS:000178640200004
J	Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S				Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S			Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines	ONCOGENE			English	Article						gene expression profile; microarray; gastric cancer	PREDICTION; METAPLASIA; PATTERNS; DATABASE	Gastric adenocarcinoma is one of the major malignancies worldwide. Gastric cell lines have been widely used as the model to study the genetics, pharmacology and biochemistry of gastric cancers. Here we describe a comprehensive survey of the gene expression profiles of 12 gastric carcinoma cell lines, using cDNA microarray with 43000 clones. For comparison, we also explored the gene expression patterns of 15 cell lines derived from lymphoid, endothelial, stromal and other epithelial cancers. Expression levels of specific genes were validated through comparison to protein expression by immunohistochemistry using cell block arrays. We found sets of genes whose expression corresponds to the molecular signature of each cell type. In the gastric cancer cell lines, apart from genes that are highly expressed corresponding to their common epithelial origin from the gastrointestinal tract, we found marked heterogeneity among the gene expression patterns of these cell lines. Some of the heterogeneity may reflect their underlying molecular characteristics or specific differentiation program. Two putative gastric carcinoma cell lines were found to be B-cell lymphoma, and another one had no epithelial specific gene expression and hence was of doubtful epithelial origin. These cell lines should no longer be used in gastric carcinoma research. In conclusion, our gene expression database can serve as a powerful resource for the study of gastric cancer using these cell lines.	Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Surg, Beijing 100871, Peoples R China; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Pathol, Beijing 100871, Peoples R China; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Peking University; Stanford University; University of Hong Kong; Stanford University; University of Hong Kong; Peking University; Stanford University	So, S (corresponding author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr,Room H3680, Stanford, CA 94305 USA.		Yuen, Siu/K-6311-2014; Chi, Jen-Tsan/AAI-4125-2020; Chu, Kent/C-4251-2009; Leung, Suet Yi/C-4340-2009; Leung, Suet Yi/T-9620-2019	Chi, Jen-Tsan/0000-0003-3433-903X; JI, JIAFU/0000-0001-6878-5543; Leung, Suet Yi/0000-0001-8614-4619				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Debruyne P, 1999, ACTA GASTRO-ENT BELG, V62, P393; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Peddanna N, 1995, ANTICANCER RES, V15, P2055; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x	22	60	71	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6549	6556		10.1038/sj.onc.1205829	http://dx.doi.org/10.1038/sj.onc.1205829			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226758				2022-12-28	WOS:000177925300015
J	Hansen, DV; Hsu, JY; Kaiser, BK; Jackson, PK; Eldridge, AG				Hansen, DV; Hsu, JY; Kaiser, BK; Jackson, PK; Eldridge, AG			Control of the centriole and centrosome cycles by ubiquitination enzymes	ONCOGENE			English	Review						ubiquitin ligases; ubiquitination; centrosome duplication	ANAPHASE-PROMOTING COMPLEX; AURORA-A KINASE; TUMOR-SUPPRESSOR COMPLEX; POLO-LIKE KINASE-1; CELL-CYCLE; MITOTIC SPINDLE; PROTEIN-KINASE; SUBSTRATE RECOGNITION; DESTRUCTION BOX; GAMMA-TUBULIN		Stanford Univ, Sch Med, Program Chem Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Jackson, PK (corresponding author), Stanford Univ, Sch Med, Program Chem Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	pjackson@stanford.edu		Jackson, Peter/0000-0002-1742-2539; Hansen, David/0000-0001-9679-7189				Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Balczon R, 2001, CHROMOSOMA, V110, P381, DOI 10.1007/s004120100157; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burton JL, 2000, MOL CELL BIOL, V20, P4614, DOI 10.1128/MCB.20.13.4614-4625.2000; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, BIOL CELL, V91, P461, DOI 10.1016/S0248-4900(99)80087-2; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Glotzer M, 2002, CURR BIOL, V12, pR344, DOI 10.1016/S0960-9822(02)00854-0; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MACK G, 1993, CELL MOTIL CYTOSKEL, V26, P239, DOI 10.1002/cm.970260307; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Marshall WF, 2001, CURR BIOL, V11, pR487, DOI 10.1016/S0960-9822(01)00289-5; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Michalides R, 2002, BRIT J CANCER, V86, P402, DOI 10.1038/sj.bjc.6600072; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ou YY, 2002, CELL MOTIL CYTOSKEL, V51, P123, DOI 10.1002/cm.10019; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PATTERSON C, 2002, SCI STKE; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Roghi C, 1998, J CELL SCI, V111, P557; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Setoguchi A, 2001, AM J VET RES, V62, P1134, DOI 10.2460/ajvr.2001.62.1134; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanaka T, 1999, CANCER RES, V59, P2041; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Wakefield JG, 2000, CURR BIOL, V10, P1367, DOI 10.1016/S0960-9822(00)00776-4; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	149	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6209	6221		10.1038/sj.onc.1205824	http://dx.doi.org/10.1038/sj.onc.1205824			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214251				2022-12-28	WOS:000177840500010
J	Hinchcliffe, EH; Sluder, G				Hinchcliffe, EH; Sluder, G			Two for two: Cdk2 and its role in centrosome doubling	ONCOGENE			English	Review						cancer; Cdk2; centrosome; cyclin; mitosis	POLE BODY DUPLICATION; CYCLIN-E; CELL-CYCLE; CENTRIOLE DUPLICATION; REPRODUCTION; KINASE; NUCLEAR; REQUIREMENT; EVENTS; P53		Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Res Inst, Notre Dame, IN 46556 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Notre Dame; University of Notre Dame; Walther Cancer Institute	Sluder, G (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.	Greenfield.sluder@umassmed.edu			NIGMS NIH HHS [GM 30758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; AUBIN JE, 1980, J CELL SCI, V43, P177; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Haase SB, 2001, NAT CELL BIOL, V3, P38, DOI 10.1038/35050543; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 2000, CURR TOP DEV BIOL, V49, P235; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; MACK G, 1993, CELL MOTIL CYTOSKEL, V26, P239, DOI 10.1002/cm.970260307; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sluder G, 1998, CELL BIOL INT, V22, P3, DOI 10.1006/cbir.1997.0249; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Sluder G, 1997, J CELL SCI, V110, P421; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X	55	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6154	6160		10.1038/sj.onc.1205826	http://dx.doi.org/10.1038/sj.onc.1205826			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214244				2022-12-28	WOS:000177840500003
J	Sansom, OJ; Clarke, AR				Sansom, OJ; Clarke, AR			The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice	ONCOGENE			English	Article						mismatch repair; apoptosis; P53; clonogenic survival; cisplatin	DNA MISMATCH REPAIR; MURINE SMALL-INTESTINE; DRUG-RESISTANCE; MUTATION FREQUENCY; ANTICANCER AGENTS; GAMMA-IRRADIATION; HMLH1 EXPRESSION; TUMOR-CELLS; DAMAGE; CISPLATIN	Apoptosis and long term enterocyte survival were examined in vivo after exposure to three cytotoxic agents (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU)) within mice either singly or doubly mutant for p53 and Msh2. P53 deficiency caused abrogation of the immediate apoptotic response to each agent, but only led to increased survival after cisplatin treatment. Msh2 deficiency reduced the apoptotic response to each agent, but only led to increased crypt survival after NMNU treatment. Following cisplatin treatment, the response of (Msh2(-/-), p53(-/-)) mice paralleled that of the p53(-/-) mice. A delayed wave of apoptosis was observed in both p53(-/-) and (Msh2(-/-), p53(-/-)) mice demonstrating this phenomenon to be independent of functional Mismatch repair (MMR). We conclude that loss of either p53 or Msh2 dependent apoptosis does not predict long-term crypt survival in vivo, however genetic status clearly can modulate survival for some agents such as cisplatin.	Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BOSARI S, 1995, VIRCHOWS ARCH, V427, P229; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown JM, 1999, CANCER RES, V59, P1391; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fink D, 1998, CLIN CANCER RES, V4, P1; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Gong JG, 1999, NATURE, V399, P806; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hemminki K., 1994, V125, P313; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Lin XJ, 2001, CANCER RES, V61, P1508; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Ochs K, 2000, CANCER RES, V60, P5815; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1985, CELL CLONES MANUAL M; Pritchard DM, 1998, CANCER RES, V58, P5453; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	37	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5934	5939		10.1038/sj.onc.1205760	http://dx.doi.org/10.1038/sj.onc.1205760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185594				2022-12-28	WOS:000177520900014
J	Merel, P; Prieur, A; Pfeiffer, P; Delattre, O				Merel, P; Prieur, A; Pfeiffer, P; Delattre, O			Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines	ONCOGENE			English	Article						breast cancer; non-homologous end joining; DNA repair; chromosome instability	COMPARATIVE GENOMIC HYBRIDIZATION; REPAIR; MUTATIONS; STABILITY; BRCA1; PATHWAY; RECOMBINATION; MECHANISMS; GENE	Structural abnormalities of chromosomes, including translocations and deletions, are extremely frequent in human cancer cells and particularly in breast cancer cells. One hypothesis to account for these alterations is a deficiency in the repair of DNA double-strand breaks (DSB). This repair process relies on two distinct pathways, homologous recombination (HR) and non-homologous DNA end joining (NHEJ). To investigate this latter pathway, we have studied the ability of cell-free extracts from a variety of human cells to rejoin different types of DSBs. The end joining activity of eleven sporadic breast cancer cell lines (BCCLs) was compared with that of control cells including primary human fibroblasts and cells harbouring a limited number of chromosome abnormalities. In vitro rejoining activity was not detected in extracts from MO59J DNA-PKcs-deficient cells and was strongly inhibited by wortmannin in control extracts. In contrast, most sporadic BCCLs and BRCA1 or BRCA2 deficient cells demonstrated similar efficiencies and accuracies of in vitro NHEJ than control cells. Only two BCCLs, SKBR3 and MDA-MB-453 exhibited decreased in vitro NHEJ. This study therefore indicates that a major defect in the NHEJ pathway is unlikely to account for the high number of chromosomes abnormalities observed in sporadic and hereditary BCCLs.	INSERM, Inst Curie, Lab Pathol Mol Canc, U509, F-75248 Paris 05, France; Univ Essen Gesamthsch, Genet Univ, D-45117 Essen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Duisburg Essen	Delattre, O (corresponding author), INSERM, Inst Curie, Lab Pathol Mol Canc, U509, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				Bell DW, 1999, CANCER RES, V59, P3883; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Forozan F, 2000, CANCER RES, V60, P4519; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kytola S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang HC, 2001, CANCER RES, V61, P270; Yu VPCC, 2000, GENE DEV, V14, P1400	28	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5654	5659		10.1038/sj.onc.1205742	http://dx.doi.org/10.1038/sj.onc.1205742			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165865				2022-12-28	WOS:000177442000016
J	DeChant, AK; Dee, K; Weyman, CM				DeChant, AK; Dee, K; Weyman, CM			Raf-induced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase 3 activation	ONCOGENE			English	Article						Raf; myoblast; differentiation; apoptosis	PROTEIN-KINASE; MUSCLE DIFFERENTIATION; CELL LINEAGES; CYTOCHROME-C; INHIBITION; DEATH; TRANSFORMATION; PROLIFERATION; RECRUITMENT; MYOGENESIS	We examined the effect of a constitutively active Raf protein (Raf-CAAX) on the differentiation and the coincident apoptosis of skeletal myoblasts. We found that a low level of Raf signaling leads to accelerated differentiation when compared to parental myoblasts, while a higher level of Raf signaling induces a transformed morphology and abrogates both differentiation and the coincident apoptosis. Raf signaling abrogates apoptosis without blocking the activation of caspase 3 and the subsequent cleavage of caspase 3 substrates. Eliminating the signal from Raf through MEK does not restore the ability to differentiate or to undergo apoptosis in the myoblasts with a high level of Raf signal, nor does it abrogate the accelerated differentiation observed in myoblasts with lower levels of Raf signal. Constitutive signaling through MEK is required, however, to maintain a transformed morphology. These results indicate that the effect of Raf on the differentiation and apoptosis of skeletal myoblasts is dictated by the level of Raf signaling, and that Raf signaling sufficient to abrogate the apoptosis coincident with differentiation does so downstream of caspase 3 signaling.	Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA	Cleveland State University	Weyman, CM (corresponding author), Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA.	c.weyman@csuohio.edu			NATIONAL CANCER INSTITUTE [R01CA084212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA84212-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chinni C, 1999, J BIOL CHEM, V274, P9169, DOI 10.1074/jbc.274.14.9169; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FIDZIANSKA A, 1991, ACTA NEUROPATHOL, V81, P572, DOI 10.1007/BF00310140; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Mampuru LJ, 1996, EXP CELL RES, V226, P372, DOI 10.1006/excr.1996.0238; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sandri M, 1996, BASIC APPL MYOL, V6, P257; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5268	5279		10.1038/sj.onc.1205648	http://dx.doi.org/10.1038/sj.onc.1205648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149648				2022-12-28	WOS:000177193900008
J	Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R				Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R			Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis	ONCOGENE			English	Article						DNA repair; BADD45; JNK	DNA-DAMAGE RESPONSE; CELL-CYCLE; ACTIVATION; PROTEIN; GADD45; PHOSPHORYLATION; INDUCTION; BREAST; TRANSCRIPTION; REQUIREMENT	The breast cancer suppressor protein, BRCA1 plays an important role in mediating cell cycle arrest, apoptosis and DNA responses to DNA damage signals. In this study, we show that BRCA1 level is downregulated during UV-induced apoptosis by caspase-3 mediated cleavage. Cleavage of BRCA1 by caspase-3 produced a fragment that contained the C-terminal of the molecule. Accordingly, treatment of cells with caspase-3 inhibitor or mutation of a specific caspase-3 cleavage site (DLLD) at amino acid 1151 - 1154 of BRCA1 abolished cleavage and consequential accumulation of the BRCA1 C-terminal fragment. Whereas expression of the non-cleavable BRCA1 (D/A 1154) mutant conferred the resistance phenotype to UV-induced cell death, expression of the cleaved BRCA1 C-terminus induced cell death in the absence of UV. Examination of the mechanism of C-terminus-induced cell death revealed that the cleaved fragment triggers the apoptotic response through activation of BRCA1 downstream effectors, GADD45 and JNK. Altogether, results of our study demonstrate a functional role for caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis.	Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Pittsburgh, PA 15261 USA; Louisiana State Univ, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Louisiana State University System; Louisiana State University System	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, E1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	bask@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060945, R01GM060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93640] Funding Source: Medline; NIGMS NIH HHS [GM 60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afford S, 2000, J CLIN PATHOL-MOL PA, V53, P55, DOI 10.1136/mp.53.2.55; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2001, J CELL SCI, V114, P3771; Deng CX, 2000, BIOESSAYS, V22, P728; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Larson JS, 1997, CANCER RES, V57, P3351; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Shao NS, 1996, ONCOGENE, V13, P1; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VANDEVIJVER MJ, 1993, ADV CANCER RES, V61, P25; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang Y, 2000, GENE DEV, V14, P927; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu V, 2000, BREAST CANCER RES, V2, P82, DOI 10.1186/bcr37; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037	40	40	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5335	5345		10.1038/sj.onc.1205665	http://dx.doi.org/10.1038/sj.onc.1205665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149654				2022-12-28	WOS:000177193900014
J	Larminat, F; Germanier, M; Papouli, E; Defais, M				Larminat, F; Germanier, M; Papouli, E; Defais, M			Deficiency in BRCA2 leads to increase in non-conservative homologous recombination	ONCOGENE			English	Article						BRCA2; homologous recombination; DNA repair; DNA interstrand crosslink; Rad51; single-strand annealing	STRAND BREAK REPAIR; INTERSTRAND CROSS-LINKS; HAMSTER CELL MUTANTS; MAMMALIAN-CELLS; DNA-REPAIR; RAD51 RECOMBINATION; CHROMOSOMAL BREAKS; IONIZING-RADIATION; VERTEBRATE CELLS; PROTEIN	The BRCA2 tumor suppressor has been implicated in the maintenance of genomic integrity through a function in cellular responses to DNA damage. The BRCA2 protein directly associates with Rad51, that is essential for repair of double-strand breaks (DSBs) by homologous recombination (HR). In this report, we study the BRCA2-defective Chinese hamster cell mutant V-C8 for its ability to perform homology-directed repair (HDR) between repeated sequences. V-C8 cells were recently shown to be defective in Rad51 foci formation in response to DNA damage. Strikingly, we find that these BRCA2 mutant cells exhibit a strong stimulation of HDR activity compared to the V79 parental cells, which harbor a wild-type BRCA2. Furthermore, molecular characterization of the HDR products shows that loss of BRCA2 in V-C8 cells leads to significant reduction in Rad51-dependent gene conversion but strong enhancement of Rad51-independent single-strand annealing (SSA) events frequency. These data imply that, when HDR by conservative gene conversion is impaired, DSBs usually repaired by this pathway are instead resolved by other non-conservative HDR subpathways. Therefore, high chromosomal instability in BRCA2-deficient cells presumably results from enhancement of error-prone repair mechanisms, such as SSA.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Larminat, F (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.							Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; OVERKAMP WJI, 1993, SOMAT CELL MOLEC GEN, V19, P431, DOI 10.1007/BF01233248; Papouli E, 2000, BIOCHEM PHARMACOL, V59, P1101, DOI 10.1016/S0006-2952(00)00234-3; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; VERHAEGH GWCT, 1995, MUTAT RES-DNA REPAIR, V337, P119, DOI 10.1016/0921-8777(95)00017-E; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; ZDZIENICKA MZ, 1990, SOMAT CELL MOLEC GEN, V16, P575, DOI 10.1007/BF01233098; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	31	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5188	5192		10.1038/sj.onc.1205659	http://dx.doi.org/10.1038/sj.onc.1205659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140769				2022-12-28	WOS:000176975900017
J	Callus, BA; Mathey-Prevot, B				Callus, BA; Mathey-Prevot, B			SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc	ONCOGENE			English	Article						Drosophila; EGF-R; JAK-STAT; signalling; SOCS	NEGATIVE REGULATOR; SH2 DOMAIN; PATHWAY; BOX; ACTIVATION; RECEPTORS; EMBRYOS; REVEALS; ENCODES; MEMBERS	We have cloned a novel SOCS gene from Drosophila, socs36E, which is most homologous to the mammalian socs-5 gene. Socs36E is expressed zygotically, predominantly during embryogenesis, in a highly dynamic pattern. In vivo expression of SOCS36E in transgenic flies results in several adult phenotypes. Engrailed-GAL4 directed expression causes loss of the wing anterior cross vein, humeral outgrowths, absence of halteres and eye pigmentation defects. Expression of SOCS36E under apterous-GAL4 control resulted in outstretched wings. Full penetrance of these phenotypes required the presence of the SH2 and SOCS-box domains of SOCS36E. The observed phenotypes were consistent with defects in JAK/STAT or EGF-R signalling and were exacerbated jak (hopscotch), din flies heterozygous for either the d-stat (stat92E) or d-egf-r (der) genes. Conversely, inactivating one copy of the d-cbl gene, a negative regulator of the d-EGF-R, partially rescued the wing phenotypes. These genetic interactions imply that SOCS36E can suppress activities of the JAK/STAT and EGF-R signalling pathways in the wing disc and suggest that SOCS36E interacts with multiple pathways in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Garvan Institute of Medical Research	Callus, BA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	b.callus@garvan.org.au			NHLBI NIH HHS [R01 HL 62434-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; CLIFFORD R, 1994, GENETICS, V137, P531; Conley CA, 2000, DEVELOPMENT, V127, P3947; De Sepulveda P, 1999, EMBO J, V18, P904; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Khalsa O, 1998, DEVELOPMENT, V125, P2723; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	26	108	109	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4812	4821		10.1038/sj.onc.1205618	http://dx.doi.org/10.1038/sj.onc.1205618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101419				2022-12-28	WOS:000176716300010
J	Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS				Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS			Identification of novel candidates for replicative senescence by functional proteomics	ONCOGENE			English	Article						replicative senescence; proteomics; gene expression; mass spectrometry	RESPONSE MEDIATOR PROTEIN-2; LIM-DOMAIN PROTEIN; T-ANTIGEN; CELL-LINES; GENE; GELSOLIN; HOMEODOMAIN; EXPRESSION; DYNAMICS; NEURONS	To identify the underlying mechanisms that limit the mitotic potential of normal somatic cells, we have undertaken a high resolution differential proteomic analysis aimed at identifying proteins that were differentially expressed upon replicative senescence. Since replicative senescence in heterogenous primary fibroblast cultures is asynchronous, we analysed a group of conditionally immortalized rat embryo fibroblast cell lines that have previously been shown to undergo synchronous senescence upon inactivation of SV40 tsA58 T antigen. This identified 43 spots that were differentially expressed in these cell lines. Comparison of the identity of these features with those identified in a complimentary independent differential proteomic analysis of replicative senescence, directly in primary rat embryo fibroblasts upon serial passaging, identified nine features that were in common between the two studies even though they had been conducted entirely separately. None of these proteins have previously been recognized to be involved with replicative senescence. Thus, they represent novel starting points for elucidating the underlying mechanism that regulates the finite mitotic life span of somatic cells and how it can be overcome in cancer cells.	Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Oxford GlycoSci, Abingdon OX14 3YS, Oxon, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, Courtland Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk		Benvenuti, Silvia/0000-0002-3041-4429; Cramer, Rainer/0000-0002-8037-2511				AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Asch HL, 1996, CANCER RES, V56, P4841; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bauer K, 2000, BLOOD, V96, P4236; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Conzen SD, 1995, ONCOGENE, V11, P2295; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Darmon Alison J., 2000, Molecular Cell Biology Research Communications, V4, P219, DOI 10.1006/mcbr.2001.0281; Dong Y, 1999, INT J CANCER, V81, P930, DOI 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RA, 2002, PROTEOMICS, V2, P212, DOI 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; NAKAJIMA N, 1995, FEBS LETT, V365, P108, DOI 10.1016/0014-5793(95)00453-G; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; WANG JA, 1996, J CHINA COAL SCI, V1, P16; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592	38	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4403	4413		10.1038/sj.onc.1205525	http://dx.doi.org/10.1038/sj.onc.1205525			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080471				2022-12-28	WOS:000176317100006
J	Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E				Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E			Antisense to Epstein Barr virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes	ONCOGENE			English	Article						EBV; LMP1; antisense oligodeoxynucleotides; EBV transforming genes; anti-apoptotic genes; B cell phenotype	LATENT MEMBRANE-PROTEIN; HUMAN EPITHELIAL-CELLS; GROWTH TRANSFORMATION; NUCLEAR PROTEIN-2; BCL-2 EXPRESSION; INDUCTION; LYMPHOMA; TUMORIGENICITY; IDENTIFICATION; INHIBITION	It is generally accepted that Epstein-Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, effectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might influence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or affect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not affect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modifications in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our findings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors.	Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Mattia, E (corresponding author), Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Chichiarelli, Silvia/F-1226-2011	Galletti, Roberta/0000-0001-8299-7649; MASCIARELLI, SILVIA/0000-0002-6738-6281; Chichiarelli, Silvia/0000-0002-5682-0353				BAICHWAL VR, 1988, ONCOGENE, V2, P461; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1993, ONCOGENE, V8, P1575; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Mattia E, 1997, ONCOGENE, V15, P489, DOI 10.1038/sj.onc.1201183; MILLER G, 1990, VIROLOGY, P1921; Nicholson LJ, 1997, ONCOGENE, V15, P275, DOI 10.1038/sj.onc.1201187; Noguchi T, 2001, BRIT J HAEMATOL, V114, P84, DOI 10.1046/j.1365-2141.2001.02887.x; PATARROYO M, 1986, INT J CANCER, V38, P539, DOI 10.1002/ijc.2910380414; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610	26	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4166	4170		10.1038/sj.onc.1205515	http://dx.doi.org/10.1038/sj.onc.1205515			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037673				2022-12-28	WOS:000176186000011
J	Poetsch, M; Dittberner, T; Woenckhaus, C				Poetsch, M; Dittberner, T; Woenckhaus, C			Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36	ONCOGENE			English	Article						melanoma; RIZ; frameshift mutations	MISMATCH REPAIR GENE; ZINC-FINGER GENE; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; CELL-LINES; EXPRESSION; CYTOGENETICS; CARCINOMA; PRODUCT; CANCERS	Recently, the retinoblastoma protein interacting zinc finger gene RIZ has been proposed as a candidate for the tumor suppressor locus on 1p36, because of the common loss of RIZ1 RNA in human tumors. In addition, frameshift mutations of this gene have been demonstrated in a variety of tumors with microsatellite instability. Since alterations in this region have been described in malignant melanomas, we investigated DNA of paraffin-em bedded sections from 16 typical naevi, 19 atypical naevi, 33 primary melanoma lesions and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis of RIZ. Frameshift mutations in the RIZ gene were found in 17% of melanoma samples and 8.6% of naevi, but we could not demonstrate any missense mutations in the exons of RIZ1. No LOH of the RIZ gene nor any microsatellite instability in six dinucleotide markers or in the mononucleotide repeats IGRIIR, hMSH3, and hMSH6 could be demonstrated in the samples with RIZ frameshift mutations. Although our results do not explain the high rate of deletions in 1p36 found in this tumor, they assign RIZ a potential role in the multi-step tumor forming process of malignant melanoma of the skin.	Ernst Moritz Arndt Univ Greifswald, Inst Forens Med, D-17489 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Dermatol, D-17489 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Pathol, D-17489 Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Poetsch, M (corresponding author), Ernst Moritz Arndt Univ Greifswald, Inst Forens Med, Kuhstr 30, D-17489 Greifswald, Germany.	poetsch@mail.uni-greifswald.de						ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; Boni R, 1998, J INVEST DERMATOL, V110, P215, DOI 10.1046/j.1523-1747.1998.00109.x; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.3.CO;2-B; Fleisher AS, 2000, CANCER RES, V60, P4864; He LS, 1998, CANCER RES, V58, P4238; Heim S., 1995, CANC CYTOGENETICS CH, V2nd; Hussein MR, 2001, AM J DERMATOPATH, V23, P308, DOI 10.1097/00000372-200108000-00006; Jiang GL, 2001, CANCER RES, V61, P1796; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Korabiowska M, 1999, ONCOL REP, V6, P921; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Piao Z, 2000, CANCER RES, V60, P4701; Poetsch M, 1998, LAB INVEST, V78, P883; Poetsch M, 1999, VIRCHOWS ARCH, V435, P105, DOI 10.1007/s004280050406; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Richetta A, 2001, MELANOMA RES, V11, P283, DOI 10.1097/00008390-200106000-00010; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; SIRACKY J, 1982, NEOPLASMA, V29, P661; Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V	24	30	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3038	3042		10.1038/sj.onc.1205457	http://dx.doi.org/10.1038/sj.onc.1205457			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082534				2022-12-28	WOS:000175262700011
J	Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH				Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH			Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1	ONCOGENE			English	Article						Wnt-4; WT1; Denys-Drash syndrome; kidney development; expression profiling	DNA-BINDING; ORNITHINE-DECARBOXYLASE; REPRESSES TRANSCRIPTION; SUSCEPTIBILITY GENE; GROWTH-FACTOR; PROTEIN; EXPRESSION; TARGET; TRANSFORMATION; ASSOCIATION	The Wilms' tumour suppressor gene, WT1, encodes multiple nuclear protein isoforms, all containing four C-terminal zinc finger motifs. WT1 proteins can both activate and repress putative target genes in vitro, although the in vivo relevance of these putative target genes is often unverified. WT1 mutations can result in Wilms' tumour and the Denys-Drash Syndrome (DDS) of infantile nephropathy, XY pseudohermaphroditism and predisposition to Wilms' tumour. We have established stable transfectants of the mouse mesonephric cell line, M15, which express WT1 harbouring a common DDS point mutation (R394W). A comparison of the expression profiles of M15 and transfectant C2A was performed using Nylon-based arrays. Very few genes showed differential expression. However Wnt-4, a member of the Wnt gene family of secreted glycoproteins, was downregulated in C2A and other similar clones. Doxycycline induction of WT1-A or WT1-D expression in HEK293 stable transfectants also elicited an elevation in Wnt4 expression. Wnt4 is critical for the mesenchyme-to-epithetial transition during kidney development, making it an attractive putative WT1 target. We have mapped human Wnt-4 gene to chromosome 1p35-36, a region of frequent LOH in WT, have characterized the genomic structure of the human Wnt4 gene and isolated 9 kb of immediate promoter. While several potential WT1 binding sites exist within this promoter, reporter analysis does not strongly support the direct regulation of Wnt4 by WT1. We propose that Wnt-4 regulation by WT1 occurs at a more distant promoter or enhancer site, or is indirect.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Queensland; University of Queensland; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Little, MH (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	M.Little@imb.uq.edu.au	Sim, Edmund Ui-Hang/J-2863-2019; Smith, Aaron/A-8329-2010; Little, Melissa Helen/A-6170-2010	Sim, Edmund Ui-Hang/0000-0001-8652-8495; Little, Melissa Helen/0000-0003-0380-2263				Bergstein I, 1997, GENOMICS, V46, P450, DOI 10.1006/geno.1997.5041; Borel F, 1996, BIOCHEMISTRY-US, V35, P12070, DOI 10.1021/bi960758o; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christiansen JH, 1996, ONCOGENE, V12, P2705; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Englert C, 1997, CANCER RES, V57, P1429; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GAVIN BJ, 1990, DEVELOPMENT, V3, P2319; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kim J, 1999, MOL CELL BIOL, V19, P2289; Koesters R, 1999, CANCER RES, V59, P3880; KU M, 1993, DEVELOPMENT, V119, P1161; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Little MH, 1996, ONCOGENE, V13, P1461; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rahman N, 1998, HUM GENET, V103, P547, DOI 10.1007/PL00008708; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGER RH, 1992, CURR OPIN CELL BIOL, V4, P1; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	58	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2948	2960		10.1038/sj.onc.1205373	http://dx.doi.org/10.1038/sj.onc.1205373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082525	Green Accepted			2022-12-28	WOS:000175262700002
J	Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT				Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT			A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells	ONCOGENE			English	Article						AIBl; coactivator; breast cancer; antiestrogen; all-trans retinoic acid; TGF-beta	GROWTH-FACTOR-BETA; DEPENDENT ACTIVATION; EXPRESSION; GENE; HORMONE; AMPLIFICATION; TRANSCRIPTION; INVASIVENESS; POSITIVITY; INHIBITION	AIB1 (amplified in breast cancer 1) is a nuclear receptor coactivator gene amplified and overexpressed in breast cancer. However, the mechanisms by which AIB1 is regulated are unclear. Here we show that 17beta-estradiol represses AIB1 mRNA and protein expression in MCF-7 human breast cancer cells primarily by suppressing AIB1 gene transcription. Estrogen levels present in fetal calf serum are sufficient to maintain AIB1 mRNA and protein at low basal levels, and this repression is reversed by the addition of antiestrogens or all-trans retinoic acid. Interestingly, cycloheximide inhibition experiments revealed that secondary protein synthesis was necessary to induce AIB1 expression by antiestrogens and retinoids. Experiments with TGF-beta and TGF-beta blocking antibodies demonstrated that this growth factor modulates AIB1 expression and showed that the antiestrogen and retinoid induction of AIB1 gene expression is mediated at least in part through TGF-beta. These data reveal a mechanism of estrogen-induced down-modulation of the overall hormone sensitivity of cells through feedback inhibition of coactivator gene expression. These data also suggest that antiestrogens can shift the sensitivity of cells to nonestrogenic proliferative signaling by increasing cellular levels of AIB1 This effect may play a role in breast cancer progression and resistance to drug treatment.	Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, E307,3970 Reservoir Rd, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950				Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Degitz SJ, 1998, TERATOLOGY, V58, P197, DOI 10.1002/(SICI)1096-9926(199811)58:5<197::AID-TERA6>3.0.CO;2-8; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Farina AR, 1998, INT J CANCER, V75, P721; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Guan XY, 1996, CANCER RES, V56, P3446; Jakowlew SB, 2000, PEPTIDES, V21, P1831, DOI 10.1016/S0196-9781(00)00344-2; KAREY KP, 1988, CANCER RES, V48, P4083; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koli KM, 1997, J BIOL CHEM, V272, P8296, DOI 10.1074/jbc.272.13.8296; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nephew KP, 2000, BIOL REPROD, V63, P361, DOI 10.1095/biolreprod63.2.361; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; ONATE SA, 1995, SCIENCE, V270, P1354; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Sakakura C, 2000, INT J CANCER, V89, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	43	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7147	7155		10.1038/sj.onc.1205943	http://dx.doi.org/10.1038/sj.onc.1205943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370804				2022-12-28	WOS:000178504600002
J	Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T				Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T			Light Chain 3 associates with a Sos1 guanine nucleotide exchange factor: its significance in the Sos1-mediated Rac1 signaling leading to membrane ruffling	ONCOGENE			English	Article						Sos1; Rac1; light chain 3	PROTEIN; BINDING; RAS; AUTOPHAGOSOME; ACTIVATION; DOMAIN; YEAST; MSOS1	A 19 kDa protein was identified to associate with the Dbl oncogene homology domain of Sos1 (Sos-DH) and was purified from rat brains by GST-Sos-DH affinity chromatography. Peptide sequencing revealed that the protein is identical to light chain 3 (LC3), a microtubule-associated protein. LC3 coimmunoprecipitated with Sos1, and GST-LC3 was capable of forming complexes with Sos1 in in vitro GST-pull down assay. Furthermore, LC3 was colocalized with Sos1 in cells, as determined by immunohistochemistry. While Sos1 stimulated the guanine nucleotide exchange reaction on Rac1, LC3 suppressed the ability of Sos1 to activate Rac1 in in vitro experiments using COS cell lysates. Consistent with this, overexpression of LC3 decreased the level of active GTP-bound Rac1 in COS cells. Sos1 expression induced membrane ruffling, a downstream target for Rac1, but LC3 expression inhibited this biological effect of Sos1. These findings suggest that LC3 interacts with Sos1 and thereby negatively regulates the Sos1-dependent Rac1 activation leading to membrane ruffling.	Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, Matsumoto, Nagano 3908621, Japan; NCI, Frederick Canc Res & Dev Ctr, IRSP, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Wlodawers Program Struct Biol, Frederick, MD 21702 USA	Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.							Downward J, 1996, CANCER SURV, V27, P87; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MANN SS, 1994, J BIOL CHEM, V269, P11492; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; VAN AL, 1997, GENE DEV, V11, P2295; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	15	13	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7060	7066		10.1038/sj.onc.1205790	http://dx.doi.org/10.1038/sj.onc.1205790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370828				2022-12-28	WOS:000178424900009
J	Balsara, BR; Testa, JR				Balsara, BR; Testa, JR			Chromosomal imbalances in human lung cancer	ONCOGENE			English	Article						small cell lung carcinoma; non-small cell lung carcinoma; cytogenetics; CGH analysis	SMALL-CELL-CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; MOLECULAR CYTOGENETIC ANALYSIS; FHIT GENE; EPIGENETIC INACTIVATION; SOLID TUMORS; SHORT ARM; N-MYC; ABNORMALITIES	A wealth of cytogenetic data has demonstrated that numerous somatic genetic changes are involved in the pathogenesis of human lung cancer. Despite the complexity of the genomic changes observed in these neoplasms, recurrent chromosomal patterns have emerged. In this review, we summarize chromosomal alterations identified in small cell and non-small cell lung cancer, using classical and molecular cytogenetic techniques. These analyses have uncovered a set of chromosome regions implicated in lung cancer development and progression. However, many of the target genes remain unknown. Newer technology, such as array-CGH, when combined with cDNA microarrays and tissue microarrays, will facilitate the integration of genomic and gene expression data and pave the way toward a molecular classification of lung carcinomas. The molecular implications of consistent chromosome imbalances found in lung cancer to date are also discussed.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-58184, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bjorkqvist AM, 1998, BRIT J CANCER, V77, P260, DOI 10.1038/bjc.1998.42; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRENNAN J, 1991, CANCER RES, V51, P1708; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DEFUSCO PA, 1989, MAYO CLIN PROC, V64, P168, DOI 10.1016/S0025-6196(12)65671-7; Feder M, 1998, CANCER GENET CYTOGEN, V102, P25, DOI 10.1016/S0165-4608(97)00274-4; GEMMA A, 1988, CANCER RES, V48, P6025; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Heim S, 1995, CANC CYTOGENETICS; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Ji L, 1999, CANCER RES, V59, P3333; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE JS, 1987, CANCER RES, V47, P6349; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MIURA I, 1992, CANCER RES, V52, P1322; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Petersen I, 1997, CANCER RES, V57, P2331; RIED T, 1994, CANCER RES, V54, P1801; Roche J, 1996, ONCOGENE, V12, P1289; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SEKIDO Y, 2001, CANC PRINCIPLES PRAC, P917; SHAPIRO GI, 1995, CANCER RES, V55, P505; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SOZZI G, 1987, CANCER GENET CYTOGEN, V27, P45, DOI 10.1016/0165-4608(87)90259-7; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; TESTA JR, 1993, CANCER DETECT PREV, V17, P267; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Todd S, 1997, CANCER RES, V57, P1344; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YOKOTA J, 1988, ONCOGENE, V2, P607	53	157	165	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6877	6883		10.1038/sj.onc.1205836	http://dx.doi.org/10.1038/sj.onc.1205836			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362270				2022-12-28	WOS:000178640200003
J	Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J				Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J			Repression of IRF-4 target genes in human T cell leukemia virus-1 infection	ONCOGENE			English	Review						human T cell leukemia virus; interferon regulatory factors; cyclin B1; transcription	INTERFERON REGULATORY FACTOR-4; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; REPLICATION PROTEIN-A; TYPE-1 TAX PROTEIN; I HTLV-I; CYCLIN B1; TRANSCRIPTION FACTOR; KINASE IKK; MOLECULAR MECHANISM	The human T cell leukemia/lymphotropic virus-1 (HTLV-I) is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes. Interferon regulatory factor-4 (IRF-4) was shown previously to be constitutively expressed in T cells infected with HTLV-1. In this study, we investigated the role of IRF-4 gene regulation in the context of HTLV-1 infection using gene array technology and IRF-4 expressing T cells. Many potential IRF-4 regulated genes were identified, the vast majority of which were repressed by IRF-4 expression. Cyclin B1, a G2-M checkpoint protein identified as an IRF-4 repressed gene in the array, was further characterized in the context of HTLV-1 infection. All HTLV-1 infected cell lines and ATL patient lymphocytes demonstrated a dramatic decrease in cyclin B1 levels; subsequent analysis of the cyclin B1 promoter identified two sites important in IRF-4 binding and repression of cyclin B1 expression. Furthermore, IRF-4-mediated repression of cyclin B1 led to a significant decrease in CDC2 kinase activity in HTLV-1 infected T cells. IRF-4 expression in HTLV-1 infected T cells also downregulated other genes implicated in the mitotic checkpoint as well as genes involved in actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition. Several of the identified genes are dysregulated in ATL and may provide important mechanistic information concerning pathways critical to the emergence of ATL.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada; NCI, NIH, Bethesda, MD 20892 USA	Lady Davis Institute; McGill University; McGill University; McMaster University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brien TP, 1998, MODERN PATHOL, V11, P870; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Campbell MS, 2001, J CELL SCI, V114, P953; CANN AJ, 1996, FIELDS VIROLOGY; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chatterjee D, 2000, ANTICANCER RES, V20, P4477; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clark PR, 2001, CELL STRESS CHAPERON, V6, P121, DOI 10.1379/1466-1268(2001)006<0121:TIHAAM>2.0.CO;2; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Gaidano G, 2000, LEUKEMIA, V14, P563, DOI 10.1038/sj.leu.2401748; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; KAMADA N, 1992, CANCER RES, V52, P1481; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KASAI T, 2001, J BIOL CHEM, V29, P29; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Lacana E, 1997, J IMMUNOL, V158, P5129; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Manjili MH, 2002, FRONT BIOSCI-LANDMRK, V7, pD43, DOI 10.2741/manjili; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Mashal RD, 1996, CANCER RES, V56, P4159; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meraro D, 1999, J IMMUNOL, V163, P6468; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murakami H, 1999, VIRCHOWS ARCH, V434, P153, DOI 10.1007/s004280050319; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OConnor PM, 1997, CANCER SURV, V29, P151; Ohshima K, 1999, J PATHOL, V189, P539, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;539::AID-PATH465&gt;3.0.CO;2-T; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; Porter LA, 2000, BLOOD, V95, P2645; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SADAMORI N, 1991, ACTA HAEMATOL-BASEL, V86, P14; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Schmidt M, 2000, J CLIN ONCOL, V18, P3331, DOI 10.1200/JCO.2000.18.19.3331; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sharma S, 2000, AIDS RES HUM RETROV, V16, P1613, DOI 10.1089/08892220050193047; SHARMA S, 2002, IN PRESS J IMMUNOL; Song YH, 2000, J CELL BIOCHEM, V80, P229; Soria JC, 2000, CANCER RES, V60, P4000; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tanaka Y, 1998, BLOOD, V91, P3909; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	108	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6751	6765		10.1038/sj.onc.1205843	http://dx.doi.org/10.1038/sj.onc.1205843			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360402				2022-12-28	WOS:000178315800005
J	Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D				Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D			Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; phosphatidylinositol 3-kinase; P70-S6-kinase; p27(Kip1); Skp2	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; CELL-CYCLE PROGRESSION; GROWTH-FACTOR-I; CONSTITUTIVE ACTIVATION; FACTOR FKHR-L1; TUMOR-GROWTH; S6 KINASE; SURVIVAL; EXPRESSION	Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70(S6K)) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70(S6K) and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70(S6K) but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70(S6K). Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70(S6K) was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27(Kip1) protein. In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27(Kip1) protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3alpha/beta constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27(Kip1) and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.	Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, F-75014 Paris, France; Hop Cochin, APHP, Serv Hematol Clin & Biol, Paris, France; Hop Hotel Dieu, APHP, Lab Cytogenet, F-75181 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Bouscary, D (corresponding author), Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.			Pene, Frederic/0000-0003-3639-3849; Bouscary, Didier/0000-0003-3654-5064				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hosoi H, 1999, CANCER RES, V59, P886; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li WQ, 2000, CANCER RES, V60, P3909; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ogata A, 1997, J IMMUNOL, V159, P2212; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tu YP, 2000, CANCER RES, V60, P6763	48	272	309	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6587	6597		10.1038/sj.onc.1205923	http://dx.doi.org/10.1038/sj.onc.1205923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242656				2022-12-28	WOS:000178202300004
J	Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR				Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR			Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion	ONCOGENE			English	Article						conversion; senescence; immortalizatiom; Raf-1; p16(INK4a); human mammary epithelial cells	RAF-1 PROTEIN-KINASE; CYCLE ARREST; ONCOGENIC RAS; CANCER CELLS; SENESCENCE; TRANSFORMATION; FIBROBLASTS; EXPRESSION; ACTIVATION; INDUCTION	Using an estrogen-inducible retroviral system, we demonstrate that oncogenie Raf-1 induces growth arrest and morphological changes in finite lifespan human mammary epithelia] cells (HMEC). This arrest does not rely on expression of the cyclin-dependent kinase inhibitor (CKI) p16(INK4a), nor on changes in expression of the CKIs p21(Cip1), p14(ARF), p27(Kip1) or p57(Kip2). The Raf-induced arrest is independent of viral oncogene mediated inactivation of p53 and pRB, or e-myc overexpression. Flow cytometric analysis demonstrates that cells arrest in both G1 and G2. The Raf-induced arrest is mitigated or eliminated in some immortally transformed HMEC. Immortal HMEC that have both overcome replicative senescence and undergone the recently described conversion process maintain growth in the presence of transduced oncogenic Raf-1; they also gain EGF-independent growth and a low frequency of anchorage-independent growth. However, HMEC that have overcome replicative senescence but have not undergone conversion and HMEC immortalized by transduction with the catalytic subunit of telomerase, hTERT, remain severely growth arrested. These results indicate that the molecular mechanisms responsible for the Raf-1-induced growth arrest may Nary among different finite lifespan cell types, and that in HMEC, this mechanism is altered during the conversion process, rather than as a direct consequence of overcoming senescence or expressing hTERT.	Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Stampfer, MR (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 70A-1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA-24822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; FINER MH, 1994, BLOOD, V83, P43; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Krtolica A, 1996, CANCER RES, V56, P1168; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; MCMAHON M, 2000, BIOCHIM BIOPHYS ACTA, P1; Nijjar T, 1999, CANCER RES, V59, P5112; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	35	70	72	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6328	6339		10.1038/sj.onc.1205780	http://dx.doi.org/10.1038/sj.onc.1205780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214273	Green Submitted			2022-12-28	WOS:000177829000009
J	Dutertre, S; Descamps, S; Prigent, C				Dutertre, S; Descamps, S; Prigent, C			On the role of aurora-A in centrosome function	ONCOGENE			English	Review						aurora; cancer; centrosome; kinase	CHROMOSOME SEGREGATION REGULATORS; HISTONE H3 PHOSPHORYLATION; BIPOLAR MITOTIC SPINDLE; HUMAN BREAST-TUMORS; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; COLORECTAL CANCERS; DUCTAL CARCINOMA; FLOW-CYTOMETRY	Mammalian aurora-A belongs to a multigenic family of mitotic serine/threonine kinases comprising two other members: aurora-B and aurora-C. In this review we will focus on aurora-A that starts to localize to centrosomes only in S phase as soon as centrioles have been duplicated, the protein is then degraded in early G1. Works in various organisms have revealed that the kinase is involved in centrosome separation, duplication and maturation as well as in bipolar spindle assembly and stability. Aurora kinases are found in all organisms in which their function has been conserved throughout evolution, namely the control of chromosome segregation. In human, aurora-A has focused a lot of attention, since its overexpression has been found to be correlated with the grade of various solid tumours. Ectopic kinase overexpression in any culture cell line leads to polyploidy and centrosome amplification. However, overexpression of aurora-A in particular cell tines such as NIH3T3 is sufficient to induce growth on soft agar. Those transformed cells form tumours when implanted in immunodeficient mice, indicating that the kinase is an oncogene.	Univ Rennes 1, CNRS, UMR 6061 Genet & Dev, Grp Cycle Cellulaire,Fac Med, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Prigent, C (corresponding author), Univ Rennes 1, CNRS, UMR 6061 Genet & Dev, Grp Cycle Cellulaire,Fac Med, IFR 97,2 Ave Pr Leon Bernard,CS 34317, F-35043 Rennes, France.							Abad M, 1998, ANAL CELL PATHOL, V16, P223, DOI 10.1155/1998/158243; Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, BIOL CELL, V91, P461, DOI 10.1016/S0248-4900(99)80087-2; Giet R, 1998, EXP CELL RES, V244, P470, DOI 10.1006/excr.1998.4218; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL SCI, V114, P2095; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hu HM, 2000, DNA CELL BIOL, V19, P679, DOI 10.1089/10445490050199063; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KLEIN FA, 1982, CANCER, V50, P389, DOI 10.1002/1097-0142(19820801)50:3<389::AID-CNCR2820500302>3.0.CO;2-I; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Magennis DP, 1997, BRIT J BIOMED SCI, V54, P140; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Petersen J, 2001, J CELL SCI, V114, P4371; Pihan GA, 1998, CANCER RES, V58, P3974; Roghi C, 1998, J CELL SCI, V111, P557; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sasaki O, 1999, ANAL QUANT CYTOL, V21, P85; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Sato N, 1999, CLIN CANCER RES, V5, P963; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sturgis CD, 1999, CANCER CYTOPATHOL, V87, P155, DOI 10.1002/(SICI)1097-0142(19990625)87:3<155::AID-CNCR9>3.0.CO;2-#; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Whitehead CM, 1998, J CELL SCI, V111, P2551; Whitehead CM, 1996, CELL MOTIL CYTOSKEL, V35, P298, DOI 10.1002/(SICI)1097-0169(1996)35:4<298::AID-CM3>3.0.CO;2-3; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	74	202	226	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6175	6183		10.1038/sj.onc.1205775	http://dx.doi.org/10.1038/sj.onc.1205775			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214247				2022-12-28	WOS:000177840500006
J	Jaiswal, AS; Bloom, LB; Narayan, S				Jaiswal, AS; Bloom, LB; Narayan, S			Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1	ONCOGENE			English	Article						DNA damage; cell cycle arrest; p21; long-patch BER	POLYMERASE-BETA; NUCLEAR ANTIGEN; CDK-CYCLIN; LIGASE I; P21; PCNA; REPLICATION; EXPRESSION; BINDING; DAMAGE	Molecular interactions among cell cycle and DNA repair proteins have been described, but the impact of many of these interactions on cell cycle control and DNA repair remains unclear. The cyclin-dependent kinase inhibitor, p21, is known to be involved in DNA damage-induced cell cycle arrest and blocking DNA replication and repair. Participation of p21 has been implicated in nucleotide excision repair. However, the role of p21 in the base excision repair (BER) pathway has not been thoroughly studied. In the present investigation, we treated isogenic mouse embryonic fibroblast (MEF) cell lines containing wild-type (MEF-polbeta) or DNA polymerase beta (polbeta) gene-knockout (MEFpolbetaKO) with oxidative DNA-damaging agent, plumbagin, and examined its effect on p21 levels and BER activity. Plumbagin treatment caused a S-G(2)/M phase arrest and cell death of both MEF cell tines, induced p21 levels, and decreased p21-mediated long-patch (LP) BER by blocking DNA ligase activity in the polbeta-dependent pathway and by blocking both FEN1 and DNA ligase activity in polbeta-independent pathway. These findings suggest that plumbagin induced p21 levels play a regulatory role in cell cycle arrest, apoptosis, and polbeta-dependent and -independent LP-BER pathways in MEF cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Coll Med, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Bloom, Linda B/F-3684-2014		NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NCI NIH HHS [CA77721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ames B N, 1991, Jpn J Cancer Res, V82, P1460; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEDFORD P, 1988, CANCER RES, V48, P3019; Bennett SE, 2001, J BIOL CHEM, V276, P42588, DOI 10.1074/jbc.M106212200; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brozmanova J, 2001, NEOPLASMA, V48, P85; Cadet J, 2000, MUTAT RES-REV MUTAT, V462, P121, DOI 10.1016/S1383-5742(00)00022-3; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Esposito F, 1998, CELL DEATH DIFFER, V5, P940, DOI 10.1038/sj.cdd.4400427; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Fotedar R, 1996, ONCOGENE, V12, P2155; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HILL BT, 1994, EUR J CANCER, V30A, P832, DOI 10.1016/0959-8049(94)90301-8; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Jaiswal AS, 2002, MUTAT RES-FUND MOL M, V500, P17, DOI 10.1016/S0027-5107(01)00296-2; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KATO T, 1994, MUTAGENESIS, V9, P245, DOI 10.1093/mutage/9.3.245; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Krokan HE, 1997, BIOCHEM J, V325, P1; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LI Y, 1994, ONCOGENE, V9, P2261; McDonald E, 1996, CANCER RES, V56, P2250; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Sugie S, 1998, CANCER LETT, V127, P177, DOI 10.1016/S0304-3835(98)00035-4; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WANG LM, 1992, CANCER RES, V52, P4824; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	68	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5912	5922		10.1038/sj.onc.1205789	http://dx.doi.org/10.1038/sj.onc.1205789			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185591				2022-12-28	WOS:000177520900011
J	Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y				Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y			Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers	ONCOGENE			English	Article						beta-catenin; Wnt/wingless signaling pathway; MT1-MMP; colon cancer	MESSENGER-RNA EXPRESSION; COLON-CARCINOMA CELLS; BETA-CATENIN; GELATINASE-A; HEPATOCELLULAR CARCINOMAS; CLINICAL-SIGNIFICANCE; INTERGLOBULAR DOMAIN; PROMOTES ACTIVATION; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY	Genetic alterations of APC and CTNNB1 (beta-catenin) have been identified in a number of human cancers including tumors arising in the colon and liver. Mutations in these genes lead to abnormal accumulation of beta-catenin and constitutive activation of target genes in the Wnt signaling pathway. To clarify the precise role of accumulated beta-catenin in colorectal carcinogenesis, we searched for genes involved in the beta-catenin/Tcf signaling pathway by cDNA microarray. MT1 - MMP (membrane-type matrix metalloproteinase) was among 84 genes that were down-regulated after beta-catenin had been depleted by transduction of wild-type APC in SW480 cells. Expression of MT1 - MMP was elevated in 22 of 24 colon carcinomas we examined. Reporter assays and an electromobility-shift assay revealed a DNA fragment between - 1169 bp and - 1163 bp in the 5' flanking region of this gene to be a target of the beta-catenin/Tcf4 complex. Our results indicate that MT1 - MMP is a direct down-stream target in the Wnt signaling pathway, and that one of the ways accumulated beta-catenin contributes to colorectal carcinogenesis is by transactivating this gene.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Med Informat, SNP Res Ctr,Minato Ku, Tokyo, Japan; Univ Tokyo, Dept Canc Cell Res, Inst Med Sci, Minato Ku, Tokyo, Japan	University of Tokyo; RIKEN; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Takahashi, Meiko/0000-0002-8344-5472				Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; Fujita M, 2001, CANCER RES, V61, P7722; Ha HY, 2001, CANCER RES, V61, P984; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hlubek F, 2001, CANCER RES, V61, P8089; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imanishi Y, 2000, HUM PATHOL, V31, P895, DOI 10.1053/hupa.2000.9756; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kikuchi A, 2001, BRIT J CANCER, V85, P741, DOI 10.1054/bjoc.2001.1973; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lin YM, 2001, CANCER RES, V61, P6345; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maekawa R, 2000, CLIN EXP METASTAS, V18, P61, DOI 10.1023/A:1026553414492; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mimori K, 2001, ONCOL REP, V8, P401; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsunezuka Y, 1996, CANCER RES, V56, P5678; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415	52	213	230	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5861	5867		10.1038/sj.onc.1205755	http://dx.doi.org/10.1038/sj.onc.1205755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185585				2022-12-28	WOS:000177520900005
J	Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P				Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P			Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells	ONCOGENE			English	Article						embryonic stem cell; cell cycle; cyclin D1; extracellular regulated kinase; phosphatidylinositol 3-kinase	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; AIRWAY SMOOTH-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; CANCER CELLS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; G(1) PHASE; PHOSPHORYLATION; ACTIVATION	Mouse embryonic stem (ES) cells are known to express D-type cyclins at very low levels and these levels increase dramatically during in vitro and in vivo differentiation. Here, we investigate some of the signalling pathways regulating expression of cyclin D1 and progression to S phase, the Ras/Extracellular signal-regulated protein kinase (ERK) pathway and the phosphatidylinositol 3-kinase (P13-kinase) pathway. We demonstrate that ERK phosphorylation is fully dispensable for the regulation of cyclin D1 level and for the progression from G1 to S phase in ES cells. By contrast, P13-kinase activity is required for both. Differentiation induced by retinoic acid results in the gain of ERK-dependent control of cyclin D1 expression and of S phase progression. Differentiation is also paralleled by an increase in P13-kinase activity. This leads (a) to an increase in the p70 S6 kinase-dependent regulation of the steady-state level of cyclin D1, and (b) to a concomitant decrease in the GSK3beta-dependent rate of cyclin D1 degradation. Altogether, these multiple pathways account for the dramatic increase in the level of cyclin D1 protein which parallels ES cell differentiation. Our studies suggest that P13-kinase is an important regulator of the ES cell cycle and that its activity is not regulated by mitogen stimulation.	Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, CNRS UMR 5534, F-69622 Villeurbanne, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Savatier, P (corresponding author), Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 07, France.		SAVATIER, Pierre/J-4663-2014; AFANASSIEFF, Marielle/M-6570-2014; stephanie, gobert/AAC-4061-2020	AFANASSIEFF, Marielle/0000-0002-6353-6617; Markossian, Suzy/0000-0003-3545-569X				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Badache A, 2001, CANCER RES, V61, P383; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; DEL PL, 1997, SCIENCE, V278, P687; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Grewe M, 1999, CANCER RES, V59, P3581; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HERBER B, 1994, ONCOGENE, V9, P1295; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; Ravenhall C, 2000, BRIT J PHARMACOL, V131, P17, DOI 10.1038/sj.bjp.0703454; Savatier P, 1996, ONCOGENE, V12, P309; Savatier P, 2002, Methods Mol Biol, V185, P27; SAVATIER P, 1994, ONCOGENE, V9, P809; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Treinies I, 1999, MOL CELL BIOL, V19, P321; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	57	161	167	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5515	5528		10.1038/sj.onc.1205728	http://dx.doi.org/10.1038/sj.onc.1205728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165850				2022-12-28	WOS:000177442000001
J	Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ				Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ			Elevated JNK activation contributes to the pathogenesis of human brain tumors	ONCOGENE			English	Article						apoptosis; brain tumor; glioblastoma multiforme; EGF receptor; JNK; MAP kinase	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; LUNG-CARCINOMA CELLS; C-JUN; PROTEIN-KINASE; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; SUPPRESSES GROWTH; HA-RAS; TRANSFORMATION	The ERK pathway is typically associated with activation of the EGF receptor and has been shown to play a major role in promoting several tumor phenotypes. An analogous signaling module, the JNK pathway, has not been shown to be consistently activated by the EGF receptor but is instead more uniformly stimulated by cellular stresses and cytokines. The function of the JNK pathway in primary tumors is unclear as it has been implicated in both promoting apoptosis and cell growth in vitro, which may be a reflection of the cell lines chosen. Primary human brain tumors frequently show overexpression of the EGF receptor. To clarify the role of JNK in tumorigenesis, we have investigated the role of JNK in a large panel of primary human brain tumors and tumor derived cell lines. Here we present evidence that JNK has a major role in promoting tumorigenesis both in vivo and in vitro. Western blot analysis demonstrated that 86% (18 of 21) of primary brain tumors showed evidence of JNK activation but only 38% (8 of 21) showed evidence of ERK activation. Kinase assays revealed that 77% of brain tumor cell lines activated JNK in response to EGF (7 of 13) or had high levels of basal activity (3 of 13), whereas none of six normal cell lines analysed, including astrocytes, had these properties. Of several growth factors examined, EGF produced the highest level of JNK induction in tumor cell lines and the duration of activation was greater than that seen for ERK. Expression of a dominant-negative (dn) form of JNK potently inhibited EGF mediated anchorage independent growth and protection from cell death in two glial tumor cell lines. These findings demonstrate that enhanced JNK activation is frequently found in primary brain tumors and that this activation contributes to phenotypes related to transformation.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Mayo Clin & Res Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Coriell Inst Med Res, Differenciat Cell Lab, Camden, NJ 08103 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center; Mayo Clinic; Coriell Institute for Medical Research	Wong, AJ (corresponding author), 233 S 10th St,BLSB 1002, Philadelphia, PA 19107 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X; Kenyon, Lawrence/0000-0002-3719-9565				Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moscatello DK, 1996, ONCOGENE, V13, P85; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Teng DHF, 1997, CANCER RES, V57, P4177; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WONG AJ, 1994, SEMIN ONCOL, V21, P139; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655	40	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5038	5046		10.1038/sj.onc.1205593	http://dx.doi.org/10.1038/sj.onc.1205593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140754				2022-12-28	WOS:000176975900002
J	Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M				Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M			Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells	ONCOGENE			English	Article						cathepsin-D; antisense RNA; breast cancer; growth; metastasis	HUMAN GLIOBLASTOMA CELLS; ESTROGEN-RECEPTOR; BASEMENT-MEMBRANE; PROCATHEPSIN-D; INVASIVENESS; INVASION; PROTEIN; RNA; TUMORIGENICITY; MACROPHAGES	Overexpression of cathepsin-D in primary breast cancer has been associated with rapid development of clinical metastasis. To investigate the role of this protease in breast cancer growth and progression to metastasis, we stably transfected a highly metastatic human breast cancer cell line, MDA-MB-231, with a plasmid containing either the full-length cDNA for cathepsin-D or a 535 bp antisense cathepsin-D cDNA fragment. Clones expressing antisense cathepsin-D cDNA that exhibited a 70-80% reduction in cathepsin-D protein, both intra- and extracellularly compared to controls, were selected for further experiments. These antisense-transfected cells displayed a reduced outgrowth rate when embedded in a Matrigel matrix, formed smaller colonies in soft agar and presented a significantly decreased tumor growth and experimental lung metastasis in nude mice compared with controls. However, manipulating the cathepsin-D level in the antisense cells has no effect on their in vitro invasiveness. These studies demonstrate that cathepsin-D enhances anchorage-independent cell proliferation and subsequently facilitates tumorigenesis and metastasis of breast cancer cells. Our overall results provide the first evidence on the essential role of cathepsin-D in breast cancer, and support the development of a new cathepsin-D-targeted therapy.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Garcia, M (corresponding author), Univ Montpellier 1, INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Bissell MJ, 1999, CANCER RES, V59, p1757S; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coyne CP, 2001, MOL IMMUNOL, V38, P347, DOI 10.1016/S0161-5890(01)00074-8; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; JOHNSON MD, 1993, CANCER RES, V53, P873; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Kondraganti S, 2000, CANCER RES, V60, P6851; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; STEWART AJ, 1994, INT J CANCER, V57, P715, DOI 10.1002/ijc.2910570518; Tedone T, 1997, FASEB J, V11, P785, DOI 10.1096/fasebj.11.10.9271363; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WORMINGTON WM, 1986, P NATL ACAD SCI USA, V83, P8639, DOI 10.1073/pnas.83.22.8639	42	94	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5127	5134		10.1038/sj.onc.1205657	http://dx.doi.org/10.1038/sj.onc.1205657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140763				2022-12-28	WOS:000176975900011
J	Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T				Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T			Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer	ONCOGENE			English	Article						Brca1; mouse models; SKY; genomic imbalances; centrosome	SUPPRESSOR GENE BRCA1; CHROMOSOMAL-ABERRATIONS; COPY NUMBER; CELL-CYCLE; MOUSE; TUMORIGENESIS; CARCINOMAS; CARCINOGENESIS; MORPHOGENESIS; PROGRESSION	BRCA1 mutation carriers have an increased susceptibility to breast and ovarian cancer. Excision of exon 11 of Brca1 in the mouse, using a conditional knockout (Cre-loxP) approach, results in mammary tumor formation after long latency. To characterize the genomic instability observed in these tumors, to establish a comparative map of chromosomal imbalances and to contribute to the validation of this mouse model of breast cancer, we have characterized chromosomal imbalances and aberrations using comparative genomic hybridization (CGH), and spectral karyotyping (SKY). We found that all tumors exhibit chromosome instability as evidenced by structural chromosomal aberrations and aneuploidy, yet they display a pattern of chromosomal gain and loss that is similar to the pattern in human breast carcinomas. Of note, nine of 15 tumors exhibited a gain of distal chromosome 11, a region that is orthologous to human chromosome 17q11-qter, the mapping position of Erbb2. However, our analysis suggests that genes distal to Erbb2 are the main targets of amplification. Four of the tumors also exhibited a copy number loss of proximal chromosome 11 (11A-B), a region orthologous to human 17p. In eight of the tumors we observed whole or partial gain of chromosome 15 centering on 15D2-D3 (orthologous to human chromosome 8q24), the map location of the c-Myc gene, and six of the tumors exhibited copy number loss of whole or partial chromosome 14, including 14D3, the map location of Rb1. We conclude that despite the tremendous shuffling of chromosomes during the course of mammalian evolution, the pattern of genomic imbalances is conserved between BRCA1-associated mammary gland tumors in mice and humans. Western blot analysis showed that while p53 is absent or mutated in some tumors, at least two tumors revealed wild-type protein, suggesting that other genetic events may lead to tumorigenesis. Similar to BRCA1-deficient mouse embryonic fibroblasts, the tumor cells contained supernumerary functional centrosomes with intact centrioles whose presence results in multipolar mitoses and aneuploidy.	NIH, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIAMSD, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ried, T (corresponding author), NIH, Genet Branch, Ctr Canc Res, 50 S Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	deng, chuxia/N-6713-2016; Gadina, Massimo/R-4195-2019	Weaver Ohler, Zoe/0000-0002-6287-2504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Deng CX, 2001, SEMIN CANCER BIOL, V11, P387, DOI 10.1006/scbi.2001.0394; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Phillips JL, 2001, CANCER RES, V61, P8143; Platzer P, 2002, CANCER RES, V62, P1134; Rhei E, 1998, CANCER RES, V58, P3193; RIED T, 1995, CANCER RES, V55, P5415; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Schuyer M, 1999, MOL CELL ENDOCRINOL, V155, P143, DOI 10.1016/S0303-7207(99)00117-3; Schuyer M, 1999, EUR J OBSTET GYN R B, V82, P147, DOI 10.1016/S0301-2115(98)00217-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SPECTOR DL, 1997, CELLS LAB MANUAL; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu GJ, 2000, CANCER RES, V60, P5371; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	112	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5097	5107		10.1038/sj.onc.1205636	http://dx.doi.org/10.1038/sj.onc.1205636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140760				2022-12-28	WOS:000176975900008
J	Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK				Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK			Effect of C-terminal deletion of P53 on heat induced CD95 expression and apoptosis in a rat histiocytoma	ONCOGENE			English	Article						deletion in p53; CD95; apoptosis; heat stress	FAS-INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; DEATH FACTOR; CELL-DEATH; GENES; SHOCK; INVOLVEMENT; GROWTH; SYSTEM; LIGAND	Tumor suppressor gene product p53 in its wild-type conformation, is an effector of apoptosis. A rat histiocytic tumor, AK-5 which has a rearranged and mutated p53 gene undergoes apoptosis upon heat shock through surface expression of CD95 receptor. DNA sequence analysis of p53 gene from tumor cells revealed a deletion of 'C' at nucleotide position 942 and an addition of 'A' at position 1055. Deletion of one nucleotide caused premature termination of p53 protein which resulted in shorter p53 protein with an altered sequence from amino acids 315 to 341. Altered p53 was unable to protect BC-8, a single cell clone of AK-5 cells from apoptosis upon heat shock. BC-8 cells transfected with a wild-type p53gene (3B4 cells) were resistant to heat induced apoptosis and did not show the expression CD95 death receptor. Inhibition of p53 expression by using antisense oligo induced apoptosis upon heat shock in 3134 cells. Similarly, inhibition of CD95 expression by antisense oligo inhibited heat induced apoptosis in BC-8 cells. In addition, cell cycle regulatory molecules, cdc2 and cdk2 are differentially regulated in a non-cell cycle dependent manner in these tumor cells. These results, in view of lack of heat shock response in BC-8 cells suggest a complex interaction between p53, CD95 and hsp70 which determines the fate of the cell. In the absence of functional p53, CD95 appears to be an effector of apoptosis in BC-8 cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Srinivas, UK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.							Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DESHPANDE G, 1990, FEBS LETT, V271, P199, DOI 10.1016/0014-5793(90)80405-8; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KHAR A, 1990, IN VITRO CELL DEV B, V26, P1024; Kim JM, 1999, ENDOCRINOLOGY, V140, P2307, DOI 10.1210/en.140.5.2307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murayama Y, 2000, HUM IMMUNOL, V61, P474, DOI 10.1016/S0198-8859(00)00100-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pardhasaradhi B. V. V., 1996, Indian Journal of Experimental Biology, V34, P945; RAFF M, 1992, NATURE, V343, P76; ROBINSON JP, 1988, CURRENT PROTOCOLS CY; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Sreedhar AS, 1999, FEBS LETT, V456, P339, DOI 10.1016/S0014-5793(99)00970-9; Sreedhar AS, 2000, FEBS LETT, V472, P271, DOI 10.1016/S0014-5793(00)01467-8; Swamynathan SK, 1996, DNA CELL BIOL, V15, P897, DOI 10.1089/dna.1996.15.897; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P539; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785; Zhou M, 1998, LEUKEMIA, V12, P1756, DOI 10.1038/sj.leu.2401198	40	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4042	4049		10.1038/sj.onc.1205504	http://dx.doi.org/10.1038/sj.onc.1205504			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037686				2022-12-28	WOS:000175869900010
J	Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA				Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA			Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling	ONCOGENE			English	Article						phospholipase D; Raf; cell cycle; survival signals	PROTEIN-KINASE-C; PHOSPHATIDIC-ACID; ACTIVATION; RECEPTOR; RALA; FIBROBLASTS; INVOLVEMENT; APOPTOSIS; CANCER; PROLIFERATION	Low level expression of an active Raf kinase results in a transformed phenotype; however, high intensity Raf signals block cell cycle progression. Phospholipase D (PLD) has been implicated in regulating cell cycle progression and PLD activity is elevated in Raf transformed cells. We report here that high intensity Raf signals reduce PLD activity and that elevated expression of either PLD1 or PLD2 prevents cell cycle arrest induced by high intensity Raf signals. Overexpression of either PLD1 or PLD2 also reversed increases in p21(Cip1) and protein kinase C delta (PKC delta) cleavage seen with high intensity Raf signals. These data indicate that PLD signaling provides a novel survival signal that overcomes cell cycle arrest induced by high intensity Raf signaling.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	City University of New York (CUNY) System; Hunter College (CUNY); University of Wurzburg	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edun			NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ASKEW DS, 1991, ONCOGENE, V6, P1915; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; RAPP UR, 1987, ONCOGENES CANCER, P55; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHONG M, 2002, IN PRESS ONCOGENE, V21; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	45	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3651	3658		10.1038/sj.onc.1205380	http://dx.doi.org/10.1038/sj.onc.1205380			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032867				2022-12-28	WOS:000175793700016
J	Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB				Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB			Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH	ONCOGENE			English	Article						AIDS; gp120; Northern hybridization; reverse Northern hybridization; neuropathogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; NECROSIS-FACTOR-ALPHA; HUMAN GLIAL-CELLS; GROWTH ARREST; DIFFERENTIAL EXPRESSION; GLUTAMATE TRANSPORTERS; PRODUCTIVE INFECTION; TYPE-1 INFECTION; BRAIN-INJURY	Neurodegeneration and dementia are common complications of AIDS caused by human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system. HIV-1 target cells in the brain include microglia, infiltrating macrophages and astrocytes, but rarely neurons. Astrocytes play an important role in the maintenance of the synaptic micro-environment and in neuronal signal transmission. To investigate potential changes in cellular gene expression associated with HIV-1 infection of astrocytes, we employed an efficient and sensitive rapid subtraction hybridization approach, RaSH. Primary human astrocytes were isolated from abortus brain tissue and low-passage cells were infected with HIV-1. To identify genes that display both early and late expression modifications after HIV-1 infection and to avoid cloning genes displaying normal cell cycle fluctuations in astrocytes, RNAs were isolated and pooled from 6, 12, 24 h and 3 and 7 day uninfected and infected cells and used for RaSH. Temporal cDNA libraries were prepared from double-stranded cDNAs that were enzymatically digested into small fragments, ligated to adapters, PCR amplified, and hybridized by incubation of tester and driver PCR fragments. By subtracting temporal cDNAs derived from uninfected astrocytes from temporal cDNAs made from HIV-1 infected cells, genes displaying elevated expression in virus infected cells, termed astrocyte elevated genes (AEGs), were identified. Both known and novel AEGs, not reported in current DNA databases, are described that display early or late expression kinetics following HIV-1 infection or treatment with recombinant HIV-1 envelope glycoprotein (gp120). For selected AEGs, expression of their protein products was also tested by Western blotting and found to display elevated expression following HIV-1 infection. The comparable pattern of regulation of the AEGs following HIV-1 infection or gp120 treatment suggest that HIV-1 exposure of astrocytes, even in the absence of productive infection, can induce changes in cellular gene expression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, Div Mol Virol, New York, NY 10019 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbfl@columbia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS31492, P01 NS031492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1994, J NEUROPATH EXP NEUR, V53, P284, DOI 10.1097/00005072-199405000-00010; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Anderson CM, 2000, GLIA, V32, P1; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Bencheikh M, 1999, J NEUROVIROL, V5, P115, DOI 10.3109/13550289909021993; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENOS DJ, 1994, ADV NEUROIMMUNOL, V4, P175, DOI 10.1016/S0960-5428(06)80254-8; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BOUSSADIA O, 1993, BIOCHIM BIOPHYS ACTA, V1172, P64, DOI 10.1016/0167-4781(93)90270-N; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Furukawa T, 1999, J HUM GENET, V44, P397, DOI 10.1007/s100380050186; Gabuzda D, 1999, J NEUROVIROL, V5, P643, DOI 10.3109/13550289909021293; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; GONDO H, 1987, J IMMUNOL, V139, P3840; Gonos ES, 1998, ANN NY ACAD SCI, V851, P466, DOI 10.1111/j.1749-6632.1998.tb09024.x; Gorry PR, 1999, J VIROL, V73, P352, DOI 10.1128/JVI.73.1.352-361.1999; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HONORE B, 1994, ELECTROPHORESIS, V15, P482, DOI 10.1002/elps.1150150166; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kawagoe H, 1997, CANCER RES, V57, P2516; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Kort JJ, 1998, AIDS RES HUM RETROV, V14, P1329, DOI 10.1089/aid.1998.14.1329; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; Ludwig E, 1999, J VIROL, V73, P8279, DOI 10.1128/JVI.73.10.8279-8289.1999; MA MH, 1994, J VIROL, V68, P6824, DOI 10.1128/JVI.68.10.6824-6828.1994; Manji HK, 2000, BIOL PSYCHIAT, V48, P518, DOI 10.1016/S0006-3223(00)00929-X; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NIQUET J, 1994, NEUROSCI LETT, V180, P13, DOI 10.1016/0304-3940(94)90902-4; O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Pope A., 1978, DYNAMIC PROPERTIES G, P13; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Prieto AL, 1999, BRAIN RES, V816, P646, DOI 10.1016/S0006-8993(98)01159-7; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Rubio ME, 1999, J NEUROCHEM, V73, P942, DOI 10.1046/j.1471-4159.1999.0730942.x; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shimizu N, 1999, J VIROL, V73, P5231, DOI 10.1128/JVI.73.6.5231-5239.1999; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Simm M, 2001, GENE, V269, P93, DOI 10.1016/S0378-1119(01)00456-5; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; TSUKADA M, 1991, J GERONTOL, V46, pB213, DOI 10.1093/geronj/46.6.B213; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Yu N, 1998, P NATL ACAD SCI USA, V95, P2624, DOI 10.1073/pnas.95.5.2624	88	279	310	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3592	3602		10.1038/sj.onc.1205445	http://dx.doi.org/10.1038/sj.onc.1205445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032861				2022-12-28	WOS:000175793700010
J	Bernardin, F; Friedman, AD				Bernardin, F; Friedman, AD			AML1 stimulates G1 to S progression via its transactivation domain	ONCOGENE			English	Article						AML1; RUNX1; CBF; cell cycle; leukemia	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; T-CELL-RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; FETAL LIVER; MURINE MYELOPEROXIDASE; PROTEIN; CBF; EXPRESSION	Inhibition of AML1-mediated transactivation potently slows G1 to S cell cycle progression. In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein. We expressed three AML1-ER variants with CBFbeta-SMMHC in Ba/F3 cells. In these lines, CBFP-SMMHC expression is regulated by the zinc-responsive metallothionein promoter. Deletion of 72 AML1 C-terminal residues, which includes a transrepression domain, did not alter the activity of AML1-ER, whereas further deletion of 98 residues, removing the most potent AML1 transactivation domain (TAD), prevented rescue of cell cycle inhibition. Notably, the two variants which did not stimulate G1 exacerbated CBFbeta-SMMHC-mediated cell cycle arrest, suggesting that they dominantly inhibit AML1 activities. In addition, the two variants which stimulated G I also induced apoptosis in 5-15% of the cells, an effect consistent with excessive G1 stimulation. These observations indicate that AML1 activates transcription of one or more genes critical for the G1 to S transition via its C-terminal transactivation domain. Inactivation of AML in acute leukemia is expected to slow proliferation unless additional genetic alterations co-exist which accelerate G1.	Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Friedman, AD (corresponding author), Johns Hopkins Univ, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	adfrdman@jhmi.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAE SC, 1993, ONCOGENE, V8, P809; BritosBray M, 1996, LEUKEMIA, V10, P984; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kummalue T, 2001, BLOOD, V98, p834A; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; QUIN XQ, 1994, P NATL ACAD SCI USA, V91, P11544; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; YANG Y, 2002, IN PRESS CANC RES; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	44	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3247	3252		10.1038/sj.onc.1205447	http://dx.doi.org/10.1038/sj.onc.1205447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082641				2022-12-28	WOS:000175373600017
J	Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G				Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G			The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells	ONCOGENE			English	Article						AML1; MDS1; EVI1; t(3;21); CtBP1; HDAC1	ACUTE PROMYELOCYTIC LEUKEMIA; STIMULATING FACTOR-RECEPTOR; PRIMARY MYELOID PROGENITORS; TERMINAL BINDING-PROTEIN; FUSION PROTEIN; HISTONE DEACETYLASES; MOLECULAR-CLONING; CO-REPRESSOR; AML1; GENE	The leukemia-associated fusion gene AML1/MDS1/EVI1 (AME) encodes a chimeric transcription factor that results from the (3;21)(q26;q22) translocation. This translocation is observed in patients with therapy-related myelodysplastic syndrome (MDS), with chronic myelogenous leukemia during the blast crisis (CML-BC), and with de novo or therapy-related acute myeloid leukemia (AML). AME is obtained by in-frame fusion of the AML1 and MDS1/EVI1 genes. We have previously shown that AME is a transcriptional repressor that induces leukemia in mice. In order to elucidate the role of AME in leukemic transformation, we investigated the interaction of AME with the transcription co-regulator CtBP1 and with members of the histone deacetylase (HDAC) family. In this report, we show that AME physically interacts in vivo with CtBP1 and HDACI and that these co-repressors require distinct regions of AME for interaction. By using reporter gene assays, we demonstrate that AME represses gene transcription by CtBP1-dependent and CtBP1-independent mechanisms. Finally, we show that the interaction between AME and CtBP1 is biologically important and is necessary for growth upregulation and abnormal differentiation of the murine hematopoietic precursor cell line 32Dc13 and of murine bone marrow progenitors.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Alexandria, Dept Clin Pathol, Fac Med, Alexandria, Egypt	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Alexandria University	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,MC 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu			NCI NIH HHS [CA 67189, CA 72675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072675, R01CA067189, R29CA067189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HAST R, 1989, LEUKEMIA RES, V13, P173, DOI 10.1016/0145-2126(89)90142-2; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Keller SA, 2000, MOL CELL BIOL, V20, P7247, DOI 10.1128/MCB.20.19.7247-7258.2000; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANGENHUIJSEN MMAC, 1984, BRIT J HAEMATOL, V58, P227, DOI 10.1111/j.1365-2141.1984.tb06080.x; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; MIKHAIL FM, 2002, IN PRESS CANC GENET; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; RUBIN CM, 1990, BLOOD, V76, P2594; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zent C., 1997, Leukemia (Basingstoke), V11, P273; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	41	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3232	3240		10.1038/sj.onc.1205436	http://dx.doi.org/10.1038/sj.onc.1205436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082639				2022-12-28	WOS:000175373600015
J	Pratt, RL; Kinch, MS				Pratt, RL; Kinch, MS			Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade	ONCOGENE			English	Article						Eph kinase; Eck; signal transduction	TERNARY COMPLEX FACTORS; MAP KINASE; PROTEIN-KINASE; GROWTH; LIGANDS; TRANSFORMATION; EXPRESSION; RECEPTORS; FAMILY; DOMAIN	Intracellular signaling by receptor tyrosine kinases regulates many different aspects of cell behavior. Recent studies in our laboratory and others have demonstrated that the EphA2 receptor tyrosine kinase critically regulates tumor cell growth, migration and invasiveness. Although the cellular consequences of EphA2 signaling have been the focus of recent attention, the biochemical changes that are triggered by ligand-mediated activation of EphA2 remain largely unknown. Herein, we demonstrate that ligand stimulation of EphA2 promotes the nucleus translocation and phosphorylation of ERK kinases, followed by an increase in nuclear induction of the Elk-1 transcription factor. Ligand-mediated activation allows EphA2 to form a molecular complex with the SHC and GRB2 adaptor proteins. Specifically, we demonstrate that tyrosine phosphorylated EphA2 interacts with the PTB and SH2 domains of SHC. We also show that the interaction of EphA2 with GRB2 is indirect and mediated by SHC and that this complex is necessary for EphA2-mediated activation of ERK kinases. These studies provide a novel mechanism to demonstrate how EphA2 can convey information from the cell exterior to the nucleus.	Medimmune Inc, Gaithersburg, MD 20878 USA; Purdue Univ, Ctr Canc, Dept Basic Med Sci, W Lafayette, IN 47907 USA	AstraZeneca; Medimmune; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kinch, MS (corresponding author), Medimmune Inc, 35 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	kinchm@medimmune.com		Kinch, Michael/0000-0003-3939-3756				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Brennan C, 1997, DEVELOPMENT, V124, P655; Brunet Anne, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P43; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lu Q, 2002, BIOL REPROD, V66, P29, DOI 10.1095/biolreprod66.1.29; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCORMICK BA, 1992, PHARMACOL THERAPEUT, V53, P239, DOI 10.1016/0163-7258(92)90011-N; MCNEIL PL, 1989, METHOD CELL BIOL, V29, P153; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Schramek H, 1997, J BIOL CHEM, V272, P11426; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Verlhac MH, 2000, EMBO J, V19, P6065, DOI 10.1093/emboj/19.22.6065; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	56	112	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7690	7699		10.1038/sj.onc.1205758	http://dx.doi.org/10.1038/sj.onc.1205758			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400011				2022-12-28	WOS:000178756200008
J	Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P				Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P			Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53	ONCOGENE			English	Article						p53; Delta N-p53; p53 isoforms; N-terminal domain; cell cycle	PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; DNA-BINDING; IN-VITRO; PROTEIN; TRANSLATION; INITIATION; MDM2; P63; IDENTIFICATION	The tumor suppressor protein p53 is ubiquitously expressed as a major isoform of 53 kD, but several forms of lower molecular weight have been observed. Here, we describe a new isoform, DeltaN-p53, produced by internal initiation of translation at codon 40 and lacking the N-terminal first transactivation domain. This isoform has impaired transcriptional activation capacity, and does not complex with the p53 regulatory protein Mdm2. Furthermore, DeltaN-p53 oligomerizes with full-length p53 (FL-p53) and negatively regulates its transcriptional and growth-suppressive activities. Consistent with the lack of Mdm2 binding, DeltaN-p53 does not accumulate in response to DNA-damage, suggesting that this isoform is not involved in the response to genotoxic stress. However, in serum-starved cells expressing wild-type p53, DeltaN-p53 becomes the predominant p53 form during the synchronous progression into S phase after serum stimulation. These results suggest that DeltaN-p53 may play a role as a transient, negative regulator of p53 during cell cycle progression.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; CNRS, UMR5535, Inst Genet Mol, F-34293 Montpellier 5, France; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Weizmann Institute of Science	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Verhaegh, Gerald/L-4708-2015; Hainaut, Pierre/B-6018-2012	Verhaegh, Gerald/0000-0003-0227-2280; Hainaut, Pierre/0000-0002-1303-1610; Oren, Moshe/0000-0003-4311-7172; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Barraille P, 1999, BIOCHEM BIOPH RES CO, V257, P84, DOI 10.1006/bbrc.1999.0334; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Hainaut P, 2000, ADV CANCER RES, V77, P81; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levrero M, 2000, J CELL SCI, V113, P1661; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; Molinari M, 1996, ONCOGENE, V13, P2077; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Okorokov AL, 1997, ONCOL RES, V9, P267; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Veldhoen N, 1999, ONCOGENE, V18, P7026, DOI 10.1038/sj.onc.1203182; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	38	211	217	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6722	6728		10.1038/sj.onc.1205874	http://dx.doi.org/10.1038/sj.onc.1205874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360399				2022-12-28	WOS:000178315800002
J	Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O				Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O			Xenopus H-RasV12 promotes entry into meiotic M phase and cdc2 activation independently of Mos and p42(MAPK)	ONCOGENE			English	Article						Ras; Xenopus oocyte; cdc2; p42(MAPK); Mos	MAP KINASE PATHWAY; SIGNAL-TRANSDUCTION; MPF ACTIVATION; ONCOGENIC RAS; IN-VITRO; OOCYTES; MATURATION; PROTEINS; INDUCTION; PHOSPHORYLATION	In the Xenopus oocyte, progesterone triggers M phase Promoting Factor (MPF) activation in a protein synthesis dependent manner. Although the synthesis of the p42(MAPK) activator Mos appears to be required for MPF activation, p42(MAPK) activity has been shown to be dispensable. To clarify this paradox, we attempted to activate the p42(MAPK) pathway independently of Mos synthesis by cloning and using Xenopus H-Ras in the oocyte. We demonstrate that the injection of the constitutively active Xe H-RasV12 mutant induces p42(MAPK) and MPF activation through two independent pathways. Xe H-RasV12 induces only a partial activation of p42(MAPK) when protein synthesis and MPF activation are prevented. A full level of p42(MAPK) activation is reached when MPF is activated and Mos is present. In contrast, MPF activation induced by Xe H-RasV12 is achieved independently of Mos synthesis and p42(MAPK) activation but still depends on protein synthesis. Therefore, the amphibian oocyte represents a new model system to analyse an original H-Ras pathway ending to MPF activation and distinct from the p42(MAPK) pathway. The identification of the proteins synthesized in response to Xe H-RasV12 and required for MPF activation, represents an important clue in understanding the mechanism of progesterone action.	Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, LT-2009 Vilnius, Lithuania; Inst Curie, INSERM, U528, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Sorbonne Universite; Vilnius University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jessus, C (corresponding author), Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARNERO A, 1994, J CELL BIOCHEM, V55, P465, DOI 10.1002/jcb.240550406; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DESMEDT V, 1995, FEBS LETT, V375, P249, DOI 10.1016/0014-5793(95)01183-F; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; JESSUS C, 1987, J CELL SCI, V87, P705; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Hernandez E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rime H, 1998, DEV BIOL, V204, P592, DOI 10.1006/dbio.1998.9069; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Taieb F, 1997, MOL REPROD DEV, V48, P397, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;397::AID-MRD14&gt;3.0.CO;2-T; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	39	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6425	6433		10.1038/sj.onc.1205827	http://dx.doi.org/10.1038/sj.onc.1205827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226746				2022-12-28	WOS:000177925300003
J	Dai, W; Wang, Q; Traganos, F				Dai, W; Wang, Q; Traganos, F			Polo-like kinases and centrosome regulation	ONCOGENE			English	Review						Polo; Polo-like kinases; centrosome; spindle pole body; microtubule organization center	CAENORHABDITIS-ELEGANS CONTAINS; SACCHAROMYCES-CEREVISIAE CDC5; PROTEIN-KINASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SERINE/THREONINE KINASE; BODY DUPLICATION; BIPOLAR SPINDLE; XENOPUS-LAEVIS; GOLGI-COMPLEX		New York Med Coll, Brander Canc Inst, Dept Med, Valhalla, NY 10595 USA	New York Medical College	Dai, W (corresponding author), New York Med Coll, Brander Canc Inst, Dept Med, Valhalla, NY 10595 USA.	wei_dai@nymc.edu	Traganos, Frank/B-8021-2012					Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047, DOI 10.1091/mbc.12.7.2047; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; DESCAMPS S, 2001, SCI STKE, pE1; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Donaldson MM, 2001, J CELL SCI, V114, P2357; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; Feng Y, 2001, CELL GROWTH DIFFER, V12, P29; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Frenz LM, 2000, J CELL SCI, V113, P3399; Fry AM, 2000, J CELL SCI, V113, P1973; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLAN A, 2002, IN PRESS J BIOL CHEM; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hinchcliffe EH, 2001, CURR BIOL, V11, pR698, DOI 10.1016/S0960-9822(01)00412-2; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lange BMH, 2000, EMBO J, V19, P1252, DOI 10.1093/emboj/19.6.1252; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ouyang B, 1999, DNA SEQUENCE, V10, P109, DOI 10.3109/10425179909008427; Riparbelli MG, 2000, J CELL SCI, V113, P3341; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; SCHILD D, 1980, GENETICS, V96, P859; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200	64	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6195	6200		10.1038/sj.onc.1205710	http://dx.doi.org/10.1038/sj.onc.1205710			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214249				2022-12-28	WOS:000177840500008
J	O'Connell, KF				O'Connell, KF			The ZYG-1 kinase, a mitotic and meiotic regulator of centriole replication	ONCOGENE			English	Review						centrosome duplication; centriole; ZYG-1; C. elegans; mitosis; meiosis	CAENORHABDITIS-ELEGANS EMBRYOS; XENOPUS EGG EXTRACTS; HAMSTER OVARY CELLS; CENTROSOME DUPLICATION; PROTEIN-KINASE; GAMMA-TUBULIN; C-ELEGANS; REPRODUCTIVE CAPACITY; BODY DUPLICATION; SPINDLE POLES		NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	O'Connell, KF (corresponding author), NIDDKD, Lab Biochem & Genet, NIH, Bldg 8,Room 2A07, Bethesda, MD 20892 USA.			O'Connell, Kevin/0000-0002-9789-288X				Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bobinnec Y, 2000, J CELL SCI, V113, P3747; Browning H, 1996, DEVELOPMENT, V122, P391; CALLAINI G, 1990, J CELL SCI, V97, P539; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; Chase D, 2000, GENESIS, V26, P26, DOI 10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-O; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; KEMPHUES KJ, 1988, GENETICS, V120, P977; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; Megraw TL, 2000, CURR TOP DEV BIOL, V49, P385; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; NAVARA CS, 1994, DEV BIOL, V162, P29, DOI 10.1006/dbio.1994.1064; O'Connell KF, 1998, GENETICS, V149, P1303; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Phalle BD, 1998, J CELL BIOL, V141, P1383, DOI 10.1083/jcb.141.6.1383; PHILLIPS DM, 1967, J CELL BIOL, V33, P73, DOI 10.1083/jcb.33.1.73; Pihan GA, 2001, CANCER RES, V61, P2212; Ruiz F, 1999, CURR BIOL, V9, P43, DOI 10.1016/S0960-9822(99)80045-1; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; SLUDER G, 1989, DEV BIOL, V131, P567, DOI 10.1016/S0012-1606(89)80027-2; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; SZOLLOSI A, 1986, EUR J CELL BIOL, V40, P100; SZOLLOSI D, 1972, J CELL SCI, V11, P521; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; WOLF N, 1978, J ULTRA MOL STRUCT R, V63, P155, DOI 10.1016/S0022-5320(78)80071-9; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; Wu XY, 1999, P NATL ACAD SCI USA, V96, P1397, DOI 10.1073/pnas.96.4.1397	53	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6201	6208		10.1038/sj.onc.1205776	http://dx.doi.org/10.1038/sj.onc.1205776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214250				2022-12-28	WOS:000177840500009
J	Xu, CW; Luo, ZJ				Xu, CW; Luo, ZJ			Inactivation of Ras function by allele-specific peptide aptamers	ONCOGENE			English	Article						allele-specific; Ras; functional genomics; peptide aptamer	SIGNAL-TRANSDUCTION; GENETIC SELECTION; PLASMA-MEMBRANE; ACTIVATION; PROTEINS; CONNECTIONS; DROSOPHILA; SEQUENCE; C-RAF-1; SWITCH	One challenge facing biology is the elucidation of the function of the estimated 30000 human genes and their polymorphic variants. Reagents that affect the activity of specific genes will be useful in the dissection of cellular regulatory networks. Here, as a test case, we used a two-bait two-hybrid system to identify peptide aptamers that distinguish allelic forms of H-Ras. Some of these anti-Ras aptamters inhibit the interaction of oncogenic Ras with c-Raf1 in vitro, and abolish EGF-stimulated activation of c-Raf1 in vivo. These experiments show that the inactivation of protein function by peptide aptamers represents a viable approach to the understanding and control of signaling pathways and oncogenic missense alleles.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Boston Univ, Sch Med, Dept Med, Diabet & Metab Unit, Boston, MA 02118 USA	Memorial Sloan Kettering Cancer Center; Boston University	Xu, CW (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA.	w-xu@ski.mskcc.org	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289	NIGMS NIH HHS [GM57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	21	23	25	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5753	5757		10.1038/sj.onc.1205680	http://dx.doi.org/10.1038/sj.onc.1205680			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173045	Bronze			2022-12-28	WOS:000177463400010
J	Chen, QM; Merrett, JB; Dilley, T; Purdom, S				Chen, QM; Merrett, JB; Dilley, T; Purdom, S			Down regulation of p53 with HPV E6 delays and modifies cell death in oxidant response of human diploid fibroblasts: an apoptosis-like cell death associated with mitosis	ONCOGENE			English	Article						cell cycle; historic kinase; caspases; bcl-2; morphology	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; CYTOCHROME-C RELEASE; HYDROGEN-PEROXIDE; CASPASE ACTIVATION; EPITHELIAL-CELLS; GROWTH ARREST; BCL-2 FAMILY; GENERATION; PROTEIN	The tumor suppressor p53 protein is known to play a critical role in apoptosis. In normal human diploid fibroblasts (HDFs), expression of the human papillomaviral (HPV) E6 gene results in a reduction of p53 protein and an inhibition of oxidant induced apoptosis within 24 h. In comparison, expression of the HPV E7 gene causes down-regulation of Rb protein without inhibiting apoptosis. Here we determine whether HDFs expressing E6 undergo cell death with a delayed time course following H2O2 exposure. Appearances of caspase-3 activity, cell detachment, trypan blue uptake and aberrant nuclei were all delayed in E6 cells compared to wild type (wt) or E7 cells. A mutant E6 gene that failed to reduce p53 could not delay cell death. Morphological examination revealed nuclear condensation in dying wt or E7 cells but nuclear fragmentation in E6 cells. Flow cytometry analysis indicated an S phase distribution of dying wt or E7 cells but a G2/M phase distribution of dying E6 cells. An elevation of cyclin B was observed in dying E6 cells but not in apoptotic E7 cells. Dying E6 cells also had elevated levels of cdc-2 protein and histone kinase activity, suggesting that the cells died at mitosis. Electron microscopy studies showed that E6 cells may die at prophase or prometaphase. Overexpression of bcl-2 resulted in an inhibition of both caspase-3 and death of E7 or E6 cells. Inactivating caspases with zVAD-fmk also reduced the death rate of E7 and E6 cells. Our data indicate that expression of HPV E6 causes a delay and morphological modification of cell death induced by oxidants. E6 cells die at mitosis, which can be inhibited by bcl-2 overexpression or caspase inhibition.	Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.				NIA NIH HHS [AG17688] Funding Source: Medline; NIEHS NIH HHS [ES010826] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG017688] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2000, J CELL SCI, V113, P4087; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; EARNSHAW WC, 1994, BIOESSAYS, V16, P639, DOI 10.1002/bies.950160908; Endlich B, 2000, RADIAT RES, V153, P36, DOI 10.1667/0033-7587(2000)153[0036:CVTLMS]2.0.CO;2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Levin S, 1999, TOXICOL PATHOL, V27, P484, DOI 10.1177/019262339902700419; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAJNO G, 1995, AM J PATHOL, V146, P3; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	40	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5313	5324		10.1038/sj.onc.1205644	http://dx.doi.org/10.1038/sj.onc.1205644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149652				2022-12-28	WOS:000177193900012
J	Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK				Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK			Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4	ONCOGENE			English	Article						chromosome 4; senescence; keratinocyte; squamous cancer	REPLICATIVE LIFE-SPAN; TUMOR-SUPPRESSOR; INDEFINITE DIVISION; TELOMERASE ACTIVITY; IMMORTAL PHENOTYPE; CERVICAL-CARCINOMA; HUMAN-FIBROBLASTS; BREAST-CANCER; SENESCENCE; GROWTH	Squamous cell carcinoma (SCC) immortality is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) of other chromosomes, including chromosome 4. To test for a functional cancer mortality gene on human chromosome 4 we introduced a complete or fragmented copy of the chromosome into SCC lines by microcell-mediated chromosome transfer (MMCT). Human chromosome 4 caused a delayed crisis, specifically in SCC lines with LOH on chromosome 4, but chromosomes 3, 6, 11 and 15 were without effect. The introduction of the telomerase reverse transcriptase into the target lines extended the average telomere terminal fragment length but did not affect the frequency of mortal hybrids following MMCT of chromosome 4. Furthermore, telomerase activity was still present in hybrids displaying the mortal phenotype. The MMCT of chromosomal fragments into BICR6 mapped the mortality gene to between the centromere and 4q23. Deletion analysis of the introduced chromosome in immortal segregants narrowed the candidate interval to 2.7 Mb spanning D4S423 and D4S1557. The results suggest the existence of a gene on human chromosome 4 whose dysfunction contributes to the continuous proliferation of SCC and that this gene operates independently from telomeres, p53 and INK4A.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Brunel Univ, Dept Sci Biol, Uxbridge UB8 3PH, Middx, England	Beatson Institute; University of Cambridge; Brunel University	Parkinson, EK (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Arribas R, 1999, LAB INVEST, V79, P111; Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Bryce SD, 1999, CANCER RES, V59, P2038; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Hu W, 1998, GENOMICS, V47, P143, DOI 10.1006/geno.1997.5108; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee YA, 2000, AM J HUM GENET, V66, P326, DOI 10.1086/302718; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; McGregor F, 1997, CANCER RES, V57, P3886; MITRA AB, 1994, CANCER RES, V54, P4481; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Shah SI, 2000, ARCH OTOLARYNGOL, V126, P1073, DOI 10.1001/archotol.126.9.1073; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Snedecor GW, 1973, STAT METHODS; SOININEN R, 1992, MECH DEVELOP, V39, P111, DOI 10.1016/0925-4773(92)90030-N; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Terada Y, 2001, AM J MED GENET, V103, P176, DOI 10.1002/ajmg.1521; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Virgin JB, 1999, PROSTATE, V41, P49, DOI 10.1002/(SICI)1097-0045(19990915)41:1<49::AID-PROS7>3.0.CO;2-8; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	52	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5135	5147		10.1038/sj.onc.1205688	http://dx.doi.org/10.1038/sj.onc.1205688			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140764				2022-12-28	WOS:000176975900012
J	Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A				Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A			Human rgr: transforming activity and alteration in T-cell malignancies	ONCOGENE			English	Article						oncogene; rgr; lymphomas; gene rearrangement; Jurkat	NUCLEOTIDE DISSOCIATION STIMULATOR; ABL GENE; RAS; ONCOGENE	We have previously identified the oncogene rgr (ralGDS related) in DNA, derived from a rabbit squamous cell carcinoma. Here we describe the identification of the human orthologue of the rabbit rgr gene termed hrgr (human ralGDS related). Four alternatively spliced full-length hrgr transcripts were isolated from normal human testes and liver libraries. Truncation of hrgr confers transforming ability to its cDNA. Using a RT-PCR assay we have been able to detect the expression of an abnormally truncated transcript in several human T-cell lymphoma lines, and in fresh tissue samples of patients with T-cell malignancies. In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was detected within the hrgr gene region. We propose that these T-cell lymphomas, at least in part, owe their malignant phenotypes to genetic alterations of the hrgr gene. These findings also raise the possibility that mutations in the hrgr gene are involved in other malignancies.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Netherlands Canc Inst, Amsterdam, Netherlands	New York University; Netherlands Cancer Institute	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bouck N, 1979, Methods Enzymol, V58, P296; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; JIANG XY, 1990, BLOOD, V76, P597; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; PELLICER A, 1980, SCIENCE, V209, P1414, DOI 10.1126/science.7414320; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439	10	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5108	5116		10.1038/sj.onc.1205694	http://dx.doi.org/10.1038/sj.onc.1205694			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140761				2022-12-28	WOS:000176975900009
J	Chen, DS; Washbrook, E; Sarwar, N; Bates, GJ; Pace, PE; Thirunuvakkarasu, V; Taylor, J; Epstein, RJ; Fuller-Pace, FV; Egly, JM; Coombes, RC; Ali, S				Chen, DS; Washbrook, E; Sarwar, N; Bates, GJ; Pace, PE; Thirunuvakkarasu, V; Taylor, J; Epstein, RJ; Fuller-Pace, FV; Egly, JM; Coombes, RC; Ali, S			Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera	ONCOGENE			English	Article						estrogen receptor alpha; phosphorylation; MAP kinase; TFIIH; breast cancer	ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; ESTRADIOL-INDUCED PHOSPHORYLATION; STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; MAP KINASE; BINDING-PROPERTIES; DNA-BINDING; BILE-ACIDS	Estrogen receptor alpha (ERalpha) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter- and cell-specific manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (SI 18) is of particular interest as its mutation significantly reduces ERalpha activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclin-dependent protein kinase Cdk7. In this study we use antisera that specifically recognize ERa phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10(-7) m E2. S 118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphorylation upon addition of the MAPK inducers EGF or PMA followed the expected time courses. Finally, we show that ERalpha is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERalpha-positive breast tumours.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Imperial College London; University of Dundee; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.		Pace, Paul E/A-3104-2012; Ali, Simak/M-6912-2018	Pace, Paul E/0000-0003-1855-5760; Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Coutts AS, 1998, CANCER RES, V58, P4071; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Glass CK, 2000, GENE DEV, V14, P121; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; HORWITZ KB, 1994, J STEROID BIOCHEM, V49, P295, DOI 10.1016/0960-0760(94)90271-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922	56	185	195	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4921	4931		10.1038/sj.onc.1205420	http://dx.doi.org/10.1038/sj.onc.1205420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118371				2022-12-28	WOS:000176874800007
J	Muthumani, K; Zhang, DH; Hwang, DS; Kudchodkar, S; Dayes, NS; Desai, BM; Malik, AS; Yang, JS; Chattergoon, MA; Maguire, HC; Weiner, DB				Muthumani, K; Zhang, DH; Hwang, DS; Kudchodkar, S; Dayes, NS; Desai, BM; Malik, AS; Yang, JS; Chattergoon, MA; Maguire, HC; Weiner, DB			Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines	ONCOGENE			English	Article						adCMV-vpr; p53; Bcl-2; caspase; cytochrome c; apoptosis	ADENOASSOCIATED VIRUS VECTORS; LATE GENE-EXPRESSION; VIRAL-PROTEIN-R; RECOMBINANT ADENOVIRUSES; CYTOCHROME-C; IN-VIVO; THERAPY; CANCER; CYCLE; MACROPHAGES	The targeted delivery of genes whose products arrest the cell cycle and/or induce apoptosis represent an important tool for the understanding and controlling forms of unregulated cell growth. The vpr gene product of HIV-1 has been reported to interfere with cell growth and induce apoptosis, but the mechanism of its action is not clearly understood. In order to study these important properties of Vpr, we created a recombinant adenovirus H5.010CMV-vpr (adCMV-vpr) as a tool to deliver the vpr gene to various cell lines to examine its biology. Vpr protein expression was confirmed by Western blot analysis in adCMV-vpr infected cells. We tested the effects of adCMV-vpr on cell growth of several tumor cell lines. Infection of both p53 positive and p53 deficient tumor cell lines with adCMV-vpr resulted in dramatic induction of cell death in short-term assays. We observed that apoptosis was induced through the mitochondrial pathway as we observed changes in the cytochrome c content accompanied by caspase 9 activation. As Bcl-2 is reported to interfere with apoptosis through the mitochondrial pathway, we examined the effect of adCMV-vpr in Bcl-2 over expressing cell lines. We observed that Bcl-2 overexpression does not inhibit adCMV-vpr induced apoptosis. The properties of adCMV-vpr inducing apoptosis through caspase 9 in a p53 pathway independent manner suggest that this is an important reagent. Such a vector may give insight into approaches designed to limit the growth of pathogenic human cells.	Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, Philadelphia, PA 19104 USA; Viral Genomix, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiner, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Muthumani, Kar/C-8252-2017; Muthumani, Kar/AAQ-4939-2020; Muthumani, Karuppiah/D-1092-2009; Weiner, David B/H-8579-2014	Muthumani, Kar/0000-0002-6807-2065; Muthumani, Kar/0000-0002-6807-2065; 				Athanasopoulos T, 2000, INT J MOL MED, V6, P363; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bonnet MC, 2000, IMMUNOL LETT, V74, P11, DOI 10.1016/S0165-2478(00)00244-3; BOON B, 1998, SCIENCE, V281, P266; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Brooks LA, 2000, CANCER RES, V60, P6875; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Fisher KJ, 1996, VIROLOGY, V217, P11, DOI 10.1006/viro.1996.0088; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; JOLLY D, 1994, CANCER GENE THER, V1, P51; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; Kunke D, 2000, CANCER GENE THER, V7, P766, DOI 10.1038/sj.cgt.7700178; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lynch CM, 1997, CIRC RES, V80, P497; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; MAY E, 1991, ONCOGENE, V6, P1363; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Muthumani K, 2000, DNA CELL BIOL, V19, P179, DOI 10.1089/104454900314564; Muthumani K, 2000, J LEUKOCYTE BIOL, V68, P366; NEWBOLD R, 1984, NATURE, V310, P628, DOI 10.1038/310628a0; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; PERKUS ME, 1995, J LEUKOCYTE BIOL, V58, P1; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Qi V, 2001, INT J HYPERTHER, V17, P38; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rozenszajn LA, 2000, EXP HEMATOL, V28, P1503, DOI 10.1016/S0301-472X(00)00589-0; Sawada H, 1996, CLIN EXP METASTAS, V14, P308; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; Stirewalt DEREK L., 2000, Hematology, V5, P15; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405	51	52	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4613	4625		10.1038/sj.onc.1205549	http://dx.doi.org/10.1038/sj.onc.1205549			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096338				2022-12-28	WOS:000176625100003
J	Pugacheva, EN; Ivanov, AV; Kravchenko, JE; Kopnin, BP; Levine, AJ; Chumakov, PM				Pugacheva, EN; Ivanov, AV; Kravchenko, JE; Kopnin, BP; Levine, AJ; Chumakov, PM			Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil	ONCOGENE			English	Article						mutant p53; drug resistance; gain of function	TUMOR-SUPPRESSOR GENE; FUNCTION MUTATIONS; CELLS; CHEMOTHERAPY; PROMOTER; RAS; MODULATION; PHENOTYPE; REQUIRES	Mutated forms of p53 are often expressed in a variety of human tumors. In addition to loss of function of the p53 tumor suppressor, mutant p53s contribute to malignant process by acquisition of novel functions that enhance transformed properties of cells and resistance to anticancer therapy in vitro, and increase tumorigenecity, invasiveness and metastatic ability in vivo. Searching for genes that change expression in response to p53 gain of function mutants may give a clue to the mechanisms underlying their oncogenic effects. Recently by subtraction hybridization cloning we found that the dUTPase gene is transcriptionally upregulated in p53-null mouse fibroblasts expressing the exogenous human tumor-derived His175 p53 mutant. Here we show that conditional expression of His175 and Trp248 hot-spot p53 mutants in p53-negative mouse 10(l) fibroblasts and human SK-OV3 and H1299 tumor cells results in increase in dUTPase gene transcription, an important marker predicting the efficacy of cancer therapy with fluoropyrimidine drugs. Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Additional inactivation of the N-terminal transcription activation domain of mutant p53 (substitutions in amino-acid residues 22 and 23) results in abrogation of both induction of dUTPase transcripts and 5-FU resistance.	Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Russian Canc Res Ctr, Inst Cancerogenesis, Moscow 115478, Russia; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Princeton University	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chumakp@ccf.org	Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019	Kopnin, Boris/0000-0003-3100-2212; Pugacheva, Elena/0000-0001-9814-7446; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Aherne GW, 1999, CANC DRUG DISC DEV, P409; Benhattar J, 1996, INT J CANCER, V69, P190, DOI 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bottini A, 2000, CLIN CANCER RES, V6, P2751; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; CANMAN CE, 1994, CANCER RES, V54, P2296; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HSIAO M, 1994, AM J PATHOL, V145, P702; Kelavkar UP, 1999, P NATL ACAD SCI USA, V96, P4378, DOI 10.1073/pnas.96.8.4378; KOPNIN BP, 1995, ONCOL RES, V7, P299; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Ladner RD, 2000, CANCER RES, V60, P3493; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Peled A, 1996, CANCER RES, V56, P2148; Pugacheva EN, 2000, MOL BIOL+, V34, P127; Sambrook J, 1989, MOL CLONING; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zheng MH, 1999, J CANCER RES CLIN, V125, P357, DOI 10.1007/s004320050286	41	79	83	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4595	4600		10.1038/sj.onc.1205704	http://dx.doi.org/10.1038/sj.onc.1205704			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096336				2022-12-28	WOS:000176625100001
J	Semplici, F; Meggio, F; Pinna, LA; Oliviero, S				Semplici, F; Meggio, F; Pinna, LA; Oliviero, S			CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation	ONCOGENE			English	Article						CK2; UBC3; beta-TrCP; phosphorylation	PROTEIN-KINASE CK2; CELL-CYCLE GENE; CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; BUDDING YEAST; S TRANSITION; VPU PROTEIN; SYSTEM; INHIBITOR	Protein kinase CK2 is a ubiquitous and pleiotropic Ser/Thr protein kinase involved in cell growth and transformation. Here we report the identification by yeast interaction trap of a CK2 interacting protein, UBC3B, which is highly homologous to the E2 ubiquitin conjugating enzyme UBC3/CDC34. UBC3B complements the yeast cdc34-2 cell cycle arrest mutant in S. cerevisiae and transfers ubiquitin to a target substrate in vitro. UBC3B is specifically phosphorylated by CK2 in vitro and in giro. We mapped by deletions and site directed mutagenesis the phosphorylation site to a serine residue within the C-terminal domain in position 233 of UBC3B and in the corresponding serine residue of UBC3. Following CK2-dependent phosphorylation both UBC3B and UBC3 bind to the F-box protein beta-TrCP, the substrate recognition subunit of an SCF (Skp1, Cul1, F-box) ubiquitin ligase. Furthermore, we observed that co-transfection of CK2alpha' together with UBC3B, but not with UBC3DeltaC, enhances the degradation of beta-catenin. Taken together these data suggest that CK2-dependent phosphorylation of UBC3 and UBC3B functions by regulating beta-TrCP substrate recognition.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy; Univ Padua, Dipartimento Chim Biol, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Studio Biomembrane, I-35100 Padua, Italy	University of Siena; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Allende CC, 1998, J CELL BIOCHEM, P129; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haas AL, 1997, FASEB J, V11, P1257; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; RAYAN A, 1985, CANCER RES, V45, P2277; Raymond F, 2000, J CELL SCI, V113, P1687; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Sun BG, 1997, BBA-GENE STRUCT EXPR, V1351, P231, DOI 10.1016/S0167-4781(96)00209-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105	60	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3978	3987		10.1038/sj.onc.1205574	http://dx.doi.org/10.1038/sj.onc.1205574			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037680				2022-12-28	WOS:000175869900004
J	Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A				Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A			Thyroid cell transformation requires the expression of the HMGA1 proteins	ONCOGENE			English	Article						thyroid cell; transformation; HMGA1; AP-1 complex; differentiation	TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMGI(Y) PROTEINS; C GENE; NEOPLASTIC TRANSFORMATION; NUCLEAR PROTEINS; ONCOGENE; GROWTH; I(Y); PHENOTYPE	Elevated expression of HMGA1 and HMGA2 proteins is correlated with a highly malignant phenotype in several human tumors. We previously demonstrated that the block of HMGA2 protein synthesis prevented rat thyroid cell transformation by murine retroviruses. Suppression of HMGA2 synthesis was associated with lack of induction of HMGA1 proteins suggesting that both HMGA1 and HMGA2 play a role in the process of neoplastic transformation. To determine the role of the HMGA1 gene in thyroid cell transformation, we blocked HMGA1 protein synthesis by an antisense methodology. Here we report that transfection of an HMGA1 cDNA antisense construct into a normal rat thyroid cell line (FRTL-5 C12), followed by infection with Kirsten murine sarcoma virus (KiMSV), generated a transformed cell line that expresses high levels of the v-ras-Ki oncogene and that does not require thyroid-stimulating hormones for growth. However, this cell line does not show the malignant phenotype, i.e., it neither grows in soft agar nor induces tumors after injection in athymic mice. Moreover, the lack of the neoplastic phenotype in the virus-infected thyroid cells carrying the HMGA1 antisense construct correlates with the absence of induction of AP-1 transcriptional activity.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Trieste	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pierantoni, Giovanna Maria/O-7527-2015	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; FEDELE M, 2002, IN PRESS ONCOGENE, V21; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scala S, 2001, CARCINOGENESIS, V22, P251, DOI 10.1093/carcin/22.2.251; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; TAMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	43	74	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2971	2980		10.1038/sj.onc.1205368	http://dx.doi.org/10.1038/sj.onc.1205368			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082527				2022-12-28	WOS:000175262700004
J	Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M				Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M			Induction of multiple double-strand breaks within an hsr by meganuclease I-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements	ONCOGENE			English	Article						I-SceI meganuclease; mammalian gene amplification; double-strand break repair; fragile sites; hypoxia; chromosomal rearrangements	DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; TUMOR PROGRESSION; TRANSIENT HYPOXIA; SOLID TUMORS; CAD GENES; AMPLIFICATION; CANCER; TRANSLOCATIONS; INSTABILITY	Gene amplification is frequently associated with tumor progression, hence, understanding the underlying mechanisms is important. The study of in vitro model systems indicated that different initial mechanisms accumulate amplified copies within the chromosomes (hsr) or on extra-chromosomal elements (dmin). It has long been suggested that formation of dmin could also occur following hsr breakdown. In order to check this hypothesis, we developed an approach based on the properties of the I-SceI meganuclease, which induces targeted DNA double-strand breaks. A clone containing an I-SceI site, integrated by chance close to an endogenous dhfr gene locus, was used to select for methotrexate resistant mutants. We recovered clones in which the I-SceI site was passively co-amplified with the dhfr gene within the same hsr. We show that I-SceI-induced hsr breakdown leads to the formation of dmin and creates different types of chromosomal rearrangements, including inversions. This demonstrates, for the first time, a direct relationship between double-strand breaks and inversions. Finally, we show that activation of fragile sites by aphidicolin or hypoxia in hsr-containing cells also generates dmin and a variety of chromosomal rearrangements. This may constitute a valuable model to study the consequences of breaks induced in hsr of cancer cells in vivo.	Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Debatisse, M (corresponding author), Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, 26 Rue Ulm, F-75248 Paris 05, France.		Coquelle, Arnaud/AAE-5425-2020					BALABANMALENBAU.G, 1981, CANCER GENET CYTOGEN, V2, P339; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brizel DM, 1996, CANCER RES, V56, P941; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; LEBEAU MM, 1986, BLOOD, V67, P849; LUK CK, 1990, J NATL CANCER I, V82, P684, DOI 10.1093/jnci/82.8.684; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; Nowell P, 1998, NAT MED, V4, P1107, DOI 10.1038/2598; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Smith DI, 1998, INT J ONCOL, V12, P187; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	39	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7671	7679		10.1038/sj.onc.1205880	http://dx.doi.org/10.1038/sj.onc.1205880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400009				2022-12-28	WOS:000178756200006
J	Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E				Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E			Mathematical modeling of noise and discovery of genetic expression classes in gliomas	ONCOGENE			English	Article						glioma; genetics; mathematical modeling; mathematical computing; genetic techniques	CANDIDATE TUMOR-SUPPRESSOR; UBIQUITIN-PROTEIN LIGASE; BOX BINDING-PROTEIN; HUMAN ASTROCYTOMAS; COLORECTAL-CANCER; POLYSIALIC ACID; CHROMOSOME 8P; BREAST-CANCER; HUMAN BRAIN; CELL-LINE	The microarray array experimental system generates noisy data that require validation by other experimental methods for measuring gene expression. Here we present an algebraic modeling of noise that extracts expression measurements true to a high degree of confidence. This work profiles the expression of 19200 cDNAs in 35 human gliomas; the experiments are designed to generate four replicate spots/gene with switching of probes. The validity of the extracted measurements is confirmed by: (1) cluster analysis that generates a molecular classification differentiating glioblastoma from lower-grade tumors and radiation necrosis; (2) By what other investigators have reported in gliomas using paradigms for assaying molecular expression other than gene profiling; and (3) Real-time RT-PCR. The results yield a genetic analysis of gliomas and identify classes of genetic expression that link novel genes to the biology of gliomas.	Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Neurosurg, Chicago, IL 60612 USA	Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County	Fathallah-Shaykh, HM (corresponding author), Rush Univ, Med Ctr, 2242 W Harrison St,suite 200, Chicago, IL 60612 USA.			Engelhard, Herbert/0000-0003-4993-9265; Fathallah-Shaykh, Hassan/0000-0002-2690-7685; Rosseau, Gail/0000-0002-5392-435X	NATIONAL CANCER INSTITUTE [R29CA078825, R01CA081367] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA78825, R01-CA81367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Becker SA, 1996, CANCER RES, V56, P5092; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOECK R, 2001, J BIOL CHEM, V271, P431; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Dunlop J, 1999, BRAIN RES, V839, P235, DOI 10.1016/S0006-8993(99)01714-X; EVERITT BS, 1993, CLUSTER ANAL, P55; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fournier MV, 1999, CANCER RES, V59, P3748; Genini M, 1996, INT J CANCER, V66, P571; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HIGUCHI M, 1993, ACTA NEUROPATHOL, V85, P481; Hildebrandt H, 1998, CANCER RES, V58, P779; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; Ise T, 1999, CANCER RES, V59, P342; KAGAN J, 1995, ONCOGENE, V11, P2121; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; KOCHI N, 1983, ACTA NEUROPATHOL, V59, P119, DOI 10.1007/BF00691597; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Landry CF, 1997, CANCER RES, V57, P4098; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lerebours F, 1999, INT J CANCER, V81, P854, DOI 10.1002/(SICI)1097-0215(19990611)81:6<854::AID-IJC3>3.0.CO;2-1; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; Marr HS, 2000, CELL TISSUE RES, V302, P139, DOI 10.1007/s004410000277; Matsumoto S, 2000, FEMS MICROBIOL LETT, V182, P297, DOI 10.1016/S0378-1097(99)00606-0; Muir D, 1996, J NEURO-ONCOL, V30, P199; Munch C, 2001, J NEUROL NEUROSUR PS, V71, P675, DOI 10.1136/jnnp.71.5.675; NAKAMURA T, 1992, ONCOGENE, V7, P733; Ohta S, 1997, BIOCHEM BIOPH RES CO, V237, P307, DOI 10.1006/bbrc.1997.7113; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Richardson RM, 2001, BIOCHEMISTRY-US, V40, P3583, DOI 10.1021/bi0019242; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Sage EH, 1997, NAT MED, V3, P144; SAITOH Y, 1995, LAB INVEST, V72, P55; Salicioni AM, 2000, GENOMICS, V69, P54, DOI 10.1006/geno.2000.6315; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; Shibao K, 1999, INT J CANCER, V83, P732; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tanaka F, 2000, CANCER RES, V60, P3072; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Vocke CD, 1996, CANCER RES, V56, P2411; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; YANG HY, 1994, MOL CHEM NEUROPATHOL, V21, P155, DOI 10.1007/BF02815349; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zoladek T, 1997, GENETICS, V145, P595	60	20	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7164	7174		10.1038/sj.onc.1205654	http://dx.doi.org/10.1038/sj.onc.1205654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370806				2022-12-28	WOS:000178504600004
J	Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J				Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J			Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells	ONCOGENE			English	Article						Hp95; anoikis; tumorigenicity; cell morphology	SIGNAL-TRANSDUCTION; PROTEIN; GENE; APOPTOSIS; ADHESION; CLONING; ALG-2; IDENTIFICATION; ASTROCYTES; INTEGRINS	p95 is a putative signal transduction protein of similar to 95 kDa that contains multiple tyrosine residues that are conserved from yeast to human, a Src phosphorylation consensus sequence and a proline-rich C-terminus that binds SH3-domains. Previous studies have established that mammalian p95 is physically associated with proteins that regulate apoptotic induction and cell transformation; however, it is unclear whether p95 is a positive or negative regulator in these processes. Moreover, a p95 partner protein has been localized at both focal adhesions and actin-cytoskeletons in rat astrocytes. However, there is no evidence that mammalian p95 has roles in regulating cell adhesion or morphology. In this study, we examined the effects of p95 on the anchorage-independent growth and tumorigenicity of malignant HeLa cells, and on the growth and morphology of non-transformed NIH3T3 cells. In HeLa cells, p95 overexpression promoted detachment-induced apoptosis (anoikis), inhibited detachment of viable cells from substratum and reduced tumorigenicity. In NIH3T3 cells, p95 overexpression promoted flat cell morphology and slowed cell proliferation, whereas p95 downregulation had opposite effects. These findings indicate that the mammalian p95 is a positive regulator in apoptotic signaling and a negative regulator in cell transformation. They also suggest that p95 has roles in regulating cell adhesion and morphology.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; ARAI T, 1976, GANN, V67, P493; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; BUNGE R, 1979, J SUPRAMOL STR CELL, V11, P175, DOI 10.1002/jss.400110207; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Krebs J, 2000, BBA-MOL CELL RES, V1498, P153, DOI 10.1016/S0167-4889(00)00091-4; Kuang J, 2001, CLIN CANCER RES, V7, P3629; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Spiryda LB, 1998, J CELL SCI, V111, P3253; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x	22	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6801	6808		10.1038/sj.onc.1205849	http://dx.doi.org/10.1038/sj.onc.1205849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360406				2022-12-28	WOS:000178315800010
J	Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N				Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N			The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16;21)-positive myeloid malignancies	ONCOGENE			English	Article						MTG16; t (16;21)-positive myeloid malignancies; chromosome translocation; nucleolus; transcriptional co-repressor; histone deacetylases	HIV-1 REGULATORY PROTEINS; T(8-21) FUSION PROTEIN; SUBCELLULAR-LOCALIZATION; REPRESSES TRANSCRIPTION; ACUTE-LEUKEMIA; GENE; ETO; FAMILY; NUCLEAR; MEMBER	The MTG (Myeloid Translocation Gene) proteins are a family of novel transcriptional corepressors. We report that MTG16a, a protein isoform encoded by the MTG16 gene deranged by the t (16; 21) in myeloid malignancies, is targeted to the nucleolus. The amino acid sequence necessary for nucleolar localization was mapped to the MTG16a N-terminal region. MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (HDACs) suggesting that the protein may mediate silencing of nucleolar gene transcription. In addition, MTG16a is capable to form oligomers with other MTG proteins. As a consequence of the t (16; 21) the AML1 DNA-binding domain replaces the MTG16a N-terminal region. The AML1-MTG16 fusion protein is targeted to the nucleoplasm where it is capable to oligomerize with MTG16a and interact with HDAC1 and HDAC3. The deficiency of HDAC-containing complexes at nucleolar sites and the accumulation of HDAC-containing complexes at AML1-sites may be critical in the pathogenesis of t (16; 21) myeloid malignancies.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; Univ Milan, San Paolo Univ Hosp, Milan, Italy; Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Erasmus University Rotterdam; University of Brescia; University of Milan; Johns Hopkins University; Johns Hopkins Medicine	Hoogeveen, AT (corresponding author), Erasmus Univ, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Akhmanova A, 2000, J CELL SCI, V113, P4463; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ANASTASSOVAKRISTEVA M, 1977, J CELL SCI, V25, P103; ASOU H, 1991, BLOOD, V77, P2031; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Evert BO, 1999, HUM MOL GENET, V8, P1169, DOI 10.1093/hmg/8.7.1169; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; McCLINTOCK BARBARA, 1934, ZEITSCHR ZELLJORSCH U MIKROSK ANAT, V21, P294, DOI 10.1007/BF00374060; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pikaard CS, 2000, TRENDS GENET, V16, P495, DOI 10.1016/S0168-9525(00)02113-2; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Shimada H, 2000, BLOOD, V96, P655; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sullivan GJ, 2001, EMBO J, V20, P2867, DOI 10.1093/emboj/20.11.2867; Tamanini F, 2000, HUM MOL GENET, V9, P1487, DOI 10.1093/hmg/9.10.1487; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	38	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6703	6712		10.1038/sj.onc.1205882	http://dx.doi.org/10.1038/sj.onc.1205882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242670				2022-12-28	WOS:000178202300018
J	D'Assoro, AB; Lingle, WL; Salisbury, JL				D'Assoro, AB; Lingle, WL; Salisbury, JL			Centrosome amplification and the development of cancer	ONCOGENE			English	Review						aneuploidy; cell cycle; centriole; chromosomal instability	HUMAN-PAPILLOMAVIRUS TYPE-16; CELL-CYCLE PROGRESSION; HUMAN PROTEIN-KINASE; GENOMIC INSTABILITY; GENETIC INSTABILITY; CHROMOSOMAL INSTABILITY; SUBCELLULAR-LOCALIZATION; MICROTUBULE DYNAMICS; P53; ABNORMALITIES		Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA.	salisbury@mayo.edu		Salisbury, Jeffrey/0000-0001-9257-4578				Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; DASSORO AB, 2002, IN PRESS BREAST CANC; DEBEC A, 1992, BIOL CELL, V75, P121, DOI 10.1016/0248-4900(92)90131-J; Deng CX, 2000, BIOESSAYS, V22, P728; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; DONCHOWER LA, 1992, NATURE, V356, P215; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; DUENSING S, 2002, IN PRESS ONCOGENE; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Duesberg P, 1999, SCIENCE, V284, P2091; Dutcher SK, 2001, CURR BIOL, V11, pR419, DOI 10.1016/S0960-9822(01)00250-0; Dutcher SK, 2001, CURR OPIN CELL BIOL, V13, P49, DOI 10.1016/S0955-0674(00)00173-3; DUTERTRE, 2002, IN PRESS ONCOGENE; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; FRIEDLANDER M, 1982, J SUBMICR CYTOL PATH, V14, P401; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 2000, J CELL SCI, V113, P1973; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Helps NR, 1998, J CELL SCI, V111, P1331; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HINCHCLIFFE EH, 2002, IN PRESS ONCOGENE; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 2002, IN PRESS ONCOGENE; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; KANEKO H, 1980, ACTA PATHOL JAPON, V30, P651; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Meraldi P, 2001, J CELL SCI, V114, P3749; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MITELMAN F, 1994, CA-CANCER J CLIN, V44, P133, DOI 10.3322/canjclin.44.3.133; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OKUDA M, 2002, IN PRESS ONCOGENE; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Passalacqua M, 1999, BIOCHEM J, V337, P113, DOI 10.1042/0264-6021:3370113; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; RAO PN, 1989, J CELL SCI, V93, P63; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Roghi C, 1998, J CELL SCI, V111, P557; Salisbury JL, 1999, J HISTOCHEM CYTOCHEM, V47, P1265, DOI 10.1177/002215549904701006; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schatten H, 2000, BIOL CELL, V92, P331, DOI 10.1016/S0248-4900(00)01079-0; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; SEIFERT HW, 1978, ARCH DERMATOL RES, V263, P159, DOI 10.1007/BF00446437; SHARP GA, 1981, J CELL SCI, V47, P1; SHARP GA, 1982, EUR J CELL BIOL, V29, P97; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Skyldberg B, 2001, MODERN PATHOL, V14, P279, DOI 10.1038/modpathol.3880303; Sluder G, 1998, CELL BIOL INT, V22, P3, DOI 10.1006/cbir.1997.0249; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; TARAPORE P, 2002, IN PRESS ONCOGENE; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; VANDRE DD, 1989, J CELL SCI, V94, P245; Vandre DD, 2000, MICROSC RES TECHNIQ, V49, P458; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Whitehead CM, 1998, J CELL SCI, V111, P2551; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	136	217	229	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6146	6153		10.1038/sj.onc.1205772	http://dx.doi.org/10.1038/sj.onc.1205772			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214243				2022-12-28	WOS:000177840500002
J	Hollander, MC; Fornace, AJ				Hollander, MC; Fornace, AJ			Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a	ONCOGENE			English	Review						Gadd45a; centrosome amplification; p53(-/-)	DOUBLE-STRAND BREAKS; DNA-DAMAGING AGENTS; C-MYC GENE; ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; ANAPHASE INHIBITOR; KINASE-ACTIVITY; DEFICIENT MICE; PROTEIN-KINASE; S-PHASE	Genomic instability has been a recognized feature of many human tumors for decades. Until recently, however, there was little insight into potential mechanisms for this phenomenon. Recent work has shown first, that increased centrosome numbers (also referred to as centrosome amplification) often accompany genomic instability and second, that when centrosome numbers are increased, cells become genetically unstable. Deletion of Gadd45a leads to centrosome amplification and consequent abnormal mitosis and aneuploidy. Gadd45a is known to be involved in a G2 checkpoint and may be involved in the normal progression from G2 to M and its coordination with S phase events. Whether these functions contribute to prevention of centrosome amplification is being investigated. However, potential mechanisms can be proposed based on known protein associations with Gadd45a, as well as proteins that regulate Gadd45a transcription and are also required for efficient coordination of centrosome duplication and DNA synthesis.	NCI, Gene Response Sect, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hollander, MC (corresponding author), NCI, Gene Response Sect, CCR, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Amundson SA, 2000, CANCER RES, V60, P6101; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baumer M, 2000, J BIOL CHEM, V275, P38929, DOI 10.1074/jbc.M007925200; Bertwistle D, 1999, Breast Cancer Res, V1, P41, DOI 10.1186/bcr12; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Clarke DJ, 1999, CURR BIOL, V9, P365, DOI 10.1016/S0960-9822(99)80163-8; Clarke DJ, 2001, NAT CELL BIOL, V3, P619, DOI 10.1038/35083009; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Law W, 2001, ONCOGENE, V20, P1118, DOI 10.1038/sj.onc.1204226; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leung CH, 2001, BIOCHEM BIOPH RES CO, V285, P283, DOI 10.1006/bbrc.2001.5164; Li Q, 1999, MOL CELL BIOL, V19, P5339; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu YY, 1996, BIOCHEM J, V317, P321, DOI 10.1042/bj3170321; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; Mai S, 1996, ONCOGENE, V12, P277; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nicolaidis P, 1998, HUM REPROD, V13, P313, DOI 10.1093/humrep/13.2.313; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pihan GA, 1998, CANCER RES, V58, P3974; RODILLA V, 1993, MUTAT RES, V300, P281, DOI 10.1016/0165-1218(93)90062-I; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stumm M, 2001, CYTOGENET CELL GENET, V92, P186, DOI 10.1159/000056900; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yin XY, 2001, CANCER RES, V61, P6487; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	67	111	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6228	6233		10.1038/sj.onc.1205774	http://dx.doi.org/10.1038/sj.onc.1205774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214253				2022-12-28	WOS:000177840500012
J	Jones, PA				Jones, PA			DNA methylation and cancer	ONCOGENE			English	Article						epigenetics; DNA methylation; chromatic; structure; silencing; tumor suppressor gene		There is tremendous ferment in the field of epigenetics as the relationships between chromatin structure and DNA methylation patterns become clearer. Central to this activity is the realization that the 'histone code', which involves the post-translational modification of histones and which has important ramifications for chromatin structure, may be linked to the DNA cytosine methylation pattern. New discoveries have suggested that histone lysine 9 methylation is implicated in the spread of heterochromatin in Drosophila and other organisms. Very recently it has been found that histone lysine 9 methylation is also necessary for some DNA methylation in Neurospora and plants. There is therefore the possibility that these two processes are closely linked, suggesting ways in which DNA methylation patterns may be established during normal development. Understanding these processes is fundamental to understanding what goes awry during the process of aging and carcinogenesis where DNA methylation patterns become substantially altered and contribute to the malignant phenotype.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol, 1441 Eastlake Ave,MS 8302L, Los Angeles, CA 90089 USA.								0	230	254	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5358	5360		10.1038/sj.onc.1205597	http://dx.doi.org/10.1038/sj.onc.1205597			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154398				2022-12-28	WOS:000177197700002
J	Beck, MT; Peirce, SK; Chen, WY				Beck, MT; Peirce, SK; Chen, WY			Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R	ONCOGENE			English	Article						prolactin; prolactin antagonist; Bcl-2; breast cancer; apoptosis	MAMMARY-GLAND INVOLUTION; MESSENGER-RNA; CDNA MICROARRAY; APOPTOSIS; RECEPTOR; HORMONE; FAMILY; PROTEIN; BAX; IDENTIFICATION	To gain insight into the molecular basis of human prolactin (hPRL) antagonist induced apoptosis, we compared the differential gene expression profile of four human breast cancer cell lines following treatment with hPRL and its antagonist (hPRL-G129R). Among the genes identified, the bcl-2 gene was of particular interest. We found that bcl-2 mRNA was up regulated in three of the four cell lines that were treated with hPRL. To further confirm these results, real time RT-PCR and ELISA analyses were used to detect bcl-2 mRNA and Bcl-2 protein, respectively, in 11 different breast cancer cell lines after hPRL or hPRL-G129R treatment. Our data suggests that Bcl-2 is up-regulated in response to hPRL stimulation and is competitively inhibited by hPRL-G129R in the majority of the cell lines tested. Thus, we propose that the anti-apoptotic role of hPRL in breast cancer is mediated, at least in part, through regulation of Bcl-2.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Microbiol & Mol Med, Clemson, SC 29630 USA	Greenville Health System; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER; NCI NIH HHS [1R21CA87093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2001, BIOTECHNIQUES, V31, P782, DOI 10.2144/01314st04; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DeRisi J, 1996, NAT GENET, V14, P457; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Green L, 1999, IEEE CIRCUITS DEVICE, V15, P7, DOI 10.1109/101.808850; Greenberg RK, 2000, J ENDOVASC THER, V7, P1, DOI 10.1583/1545-1550(2000)007<0001:AEMOHC>2.3.CO;2; Guiliano D, 1999, BIOTECHNIQUES, V27, P146, DOI 10.2144/99271rr03; HAKVOORT TBM, 1994, NUCLEIC ACIDS RES, V22, P878, DOI 10.1093/nar/22.5.878; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Leff MA, 1996, ENDOCRINOLOGY, V137, P5456, DOI 10.1210/en.137.12.5456; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Ramamoorthy P, 2001, INT J ONCOL, V18, P25; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhan JH, 1997, BIOTECHNIQUES, V22, P500, DOI 10.2144/97223st05	45	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5047	5055		10.1038/sj.onc.1205637	http://dx.doi.org/10.1038/sj.onc.1205637			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140755				2022-12-28	WOS:000176975900003
J	Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB				Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB			bcl-x(L) and RAG genes are induced and the response to IL-2 enhanced in E mu EBNA-1 transgenic mouse lymphocytes	ONCOGENE			English	Article						EBV; EBNA-1; IL-2; Bcl-x(L); transgenic mice; lymphoma	EPSTEIN-BARR-VIRUS; EXPRESSION; MICE; DNA; SURVIVAL; CELLS	We have described transgenic mice expressing Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) in B-cells which show a predisposition to lymphoma. To investigate the underlying oncogenic mechanisms, we have cross bred transgenic strains of mice, examined the pre-tumour B-cell phenotype and investigated the expression levels of selected cellular genes as a response to EBNA-1 expression. We have found that bcl-X-L and the recombination activating genes (RAG) 1 and 2 are induced in pre-neoplastic samples of EBNA-1 expressing mice. Induction of bcl-x(L) may explain the observed redundancy in lymphomagenesis between transgenic EBNA-1 and bcl-2. In addition, bone marrow cells derived from the EmuEBNA-1 mice show a greater capacity for cultured growth compared to controls, particularly in the presence of IL-2. Notably, bcl-x(L) expression is responsive to IL-2. These data shed new light on the potential contribution of EBNA-1 to EBV associated tumorigenicity as well as to the viral life cycle and open a potential avenue for therapeutic intervention.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Wilson, JB (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	Joanna.Wilson@bio.gla.ac.uk	Wilson, Joanna B/B-4466-2009; Tsimbouri, Penelope/F-4373-2010	Tsimbouri, Penelope/0000-0001-5124-7458				ADAMS JM, 1992, CANCER SURV, V15, P119; Berns A, 1999, CANCER RES, V59, p1773S; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; ISCOVE NN, 1974, J CELL PHYSIOL, V83, P309, DOI 10.1002/jcp.1040830218; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kapoor P, 2001, EMBO J, V20, P222, DOI 10.1093/emboj/20.1.222; Kawa K, 2000, INT J HEMATOL, V71, P108; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Meru N, 2001, INT J CANCER, V92, P75, DOI 10.1002/1097-0215(200102)9999:9999&lt;::AID-IJC1163&gt;3.0.CO;2-M; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; RICKINSON AB, 1996, FIELDS VIROLOGY, P2360; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Tsimbouri P, 2001, Methods Mol Biol, V174, P411; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson J B, 2001, Methods Mol Biol, V174, P361; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1997, EBV REPORT, V4, P63; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026	25	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5182	5187		10.1038/sj.onc.1205490	http://dx.doi.org/10.1038/sj.onc.1205490			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140768				2022-12-28	WOS:000176975900016
J	Girard, PM; Riballo, E; Begg, AC; Waugh, A; Jeggo, PA				Girard, PM; Riballo, E; Begg, AC; Waugh, A; Jeggo, PA			Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest	ONCOGENE			English	Article						NBS; ATM; cell cycle checkpoint; ionizing radiation; kinase activity	NIJMEGEN-BREAKAGE-SYNDROME; ATAXIA-TELANGIECTASIA PATIENTS; LYMPHOBLASTOID CELL-LINES; REPLICATION PROTEIN-A; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; IONIZING-RADIATION; HISTONE H2AX; REPAIR	Cell lines from Nijmegen Breakage Syndrome (NBS) and ataxia telangiectasia (A-T) patients show defective S phase checkpoint arrest. In contrast, only A-T but not NBS cells are significantly defective in radiation-induced G1/S arrest. Phosphorylation of some ATM substrates has been shown to occur in NBS cells. It has, therefore, been concluded that Nbs1 checkpoint function is S phase specific. Here, we have compared NBS with A-T cell lines (AT-5762ins137) that express a low level of normal ATM protein to evaluate the impact of residual Nbs1 function in NBS cells. The radiation-induced cell cycle response of these NBS and 'leaky' A-T cells is almost identical; normal G2/M arrest after 2 Gy, intermediate GI/S arrest depending on the dose and an A-T-like S phase checkpoint defect. Thus, the checkpoint assays differ in their sensitivity to low ATM activity. Radiation-induced phosphorylation of the ATM-dependent substrates Chk2, RPAp34 and p53-Sert5 are similarly impaired in AT-5762ins137 and NBS cells in a dose dependent manner. In contrast, NBS cells show normal ability to activate ATM kinase following irradiation in vitro and in vivo. We propose that Nbs1 facilitates ATM-dependent phosphorylation of multiple downstream substrates, including those required for GI/S arrest.	Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; Netherlands Canc Inst Antoni Van Leeuvenhoekhuis, Dept Expt Therapy, NL-1066 CX Amsterdam, Netherlands	University of Sussex; Netherlands Cancer Institute	Jeggo, PA (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	p.a.jeggo@sussex.ac.uk						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Antoccia A, 1997, INT J RADIAT BIOL, V71, P41, DOI 10.1080/095530097144409; Antoccia A, 1999, INT J RADIAT BIOL, V75, P583; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; Badie C, 1997, CANCER RES, V57, P4600; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEGG AC, 1988, RADIOTHER ONCOL, V11, P337, DOI 10.1016/0167-8140(88)90205-8; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2000, CANCER RES, V60, P4881; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; JASPERS NG, 1985, KROC F SERIES, P147; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Lakin ND, 1996, ONCOGENE, V13, P2707; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; McConville CM, 1996, AM J HUM GENET, V59, P320; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Morgan SE, 1997, CANCER RES, V57, P3386; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; TAALMAN RDFM, 1989, AM J MED GENET, V32, P425, DOI 10.1002/ajmg.1320320332; Taylor A. M. R., 1996, P138; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wegner RD, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P324; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	44	97	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4191	4199		10.1038/sj.onc.1205596	http://dx.doi.org/10.1038/sj.onc.1205596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082606				2022-12-28	WOS:000176174200001
J	Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M				Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M			Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks	ONCOGENE			English	Article						homologous recombination; DNA double-strand break repair; XRCC3; RAD51; polymorphism	DNA-REPAIR; CHROMOSOME STABILITY; GENES; POLYMORPHISMS	Polymorphisms in DNA repair genes, including double-strand break (DSB) repair genes, are postulated to confer increased cancer risk. A variant of the XRCC3 gene, which is involved in DSB repair, has been associated with increased risk of malignant skin melanoma and bladder cancer. We tested the hypothesis that this variant, Thr241Met, may affect cancer risk by disrupting a critical function of XRCC3, i.e., promoting homology-directed repair (HDR) of chromosomal DSBs. Using a quantitative fluorescence assay, we find that the variant XRCC3 protein is functionally active for HDR, complementing the HDR defects of an XRCC3 mutant cell line as well as the wild-type protein. We also examined cells expressing this variant for sensitivity to the interstrand cross-linking agent, mitomycin C (MMC), as HDR mutant cell lines, including the XRCC3 mutant, have been found to be hypersensitive to this DNA damaging agent. Cells expressing the variant protein were found to be no more sensitive than cells expressing the wild-type protein. These results suggest that the increased cancer risk associated with this variant may not be due to an intrinsic HDR defect.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org		Pierce, Andrew/0000-0001-9062-0307	NIGMS NIH HHS [GM54688] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; MIYAZAKI J, 1989, GENE, V79, P269; Moynahan ME, 2001, CANCER RES, V61, P4842; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Shen MR, 1998, CANCER RES, V58, P604; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Vogelstein B., 1998, GENETIC BASIS HUMAN; Winsey SL, 2000, CANCER RES, V60, P5612	20	95	96	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4176	4180		10.1038/sj.onc.1205539	http://dx.doi.org/10.1038/sj.onc.1205539			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037675				2022-12-28	WOS:000176186000013
J	Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB				Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB			MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance	ONCOGENE			English	Article						breast cancer; estrogen receptor; MAPK; cross-talk; anti-estrogens	ACTIVATED PROTEIN-KINASE; DEPENDENT TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; ER-ALPHA; PHOSPHORYLATION; ESTRADIOL; IDENTIFICATION; DOMAINS; CELLS; COACTIVATOR	The estrogen receptor alpha (ERalpha) signaling plays an essential role in breast cancer progression and endocrine therapy. Mitogen-activated protein kinase (MAPK/Erk1/2) has been implicated in ligand-independent activation of ER, resulting in the cross-talk between growth factor and ER mediated signaling. In this study, we examined the effect of the cross-talk on estradiol (E-2)-mediated signaling, tumor growth and its effect on anti-estrogen therapy. Our findings demonstrate that expression of constitutively activated mitogen activated kinase kinase (MEK1), an immediate upstream activator of MAPK in estrogen receptor positive MCF-7 breast cancer cells (MEK/MCF-7), showed an increase in ERalpha-driven transcriptional activation. In MEK/MCF-7 cells maximal transactivation levels were achieved in response to treatment with much lower E-2 concentrations (10(10) M E-2) when compared to MCF-7 control cells (10(8) M E-2) Furthermore, we have seen an increased association between ERalpha and its nuclear coactivators AIB1 or TIF2, in MEK/MCF-7 cells relative to those seen in MCF-7 control cells. In addition, in vivo studies show that mEK/MCF-7 cell tumors are similar tothreefold larger than those of MCF-7 cell, in the presence of E-2. Immunohistochemical staining demonstrates that progesterone receptor (PR) and pS2, two E-2-regulated gene products, are significantly increased in MEK/MCF-7 cell tumors compared to those of MCF-7 control tumors, suggesting that activation of ERalpha by MAPK enhances the expression of E-2-regulated genes and accelerates tumor growth. Remarkably, the antiestrogens tamoxifen and ICI 182,780, were shown both in vitro and in giro studies to efficiently antagonize the stimulatory effects of E-2 on ER regulated transactivation and tumor growth in MEK/MCF-7 as well as MCF-7 cell lines. Taken together, these data suggest that MAPK/ER cross-talk enhances ERalpha-mediated signaling and accelerates E-2-dependent tumor growth without diminishing sensitivity to the inhibitory effects of anti-estrogens.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83964, CA 64248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Kurokawa H, 2000, CANCER RES, V60, P5887; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun M, 2001, CANCER RES, V61, P5985; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Welch DR, 2000, CANCER RES, V60, P1552; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	42	91	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4000	4008		10.1038/sj.onc.1205506	http://dx.doi.org/10.1038/sj.onc.1205506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037682				2022-12-28	WOS:000175869900006
J	Palmero, I; Murga, M; Zubiaga, A; Serrano, M				Palmero, I; Murga, M; Zubiaga, A; Serrano, M			Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2	ONCOGENE			English	Article						ARF; p53; E2F; tumour suppressor; oncogene	THYMIC NEGATIVE SELECTION; TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTION FACTOR; INK4A LOCUS; S-PHASE; P53-DEPENDENT APOPTOSIS; CELLULAR PROLIFERATION; GROWTH-CHARACTERISTICS; UV-IRRADIATION	The ARF tumour suppressor protein (p14(ARF) in human and p19(ARF) in mouse) is a major mediator of the activation of p53 in response to oncogenic stress. Little is known about the signalling pathways connecting oncogenic stimuli to the activation of ARF. Regulation of ARF occurs primarily at the transcriptional level and several modulators of ARF transcription have been identified. Notably, ectopic expression of E2F1 upregulates ARF transcriptionally, and both E2F1 and ARF have been implicated in apoptosis and cell-cycle arrest. We have used primary mouse fibroblasts deficient for E2F1, E2F2, or both to determine the possible role of these E2F proteins as upstream regulators of ARF in response to oncogenic stimuli and other stresses. In particular, we have studied the effects of oncogenic Ras and the viral oncoprotein E1A on ARF levels, neoplastic transformation, and sensitization to apoptosis. We have also examined the behaviour of the E2F-deficient MEFs with respect to immortalization and sensitivity to DNA damage. None of the ARF-mediated responses that we have analysed is significantly affected in E2F1(-/-), E2F2(-/-) or E2F1/2(-/-) MEFs, and ARF is upregulated normally in all cases. Taken together, our results indicate that the activation of ARF in response to oncogenic stress can occur by E2F1- and E2F2-independent mechanisms. This challenges previous suggestions implicating E2F factors as key mediators in the activation of ARF by oncogenic stress.	CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Basque Country, Fac Sci, Dept Anim Biol & Genet, E-48080 Bilbao, Spain; Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Serrano, M (corresponding author), CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		zubiaga, ana/S-3457-2019; Palmero, Ignacio/B-4346-2013; Serrano, Manuel/H-2634-2015	zubiaga, ana/0000-0002-2132-9708; Serrano, Manuel/0000-0001-7177-9312				AMRTELLI F, 2001, P NATL ACAD SCI USA, V98, P4455; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRUMMELKAMP TR, 2001, J BIOL CHEM, V17, P17; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARVEY M, 1993, ONCOGENE, V8, P2457; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Huang YY, 1997, CANCER RES, V57, P3640; Humbert PO, 2000, GENE DEV, V14, P690; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meng RD, 1999, INT J ONCOL, V14, P5; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	88	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2939	2947		10.1038/sj/onc/1205371	http://dx.doi.org/10.1038/sj/onc/1205371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082524				2022-12-28	WOS:000175262700001
J	Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ				Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ			Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells	ONCOGENE			English	Article						SPARC; osteonectin; c-Jun; target genes	EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; V-JUN; NEOPLASTIC PROGRESSION; FUNCTIONAL ANTAGONISM; OVARIAN-CANCER; FAMILY MEMBERS; HUMAN-MELANOMA	Overexpression of the c-Jun proto-oncogene in MCF7 breast cancer cells results in a variety of phenotype changes related to malignant progression including increased motility and invasion. Concurrent with these phenotypic effects are changes in the expression of multiple gene targets. We previously demonstrated that expression of the SPARC/osteonectin gene, while undetectable in the MCF7 cell line, is highly induced in response to stable c-Jun overexpression (c-Jun/MCF7). Because the SPARC gene product is associated with tumor cell invasion in a variety of different cancers, we have examined its role in mediating the phenotypic changes induced by c-Jun in MCF7 cells. We found that antisense mediated suppression of SPARC dramatically inhibits both motility and invasion in this c-Jun/MCF7 model. In contrast, stable overexpression of SPARC in the parental MCF7 cell line is not sufficient to stimulate cell motility or invasion. Examination of the promoter region of the human SPARC gene reveals three non-canonical AP-1 sites. We demonstrate that one of these sites binds c-Jun/Fra1 heterodimers in vitro, but that this and the other AP-1 like sites are dispensable with respect to c-Jun stimulated SPARC promoter activation. Deletion analysis identified a region between -120 and -70 as a c-Jun responsive element sufficient to induce maximal promoter activation. This region does not contain any AP-1 sites but does mediate binding by SP1 'like' complexes. Furthermore, this region is necessary for SP1/SP3 responsiveness in Drosophila SL2 cells. These results demonstrate that SPARC plays an important role in stimulating motility and the invasive behavior of c-Jun/MCF7 cells and that SPARC promoter activation by c-Jun appears to occur through an indirect mechanism.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, U412, F-69364 Lyon 07, France	Eastern Virginia Medical School; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COLOMBO MP, 1991, EUR J CANCER, V27, P58, DOI 10.1016/0277-5379(91)90062-I; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DECESARE D, 1995, ONCOGENE, V11, P365; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gilles C, 1998, CANCER RES, V58, P5529; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1996, ONCOGENE, V12, P135; Horne GM, 1996, BRIT J CANCER, V73, P29, DOI 10.1038/bjc.1996.6; Jacob K, 1999, CANCER RES, V59, P4453; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kato Yasumasa, 2000, Pathology Oncology and Research, V6, P24; Kim Youn Wha, 1998, Journal of Korean Medical Science, V13, P652; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Mok SC, 1996, ONCOGENE, V12, P1895; Motamed K, 1999, INT J BIOCHEM CELL B, V31, P1363, DOI 10.1016/S1357-2725(99)00090-4; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sturm RA, 2002, CANCER RES, V62, P226; Thomas R, 2000, CLIN CANCER RES, V6, P1140; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; TOURAY M, 1991, ONCOGENE, V6, P1227; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zajchowski DA, 2001, CANCER RES, V61, P5168	68	95	102	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7077	7091		10.1038/sj.onc.1205857	http://dx.doi.org/10.1038/sj.onc.1205857			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370830				2022-12-28	WOS:000178424900011
J	Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y				Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y			Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera	ONCOGENE			English	Article						antibody; KLK4; prostase; prostate cancer; protein expression	KALLIKREIN GENE FAMILY; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; SERINE-PROTEASE; ANTIGEN; LOCALIZATION; MEMBER	The ability to identify prostate tumor or prostate tissue specific genes that are expressed at high levels and use their protein products as targets could greatly aid in the diagnosis and treatment of prostate cancer. Using a polymerase chain reaction (PCR)-based subtraction technique, we have recovered the recently described KLK4 (prostase) gene from human prostate cDNA. In this study, KLK4 gene expression in human prostate tumors was further characterized using cDNA quantitative PCR and immunohistochemistry, demonstrating that the gene is specifically expressed at both the mRNA and protein levels in normal human prostate tissue, and in both primary and metastatic prostate tumor samples. Quantitative mRNA analysis also demonstrated low level expression including adrenal gland, salivary gland and thyroid. Finally, it was demonstrated that prostate cancer patient sera contain antibodies that bind specifically to recombinant KLK4 protein. This antibody has been used to detect KLK4-specific peptides in epitope mapping experiments. The relatively specific expression profile and elevated level of KLK4 mRNA and protein in both tumor and normal prostate tissues, in addition to detectable KLK4-specific antibody in cancer patient sera, supports additional efforts to determine if KLK4 can play a role in the diagnosis of prostate cancer, the monitoring of residual disease, or act as a target for immunotherapy.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Infect Dis Res Inst, Seattle, WA 98104 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Day, CH (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	day@corixa.com			NCI NIH HHS [CA76822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABIAAD AS, 1992, J UROLOGY, V147, P952, DOI 10.1016/S0022-5347(17)37431-1; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Daher R, 1998, CLIN CHEM LAB MED, V36, P671, DOI 10.1515/CCLM.1998.120; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong Y, 2001, CLIN CANCER RES, V7, P2363; DuPont BR, 1999, CYTOGENET CELL GENET, V86, P212, DOI 10.1159/000015340; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Myers SA, 2001, J CLIN ENDOCR METAB, V86, P2323, DOI 10.1210/jc.86.5.2323; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Obiezu CV, 2001, CLIN CANCER RES, V7, P2380; SISSONS GRJ, 1992, BRIT J RADIOL, V65, P861, DOI 10.1259/0007-1285-65-778-861; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Thiounn N, 1997, UROLOGY, V50, P245, DOI 10.1016/S0090-4295(97)00272-0; Watson MA, 1999, CANCER RES, V59, P3028; Yousef GM, 1999, CANCER RES, V59, P4252	19	27	27	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7114	7120		10.1038/sj.onc.1205786	http://dx.doi.org/10.1038/sj.onc.1205786			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370833				2022-12-28	WOS:000178424900014
J	Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R				Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R			Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein	ONCOGENE			English	Article						PTCH1 tumour suppressor gene; alternative first exons; SHH; Smoh	BASAL-CELL CARCINOMA; STEROL-SENSING DOMAIN; SONIC HEDGEHOG; HUMAN HOMOLOG; VESICULAR TRAFFICKING; SOMATIC MUTATIONS; PATCHED PROTEIN; GENE; RECEPTOR; REGION	The PTCH1 gene is a human tumour suppressor gene frequently mutated in basal cell carcinoma (BCC) and several other tumour types. It encodes a receptor for soluble factors of the hedgehog family. Binding of hedgehog to the receptor relieves its inhibitory action on the transmembrane co-receptor Smoh. In this study we describe alternative first exons of the PTCH1 tumour suppressor gene and show that they are differentially regulated in normal tissues, exon 1B being expressed at very low levels and the major mRNA species containing exon 1 or 1A. Exon 1B transcripts were found to be specifically upregulated in nodular BCCs. The different PTCH1 transcripts all encode proteins that interact with Smoh in doubly transfected cells. Furthermore, functional assays demonstrated that whereas all PTCH1 isoforms can inhibit the activity of SHH, only the PTCH1B isoform is capable of fully inhibiting Smoh activity. The results indicate that in tumour cells the PTCH1B promoter is specifically activated and importantly, that the N-terminal part of PTCH1 including exon 1B is required for full inhibition of Smoh signaling but not for physical interaction with Smoh.	Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden; Tallinn Univ Technol, NICPB, EE-200108 Tallinn, Estonia; Tallinn Univ Technol, Gene Technol Ctr, EE-200108 Tallinn, Estonia	Karolinska Institutet; National Institute of Chemical Physics & Biophysics (NICPB); Tallinn University of Technology; Tallinn University of Technology	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden.	Rune.Toftgard@cnt.ki.se	Kogerman, Priit/B-6333-2008	Zaphiropoulos, Peter/0000-0003-4298-3861				Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; RUIZ I, 1997, CELL, V90, P193; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Unden AB, 1997, CANCER RES, V57, P2336; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	22	54	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6007	6016		10.1038/sj.onc.1205865	http://dx.doi.org/10.1038/sj.onc.1205865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203113				2022-12-28	WOS:000177671300004
J	Clark, SJ; Melki, J				Clark, SJ; Melki, J			DNA methylation and gene silencing in cancer: which is the guilty party?	ONCOGENE			English	Article						DNA methylation; gene expression; silencing; trigger; cancer	CPG-ISLAND METHYLATION; ACUTE MYELOID-LEUKEMIA; DE-NOVO METHYLATION; METHYLTRANSFERASE GENE; MAMMALIAN DEVELOPMENT; P16(INK4) EXPRESSION; MOUSE; PROMOTER; CELLS; HYPOMETHYLATION	The DNA methylation pattern of a cell is exquisitely controlled during early development resulting in distinct methylation patterns. The tight control of DNA methylation is released in the cancer cell characterized by a reversal of methylation states. CpG island associated genes, in particular tumour suppressor or related genes, are often hypermethylated and this is associated with silencing of these genes. Therefore methylation is commonly convicted as a critical causal event in silencing this important class of genes in cancer. In this review, we argue that methylation is not the initial guilty party in triggering gene silencing in cancer, but that methylation of CpG islands is a consequence of prior gene silencing, similar to the role of methylation in maintaining the silencing of CpG island genes on the inactive X chromosome. We propose that gene silencing is the critical precursor in cancer, as it changes the dynamic interplay between de novo methylation and demethylation of the CpG island and tilts the balance to favour hypermethylation and chromatin inactivation.	CSIRO Mol Sci, Sydney Lab, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; Univ Sydney, Fac Med, Sydney, NSW 2050, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; University of Sydney	Clark, SJ (corresponding author), CSIRO Mol Sci, Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.		Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030				Aggerholm A, 1999, CANCER RES, V59, P436; Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; BELINSKY SA, 1996, P NATL ACAD SCI USA, V93, P4054; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Ehrlich M, 2000, J CLIN LIGAND ASSAY, V23, P144; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Huschtscha LI, 1998, CANCER RES, V58, P3508; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jost JP, 1997, NUCLEIC ACIDS RES, V25, P4545, DOI 10.1093/nar/25.22.4545; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MOLLOY PL, 1990, PHILOS T ROY SOC B, V326, P267, DOI 10.1098/rstb.1990.0010; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1987, DEVELOPMENT, V99, P371; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Noble JR, 1996, ONCOGENE, V13, P1259; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Schmutte C, 1996, CANCER RES, V56, P2375; Schwarz S, 2000, EUR J CELL BIOL, V79, P488, DOI 10.1078/0171-9335-00070; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849; Stirzaker C, 1997, CANCER RES, V57, P2229; THAYER RE, 1993, GENE, V133, P273, DOI 10.1016/0378-1119(93)90651-I; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	71	234	244	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5380	5387		10.1038/sj.onc.1205598	http://dx.doi.org/10.1038/sj.onc.1205598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154400	Bronze			2022-12-28	WOS:000177197700004
J	Karpf, AR; Jones, DA				Karpf, AR; Jones, DA			Reactivating the expression of methylation silenced genes in human cancer	ONCOGENE			English	Article						DNA methylation; cancer; 5-aza-2 '-deoxycytidine; DNA methyltransferase	DNA METHYLATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSOR; DRUG-RESISTANCE; MAMMALIAN-CELLS; GENOMIC DNA; METHYLTRANSFERASE; BINDING; DEMETHYLATION; PROTEINS	DNA methylation alterations are now widely recognized as a contributing factor in human tumorigenesis. A significant number of tumor suppressor genes are transcriptionally silenced by promoter hypermethylation, and recent research implicates alterations in chromatin structure as the mechanistic basis for this repression. The enzymes responsible for catalyzing DNA-cytosine methylation, as well as the proteins involved in interpreting the DNA methylation signal, have now been elucidated. Technological advances, including gene expression microarrays and genome scanning techniques, have allowed the comprehensive measurement of DNA methylation changes in human cancers. An important distinction between DNA methylation (epigenetic) and mutation or deletion (genetic) tumor suppressor gene inactivation is that epigenetic inactivation can be abrogated by small molecules, including DNA methyltransferase and histone deacetylase inhibitors. Further, strategies have been developed that combine treatments with drugs that reactivate silenced gene expression with secondary agents that target the re-expressed genes and/or reconstituted signal transduction pathways. In this review, we will discuss in detail the mechanisms of gene silencing by DNA methylation, the techniques used to decipher the complement of methylation-inactivated genes in human cancers, and current and future strategies for reactivating the expression of methylation-silenced genes.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Karpf, AR (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	adam.karpf@hci.utah.edu; david.jones@hci.utah.edu		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [P01-CA73992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Albanesi T, 1999, MUTAT RES-FUND MOL M, V429, P239, DOI 10.1016/S0027-5107(99)00112-8; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bender CM, 1998, PHARM RES-DORDR, V15, P175, DOI 10.1023/A:1011946030404; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 1996, J GASTROEN HEPATOL, V11, P1079, DOI 10.1111/j.1440-1746.1996.tb00040.x; FEINBERG AP, 1988, CANCER RES, V48, P1159; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jones DA, 2001, CLIN CANCER RES, V7, p3827S; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LESHIN M, 1985, P NATL ACAD SCI USA, V82, P3005, DOI 10.1073/pnas.82.9.3005; Liang G, 2002, CANCER RES, V62, P961; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Neidhart M, 2000, ARTHRITIS RHEUM-US, V43, P2634, DOI 10.1002/1529-0131(200012)43:12<2634::AID-ANR3>3.0.CO;2-1; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plumb JA, 2000, CANCER RES, V60, P6039; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wang R, 1998, CHINESE MED J-PEKING, V111, P339; WEBER J, 1994, CANCER RES, V54, P1766; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yan PS, 2001, CANCER RES, V61, P8375; Yan PS, 2000, CLIN CANCER RES, V6, P1432	66	219	249	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5496	5503		10.1038/sj.onc.1205602	http://dx.doi.org/10.1038/sj.onc.1205602			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154410				2022-12-28	WOS:000177197700014
J	Kim, KM; Shibata, D				Kim, KM; Shibata, D			Methylation reveals a niche: stem cell succession in human colon crypts	ONCOGENE			English	Article						colorectal cancer; progression; stem cells; niche; crypt	COLORECTAL-CANCER; SOMATIC MUTATION; DNA METHYLATION; CPG-ISLAND; EVOLUTION; DEFICIENCY; PATTERNS; P53; TUMORIGENICITY; SUPPRESSION	Little it known about human stem cells although they are likely to be the earliest progenitors of carcinomas. Just as methylation can substitute for mutations to inactivate tumor suppressor genes, methylation can also substitute for mutations in a phylogenetic analysis. This review explains why stem cell dynamics may be important to tumor progression and how methylation patterns found in a normal human colon can be used to reconstruct the behavior of crypt stem cells. Histories are recorded in sequences and strategies used to reconstruct phylogenies from sequences likely apply to methylation patterns because both exhibit somatic inheritance. Such a quantitative analysis of colon methylation patterns infers stem cells live in niches containing multiple 'stem' cells. Although niche stem cell numbers remain constant, clonal succession is inherent to niches because periodically progeny from a single stem cell become dominant. These niche succession cycles may potentially accumulate multiple alterations because they resemble superficially the clonal succession of tumor progression except that they occur invisibly in the absence of selection or phenotypic change. Alterations without immediate selective value may hitchhike passively in the stem cells that become dominant during niche succession cycles. The inherent ability of a niche to fix alterations (Muller's ratchet) is another potential mechanism besides instability and selection to sequentially accumulate multiple alterations. Many alterations found in colorectal tumors may reflect such occult clonal progression in normal colon.	Univ So Calif, Sch Med, Norris Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA	University of Southern California	Shibata, D (corresponding author), 1200 N State St,Unit 1,Room 2428, Los Angeles, CA 90033 USA.				NIDDK NIH HHS [DK 61140] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK061140] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1998, CANCER RES, V58, P5489; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Campbell F, 1996, GUT, V39, P569, DOI 10.1136/gut.39.4.569; Chao L, 1997, GENE, V205, P301, DOI 10.1016/S0378-1119(97)00405-8; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARKE AR, 1995, ONCOGENE, V11, P1913; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELSENSTEIN J, 1974, GENETICS, V78, P737; FOULDS L, 1954, CANCER RES, V14, P327; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LOEB LA, 1991, CANCER RES, V51, P3075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARK HS, 1995, AM J PATHOL, V147, P1416; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Pearson H, 2002, NATURE, V415, P8, DOI 10.1038/415008a; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Ro S, 2001, P NATL ACAD SCI USA, V98, P10519, DOI 10.1073/pnas.201405498; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; SMITH JM, 1990, NATURE, V348, P391, DOI 10.1038/348391a0; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; WILLIAMS ED, 1992, AM J PATHOL, V141, P773; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998	47	83	90	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5441	5449		10.1038/sj.onc.1205604	http://dx.doi.org/10.1038/sj.onc.1205604			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154406				2022-12-28	WOS:000177197700010
J	Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR				Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR			Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant	ONCOGENE			English	Article						multidrug resistance; caspases; apoptosis; proteinase-3; leukemia; doxorubicin	FLOW-CYTOMETRIC DETECTION; CYTOCHROME-C; REACTIVE OXYGEN; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; MULTIDRUG RESISTANCE; GROWTH ARREST; TUMOR-CELLS; BCR-ABL; ACTIVATION	We report here that expression or proteinase 3 (PR3), a serine protease, is down-regulated in the HL60/ADR multidrug resistant variant of the human myelogenous leukemia cell line HL-60, and that down-regulation of PR3 is associated with doxorubicin (DOX) resistance in these cells. To determine whether PR3 is involved in DOX-induced apoptosis in HL-60 cells, and whether its loss causes resistance to DOX, we inhibited PR3 expression by an anti-sense PR3 oligodeoxynucleotide and showed that inhibition of PR3 expression results in a significant reduction in DOX-induced DNA fragmentation and increased resistance to DOX-induced apoptosis. Our results revealed that PR3-mediated DOX-induced apoptosis in HL-60 cells is independent of the loss of mitochondrial membrane potential (AT) and activation of the caspase-8 and -9 pathways. Moreover, while PR3 is involved in the cleavage of caspase-3, PR3-mediated DOX-induced DNA fragmentation and apoptosis were not prevented by a specific inhibitor of caspase-3. These data suggest that activation of caspase-3 alone is not sufficient to trigger PR3-mediated DOX-induced apoptosis. Treatment with an anti-PR3 oligomer significantly decreased reactive oxygen species (ROS) generation in cells treated with low concentrations of DOX, revealing a role for PR3 in enhancing production of DOX-induced ROS. Moreover, DOX-induced apoptosis at 0.001 - 0.01 muM was only inhibited in HL-60 cells pre-treated with the antioxidant N-acetyl-cysteine in the absence of anti-PR3, revealing that DOX-induced apoptosis in these cells is PR3- and ROS-dependent. Our results show that Ill is involved in DOX-induced ROS-dependent apoptosis and that its loss is associated with resistance to DOX in HL-60 cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734, R01CA056078, R01CA090878] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56078, CA 80734, CA 90878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arrigo AP, 1998, BIOL CHEM, V379, P19; Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Bauer G, 2000, ANTICANCER RES, V20, P4115; Bauer V, 1999, GEN PHYSIOL BIOPHYS, V18, P7; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAMPOS L, 1993, BLOOD, V81, P3091; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHEN T, 1994, BIOCHEM BIOPH RES CO, V200, P1130, DOI 10.1006/bbrc.1994.1568; Decaudin D, 1997, CANCER RES, V57, P62; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; Harper L, 2001, KIDNEY INT, V59, P1729, DOI 10.1046/j.1523-1755.2001.0590051729.x; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hirsch T, 1998, J IMMUNOL, V161, P35; Hishita T, 2001, CANCER RES, V61, P2878; HOIDAL JR, 1994, METHOD ENZYMOL, V244, P61; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Horman S, 2000, CELL PROLIFERAT, V33, P331, DOI 10.1046/j.1365-2184.2000.00188.x; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LABBAYE C, 1993, BLOOD, V81, P475; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li X, 2000, EXP CELL RES, V257, P290, DOI 10.1006/excr.2000.4901; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Mayet WJ, 1997, EUR J CLIN INVEST, V27, P893, DOI 10.1046/j.1365-2362.1997.2160771.x; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Morano KA, 1999, GENE EXPRESSION, V7, P271; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; RAO NV, 1991, J BIOL CHEM, V266, P9540; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Safa AR, 1998, METHOD ENZYMOL, V292, P289; Schwarting A, 2000, KIDNEY INT, V57, P2412, DOI 10.1046/j.1523-1755.2000.00100.x; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SLAPERCORTENBACH ICM, 1988, BLOOD, V72, P1639; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; Sun JY, 1998, J IMMUNOL METHODS, V211, P111, DOI 10.1016/S0022-1759(97)00203-2; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taekema-Roelvink MEJ, 1998, SCAND J IMMUNOL, V48, P37; Tammariello SP, 2000, J NEUROSCI, V20; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wong TWL, 2000, LIFE SCI, V67, pPL1111; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; Wu CH, 2001, ONCOGENE, V20, P7006, DOI 10.1038/sj.onc.1204893; Yang JJ, 2001, AM J PATHOL, V158, P581, DOI 10.1016/S0002-9440(10)64000-X; Yang JJ, 1996, AM J PATHOL, V149, P1617; Zimber A, 2000, CANCER RES, V60, P672	75	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5160	5174		10.1038/sj.onc.1205639	http://dx.doi.org/10.1038/sj.onc.1205639			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140766				2022-12-28	WOS:000176975900014
J	Gery, S; Sawyers, CL; Agus, DB; Said, JW; Koeffler, HP				Gery, S; Sawyers, CL; Agus, DB; Said, JW; Koeffler, HP			TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen-regulated; epidermal growth factor; follistatin and antiproliferative	EPIDERMAL GROWTH-FACTOR; TRANSMEMBRANE PROTEIN; TYROSINE KINASE; RECEPTOR GENE; EXPRESSION; PROGRESSION; FOLLISTATIN; IDENTIFICATION; TRANSCRIPTION; INDEPENDENCE	We have identified a gene that is highly expressed in the androgen-dependent prostate cancer cell line, LNCaP. Sequence analysis revealed that it was identical to a recently cloned gene designated TMEFF2, which encodes a transmembrane protein containing an epidermal growth factor (EGF)-like motif and two follistatin domains. This gene was highly expressed only in primary samples of normal prostate and prostate cancer as well as normal brain. Expression of the gene was controlled by androgen as shown by dihydrotestosterone markedly increasing TMEFF2 expression in LNCaP cells. Also, androgen-dependent human prostate cancer xenografts (CWR22) expressed high levels of TMEFF2 and these levels markedly decreased by day 10 after castration of the mice. Furthermore, a large number of androgen-dependent xenografts (CWR22, LuCaP-35, LAPC-4AD, LAPC-9AD) exhibited higher levels of TMEFF2 mRNA than androgen-independent xenografts (CWR22R, LAPC-3AI, LAPC-4AI, LAPC-9AI). Ectopic expression of TMEFF2 in DU145 and PC3 cells resulted in their prominent inhibition of growth. Taken together, the results demonstrate that TMEFF2 is a androgen-regulated gene, which can suppress growth of prostate cancer cells and our xenograft data show that escape of prostate cancer cells from androgen modulation causes them to decrease their expression of this gene, which may result in their more malignant behavior.	Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Ctr Hlth Sci, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gery, S (corresponding author), Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Sawyers, Charles/G-5327-2016	Agus, David B./0000-0002-7499-7822	NCI NIH HHS [CA26038-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Amler LC, 2000, CANCER RES, V60, P6134; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Benedit P, 2001, ONCOGENE, V20, P1455, DOI 10.1038/sj.onc.1204233; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Chen TS, 2000, CANCER RES, V60, P2132; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; Gregory CW, 1998, CANCER RES, V58, P5718; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; HSIEH TY, 1996, BIOCHEM BIOPH RES CO, V2231, P141; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lau KM, 2000, CANCER RES, V60, P3175; Liang GN, 2000, CANCER RES, V60, P4907; Millikan LE, 1999, CLIN DERMATOL, V17, P353, DOI 10.1016/S0738-081X(99)00018-8; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Russell PJ, 1998, CLIN CHEM, V44, P705; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; VELDSCHOLTE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P187, DOI 10.1016/0167-4889(90)90075-O; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Xu JC, 2001, CANCER RES, V61, P1563; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298; Zhao XY, 2001, STEROIDS, V66, P293, DOI 10.1016/S0039-128X(00)00164-1; Zitzelsberger H, 2001, BRIT J CANCER, V84, P202, DOI 10.1054/bjoc.2000.1533	34	57	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4739	4746		10.1038/sj.onc.1205142	http://dx.doi.org/10.1038/sj.onc.1205142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101412				2022-12-28	WOS:000176716300003
J	Kartasheva, NN; Contente, A; Lenz-Stoppler, C; Roth, J; Dobbelstein, M				Kartasheva, NN; Contente, A; Lenz-Stoppler, C; Roth, J; Dobbelstein, M			p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop	ONCOGENE			English	Article						apoptosis; mdm2; p53; p73; promoter	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; LARGE T-ANTIGEN; WILD-TYPE P53; DNA-BINDING; P73 GENE; ADENOVIRUS TYPE-5; TRANSCRIPTION ANALYSES; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS	The p53 tumor suppressor protein activates transcription and induces cell death. A close homologue of p53, termed p73, is expressed in transactivating (TA) forms that induce growth arrest and apoptosis much like p53. However, the p73 gene contains a second promoter, giving rise to the expression of p73DeltaN, a species of p73 proteins that lack the N-terminal transactivation domain. We show here that the expression of p73DeltaN is induced by p53 on the mRNA and protein level. The promoter that regulates p73DeltaN expression in human cells was cloned and found to be activated by p53, as well as by p73TA, directly through a specific DNA element. The p73DeltaN proteins, that are thereby expressed, bound to p53-responsive promoter DNA, competed with p53 for DNA binding, antagonized the activation of transcription by p53, and prevented p53-induced cell death. In addition, a transcriptional repressor domain was identified within the splicing variant p73DeltaNalpha. The combination of p73DeltaNalpha and mdm2 antagonized p53 more strongly than either p73Nalpha or mdm2 alone. Blocking endogenous p73DeltaN by a trans dominant fragment, or its removal by siRNA, increased the activity of a p53-responsive promoter in cells that contain a wild type p53 gene. Thus, the induction of p73DeltaN expression by p53 establishes an autoregulatory feedback loop that keeps the trigger of cell death under tight control.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Marburg, Abt Gastroenterol & Stoffwechsel, D-35043 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Philipps University Marburg; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Arita D, 1997, JPN J CANCER RES, V88, P39, DOI 10.1111/j.1349-7006.1997.tb00299.x; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BIEDLER JL, 1973, CANCER RES, V33, P2643; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Koch P, 2001, CANCER RES, V61, P5941; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nishi H, 1999, INT J ONCOL, V15, P1149; Nomoto S, 1998, CANCER RES, V58, P1380; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prabhu NS, 1998, INT J ONCOL, V13, P5; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; RUTZKY LP, 1980, CANCER RES, V40, P1443; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	76	123	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4715	4727		10.1038/sj.onc.1205584	http://dx.doi.org/10.1038/sj.onc.1205584			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101410				2022-12-28	WOS:000176716300001
J	Taniguchi, K; Roberts, LR; Aderca, IN; Dong, XY; Qian, CP; Murphy, LM; Nagorney, DM; Burgart, LJ; Roche, PC; Smith, DI; Ross, JA; Liu, WG				Taniguchi, K; Roberts, LR; Aderca, IN; Dong, XY; Qian, CP; Murphy, LM; Nagorney, DM; Burgart, LJ; Roche, PC; Smith, DI; Ross, JA; Liu, WG			Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas	ONCOGENE			English	Article						AXIN1; AXIN2; beta-catenin; mutations; hepatoblastoma; hepatocellular carcinoma	FUNCTIONAL INTERACTION; SOMATIC MUTATIONS; HEPATITIS-B; GENE; EXPRESSION; PATHWAY; CANCER; VIRUS; HEPATOCARCINOGENESIS; ACTIVATION	Activation of Wnt signaling through P-catenin mutations contributes to the development of hepatocellular carcinoma (HCC) and hepatoblastoma (HB). To explore the contribution of additional Wnt pathway molecules to hepatocarcinogenesis, we examined beta-catenin, AXIN1 and AXIN2 mutations in 73 HCCs and 27 HBs. beta-catenin mutations were detected in 19.2% (14 out of 73) HCCs and 70.4% (19 out of 27) HBs. beta-catenin mutations in HCCs were primarily point mutations, whereas more than half of the HBs had deletions. AXIN1 mutations occurred in seven (9.6%) HCCs and two (7.4%) HBs. The AXIN1 mutations included seven missense mutations, a I bp deletion, and a 12 bp insertion. The predominance of missense mutations found in the AXIN1 gene is different from the small deletions or nonsense mutations described previously. Loss of heterozygosity at the AXIN1 locus was present in four of five informative HCCs with AXIN1 mutations, suggesting a tumor suppressor function of this gene. AXIN2 mutations were found in two (2.7%) HCCs but not in HBs. Two HCCs had both AXIN1 and beta-catenin mutations, and one HCC had both AXIN2 and beta-catenin mutations. About half the HCCs with AXIN1 or AXIN2 mutations showed beta-catenin accumulation in the nucleus, cytoplasm or membrane. Overall, these data indicate that besides the approximately 20% of HCCs and 80% of HBs with beta-catenin mutations contributing to hepatocarcinogenesis, AXIN1 and AXIN2 mutations appear to be important in an additional 10% of HCCs and HBs.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA; Univ Minnesota, Ctr Canc, Dept Pediat, Minneapolis, MN 55455 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.			Roberts, Lewis/0000-0001-7885-8574	NCI NIH HHS [CA82862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA082862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Dahmen RP, 2001, CANCER RES, V61, P7039; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dong X, 2001, CYTOGENET CELL GENET, V93, P26, DOI 10.1159/000056942; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Hui AM, 1999, SCAND J GASTROENTERO, V34, P737; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Koch A, 1999, CANCER RES, V59, P269; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mai M, 1999, GENOMICS, V55, P341, DOI 10.1006/geno.1998.5650; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyoshi Y, 1998, CANCER RES, V58, P2524; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Raney B, 1997, J PEDIAT HEMATOL ONC, V19, P418, DOI 10.1097/00043426-199709000-00002; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Wu R, 2001, CANCER RES, V61, P8247; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	32	376	406	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4863	4871		10.1038/sj.onc.1205591	http://dx.doi.org/10.1038/sj.onc.1205591			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101426				2022-12-28	WOS:000176716300017
J	Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y				Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y			Restoration of E-cadherin-based cell-cell adhesion by overexpression of nectin in HSC-39 cells, a human signet ring cell gastric cancer cell line	ONCOGENE			English	Article						nectin; afadin; cadherin; catenin; cell-cell adhesion	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; JUNCTIONAL COMPLEX; ADHERENS JUNCTION; EPITHELIAL-CELLS; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; STRUCTURAL BASIS	Nectin is an immunoglobulin-like adhesion molecule that comprises a family consisting of four members, nectin-1, -2, -3, and -4. Nectin is associated with the actin cytoskeleton through afadin, a nectin- and actin filament-binding protein. The nectin-afadin and cadherin-catenin systems are associated with each other and cooperatively form cell-cell adherens junctions in intact epithelial cells. HSC-39 cells, a human signet ring cell gastric cancer cell line, express E-cadherin but do not form cell-cell adhesion. The beta-catenin gene has been shown to be truncated at the N-terminal region including the alpha-catenin-binding domain in HSC-39 cells, but overexpression of normal beta-catenin failed to form cell-cell adhesion. HSC-39 cells expressed nectin-1, -2, and afadin, but not nectin-3. Overexpression of nectin-3 or -2 formed cell-cell adhesion and accumulation of E-cadherin, but not actin filaments, at the cell-cell adhesion sites. Overexpression of a truncated form of nectin-2 incapable of interacting with afadin failed to form cell-cell adhesion. However, the nectin-formed cell-cell adhesion was not so strong as that observed in epithelial cells, such as CaCo-2 cells. Co-expression of nectin-2 and normal beta-catenin did not form strong cell-cell adhesion. These results suggest that an unidentified mechanism, by which nectin and E-cadherin form the actin cytoskeleton-associated adherens junctions to form strong cell-cell adhesion, is impaired in HSC-39 cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Hirakata, Osaka 5730101, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan	Osaka University; Osaka University; Setsunan University; National Cancer Center - Japan; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Takeichi, Masatoshi/G-5903-2012; Ikeda, Wataru/V-8531-2019	Takeichi, Masatoshi/0000-0002-9931-3378; Ikeda, Wataru/0000-0002-6907-9058; Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ADAMSON ED, 1990, DEV BIOL, V138, P338, DOI 10.1016/0012-1606(90)90201-S; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kemler R, 1992, Semin Cell Biol, V3, P149; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M, 2000, J CELL SCI, V113, P2207; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127	58	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4108	4119		10.1038/sj.onc.1205517	http://dx.doi.org/10.1038/sj.onc.1205517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037667	Bronze			2022-12-28	WOS:000176186000005
J	Mukasa, A; Ueki, K; Matsumoto, S; Tsutsumi, S; Nishikawa, R; Fujimaki, T; Asai, A; Kirino, T; Aburatani, H				Mukasa, A; Ueki, K; Matsumoto, S; Tsutsumi, S; Nishikawa, R; Fujimaki, T; Asai, A; Kirino, T; Aburatani, H			Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p	ONCOGENE			English	Article						oligodendroglioma; oligonucleotide microarray; loss of heterozygosity	DRUG-RESISTANCE GENES; MUTATION; IDENTIFICATION; HYBRIDIZATION; CHEMOTHERAPY; ASTROCYTOMAS; CHROMOSOME-1; ORGANIZATION; MICROARRAYS; REGIONS	Oligodendrogliomas frequently, but not always show sensitivity to chemotherapy and recent studies demonstrated that allelic loss of chromosome 1p is highly associated with this chemosensitivity. To gain insight into the molecular mechanism of such difference, we examined comprehensive gene expression profiles of 11 oligodendroglial tumors, six with and five without 1pLOH (loss of heterozygosity), and two normal brain tissues using the oligonucleotide microarray (GeneChip). Statistically significant numbers of genes were expressed differentially between the two genetic subsets. Clustering analysis separated the tumor subsets well. The tumors with 1pLOH had similar expression profiles to the normal brain for those differentially expressed genes. Many genes showing higher expression in tumors with 1pLOH were presumed to have functions in nervous tissues. Notably, the majority of the 123 genes showing significant expression reduction in tumors with 1PLOH were either on chromosome 1 (50%) or on 19 (10%), and the average expression reduction ratio was about 50% (0.54 +/- 0.13) possibly reflecting the chromosomal deletion. Thus, the biological difference between the genetic subsets of oligodendroglioma was indeed reflected to gene expression profile, which provided baseline information for further studies to elucidate the mechanism of chemosensitivity in gliomas.	Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; Saitama Med Sch, Dept Neurosurg, Moroyama, Saitama 3500495, Japan; Teikyo Univ, Sch Med, Dept Neurosurg, Itabashi Ku, Tokyo 1738606, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Teikyo University; Japan Science & Technology Agency (JST)	Aburatani, H (corresponding author), Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Mukasa, Akitake/H-7615-2019	Mukasa, Akitake/0000-0001-7776-9086				Bigner SH, 1999, AM J PATHOL, V155, P375, DOI 10.1016/S0002-9440(10)65134-6; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FULTS D, 1992, CANCER RES, V52, P674; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Huang HT, 2000, CANCER RES, V60, P6868; Husemann K, 1999, J NEUROPATH EXP NEUR, V58, P1041, DOI 10.1097/00005072-199910000-00002; Ino Y, 2001, CLIN CANCER RES, V7, P839; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; Kleihues P, 2000, PATHOLOGY GENETICS T; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Nutt CL, 2000, CANCER RES, V60, P4812; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Tanaka S, 2000, J NEURO-ONCOL, V46, P157, DOI 10.1023/A:1006399903635; Ueki K, 1996, CANCER RES, V56, P150; Ueki K, 2002, CLIN CANCER RES, V8, P196; Watson MA, 2001, CANCER RES, V61, P1825	28	68	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					3961	3968		10.1038/sj.onc.1205495	http://dx.doi.org/10.1038/sj.onc.1205495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037678				2022-12-28	WOS:000175869900002
J	Chikatsu, N; Nakamura, Y; Sato, H; Fujita, T; Asano, S; Motokura, T				Chikatsu, N; Nakamura, Y; Sato, H; Fujita, T; Asano, S; Motokura, T			p53 mutations and tetraploids under r- and K-selection	ONCOGENE			English	Article						p53; r-selection; K-selection; multistep tumorigenesis	ACTIVATED RAS ONCOGENE; EMBRYO FIBROBLASTS; NEOPLASTIC TRANSFORMATION; MAMMALIAN-CELLS; GENE-EXPRESSION; MUTATED P53; DNA; CARCINOGENESIS; OVEREXPRESSION; TRANSCRIPTION	Cotransfection of rat embryo fibroblasts with c-myc and activated H-ras oncogenes is one experimental model of the multistep oncogenesis associated with p53 mutations and aneuploidy. Using the model, we found that selection processes, e.g., r- and K-selection, affect emergence of p53 mutants and tetraploids. Culture optimum for logarithmic growth (r-selection) selected p53 mutants as they proliferated rapidly, while in confluent culture (K-selection) tetraploids emerged regardless of the p53 status. Transfection of the mutated p53 gene with dominant negative functions eradicated untransfected cells under both r- and K-selection. However, these p53 mutants can be eradicated under K-selection by cells with normal p53 function and that had been selected under prolonged K-selection. The presence of competitors and the type of selection should determine whether or not p53 mutants and/or tetraploids predominate. These observations strengthen the importance of selection processes in case of cancer.	Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, Tokyo 1128688, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Motokura, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, 3-28-6 Mejirodai, Tokyo 1128688, Japan.	motokura-tky@umin.ac.jp	Motokura, Toru/X-3682-2019					Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; CAVALIERSMITH T, 1980, BIOSYSTEMS, V12, P43, DOI 10.1016/0303-2647(80)90037-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HARVEY M, 1993, ONCOGENE, V8, P2457; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MAC ARTHUR ROBERT H., 1967; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Motokura T, 1995, J BIOL CHEM, V270, P30857, DOI 10.1074/jbc.270.52.30857; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; SUGANO K, 1993, LAB INVEST, V68, P361; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965; Uchimaru K, 1998, LEUKEMIA RES, V22, P413, DOI 10.1016/S0145-2126(98)00004-6; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	28	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3043	3049		10.1038/sj.onc.1205413	http://dx.doi.org/10.1038/sj.onc.1205413			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082535				2022-12-28	WOS:000175262700012
J	Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ				Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ			RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	ONCOGENE			English	Article						E6; p53; Li-Fraumeni; mdm2; RNA polymerase III; transcription	WILD-TYPE P53; TATA-BINDING-PROTEIN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; HUMAN TUMORS; DNA-BINDING; REPRESSION; CANCER; GROWTH	RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA and 5S rRNA. Wild-type p53 can repress pol III transcription both in vitro and in vivo. Many tumours carry substitutions in p53 which have selective effects on its functions. We identify tumour-derived mutations that compromise the ability of p53 to regulate pol III transcription. Furthermore, substitution R175H, the most common mutation in cancers, converts p53 from a repressor to an activator of pol III. Oncoproteins neutralize p53 in some tumours; we show that human papillomavirus E6 and cellular hdm2 can both release pol III from repression by p53. These data suggest that the restraining influence of p53 on pol III will be lost in many tumours. In addition to these features of sporadic cancers, some individuals inherit mutant forms of p53 and consequently suffer from Li-Fraumeni syndrome, showing genetic predisposition to certain malignancies. We find that pol III transcriptional activity is often highly elevated in primary fibroblasts from Li-Fraumeni patients, especially if the germline p53 mutation is followed by loss of the remaining allele. Our data suggest that p53 status can have a profound effect upon pol III transcription and hence on the biosynthetic capacity of cells.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Paterson Inst Canc Res, Canc Res UK Dept Canc Genet, Manchester M20 9BX, Lancs, England	University of Glasgow; Paterson Institute for Cancer Research	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@bio.gla.ac.uk	Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONCHOWER LA, 1992, NATURE, V356, P215; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Eichhorn K, 2001, J BIOL CHEM, V276, P21158, DOI 10.1074/jbc.M102295200; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOH HS, 1995, CANCER RES, V55, P5217; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	87	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2961	2970		10.1038/sj.onc.1205372	http://dx.doi.org/10.1038/sj.onc.1205372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082526				2022-12-28	WOS:000175262700003
J	Nelson, HH; Kelsey, KT				Nelson, HH; Kelsey, KT			The molecular epidemiology of asbestos and tobacco in lung cancer	ONCOGENE			English	Article						lung cancer; asbestos; tobacco	PLEURAL MESOTHELIAL CELLS; SISTER-CHROMATID EXCHANGE; OXIDATIVE DNA-DAMAGE; K-RAS MUTATIONS; MAN-MADE FIBERS; CROCIDOLITE ASBESTOS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; HUMAN-LYMPHOCYTES; CEMENT WORKERS	Asbestos is a well-known toxin and lung carcinogen. Epidemiologic studies have established tobacco smoke and asbestos exposures synergistically interact to enhance lung cancer risk. The biologic mechanism responsible for this interaction has been the subject of considerable debate. Studies have suggested that asbestos may act as a carcinogen by generating free radical and reactive oxygen species, by inducing tissue injury and subsequent cellular growth, via large-scale chromosome loss and by enhancing delivery of tobacco carcinogens to the respiratory epithelium. Recent molecular epidemiologic approaches further suggest that asbestos enhances the mutagenicity of tobacco carcinogens and that it acts, at least in part, independent of the tissue damage responsible for fibrosis.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environ Epidemiol Program, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.	Kelsey@hsph.harvard.edu	Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [R01CA082354, R01CA057494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P42ES005947, P42ES007373] Funding Source: NIH RePORTER; NCI NIH HHS [CA57494, CA82354] Funding Source: Medline; NIEHS NIH HHS [ES0002, P42ES07373, P42ES5947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI S, 1994, CARCINOGENESIS, V15, P753, DOI 10.1093/carcin/15.4.753; ADACHI S, 1992, INT ARCH OCC ENV HEA, V63, P553, DOI 10.1007/BF00386345; AUERBACH O, 1979, CANCER, V43, P636, DOI 10.1002/1097-0142(197902)43:2<636::AID-CNCR2820430234>3.0.CO;2-7; AUERBACH O, 1984, CANCER, V54, P3017, DOI 10.1002/1097-0142(19841215)54:12<3017::AID-CNCR2820541233>3.0.CO;2-9; AULT JG, 1995, CANCER RES, V55, P792; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P637; BOTH K, 1994, INT J CANCER, V59, P538, DOI 10.1002/ijc.2910590417; Brodkin CA, 1997, AM J IND MED, V32, P582, DOI 10.1002/(SICI)1097-0274(199712)32:6<582::AID-AJIM2>3.0.CO;2-S; BROWN RC, 1983, ENVIRON HEALTH PERSP, V51, P315, DOI 10.2307/3429770; BROWNE K, 1986, BRIT J IND MED, V43, P145; Chao CC, 1996, ARCH BIOCHEM BIOPHYS, V326, P152, DOI 10.1006/abbi.1996.0059; Chen Q, 1996, CARCINOGENESIS, V17, P2525, DOI 10.1093/carcin/17.11.2525; CHURG A, 1995, AM J RESP CRIT CARE, V151, P1409, DOI 10.1164/ajrccm.151.5.7735593; CHURG A, 1985, JAMA-J AM MED ASSOC, V253, P2984, DOI 10.1001/jama.253.20.2984; COLE RW, 1991, CANCER RES, V51, P4942; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; deKlerk NH, 1996, OCCUP ENVIRON MED, V53, P157, DOI 10.1136/oem.53.3.157; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DONG HY, 1994, CARCINOGENESIS, V15, P1251, DOI 10.1093/carcin/15.6.1251; Donmez H, 1996, MUTAT RES-ENVIR MUTA, V361, P129, DOI 10.1016/S0165-1161(96)90247-2; DOPP E, 1995, ENVIRON HEALTH PERSP, V103, P268, DOI 10.2307/3432547; FATMA N, 1991, BRIT J IND MED, V48, P103; Fubini B, 1995, TOXICOL LETT, V82-3, P951, DOI 10.1016/0378-4274(95)03531-1; Fung H, 1997, CARCINOGENESIS, V18, P825, DOI 10.1093/carcin/18.4.825; GERDE P, 1988, BRIT J IND MED, V45, P682; GERDE P, 1989, ENVIRON HEALTH PERSP, V79, P249; GOODGLICK LA, 1986, CANCER RES, V46, P5558; HEI TK, 1992, CANCER RES, V52, P6305; HEI TK, 1995, CARCINOGENESIS, V16, P1573, DOI 10.1093/carcin/16.7.1573; HESTERBERG TW, 1985, CARCINOGENESIS, V6, P473, DOI 10.1093/carcin/6.3.473; HILLERDAL G, 1983, BRIT J IND MED, V40, P380; HIRAO T, 2002, IN PRESS CARCINOGENE; HOURIHANE DO, 1966, POSTGRAD MED J, V42, P613, DOI 10.1136/pgmj.42.492.613; Huncharek Michael, 1993, Journal of Public Health Policy, V14, P51, DOI 10.2307/3342826; Husgafvel-Pursiainen K, 1999, AM J RESP CELL MOL, V20, P667, DOI 10.1165/ajrcmb.20.4.3404; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; HUSGAFVELPURSIAINEN K, 1995, J OCCUP ENVIRON MED, V37, P69, DOI 10.1097/00043764-199501000-00010; HUUSKONEN MS, 1978, SCAND J WORK ENV HEA, V4, P265, DOI 10.5271/sjweh.2699; JACOB G, 1965, ANN NY ACAD SCI, V132, P536, DOI 10.1111/j.1749-6632.1965.tb41134.x; JAURAND MC, 1986, MUTAT RES, V169, P141, DOI 10.1016/0165-1218(86)90093-5; Jensen CG, 1996, CARCINOGENESIS, V17, P2013, DOI 10.1093/carcin/17.9.2013; JOHANSSON L, 1992, BRIT J IND MED, V49, P626; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; KANNERST.M, 1972, CANCER, V30, P14, DOI 10.1002/1097-0142(197207)30:1<14::AID-CNCR2820300104>3.0.CO;2-9; KARJALAINEN A, 1993, SCAND J WORK ENV HEA, V19, P102, DOI 10.5271/sjweh.1490; KARJALAINEN A, 1994, SCAND J WORK ENV HEA, V20, P243, DOI 10.5271/sjweh.1401; Kazan-Allen L, 2001, INT J HEALTH SERV, V31, P481, DOI 10.2190/R5WM-Q78P-E5XQ-34E8; Kim DH, 2001, CANCER RES, V61, P3419; KODAMA Y, 1993, CARCINOGENESIS, V14, P691, DOI 10.1093/carcin/14.4.691; KORKINA LG, 1992, MUTAT RES, V265, P245, DOI 10.1016/0027-5107(92)90053-5; LAKOWICZ JR, 1980, BIOCHIM BIOPHYS ACTA, V629, P243, DOI 10.1016/0304-4165(80)90098-7; Lee BW, 1998, AM J RESP CRIT CARE, V157, P748, DOI 10.1164/ajrccm.157.3.9707025; LILIS R, 1991, AM J IND MED, V20, P145, DOI 10.1002/ajim.4700200203; Liu BC, 1998, BIOMED ENVIRON SCI, V11, P226; LUND LG, 1992, CARCINOGENESIS, V13, P637, DOI 10.1093/carcin/13.4.637; MAPLES KR, 1992, CARCINOGENESIS, V13, P2035, DOI 10.1093/carcin/13.11.2035; Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X; MARCZYNSKI B, 1994, HUM EXP TOXICOL, V13, P3, DOI 10.1177/096032719401300102; MENRAD H, 1986, ENVIRON RES, V40, P84; MOLLO F, 1995, INT J CANCER, V60, P289; MOSSMAN B, 1983, ANNU REV PHARMACOL, V23, P595, DOI 10.1146/annurev.pa.23.040183.003115; MOSSMAN BT, 1986, LAB INVEST, V54, P204; MurataKamiya N, 1997, INT ARCH OCC ENV HEA, V70, P321, DOI 10.1007/s004200050225; NEJJARI A, 1993, BRIT J IND MED, V50, P501; Nelson HH, 1998, CANCER RES, V58, P1804; Nelson HH, 1999, CANCER RES, V59, P4570; NUORVA K, 1994, AM J RESP CRIT CARE, V150, P528, DOI 10.1164/ajrccm.150.2.8049841; Okayasu R, 1999, BRIT J CANCER, V79, P1319, DOI 10.1038/sj.bjc.6690213; PALEKAR LD, 1987, CARCINOGENESIS, V8, P553, DOI 10.1093/carcin/8.4.553; Park SH, 1998, CANCER RES, V58, P1144; Pylkkanen L, 2002, INT J ONCOL, V20, P285; RAFFN E, 1993, BRIT J IND MED, V50, P85; ROM WN, 1983, JNCI-J NATL CANCER I, V70, P45; ROM WN, 1998, ENV OCCUPATIONAL MED, P349; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; RUSSI MB, 1994, TXB CLIN OCCUPATIONA, P543; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; SCHAPIRA RM, 1994, AM J RESP CELL MOL, V10, P573, DOI 10.1165/ajrcmb.10.5.8179922; Sekhon H, 1995, INT J EXP PATHOL, V76, P411; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; SINCOCK A, 1975, NATURE, V257, P56, DOI 10.1038/257056a0; SOUTAR CA, 1974, BRIT J DIS CHEST, V68, P235; Takahashi, 1997, Int J Occup Environ Health, V3, P111; TAKEUCHI T, 1994, CARCINOGENESIS, V15, P635, DOI 10.1093/carcin/15.4.635; TALCOTT JA, 1988, CURR PROB CANCER, V12, P133; VAINIO H, 1994, SCAND J WORK ENV HEA, V20, P235, DOI 10.5271/sjweh.1402; VALERIO F, 1983, MUTAT RES, V122, P397, DOI 10.1016/0165-7992(83)90026-X; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543; WEISS W, 1988, J OCCUP ENVIRON MED, V30, P33; WEISS W, 1988, BRIT J IND MED, V45, P544; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; WHITWELL F, 1974, BRIT J IND MED, V31, P298; WILT J, 1998, OCCUPATIONAL LUNG DI, P119; Xu A, 1999, CANCER RES, V59, P5922; YEGLES M, 1993, AM J RESP CELL MOL, V9, P186, DOI 10.1165/ajrcmb/9.2.186; ZALMA R, 1987, CAN J CHEM, V65, P2338, DOI 10.1139/v87-390; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	97	53	56	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7284	7288		10.1038/sj.onc.1205804	http://dx.doi.org/10.1038/sj.onc.1205804			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379872				2022-12-28	WOS:000178618000002
J	Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP				Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP			Frequent hypermethylation of the RASSF1A gene in prostate cancer	ONCOGENE			English	Article						RASSF1A; methylation; tumor suppressor gene; prostate cancer	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; ANDROGEN RECEPTOR GENE; CPG ISLAND; EPIGENETIC INACTIVATION; METHYLATION PATTERNS; BREAST CANCERS; LUNG-CANCER; PROGRESSION; PROMOTER	Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7-10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.	Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Human Genet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA.				NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns P, 2001, CLIN CANCER RES, V7, P2727; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lerman MI, 2000, CANCER RES, V60, P6116; Li LC, 2000, CANCER RES, V60, P702; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lo KW, 2001, CANCER RES, V61, P3877; Marcelli M, 2000, CANCER RES, V60, P944; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Ozen M, 2000, ANTICANCER RES, V20, P1905; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Rokman A, 2001, CANCER RES, V61, P6038; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Singal R, 2001, CANCER RES, V61, P4820; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wang L, 2001, CANCER RES, V61, P6494; Wistuba II, 2000, CANCER RES, V60, P1949; Wu YQ, 2001, CANCER RES, V61, P8651; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	47	123	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6835	6840		10.1038/sj.onc.1205814	http://dx.doi.org/10.1038/sj.onc.1205814			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360410				2022-12-28	WOS:000178315800014
J	Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H				Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H			A scaffold protein in the c-Jun N-terminal kinase signaling pathway is associated with focal adhesion kinase and tyrosine-phosphorylated	ONCOGENE			English	Article						FAK; JSAP1; Src; tyrosine phosphorylation	PROMOTED CELL-MIGRATION; SRC FAMILY KINASES; NH2-TERMINAL KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; V-SRC; P130(CAS); FIBRONECTIN; ACTIVATION; AUTOPHOSPHORYLATION; INVOLVEMENT	Focal adhesion kinase (FAK) becomes activated and tyrosine-phosphorylated in response to cell adhesion to extracellular matrix proteins in a variety of cell types, and associates with a number of signaling molecules, structural proteins, and beta integrin cytoplasmic domains. Here we demonstrated that c-Jun N-terminal kinase (JNK)/stress activated protein kinase-associated protein 1 (JSAP1), a scaffold factor in the mitogen-activated protein kinase (MAPK) cascades, forms a complex with the N-terminus of FAK. The complex formation was further stimulated by c-Src, in which JSAP1 was tyrosine-phosphorylated and other FAK/Src signaling molecules were recruited. Fibronectin (FN) stimulation of cells expressing JSAP1 induced its tyrosine phosphorylation concomitant with association with FAK. Expression of JSAP1 in Hela cells facilitated formation of well-organized focal contacts and actin stress fibers, and promoted cell spreading onto FN. Taken together, these results suggest that JSAP1 is involved an integrin-mediated signaling pathway through FAK/Src by recruiting other signaling molecules, resulting in promotion of cell spreading onto FN.	Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Takino, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524, ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ito M, 1999, MOL CELL BIOL, V19, P7539; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	28	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6488	6497		10.1038/sj.onc.1205840	http://dx.doi.org/10.1038/sj.onc.1205840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226752	Green Submitted			2022-12-28	WOS:000177925300009
J	Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB				Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB			Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells	ONCOGENE			English	Article						Rheb; B-Raf kinase; MAP kinase; mammalian cells	EPIDERMAL GROWTH-FACTOR; SMALL GTPASES; A-RAF; PROTEIN; IDENTIFICATION; GENE; FIBROBLASTS; PATHWAY; YEAST; CAMP	Rheb (Ras homolog enriched in brain) is a member of the Ras family of proteins, and is in the immediate Ras/Rap/Ral subfamily. We found in three different mammalian cell lines that Rheb was highly activated, to levels much higher than for Ras or Rap 1, and that Rheb's activation state was unaffected by changes in growth conditions. Rheb's high activation was not secondary to unique glycine to arginine, or glycine to serine substitutions at positions 14 and 15, corresponding to Ras residues 12 and 13, since Rheb R14G and R14G, S15G mutants had similarly high activation levels as wild type Rheb. These data are consistent with earlier work which showed that purified Rheb has similar GTPase activity as Ras, and suggest a relative intracellular deficiency of Rheb GTPase activating proteins (GAPs) compared to Rheb activators. Further evidence for relatively low intracellular GAP activity was that increased Rheb expression led to a marked increase in Rheb activation. Rheb, like Ras and Rap1, bound B-Raf kinase, but in contrast to Ras and Rap 1, Rheb inhibited B-Raf kinase activity and prevented B-Raf-dependent activation of the transcription factor Elk-l. Thus, Rheb appears to be a unique member of the Ras/Rap/Ral subfamily, and in mammatian systems may serve to regulate B-Raf kinase activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115, R21CA076968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [CA81115, CA76968] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NIMH NIH HHS [MH53608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Guha A, 1996, ONCOGENE, V12, P507; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Mach KE, 2000, GENETICS, V155, P611; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; PAPIN C, 1995, ONCOGENE, V10, P1647; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TIAN W, 2000, AM J PHYSIOL, V278, P372; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	43	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6356	6365		10.1038/sj.onc.1205792	http://dx.doi.org/10.1038/sj.onc.1205792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214276				2022-12-28	WOS:000177829000012
J	Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H				Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H			Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells	ONCOGENE			English	Article						myosin II regulatory light chain; diphosphorylation; Rho-kinase; reorganization of actin filaments; nonmuscle cells	SMOOTH-MUSCLE MYOSIN; GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; FOCAL ADHESIONS; SERINE/THREONINE KINASE; PLATELET MYOSIN; CLEAVAGE FURROW; TUMOR-CELLS; HELA-CELLS; 2ND SITE	Phosphorylation of myosin 11 regulatory light chain (MRLC) is important for cell motility and cytokinesis in nonmuscle cells. Although the regulation of monophosphorylated MRLC at serine 19 throughout the cell cycle was examined in detail, MRLC diphosphorylation at both threonine 18 and serine 19 is still unclear. Here we found that Rho-kinase has an activity for MRLC diphosphorylation in nonmuscle cells using sequential column chromatographies. Transfection of Rho-kinase-EGFP induced the excess diphosphorylated MRLC and the bundling of the actin filaments. Conversely, the treatment of cells with a specific inhibitor of Rho-kinase, Y-27632, resulted in the decrease of endogenous diphosphorylated MRLC and actin stress fibers. Immunolocatization studies showed that both diphosphorylated MRLC and Rho-kinase accumulated and colocalized at the contractile ring and the midbody in dividing cells. Taken together, it is suggested that Rho-kinase contributes to MRLC diphosphorylation and reorganization of actin filaments in nonmuscle cells.	Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan; Hiroshima Univ, Dept Mol Radiobiol, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University	Hosoya, H (corresponding author), Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan.			Hamao, Kozue/0000-0002-9594-1940				Ai S, 2001, ATHEROSCLEROSIS, V155, P321, DOI 10.1016/S0021-9150(00)00585-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; APPLEGATE D, 1992, J CELL BIOL, V117, P1223, DOI 10.1083/jcb.117.6.1223; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Helige C, 1997, INVAS METAST, V17, P26; Hino M, 2000, BIOCHEM BIOPH RES CO, V271, P164, DOI 10.1006/bbrc.2000.2553; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kolega J, 1999, CELL MOTIL CYTOSKEL, V43, P255, DOI 10.1002/(SICI)1097-0169(1999)43:3<255::AID-CM8>3.0.CO;2-T; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Murata-Hori M, 1998, BIOMED RES-TOKYO, V19, P111, DOI 10.2220/biomedres.19.111; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suizu F, 2000, J BIOCHEM-TOKYO, V128, P435, DOI 10.1093/oxfordjournals.jbchem.a022771; TAKAISHI K, 1994, ONCOGENE, V9, P273; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	42	70	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5852	5860		10.1038/sj.onc.1205747	http://dx.doi.org/10.1038/sj.onc.1205747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185584				2022-12-28	WOS:000177520900004
J	Morotti, A; Mila, S; Accornero, P; Tagliabue, E; Ponzetto, C				Morotti, A; Mila, S; Accornero, P; Tagliabue, E; Ponzetto, C			K252a inhibits the oncogenic properties of Met, the HGF receptor	ONCOGENE			English	Article						K252a; Met; tyrosine kinase inhibitors; anticancer drugs	HEPATOCYTE GROWTH-FACTOR; ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; FACTOR SCATTER FACTOR; LIGAND-INDEPENDENT ACTIVATION; C-MET; GASTRIC-CARCINOMA; CELL-LINES; SELECTIVE INHIBITOR; POINT MUTATION	The ATP analog K252a is a potent inhibitor for receptor tyrosine kinases of the Trk family. Here we show that nanomolar concentrations of K252a prevent HGF-mediated scattering in MLP-29 cells (30 nM), reduce Met-driven proliferation in GTL-16 gastric carcinoma cells (100 nM), and cause reversion in NIH3T3 fibroblasts transformed by the oncogenic form of the receptor, Tpr-Met (75 nM). K252a inhibits Met autophosphorylation in cultured cells and in immunoprecipitates and prevents activation of its downstream effectors MAPKinase and Akt. Interestingly, K252a seems to be more effective at inhibiting the mutated form of Met (M1268T) found in papillary carcinoma of the kidney than the wild type receptor. Pretreatment of both Tpr-Met-transformed NIH3T3 fibroblasts and of GTL-16 gastric carcinoma cells with K252a results in loss of their ability to form lung metastases in nude mice upon injection into the caudal vein. These observations suggest that K252a derivatives, which are active in vivo as anti-cancer drugs in models of Trk-driven malignancies, should also be effective for treatment of Met-mediated tumors.	Univ Turin, Dept Anat Pharmacol & Forens Med, I-10126 Turin, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ponzetto, C (corresponding author), Univ Turin, Dept Anat Pharmacol & Forens Med, Cso Massimo Azeglio 52, I-10126 Turin, Italy.		Accornero, Paolo/B-1396-2008; Morotti, Alessandro/J-7590-2018	Morotti, Alessandro/0000-0002-8407-2903				Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; AKINAGA S, 1992, CANCER CHEMOTH PHARM, V29, P266, DOI 10.1007/BF00685943; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Camoratto AM, 1997, INT J CANCER, V72, P673, DOI 10.1002/(SICI)1097-0215(19970807)72:4<673::AID-IJC20>3.0.CO;2-B; Chin LS, 1997, CLIN CANCER RES, V3, P771; Cortner J, 1995, EXS, V74, P89; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Goldman JM, 2001, NEW ENGL J MED, V344, P1084, DOI 10.1056/NEJM200104053441409; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kaji M, 1996, CANCER GENE THER, V3, P393; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KOIZUMI S, 1988, J NEUROSCI, V8, P715; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; MATSUDA Y, 1988, J NEUROSCI LETT, V256, P11; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NYE SH, 1992, MOL BIOL CELL, V3, P667; OBEIDI FAA, 2000, ONCOGENE, V19, P5690; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CANCER RES, V53, P5355; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; TAPLEY P, 1992, ONCOGENE, V7, P371; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Yu J, 2000, CANCER-AM CANCER SOC, V88, P1801, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1801::AID-CNCR7>3.0.CO;2-U; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	50	129	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4885	4893		10.1038/sj.onc.1205622	http://dx.doi.org/10.1038/sj.onc.1205622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118367				2022-12-28	WOS:000176874800003
J	Kattmann, D; Klempnauer, KH				Kattmann, D; Klempnauer, KH			Identification and characterization of the Myb-inducible promoter of the chicken adenosine receptor 2B gene	ONCOGENE			English	Article						v-myb oncogene; target gene; A2B adenosine receptor; promoter	V-MYB; C-MYB; MYELOMONOCYTIC CELLS; C/EBP-BETA; TRANSCRIPTION FACTORS; MIM-1 GENE; SYNERGISTIC ACTIVATION; CELLULAR PROGENITOR; TRANS-ACTIVATION; PDCD4 GENE	Numerous studies have shown that the retroviral oncogene v-myb encodes a transcription factor (v-Myb) which interferes with the differentiation program of myelomonocytic cells. It is generally thought that v-Myb deregulates the expression of specific target genes and thereby causes transformation of these cells. By using an estrogen-inducible version of v-Myb we have previously identified the gene for the chicken A2B adenosine receptor (A2B-AR), a member of the seven-pass transmembrane receptor superfamily, as a bona fide target gene for v-Myb. The chicken A2B-AR gene is expressed in v-myb transformed myeloblasts as well as in c-myb expressing erythroblasts, offering the opportunity to study how Myb transcription factors activate a target gene in two different hematopoietic lineages. Here, we report the characterization of the promoter of the A2B-AR gene. We show that the A2B-AR promoter region contains an exceptionally large number of Myb binding sites, many of which contribute to the Myb-inducibility of the promoter. The same sites were required for promoter activity in myelomonocytic and erythroid cells. In contrast to the promoters of other Myb target genes the A2B-AR promoter was not activated synergistically by Myb and other lineage-specific transcription factors that have been identified as Myb cooperation partners before. Taken together, our data suggest that the activation of the A2B-AR promoter by Myb depends on the simultaneous binding of a large number of Myb molecules.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Burk O, 1999, BBA-GENE STRUCT EXPR, V1446, P243, DOI 10.1016/S0167-4781(99)00097-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; SCOTT LM, 1992, BLOOD, V80, P1725; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272	46	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4663	4672		10.1038/sj.onc.1205579	http://dx.doi.org/10.1038/sj.onc.1205579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096342				2022-12-28	WOS:000176625100007
